FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Geddes, JR Goodwin, GM Rendell, J Azorin, JM Cipriani, A Ostacher, MJ Morriss, R Alder, N Juszczak, E Lewis, S Attenburrow, MJ Carter, B Hainsworth, J Healey, C Stevens, W Van der Cucht, E Young, H Davies, C Peto, R Barnes, TRE Curtis, V Johnson, T de Silva, A Marven, M Berry, D Arif, M Bruce, J Drybala, G Hayden, E Jhingan, HP Marudkar, M Hillier, R Barrett, S Lidder, JS McCartney, M Middleton, H Ononve, F Solanki, RD Agell, I Anjum, R Hunt, N Jones, P Ramana, R Chase, J Ayuba, L Macmillan, I Michael, A Frangou, S Gijsman, H Parker, E Phillips, M Behr, G Tyrer, P Conway, A Ferrier, N Oakley, T Tower, N Young, A Chitty, R Littlejohns, C Suri, A Iqbal, M Zikis, P Anderson, I O'Driscoll, D Robbins, N Ash, G Chaudhry, I Duddu, V Reed, P Van Wyk, S Vohra, A Zingela, Z Mahmood, T Diedricks, H Faizal, MA McCarthy, J Morriss, R Briess, D Ceccherini-Nelli, A Clifford, E Croos, R Davis, JDR De Silva, L Eranti, S Mahmoud, R Maurya, A Partovi-Tabar, P Rahim, Y Tuson, J Greening, J Campbell, C Grewal, JS Kumar, A Schultewolter, D Baldwin, D Best, N Herod, N Polson, R Shawcross, C Khan, U Almoshmosh, N El-Adl, M Rao, C Timmins, B Attenburrow, MJ Bale, R Bansal, S Bhagwagar, Z Carre, A Cartright, J Chalmers, J Chisuse, A Davison, P Elwell, D Fazel, S Geaney, D Hampson, S Harrison, P Henderson, E Johnson, S Massey, C Ogilvie, A O'Leary, D Oppenheimer, C Orr, M Quested, D Sargent, P Wilkinson, P Hussain, T Franklin, S King, J White, J Anagnosti, O Bruce-Jones, B Evans, J Woodin, G Kirov, G Laugharne, R Blewett, AE Gupta, S Saluja, B Kelly, C Leeman, T Macauley, M Shields, D Anderson, J McRae, A Taylor, M Carrick, L Hare, E Morrison, D Azorin, JM Maurel, M Derouet, J le Garzic, N Millet, B Droulout, T Henry, C Leboyer, M Meary, A Barbui, C Cipriani, A Imperadore, G Tansella, M Ostacher, M Sachs, G AF Geddes, John R. Goodwin, Guy M. Rendell, Jennifer Azorin, Jean-Michel Cipriani, Andrea Ostacher, Michael J. Morriss, Richard Alder, Nicola Juszczak, Ed Lewis, Shon Attenburrow, Mary-Jane Carter, Brigid Hainsworth, Jane Healey, Christine Stevens, Will Van der Cucht, Emma Young, Heather Davies, Christina Peto, Richard Barnes, Thomas R. E. Curtis, Vivienne Johnson, Tony de Silva, Asita Marven, Michael Berry, David Arif, Mohammed Bruce, Janet Drybala, Gary Hayden, Enda Jhingan, Harsh P. Marudkar, Mangesh Hillier, Richard Barrett, Sara Lidder, Jasvinder Sing McCartney, Mark Middleton, Hugh Ononve, Frank Solanki, Ramesh D. Agell, Ignasi Anjum, Rubina Hunt, Neil Jones, Peter Ramana, Rajim Chase, Jeremy Ayuba, Larry Macmillan, Iain Michael, Albert Frangou, Sophia Gijsman, Harm Parker, Elizabeth Phillips, Mary Behr, Graham Tyrer, Peter Conway, Alison Ferrier, Nicol Oakley, Tim Tower, Nicholas Young, Allan Chitty, Roger Littlejohns, Carl Suri, Anil Iqbal, Mohammad Zikis, Panayiotis Anderson, Ian O'Driscoll, David Robbins, Natalie Ash, Graham Chaudhry, Imran Duddu, Venu Reed, Paul Van Wyk, Stephan Vohra, Adarsh Zingela, Zukiswa Mahmood, Tariq Diedricks, Heidi Faizal, Mohammad A. McCarthy, James Morriss, Richard Briess, David Ceccherini-Nelli, Alfonso Clifford, Elizabeth Croos, Robert Davis, Jane Da Rosa De Silva, Lalitha Eranti, Savitha Mahmoud, Rafi Maurya, Anil Partovi-Tabar, Peter Rahim, Yousuf Tuson, Jacqueline Greening, Jayne Campbell, Colin Grewal, Jasdey Singh Kumar, Ashok Schultewolter, Dieter Baldwin, David Best, Nick Herod, Nicola Polson, Richard Shawcross, Charles Khan, Umama Almoshmosh, Nadim El-Adl, Mamdouh Rao, Chandrashekar Timmins, Bryan Attenburrow, Mary-Jane Bale, Rob Bansal, Sandeep Bhagwagar, Zubin Carre, Ali Cartright, Julia Chalmers, Julie Chisuse, Apa Davison, Phil Elwell, David Fazel, Seena Geaney, David Hampson, Simon Harrison, Paul Henderson, Emma Johnson, Sophie Massey, Christopher Ogilvie, Alan O'Leary, Denis Oppenheimer, Catherine Orr, Michael Quested, Digby Sargent, Peter Wilkinson, Philip Hussain, Tafazul Franklin, Steve King, John White, Janet Anagnosti, Ourania Bruce-Jones, Bill Evans, Jonathan Woodin, Geoffrey Kirov, George Laugharne, Richard Blewett, Andrew E. Gupta, Subhash Saluja, Bharat Kelly, Chris Leeman, Timothy Macauley, Mark Shields, Deidre Anderson, Jacqui McRae, Alison Taylor, Mark Carrick, Lucy Hare, Elizabeth Morrison, Diana Azorin, Jean-Michel Maurel, Muriele Derouet, Jacques le Garzic, Natalie Millet, Bruno Droulout, Tiphaine Henry, Chantal Leboyer, Marion Meary, Alexandre Barbui, Corrado Cipriani, Andrea Imperadore, Giuseppe Tansella, Michele Ostacher, Michael Sachs, Gary CA BALANCE Investigators Collaborator TI Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial SO LANCET LA English DT Article ID DOUBLE-BLIND; MAINTENANCE TRIAL; MENTAL-HEALTH; RUN-IN; DIVALPROEX; METAANALYSIS; LAMOTRIGINE; DEPRESSION; MORTALITY; PATIENT AB Background Lithium carbonate and valproate semisodium are both recommended as monotherapy for prevention of relapse in bipolar disorder, but are not individually fully effective in many patients. If combination therapy with both agents is better than monotherapy, many relapses and consequent disability could be avoided. We aimed to establish whether lithium plus valproate was better than monotherapy with either drug alone for relapse prevention in bipolar I disorder. Methods 330 patients aged 16 years and older with bipolar I disorder from 41 sites in the UK, France, USA, and Italy were randomly allocated to open-label lithium monotherapy (plasma concentration 0.4-1.0 mmol/L, n=110), valproate monotherapy (750-1250 mg, n=110), or both agents in combination (n=110), after an active run-in of 4-8 weeks on the combination. Randomisation was by computer program, and investigators and participants were informed of treatment allocation. All outcome events were considered by the trial management team, who were masked to treatment assignment. Participants were followed up for up to 24 months. The primary outcome was initiation of new intervention for an emergent mood episode, which was compared between groups by Cox regression. Analysis was by intention to treat. This study is registered, number ISRCTN 55261332. Findings 59 (54%) of 110 people in the combination therapy group, 65 (59%) of 110 in the lithium group, and 76 (69%) of 110 in the valproate group had a primary outcome event during follow-up. Hazard ratios for the primary outcome were 0.59 (95% CI 0.42-0.83, p=0.0023) for combination therapy versus valproate, 0.82 (0.58-1.17, p=0.27) for combination therapy versus lithium, and 0.71 (0.51-1.00, p=0.0472) for lithium versus valproate. 16 participants had serious adverse events after randomisation: seven receiving valproate monotherapy (three deaths); five lithium monotherapy (two deaths); and four combination therapy (one death). Interpretation For people with bipolar I disorder, for whom long-term therapy is clinically indicated, both combination therapy with lithium plus valproate and lithium monotherapy are more likely to prevent relapse than is valproate monotherapy. This benefit seems to be irrespective of baseline severity of illness and is maintained for up to 2 years. BALANCE could neither reliably confirm nor refute a benefit of combination therapy compared with lithium monotherapy. C1 [Geddes, John R.; Goodwin, Guy M.; Rendell, Jennifer; Juszczak, Ed; Attenburrow, Mary-Jane; Carter, Brigid; Hainsworth, Jane; Healey, Christine; Stevens, Will; Van der Cucht, Emma; Young, Heather] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford Clin Trials Unit Mental Illness,Trial Mana, Oxford OX3 7JX, England. [Davies, Christina; Peto, Richard] Univ Oxford, MRC Canc Res UK BHF Clin Trial Serv Unit, Oxford, England. [Davies, Christina; Peto, Richard] Univ Oxford, Epidemiol Studies Unit, Oxford, England. [Marven, Michael] Oxford & Buckinghamshire NHS Fdn Trust, Oxford, England. [Berry, David] Guys & St Thomas NHS Fdn Trust, Med Toxicol Unit, London, England. [Arif, Mohammed; Bruce, Janet; Drybala, Gary; Hayden, Enda; Jhingan, Harsh P.; Marudkar, Mangesh] Leicestershire Partnership NHS Trust, Leicester, Leics, England. [Hillier, Richard] Lincolnshire Partnership NHS Fdn Trust, Lincoln, England. [Barrett, Sara; Lidder, Jasvinder Sing; McCartney, Mark; Middleton, Hugh; Ononve, Frank; Solanki, Ramesh D.] Nottinghamshire Healthcare NHS Trust, Nottingham, England. [Agell, Ignasi; Anjum, Rubina] S Staffordshire & Shropshire Healthcare NHS Fdn T, Stafford, England. [Hunt, Neil; Jones, Peter; Ramana, Rajim] Cambridgeshire & Peterborough NHS Fdn Trust, Cambridge, England. [Chase, Jeremy] Hertfordshire Partnership NHS Fdn Trust, Hertford, England. [Ayuba, Larry; Macmillan, Iain] Norfolk & Waveney Mental Hlth NHS Fdn Trust, Norfolk, England. [Michael, Albert] Suffolk Mental Hlth Partnership NHS Trust, Suffolk, England. [Frangou, Sophia; Gijsman, Harm; Parker, Elizabeth; Phillips, Mary] S London & Maudsley NHS Fdn Trust, London, England. [Behr, Graham; Tyrer, Peter] W London Mental Hlth NHS Trust, London, England. [Iqbal, Mohammad; Zikis, Panayiotis] Dudley Primary Care Trust, Dudley, England. [Anderson, Ian; O'Driscoll, David; Robbins, Natalie] Greater Manchester W Mental Hlth NHS Fdn Trust, Manchester, Lancs, England. [Mahmood, Tariq] Mersey Care NHS Trust, Liverpool, Merseyside, England. [Morriss, Richard; Diedricks, Heidi; Faizal, Mohammad A.; McCarthy, James] Leeds Partnerships NHS Fdn Trust, Leeds, W Yorkshire, England. [Greening, Jayne] Birmingham & Solihull Mental Hlth NHS Fdn Trust, Birmingham, W Midlands, England. [Campbell, Colin; Grewal, Jasdey Singh; Kumar, Ashok; Schultewolter, Dieter] Coventry & Warwickshire Partnership NHS Trust, Coventry, W Midlands, England. [Baldwin, David; Best, Nick; Herod, Nicola; Polson, Richard; Shawcross, Charles] Hampshire Partnership NHS Trust, Southampton, Hants, England. [Almoshmosh, Nadim; El-Adl, Mamdouh; Rao, Chandrashekar; Timmins, Bryan] Northamptonshire Healthcare NHS Trust, Northampton, England. [Geddes, John R.; Goodwin, Guy M.; Attenburrow, Mary-Jane; Bale, Rob; Bansal, Sandeep; Bhagwagar, Zubin; Carre, Ali; Cartright, Julia; Chalmers, Julie; Chisuse, Apa; Davison, Phil; Elwell, David; Fazel, Seena; Geaney, David; Hampson, Simon; Harrison, Paul; Henderson, Emma; Johnson, Sophie; Massey, Christopher; Ogilvie, Alan; O'Leary, Denis; Oppenheimer, Catherine; Orr, Michael; Quested, Digby; Sargent, Peter; Wilkinson, Philip] Oxford & Buckinghamshire NHS Fdn Trust, Oxford, England. [Hussain, Tafazul] Oxfordshire Learning Disabil NHS Trust, Oxford, England. [Franklin, Steve; King, John; White, Janet] Worcestershire Mental Hlth Partnership NHS Trust, Worcester, England. [Kirov, George] Cardiff & Vale NHS Trust, Cardiff, S Glam, Wales. [Laugharne, Richard] Cornwall Partnership NHS Trust, Cornwall, England. [Kelly, Chris] Belfast City Hosp Trust, Belfast, Antrim, North Ireland. [Azorin, Jean-Michel; Maurel, Muriele] CHU St Marguerite, Marseille, France. [Ostacher, Michael; Sachs, Gary] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Geddes, JR (reprint author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford Clin Trials Unit Mental Illness,Trial Mana, Oxford OX3 7JX, England. EM john.geddes@psych.ox.ac.uk RI Cipriani, Andrea/E-5951-2010; Geddes, John/B-8240-2011; Barbui, Corrado/E-7146-2010; turton, miranda/F-4682-2011; Tansella, Michele/B-4106-2010; Frangou, Sophia/A-2672-2013; Bhagwagar, Zubin/H-1071-2012; Macmillan, Iain/L-8933-2013; Suri, Anil/P-5128-2016 OI Jones, Peter/0000-0002-0387-880X; Ostacher, Michael/0000-0003-0353-7535; Lewis, Shon/0000-0003-1861-4652; Cipriani, Andrea/0000-0001-5179-8321; Bhagwagar, Zubin/0000-0002-1101-768X; Macmillan, Iain/0000-0002-7909-1560; Suri, Anil/0000-0001-5231-5555 FU Stanley Medical Research Institute; Sanofi-Aventis FX We thank the participants and the clinical and administrative staff in all four countries who assisted with the trial. BALANCE was funded by the Stanley Medical Research Institute, with French centres funded by Sanofi-Aventis. All study drugs for the UK and France were donated by Sanofi-Aventis, the manufacturers of lithium carbonate (Priadel) and valproate semisodium (Depakote). In the UK, the study was adopted by the Mental Health Research Network in February, 2005. NR 37 TC 218 Z9 222 U1 1 U2 29 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD JAN-FEB PY 2010 VL 375 IS 9712 BP 385 EP 395 DI 10.1016/S0140-6736(09)61828-6 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 552PK UT WOS:000274305500026 ER PT J AU Rajkumar, SV Jacobus, S Callander, NS Fonseca, R Vesole, DH Williams, ME Abonour, R Siegel, DS Katz, M Greipp, PR AF Rajkumar, S. Vincent Jacobus, Susanna Callander, Natalie S. Fonseca, Rafael Vesole, David H. Williams, Michael E. Abonour, Rafat Siegel, David S. Katz, Michael Greipp, Philip R. CA Eastern Cooperative Oncology Grp TI Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial SO LANCET ONCOLOGY LA English DT Article ID STEM-CELL TRANSPLANTATION; COMBINATION THERAPY; THALIDOMIDE; CHEMOTHERAPY; PREDNISONE; MELPHALAN; BORTEZOMIB; IMPACT AB Background High-dose dexamethasone is a mainstay of therapy for multiple myeloma. We studied whether low-dose dexamethasone in combination with lenalidomide is non-inferior to and has lower toxicity than high-dose dexamethasone plus lenalidomide. Methods Patients with untreated symptomatic myeloma were randomly assigned in this open-label non-inferiority trial to lenalidomide 25 mg on days 1-21 plus dexamethasone 40 mg on days 1-4, 9-12, and 17-20 of a 28-day cycle high dose), or lenalidomide given on the same schedule with dexamethasone 40 mg on days 1, 8, 15, and 22 of a 28-day cycle (low dose). After four cycles, patients could discontinue therapy to pursue stem-cell transplantation or continue treatment until disease progression. The primary endpoint was response rate after four cycles assessed with European Group for Blood and Bone Marrow Transplant criteria. The non-inferiority margin was an absolute difference of 15% in response rate. Analysis was by modified intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00098475. Findings 445 patients were randomly assigned: 223 to high-dose and 222 to low-dose regimens. 169 (79%) of 214 patients receiving high-dose therapy and 142 (68%) of 205 patients on low-dose therapy had complete or partial response within four cycles (odds ratio 1.75, 80% CI 1.30-2.32; p=0.008). However, at the second interim analysis at 1 year, overall survival was 96% (95% CI 94-99) in the low-dose dexamethasone group compared with 87% (82-92) in the high-dose group (p=0.0002). As a result, the trial was stopped and patients on high-dose therapy were crossed over to low-dose therapy. 117 patients (52%) on the high-dose regimen had grade three or worse toxic effects in the first 4 months, compared with 76 (35%) of the 220 on the low-dose regimen for whom toxicity data were available (p=0.0001), 12 of 222 on high dose and one of 220 on low-dose dexamethasone died in the first 4 months (p=0.003). The three most common grade three or higher toxicities were deep-vein thrombosis, 57 (26%) of 223 versus 27 (12%) of 220 (p=0.0003); infections including pneumonia, 35 (16%) of 223 versus 20 (9%) of 220 (p=0.04), and fatigue 33 (15%) of 223 versus 20 (9%) of 220 (p=0.08), respectively. Interpretation Lenalidomide plus low-dose dexamethasone is associated with better short-term overall survival and with lower toxicity than lenalidomide plus high-dose dexamethasone in patients with newly diagnosed myeloma. C1 [Rajkumar, S. Vincent] Mayo Clin, Div Hematol, Rochester, MN 55905 USA. [Jacobus, Susanna] Dana Farber Canc Inst, Boston, MA 02115 USA. [Callander, Natalie S.] Univ Wisconsin, Madison, WI USA. [Fonseca, Rafael] Mayo Clin Arizona, Scottsdale, AZ USA. [Vesole, David H.] St Vincents Hosp, New York, NY USA. [Williams, Michael E.] Univ Virginia Hlth Syst, Charlottesville, VA USA. [Abonour, Rafat] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA. [Siegel, David S.] Hackensack Univ, Med Ctr, Hackensack, NJ USA. [Katz, Michael] Int Myeloma Fdn, N Hollywood, CA USA. RP Rajkumar, SV (reprint author), Mayo Clin, Div Hematol, 200 1st St SW, Rochester, MN 55905 USA. EM rajkumar.vincent@mayo.edu OI Fonseca, Rafael/0000-0002-5938-3769; Rajkumar, S. Vincent/0000-0002-5862-1833 FU US National Cancer Institute (NCI); National Cancer Institute [CA23318, CA66636, CA21115, CA13650, CA93842]; National Institutes of Health; Department of Health and Human Senrices FX This study was funded and sponsored by the US National Cancer Institute (NCI). This study was coordinated by the Eastern Cooperative Oncology Group (Chair Robert L Comis) and supported by Public Health Service Grants CA23318, CA66636, CA21115, CA13650, and CA93842 from the National Cancer Institute, National Institutes of Health, and the Department of Health and Human Senrices. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute. NR 28 TC 461 Z9 470 U1 3 U2 26 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1470-2045 J9 LANCET ONCOL JI Lancet Oncol. PD JAN PY 2010 VL 11 IS 1 BP 29 EP 37 PG 9 WC Oncology SC Oncology GA 547GH UT WOS:000273874100019 PM 19853510 ER PT J AU Zhu, AX Meyerhardt, JA Blaszkowsky, LS Kambadakone, A Muzikansky, A Zheng, H Clark, JW Abrams, TA Chan, JA Enzinger, PC Bhargava, P Kwak, EL Allen, JN Jain, SR Stuart, K Horgan, K Sheehan, S Fuchs, CS Ryan, DP Sahani, DV AF Zhu, Andrew X. Meyerhardt, Jeffrey A. Blaszkowsky, Lawrence S. R Kambadakone, Avinash Muzikansky, Alona Zheng, Hui Clark, Jeffrey W. Abrams, Thomas A. Chan, Jennifer A. Enzinger, Peter C. Bhargava, Pankaj Kwak, Eunice L. Allen, Jill N. Jain, Sanjay R. Stuart, Keith Horgan, Kerry Sheehan, Susan Fuchs, Charles S. Ryan, David P. Sahani, Dushyant V. TI Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study SO LANCET ONCOLOGY LA English DT Article ID ADVANCED HEPATOCELLULAR-CARCINOMA; METASTATIC COLORECTAL-CANCER; CISPLATIN; CHEMOTHERAPY; COMBINATION; CHOLANGIOCARCINOMAS; FLUOROURACIL; CAPECITABINE; PACLITAXEL; LEUCOVORIN AB Background Previous phase 2 studies have shown antitumour activity with gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary-tract cancers (BTCs). In this phase 2 study, we assessed the efficacy and safety of combined bevacizumab with GEMOX (GEMOX-B) in patients with advanced BTCs, and investigated how changes in 18-fluorodeoxyglucose ([(18)F]FDG)-PET correlate with clinical outcome. Methods Patients with advanced measurable BTCs were given the following treatment on days 1 and 15 of a 28-day cycle: bevacizumab 10 mg/kg, followed by gemcitabine 1000 mg/m(2) (10 mg/m(2) per min) and oxaliplatin 85 mg/m(2) (2-h infusion). [(18)F]FDG-PET scans were obtained at baseline and after completion of the second cycle. The primary endpoint was progression-free survival (PFS). Efficacy and safety analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00361231. Findings 35 patients were enrolled and evaluable for efficacy and toxicity. Median PFS was 7.0 months (95% CI 5.3-10.3), and PFS at 6 months was 63% (47-79), which was below the targeted rate of 70%. Grade 3-4 toxic effects included neutropenia (n=7), raised alanine aminotransferase concentrations (n=5), peripheral neuropathy (n=5), and hypertension (n=5). [(18)F]FDG-PET scans showed a significant decrease in maximum standardised uptake value (SUV(max)) after two cycles of treatment (5-72 [SD 2.01] at baseline; 3.73 [SD 1.88] after two cycles; p<0.0001). These changes were more pronounced in patients with partial response or stable disease than those with progressive disease (24 patients, -2.80 [SD 1.95] vs five patients, 1.41 [SD 3.13]; p=0.009). Change in SUV(max) was a significant predictor of PFS (HR 1.35, 1.14-1.60, p=0.0006) and overall survival (1.25, 1.05-1.50, p=0.01). Interpretation GEMOX-B showed antitumour activity with tolerable safety in patients with advanced BTCs. Decreases in SUV(max) on [(18)F]FDG-PET scans after treatment were associated with disease control and increases in PFS and overall survival. C1 [Zhu, Andrew X.] Massachusetts Gen Hosp, Tucker Gosnell Ctr Gastrointestinal Canc, Ctr Canc, Boston, MA 02114 USA. [Meyerhardt, Jeffrey A.; Abrams, Thomas A.; Chan, Jennifer A.; Enzinger, Peter C.; Bhargava, Pankaj; Fuchs, Charles S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA. [R Kambadakone, Avinash; Sahani, Dushyant V.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Muzikansky, Alona; Zheng, Hui] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. [Jain, Sanjay R.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Stuart, Keith] Lahey Clin Med Ctr, Dept Hematol & Oncol, Burlington, MA 01803 USA. RP Zhu, AX (reprint author), Massachusetts Gen Hosp, Tucker Gosnell Ctr Gastrointestinal Canc, Ctr Canc, Boston, MA 02114 USA. EM azhu@partners.org FU Genentech Oncology and Sanofi-Aventis; Tracy McNally and Glen Miller; Genentech USA, Inc. FX This study was funded by Genentech Oncology and Sanofi-Aventis. Support for third-party editorial assistance for this manuscript, furnished by Tracy McNally and Glen Miller, was provided by Genentech USA, Inc. NR 36 TC 102 Z9 110 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1470-2045 J9 LANCET ONCOL JI Lancet Oncol. PD JAN PY 2010 VL 11 IS 1 BP 48 EP 54 PG 7 WC Oncology SC Oncology GA 547GH UT WOS:000273874100021 PM 19932054 ER PT J AU Albain, KS Barlow, WE Shak, S Hortobagyi, GN Livingston, RB Yeh, IT Ravdin, P Bugarini, R Boehner, FL Davidson, NE Sledge, GW Winer, EP Hudis, C Ingle, JN Perez, EA Pritchard, KI Shepherd, L Gralow, JR Yoshizawa, C Allred, DC Osborne, CK Hayes, DF AF Albain, Kathy S. Barlow, William E. Shak, Steven Hortobagyi, Gabriel N. Livingston, Robert B. Yeh, I-Tien Ravdin, Peter Bugarini, Roberto Boehner, Frederick L. Davidson, Nancy E. Sledge, George W. Winer, Eric P. Hudis, Clifford Ingle, James N. Perez, Edith A. Pritchard, Kathleen I. Shepherd, Lois Gralow, Julie R. Yoshizawa, Carl Allred, D. Craig Osborne, C. Kent Hayes, Daniel F. CA Breast Canc Intergrp N Amer TI Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial SO LANCET ONCOLOGY LA English DT Article ID INTERNATIONAL EXPERT CONSENSUS; GENE-EXPRESSION; PRIMARY THERAPY; TUMOR-MARKER; SURVIVAL; RECOMMENDATIONS; HIGHLIGHTS; SIGNATURE; DEATH; RISK AB Background The 21-gene recurrence score assay is prognostic for women with node-negative, oestrogen-receptor-positive breast cancer treated with tamoxifen. A low recurrence score predicts little benefit of chemotherapy. For node-positive breast cancer, we investigated whether the recurrence score was prognostic in women treated with tamoxifen alone and whether it identified those who might not benefit from anthracycline-based chemotherapy, despite higher risks of recurrence. Methods The phase 3 trial SWOG-8814 for postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer showed that chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil (CAF) before tamoxifen (CAF-T) added survival benefit to treatment with tamoxifen alone. Optional tumour banking yielded specimens for determination of recurrence score by RT-PCR. In this retrospective analysis, we assessed the effect of recurrence score on disease-free survival by treatment group (tamoxifen vs CAM) using Cox regression, adjusting for number of positive nodes. Findings There were 367 specimens (40% of the 927 patients in the tamoxifen and CAF-T groups) with sufficient RNA for analysis (tamoxifen, n=148; CAF-T, n=219). The recurrence score was prognostic in the tamoxifen-alone group (p=0.006; hazard ratio [HR] 2.64, 95% CI 1.33-5.27, for a 50-point difference in recurrence score). There was no benefit of CAF in patients with a low recurrence score (score <18; log-rank p=0.97; HR 1.02, 0.54-1-93), but an improvement in disease-free survival for those with a high recurrence score (score >= 31; log-rank p=0.033; HR 0.59, 0.35-1.01), after adjustment for number of positive nodes. The recurrence score by treatment interaction was significant in the first 5 years (p=0.029), with no additional prediction beyond 5 years (p=0.58), although the cumulative benefit remained at 10 years. Results were similar for overall survival and breast-cancer-specific survival. Interpretation The recurrence score is prognostic for tamoxifen-treated patients with positive nodes and predicts significant benefit of CAF in tumours with a high recurrence score. A low recurrence score identifies women who might not benefit from anthracycline-based chemotherapy, despite positive nodes. C1 [Albain, Kathy S.] Loyola Univ Chicago, Stritch Sch Med, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA. [Barlow, William E.] SW Oncol Grp, Ctr Stat, Seattle, WA USA. [Hortobagyi, Gabriel N.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Livingston, Robert B.] Univ Arizona, Ctr Canc, Tucson, AZ USA. [Yeh, I-Tien; Ravdin, Peter] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Davidson, Nancy E.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA. [Sledge, George W.] Indiana Univ, Med Ctr, Indianapolis, IN USA. [Winer, Eric P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Hudis, Clifford] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Ingle, James N.] Mayo Clin, Rochester, MN USA. [Perez, Edith A.] Mayo Clin, Jacksonville, FL 32224 USA. [Pritchard, Kathleen I.] Univ Toronto, Sunnybrook Canc Ctr, Toronto, ON, Canada. [Shepherd, Lois] Queens Univ, Clin Trials Grp, Natl Canc Inst Canada, Kingston, ON, Canada. [Gralow, Julie R.] Seattle Canc Care Alliance, Seattle, WA USA. [Allred, D. Craig] Washington Univ, Sch Med, St Louis, MO USA. [Osborne, C. Kent] Baylor Coll Med, Ctr Canc, Houston, TX 77030 USA. [Hayes, Daniel F.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. RP Albain, KS (reprint author), Loyola Univ Chicago, Stritch Sch Med, Cardinal Bernardin Canc Ctr, 2160 S 1st Ave, Maywood, IL 60153 USA. EM kalbain@lumc.edu RI Pritchard, Kathleen/I-2184-2014 OI Pritchard, Kathleen/0000-0003-0758-9666 FU US National Cancer Institute [SWOG-8814]; National Cancer Institute, Department of Health and Human Services [CA32102, CA38926, CA21115, CA02599, CA60138, CA25224, CA77202-06, CA04920, CA58658, CA13612, CA37981, CA76447, CA22433, CA59416, CA20319, CA58686, CA04919, CA46441, CA58861, CA27057, CA32734, CA35281, CA12644, CA16385, CA45560, CA58882, CA14028, CA35176, CA46282, CA46113, CA52650]; National Cancer Institute of Canada and Canadian Cancer Society; Genomic Health FX The SWOG-8814 trial was funded entirely by the US National Cancer Institute. This retrospective assessment of banked tumour tissue was supported in part by the following Public Health Service Cooperative Agreement grant numbers awarded by the National Cancer Institute, Department of Health and Human Services, CA32102, CA38926, CA21115, CA02599, CA60138, CA25224, CA77202-06, CA04920, CA58658, CA13612, CA37981, CA76447, CA22433, CA59416, CA20319, CA58686, CA04919, CA46441, CA58861, CA27057, CA32734, CA35281, CA12644, CA16385, CA45560, CA58882, CA14028, CA35176, CA46282, CA46113, CA52650, CA03096, CA28862, CA35090, CA58723, CA35283, CA45807, CA35200, CA35119, CA45450, CA46136, CA42777, CA35261, CA45466, CA35117, CA46368, CA58348, CA12213, CA52654, CA35128, CA58415, CA52623, CA35192, CA45377, CA35996, CA52757, CA76132, CA35431, CA76462, CA45461, CA35084, CA765,429, CA35178, CA67663, CA63844, and CA52772; by the National Cancer Institute of Canada and Canadian Cancer Society; and supported in part by Genomic Health. NR 33 TC 506 Z9 524 U1 5 U2 46 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1470-2045 J9 LANCET ONCOL JI Lancet Oncol. PD JAN PY 2010 VL 11 IS 1 BP 55 EP 65 PG 11 WC Oncology SC Oncology GA 547GH UT WOS:000273874100022 PM 20005174 ER PT J AU Caplan, D AF Caplan, David TI Task effects on BOLD signal correlates of implicit syntactic processing SO LANGUAGE AND COGNITIVE PROCESSES LA English DT Article DE BOLD signal; Font change detection; syntactic processing; Parsing; Interpretative operations ID EVENT-RELATED FMRI; SPOKEN-LANGUAGE COMPREHENSION; SURFACE-BASED ANALYSIS; SENTENCE COMPREHENSION; AMBIGUITY RESOLUTION; RELATIVE CLAUSES; INDIVIDUAL-DIFFERENCES; CORTICAL SURFACE; WORKING-MEMORY; EYE-MOVEMENTS AB BOLD signal was measured in 16 participants who made timed font change detection judgments in visually presented sentences that varied in syntactic structure and the order of animate and inanimate nouns. Behavioural data indicated that sentences were processed to the level of syntactic structure. BOLD signal increased in visual association areas bilaterally and left supramarginal gyrus in the contrast of sentences with object- and subject-extracted relative clauses without font changes in which the animacy order of the nouns biased against the syntactically determined meaning of the sentence. This result differs from the findings in a nonword detection task (Caplan, Chen, Waters, 2008a), in which the same contrast led to increased BOLD signal in the left inferior frontal gyrus. The difference in areas of activation indicates that the sentences were processed differently in the two tasks. These differences were further explored in an eye tracking study using the materials in the two tasks. Issues pertaining to how parsing and interpretive operations are affected by a task that is being performed, and how this might affect BOLD signal correlates of syntactic contrasts, are discussed. C1 Massachusetts Gen Hosp, Neuropsychol Lab, Boston, MA 02114 USA. RP Caplan, D (reprint author), Massachusetts Gen Hosp, Neuropsychol Lab, 175 Cambridge St,Suite 340, Boston, MA 02114 USA. EM dcaplan@partners.org FU NIDCD NIH HHS [R01 DC002146-12, R01 DC002146] NR 60 TC 7 Z9 7 U1 3 U2 3 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0169-0965 J9 LANG COGNITIVE PROC JI Lang. Cogn. Process. PY 2010 VL 25 IS 6 BP 866 EP 901 AR PII 920645630 DI 10.1080/01690961003672447 PG 36 WC Linguistics; Psychology, Experimental SC Linguistics; Psychology GA 611WX UT WOS:000278856700005 PM 20671983 ER PT J AU Saxena, S Gierl, B Eibling, DE AF Saxena, Shashank Gierl, Brian Eibling, David E. TI Supraglottic Swelling May Not Correlate With Tongue Swelling in Angiotensin Converting Enzyme Inhibitor-Induced Angioedema SO LARYNGOSCOPE LA English DT Article DE Angioedema; laryngeal edema; angiotension converting enzyme inhibitors ID PERIOPERATIVE ANGIOEDEMA; ACE-INHIBITORS; MANAGEMENT; THERAPY AB Angioneurotic edema of upper airway tissues due to angiotensin converting enzyme inhibitor (ACEI) usage is a known perioperative complication of this class of medications. Swelling can begin rapidly, and typically involves the tongue and oral cavity. We have recently encountered four cases in which supraglottic edema developed after onset of tongue swelling and progressed despite resolving tongue edema. We present a representative case. This observation. suggests that all patients with ACEI-induced angioedema should undergo laryngeal fiberoptic examination and appropriate airway management. C1 [Saxena, Shashank] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA. [Eibling, David E.] VA Pittsburgh Hlth Care Syst, Dept Otolaryngol, Pittsburgh, PA USA. RP Saxena, S (reprint author), Univ Pittsburgh, Sch Med, Dept Anesthesiol, A 1305 Scaife Hall, Pittsburgh, PA 15261 USA. EM saxenas@anes.upmc.edu NR 21 TC 8 Z9 8 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD JAN PY 2010 VL 120 IS 1 BP 62 EP 64 DI 10.1002/lary.20683 PG 3 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 539HZ UT WOS:000273245900012 PM 19890965 ER PT J AU Konrad-Martin, D Austin, DF Griest, S McMillan, GP McDermott, D Fausti, S AF Konrad-Martin, Dawn Austin, Donald F. Griest, Susan McMillan, Garnett P. McDermott, Daniel Fausti, Stephen TI Diabetes-Related Changes in Auditory Brainstem Responses SO LARYNGOSCOPE LA English DT Article DE Auditory brainstem response; diabetes; hearing loss; Veterans ID HEARING-LOSS; MELLITUS; IMPAIRMENT AB Objectives/Hypothesis: Determine effects on auditory brainstem response (ABR) of diabetes mellitus (DM) severity. Study Design: A cross-sectional study investigating DM severity and ABR in military Veteran subjects with (166) and without (138) DM and with no more than moderate hearing loss. Methods: Subjects were classified by three age tertiles (<50, 50-56, and 57+). DM severity was classified as insulin-dependent (IDDM), non-insulin-dependent (NIDDM), or no DM. Other DM measures included serum glucose, HbA1c, and several DM-related complications. ABR measures included wave I, III, and V latencies; I-III, III-V, and I-V latency intervals; and wave V amplitude; for each ear at three repetition rates (11, 51, and 71 clicks/second), and both polarities. Outcomes were stratified by age tertile and adjusted for pure tone threshold at 3 kHz. Repeated measures multivariate analysis of covariance modeled the ABR response at each repetition rate for DM severity (main effect) and hearing at 3 kHz (covariate). Modeled contrasts between ABR variables in subjects with and without DM were examined. Results: Significant differences existed between no DM and IDDM groups in the younger tertile only. Adjusting for threshold at 3 kHz had minimal effect. Self-reported noise exposure was not related to ABR differences, but HbA1c and poor circulation were. Conclusions: IDDM is associated with an increased wave V latency, wave I-V interval, and reduced wave V amplitude among Veterans under 50 years. Results were related to several DM complications. C1 [Konrad-Martin, Dawn] Portland VA Med Ctr, VA RR&D, Natl Ctr Rehabil Auditory Res, Vet Affairs Rehabil Res & Dev Serv, Portland, OR 97239 USA. [Austin, Donald F.] Oregon Hlth & Sci Univ, Sch Med, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. [Konrad-Martin, Dawn; Griest, Susan; Fausti, Stephen] Oregon Hlth & Sci Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA. RP Konrad-Martin, D (reprint author), Portland VA Med Ctr, VA RR&D, Natl Ctr Rehabil Auditory Res, Vet Affairs Rehabil Res & Dev Serv, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM dawn.martin@va.gov FU United States Department of Veterans Affairs (VA); Veterans Health Administration, Office of Research and Development Rehabilitation Research and Development (RRD) Service [C3446R, C4447K] FX This work was supported by the United States Department of Veterans Affairs (VA), Veterans Health Administration, Office of Research and Development Rehabilitation Research and Development (RR&D) Service grants C3446R and C4447K. NR 15 TC 14 Z9 19 U1 1 U2 3 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD JAN PY 2010 VL 120 IS 1 BP 150 EP 158 DI 10.1002/lary.20636 PG 9 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 539HZ UT WOS:000273245900027 PM 19904812 ER PT J AU Fink, DS Benoit, MM Lamuraglia, GM Deschler, DG AF Fink, Daniel S. Benoit, Margo McKenna Lamuraglia, Glenn M. Deschler, Daniel G. TI Paraganglioma of the Hypoglossal Nerve SO LARYNGOSCOPE LA English DT Meeting Abstract C1 [Fink, Daniel S.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Div Vasc Surg, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. RP Fink, DS (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. NR 8 TC 0 Z9 2 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2010 VL 120 SU 4 BP S147 EP S147 DI 10.1002/lary.21611 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 709LD UT WOS:000286438600023 PM 21225745 ER PT J AU Kakarala, K Faquin, WC Desehler, DG AF Kakarala, Kiran Faquin, William C. Desehler, Daniel G. TI A Comparison of Histopathologic Margin Assessment after Steel Scalpel, Monopolar Electrosurgery, and Ultrasonic Scalpel Glossectomy in a Rat Model SO LARYNGOSCOPE LA English DT Meeting Abstract ID SQUAMOUS CARCINOMA; SURGICAL-TREATMENT; ORAL-MUCOSA; TONGUE; CO2-LASER; CANCER; NECK C1 [Kakarala, Kiran; Desehler, Daniel G.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Div Head & Neck Surg, Boston, MA 02114 USA. [Faquin, William C.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Kakarala, Kiran; Desehler, Daniel G.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. RP Kakarala, K (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Div Head & Neck Surg, 243 Charles St, Boston, MA 02114 USA. OI Kakarala, Kiran/0000-0002-1003-8024 NR 13 TC 4 Z9 5 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2010 VL 120 SU 4 BP S155 EP S155 DI 10.1002/lary.21619 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 709LD UT WOS:000286438600031 PM 21225753 ER PT J AU Kakarala, K Sadow, PM Emerick, KS AF Kakarala, Kiran Sadow, Peter M. Emerick, Kevin S. TI Cervical Lymph Node Collision Tumor Consisting of Metastatic Squamous Cell Carcinoma and B-Cell Lymphoma SO LARYNGOSCOPE LA English DT Meeting Abstract C1 [Kakarala, Kiran; Emerick, Kevin S.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Div Head & Neck Surg, Boston, MA 02114 USA. [Sadow, Peter M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Kakarala, Kiran; Emerick, Kevin S.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. RP Kakarala, K (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Div Head & Neck Surg, 243 Charles St, Boston, MA 02114 USA. NR 8 TC 2 Z9 2 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2010 VL 120 SU 4 BP S156 EP S156 DI 10.1002/lary.21620 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 709LD UT WOS:000286438600032 PM 21225754 ER PT J AU Kakarala, K Durand, ML Emerick, KS AF Kakarala, Kiran Durand, Marlene L. Emerick, Kevin S. TI Retropharyngeal Abscess in the Setting of Immune Modulation for Rheumatoid Arthritis SO LARYNGOSCOPE LA English DT Meeting Abstract ID RESISTANT STAPHYLOCOCCUS-AUREUS C1 [Kakarala, Kiran; Emerick, Kevin S.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Div Head & Neck Surg, Boston, MA 02114 USA. [Durand, Marlene L.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA. [Kakarala, Kiran; Emerick, Kevin S.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. RP Kakarala, K (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Div Head & Neck Surg, 243 Charles St, Boston, MA 02114 USA. NR 7 TC 1 Z9 1 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2010 VL 120 SU 4 BP S131 EP S131 DI 10.1002/lary.21595 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 709LD UT WOS:000286438600007 PM 21225729 ER PT J AU Lee, LN Scott, AR Chan, AW Frankenthaler, RA AF Lee, Linda N. Scott, Andrew R. Chan, Annie W. Frankenthaler, Robert A. TI Management of Transitional Cell Carcinoma of the Lacrimal Sac: A Multidisciplinary Approach to Orbit Sparing Treatment SO LARYNGOSCOPE LA English DT Meeting Abstract C1 [Lee, Linda N.; Scott, Andrew R.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. [Chan, Annie W.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Frankenthaler, Robert A.] Beth Israel Deaconess Med Ctr, Div Otolaryngol Head & Neck Surg, Boston, MA 02215 USA. [Lee, Linda N.; Scott, Andrew R.; Frankenthaler, Robert A.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. RP Lee, LN (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. NR 0 TC 3 Z9 3 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2010 VL 120 SU 4 BP S161 EP S161 DI 10.1002/lary.21625 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 709LD UT WOS:000286438600037 PM 21225759 ER PT J AU Lin, HW Bhattacharyya, N AF Lin, Harrison W. Bhattacharyya, Neil TI Clinical behavior of follicular variant of papillary thyroid carcinoma: presentation and survival SO LARYNGOSCOPE LA English DT Meeting Abstract C1 [Lin, Harrison W.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. Brigham & Womens Hosp, Div Otolaryngol Head & Neck Surg, Boston, MA 02115 USA. RP Lin, HW (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. NR 5 TC 7 Z9 8 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2010 VL 120 SU 4 BP S163 EP S163 DI 10.1002/lary.21627 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 709LD UT WOS:000286438600039 PM 21225761 ER PT J AU McLellan, M Hasserjian, R Emerick, K AF McLellan, Megan Hasserjian, Robert Emerick, Kevin TI Marginal zone B-cell lymphoma of the head and neck: a rare case and review SO LARYNGOSCOPE LA English DT Meeting Abstract ID NON-HODGKINS-LYMPHOMA; CLASSIFICATION C1 [McLellan, Megan; Hasserjian, Robert; Emerick, Kevin] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [McLellan, Megan; Emerick, Kevin] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Hasserjian, Robert] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP McLellan, M (reprint author), Harvard Univ, Sch Med, Cambridge, MA 02138 USA. NR 13 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2010 VL 120 SU 4 BP S165 EP S165 DI 10.1002/lary.21629 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 709LD UT WOS:000286438600041 PM 21225763 ER PT J AU Roberts, DS Faquin, WC Deschler, DG AF Roberts, Daniel S. Faquin, William C. Deschler, Daniel G. TI Giant cell tumors of the temporal bone and infratemporal fossa: a case report and review of the literature SO LARYNGOSCOPE LA English DT Meeting Abstract ID SKULL C1 [Roberts, Daniel S.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. RP Roberts, DS (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. NR 5 TC 1 Z9 1 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2010 VL 120 SU 4 BP S180 EP S180 DI 10.1002/lary.21644 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 709LD UT WOS:000286438600056 PM 21225778 ER PT J AU Shargorodsky, J Lee, GS Whittemore, KR AF Shargorodsky, Jossef Lee, Gi Soo Whittemore, Kenneth R. TI Bacterial Tracheitis: A Therapeutic Approach SO LARYNGOSCOPE LA English DT Meeting Abstract C1 [Shargorodsky, Jossef] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. [Shargorodsky, Jossef] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [Lee, Gi Soo; Whittemore, Kenneth R.] Childrens Hosp Boston, Dept Otolaryngol & Commun Enhancement, Boston, MA USA. RP Shargorodsky, J (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. NR 0 TC 0 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2010 VL 120 SU 4 BP S227 EP S227 DI 10.1002/lary.21694 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 709LD UT WOS:000286438600103 PM 21225825 ER PT J AU Silver, AL Faquin, WC Caruso, PA Deschler, DG AF Silver, Amanda L. Faquin, William C. Caruso, Paul A. Deschler, Daniel G. TI Follicular Dendritic Cell Sarcoma Presenting in the Submandibular Region in an 11 Year-Old SO LARYNGOSCOPE LA English DT Meeting Abstract ID DISEASE; HEAD C1 [Silver, Amanda L.; Deschler, Daniel G.] Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Div Head & Neck Surg, Boston, MA 02114 USA. [Faquin, William C.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Caruso, Paul A.] Massachusetts Eye & Ear Infirm, Dept Radiol, Boston, MA 02114 USA. RP Silver, AL (reprint author), Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Div Head & Neck Surg, Boston, MA 02114 USA. NR 8 TC 6 Z9 6 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2010 VL 120 SU 4 BP S183 EP S183 DI 10.1002/lary.21647 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 709LD UT WOS:000286438600059 PM 21225781 ER PT J AU Song, PC Sung, K Franco, RA AF Song, Phillip C. Sung, Kwang Franco, Ramon A., Jr. TI Voice Outcomes After Endoscopic Injection Laryngoplasty with Hyaluronic Acid Stabilized Gel SO LARYNGOSCOPE LA English DT Meeting Abstract ID VOCAL FOLD; VALIDATION C1 [Song, Phillip C.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Div Laryngol, Boston, MA 02114 USA. RP Song, PC (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Div Laryngol, Boston, MA 02114 USA. EM Phillip_Song@meei.harvard.edu NR 5 TC 14 Z9 14 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2010 VL 120 SU 4 BP S199 EP S199 DI 10.1002/lary.21666 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 709LD UT WOS:000286438600075 PM 21225797 ER PT J AU Tierney, HT Abdul-Aziz, D Kolman, O Deschler, DG AF Tierney, Hien T. Abdul-Aziz, Dunia Kolman, Olga Deschler, Daniel G. TI Surgical Management of Cervical Chyloma Following Parathyroidectomy SO LARYNGOSCOPE LA English DT Meeting Abstract C1 [Tierney, Hien T.] Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Div Head & Neck Surg, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Tierney, HT (reprint author), Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Div Head & Neck Surg, Boston, MA 02114 USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2010 VL 120 SU 4 BP S187 EP S187 DI 10.1002/lary.21651 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 709LD UT WOS:000286438600063 PM 21225785 ER PT J AU Thongsima, S Zurakowski, D Manstein, D AF Thongsima, Siremon Zurakowski, David Manstein, Dieter TI Histological Comparison of Two Different Fractional Photothermolysis Devices Operating at 1,550 nm SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE non-ablative; fractional resurfacing; fractional photothermolysis; Fraxel; infrared lasers; SR1500; SR750; re:store; MTZ; lesion size ID CARBON-DIOXIDE LASER; PHOTOAGED FACIAL SKIN; DIODE-LASER; YAG LASER; RHYTIDES AB Background: There are a wide variety of fractional resurfacing devices that are available and it is important to understand the tissue effect of different devices at different parameters to ensure a well-controlled treatment. Thus, we have chosen to characterize and compare two different fractional laser devices, the Fraxel SR750 and SR1500 (re:store (TM)) (Solta Medical, Hayward, CA). While the SR750 has a fixed focus spot diameter, the SR1500 features an internally controlled zoom optic allowing for an adjustable spot size. Materials and Methods: Exposures were performed in vitro on human skin samples at 37 C. The exposures were performed for the SR750 at pulse energies between 6 and 40 mJ at 125 MTZ/cm(2) with up to 20 passes, and for the SR1500 between 6 and 100 mJ, at Treatment Level 7 and 8 passes. The skin samples then were processed for serial frozen sectioning, stained with Nitro-Blue-Tetrazolium-Chloride (NBTC) and lesion depth and width was determined. Results: Mean lesion depth was significantly greater for lesions treated with the SR1500 laser compared to the SR750 at pulse energies of 6, 10, 30, and 40 mJ (P < 0.001) with a borderline difference at 20 mJ. Mean lesion width was comparable for energies up to 20 mJ and relatively increased for the SR1500 for higher energies. The depth-to-width ratio (DWR) was in general higher for the SR1500, reaching significance at 6, 10, and 40 mJ. Conclusion: We have characterized the lesion depth and width for the for two different Fractional Photothermolysis devices (SR750 vs. SR1500). The device with the adjustable spot size (SR1500 or Fraxel re:store (TM)) provides generally deeper lesions at the same energy level. It remains to be shown whether increased lesion depth improves efficacy for certain clinical applications. Lasers Surg. Med. 42:32-37, 2010. (C) 2010 Wiley-Liss, Inc. C1 [Manstein, Dieter] Harvard Univ, Sch Med, Dept Dermatol, Wellman Ctr Photomed, Boston, MA 02115 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed,Dept Dermatol, Boston, MA 02115 USA. RP Manstein, D (reprint author), Harvard Univ, Sch Med, Dept Dermatol, Wellman Ctr Photomed, Boston, MA 02115 USA. EM dmanstein@partners.org FU Solta Medical FX Contract grant sponsor: Solta Medical.; This study was funded by Solta Medical, Dieter Manstein receives royalties from Solta Medical. NR 21 TC 18 Z9 18 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD JAN PY 2010 VL 42 IS 1 BP 32 EP 37 DI 10.1002/lsm.20882 PG 6 WC Dermatology; Surgery SC Dermatology; Surgery GA 554MA UT WOS:000274437900005 PM 20077494 ER PT J AU Dai, TH Tegos, GP Zhiyentayev, T Mylonakis, E Hamblin, MR AF Dai, Tianhong Tegos, George P. Zhiyentayev, Timur Mylonakis, Eleftherios Hamblin, Michael R. TI Photodynamic Therapy for Methicillin-Resistant Staphylococcus aureus Infection in a Mouse Skin Abrasion Model SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE photodynamic therapy; MRSA; wound infection; skin abrasion; mouse model; bioluminescence imaging; fluorescence imaging ID BIOFILMS; DISEASE AB Background and Objective: Methicillin-resistant Staphylococcus aureus (MRSA) skin infections are now known to be a common and important problem in the Unites States. The objective of this study was to investigate the efficacy of photodynamic therapy (PDT) for the treatment of MRSA infection in skin abrasion wounds using a mouse model. Study Design/Materials and Methods: A mouse model of skin abrasion wound infected with MRSA was developed. Bioluminescent strain of MRSA, a derivative of ATCC 33591, was used to allow the real-time monitoring of the extent of infection in mouse wounds. PDT was performed with the combination of a polyethylenimine (PEI)-ce6 photosensitizer (PS) and non-coherent red light. In vivo fluorescence imaging was carried out to evaluate the effect of photobleaching of PS during PDT. Results: In vivo fluorescence imaging of conjugate PEI-ce6 applied in mice indicated the photobleaching effect of the PS during PDT. PDT induced on average 2.7 log(10) of inactivation of MRSA as judged by loss of bioluminescence in mouse skin abrasion wounds and accelerated the wound healing on average by 8.6 days in comparison to the untreated infected wounds. Photobleaching of PS in the wound was overcome by adding the PS solution in aliquots. Conclusion: PDT may represent an alternative approach for the treatment of MRSA skin infections. Lasers Surg. Med. 42:38-44, 2010. (C) 2010 Wiley-Liss, Inc. C1 [Dai, Tianhong; Tegos, George P.; Zhiyentayev, Timur; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Dai, Tianhong; Tegos, George P.; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Zhiyentayev, Timur] MIT, Dept Chem, Cambridge, MA 02139 USA. [Mylonakis, Eleftherios] Massachusetts Gen Hosp, Dept Infect Dis, Boston, MA 02114 USA. [Hamblin, Michael R.] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, BAR414,40 Blossom St, Boston, MA 02114 USA. EM hamblin@helix.mgh.harvard.edu RI Tegos, George/C-8830-2011; OI Hamblin, Michael/0000-0001-6431-4605 FU NIH [AI050875]; DOD/AFOSR [FA9550-04-1-0079]; Bullock-Wellman Fellowship Award; Massachusetts Technology Transfer Center Award; ASLMS FX Contract grant sponsor: NIH; Contract grant number: AI050875; Contract grant sponsor: DOD/AFOSR; Contract grant number: FA9550-04-1-0079.; This work was supported by the NIH (grant AI050875 to M.R.H.) and DOD/AFOSR FA9550-04-1-0079. T.D. was supported by a Bullock-Wellman Fellowship Award and GPT by a Massachusetts Technology Transfer Center Award. T.D. also received a travel grant from the ASLMS for attending the 29th ASLMS Annual Conference and presenting the preliminary data. This contribution satisfies the condition of the travel grant that a manuscript should be submitted to the LSM within 1 year after the annual conference. We are grateful to Christopher H. Contag, Tayyaba Hasan, and Albert T. McManus for helpful advice and discussion and to Xenogen Corp. (now Caliper Life Sciences) for the gift of XEN31. NR 22 TC 86 Z9 96 U1 1 U2 18 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD JAN PY 2010 VL 42 IS 1 BP 38 EP 44 DI 10.1002/lsm.20887 PG 7 WC Dermatology; Surgery SC Dermatology; Surgery GA 554MA UT WOS:000274437900006 PM 20077489 ER PT J AU Jia, WC Sun, V Choi, B Phung, T Liu, T Nelson, JS Mihm, MC AF Jia, Wangcun Sun, Victor Choi, Bernard Phung, Thuy Liu, Tom Nelson, J. Stuart Mihm, Martin C., Jr. TI SAFE AND EFFECTIVE TOPICAL ANTIANGIOGENIC THERAPY FOR INHIBITING REPERFUSION OF PHOTOCOAGULATED BLOOD VESSELS IN AN ANIMAL MODEL SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 16-18, 2010 CL Phoenix, AZ SP Amer Soc Laser Med & Surg C1 Univ Calif Irvine, Beckman Laser Inst & Med Clin, Irvine, CA 92715 USA. Baylor Coll Med, Houston, TX 77030 USA. Conrex Pharmaceut, Newtown Sq, PA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2010 SU 22 BP 1 EP 2 PG 2 WC Dermatology; Surgery SC Dermatology; Surgery GA 578LL UT WOS:000276295000004 ER PT J AU Huang, LY Timur, Z Dulat, A Yi, X Michael, H AF Huang, Liyi Timur, Zhiyentayev Dulat, Azhibek Yi, Xuan Michael, Hamblin TI PHOTODYNAMIC INACTIVATION OF BACTERIA USING POLYETHYLENIMINE-CHLORIN E6 CONJUGATES. EFFECT OF POLYMER MOLECULAR WEIGHT, SUBSTITUTION RATIO OF CHLORIN E6 AND PH SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 16-18, 2010 CL Phoenix, AZ SP Amer Soc Laser Med & Surg C1 [Huang, Liyi; Timur, Zhiyentayev; Dulat, Azhibek; Yi, Xuan; Michael, Hamblin] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2010 SU 22 BP 6 EP 6 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 578LL UT WOS:000276295000017 ER PT J AU Purschke, M Anderson, R Manstein, D AF Purschke, Martin Anderson, Rox Manstein, Dieter TI THERMAL INJURY PRODUCES REACTIVE OXYGEN SPECIES EFFECTING SURROUNDING NON-HEATED CELLS SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 16-18, 2010 CL Phoenix, AZ SP Amer Soc Laser Med & Surg C1 [Purschke, Martin; Anderson, Rox; Manstein, Dieter] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2010 SU 22 BP 12 EP 13 PG 2 WC Dermatology; Surgery SC Dermatology; Surgery GA 578LL UT WOS:000276295000036 ER PT J AU Phung, T Rojano, R Hsieh, P Mihm, M Nelson, S Benjamin, L AF Phung, Thuy Rojano, Rafael Hsieh, Phyllis Mihm, Martin Nelson, Stuart Benjamin, Laura TI COMBINED PULSED DYE LASER AND TOPICAL RAPAMYCIN TREATMENT INHIBITS CUTANEOUS PATHOLOGICAL ANGIOGENESIS SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 16-18, 2010 CL Phoenix, AZ SP Amer Soc Laser Med & Surg C1 Baylor Coll Med, Houston, TX 77030 USA. Conrex Pharmaceut Inc, Newtown Sq, PA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Calif Irvine, Beckman Laser Inst & Med Clin, Irvine, CA 92715 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2010 SU 22 BP 15 EP 15 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 578LL UT WOS:000276295000043 ER PT J AU Joseph, C Yaroslavsky, A Goyette, T Giles, R Nixon, W AF Joseph, Cecil Yaroslavsky, Anna Goyette, Thomas Giles, Robert Nixon, William TI REFRACTIVE INDICES OF HUMAN AND MOUSE SKIN CANCERS IN TERAHERTZ WAVELENGTH RANGE SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 16-18, 2010 CL Phoenix, AZ SP Amer Soc Laser Med & Surg C1 Univ Massachusetts Lowell, Submillimeter Wave Technol Lab, Lowell, MA USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. USA, Natl Ground Intelligence Ctr, Charlottesville, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2010 SU 22 BP 16 EP 16 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 578LL UT WOS:000276295000047 ER PT J AU Yaroslavsky, A Sheth, S Curry, W Farell, C Barker, F AF Yaroslavsky, Anna Sheth, Samir Curry, William Farell, Christopher Barker, Fred TI IMAGING BRAIN TUMORS USING WIDE-FIELD HIGH-RESOLUTION OPTICAL SYSTEM SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 16-18, 2010 CL Phoenix, AZ SP Amer Soc Laser Med & Surg C1 [Yaroslavsky, Anna; Sheth, Samir; Curry, William; Farell, Christopher; Barker, Fred] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2010 SU 22 BP 18 EP 18 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 578LL UT WOS:000276295000052 ER PT J AU Yaroslavsky, A Mroz, P Park, J Hamblin, M AF Yaroslavsky, Anna Mroz, Pawel Park, Jesung Hamblin, Michael TI COMPARATIVE EVALUATION OF SQUAMOUS CELL CARCINOMA MOUSE MODELS USED FOR TESTING MULTIMODAL OPTICAL IMAGER SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 16-18, 2010 CL Phoenix, AZ SP Amer Soc Laser Med & Surg C1 [Yaroslavsky, Anna; Mroz, Pawel; Park, Jesung; Hamblin, Michael] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2010 SU 22 BP 18 EP 18 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 578LL UT WOS:000276295000053 ER PT J AU Shek, SY Yeung, CK Ho, SGY Chan, NPY Chan, HHL AF Shek, Samantha Y. Yeung, C. K. Ho, Stephanie G. Y. Chan, Nicola P. Y. Chan, Henry H. L. TI NON-INVASIVE CRYOLYPOYSIS FOR BODY CONTOURING IN CHINESE-A FIRST COMMERCIAL EXPERIENCE SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 16-18, 2010 CL Phoenix, AZ SP Amer Soc Laser Med & Surg C1 Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2010 SU 22 BP 20 EP 21 PG 2 WC Dermatology; Surgery SC Dermatology; Surgery GA 578LL UT WOS:000276295000059 ER PT J AU Haedersdal, M Katsnelson, J Sakamoto, FH Farinelli, WA Doukas, AD Tam, J Anderson, RR AF Haedersdal, Merete Katsnelson, Julia Sakamoto, Fernanda H. Farinelli, William A. Doukas, Apostolos D. Tam, Josh Anderson, R. Rox TI PHOTODYNAMIC THERAPY WITH METHYL 5-AMINOLEVULINATE (MAL-PDT) AFTER FRACTIONAL CO2 RESURFACING-AN ANIMAL MODEL SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 16-18, 2010 CL Phoenix, AZ SP Amer Soc Laser Med & Surg C1 Univ Copenhagen, Bispebjerg Hosp, Copenhagen, Denmark. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2010 SU 22 BP 26 EP 27 PG 2 WC Dermatology; Surgery SC Dermatology; Surgery GA 578LL UT WOS:000276295000077 ER PT J AU Haedersdal, M Sakamoto, FH Farinelli, WA Doukas, AG Tam, J Anderson, RR AF Haedersdal, Merete Sakamoto, Fernanda H. Farinelli, William A. Doukas, Apostolos G. Tam, Josh Anderson, R. Rox TI FRACTIONAL CO2 LASER-ASSISTED DRUG DELIVERY SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 16-18, 2010 CL Phoenix, AZ SP Amer Soc Laser Med & Surg C1 [Haedersdal, Merete; Sakamoto, Fernanda H.; Farinelli, William A.; Doukas, Apostolos G.; Tam, Josh; Anderson, R. Rox] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2010 SU 22 BP 28 EP 28 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 578LL UT WOS:000276295000082 ER PT J AU Tannous, Z Konnikov, N Jarell, A AF Tannous, Zeina Konnikov, Nellie Jarell, Abel TI RESPONSE AND ONE YEAR FOLLOW UP OF BASAL CELL CARCINOMAS TREATED WITH PULSED DYE LASER SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 16-18, 2010 CL Phoenix, AZ SP Amer Soc Laser Med & Surg C1 VA Boston Healthcare Syst, Boston, MA USA. UCSF, San Francisco, CA USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2010 SU 22 BP 37 EP 37 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 578LL UT WOS:000276295000109 ER PT J AU Izikson, L Farinelli, W Tannous, Z Sakamoto, F Anderson, RR AF Izikson, Leonid Farinelli, William Tannous, Zeina Sakamoto, Fernanda Anderson, R. Rox TI TREATMENT OF CARBON TATTOOS IN A PORCINE MODEL WITH A NOVEL 758 nm, 500 PICOSECOND LASER SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 16-18, 2010 CL Phoenix, AZ SP Amer Soc Laser Med & Surg C1 [Izikson, Leonid; Farinelli, William; Tannous, Zeina; Sakamoto, Fernanda; Anderson, R. Rox] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2010 SU 22 BP 38 EP 38 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 578LL UT WOS:000276295000110 ER PT J AU Chan, NPY Ho, SGY Yeung, CK Shek, SY Kono, T Chan, HHL AF Chan, Nicola P. Y. Ho, Stephanie G. Y. Yeung, C. K. Shek, Samantha Y. Kono, T. Chan, Henry H. L. TI THE USE OF NON-ABLATIVE FRACTIONAL RESURFACING IN ASIAN ACNE SCAR PATIENTS SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 16-18, 2010 CL Phoenix, AZ SP Amer Soc Laser Med & Surg C1 Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2010 SU 22 BP 43 EP 43 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 578LL UT WOS:000276295000126 ER PT J AU Hamblin, M Wu, QH Huang, YY Chen, ACH Hamblin, MR AF Hamblin, Michael Wu, QiuHe Huang, Ying-Ying Chen, Aaron C-H. Hamblin, Michael R. TI TRANSCRANIAL LOW LEVEL LIGHT THERAPY FOR TRAUMATIC BRAIN INJURY: IN VITRO AND IN VIVO STUDIES SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 16-18, 2010 CL Phoenix, AZ SP Amer Soc Laser Med & Surg C1 [Hamblin, Michael; Wu, QiuHe; Huang, Ying-Ying; Chen, Aaron C-H.; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RI Huang, Ying-ying/G-3153-2011 OI Huang, Ying-ying/0000-0003-3066-6981 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2010 SU 22 BP 58 EP 58 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 578LL UT WOS:000276295000170 ER PT J AU Hoy, C Ben-Yakar, A Everett, WN Kobler, J AF Hoy, Christopher Ben-Yakar, Adela Everett, W. Neil Kobler, James TI TOWARDS CLINICAL ULTRAFAST LASER MICROSURGERY FOR THE TREATMENT OF VOCAL FOLD SCARRING SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 16-18, 2010 CL Phoenix, AZ SP Amer Soc Laser Med & Surg C1 Univ Texas Austin, Austin, TX 78712 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RI Hoy, Christopher/H-5004-2013 OI Hoy, Christopher/0000-0002-4567-6958 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2010 SU 22 BP 69 EP 69 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 578LL UT WOS:000276295000201 ER PT J AU Halmi, B Slayton, M Lyke, S Makin, I Link, D Anderson, RR AF Halmi, Bill Slayton, Michael Lyke, Stephanie Makin, Inder Link, Denise Anderson, R. Rox TI TEMPORARY IMPROVEMENT OF MILD TO MODERATE INFLAMMATORY ACNE SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 16-18, 2010 CL Phoenix, AZ SP Amer Soc Laser Med & Surg C1 Xthetix, Inc Mesa, AZ USA. Arizona State Univ, Tempe, AZ USA. Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2010 SU 22 BP 71 EP 72 PG 2 WC Dermatology; Surgery SC Dermatology; Surgery GA 578LL UT WOS:000276295000209 ER PT J AU Bayer, H Manstein, D Metze, D Luger, TA Laubach, HJ AF Bayer, Hans Manstein, Dieter Metze, Dieter Luger, Thomas Anton Laubach, Hans Joachim TI NONABLATIVE FRACTIONAL PHOTOTHERMOLYSIS FOR DIFFERENT SUBTYPES OF POROKERATOSIS: A CASE SERIES SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 16-18, 2010 CL Phoenix, AZ SP Amer Soc Laser Med & Surg C1 Deutsch Gesell Dermatochirurg, Munster, Germany. Massachusetts Gen Hosp, Wellman Labs Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2010 SU 22 BP 77 EP 78 PG 2 WC Dermatology; Surgery SC Dermatology; Surgery GA 578LL UT WOS:000276295000227 ER PT J AU Luttmann, A Hariri, L Rice, PF Winkler, A Bracamontec, E Sokoloff, M Nguyen, M Barton, J AF Luttmann, Amber Hariri, Lida Rice, Photini Faith Winkler, Amy Bracamontec, Erika Sokoloff, Mitchell Nguyen, Mike Barton, Jennifer TI OPTICAL COHERENCE TOMOGRAPHY IMAGING OF EX VIVO HUMAN KIDNEY SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 16-18, 2010 CL Phoenix, AZ SP Amer Soc Laser Med & Surg C1 Univ Arizona, Tucson, AZ USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2010 SU 22 BP 86 EP 87 PG 2 WC Dermatology; Surgery SC Dermatology; Surgery GA 578LL UT WOS:000276295000255 ER PT B AU Kassarjian, A Martel-Villagran, J Bueno-Horcajadas, A AF Kassarjian, Ara Martel-Villagran, Jose Bueno-Horcajadas, Angel BE Ribes, R Vilanova, JC TI Hip and Pelvis SO LEARNING MUSCULOSKELETAL IMAGING LA English DT Article; Book Chapter ID TRANSIENT OSTEOPOROSIS; FEMOROACETABULAR IMPINGEMENT; ATHLETIC PUBALGIA; MRI FINDINGS; POSTPARTUM; FEATURES; OSTEOPOIKILOSIS; OSTEOARTHRITIS; AVULSION; INJURIES C1 [Kassarjian, Ara] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Martel-Villagran, Jose] Corades SL, Madrid, Spain. [Bueno-Horcajadas, Angel] Hosp Univ Fdn Alcorcon, Madrid, Spain. RP Kassarjian, A (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 25 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-3-540-87999-2 PY 2010 BP 157 EP 178 DI 10.1007/978-3-540-88000-4_8 D2 10.1007/978-3-540-88000-4 PG 22 WC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging SC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging GA BOL30 UT WOS:000276934200008 ER PT J AU Rix, U Rix, LLR Terker, AS Fernbach, NV Hantschel, O Planyavsky, M Breitwieser, FP Herrmann, H Colinge, J Bennett, KL Augustin, M Till, JH Heinrich, MC Valent, P Superti-Furga, G AF Rix, U. Rix, L. L. Remsing Terker, A. S. Fernbach, N. V. Hantschel, O. Planyavsky, M. Breitwieser, F. P. Herrmann, H. Colinge, J. Bennett, K. L. Augustin, M. Till, J. H. Heinrich, M. C. Valent, P. Superti-Furga, G. TI A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells SO LEUKEMIA LA English DT Article DE CML; INNO-406; kinase profiling; chemical proteomics; kinase inhibitor ID TYROSINE KINASE; LYN KINASE; INTERFERING RNA; IMATINIB; DASATINIB; RESISTANT; SENSITIVITY; ACTIVATION; EXPRESSION; NILOTINIB AB Resistance to the BCR-ABL tyrosine kinase inhibitor imatinib poses a pressing challenge in treating chronic myeloid leukemia (CML). This resistance is often caused by point mutations in the ABL kinase domain or by overexpression of LYN. The second-generation BCR-ABL inhibitor INNO-406 is known to inhibit most BCR-ABL mutants and LYN efficiently. Knowledge of its full target spectrum would provide the molecular basis for potential side effects or suggest novel therapeutic applications and possible combination therapies. We have performed an unbiased chemical proteomics native target profile of INNO-406 in CML cells combined with functional assays using 272 recombinant kinases thereby identifying several new INNO-406 targets. These include the kinases ZAK, DDR1/2 and various ephrin receptors. The oxidoreductase NQO2, inhibited by both imatinib and nilotinib, is not a relevant target of INNO-406. Overall, INNO-406 has an improved activity over imatinib but a slightly broader target profile than both imatinib and nilotinib. In contrast to dasatinib and bosutinib, INNO-406 does not inhibit all SRC kinases and most TEC family kinases and is therefore expected to elicit fewer side effects. Altogether, these properties may make INNO-406 a valuable component in the drug arsenal against CML. Leukemia (2010) 24, 44-50; doi:10.1038/leu.2009.228; published online 5 November 2009 C1 [Rix, U.; Rix, L. L. Remsing; Fernbach, N. V.; Hantschel, O.; Planyavsky, M.; Breitwieser, F. P.; Colinge, J.; Bennett, K. L.; Superti-Furga, G.] Austrian Acad Sci, CeMM Ctr Mol Med, A-1090 Vienna, Austria. [Terker, A. S.; Heinrich, M. C.] Portland VA Med Ctr, Div Hematol & Med Oncol, Portland, OR USA. [Terker, A. S.; Heinrich, M. C.] OHSU Knight Canc Inst, Portland, OR USA. [Herrmann, H.; Valent, P.] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Vienna, Austria. [Augustin, M.; Till, J. H.] Millipore UK Ltd, Dundee, Scotland. RP Superti-Furga, G (reprint author), Austrian Acad Sci, CeMM Ctr Mol Med, Lazarettgasse 19, A-1090 Vienna, Austria. EM gsuperti@cemm.oeaw.ac.at RI Superti-Furga, Giulio/F-4755-2015; Hantschel, Oliver/H-4705-2013 OI Superti-Furga, Giulio/0000-0002-0570-1768; Terker, Andrew/0000-0003-1498-9043; Hantschel, Oliver/0000-0001-8569-8169 FU Leukemia and Lymphoma Society [5081-05]; Austrian Federal Ministry for Science and Research (BMWF) [GZ200.142/I-VI/I/2006, GZ200.145/I-VI/I/2006]; Austrian Science Fund (FWF) [P18737-B11]; Austrian National Bank (ONB); Austrian Academy of Sciences (OAW) FX This study was supported by the Leukemia and Lymphoma Society (Grant number 5081-05), the Austrian Federal Ministry for Science and Research (BMWF) under the GEN-AU program (GZ200.142/I-VI/I/2006 and GZ200.145/I-VI/I/2006), the Austrian Science Fund (FWF; P18737-B11), the Austrian National Bank (ONB) and the Austrian Academy of Sciences (OAW). We thank Norbert Venturini for preparation of the SDS-PAGE gels and Florian Grebien for helpful discussions. NR 30 TC 38 Z9 42 U1 0 U2 9 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 J9 LEUKEMIA JI Leukemia PD JAN PY 2010 VL 24 IS 1 BP 44 EP 50 DI 10.1038/leu.2009.228 PG 7 WC Oncology; Hematology SC Oncology; Hematology GA 543KW UT WOS:000273577100006 PM 19890374 ER PT J AU Zumsteg, ZS Ng, AK AF Zumsteg, Zachary S. Ng, Andrea K. TI Mucosa-associated lymphoid tissue lymphoma of the breast: bilateral metachronous presentation SO LEUKEMIA & LYMPHOMA LA English DT Letter ID OF-THE-LITERATURE; B-CELL LYMPHOMA; PROGNOSTIC-FACTORS; RADIATION-THERAPY; MALT LYMPHOMA; OUTCOMES C1 [Zumsteg, Zachary S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiat Oncol, Los Angeles, CA 90095 USA. [Ng, Andrea K.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. [Ng, Andrea K.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Ng, AK (reprint author), 75 Francis St,ASB1-L2, Boston, MA 02115 USA. EM ang@lroc.harvard.edu NR 15 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1042-8194 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PD JAN PY 2010 VL 51 IS 1 BP 168 EP 170 DI 10.3109/10428190903406830 PG 3 WC Oncology; Hematology SC Oncology; Hematology GA 551HO UT WOS:000274197900027 PM 19886841 ER PT S AU Harris, GJ AF Harris, Gordon J. BE Li, K Jia, L Sun, X Fei, M Irwin, GW TI Keynote Address: The 3D Imaging Service at Massachusetts General Hospital: 11 Years Experience SO LIFE SYSTEM MODELING AND INTELLIGENT COMPUTING SE Lecture Notes in Bioinformatics LA English DT Proceedings Paper CT International Conference on Life System Modeling and Simulation/International Conference on Intelligent Computing for Sustainable Energy and Environment CY SEP 17-20, 2010 CL Wuxi, PEOPLES R CHINA SP Shanghai Univ, Queens Univ, Jiangnan Univ, CASS, Syst Modeling & Simulat Techn Comm, China Instrument & Control Soc, Embedded Instrument & Syst Techn Comm C1 [Harris, Gordon J.] Massachusetts Gen Hosp, 3D Imaging Serv, Boston, MA 02114 USA. RP Harris, GJ (reprint author), Massachusetts Gen Hosp, 3D Imaging Serv, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0302-9743 BN 978-3-642-15614-4 J9 LECT N BIOINFORMAT PY 2010 VL 6330 BP 27 EP 32 DI 10.1007/978-3-642-15615-1_4 PG 6 WC Biochemical Research Methods; Computer Science, Artificial Intelligence; Computer Science, Information Systems; Mathematical & Computational Biology SC Biochemistry & Molecular Biology; Computer Science; Mathematical & Computational Biology GA BUI52 UT WOS:000289457200004 ER PT B AU Sarder, P Zhang, WX Cobb, JP Nehorai, A AF Sarder, Pinaki Zhang, Weixiong Cobb, J. Perren Nehorai, Arye BE Yu, PS Han, J Faloutsos, C TI Gene Reachability Using Page Ranking on Gene Co-expression Networks SO LINK MINING: MODELS, ALGORITHMS, AND APPLICATIONS LA English DT Article; Book Chapter AB We modify the Google Page-Rank algorithm, which is primarily used for ranking web pages, to analyze the gene reachability in complex gene co-expression networks. Our modification is based on the average connections per gene. We propose a new method to compute the metric of average connections per gene, inspired by the Page-Rank algorithm. We calculate this average as eight for human genome data and three to seven for yeast genome data. Our algorithm provides clustering of genes. The proposed analogy between web pages and genes may offer a new way to interpret gene networks. C1 [Nehorai, Arye] Washington Univ, Dept Elect & Syst Engn, St Louis, MO 63130 USA. [Cobb, J. Perren] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Sarder, Pinaki; Zhang, Weixiong] Washington Univ, Dept Comp Sci & Engn, St Louis, MO 63130 USA. [Zhang, Weixiong] Washington Univ, Dept Genet, St Louis, MO 63130 USA. RP Nehorai, A (reprint author), Washington Univ, Dept Elect & Syst Engn, St Louis, MO 63130 USA. EM nehorai@ese.wustl.edu NR 9 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-6514-1 PY 2010 BP 557 EP 568 DI 10.1007/978-1-4419-6515-8_21 D2 10.1007/978-1-4419-6515-8 PG 12 WC Computer Science, Artificial Intelligence; Computer Science, Information Systems; Computer Science, Interdisciplinary Applications SC Computer Science GA BRH57 UT WOS:000282721500021 ER PT S AU Hilderbrand, SA AF Hilderbrand, Scott A. BE Papkovsky, DB TI Labels and Probes for Live Cell Imaging: Overview and Selection Guide SO LIVE CELL IMAGING: METHODS AND PROTOCOLS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Fluorescence; fluorescent labels; fluorogenic probes; sensors; microscopy; imaging ID INFRARED FLUORESCENCE PROBE; SEMICONDUCTOR QUANTUM DOTS; NITRIC-OXIDE DETECTION; FREE CLICK CHEMISTRY; AMINO-ACID-SEQUENCE; IN-VIVO; LIVING CELLS; HYDROGEN-PEROXIDE; BIOLOGICAL APPLICATIONS; COPPER-FREE AB Fluorescence imaging is all important tool for molecular biology research. There is a wide array of fluorescent labels and activatable probes available for investigation of biochemical processes at a molecular level in living cells. Given the large number of potential imaging agents and numerous variables that call impact the utility of these fluorescent materials for imaging, selection of the appropriate probes call be a difficult task. In this report an overview of fluorescent imaging agents and details oil their optical and physical properties that can impact their function are presented. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Mol Imaging Res, Charlestown, MA USA. RP Hilderbrand, SA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Mol Imaging Res, Charlestown, MA USA. NR 140 TC 9 Z9 9 U1 0 U2 12 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-60761-403-6 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2010 VL 591 BP 17 EP 45 DI 10.1007/978-1-60761-404-3_2 D2 10.1007/978-1-60761-404-3 PG 29 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BNC63 UT WOS:000274162900002 PM 19957122 ER PT J AU Nurok, M Eslick, I Carvalho, CRR Costabel, U D'Armiento, J Glanville, AR Harari, S Henske, EP Inoue, Y Johnson, SR Lacronique, J Lazor, R Moss, J Ruoss, SJ Ryu, JH Seyama, K Watz, H Xu, KF Hohmann, EL Moss, F AF Nurok, Michael Eslick, Ian Carvalho, Carlos R. R. Costabel, Ulrich D'Armiento, Jeanine Glanville, Allan R. Harari, Sergio Henske, Elizabeth P. Inoue, Yoshikazu Johnson, Simon R. Lacronique, Jacques Lazor, Romain Moss, Joel Ruoss, Stephen J. Ryu, Jay H. Seyama, Kuniaki Watz, Henrik Xu, Kai-Feng Hohmann, Elizabeth L. Moss, Frank TI The International LAM Registry: A Component of an Innovative Web-Based Clinician, Researcher, and Patient-Driven Rare Disease Research Platform SO LYMPHATIC RESEARCH AND BIOLOGY LA English DT Article ID TUBEROUS SCLEROSIS COMPLEX; PULMONARY LYMPHANGIOLEIOMYOMATOSIS; LUNG TRANSPLANTATION; WOMEN AB Background: A relative friability to capture a sufficiently large patient population in any one geographic location has traditionally limited research into rare diseases. Methods and Results: Clinicians interested in the rare disease lymphangioleiomyomatosis (LAM) have worked with the LAM Treatment Alliance, the MIT Media Lab, and Clozure Associates to cooperate in the design of a state-of-the-art data coordination platform that can be used for clinical trials and other research focused on the global LAM patient population. This platform is a component of a set of web-based resources, including a patient self-report data portal, aimed at accelerating research in rare diseases in a rigorous fashion. Conclusions: Collaboration between clinicians, researchers, advocacy groups, and patients can create essential community resource infrastructure to accelerate rare disease research. The International LAM Registry is an example of such an effort. C1 [Nurok, Michael] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Surg Crit Care, Boston, MA 02115 USA. [Nurok, Michael] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiac, Boston, MA 02115 USA. [Nurok, Michael] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Thorac Anesthesia, Boston, MA 02115 USA. [Eslick, Ian; Moss, Frank] MIT, Media Lab, Cambridge, MA 02139 USA. [Carvalho, Carlos R. R.] Univ Sao Paulo, Heart Inst InCor, Div Pulm, Sao Paulo, Brazil. [Costabel, Ulrich] Ruhrlandklin Univ Klinikum, Dept Pneumol Allergy, Essen, Germany. [D'Armiento, Jeanine] Columbia Univ Coll Phys & Surg, Dept Med, Div Pulm & Crit Care, New York, NY 10032 USA. [Glanville, Allan R.] St Vincents Hosp, Div Thorac Med, Lung Transplantat Grp, Darlinghurst, NSW 2010, Australia. [Harari, Sergio] Osped San Giuseppe, Unita Pneumol & Terapia Semiintens Resp, Milan, Italy. [Henske, Elizabeth P.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Ctr LAM Res & Clin Care, Boston, MA 02115 USA. [Henske, Elizabeth P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Inoue, Yoshikazu] Natl Hosp Org Kinki Chuo, Chest Med Ctr, Clin Res Ctr, Dept Diffuse Lung Dis & Resp Failure, Osaka, Japan. [Johnson, Simon R.] Univ Nottingham, Div Therapeut & Mol Med, Nottingham NG7 2RD, England. [Johnson, Simon R.] Univ Nottingham, Nottingham Resp Biomed Res Unit, Nottingham NG7 2RD, England. [Lacronique, Jacques] Hop Cochin, Serv Pneumol, F-75674 Paris, France. [Lazor, Romain] CHU Vaudois, Clin Interstitial & Rare Lung Dis, Dept Resp Med, CH-1011 Lausanne, Switzerland. [Moss, Joel] NHLBI, Translat Med Branch, NIH, Bethesda, MD 20892 USA. [Ruoss, Stephen J.] Stanford Univ, Med Ctr, Div Pulm & Crit Care Med, Stanford, CA 94305 USA. [Ryu, Jay H.] Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN USA. [Seyama, Kuniaki] Juntendo Univ, Sch Med, Dept Resp Med, Tokyo 113, Japan. [Watz, Henrik] Krankenhaus Grosshansdorf, Zentrum Pneumol & Thoraxchirurg, Pneumol Forsch Inst GmbH, D-2070 Grosshansdorf, Germany. [Hohmann, Elizabeth L.] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Resp Med, Beijing 100037, Peoples R China. [Moss, Frank] Partners Healthcare, Partners Human Res Comm, Boston, MA USA. RP Nurok, M (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Surg Crit Care, 75 Francis St, Boston, MA 02115 USA. EM mnurok@partners.org RI Carvalho, Carlos/H-2161-2011; OI Harari, Sergio/0000-0001-8629-7391; Johnson, Simon/0000-0002-9837-2763 FU LAM Treatment Alliance [501(c)(3)] FX Source of Support: The LAM Treatment Alliance, 501(c)(3) NR 16 TC 7 Z9 7 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1539-6851 J9 LYMPHAT RES BIOL JI Lymphat. Res. Biol. PY 2010 VL 8 IS 1 BP 81 EP 87 DI 10.1089/lrb.2009.0028 PG 7 WC Medicine, Research & Experimental; Physiology SC Research & Experimental Medicine; Physiology GA 598WO UT WOS:000277870500011 PM 20235890 ER PT S AU Simon, DJ AF Simon, David J. BE DeStrooper, B Christen, Y TI Interactions between microRNAs and Transcription Factors in the Development and Function of the Nervous System SO MACRO-ROLES FOR MICRORNAS IN THE LIFE AND DEATH OF NEURONS SE Research and Perspectives in Neurosciences LA English DT Proceedings Paper CT Conference on Macro-roles for microRNAs in the Life and Death of Neurons CY APR 20, 2009 CL Paris, FRANCE ID CAENORHABDITIS-ELEGANS; C-ELEGANS; DROSOPHILA; PROTEIN; LET-7; DIFFERENTIATION; EXPRESSION; REPRESSION; NEURONS; TARGETS AB The formation and maturation of the nervous system requires precise control over the magnitude and timing of gene expression. MicroRNAs have emerged as potent regulators of translation, with roles ranging from the initial establishment of connectivity to activity-dependent refinement of the synapse. Many of the microRNA targets identified in the nervous system are themselves transcription factors, adding an additional layer of complexity in gene expression. Moreover, microRNAs and transcription factors are often embedded in feedback loops that reinforce changes in gene expression. These interactions lie at the heart of many cell fate decisions during the development of the nervous system. In addition, translational control of transcription factor abundance plays a prominent role in the regulation of retrograde signaling at neuromuscular synapses of both C elegans and Drosophila. C1 Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. RP Simon, DJ (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, 185 Cambridge St,Simches 7, Boston, MA 02114 USA. NR 38 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0945-6082 BN 978-3-642-04297-3 J9 RES PER NEUROSCI JI Res. Perspect. Neurosci. PY 2010 BP 19 EP 26 DI 10.1007/978-3-642-04298-0_3 PG 8 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BRE01 UT WOS:000282460400003 ER PT B AU Noble, VE Liteplo, A Brown, DFM AF Noble, Vicki E. Liteplo, Andrew Brown, David F. M. BE Jorres, A Ronco, C Kellum, JA TI Renal Ultrasound SO MANAGEMENT OF ACUTE KIDNEY PROBLEMS LA English DT Article; Book Chapter ID ULTRASONOGRAPHY; SONOGRAPHY; UROGRAPHY; DIAGNOSIS; TRAUMA; CT; US C1 [Noble, Vicki E.; Liteplo, Andrew; Brown, David F. M.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. RP Brown, DFM (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, 55 Fruit St, Boston, MA 02114 USA. EM vnoble@partners.org; dbrown2@partners.org NR 17 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-3-540-69413-7 PY 2010 BP 109 EP 116 DI 10.1007/978-3-540-69441-0_3.3 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA BNL64 UT WOS:000274865400011 ER PT B AU Greenberg, D AF Greenberg, Donna BE Jatoi, I Kaufmann, M TI Psychological Support for the Breast Cancer Patient SO MANAGEMENT OF BREAST DISEASES LA English DT Article; Book Chapter ID RANDOMIZED CONTROLLED-TRIAL; EXPRESSIVE GROUP-THERAPY; QUALITY-OF-LIFE; PLACEBO-CONTROLLED TRIAL; HOT FLASHES; PERIMENOPAUSAL WOMEN; POSTMENOPAUSAL WOMEN; ADJUVANT THERAPY; CHRONIC-FATIGUE; DOUBLE-BLIND C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA. RP Greenberg, D (reprint author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA. EM dbgreenberg@bics.bwh.harvard.edu NR 60 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-3-540-69742-8 PY 2010 BP 541 EP 549 DI 10.1007/978-3-540-69743-5_28 D2 10.1007/978-3-540-69743-5 PG 9 WC Obstetrics & Gynecology; Pathology SC Obstetrics & Gynecology; Pathology GA BNL35 UT WOS:000274860000028 ER PT B AU Strasser-Weippl, K Goss, PE AF Strasser-Weippl, Kathrin Goss, Paul E. BE Jatoi, I Kaufmann, M TI Chemoprevention of Breast Cancer SO MANAGEMENT OF BREAST DISEASES LA English DT Article; Book Chapter ID BONE-MINERAL DENSITY; HEALTHY POSTMENOPAUSAL WOMEN; ADJUVANT TAMOXIFEN THERAPY; LIAROZOLE FUMARATE R85246; RANDOMIZED CLINICAL-TRIAL; INTERMEDIATE END-POINTS; INDUCED MAMMARY-TUMORS; BOWEL PROJECT P-1; AROMATASE INHIBITORS; ANTIESTROGEN EM-800 C1 [Goss, Paul E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. [Strasser-Weippl, Kathrin] Wilhelminen Hosp, Vienna, Austria. RP Goss, PE (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. EM pgoss@partners.org NR 116 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-3-540-69742-8 PY 2010 BP 569 EP 583 DI 10.1007/978-3-540-69743-5_30 D2 10.1007/978-3-540-69743-5 PG 15 WC Obstetrics & Gynecology; Pathology SC Obstetrics & Gynecology; Pathology GA BNL35 UT WOS:000274860000030 ER PT B AU Sullivan, T Taghian, AG AF Sullivan, T. Taghian, A. G. BE Belkacemi, Y Miramanoff, RO Ozsahin, M TI Tubular carcinoma of the breast SO MANAGEMENT OF RARE ADULT TUMOURS LA English DT Article; Book Chapter ID LYMPH-NODE METASTASES; STAGE-I; CANCER; THERAPY; WOMEN; IRRADIATION; RECURRENCE; TAMOXIFEN; OLDER; PURE C1 [Sullivan, T.; Taghian, A. G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol,Breast Serv, Boston, MA 02114 USA. RP Sullivan, T (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol,Breast Serv, 100 Blossom St, Boston, MA 02114 USA. NR 37 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG FRANCE PI PARIS PA 1 RUE PAUL CEZANNE, 75008 PARIS, FRANCE BN 978-2-287-92245-9 PY 2010 BP 341 EP 348 PG 8 WC Oncology SC Oncology GA BQJ58 UT WOS:000281173400039 ER PT B AU Martin, SI Fishman, JA AF Martin, Stanley I. Fishman, Jay A. BE Kleinberg, M TI Viruses SO MANAGING INFECTIONS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES SE Contemporary Hematology LA English DT Article; Book Chapter DE Antivirals; Cytomegalovirus; Herpes viruses; Hematological malignancy; Respiratory viruses; Epstein-Barr virus; Polyoma virus; Adenovirus; Viral infections ID BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; POLYMERASE-CHAIN-REACTION; RESPIRATORY SYNCYTIAL VIRUS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; VARICELLA-ZOSTER-VIRUS; HERPES-SIMPLEX ENCEPHALITIS; HUMAN METAPNEUMOVIRUS INFECTION; CHRONIC LYMPHOCYTIC-LEUKEMIA; CHRONIC HEPATITIS-B AB Viral infections are an important and often unrecognized component of disease in immunocompromised patients. The diagnosis and management of viral infections have expanded largely because of new quantitative molecular diagnostic assays. Well-recognized pathogens such as herpes simplex virus (HSV), cytomegalovirus (CMV), and respiratory viruses have been joined by newly recognized pathogens such as BK virus. human herpesvirus-6 (HHV-6), and human metapneumovirus in this highly susceptible patient population. The role of Epstein-Barr virus (EBV) and Human herpesvirus-8 (HHV-8) in lymphoproliferative diseases also continue to be clarified. As a result, the management of viral infections in patients with hematologic malignancies continues to be a growing challenge for the clinician. C1 [Martin, Stanley I.] Ohio State Univ, Med Ctr, Div Infect Dis, Transplant Infect Dis Serv, Columbus, OH 43210 USA. [Fishman, Jay A.] Harvard Univ, Sch Med, Boston, MA USA. [Fishman, Jay A.] Massachusetts Gen Hosp, Transplant Infect Dis & Compromised Host Program, Boston, MA 02114 USA. [Fishman, Jay A.] MGH Transplantat Ctr, Boston, MA USA. RP Martin, SI (reprint author), Ohio State Univ, Med Ctr, Div Infect Dis, Transplant Infect Dis Serv, Columbus, OH 43210 USA. NR 287 TC 14 Z9 14 U1 1 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-986-4 J9 CONTEMP HEMATOL PY 2010 BP 15 EP 69 DI 10.1007/978-1-59745-415-5_2 D2 10.1007/978-1-59745-415-5 PG 55 WC Oncology; Hematology; Infectious Diseases SC Oncology; Hematology; Infectious Diseases GA BMR57 UT WOS:000273399700002 ER PT B AU Forrest, GN Kleinberg, M AF Forrest, Graeme N. Kleinberg, Michael BE Kleinberg, M TI Issues in Anti-infective Management SO MANAGING INFECTIONS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES SE Contemporary Hematology LA English DT Article; Book Chapter DE Anti-infective management; Cost-effectiveness; Drug interactions; Drug safety; Computerized support; HIV-related malignancies ID VANCOMYCIN-RESISTANT ENTEROCOCCI; NON-HODGKINS-LYMPHOMA; ANTIMICROBIAL STEWARDSHIP PROGRAMS; ACTIVE ANTIRETROVIRAL THERAPY; CONVENTIONAL AMPHOTERICIN-B; INFECTIOUS-DISEASES-SOCIETY; POSITIVE BLOOD CULTURES; STEM-CELL TRANSPLANT; STAPHYLOCOCCUS-AUREUS; NEUTROPENIC PATIENTS AB Early antimicrobial therapy to patients with hematologic malignancies has been shown to improve their survival and outcomes. Structured properly, an institution-wide anti-infective program can improve the efficient management of infections with minimized toxicities in a cost-effective manner. Program objectives should encompass standardized approaches to antimicrobial prescribing, systems that can predict potentially dangerous therapeutic toxicities, and monitoring to assess outcome successes. This is ever more critical with the emergence of anti microbial resistant organisms, newer expensive antimicrobial agents, and the significant drug interactions between anti-infectives and chemotherapeutic agents. Patients with HIV-associated malignancies represent a special challenge because of the complexities involved in managing two concurrent diseases and the potential for drug interactions potentiating toxicities between highly active antiretroviral therapy (HAART) and many chemotherapy agents. C1 [Forrest, Graeme N.] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Div Infect Dis, Portland, OR 97239 USA. [Kleinberg, Michael] Univ Maryland, Sch Med, Infect Dis Sect, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA. RP Forrest, GN (reprint author), Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Div Infect Dis, 3701 SW US Vet Hosp Rd P3ID, Portland, OR 97239 USA. NR 72 TC 0 Z9 0 U1 0 U2 1 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-986-4 J9 CONTEMP HEMATOL PY 2010 BP 345 EP 364 D2 10.1007/978-1-59745-415-5 PG 20 WC Oncology; Hematology; Infectious Diseases SC Oncology; Hematology; Infectious Diseases GA BMR57 UT WOS:000273399700013 ER PT B AU Trakatelli, M de Vries, E Katsanos, G Tzachanis, D Eggermont, A AF Trakatelli, Myrto de Vries, Esther Katsanos, G. Tzachanis, Dimitris Eggermont, Alexander BE Stockfleth, E Rosen, T Shumack, S TI Cutaneous Malignant Melanoma SO MANANGING SKIN CANCER LA English DT Article; Book Chapter ID RANDOMIZED PHASE-III; SENTINEL-NODE BIOPSY; COOPERATIVE-ONCOLOGY-GROUP; HIGH-RISK MELANOMA; DOSE RECOMBINANT INTERLEUKIN-2; TEMOZOLOMIDE PLUS THALIDOMIDE; ALLOGENEIC-TUMOR VACCINE; AMERICAN JOINT COMMITTEE; ACTIVATED KILLER-CELLS; IN-TRANSIT METASTASES C1 [Trakatelli, Myrto] Papageorgiou Hosp, Dept Dermatol & Venerol, Thessaloniki 56403, Greece. [de Vries, Esther] Erasmus MC, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands. [Eggermont, Alexander] Erasmus Univ, Med Ctr, Dept Surg Oncol, Dr Daniel Den Hoed Canc Ctr, Rotterdam, Netherlands. [Tzachanis, Dimitris] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Med Oncol,Dept Adult Oncol, Boston, MA 02115 USA. RP Trakatelli, M (reprint author), Papageorgiou Hosp, Dept Dermatol & Venerol, Ring Rd N Efkarpia, Thessaloniki 56403, Greece. EM mtrakatelli@hotmail.com; e.devries@erasmusmc.nl; dtzachanis@bidmc.harvard.edu; a.m.m.eggermont@erasmusmc.nl NR 235 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-3-540-79346-5 PY 2010 BP 79 EP 110 DI 10.1007/978-3-540-79347-2_6 D2 10.1007/978-3-540-79347-2 PG 32 WC Oncology; Dermatology SC Oncology; Dermatology GA BNK77 UT WOS:000274813400006 ER PT B AU Joseph, J AF Joseph, Jacob BE Joseph, J TI MAST CELLS AND CARDIOVASCULAR DISEASE Introduction SO MAST CELLS AND CARDIOVASCULAR DISEASE LA English DT Editorial Material; Book Chapter ID PROGENITORS; EFFECTOR; MICE C1 [Joseph, Jacob] Boston Univ, Sch Med, MIT, Heart Failure Program,VA Boston Healthcare, Boston, MA 02215 USA. RP Joseph, J (reprint author), VA Boston Healthcare Syst, Cardiol Sect 111, 1400 VFW Pkwy, W Roxbury, MA 02132 USA. NR 18 TC 0 Z9 0 U1 0 U2 0 PU NOVA SCIENCE PUBLISHERS, INC PI HAUPPAUGE PA 400 OSER AVE, STE 1600, HAUPPAUGE, NY 11788-3635 USA BN 978-1-61668-593-5 PY 2010 BP 1 EP 4 PG 4 WC Cardiac & Cardiovascular Systems; Immunology SC Cardiovascular System & Cardiology; Immunology GA BSE60 UT WOS:000284287300001 ER PT B AU Joseph, J AF Joseph, Jacob BE Joseph, J TI Mast Cells: Masters of Ceremony in Cardiovascular Disease? SO MAST CELLS AND CARDIOVASCULAR DISEASE LA English DT Article; Book Chapter ID HEART-FAILURE C1 [Joseph, Jacob] Harvard Univ, Sch Med, Boston Univ, MIT,Sch Med, Cambridge, MA 02138 USA. [Joseph, Jacob] VA Boston Healthcare, Heart Failure Program, Boston, MA USA. RP Joseph, J (reprint author), VA Boston Healthcare Syst, Cardiol Sect 111, 1400 VFW Pkwy, W Roxbury, MA 02132 USA. EM jacob.joseph@bmc.org; jacob.joseph@bmc.org NR 10 TC 0 Z9 0 U1 0 U2 0 PU NOVA SCIENCE PUBLISHERS, INC PI HAUPPAUGE PA 400 OSER AVE, STE 1600, HAUPPAUGE, NY 11788-3635 USA BN 978-1-61668-593-5 PY 2010 BP 243 EP 247 PG 5 WC Cardiac & Cardiovascular Systems; Immunology SC Cardiovascular System & Cardiology; Immunology GA BSE60 UT WOS:000284287300013 ER PT S AU Hamblin, MR Waynant, RW Anders, J AF Hamblin, Michael R. Waynant, Ronald W. Anders, Juanita BE Hamblin, MR Waynant, RW Anders, J TI Introduction SO MECHANISMS FOR LOW-LIGHT THERAPY V SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Mechanisms for Low-Light Therapy V CY JAN 23-25, 2010 CL San Francisco, CA SP SPIE C1 [Hamblin, Michael R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-7948-8 J9 PROC SPIE PY 2010 VL 7552 BP IX EP IX PG 1 WC Engineering, Biomedical; Optics; Physics, Applied SC Engineering; Optics; Physics GA BSS03 UT WOS:000285576000001 ER PT S AU Huang, YY Chen, ACH Sharma, SK Wu, QH Hamblin, MR AF Huang, Ying-Ying Chen, Aaron C-H Sharma, Sulbha K. Wu, Qiuhe Hamblin, Michael R. BE Hamblin, MR Waynant, RW Anders, J TI Comparison of cellular responses induced by low level light in different cell types SO MECHANISMS FOR LOW-LIGHT THERAPY V SE Proceedings of SPIE-The International Society for Optical Engineering LA English DT Proceedings Paper CT Conference on Mechanisms for Low-Light Therapy V CY JAN 23-25, 2010 CL San Francisco, CA SP SPIE DE biostimulation; low level laser therapy; mitochondria; cytochrome c oxidase; reactive oxygen species; nuclear factor kappa B; ATP ID HELIUM-NEON LASER; RAT-LIVER MITOCHONDRIA; HIPPOCAMPAL-NEURONS; IRRADIATED INVITRO; IN-VITRO; SURVIVAL; PROLIFERATION; INCREASE; 2-MERCAPTOETHANOL; SERUM AB Discoveries are rapidly being made in multiple laboratories that shed "light" on the fundamental molecular and cellular mechanisms underlying the use of low level light therapy (LLLT) in vitro, in animal models and in clinical practice. Increases in cellular levels of respiration, in cytochrome c oxidase activity, in ATP levels and in cyclic AMP have been found. Increased expression of reactive oxygen species and release of nitric oxide have also been shown. In order for these molecular changes to have a major effect on cell behavior, it is likely that various transcription factors will be activated, possibly via different signal transduction pathways. In this report we compare and contrast the effects of LLLT in vitro on murine embryonic fibroblasts, primary cortical neurons, cardiomyocytes and bone-marrow derived dendritic cells. We also examined two human cell lines, HeLa cancer cells and HaCaT keratinocytes. The effects of 810-nm near-infra-red light delivered at low and high fluences were addressed. Reactive oxygen species generation, transcription factor activation and ATP increases are reported. The data has led to the hypothesis that cells with a high level of mitochondrial activity (mitochondrial membrane potential) have a higher response to light than cells with low mitochondrial activity. C1 [Huang, Ying-Ying; Chen, Aaron C-H; Sharma, Sulbha K.; Wu, Qiuhe; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, BAR414,40 Blossom St, Boston, MA 02114 USA. EM hamblin@helix.mgh.harvard.edu; hamblin@helix.mgh.harvard.edu OI Hamblin, Michael/0000-0001-6431-4605 NR 18 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-7948-8 J9 P SOC PHOTO-OPT INS PY 2010 VL 7552 AR 75520A DI 10.1117/12.841018 PG 10 WC Engineering, Biomedical; Optics; Physics, Applied SC Engineering; Optics; Physics GA BSS03 UT WOS:000285576000006 ER PT S AU Wu, QH Huang, YY Dhital, S Sharma, SK Chen, ACH Whalen, MJ Hamblin, MR AF Wu, Qiuhe Huang, Ying-Ying Dhital, Saphala Sharma, Sulbha K. Chen, Aaron C-H Whalen, Michael J. Hamblin, Michael R. BE Hamblin, MR Waynant, RW Anders, J TI Low level laser therapy for traumatic brain injury SO MECHANISMS FOR LOW-LIGHT THERAPY V SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Mechanisms for Low-Light Therapy V CY JAN 23-25, 2010 CL San Francisco, CA SP SPIE DE photobiomodulation; low level laser therapy; traumatic brain injury; mouse model; neurological testing ID CYTOCHROME-C-OXIDASE; IR RADIATION; MICE AB Low level laser (or light) therapy (LLLT) has been clinically applied for many indications in medicine that require the following processes: protection from cell and tissue death, stimulation of healing and repair of injuries, and reduction of pain, swelling and inflammation. One area that is attracting growing interest is the use of transcranial LLLT to treat stroke and traumatic brain injury (TBI). The fact that near-infrared light can penetrate into the brain would allow non-invasive treatment to be carried out with a low likelihood of treatment-related adverse events. LLLT may have beneficial effects in the acute treatment of brain damage injury by increasing respiration in the mitochondria, causing activation of transcription factors, reducing key inflammatory mediators, and inhibiting apoptosis. We tested LLLT in a mouse model of TBI produced by a controlled weight drop onto the skull. Mice received a single treatment with 660-nm, 810-nm or 980-nm laser (36 J/cm(2)) four hours post-injury and were followed up by neurological performance testing for 4 weeks. Mice with moderate to severe TBI treated with 660-nm and 810-nm laser had a significant improvement in neurological score over the course of the follow-up and histological examination of the brains at sacrifice revealed less lesion area compared to untreated controls. Further studies are underway. C1 [Wu, Qiuhe; Huang, Ying-Ying; Dhital, Saphala; Sharma, Sulbha K.; Chen, Aaron C-H; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, BAR414,40 Blossom St, Boston, MA 02114 USA. EM Hamblin@helix.mgh.harvard.edu; Hamblin@helix.mgh.harvard.edu OI Dhital, Saphala/0000-0001-5566-0733; Hamblin, Michael/0000-0001-6431-4605 NR 13 TC 3 Z9 3 U1 2 U2 6 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-7948-8 J9 PROC SPIE PY 2010 VL 7552 AR 755206 DI 10.1117/12.841014 PG 8 WC Engineering, Biomedical; Optics; Physics, Applied SC Engineering; Optics; Physics GA BSS03 UT WOS:000285576000004 ER PT J AU Chen, J Li, J Lim, FC Wu, Q Douek, DC Scott, DK Ravussin, E Hsu, HC Jazwinski, SM Mountz, JD AF Chen, Jian Li, Jun Lim, Fei Chu Wu, Qi Douek, Daniel C. Scott, Donald K. Ravussin, Eric Hsu, Hui-Chen Jazwinski, S. Michal Mountz, John D. CA Louisiana Healthy Aging Study TI Maintenance of naive CD8 T cells in nonagenarians by leptin, IGFBP3 and T3 SO MECHANISMS OF AGEING AND DEVELOPMENT LA English DT Article DE Nonagenarians; Naive CD8; TREC; IGFBP3; Leptin; T3 ID RECENT THYMIC EMIGRANTS; RECEPTOR EXCISION CIRCLES; FACTOR-BINDING PROTEIN-3; HEMATOPOIETIC STEM-CELL; IMMUNE-SYSTEM; HUMAN LONGEVITY; AGE; EXPRESSION; IMMUNOSENESCENCE; APOPTOSIS AB Research into the age-associated decline in the immune system has focused on the factors that contribute to the accumulation of senescent CD8 T cells. Less attention has been paid to the non-immune factors that may maintain the pool of naive CD8 T cells. Here, we analyzed the status of the naive CD8 T-cell Population in healthy nonagenarians (>= 90-year-old), old (60-79-year-old), and young (20-34-year-old) subjects Naive CD8 T cells were defined as CD28(+)CD95(-) as this phenotype showed a strong co-expression of the CD45RA(+), CD45RO(-), and CD 127(+) phenotypes. Although there was an age-associated decline in the percentage of CD28(+)CD95(-)CD8 T cells, the healthy nonagenarians maintained a pool of naive CD28(+)CD95(-) cells that contained T-cell receptor excision circles (TREC)(+) cells The percentages of naive CD28(+)CD95(-) CD8 T cells in the nonagenarians correlated with the sera levels of insulin-like growth factor binding protein 3 (IGFBP3) and leptin Higher levels of triiodothyronine (T3) negatively correlated with the accumulation of TREC(-)CD28(-)CD95(+) CD8 T cells from nonagenarians These results Suggest a model in which IGFBP3. leptin and T3 act as non-immune factors to maintain a larger pool of naive CD8 T cells in healthy nonagenarians Published by Elsevier Ireland Ltd. C1 [Mountz, John D.] Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA. [Douek, Daniel C.] NIH, Vaccine Res Ctr, Bethesda, MD USA. [Scott, Donald K.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA. [Jazwinski, S. Michal] Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70118 USA. [Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Mountz, JD (reprint author), Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, 1825 Univ Blvd,Room 307 Shelby Bldg, Birmingham, AL 35294 USA. RI Ermolao, Andrea/I-5463-2012 FU NIH/NIA [PO1 AG022064-01A1]; Millennium Trust [HEF(2001-06)-02] FX This research was supported by NIH/NIA PO1 AG022064-01A1 and by the Louisiana Board of Regents through the Millennium Trust Health Excellence Fund [HEF(2001-06)-02] We thank the Recruitment and Clinical Testing Core at the Pennington Biomedical Research Center for collecting the blood samples and the Sampling and Data Management Core at Louisiana State University Health Sciences Center for storage, quality control, and analyses of the data presented herein We thank Dr. David Allison for providing advice on Statistical Analysis. We also acknowledge Ms. Enid Keyser and at the Rheumatic Diseases Core Center - Analytic and Preparative Flow Cytometry Facility at University of Alabama-Birmingham for operating the FACS instrument, Dr. Fiona Hunter for expert edition of the manuscript, and Ms. Carol Humber for excellent secretarial assistance. NR 59 TC 19 Z9 20 U1 0 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0047-6374 J9 MECH AGEING DEV JI Mech. Ageing Dev. PD JAN PY 2010 VL 131 IS 1 BP 29 EP 37 DI 10.1016/j.mad.2009.11.003 PG 9 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 560ZU UT WOS:000274945300005 PM 19941883 ER PT J AU Xiang, M Fan, J Fan, J AF Xiang, Meng Fan, Janet Fan, Jie TI Association of Toll-Like Receptor Signaling and Reactive Oxygen Species: A Potential Therapeutic Target for Posttrauma Acute Lung Injury SO MEDIATORS OF INFLAMMATION LA English DT Review ID MULTIPLE ORGAN FAILURE; NF-KAPPA-B; RESPIRATORY-DISTRESS SYNDROME; NEUTROPHIL NADPH OXIDASE; MEDIATES HEPATIC-INJURY; GROUP BOX-1 PROTEIN; TLR2 UP-REGULATION; HEMORRHAGIC-SHOCK; INNATE IMMUNITY; NAD(P)H OXIDASE AB Acute lung injury (ALI) frequently occurs in traumatic patients and serves as an important component of systemic inflammatory response syndrome (SIRS). Hemorrhagic shock (HS) that results from major trauma promotes the development of SIRS and ALI by priming the innate immune system for an exaggerated inflammatory response. Recent studies have reported that the mechanism underlying the priming of pulmonary inflammation involves the complicated cross-talk between Toll-like receptors (TLRs) and interactions between neutrophils (PMNs) and alveolar macrophages (AM phi) as well as endothelial cells (ECs), in which reactive oxygen species (ROS) are the key mediator. This paper summarizes some novel mechanisms underlying HS-primed lung inflammation focusing on the role of TLRs and ROS, and therefore suggests a new therapeutic target for posttrauma ALI. C1 [Xiang, Meng; Fan, Jie] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15260 USA. [Xiang, Meng] Fudan Univ, Dept Pathophysiol, Shanghai 200032, Peoples R China. [Fan, Janet] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15260 USA. [Fan, Jie] VA Pittsburgh Healthcare Syst, Surg Res, Pittsburgh, PA 15240 USA. RP Fan, J (reprint author), Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15260 USA. EM fanj2@upmc.edu FU National Institutes of Health [R01-HL-079669, P50-GM-53789]; VA Merit Award FX This work was supported by the National Institutes of Health Grant R01-HL-079669, National Institutes of Health Center Grant P50-GM-53789, and a VA Merit Award. NR 81 TC 11 Z9 12 U1 0 U2 6 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 0962-9351 J9 MEDIAT INFLAMM JI Mediat. Inflamm. PY 2010 AR 916425 DI 10.1155/2010/916425 PG 8 WC Cell Biology; Immunology SC Cell Biology; Immunology GA 640ZI UT WOS:000281092500001 ER PT J AU Dickinson, KC Sharma, R Duckart, JP Corson, K Gerrity, MS Dobscha, SK AF Dickinson, Kathryn C. Sharma, Rajiv Duckart, Jonathan P. Corson, Kathryn Gerrity, Martha S. Dobscha, Steven K. TI VA Healthcare Costs of a Collaborative Intervention for Chronic Pain in Primary Care SO MEDICAL CARE LA English DT Article DE chronic pain; collaborative care; pain improvement; cost; primary care ID RANDOMIZED CONTROLLED-TRIAL; IMPROVING PRIMARY-CARE; MORRIS DISABILITY QUESTIONNAIRE; DECISION-SUPPORT-SYSTEM; LOW-BACK-PAIN; CHRONIC ILLNESS; PHYSICAL-THERAPY; PERSISTENT PAIN; OLDER PERSONS; DEPRESSION AB Background: Chronic pain is costly to individuals and the healthcare system, and is often undertreated. Collaborative care models show promise for improving treatment of patients with chronic pain. The objectives of this article are to report the incremental benefit and incremental health services costs of a collaborative intervention for chronic pain from a veterans affairs (VA) healthcare perspective. Methods: Data on VA treatment costs incurred by participants were obtained from the VA's Decision Support System for all utilization except certain intervention activities which were tracked in a separate database. Outcome data were from a cluster-randomized trial of a collaborative intervention for chronic pain among 401 primary care patients at a VA medical center. Intervention group participants received assessments and care management; stepped-care components were offered to patients requiring more specialized care. The main outcome measure was pain disability-free days (PDFDs), calculated from Roland-Morris Disability Questionnaire scores. Results: Participants in the intervention group experienced an average of 16 additional PDFDs over the 12-month follow-up window as compared with usual care participants; this came at an adjusted incremental cost of $364 per PDFD for a typical participant. Important predictors of costs were baseline medical comorbidities, depression severity, and prior year's treatment costs. Conclusions: This collaborative intervention resulted in more pain disability-free days and was more expensive than usual care. Further research is necessary to identify if the intervention is more cost-effective for some patient subgroups and to learn whether pain improvements and higher costs persist after the intervention has ended. C1 [Dickinson, Kathryn C.; Sharma, Rajiv; Duckart, Jonathan P.; Corson, Kathryn; Gerrity, Martha S.; Dobscha, Steven K.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, Portland, OR 97207 USA. [Sharma, Rajiv] Portland State Univ, Dept Econ, Portland, OR 97207 USA. [Corson, Kathryn; Dobscha, Steven K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Gerrity, Martha S.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Gerrity, Martha S.] Portland VA Med Ctr, Div Hosp & Specialty Med, Portland, OR 97207 USA. RP Dickinson, KC (reprint author), Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, POB 1034 P3DEP-PC, Portland, OR 97207 USA. EM kathryn.dickinson@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service Projects [PMI 03-195, REA 06-174] FX Supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service Projects PMI 03-195 and REA 06-174. NR 49 TC 10 Z9 10 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JAN PY 2010 VL 48 IS 1 BP 38 EP 44 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 537YD UT WOS:000273149500007 PM 19952802 ER PT J AU Volandes, AE Barry, MJ Chang, YC Paasche-Orlow, MK AF Volandes, Angelo E. Barry, Michael J. Chang, Yuchiao Paasche-Orlow, Michael K. TI Improving Decision Making at the End of Life With Video Images SO MEDICAL DECISION MAKING LA English DT Article DE end-of-life decision making; video; decision aids; uncertainty; advance care planning; health literacy; ethics; palliative care; dementia; Alzheimer's disease ID CONTROLLED-TRIAL; HEALTH LITERACY; OF-LIFE; COMMUNICATION; PICTURES AB Background. Decision making at the end of life is frequently complex and often filled with uncertainty. We hypothesized that people with limited health literacy would have more uncertainty about end-of-life decision making than people with adequate literacy. We also hypothesized that video images would decrease uncertainty. Design. Before and after oral survey. Participants. Subjects presenting to their primary care physicians. Methods. Subjects were asked about their preferences for end-of-life care after they heard a verbal description of advanced dementia and were asked to rate the level of their uncertainty. Subjects then viewed a video of a patient with advanced dementia and were asked again about their preferences and uncertainty. Uncertainty was measured using the Decisional Conflict Scale with score ranges from 3 (high uncertainty) to 15 (no uncertainty). Health literacy was measured using the Rapid Estimate of Adult Literacy in Medicine, and subjects were divided into 3 literacy categories: low (0-45, 6th grade and below), marginal (46-60, 7th- 8th grade), and adequate (61-66, 9th grade and above). Results. A total of 146 patients completed the interview. Prior to the video, the average uncertainty scores for subjects with low, marginal, and adequate health literacy were 10.8, 12.4, and 13.5, respectively (P < 0.0001). After the video, the 3 groups had similar uncertainty about their decisions. The average uncertainty scores for subjects with low, marginal, and adequate health literacy were 13.6, 14.1, and 14.5, respectively (P = 0.046). Conclusions. Subjects with limited health literacy expressed more uncertainty about their preferences for end-of-life care than did subjects with adequate literacy. Our video decision aid improved end-of-life decision making by decreasing uncertainty regarding subjects' preferences, especially for those with limited literacy. C1 [Volandes, Angelo E.; Barry, Michael J.; Chang, Yuchiao] Massachusetts Gen Hosp, Gen Med Unit, Boston, MA 02114 USA. [Volandes, Angelo E.; Barry, Michael J.; Chang, Yuchiao] Harvard Univ, Sch Med, Boston, MA USA. [Paasche-Orlow, Michael K.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. RP Volandes, AE (reprint author), Massachusetts Gen Hosp, Gen Med Unit, 50 Staniford St,9th Floor, Boston, MA 02114 USA. EM avolandes@partners.org OI Paasche-Orlow, Michael/0000-0002-9276-7190 NR 18 TC 29 Z9 29 U1 1 U2 9 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0272-989X J9 MED DECIS MAKING JI Med. Decis. Mak. PD JAN-FEB PY 2010 VL 30 IS 1 BP 29 EP 34 DI 10.1177/0272989X09341587 PG 6 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 549WI UT WOS:000274084700004 PM 19675323 ER PT J AU Fung, CC Lagha, RR Henderson, P Gomez, AG AF Fung, Cha-Chi Lagha, Regina Richter Henderson, Paula Gomez, Arthur G. TI Working with interpreters: how student behavior affects quality of patient interaction when using interpreters SO MEDICAL EDUCATION ONLINE LA English DT Article DE cross-cultural communication barriers; physician-patient relations; patient-centered care; interpreter use; educational intervention; performance-based assessment AB Background: Despite the prevalence of medical interpreting in the clinical environment, few medical professionals receive training in best practices when using an interpreter. We designed and implemented an educational workshop on using interpreters as part of the cultural competency curriculum for second year medical students (MSIIs) at David Geffen School of Medicine at UCLA. The purpose of this study is twofold: first, to evaluate the effectiveness of the workshop and second, if deficiencies are found, to investigate whether the deficiencies affected the quality of the patient encounter when using an interpreter. Methods: A total of 152 MSIIs completed the 3-hour workshop and a 1-station objective-structured clinical examination, 8 weeks later to assess skills. Descriptive statistics and independent sample t-tests were used to assess workshop effectiveness. Results: Based on a passing score of 70%, 39.4% of the class failed. Two skills seemed particularly problematic: assuring confidentiality (missed by 50%) and positioning the interpreter (missed by 70%). While addressing confidentiality did not have a significant impact on standardized patient satisfaction, interpreter position did. Conclusion: Instructing the interpreter to sit behind the patient helps sustain eye contact between clinician and patient, while assuring confidentiality is a tenet of quality clinical encounters. Teaching students and faculty to emphasize both is warranted to improve cross-language clinical encounters. C1 [Fung, Cha-Chi; Lagha, Regina Richter; Henderson, Paula; Gomez, Arthur G.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Educ Dev & Res, Los Angeles, CA 90095 USA. [Lagha, Regina Richter] Univ Calif Los Angeles, Grad Sch Educ & Informat Studies, Los Angeles, CA 90095 USA. [Gomez, Arthur G.] West Los Angeles Healthcare Ctr, VA Greater Los Angeles, Los Angeles, CA USA. RP Fung, CC (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr Educ Dev & Res, Box 957381, Los Angeles, CA 90095 USA. EM ccfung@mednet.ucla.edu NR 18 TC 1 Z9 1 U1 1 U2 2 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1087-2981 J9 MED EDUC ONLINE JI Med. Educ. Online PY 2010 VL 15 AR 5151 DI 10.3402/meo.v15i0.5151 PG 7 WC Education & Educational Research SC Education & Educational Research GA V28SG UT WOS:000208699900011 ER PT J AU Pena, A AF Pena, Adolfo TI The Dreyfus model of clinical problem-solving skills acquisition: a critical perspective SO MEDICAL EDUCATION ONLINE LA English DT Article DE clinical skills; Dreyfus' model; expertise; intuition; learning; medical education; novice to expert AB Context: The Dreyfus model describes how individuals progress through various levels in their acquisition of skills and subsumes ideas with regard to how individuals learn. Such a model is being accepted almost without debate from physicians to explain the 'acquisition' of clinical skills. Objectives: This paper reviews such a model, discusses several controversial points, clarifies what kind of knowledge the model is about, and examines its coherence in terms of problem-solving skills. Dreyfus' main idea that intuition is a major aspect of expertise is also discussed in some detail. Relevant scientific evidence from cognitive science, psychology, and neuroscience is reviewed to accomplish these aims. Conclusions: Although the Dreyfus model may partially explain the 'acquisition' of some skills, it is debatable if it can explain the acquisition of clinical skills. The complex nature of clinical problem-solving skills and the rich interplay between the implicit and explicit forms of knowledge must be taken into consideration when we want to explain 'acquisition' of clinical skills. The idea that experts work from intuition, not from reason, should be evaluated carefully. C1 [Pena, Adolfo] Birmingham VA Med Ctr, Birmingham, AL USA. [Pena, Adolfo] Univ Alabama Birmingham, Birmingham, AL USA. RP Pena, A (reprint author), VA Birmingham Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, 151 REAP,700 South 19th St, Birmingham, AL 35233 USA. EM adolfope@uab.edu NR 80 TC 5 Z9 5 U1 4 U2 13 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1087-2981 J9 MED EDUC ONLINE JI Med. Educ. Online PY 2010 VL 15 AR 4846 DI 10.3402/meo.v15i0.4846 PG 11 WC Education & Educational Research SC Education & Educational Research GA V28SG UT WOS:000208699900004 ER PT S AU Menze, BH Van Leemput, K Lashkari, D Weber, MA Ayache, N Golland, P AF Menze, Bjoern H. Van Leemput, Koen Lashkari, Danial Weber, Marc-Andre Ayache, Nicholas Golland, Polina BE Jiang, T Navab, N Pluim, JPW Viergever, MA TI A Generative Model for Brain Tumor Segmentation in Multi-Modal Images SO MEDICAL IMAGE COMPUTING AND COMPUTER-ASSISTED INTERVENTION - MICCAI 2010, PT II, SE Lecture Notes in Computer Science LA English DT Proceedings Paper CT 13th International Conference on Medical Image Computing and Computer-Assisted Intervention (MICCAI) CY SEP 20-24, 2010 CL China Natl Convent Ctr, Beijing, PEOPLES R CHINA SP MICCAI Soc HO China Natl Convent Ctr ID OUTLIER DETECTION; REGISTRATION; FRAMEWORK AB We introduce a generative probabilistic model for segmentation of tumors in multi-dimensional images. The model allows for different tumor boundaries in each channel, reflecting difference in tumor appearance across modalities. We augment a probabilistic atlas of healthy tissue priors with a. latent atlas of the lesion and derive the estimation algorithm to extract tumor boundaries and the latent atlas from the image data. We present experiments on 25 glioma patient data sets, demonstrating significant improvement over the traditional multivariate tumor segmentation. C1 [Menze, Bjoern H.; Van Leemput, Koen; Lashkari, Danial; Golland, Polina] MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA. [Menze, Bjoern H.; Ayache, Nicholas] Inst Natl Rech Informat & Automat Lorraine, Asclepios Res Project, Sophia Antipolis, France. [Van Leemput, Koen] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02115 USA. [Van Leemput, Koen] Aalto Univ, Dept Comp Sci & Informat, Espoo, Finland. [Weber, Marc-Andre] Univ Heidelberg Hosp, Dept Diagnost Radiol, D-69115 Heidelberg, Germany. RP Menze, BH (reprint author), MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA. RI Van Leemput, Koen/A-9197-2009 OI Van Leemput, Koen/0000-0001-6466-5309 FU German Academy of Sciences Leopoldina (Fellowship Programme LPDS); Academy of Finland [133611]; INRIA CompuTumor; NSF CAREER Award [0642971]; [NIH NIBIB NAMIC U54-EB005149]; [NIH NCRR NAC P41-RR13218]; [NIH NINDS R01-NS051826]; [NIH R01-NS052585]; [NIH R01-EB006758]; [NIH R01-EB009051]; [NIH P41-RR01407] FX This work was supported by the German Academy of Sciences Leopoldina (Fellowship Programme LPDS 2009-10), the Academy of Finland (133611), INRIA CompuTumor, NIH NIBIB NAMIC U54-EB005149, NIH NCRR NAC P41-RR13218, NIH NINDS R01-NS051826, NIH R01-NS052585, NIH R01-EB006758, NIH R01-EB009051, NIH P41-RR014075 and the NSF CAREER Award 0642971. NR 19 TC 36 Z9 37 U1 2 U2 4 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0302-9743 BN 978-3-642-15744-8 J9 LECT NOTES COMPUT SC PY 2010 VL 6362 BP 151 EP + PG 3 WC Computer Science, Software Engineering; Computer Science, Theory & Methods; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging GA BTR11 UT WOS:000287828300019 ER PT S AU Cai, WL Liu, B Yoshida, H AF Cai, Wenli Liu, Bob Yoshida, Hiroyuki BE Karssemeijer, N Summers, RM TI Dual-energy electronic cleansing for non-cathartic CT Colonography: a phantom study SO MEDICAL IMAGING 2010: COMPUTER - AIDED DIAGNOSIS SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Medical Imaging 2010 - Computer-Aided Diagnosis CY FEB 16-18, 2010 CL San Diego, CA SP SPIE, Medtronic, Inc, Aeroflex, Inc, Tungsten Heavy Powder, Inc DE computer-aided diagnosis; X-ray and CT; abdominal; CT colonography; electronic cleansing ID VIRTUAL COLONOSCOPY; COMPUTED-TOMOGRAPHY; TISSUE SEGMENTATION; IMAGES; FEASIBILITY; POLYPS; VOLUME AB Partial volume effect and inhomogeneity are two major causes of artifacts in electronic cleansing (EC) for non-cathartic CT colonography (CTC). Our purpose was to develop a novel method of EC for non-cathartic dual-energy CTC (DE-CTC) using a subvoxel multi-spectral material classifier and a regional material decomposition method for differentiation of residual fecal materials from colonic soft-tissue structures. In this study, an anthropomorphic colon phantom, which was filled with a mixture of aqueous fiber (psyllium), ground foodstuff (cereal), and non-ionic iodinated agent (Omnipaque iohexol, GE Healthcare, Milwaukee, WI), was scanned by a dual-energy CT scanner (SOMATON, Siemens) with two photon energies: 80 kVp and 140 kVp. The DE-CTC images were subjected to a dual-energy EC (DE-EC) scheme, in which a multi-spectral material classifier was used to compute the fraction of each material within one voxel by an expectation-maximization (EM) algorithm. This was followed by a regional material segmentation method for identifying of homogeneous sub-regions (tiles) as fecal materials from other tissue types. The results were compared with the structural-analysis cleansing (SA-EC) method based upon the CTC images of native phantom without fillings. The mean cleansing ratio of the DE-EC scheme was 96.57 +/- 1.21% compared to 76.3 +/- 5.56% of the SA-EC scheme. The soft-tissue preservation ratio of the DE-EC scheme was 97.05%+/- 0.64% compared to 99.25 +/- 0.77% of the SA-EC scheme. C1 [Cai, Wenli] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Cai, WL (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM Cai.Wenli@mgh.harvard.edu NR 27 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-8025-5 J9 PROC SPIE PY 2010 VL 7624 AR 76240C DI 10.1117/12.845613 PG 8 WC Engineering, Biomedical; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Optics; Radiology, Nuclear Medicine & Medical Imaging GA BSK55 UT WOS:000284752400010 ER PT S AU Do, S Karl, C Kalra, MK Brady, TJ Pien, H AF Do, Synho Karl, Clem Kalra, Mannudeep K. Brady, Thomas J. Pien, Homer BE Samei, E Pelc, NJ TI Clinical low dose CT image reconstruction using high-order total variation techniques SO MEDICAL IMAGING 2010: PHYSICS OF MEDICAL IMAGING SE Proceedings of SPIE-The International Society for Optical Engineering LA English DT Proceedings Paper CT Conference on Medical Imaging - Physics of Medical Imaging CY FEB 15-18, 2010 CL San Diego, CA SP SPIE DE low dose imaging; MDCT; iterative image reconstruction; total variation; high-order total variation; staircase artifact ID TOTAL VARIATION MINIMIZATION; RESTORATION; RECOVERY AB Total variation (TV) based iterative image reconstruction has been shown to possess desirable noise suppression and edge preservation characteristics. However, such approaches also produce "staircase effects" where intensity ramps are discretized into steps, resulting in images which appear blocky or patchy. In this paper, we present an improved regularization technique by incorporating higher-order derivatives to reduce staircase artifacts without sacrificing edge sharpness. In this preliminary investigation we demonstrate our approach using both phantom and clinical images acquired at 25% of conventional radiation dosage (i.e., 75% dose reduction). C1 [Do, Synho; Kalra, Mannudeep K.; Brady, Thomas J.; Pien, Homer] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Do, S (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 10 TC 3 Z9 3 U1 1 U2 1 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-8023-1 J9 P SOC PHOTO-OPT INS PY 2010 VL 7622 AR 76225D DI 10.1117/12.844307 PG 8 WC Optics; Radiology, Nuclear Medicine & Medical Imaging SC Optics; Radiology, Nuclear Medicine & Medical Imaging GA BSO01 UT WOS:000285047200182 ER PT S AU Li, XH Liu, B AF Li, Xinhua Liu, Bob BE Samei, E Pelc, NJ TI Quantifying breast density with a cone-beam breast CT SO MEDICAL IMAGING 2010: PHYSICS OF MEDICAL IMAGING SE Proceedings of SPIE-The International Society for Optical Engineering LA English DT Proceedings Paper CT Conference on Medical Imaging - Physics of Medical Imaging CY FEB 15-18, 2010 CL San Diego, CA SP SPIE DE Breast Density; Breast CT; Image Reconstruction; simulation ID ALGORITHM AB Volumetric breast density was evaluated using a simulated cone beam breast CT with 80 kVp. The breast was modeled as a cylinder with background tissue composition of 20% glandular and 80% adipose. Various objects with different sizes and tissue compositions were embedded. Ray-tracing algorithm was utilized to obtain projection images in a full rotation without considering scatter, beam hardening and imaging noise. Filtered backprojection was adopted for image reconstruction with high quality. Reconstructed images had flat profiles except at large cone angle of 8.6 degrees to 10 degrees. They were calibrated using known linear attenuation coefficients of two image contrast objects. A 3D mapping of tissue densities could be directly computed within 5% error. Tissue volumes were obtained by counting voxels in appropriate attenuation coefficient ranges. Results of contrast objects were consistent with true volumes within 10% error. However, cone angle artifact decreased pixel values, and a reduction algorithm was required for accurate tissue assessment at large cone angles. This study indicates the possibility of excellent quantitative breast density measurements and volume assessments with cone-beam breast CT. C1 [Li, Xinhua; Liu, Bob] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Li, XH (reprint author), Massachusetts Gen Hosp, Dept Radiol, 0 Emerson Pl, Boston, MA 02114 USA. EM xli16@partners.org; bliu7@partners.org NR 10 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-8023-1 J9 P SOC PHOTO-OPT INS PY 2010 VL 7622 AR 762245 DI 10.1117/12.844369 PG 11 WC Optics; Radiology, Nuclear Medicine & Medical Imaging SC Optics; Radiology, Nuclear Medicine & Medical Imaging GA BSO01 UT WOS:000285047200142 ER PT J AU Court, L Wagar, M Berbeco, R Reisner, A Winey, B Schofield, D Ionascu, D Allen, AM Popple, R Lingos, T AF Court, Laurence Wagar, Matthew Berbeco, Ross Reisner, Adam Winey, Brian Schofield, Debbie Ionascu, Dan Allen, Aaron M. Popple, Richard Lingos, Tania TI Evaluation of the interplay effect when using RapidArc to treat targets moving in the craniocaudal or right-left direction SO MEDICAL PHYSICS LA English DT Article DE respiratory motion; RapidArc; interplay effect ID VOLUMETRIC MODULATED ARC; ORGAN MOTION; INTRAFRACTION MOTION; INTENSITY MODULATION; RESPIRATORY MOTION; IMRT TREATMENTS; DOSE DELIVERY; THERAPY; RADIOTHERAPY; IMPACT AB Purpose: We have investigated the dosimetric errors caused by the interplay between the motions of the LINAC and the tumor during the delivery of a volume modulated arc therapy treatment. This includes the development of an IMRT QA technique, applied here to evaluate RapidArc plans of varying complexity. Methods: An IMRT QA technique was developed, which involves taking a movie of the delivered dose (0.2 s frames) using a 2D ion chamber array. Each frame of the movie is then moved according to a respiratory trace and the cumulative dose calculated. The advantage of this approach is that the impact of turning the beam on at different points in the respiratory trace, and of different types of motion, can be evaluated using data from a single irradiation. We evaluated this technique by comparing with the results when we actually moved the phantom during irradiation. RapidArc plans were created to treat a 62 cc spherical tumor in a lung phantom (16 plans) and a 454 cc irregular tumor in an actual patient (five plans). The complexity of each field was controlled by adjusting the MU (312-966 MU). Each plan was delivered to a phantom, and a movie of the delivered dose taken using a 2D ion chamber array. Patient motion was modeled by shifting each dose frame according to a respiratory trace, starting the motion at different phases. The expected dose distribution was calculated by blurring the static dose distribution with the target motion. The dose error due to the interplay effect was then calculated by comparing the delivered dose with the expected dose distribution. Peak-to-peak motion of 0.5, 1.0, and 2.0 cm in the craniocaudal and right-left directions, with target periods of 3 and 5 s, were evaluated for each plan (252 different target motion/plan combinations). Results: The daily dose error due to the interplay effect was less than 10% for 98.4% of all pixels in the target for all plans investigated. The percentage of pixels for which the daily dose error could be larger than 5% increased with increasing plan complexity (field MU), but was less than 15% for all plans if the motion was 1 cm or less. For 2 cm motion, the dose error could be larger than 5% for 40% of pixels, but was less than 5% for more than 80% of pixels for MU < 550, and was less than 10% for 99% of all pixels. The interplay effect was smaller for 3 s periods than for 5 s periods. Conclusions: The interplay between the motions of the LINAC and the target can result in an error in the delivered dose. This effect increases with plan complexity, and with target magnitude and period. It may average out after many fractions. (C) 2010 American Association of Physicists in Medicine. [DOI: 10.1118/1.3263614] C1 [Court, Laurence; Wagar, Matthew; Berbeco, Ross; Reisner, Adam; Winey, Brian; Schofield, Debbie; Ionascu, Dan; Allen, Aaron M.; Lingos, Tania] Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02115 USA. [Allen, Aaron M.] Rabin Med Ctr, Dept Radiat Oncol, Petah Tiqwa, Israel. [Popple, Richard] Univ Alabama, Dept Radiat Oncol, Birmingham, AL 35249 USA. RP Court, L (reprint author), Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02115 USA. EM lcourt@lroc.harvard.edu OI Popple, Richard/0000-0003-1252-738X FU Kayes Family New Technology FX This project was partially funded by a Kayes Family New Technology Grant. We would like to thank the reviewers and editors for their helpful comments. NR 21 TC 28 Z9 29 U1 0 U2 3 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JAN PY 2010 VL 37 IS 1 BP 4 EP 11 DI 10.1118/1.3263614 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 538GI UT WOS:000273172100002 PM 20175460 ER PT J AU Zhu, XP Reese, TG Crowley, EM El Fakhri, G AF Zhu, Xuping Reese, Timothy G. Crowley, Elizabeth M. El Fakhri, Georges TI Improved MAGIC gel for higher sensitivity and elemental tissue equivalent 3D dosimetry SO MEDICAL PHYSICS LA English DT Article DE gel dosimeter; proton therapy; positron emission tomography ID POSITRON-EMISSION-TOMOGRAPHY; PROTON THERAPY; VERIFICATION; IRRADIATION; DELIVERY; SYSTEM; PET/CT; RANGE AB Purpose: Polymer-based gel dosimeter (MAGIC type) is a preferable phantom material for PET range verification of proton beam therapy. However, improvement in elemental tissue equivalency (specifically O/C ratio) is very desirable to ensure realistic time-activity measurements. Methods: Glucose and urea was added to the original MAGIC formulation to adjust the O/C ratio. The dose responses of the new formulations were tested with MRI transverse relaxation rate (R(2)) measurements. Results: The new ingredients improved not only the elemental composition but also the sensitivity of the MAGIC gel. The O/C ratios of our new gels agree with that of soft tissue within 1%. The slopes of dose response curves were 1.6-2.7 times larger with glucose. The melting point also increased by 5 degrees C. Further addition of urea resulted in a similar slope but with an increased intercept and a decreased melting point. Conclusions: Our improved MAGIC gel formulations have higher sensitivity and better elemental tissue equivalency for 3D dosimetry applications involving nuclear reactions. (C) 2010 American Association of Physicists in Medicine. [DOI: 10.1118/1.3260844] C1 [Zhu, Xuping; El Fakhri, Georges] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Reese, Timothy G.] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Crowley, Elizabeth M.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RP Zhu, XP (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA. EM xzhu4@partners.org FU NIH [R21-CA134812, T32-EB002102] FX Dr. Lee Josephson of MGH Department of Radiology provided valuable insights into the role of glucose in the gel system. This work was supported by NIH Grant Nos. R21-CA134812 and T32-EB002102. NR 23 TC 9 Z9 9 U1 1 U2 6 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JAN PY 2010 VL 37 IS 1 BP 183 EP 188 DI 10.1118/1.3260844 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 538GI UT WOS:000273172100022 PM 20175480 ER PT J AU Clasie, B Wroe, A Kooy, H Depauw, N Flanz, J Paganetti, H Rosenfeld, A AF Clasie, Ben Wroe, Andrew Kooy, Hanne Depauw, Nicolas Flanz, Jay Paganetti, Harald Rosenfeld, Anatoly TI Assessment of out-of-field absorbed dose and equivalent dose in proton fields SO MEDICAL PHYSICS LA English DT Article DE proton therapy; GEANT; Monte Carlo; second malignancies; neutrons ID MONTE-CARLO SIMULATIONS; RADIATION TREATMENT; SECONDARY NEUTRONS; PROSTATE-CANCER; THERAPY; RADIOTHERAPY; BEAMS; PARTICLES; EXPOSURES; DOSIMETRY AB Purpose: In proton therapy, as in other forms of radiation therapy, scattered and secondary particles produce undesired dose outside the target volume that may increase the risk of radiation-induced secondary cancer and interact with electronic devices in the treatment room. The authors implement a Monte Carlo model of this dose deposited outside passively scattered fields and compare it to measurements, determine the out-of-field equivalent dose, and estimate the change in the dose if the same target volumes were treated with an active beam scanning technique. Methods: Measurements are done with a thimble ionization chamber and the Wellhofer MatriXX detector inside a Lucite phantom with field configurations based on the treatment of prostate cancer and medulloblastoma. The authors use a GEANT4 Monte Carlo simulation, demonstrated to agree well with measurements inside the primary field, to simulate fields delivered in the measurements. The partial contributions to the dose are separated in the simulation by particle type and origin. Results: The agreement between experiment and simulation in the out-of-field absorbed dose is within 30% at 10-20 cm from the field edge and 90% of the data agrees within 2 standard deviations. In passive scattering, the neutron contribution to the total dose dominates in the region downstream of the Bragg peak (65%-80% due to internally produced neutrons) and inside the phantom at distances more than 10-15 cm from the field edge. The equivalent doses using 10 for the neutron weighting factor at the entrance to the phantom and at 20 cm from the field edge are 2.2 and 2.6 mSv/Gy for the prostate cancer and cranial medulloblastoma fields, respectively. The equivalent dose at 15-20 cm from the field edge decreases with depth in passive scattering and increases with depth in active scanning. Therefore, active scanning has smaller out-of-field equivalent dose by factors of 30-45 in the entrance region and this factor decreases with depth. Conclusions: The dose deposited immediately downstream of the primary field, in these cases, is dominated by internally produced neutrons; therefore, scattered and scanned fields may have similar risk of second cancer in this region. The authors confirm that there is a reduction in the out-of-field dose in active scanning but the effect decreases with depth. GEANT4 is suitable for simulating the dose deposited outside the primary field. The agreement with measurements is comparable to or better than the agreement reported for other implementations of Monte Carlo models. Depending on the position, the absorbed dose outside the primary field is dominated by contributions from primary protons that may or may not have scattered in the brass collimating devices. This is noteworthy as the quality factor of the low LET protons is well known and the relative dose risk in this region can thus be assessed accurately. (C) 2010 American Association of Physicists in Medicine. [DOI: 10.1118/1.3271390] C1 [Clasie, Ben; Kooy, Hanne; Depauw, Nicolas; Flanz, Jay; Paganetti, Harald] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Clasie, Ben; Kooy, Hanne; Depauw, Nicolas; Flanz, Jay; Paganetti, Harald] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Wroe, Andrew] Loma Linda Univ, Med Ctr, Dept Radiat Med, Loma Linda, CA 92354 USA. [Wroe, Andrew; Rosenfeld, Anatoly] Univ Wollongong, Ctr Med Radiat Phys, Wollongong, NSW 2522, Australia. RP Clasie, B (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. EM bclasie@partners.org RI Rosenfeld, Anatoly/D-1989-2014 FU National Institutes of Health [PO1 CA 21239] FX The authors thank Susana Guatelli, Joseph Perl, Maria Grazia Pia, and Valery Taranenko for their help and suggestions. This work was supported in part by National Institutes of Health (Grant No. PO1 CA 21239). NR 39 TC 35 Z9 35 U1 0 U2 7 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JAN PY 2010 VL 37 IS 1 BP 311 EP 321 DI 10.1118/1.3271390 PG 11 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 538GI UT WOS:000273172100036 PM 20175494 ER PT J AU Kougias, P Weakley, SM Yao, QZ Lin, PH Chen, CY AF Kougias, Panagiotis Weakley, Sarah M. Yao, Qizhi Lin, Peter H. Chen, Changyi TI Arterial baroreceptors in the management of systemic hypertension SO MEDICAL SCIENCE MONITOR LA English DT Review DE baroreceptor; barereflex; hypertension; sinoaortic denervation ID SYMPATHETIC-NERVE ACTIVITY; LONG-TERM CONTROL; BLOOD-PRESSURE; BAROREFLEX SENSITIVITY; CAROTID-ENDARTERECTOMY; AORTIC BARORECEPTORS; CONSCIOUS DOGS; HEART-RATE; CARDIOVASCULAR REGULATION; ANGIOTENSIN HYPERTENSION AB Hypertension is a multifactorial disease associated with significant morbidity. Increased sympathetic nervous system activity has been noted as an important etiologic factor and is, in part, regulated by afferent input arising from arterial and cardiopulmonary baroreceptors, activation of which causes inhibition of sympathetic output. It was thought for many years that baroreceptors control only short-term blood pressure changes, a conclusion stemming from observations in sinoaortic denervation (SAD) animal models and the phenomenon of rapid baroreceptor resetting, also seen in animal models. Newer observations, however, indicate that SAD is rather imperfect and resetting is rarely complete. Recent studies reveal that baroreceptors control sympathetic output on a more long-term basis and participate in fluid volume regulation by the kidney, and thus have the potential to adjust blood pressure chronically. Importantly, these findings are consistent with studies and observations in humans. Meanwhile, a model of electrical stimulation of the carotid sinus has been developed and successfully tested in animals. Following these encouraging results human trials to evaluate the clinical application of electrical carotid sinus manipulation in the treatment of systemic hypertension have commenced, and results so far indicate that this represents an exciting potential tool in the clinician's armament against chronic arterial hypertension. C1 [Kougias, Panagiotis; Weakley, Sarah M.; Yao, Qizhi; Lin, Peter H.; Chen, Changyi] Baylor Coll Med, Michael E DeBakey Dept Surg, Mol Surg Res Ctr, Div Vasc Surg & Endovasc Therapy, Houston, TX 77030 USA. [Kougias, Panagiotis; Yao, Qizhi; Lin, Peter H.; Chen, Changyi] Michael E DeBakey Vet Affairs Med Ctr, Dept Surg, Houston, TX 77030 USA. RP Kougias, P (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Surg, 2002 Holcombe Blvd 112, Houston, TX 77030 USA. EM pkougias@bcm.edu FU Michael E. DeBakey Department of Surgery at the Baylor College of Medicine, Houston, TX, U.S.A.; National Institutes of Health, U.S.A. [T32 HL076345] FX This study was partially supported by the Michael E. DeBakey Department of Surgery at the Baylor College of Medicine, Houston, TX, U.S.A. and a grant (T32 HL076345) from the National Institutes of Health, U.S.A. NR 69 TC 14 Z9 15 U1 1 U2 7 PU INT SCIENTIFIC LITERATURE, INC PI ALBERTSON PA 1125 WILLIS AVE, ALBERTSON, NY 11507 USA SN 1234-1010 J9 MED SCI MONITOR JI Med. Sci. Monitor PY 2010 VL 16 IS 1 BP RA1 EP RA8 PG 8 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 537NT UT WOS:000273120400023 PM 20037502 ER PT J AU Edson, RS Beckman, TJ West, CP Aronowitz, PB Badgett, RG Feldstein, DA Henderson, MC Kolars, JC McDonald, FS AF Edson, Randall S. Beckman, Thomas J. West, Colin P. Aronowitz, Paul B. Badgett, Robert G. Feldstein, David A. Henderson, Mark C. Kolars, Joseph C. McDonald, Furman S. TI A multi-institutional survey of internal medicine residents' learning habits SO MEDICAL TEACHER LA English DT Article ID KNOWLEDGE ACQUISITION; READING HABITS; HOUSE-STAFF AB Background: Resident physicians are expected to demonstrate medical knowledge. However, little is known about the residents' reading habits and learning preferences. Aim: To assess residents' reading habits and preferred educational resources. Methods: Residents at five internal medicine training programs were surveyed regarding their reading and learning habits and preferences. Results: The majority (77.7%) of residents reported reading less than 7 h a week. Most residents (81.4%) read in response to patient care encounters. The preferred educational format was electronic; 94.6% of residents cited UpToDate (R) as the most effective resource for knowledge acquisition, and 88.9% of residents reported that UpToDate (R) was their first choice for answering clinical questions. Conclusions: Residents spent little time reading and sought knowledge primarily from electronic resources. Most residents read in the context of patient care. Future research should focus on strategies for helping resident physicians learn in the electronic age. C1 [Edson, Randall S.; Beckman, Thomas J.; West, Colin P.; McDonald, Furman S.] Mayo Clin, Coll Med, Rochester, MN 55905 USA. [Aronowitz, Paul B.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Aronowitz, Paul B.] Calif Pacific Med Ctr, San Francisco, CA USA. [Badgett, Robert G.] Univ Texas San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Feldstein, David A.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Henderson, Mark C.] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA. [Kolars, Joseph C.] Univ Michigan, Ann Arbor, MI 48109 USA. RP Edson, RS (reprint author), Mayo Clin, Coll Med, 200 1st St SW, Rochester, MN 55905 USA. EM edson.randall@mayo.edu OI Badgett, Robert/0000-0003-2888-3303 NR 10 TC 18 Z9 18 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0142-159X J9 MED TEACH JI Med. Teach. PY 2010 VL 32 IS 9 BP 773 EP 775 DI 10.3109/01421591003692698 PG 3 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 663NJ UT WOS:000282894300016 PM 20795809 ER PT S AU Westerfeld, C AF Westerfeld, Corey BA Yan, Q BF Yan, Q TI ABC Transporters in Ophthalmic Disease SO MEMBRANE TRANSPORTERS IN DRUG DISCOVERY AND DEVELOPMENT: METHODS AND PROTOCOLS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE ABC transporters; ABCR gene; ABCA4 gene; Stargardt's disease; fundus flavimaculatus; cone-rod dystrophy; retinitis pigmentosa; age-related macular degeneration ID CONE-ROD DYSTROPHY; RECESSIVE STARGARDT DISEASE; MACULAR DEGENERATION; GENE ABCR; RETINITIS-PIGMENTOSA; FUNDUS-FLAVIMACULATUS; CHLORIDE CHANNELS; OUTER SEGMENTS; ATP; MUTATIONS AB ABC transporters have been implicated in a variety of human diseases. The A BCR gene and its protein have been linked to Stargardt's disease, fundus flavimaculatus, cone rod dystrophy, retinitis pigmentosa, and age-related macular degeneration. The genetic and molecular pathways involved in the pathogenesis of ABCR-related ophthalmic conditions will be explored. Future diagnostic and therapeutic objectives for these diseases will also be discussed. C1 Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA. RP Westerfeld, C (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA. NR 51 TC 0 Z9 0 U1 0 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-60761-699-3 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2010 VL 637 BP 221 EP 230 DI 10.1007/978-1-60761-700-6_11 D2 10.1007/978-1-60761-700-6 PG 10 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BOU19 UT WOS:000277617000011 PM 20419437 ER PT S AU Lauritzen, HPMM AF Lauritzen, Hans P. M. M. BA Yan, Q BF Yan, Q TI Imaging of Protein Translocation In Situ in Skeletal Muscle of Living Mice SO MEMBRANE TRANSPORTERS IN DRUG DISCOVERY AND DEVELOPMENT: METHODS AND PROTOCOLS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Glucose transporter translocation; intravital imaging; GFP fusion ID T-TUBULES; GLUT4; INSULIN; FIBERS; VIVO AB Skeletal muscle plays a key role in regulating whole body glucose homeostasis and severe dysfunction in insulin-mediated glucose uptake is the hallmark of insulin-resistant states and type II diabetes. Therefore it is highly pathophysiologically relevant to perform detailed studies of insulin signaling inside skeletal muscle cells in order to elucidate the specific molecular events during both normal and insulin-resistant conditions. So far, cell biology imaging techniques have been limited to in vitro cultured muscle originating from primary or cell line-based myoblasts. However, these types of cultured muscle lack many characteristics of fully differentiated muscle cells. By performing intravital protein translocation analysis directly in situ in living animals, we have been able to give a high-resolution account of the spatial and temporal details during insulin signaling in vivo in muscle that does not have the limitations of in vitro cultures. We have shown that after iv. insulin injection, PI 3-kinase activation and, in turn, GLUT4 translocation are initiated at the plasma membrane proper, the sarcolemma. Then insulin signaling progresses into the t-tubules with a velocity corresponding to the diffusion of sulforhodamine B-conjugated insulin molecules. By using intravital confocal time-lapse analysis we have revealed that the t-tubules are the membrane surface where the majority of the insulin signaling is located. C1 [Lauritzen, Hans P. M. M.] Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA. [Lauritzen, Hans P. M. M.] Harvard Univ, Sch Med, Boston, MA USA. RP Lauritzen, HPMM (reprint author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA. FU NIDDK NIH HHS [P30DK036836] NR 11 TC 5 Z9 5 U1 0 U2 1 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-60761-699-3 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2010 VL 637 BP 231 EP 244 DI 10.1007/978-1-60761-700-6_12 D2 10.1007/978-1-60761-700-6 PG 14 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BOU19 UT WOS:000277617000012 PM 20419438 ER PT J AU Schiff, I AF Schiff, Isaac TI A fond farewell to Dr. Wulf H. Utian upon his retirement from NAMS SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY LA English DT Biographical-Item C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Vincent Obstet & Gynecol Serv, Boston, MA 02115 USA. RP Schiff, I (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Vincent Obstet & Gynecol Serv, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1072-3714 J9 MENOPAUSE JI Menopause-J. N. Am. Menopause Soc. PD JAN-FEB PY 2010 VL 17 IS 1 BP 1 EP 2 DI 10.1097/gme.0b013e3181c18195 PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 542TC UT WOS:000273517400001 ER PT J AU Goodman, A AF Goodman, Annekathryn TI Laparoscopy versus laparotomy in the surgical management of gynecologic disease in older women: a shifting paradigm SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY LA English DT Editorial Material C1 Massachusetts Gen Hosp, Vincent Obstet & Gynecol Serv, Boston, MA 02114 USA. RP Goodman, A (reprint author), Massachusetts Gen Hosp, Vincent Obstet & Gynecol Serv, Boston, MA 02114 USA. NR 5 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1072-3714 J9 MENOPAUSE JI Menopause-J. N. Am. Menopause Soc. PD JAN-FEB PY 2010 VL 17 IS 1 BP 19 EP 20 DI 10.1097/gme.0b013e3181c17c06 PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 542TC UT WOS:000273517400008 PM 20061892 ER PT J AU Huang, AJ Moore, EE Boyko, EJ Scholes, D Lin, F Vittinghoff, E Fihn, SD AF Huang, Alison J. Moore, Elya E. Boyko, Edward J. Scholes, Delia Lin, Feng Vittinghoff, Eric Fihn, Stephan D. TI Vaginal symptoms in postmenopausal women: self-reported severity, natural history, and risk factors SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY LA English DT Article DE Vaginal dryness; Menopause; Vaginal atrophy; Dyspareunia; Sexual dysfunction ID UROGENITAL ATROPHY; ESTROGEN; HEALTH; POPULATION; PREVALENCE; HORMONES; FLORA AB Objective: This study aimed to examine factors other than estrogen deficiency influencing the development and persistence of vaginal dryness, itching, and painful sexual intercourse after menopause. Methods: We analyzed data from a 2-year, population-based cohort of 1,0 17 postmenopausal women aged 5 5 to 75 years. Vaginal symptoms were assessed by interviewer-administered questionnaire, and vaginal swabs were performed to assess vaginal pH and microbial flora at baseline, 12 months, and 24 months. Generalized estimating equations were used to identify characteristics associated with symptoms. Results: Half of the women (n = 47 1) reported problematic vaginal dryness, a third (n = 3 16) reported itching, and 40% of sexually active women (n = 166) reported painful intercourse at baseline. Of women not taking estrogen, half of those reporting baseline symptoms were symptomatic after 24 months. Vaginal dryness was associated with Younger age (odds ratio [OR], 0.81; 95% CI, 0.69-0.94, per 5-y increase), nonwhite race (ie, African American, Hispanic, Asian or Pacific Islander, or American Indian [OR, 1.53; 95% CI, 1.04-2.27]), diabetes (OR, 1.5 1; 95% Cl, 1.07-2.12), lower 36-item Short-Form Health Survey physical functioning scores (OR, 0.90; 95% Cl, 0.85-0.97, per 10-point increase), lower body mass index (OR, 0.81; 95% Cl, 0.71-0.93, per 5 kg/m(2) increase), recent sexual activity (OR, 1.14; 95% CI, 1.08-1.21), and vaginal colonization with enterococci (OR, 1.25; 95% Cl, 1.04-1.51). Vaginal itching was also associated with lower physical functioning scores (OR, 0.86; 95% Cl, 0.80-0.92, per 10-point increase). Risk factors for painful intercourse included younger age (OR, 0.72; 95% CI, 0.56-0.93, per 5-y increase), diabetes (OR, 3.48; 95% Cl, 1.93-6.27), lower body mass index (OR, 0.76; 95% Cl, 0.61-0.95, per 5 kg/m(2) increase), and higher vaginal pH (OR, 1.10; 95% Cl, 1.00-1.21, per 0.5 units). Conclusions: Vaginal symptoms affect a large proportion of postmenopausal women, particularly those with diabetes and those with lower body mass index, but may resolve for up to half of women without estrogen therapy. C1 [Huang, Alison J.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Moore, Elya E.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia. [Boyko, Edward J.] Univ Washington, Dept Med, Seattle, WA USA. [Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Seattle ERIC, Seattle, WA USA. [Scholes, Delia] Grp Hlth Cooperat Puget Sound, Grp Hlth Ctr Hlth Studies, Seattle, WA 98121 USA. [Lin, Feng; Vittinghoff, Eric] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Fihn, Stephan D.] Dept Vet Affairs, Washington, DC USA. RP Huang, AJ (reprint author), 1635 Divisadero St,Suite 600, San Francisco, CA 94115 USA. EM ahuang@ucsfmed.org FU National Institutes of Health (NIH) [T32AI07140, RO1 DK43134]; National Center for Research Resources, a component of the NIH [RR024130] FX The Prospective Evaluation of Postmenopausal Cystitis study was Supported by National Institutes of Health (NIH) grants T32AI07140 and RO1 DK43134 and the resources and facilities at the Veterans Affairs Puget Sound Health Care System, Seattle, WA. Dr. Huang is supported by KL2 Grant RR024130 from the National Center for Research Resources, a component of the NIH and NIH Clinical and Translational Science Award for Medical Research. NR 23 TC 15 Z9 16 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1072-3714 EI 1530-0374 J9 MENOPAUSE JI Menopause-J. N. Am. Menopause Soc. PD JAN-FEB PY 2010 VL 17 IS 1 BP 121 EP 126 DI 10.1097/gme.0b013e3181acb9ed PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 542TC UT WOS:000273517400020 PM 19574936 ER PT B AU Murray, SS Brochmann, EJ Behnam, K Harker, JO AF Murray, Samuel S. Brochmann, Elsa J. Behnam, Keyvan Harker, Judith O. BE Maguire, T Novik, E TI A Statistical Method to Reduce In Vivo Product Testing Using Related In Vitro Tests and ROC Analysis SO METHODS IN BIOENGINEERING: ALTERNATIVE TECHNOLOGIES TO ANIMAL TESTING SE Artech House Methods in Bioengineering Series LA English DT Article; Book Chapter DE alternatives to animal testing; cut-point analysis; ROC analysis AB Many biological materials, therapeutics, and reagents are tested in animals. It seems self-evident that an in vivo test would most reliably replicate the conditions of the relevant clinical or biological situation. However, in many cases precise and reproducible in vitro tests also exist. Quality control personnel and investigators rely excessively on in vivo gold-standard tests because of a sense of uncertainty as to how reliably the secondary test functions as a replacement for the primary in vivo test. In this chapter we present a statistical method in which the results of the secondary test are calibrated against the results of the primary test in such a way as to allow the investigator to employ the secondary test in the context of very precisely defined and controlled levels of uncertainty. This method will allow for a substantial reduction in the use of animal subjects. C1 [Murray, Samuel S.] Univ Calif Los Angeles, Interdept Program Biomed Engn, Los Angeles, CA USA. [Murray, Samuel S.; Brochmann, Elsa J.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Murray, Samuel S.; Brochmann, Elsa J.] Univ Calif Los Angeles, VA Greater Los Angeles, Geriatr Res Educ & Clin Ctr, Los Angeles, CA 90024 USA. [Behnam, Keyvan; Harker, Judith O.] VA Greater Los Angeles, Res Serv, Sepulveda, CA 91343 USA. [Behnam, Keyvan] Lanx Inc, Broomfield, CO USA. RP Murray, SS (reprint author), VA Med Ctr, VA Greater Los Angeles, Geriatr Res Educ & Clin Ctr, GRECC 11-E,,16111 Plummer St, Sepulveda, CA 91343 USA. EM Samuel.Murray@va.gov NR 7 TC 0 Z9 0 U1 0 U2 0 PU ARTECH HOUSE PI NORWOOD PA 685 CANTON ST, NORWOOD, MA 02062 USA BN 978-1-60807-011-4 J9 ARTECH HSE METH BIOE JI Art. Hse. Meth. Bioengr. Ser. PY 2010 BP 147 EP 158 PG 12 WC Engineering, Biomedical SC Engineering GA BPH05 UT WOS:000278836700008 ER PT B AU Agrawal, N Toner, M Irimia, D AF Agrawal, Nitin Toner, Mehmet Irimia, Daniel BE Zahn, JD TI Neutrophil Chemotaxis Assay from Whole Blood Samples SO METHODS IN BIOENGINEERING: BIOMICROFABRICATION AND BIOMICROFLUIDICS SE Artech House Methods in Bioengineering Series LA English DT Article; Book Chapter DE chemotaxis; neutrophil; chemokine; gradient; microfluidic; P-selectin ID POLYMORPHONUCLEAR LEUKOCYTES; GRADIENT GENERATOR; MIGRATION; RECRUITMENT; CHEMOKINES; ADHESION AB Neutrophils constitute an integral part of the immune system and possess abilities to sense chemical gradients and migrate towards sites of infection and inflammation in the body. These processes, also known as chemotaxis, are critical for early immune responses and for preserving the sterility of the body's internal environment. To better understand the complexities involved in chemotaxis process in vivo, usually neutrophils are isolated and chemotaxis assays are performed in vitro under a higher degree of microenvironment control. However, most in vitro chemotaxis studies often require large volumes of blood to isolate neutrophils and the isolation protocols could alter the original neutrophils activity levels. In this chapter, a microfluidic device is described that captures neutrophils from just one drop of whole blood and quantitatively measures neutrophil chemotaxis towards stable gradients of chemokines. To better replicate in vivo conditions, a systematic approach to creating various temporal sequences of linear and non-linear spatial gradients in microfluidic devices has been developed and discussed in this chapter. C1 [Agrawal, Nitin; Toner, Mehmet] Massachusetts Gen Hosp, Shriners Hosp Children, Ctr Engn Med & Surg Serv, BioMEMS Resource Ctr, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Agrawal, N (reprint author), Massachusetts Gen Hosp, Shriners Hosp Children, Ctr Engn Med & Surg Serv, BioMEMS Resource Ctr, Boston, MA 02114 USA. EM dirimia@hms.harvard.edu NR 19 TC 0 Z9 0 U1 0 U2 3 PU ARTECH HOUSE PI NORWOOD PA 685 CANTON ST, NORWOOD, MA 02062 USA BN 978-1-59693-400-9 J9 ARTECH HSE METH BIOE JI Art. Hse. Meth. Bioengr. Ser. PY 2010 BP 209 EP 224 PG 16 WC Biotechnology & Applied Microbiology; Engineering, Biomedical SC Biotechnology & Applied Microbiology; Engineering GA BMB93 UT WOS:000271804800008 ER PT S AU Dreze, M Monachello, D Lurin, C Cusick, ME Hill, DE Vidal, M Braun, P AF Dreze, Matija Monachello, Dario Lurin, Claire Cusick, Michael E. Hill, David E. Vidal, Marc Braun, Pascal BE Weissman, J Guthrie, C Fink, GR TI HIGH-QUALITY BINARY INTERACTOME MAPPING SO METHODS IN ENZYMOLOGY, VOL 470: GUIDE TO YEAST GENETICS:: FUNCTIONAL GENOMICS, PROTEOMICS, AND OTHER SYSTEMS ANALYSIS, 2ND EDITION SE Methods in Enzymology LA English DT Review; Book Chapter ID PROTEIN-PROTEIN INTERACTIONS; REVERSE 2-HYBRID SYSTEM; OPEN READING FRAMES; ORFEOME VERSION 1.1; SACCHAROMYCES-CEREVISIAE; INTERACTION NETWORK; INTERACTION MAP; YEAST; PHOSPHATASE; CONFIDENCE AB Physical interactions mediated by proteins are critical for most cellular functions and altogether form a complex macromolecular "interactome" network. Systematic mapping of protein protein, protein DNA, protein RNA, and protein metabolite interactions at the scale of the whole proteome can advance understanding of interactome networks with applications ranging from single protein functional characterization to discoveries on local and global systems properties. Since the early efforts at mapping protein protein interactome networks a decade ago, the field has progressed rapidly giving rise to a growing number of interactome maps produced using high-throughput implementations of either binary protein protein interaction assays or co-complex protein association methods. Although high-throughput methods are often thought to necessarily produce lower quality information than low-throughput experiments, we have recently demonstrated that proteome-scale interactome datasets can be produced with equal or superior quality than that observed in literature-curated datasets derived from large numbers of small-scale experiments. In addition to performing all experimental steps thoroughly and including all necessary controls and quality standards, careful verification of all interacting pairs and validation tests using independent, orthogonal assays are crucial to ensure the release of interactome maps of the highest possible quality. This chapter describes a high-quality, high-throughput binary protein protein interactome mapping pipeline that includes these features. C1 [Dreze, Matija; Monachello, Dario; Cusick, Michael E.; Hill, David E.; Vidal, Marc; Braun, Pascal] Dana Farber Canc Inst, CCSB, Boston, MA 02115 USA. [Dreze, Matija; Monachello, Dario; Cusick, Michael E.; Hill, David E.; Vidal, Marc; Braun, Pascal] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Dreze, Matija; Cusick, Michael E.; Hill, David E.; Vidal, Marc; Braun, Pascal] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. [Dreze, Matija] Fac Univ Notre Dame Paix, B-5000 Namur, Belgium. [Monachello, Dario; Lurin, Claire] URGV, Evry, France. RP Dreze, M (reprint author), Dana Farber Canc Inst, CCSB, Boston, MA 02115 USA. RI Hill, David/B-6617-2011; Braun, Pascal/B-9669-2013; OI Braun, Pascal/0000-0003-2012-6746; , /0000-0001-7002-8488 FU NHGRI NIH HHS [P50 HG004233, P50-HG004233, R01-HG001715] NR 43 TC 67 Z9 69 U1 0 U2 13 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0076-6879 BN 978-0-12-375172-0 J9 METHOD ENZYMOL JI Methods Enzymol. PY 2010 VL 470 BP 281 EP 315 DI 10.1016/S0076-6879(10)70012-4 PG 35 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BNX73 UT WOS:000275827900012 PM 20946815 ER PT S AU Perez, VI Pierce, A de Waal, EM Ward, WF Bokov, A Chaudhuri, A Richardson, A AF Perez, Viviana I. Pierce, Anson de Waal, Eric M. Ward, Walter F. Bokov, Alex Chaudhuri, Asish Richardson, Arlan BE Cadenas, E Packer, L TI DETECTION AND QUANTIFICATION OF PROTEIN DISULFIDES IN BIOLOGICAL TISSUES: A FLUORESCENCE-BASED PROTEOMIC APPROACH SO METHODS IN ENZYMOLOGY, VOL 473: THIOL REDOX TRANSITIONS IN CELL SIGNALING, PT A: CHEMISTRY AND BIOCHEMISTRY OF LOW MOLECULAR WEIGHT AND PROTEIN THIOLS SE Methods in Enzymology LA English DT Review; Book Chapter ID OXIDATIVE STRESS; METHIONINE OXIDATION; TOXICITY; DISEASE; MUSCLE; DAMAGE AB While most of the amino acids in proteins are potential targets for oxidation, the thiol group in cysteine is one of the most reactive amino acid side chains. The thiol group can be oxidized to several states, including the disulfide bond. Despite the known sensitivity of cysteine to oxidation and the physiological importance of the thiol group to protein structure and function, little information is available on the oxidative modification of cysteine residues in proteins because of the lack of reproducible and sensitive assays to measure cysteine oxidation in the proteome. We have developed a fluorescence-based assay that allows one to quantify both the global level of protein disulfides in the cellular proteome as well as the disulfide content of individual proteins. This fluorescence-based assay is able to detect an increase in global protein disulfide levels after oxidative stress in vitro or in vivo. Using this assay, we show that the global protein disulfide levels increase significantly with age in liver cytosolic proteins, and we identified 11 proteins that show a more than twofold increase in disulfide content with age. Thus, the fluorescence-based assay we have developed allows one to quantify changes in the oxidation of cysteine residues to disulfides in the proteome of a cell or tissue. C1 [Perez, Viviana I.; Pierce, Anson; Bokov, Alex; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Ward, Walter F.; Chaudhuri, Asish] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [de Waal, Eric M.] Univ Texas San Antonio, Dept Biol, San Antonio, TX USA. [Perez, Viviana I.; Pierce, Anson; Ward, Walter F.; Chaudhuri, Asish; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Chaudhuri, Asish] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Bokov, Alex] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Pierce, Anson; Chaudhuri, Asish; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. RP Perez, VI (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. RI Pierce, Anson/D-1079-2012 OI Pierce, Anson/0000-0002-1383-0180 FU NIA NIH HHS [R01 AG025362]; PHS HHS [R37HE26557] NR 30 TC 6 Z9 6 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0076-6879 BN 978-0-12-381345-9 J9 METHOD ENZYMOL JI Methods Enzymol. PY 2010 VL 473 BP 161 EP 177 DI 10.1016/S0076-6879(10)73008-1 PG 17 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BPK52 UT WOS:000279058700008 PM 20513477 ER PT S AU Toprak, E Kural, C Selvin, PR AF Toprak, Erdal Kural, Comert Selvin, Paul R. BE Walter, NG TI SUPER-ACCURACY AND SUPER-RESOLUTION: GETTING AROUND THE DIFFRACTION LIMIT SO METHODS IN ENZYMOLOGY, VOL 475: SINGLE MOLECULE TOOLS, PT B: SUPER-RESOLUTION, PARTICLE TRACKING, MULTIPARAMETER, AND FORCE BASED METHODS SE Methods in Enzymology LA English DT Review; Book Chapter ID HAND-OVER-HAND; SINGLE KINESIN MOLECULES; FIELD OPTICAL NANOSCOPY; FLUORESCENCE MICROSCOPY; QUANTUM DOTS; STRUCTURED-ILLUMINATION; LIVE CELLS; IN-VIVO; RESOLUTION COLOCALIZATION; NANOMETER LOCALIZATION AB In many research areas such as biology, biochemistry, and biophysics, measuring distances or identifying and counting objects can be of great importance. To do this, researchers often need complicated and expensive tools in order to have accurate measurements. In addition, these measurements are often done under nonphysiological settings. X-ray diffraction, for example, gets Angstrom-level structures, but it requires. crystallizing a biological specimen. Electron microscopy (EM) has about 10 angstrom resolution, but often requires frozen (liquid nitrogen) samples. Optical microscopy, while coming closest to physiologically relevant conditions, has been limited by the minimum distances to be measured, typically about the diffraction limit, or similar to 200 nm. However, most biological molecules are <5-10 nm in diameter, and getting molecular details requires imaging at this scale. In this chapter, we will describe some of the experimental approaches, from our lab and others, that push the limits of localization accuracy and optical resolution in fluorescence microscopy. C1 [Toprak, Erdal; Kural, Comert; Selvin, Paul R.] Univ Illinois, Dept Biophys, Urbana, IL 61801 USA. [Toprak, Erdal] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA. [Kural, Comert] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA USA. [Selvin, Paul R.] Univ Illinois, Dept Phys, Urbana, IL 61801 USA. RP Toprak, E (reprint author), Univ Illinois, Dept Biophys, Urbana, IL 61801 USA. RI Toprak, Erdal/P-6340-2014 NR 90 TC 10 Z9 10 U1 1 U2 12 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0076-6879 BN 978-0-12-381482-1 J9 METHOD ENZYMOL JI Methods Enzymol. PY 2010 VL 475 BP 1 EP 26 DI 10.1016/S0076-6879(10)75001-1 PG 26 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BQD36 UT WOS:000280733800001 PM 20627151 ER PT B AU Lin, FH Tsai, SY AF Lin, Fa-Hsuan Tsai, Shang-Yueh BE Hayat, MA TI Parallel Magnetic Resonance Imaging Acquisition and Reconstruction: Application to Functional and Spectroscopic Imaging in Human Brain SO METHODS OF CANCER DIAGNOSIS, THERAPY, AND PROGNOSIS: BRAIN CANCER SE Methods of Cancer Diagnosis Therapy and Prognosis LA English DT Article; Book Chapter ID K-SPACE TRAJECTORIES; SINGLE-SHOT; MULTIPLE DETECTORS; SENSE-EPI; FAST MRI; COIL; FMRI; TUMORS; SMASH; DIAGNOSIS C1 [Lin, Fa-Hsuan; Tsai, Shang-Yueh] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA 02129 USA. RP Lin, FH (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Bldg 149 Room 230,13th St, Charlestown, MA 02129 USA. RI Lin, Fa-Hsuan/G-6988-2012 OI Lin, Fa-Hsuan/0000-0002-9539-1731 NR 58 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-90-481-8664-8 J9 METHODS CANCER DIAGN PY 2010 VL 8 BP 245 EP 262 DI 10.1007/978-90-481-8665-5_20 D2 10.1007/978-90-481-8665-5 PG 18 WC Oncology; Medicine, General & Internal SC Oncology; General & Internal Medicine GA BSQ98 UT WOS:000285524100020 ER PT B AU Percival, SL Cooper, RA Lipsky, BA AF Percival, Steven L. Cooper, Rose A. Lipsky, Benjamin A. BE Percival, S Cutting, K TI Antimicrobial Interventions for Wounds SO MICROBIOLOGY OF WOUNDS LA English DT Article; Book Chapter ID PSEUDOMONAS-AERUGINOSA BIOFILMS; RESISTANT STAPHYLOCOCCUS-AUREUS; RANDOMIZED CONTROLLED-TRIAL; GRAM-NEGATIVE BACTERIA; CATHETER LOCK SOLUTION; DIABETIC FOOT ULCERS; VENOUS LEG ULCERS; IN-VITRO ACTIVITY; HYDROGEN-PEROXIDE; POLYHEXAMETHYLENE BIGUANIDE C1 [Percival, Steven L.] W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr N, Morgantown, WV 26506 USA. [Percival, Steven L.] Adv Med Solut, Winsford, Cheshire, England. [Cooper, Rose A.] Cardiff Inst Higher Educ, Cardiff, S Glam, Wales. [Lipsky, Benjamin A.] Univ Washington, Sch Med, Dept Med, Vet Affairs Puget Sound Hlth Care Syst,Div Gen In, Seattle, WA 98195 USA. RP Percival, SL (reprint author), W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr N, Morgantown, WV 26506 USA. NR 206 TC 4 Z9 4 U1 0 U2 1 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA BN 978-1-4200-7994-4; 978-1-4200-7993-7 PY 2010 BP 293 EP 327 DI 10.1201/9781420079944-c11 D2 10.1201/9781420079944 PG 35 WC Medicine, General & Internal; Microbiology SC General & Internal Medicine; Microbiology GA BQR89 UT WOS:000281681000012 ER PT J AU Fukumura, D Duda, DG Munn, LL Jain, RK AF Fukumura, Dai Duda, Dan G. Munn, Lance L. Jain, Rakesh K. TI Tumor Microvasculature and Microenvironment: Novel Insights Through Intravital Imaging in Pre-Clinical Models SO MICROCIRCULATION LA English DT Review DE intravital microscopy; angiogenesis; lymphangiogenesis; tumor; stromal cells; microenvironment; vascular normalization ID ENDOTHELIAL GROWTH-FACTOR; GREEN FLUORESCENT PROTEIN; METASTATIC COLORECTAL-CANCER; VASCULAR-PERMEABILITY FACTOR; HUMAN ADENOCARCINOMA LS174T; INDUCED LEUKOCYTE ADHESION; HUMAN-MELANOMA CELLS; IN-VIVO MEASUREMENT; HIGH-RESOLUTION; NITRIC-OXIDE AB P>Intravital imaging techniques have provided unprecedented insight into tumor microcirculation and microenvironment. For example, these techniques allowed quantitative evaluations of tumor blood vasculature to uncover its abnormal organization, structure and function (e.g., hyper-permeability, heterogeneous and compromised blood flow). Similarly, imaging of functional lymphatics has documented their absence inside tumors. These abnormalities result in elevated interstitial fluid pressure and hinder the delivery of therapeutic agents to tumors. In addition, they induce a hostile microenvironment characterized by hypoxia and acidosis, as documented by intravital imaging. The abnormal microenvironment further lowers the effectiveness of anti-tumor treatments such as radiation therapy and chemotherapy. In addition to these mechanistic insights, intravital imaging may also offer new opportunities to improve therapy. For example, tumor angiogenesis results in immature, dysfunctional vessels-primarily caused by an imbalance in production of pro- and anti-angiogenic factors by the tumors. Restoring the balance of pro- and anti-angiogenic signaling in tumors can "normalize" tumor vasculature and thus, improve its function, as demonstrated by intravital imaging studies in preclinical models and in cancer patients. Administration of cytotoxic therapy during periods of vascular normalization has the potential to enhance treatment efficacy. C1 [Fukumura, Dai] Massachusetts Gen Hosp, Edwin L Steele Lab Tumor Biol, Dept Radiat Oncol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Fukumura, D (reprint author), Massachusetts Gen Hosp, Edwin L Steele Lab Tumor Biol, Dept Radiat Oncol, 100 Blossom St,Cox 7, Boston, MA 02114 USA. EM dai@steele.mgh.harvard.edu; jain@steele.mgh.harvard.edu RI Munn, Lance/L-3950-2016 OI Munn, Lance/0000-0003-0698-7232 FU National Cancer Institute [P01-CA-080124, R01-CA085140, R01-CA096915, R01-CA115767, R01-CA126642, R21-139168] FX This review is based on the following previous review articles: Jain RK, Munn LL, Fukumura D (2002): Dissecting tumor pathophysiology using intravital microscopy. Nature Reviews Cancer 2:266-76; Jain RK (2005): Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62; Fukumura D (2005): Role of microenvironment on gene expression, angiogenesis and microvascular functions in tumors. In: Meadows GG (ed) "Integration/Interaction of Oncologic Growth." Dordrecht: Springer Science + Business Media B.V., pp. 23-36; Fukumura D and Jain RK (2007): Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. Journal of Cellular Biochemistry 101: 937-949; Fukumura D, Jain RK (2007): Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvascular Research 74:72-84; Jain RK, Booth MF, Padera TP, Munn LL, Fukumura D, Brown E (2008): Applications of non-linear intravital microscopy in tumor biology In: So P., Masters B. (eds) Handbook of Biological Nonlinear Optical Microscopy. New York, NY: Oxford University Press. Chapter 29. pp. 735-56; Fukumura D, Jain RK (2008): Imaging angiogenesis and the microenvironment. APMIS 116: 695-715. The work summarized here has been supported by continuous support from the National Cancer Institute since 1980 including P01-CA-080124 (R.K. Jain and D. Fukumura), R01-CA085140 (R.K. Jain), R01-CA096915 (D. Fukumura), R01-CA115767 (R.K. Jain), R01-CA126642 (R.K. Jain) and R21-139168 (D.G. Duda). NR 170 TC 168 Z9 175 U1 4 U2 59 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1073-9688 J9 MICROCIRCULATION JI Microcirculation PY 2010 VL 17 IS 3 BP 206 EP 225 DI 10.1111/j.1549-8719.2010.00029.x PG 20 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 576NI UT WOS:000276150900005 PM 20374484 ER PT B AU Grimes, KJ Henderson, BA AF Grimes, Kelly J. Henderson, Bonnie An BE Agarwal, A Lindstrom, RL TI MICS INJECTOR SYSTEMS SO MICROINCISIONAL CATARACT SURGERY; THE ART AND SCIENCE LA English DT Article; Book Chapter ID PHAKONIT; MICROPHAKONIT; LENS C1 [Grimes, Kelly J.; Henderson, Bonnie An] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Grimes, Kelly J.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Henderson, Bonnie An] Ophthalm Consultants Boston, Boston, MA USA. RP Grimes, KJ (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA. NR 11 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-943-9 PY 2010 BP 157 EP 163 PG 7 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA BOL09 UT WOS:000276924000017 ER PT B AU Hariri, S Freiberg, AA AF Hariri, Sanaz Freiberg, Andrew A. BE Scuderi, GR Tria, AJ TI Anterolateral Mini-incision Total Hip Arthroplasty SO MINIMALLY INVASIVE SURGERY IN ORTHOPEDICS LA English DT Article; Book Chapter ID TROCHANTERIC OSTEOTOMY; GREATER TROCHANTER; LATERAL APPROACH; REPLACEMENT C1 [Hariri, Sanaz; Freiberg, Andrew A.] Massachusetts Gen Hosp, Dept Orthoped, Yawkey Ctr Outpatient Care, Boston, MA 02114 USA. RP Freiberg, AA (reprint author), Massachusetts Gen Hosp, Dept Orthoped, Yawkey Ctr Outpatient Care, 55 Fruit St,Suite 3700, Boston, MA 02114 USA. EM afreiburg@partners.org NR 16 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-76607-2 PY 2010 BP 157 EP 162 DI 10.1007/978-0-387-76608-9_18 D2 10.1007/978-0-387-76608-9 PG 6 WC Orthopedics; Surgery SC Orthopedics; Surgery GA BLY98 UT WOS:000271472700018 ER PT B AU Berger, R Freiberg, A Mont, M Falez, F Hartzband, M Bal, S AF Berger, Richard Freiberg, Andrew Mont, Michael Falez, Francesco Hartzband, Mark Bal, Sonny BE Scuderi, GR Tria, AJ TI Round Table Discussion of Mini-incision Total Hip Arthroplasty SO MINIMALLY INVASIVE SURGERY IN ORTHOPEDICS LA English DT Editorial Material; Book Chapter C1 [Berger, Richard] Rush Presbyterian St Lukes Med Ctr, Dept Orthopaed Surg, Chicago, IL 60612 USA. [Bal, Sonny] Univ Missouri, Dept Orthopaed Surg, Columbia, MO USA. [Falez, Francesco] S Spirito Sassia Hosp, Dept Orthopaed & Traumatol, Rome, Italy. [Freiberg, Andrew] Massachusetts Gen Hosp, Dept Orthoped Surg, Yawkey Ctr Outpatient Care, Boston, MA 02114 USA. [Hartzband, Mark] Hackensack Univ, Med Ctr, Joint Replacement Serv, Dept Orthoped, Hackensack, NJ USA. [Hartzband, Mark] Hartzband Ctr Hip & Knee Replacement, Paramus, NJ USA. [Mont, Michael] Sinai Hosp, Rubin Inst Adv Orthopaed, Ctr Joint Preservat & Reconstruct, Baltimore, MD 21215 USA. RP Berger, R (reprint author), Rush Presbyterian St Lukes Med Ctr, Dept Orthopaed Surg, 1653 W Congress Pkwy, Chicago, IL 60612 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-76607-2 PY 2010 BP 221 EP 225 DI 10.1007/978-0-387-76608-9_25 D2 10.1007/978-0-387-76608-9 PG 5 WC Orthopedics; Surgery SC Orthopedics; Surgery GA BLY98 UT WOS:000271472700025 ER PT B AU Naseri, A Chang, DF AF Naseri, Ayman Chang, David F. BE Alio, JL Fine, IH TI Endophthalmitis Prevention SO MINIMIZING INCISIONS AND MAXIMIZING OUTCOMES IN CATARACT SURGERY LA English DT Article; Book Chapter ID CORNEAL CATARACT INCISIONS; PROPHYLACTIC INTRACAMERAL CEFUROXIME; 0.5-PERCENT OPHTHALMIC SOLUTION; ACUTE-ONSET ENDOPHTHALMITIS; OCULAR SURFACE FLUID; POSTOPERATIVE ENDOPHTHALMITIS; AQUEOUS-HUMOR; MOXIFLOXACIN 0.5-PERCENT; GATIFLOXACIN 0.3-PERCENT; SURGERY PATIENTS C1 [Naseri, Ayman] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA. [Naseri, Ayman] San Francisco VA Med Ctr, San Francisco, CA USA. RP Naseri, A (reprint author), Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA. EM Ayman.Naseri@va.gov NR 45 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-3-642-02861-8 PY 2010 BP 156 EP 162 DI 10.1007/978-3-642-02862-5_23 PG 7 WC Ophthalmology SC Ophthalmology GA BMW13 UT WOS:000273701300023 ER PT B AU Galka, A Wong, KKF Ozaki, T AF Galka, A. Wong, K. K. F. Ozaki, T. BE SteynRoss, DA SteynRoss, M TI Generalized state-space models for modeling nonstationary EEG time-series SO MODELING PHASE TRANSITIONS IN THE BRAIN SE Springer Series in Computational Neuroscience LA English DT Article; Book Chapter ID MAXIMUM-LIKELIHOOD; DECOMPOSITION; VARIANCE C1 [Galka, A.] Univ Kiel, Dept Neurol, D-24105 Kiel, Germany. [Wong, K. K. F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. [Ozaki, T.] Tohoku Univ, Aoba Ku, Sendai, Miyagi 9808576, Japan. RP Galka, A (reprint author), Univ Kiel, Dept Neurol, Schittenhelmstr 10, D-24105 Kiel, Germany. EM a.galka@neurologie.uni-kiel.de RI Wong, Kin Foon Kevin/C-7896-2014 NR 25 TC 6 Z9 6 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-0795-0 J9 SPR SER COMPUT NEURO JI Springer Ser. Comput. Neurosci. PY 2010 VL 4 BP 27 EP 52 DI 10.1007/978-1-4419-0796-7_2 PG 26 WC Mathematics, Applied; Neurosciences SC Mathematics; Neurosciences & Neurology GA BNP89 UT WOS:000275191100003 ER PT J AU Troxell, ML Levine, J Beadling, C Warrick, A Dunlap, J Presnell, A Patterson, J Shukla, A Olson, NR Heinrich, MC Corless, CL AF Troxell, Megan L. Levine, Judith Beadling, Carol Warrick, Andrea Dunlap, Jennifer Presnell, Ajia Patterson, Janice Shukla, Arielle Olson, Neal R. Heinrich, Michael C. Corless, Christopher L. TI High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast SO MODERN PATHOLOGY LA English DT Article DE phosphoinositol-3-kinase (PIK3CA); AKT1; breast; papilloma; papillary carcinoma ID COMPARATIVE GENOMIC HYBRIDIZATION; INTRADUCTAL PROLIFERATIVE LESIONS; POLYMERASE-CHAIN-REACTION; IN-SITU; DUCTAL HYPERPLASIA; CLONAL ANALYSIS; HIGH-FREQUENCY; HUMAN CANCERS; PTEN LOSS; CARCINOMA AB Papillary lesions of the breast have an uncertain relationship to the histogenesis of breast carcinoma, and are thus diagnostically and managerially challenging. Molecular genetic studies have provided evidence that ductal carcinoma in situ and even atypical ductal hyperplasia are precursors of invasive carcinoma. However, papillary lesions have been seldom studied. We screened papillary breast neoplasms for activating point mutations in PIK3CA, AKT1, and RAS protein-family members, which are common in invasive ductal carcinomas. DNA extracts were prepared from sections of 89 papillary lesions, including 61 benign papillomas ( 28 without significant hyperplasia; 33 with moderate to florid hyperplasia), 11 papillomas with atypical ductal hyperplasia, 7 papillomas with carcinoma in situ, and 10 papillary carcinomas. Extracts were screened for PIK3CA and AKT1 mutations using mass spectrometry; cases that were negative were further screened for mutations in AKT2, BRAF, CDK, EGFR, ERBB2, KRAS, NRAS, and HRAS. Mutations were confirmed by sequencing or HPLC assay. A total of 55 of 89 papillary neoplasms harbored mutations (62%), predominantly in AKT1 (E17K, 27 cases) and PIK3CA (exon 20 > exon 9, 27 cases). Papillomas had more mutations in AKT1 (54%) than in PIK3CA (21%), whereas papillomas with hyperplasia had more PIK3CA (42%) than AKT1 (15%) mutations, as did papillomas with atypical ductal hyperplasia ( PIK3CA 45%, AKT1 27%, and NRAS 9%). Among seven papillomas with carcinoma in situ, three had AKT1 mutations. The 10 papillary carcinomas showed an overall lower frequency of mutations, including 1 with an AKT1 mutation ( in a tumor arising from a papilloma), 1 with an NRAS gene mutation (Q61H), and 2 with PIK3CA mutations ( 1 overlapping with the NRAS Q61H). These findings indicate that approximately two-thirds of papillomas are driven by mutations in the PI3CA/AKT pathway. Some papillary carcinomas may arise from these lesions, but others may have different molecular origins. Modern Pathology ( 2010) 23, 27-37; doi: 10.1038/modpathol.2009.142; published online 6 November 2009 C1 [Troxell, Megan L.] Oregon Hlth & Sci Univ, Dept Pathol, Knight Canc Inst, Portland, OR 97239 USA. [Olson, Neal R.] Kaiser Permanente NW, Dept Pathol, Portland, OR USA. [Heinrich, Michael C.] Portland VA Med Ctr, Portland, OR USA. [Heinrich, Michael C.] Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97239 USA. RP Troxell, ML (reprint author), Oregon Hlth & Sci Univ, Dept Pathol, Knight Canc Inst, 3181 SW Sam Jackson Pk Rd,L471, Portland, OR 97239 USA. EM troxellm@ohsu.edu OI Patterson, Janice/0000-0002-8969-2933 FU Department of Veterans Affairs (MCH); Oregon Health & Science University Medical Research Foundation FX We acknowledge expert technical assistance of Carolyn Gendron, Emily Justusson, Dylan Nelson, Cara Poage, Linh Matsumura, Jennifer Podolak, and administrative assistance of Sally Ison and Lynne Rowell. This work was supported in part by a VA Merit Review Grant from the Department of Veterans Affairs (MCH) and by a grant from the Oregon Health & Science University Medical Research Foundation. NR 51 TC 44 Z9 45 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2010 VL 23 IS 1 BP 27 EP 37 DI 10.1038/modpathol.2009.142 PG 11 WC Pathology SC Pathology GA 539IV UT WOS:000273248500003 PM 19898424 ER PT J AU Park, DY Srivastava, A Kim, GH Mino-Kenudson, M Deshpande, V Zukerberg, LR Song, GA Lauwers, GY AF Park, Do Youn Srivastava, Amitabh Kim, Gwang Ha Mino-Kenudson, Mari Deshpande, Vikram Zukerberg, Lawrence R. Song, Geum Am Lauwers, Gregory Y. TI CDX2 expression in the intestinal-type gastric epithelial neoplasia: frequency and significance SO MODERN PATHOLOGY LA English DT Article DE CDX2; dysplasia; gastric cancer; mucin ID HOMEOBOX GENE-EXPRESSION; GASTROINTESTINAL-TRACT; COLORECTAL CARCINOGENESIS; MUCIN EXPRESSION; MUTANT MICE; DIFFERENTIATION; METAPLASIA; CANCER; CARCINOMA; CLASSIFICATION AB CDX2 is an intestinal transcription factor responsible for regulating the proliferation and differentiation of intestinal epithelial cells. In gastric adenocarcinoma, CDX2 expression is known to be associated with limited invasiveness and intestinal phenotypes. The aims of this study were to analyze CDX2 expression in a series of well-characterized cases of gastric epithelial dysplasia, based on the morphologic and mucin phenotypes, and also to analyze CDX2 expression along the metaplasia-dysplasia-carcinoma sequence. CDX2 expression was evaluated in 69 cases of gastric epithelial dysplasia, 88 cases of intestinal-type early gastric cancers, and 56 cases of advanced gastric cancers. Increased CDX2 expression was more frequently associated with adenomatous-type gastric epithelial dysplasia (27/31, 87%) compared with foveolar (7/15, 47%) or hybrid (10/23, 44%) types of gastric epithelial dysplasia ( P = 0.001). CDX2 expression correlated with an increase in CD10 expression ( P = 0.005), and a decrease in MUC5AC expression ( P = 0.001) in gastric epithelial dysplasia. CDX2 expression was also gradually decreased from gastric epithelial dysplasia, to early and advanced gastric cancers ( present in 64, 40 and 27% of the cases, respectively). A negative correlation was also observed between CDX2 expression and the depth of tumor invasion. Our results indicate that CDX2 expression is associated with specific morphological and mucin phenotypes of gastric epithelial dysplasias, and decreases progressively with the advancing stage of gastric cancers, suggesting a possible tumor suppressor role for CDX2. Modern Pathology ( 2010) 23, 54-61; doi: 10.1038/modpathol.2009.135; published online 9 October 2009 C1 [Lauwers, Gregory Y.] Massachusetts Gen Hosp, Dept Pathol, Gastrointestinal Pathol Serv, Boston, MA 02114 USA. [Park, Do Youn] Pusan Natl Univ Hosp, Dept Pathol, Pusan, South Korea. [Srivastava, Amitabh] Dartmouth Hitchcock Med Ctr, Dept Pathol, Lebanon, NH 03766 USA. [Srivastava, Amitabh] Dartmouth Med Sch, Lebanon, NH USA. [Kim, Gwang Ha; Song, Geum Am] Pusan Natl Univ Hosp, Dept Gastroenterol, Pusan, South Korea. [Kim, Gwang Ha; Song, Geum Am] Pusan Natl Univ, Med Res Inst, Pusan, South Korea. RP Lauwers, GY (reprint author), Massachusetts Gen Hosp, Dept Pathol, Gastrointestinal Pathol Serv, 55 Fruit St,WRN 2, Boston, MA 02114 USA. EM glauwers@partners.org FU Ministry for Health, Welfare and Family affairs, Republic of Korea [0920050] FX Presented in part at the annual meeting of United States and Canadian Academy of Pathology, San Diego, CA, 24-30 March 2007. This study was supported by a grant from the National R&D Program for Cancer Control, Ministry for Health, Welfare and Family affairs, Republic of Korea ( Project ID: 0920050). NR 29 TC 32 Z9 33 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2010 VL 23 IS 1 BP 54 EP 61 DI 10.1038/modpathol.2009.135 PG 8 WC Pathology SC Pathology GA 539IV UT WOS:000273248500006 PM 19820687 ER PT S AU Qin, WP Bauman, WA Cardozo, C AF Qin, Weiping Bauman, William A. Cardozo, Christopher BE Mechanick, JI Sun, L Zaidi, M TI Bone and muscle loss after spinal cord injury: organ interactions SO MOLECULAR AND INTEGRATIVE PHYSIOLOGY OF THE MUSCULOSKELETAL SYSTEM SE Annals of the New York Academy of Sciences LA English DT Article; Book Chapter DE spinal cord injury; bone loss; muscle atrophy; body composition; testosterone; estrogen; insulin-like growth factor 1; methylprednisolone ID GROWTH-FACTOR-I; RANDOMIZED CONTROLLED-TRIAL; GLUCOCORTICOID-INDUCED OSTEOPOROSIS; QUANTITATIVE COMPUTED-TOMOGRAPHY; VASOACTIVE-INTESTINAL-PEPTIDE; FOXO TRANSCRIPTION FACTORS; SKELETAL-MUSCLE; MINERAL DENSITY; PARAPLEGIC PATIENTS; GENE-EXPRESSION AB Spinal cord injury (SCI) results in paralysis and marked loss of skeletal muscle and bone below the level of injury. Modest muscle activity prevents atrophy, whereas much larger and as yet poorly defined bone loading seems necessary to prevent bone loss. Once established, bone loss may be irreversible. SCI is associated with reductions in growth hormone, IGF-1, and testosterone, deficiencies likely to exacerbate further loss of muscle and bone. Reduced muscle mass and inactivity are assumed to be contributors to the high prevalence of insulin resistance and diabetes in this population. Alterations in muscle gene expression after SCI share common features with other muscle loss states, but even so, show distinct profiles, possibly reflecting influences of neuromuscular activity due to spasticity. Changes in bone cells and markers after SCI have similarities with other conditions of unloading, although after SCI these changes are much more dramatic, perhaps reflecting the much greater magnitude of unloading. Adiposity and marrow fat are increased after SCI with intriguing, though poorly understood, implications for the function of skeletal muscle and bone cells. C1 [Qin, Weiping; Bauman, William A.; Cardozo, Christopher] James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY 10468 USA. [Qin, Weiping; Bauman, William A.; Cardozo, Christopher] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Bauman, William A.; Cardozo, Christopher] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. RP Qin, WP (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Weiping.qin@mssm.edu NR 211 TC 53 Z9 54 U1 0 U2 10 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA SN 0077-8923 BN 978-1-57331-831-0 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2010 VL 1211 BP 66 EP 84 DI 10.1111/j.1749-6632.2010.05806.x PG 19 WC Endocrinology & Metabolism; Multidisciplinary Sciences; Physiology SC Endocrinology & Metabolism; Science & Technology - Other Topics; Physiology GA BTO14 UT WOS:000287463400007 PM 21062296 ER PT J AU Sasanfar, R Haddad, SA Tolouei, A Ghadami, M Yu, DM Santangelo, SL AF Sasanfar, Roksana Haddad, Stephen A. Tolouei, Ala Ghadami, Majid Yu, Dongmei Santangelo, Susan L. TI Paternal age increases the risk for autism in an Iranian population sample SO MOLECULAR AUTISM LA English DT Article AB Background: Autism is a neurodevelopmental disorder which is known to have a strong genetic component and is most likely oligogenic. However, the necessary role of environmental factors has been well documented. Prior research suggests that parental characteristics, such as age and level of education, may be associated with a risk of autism. Parental age has been shown to be associated with many disorders, such as schizophrenia, childhood cancer and fetal death. However, results from studies of parental age and autism are inconsistent. Methods: In the present study, we investigated the association of autism with parental age in 179 autism cases and 1611 matched cohort children from Iran. Each case was matched with nine cohort controls on parental education, sex, order of birth, consanguineous marriage, urbanism and province of residence. The Cox regression model was used to carry out conditional logistic regression on the matched data. Results: There was a significant association between higher paternal age, but not maternal age, and an increasing risk of autism. An analysis of the combined effect of parental age and education also revealed that parents with higher education had an increased risk of having autistic children, with a dose-response effect of parental age. Conclusions: This study, which is the first epidemiological study of autism in Iran, provides evidence of the association of paternal age and risk of autism. C1 [Sasanfar, Roksana; Santangelo, Susan L.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Sasanfar, Roksana; Haddad, Stephen A.; Yu, Dongmei; Santangelo, Susan L.] Massachusetts Gen Hosp, Ctr Human Genet Res, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA. [Tolouei, Ala] Special Educ Org, Tehran, Iran. [Ghadami, Majid] Minist Educ, Res Ctr, Tehran, Iran. [Santangelo, Susan L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. RP Santangelo, SL (reprint author), Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. EM ssantangelo@pngu.mgh.harvard.edu FU Special Education Organization of Iran FX We would like to acknowledge the Special Education Organization of Iran for their support. We also would like to thank all participating families, particularly those with a child with autism, for the generous contribution of their time to this study. We especially appreciate the assistance and support of Maryam Mehdi Velojerdi, Seyyed Vahid Akhtari, Dr Azam Hosseinipour, Ameneh Mahmudizadeh and Adis Kraskian Mojenbari. NR 65 TC 23 Z9 24 U1 1 U2 9 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 2040-2392 J9 MOL AUTISM JI Mol. Autism PY 2010 VL 1 AR 2 DI 10.1186/2040-2392-1-2 PG 10 WC Genetics & Heredity; Neurosciences SC Genetics & Heredity; Neurosciences & Neurology GA V30IE UT WOS:000208808900002 PM 20678245 ER PT J AU Stanton, BZ Peng, LF AF Stanton, Benjamin Z. Peng, Lee F. TI Small-molecule modulators of the Sonic Hedgehog signaling pathway SO MOLECULAR BIOSYSTEMS LA English DT Review ID INTRAFLAGELLAR TRANSPORT PROTEINS; EMBRYONIC HAIR FOLLICLE; BASAL-CELL CARCINOMAS; PRIMARY CILIUM; MEDIATED TRANSCRIPTION; VERATRUM CALIFORNICUM; PANCREATIC-CANCER; NEURAL-TUBE; GLI; ACTIVATION AB Sonic hedgehog (Shh) is the most widely characterized of the three vertebrate Hedgehog homologs, and is essential for proper embryonic development. Shh binds to its receptor, Patched (Ptch1), resulting in the de-repression of Smoothened (Smo). This leads to the activation of Gli2, which regulates the transcription of target genes that include Gli1 and Ptch1. Several synthetic and naturally occurring small-molecule modulators of Smo have been discovered. Shh-signaling antagonists that bind to Smo include cyclopamine, SANT1, and Cur-61414. Shh signaling agonists that bind to Smo include the synthetic small molecules purmorphamine and SAG. Small molecules that inhibit Shh signaling downstream of Smo, GANT58 and GANT61 have also been reported. Robotnikinin inhibits the Shh pathway by directly targeting Shh. Although progress has been made in understanding and modulating Shh signaling, fundamental aspects of Shh signal transduction remain obscure, including the mechanism(s) whereby Ptch1 regulates Smo activity. Small-molecule modulators of Shh signaling provide a means to regulate the activity of a pathway implicated in medulloblastoma, basal cell carcinoma (BCC), pancreatic cancer, prostate cancer and developmental disorders. Several Shh inhibitors have not succeeded in the clinic for unknown reasons, but clinical trials in BCC and pancreatic cancer with the promising Smo antagonists GDC-0449 and IPI-926 are currently underway. C1 [Stanton, Benjamin Z.; Peng, Lee F.] Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA. [Peng, Lee F.] Massachusetts Gen Hosp, GI Unit, Dept Med, Boston, MA 02114 USA. [Peng, Lee F.] Harvard Univ, Dept Med, Sch Med, Boston, MA 02115 USA. RP Peng, LF (reprint author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA. EM lpeng@partners.org FU National Pancreas Foundation; American Gastroenterological Association; American Liver Foundation FX The authors would like to thank James K. Chen, Stuart L. Schreiber, and Angela N. Koehler for their careful editing and helpful suggestions. L.F.P. is supported by funding from the National Pancreas Foundation, the American Gastroenterological Association, and the American Liver Foundation. NR 88 TC 103 Z9 108 U1 3 U2 33 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1742-206X J9 MOL BIOSYST JI Mol. Biosyst. PY 2010 VL 6 IS 1 BP 44 EP 54 DI 10.1039/b910196a PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 534DH UT WOS:000272875200005 PM 20024066 ER PT J AU Venancio, TM Balaji, S Aravind, L AF Venancio, Thiago M. Balaji, S. Aravind, L. TI High-confidence mapping of chemical compounds and protein complexes reveals novel aspects of chemical stress response in yeast SO MOLECULAR BIOSYSTEMS LA English DT Article ID SACCHAROMYCES-CEREVISIAE; BIOACTIVE COMPOUNDS; GENOME; ACTIN; TRAFFICKING; EXPRESSION; NETWORKS; DYNAMICS; UPDATE; TARGET AB Chemical genetics in yeast has shown great potential for clarifying the pharmacology of various drugs. Investigating these results from a systems perspective has uncovered many facets of natural chemical tolerance, but many cellular interactions of chemicals still remain poorly understood. To uncover previously overlooked players in resistance to chemical stress we integrated several independent chemical genetics datasets with protein-protein interactions and a comprehensive collection of yeast protein complexes. As a consequence we were able to identify the potential targets and mode of action of certain poorly understood compounds. However, most complexes recovered in our analysis appear to perform indirect roles in countering deleterious effects of chemicals by constituting an underlying intricate buffering system that has been so far under-appreciated. This buffering role appears to be largely contributed to by complexes pertaining to chromatin and vesicular dynamics. The former set of complexes seems to act by setting up or maintaining gene expression states necessary to protect the cell against chemical effects. Among the latter complexes we found an important role for specific vesicle tethering complexes in tolerating particular sets of compounds, indicating that different chemicals might be routed via different points in the intracellular trafficking system. We also suggest a general operational similarity between these complexes and molecular capacitors (e. g. the chaperone Hsp90). Both have a key role in increasing the system's robustness, although at different levels, through buffering stress and mutation, respectively. It is therefore conceivable that some of these complexes identified here might have roles in molding the evolution of chemical resistance and response. C1 [Venancio, Thiago M.; Balaji, S.; Aravind, L.] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA. [Balaji, S.] Harvard Univ, Ctr Canc Syst Biol, Dana Farber Canc Inst, Sch Med, Boston, MA 02115 USA. RP Venancio, TM (reprint author), NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA. EM venancit@ncbi.nlm.nih.gov; aravind@ncbi.nlm.nih.gov RI Venancio, Thiago/B-5003-2011; Entomologiamolecular, Inct/J-8214-2013 FU National Institutes of Health, USA FX We acknowledge the Intramural Research Program of the National Institutes of Health, USA, for funding our research. Due to space constraints we apologize for not citing all the manuscripts from which we extracted data but provide them in the ESI (Additional file 1). NR 43 TC 10 Z9 11 U1 0 U2 1 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1742-206X J9 MOL BIOSYST JI Mol. Biosyst. PY 2010 VL 6 IS 1 BP 175 EP 181 DI 10.1039/b911821g PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 534DH UT WOS:000272875200020 PM 20024079 ER PT J AU Venancio, TM Balaji, S Geetha, S Aravind, L AF Venancio, Thiago M. Balaji, S. Geetha, S. Aravind, L. TI Robustness and evolvability in natural chemical resistance: identification of novel systems properties, biochemical mechanisms and regulatory interactions SO MOLECULAR BIOSYSTEMS LA English DT Article ID GENOME-WIDE SCREEN; SACCHAROMYCES-CEREVISIAE GENOME; YEAST DELETION MUTANTS; DOMAIN PROTEINS SLM1; DNA-DAMAGING AGENTS; VACUOLAR H+-ATPASE; GENE-EXPRESSION; FUNCTIONAL-ORGANIZATION; TRYPTOPHAN PERMEASE; BIOACTIVE COMPOUNDS AB A vast amount of data on the natural resistance of Saccharomyces cerevisiae to a diverse array of chemicals has been generated over the past decade (chemical genetics). We endeavored to use this data to better characterize the "systems" level properties of this phenomenon. By collating data from over 30 different genome-scale studies on growth of gene deletion mutants in presence of diverse chemicals, we assembled the largest currently available gene-chemical network. We also derived a second gene-gene network that links genes with significantly overlapping chemical-genetic profiles. We analyzed properties of these networks and investigated their significance by overlaying various sources of information, such as presence of TATA boxes in their promoters (which typically correlate with transcriptional noise), association with TFIID or SAGA, and propensity to function as phenotypic capacitors. We further combined these networks with ubiquitin and protein kinase-substrate networks to understand chemical tolerance in the context of major post-translational regulatory processes. Hubs in the gene-chemical network (multidrug resistance genes) are notably enriched for phenotypic capacitors (buffers against phenotypic variation), suggesting the generality of these players in buffering mechanistically unrelated deleterious forces impinging on the cell. More strikingly, analysis of the gene-gene network derived from the gene-chemical network uncovered another set of genes that appear to function in providing chemical tolerance in a cooperative manner. These appear to be enriched in lineage-specific and rapidly diverging members that also show a corresponding tendency for SAGA-dependent regulation, evolutionary divergence and noisy expression patterns. This set represents a previously underappreciated component of the chemical response that enables cells to explore alternative survival strategies. Thus, systems robustness and evolvability are simultaneously active as general forces in tolerating environmental variation. We also recover the actual genes involved in the above-discussed network properties and predict the biochemistry of their products. Certain key components of the ubiquitin system (e. g. Rcy1, Wss1 and Ubp16), peroxisome recycling (e. g. Irs4) and phosphorylation cascades (e. g. NPR1, MCK1 and HOG) are major participants and regulators of chemical resistance. We also show that a major sub-network boosting mitochondrial protein synthesis is important for exploration of alternative survival strategies under chemical stress. Further, we find evidence that cellular exploration of survival strategies under chemical stress and secondary metabolism draw from a common pool of biochemical players (e. g. acetyltransferases and a novel NTN hydrolase). C1 [Venancio, Thiago M.; Balaji, S.; Aravind, L.] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA. [Balaji, S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA. [Geetha, S.] Joslin Diabet Ctr, Boston, MA 02215 USA. RP Venancio, TM (reprint author), NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA. EM thiago.venancio@gmail.com; balaji.ncbi@gmail.com; hemeetha@gmail.com; aravind@mail.nih.gov RI Venancio, Thiago/B-5003-2011; Entomologiamolecular, Inct/J-8214-2013 FU National Institutes of Health, USA FX We acknowledge the Intramural Research Program of the National Institutes of Health, USA for funding our research. We also would like to acknowledge all the authors who have made their genome-scale datasets publicly available. We tried to make the most extensive collection possible and express our regret if we accidentally missed some study in the data gathering process. NR 131 TC 9 Z9 11 U1 0 U2 7 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1742-206X J9 MOL BIOSYST JI Mol. Biosyst. PY 2010 VL 6 IS 8 BP 1475 EP 1491 DI 10.1039/c002567b PG 17 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 625SC UT WOS:000279914300019 PM 20517567 ER PT J AU Emdad, L Sarkar, D Lee, SG Su, ZZ Yoo, BK Dash, R Yacoub, A Fuller, CE Shah, K Dent, P Bruce, JN Fisher, PB AF Emdad, Luni Sarkar, Devanand Lee, Seok-Geun Su, Zhao Zhong Yoo, Byoung Kwon Dash, Rupesh Yacoub, Adly Fuller, Christine E. Shah, Khalid Dent, Paul Bruce, Jeffrey N. Fisher, Paul B. TI Astrocyte Elevated Gene-1: A Novel Target for Human Glioma Therapy SO MOLECULAR CANCER THERAPEUTICS LA English DT Article ID FACTOR-KAPPA-B; MATRIX METALLOPROTEINASES; TUMOR PROGRESSION; CANCER PROGRESSION; UP-REGULATION; METASTASIS; ACTIVATION; EXPRESSION; SURVIVAL; GROWTH AB Malignant gliomas including glioblastoma multiforme (GBM) and anaplastic astrocytomas are the most common primary brain tumors. Despite multimodal treatment including surgery, chemotherapy, and radiation, median survival for patients with GBMs is only 12 to 15 months. Identifying molecules critical for glioma progression is crucial for devising effective targeted therapy. In the present study, we investigated the potential contribution of astrocyte elevated gene-1 (AEG-1) in gliomagenesis and explored the possibility of AEG-1 as a therapeutic target for malignant glioma. We analyzed the expression levels of AEG-1 in 9 normal brain tissues and 98 brain tumor patient samples by Western blot analysis and immunohistochemistry. AEG-1 expression was significantly elevated in >90% of diverse human brain tumor samples including GBMs and astrocytic tumors, and also in human glioma cell lines compared with normal brain tissues and normal astrocytes. Knockdown of AEG-1 by small interfering RNA inhibited cell viability, cloning efficiency, and invasive ability of U87 human glioma cells and 9L rat gliosarcoma cells. We also found that matrix metalloproteases (MMP-2 and MMP-9) are involved in AEG-1-mediated invasion of glioma cells. In an orthotopic nude mouse brain tumor model using primary human GBM12 tumor cells, AEG-1 small interfering RNA significantly suppressed glioma cell growth in vivo. Taken together, these provocative results indicate that AEG-1 may play a crucial role in the pathogenesis of glioma and that AEG-1 could represent a viable potential target for malignant glioma therapy. Mol Cancer Ther; 9(1); 79-88. (C) 2010 AACR. C1 [Fisher, Paul B.] Virginia Commonwealth Univ, Sch Med, VCU Inst Mol Med, Dept Human & Mol Genet, Richmond, VA 23298 USA. [Bruce, Jeffrey N.] Columbia Univ, Med Ctr, Neurol Inst, Dept Neurol Surg, New York, NY USA. [Emdad, Luni] Columbia Univ, Mt Sinai Sch Med, Dept Neurosurg, New York, NY USA. [Emdad, Luni] Columbia Univ, Mt Sinai Sch Med, Dept Oncol Sci, New York, NY USA. [Sarkar, Devanand; Lee, Seok-Geun; Dent, Paul; Fisher, Paul B.] Virginia Commonwealth Univ, Sch Med, VCU Massey Canc Ctr, Richmond, VA 23298 USA. [Yacoub, Adly; Dent, Paul] Virginia Commonwealth Univ, Sch Med, Dept Biochem & Radiat Oncol, Richmond, VA 23298 USA. [Fuller, Christine E.] Virginia Commonwealth Univ, Sch Med, Dept Pathol, Richmond, VA 23298 USA. [Shah, Khalid] Harvard Univ, Sch Med, Dept Radiol, Ctr Mol Imaging Res,Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Fisher, PB (reprint author), Virginia Commonwealth Univ, Sch Med, VCU Inst Mol Med, Dept Human & Mol Genet, Sanger Hall 11-015,1101 E Marshall St, Richmond, VA 23298 USA. EM pbfisher@vcu.edu RI Lee, Seok-Geun/B-3408-2011; OI Lee, Seok-Geun/0000-0002-0060-5777; dash, rupesh/0000-0001-5740-7053 FU NIH [R01 CA134721, P01 CA104177]; Samuel Waxman Cancer Research Foundation; Goldhirsh Foundation; Dana Foundation; American Brain Tumor Association FX The present study was funded in part through NIH grants R01 CA134721 (P.B. Fisher), P01 CA104177 (P.B. Fisher and P. Dent), and the Samuel Waxman Cancer Research Foundation (P.B. Fisher); the Goldhirsh Foundation and the Dana Foundation (D. Sarkar); and a Joelle Syverson Fellowship from the American Brain Tumor Association (L. Emdad). NR 39 TC 67 Z9 81 U1 1 U2 5 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD JAN PY 2010 VL 9 IS 1 BP 79 EP 88 DI 10.1158/1535-7163.MCT-09-0752 PG 10 WC Oncology SC Oncology GA 606EM UT WOS:000278405000007 PM 20053777 ER PT J AU Borinstein, SC Conerly, M Dzieciatkowski, S Biswas, S Washington, MK Trobridge, P Henikoff, S Grady, WM AF Borinstein, Scott C. Conerly, Melissa Dzieciatkowski, Slavomir Biswas, Swati Washington, M. Kay Trobridge, Patty Henikoff, Steve Grady, William M. TI Aberrant DNA Methylation Occurs in Colon Neoplasms Arising in the Azoxymethane Colon Cancer Model SO MOLECULAR CARCINOGENESIS LA English DT Article DE DNA methylation; azoxymethane; colorectal cancer; epigenetics ID CPG ISLAND METHYLATION; FACTOR-BETA RECEPTOR; DE-NOVO METHYLATION; PROMOTER HYPERMETHYLATION; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; MOUSE MODELS; CELL LINES; INTESTINAL CANCER; PROSTATE-CANCER AB Mouse models of intestinal tumors have advanced our understanding of the role of gene mutations in colorectal malignancy. However, the utility of these systems for studying the role of epigenetic alterations in intestinal neoplasms remains to be defined. Consequently, we assessed the role of aberrant DNA methylation in the azoxymethane (AOM) rodent model of colon cancer. AOM induced tumors display global DNA hypomethylation, which is similar to human colorectal cancer. We next assessed the methylation status of a panel of candidate genes previously shown to be aberrantly methylated in human cancer or in mouse models of malignant neoplasms. This analysis revealed different patterns of DNA methylation that were gene specific. Zik1 and Gja9 demonstrated cancer-specific aberrant DNA methylation, whereas, Cdkn2a/p16, lgfbp3, Mgmt, 04, and Cxcr4 were methylated in both the AOM tumors and normal colon mucosa. No aberrant methylation of Dapk1 or Mlt1 was detected in the neoplasms, but normal colon mucosa samples displayed methylation of these genes. Finally, p19(Arf) Tslc1, Hltf, and Mlh1 were unmethylated in both the AOM tumors and normal colon mucosa. Thus, aberrant DNA methylation does occur in AOM tumors, although the frequency of aberrantly methylated genes appears to be less common than in human colorectal cancer. Additional studies are necessary to further characterize the patterns of aberrantly methylated genes in AOM tumors. (C) 2009 Wiley-Liss, Inc. C1 [Borinstein, Scott C.; Dzieciatkowski, Slavomir; Trobridge, Patty; Grady, William M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. [Borinstein, Scott C.] Seattle Childrens Hosp, Seattle, WA USA. [Borinstein, Scott C.] Univ Washington, Dept Pediat, Div Pediat Hematol Oncol, Seattle, WA 98195 USA. [Conerly, Melissa; Henikoff, Steve] Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA. [Biswas, Swati; Washington, M. Kay] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Grady, William M.] Univ Washington, Dept Med, Div Gastroenterol, Seattle, WA USA. [Grady, William M.] VA Puget Sound Hlth Care Syst, R&D Serv, Seattle, WA USA. RP Grady, WM (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D4-100,POB 19024, Seattle, WA 98109 USA. FU Fred Hutchinson Cancer Research Center; [2T32CA009351]; [P30 CA015704] FX S.C.B. was supported by pediatric hematology/ oncology training grant 2T32CA009351. These studies were also supported by pilot project funding from P30 CA015704 (WMG). We also wish to acknowledge Support from the Experimental Histopathology Core and Animal Care Core at the Fred Hutchinson Cancer Research Center and the Mouse Pathology Core Facility at Vanderbilt University Medical Center) for their technical assistance for preparing tissue samples for histological analysis. NR 74 TC 30 Z9 33 U1 2 U2 4 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0899-1987 J9 MOL CARCINOGEN JI Mol. Carcinog. PD JAN PY 2010 VL 49 IS 1 BP 94 EP 103 DI 10.1002/mc.20581 PG 10 WC Biochemistry & Molecular Biology; Oncology SC Biochemistry & Molecular Biology; Oncology GA 540GO UT WOS:000273319600010 PM 19777566 ER PT J AU Patenaude, AF AF Patenaude, Andrea Farkas BE Patrinos, GP Ansorge, WJ TI Genetic Testing and Psychology SO MOLECULAR DIAGNOSTICS, 2ND EDITION LA English DT Article; Book Chapter ID BREAST-CANCER PATIENTS; QUALITY-OF-LIFE; CONTRALATERAL PROPHYLACTIC MASTECTOMY; HEREDITARY BREAST/OVARIAN CANCER; NONPOLYPOSIS COLORECTAL-CANCER; FAMILIAL ADENOMATOUS POLYPOSIS; MULTICENTER CLINICAL COHORT; BRCA2 MUTATION CARRIERS; AFRICAN-AMERICAN WOMEN; OVARIAN-CANCER C1 [Patenaude, Andrea Farkas] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Pediat Oncol, Boston, MA 02445 USA. [Patenaude, Andrea Farkas] Harvard Univ, Sch Med, Dana Farber Canc Inst, Canc Risk & Prevent Program, Boston, MA 02445 USA. [Patenaude, Andrea Farkas] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02445 USA. RP Patenaude, AF (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Pediat Oncol, 44 Binney St, Boston, MA 02445 USA. NR 125 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-092318-5 PY 2010 BP 549 EP 562 DI 10.1016/B978-0-12-374537-8.00038-9 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BCO38 UT WOS:000310852300041 ER PT J AU Mulder, A Kardol, MJ Arn, JS Eijsink, C Franke, MEI Schreuder, GMT Haasnoot, GW Doxiadis, IIN Sachs, DH Smith, DM Claas, FHJ AF Mulder, Arend Kardol, Marrie J. Arn, J. Scott Eijsink, Chantal Franke, Marry E. I. Schreuder, Geziena M. T. Haasnoot, Geert W. Doxiadis, Ilias I. N. Sachs, David H. Smith, Douglas M. Claas, Frans H. J. TI Human monoclonal HLA antibodies reveal interspecies crossreactive swine MHC class I epitopes relevant for xenotransplantation SO MOLECULAR IMMUNOLOGY LA English DT Article DE SLA; Monoclonal antibodies; Swine; MHC; Xenotransplantation; Hyperacute rejection ID HIGHLY SENSITIZED PATIENTS; LEUKOCYTE ANTIGENS; WAITING TIME; TRANSPLANTATION; HLAMATCHMAKER; RECOGNITION; LYMPHOCYTES; SURVIVAL; TOOL; SLA AB Crossreactivity of anti-HLA antibodies with SLA alleles may limit the use of pig xenografts in some highly sensitized patients. An understanding of the molecular basis for this crossreactivity may allow better selection of xenograft donors. We have tested 68 human monoclonal HLA class I antibodies (mAbs) for reactivity with pig lymphocytes from SLA defined pigs and found nine to be crossreactive. Eight of nine were broadly HLA reactive IgM-mAbs. The putative HLA epitopes for seven mAbs. were conserved in the aminoacid sequence of the SLA alleles studied. The lack of reactivity of a large number of mAbs largely correlated with the absence of the putative epitopes in the SLA alleles studied. We conclude that most patients with anti-HLA class I antibodies should be able to find pig donors lacking SLA antigens that cross react with their antibodies and that many of the crossreacting epitopes can be defined by analysis of shared epitopes in the aminoacid sequence of human and pig MHC antigens. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Mulder, Arend; Kardol, Marrie J.; Eijsink, Chantal; Franke, Marry E. I.; Schreuder, Geziena M. T.; Haasnoot, Geert W.; Doxiadis, Ilias I. N.; Claas, Frans H. J.] Leiden Univ, Med Ctr, Dept Immunohaematol & Bloodtransfus, NL-2300 RC Leiden, Netherlands. [Arn, J. Scott; Sachs, David H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02129 USA. [Smith, Douglas M.] Univ Michigan, Med Ctr, Pathol Res Labs, Ann Arbor, MI 48104 USA. RP Mulder, A (reprint author), Leiden Univ, Med Ctr, Dept Immunohaematol & Bloodtransfus, Bldg 1,Mailstop E3Q,POB 9600, NL-2300 RC Leiden, Netherlands. EM a.mulder@lumc.nl NR 23 TC 34 Z9 34 U1 1 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0161-5890 J9 MOL IMMUNOL JI Mol. Immunol. PD JAN PY 2010 VL 47 IS 4 BP 809 EP 815 DI 10.1016/j.molimm.2009.10.004 PG 7 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA 555JS UT WOS:000274507400022 PM 19931911 ER PT J AU Xiang, M Fan, J AF Xiang, Meng Fan, Jie TI Pattern Recognition Receptor-Dependent Mechanisms of Acute Lung Injury SO MOLECULAR MEDICINE LA English DT Review ID TOLL-LIKE RECEPTORS; RESPIRATORY-DISTRESS-SYNDROME; NF-KAPPA-B; INNATE IMMUNE-RESPONSES; AIRWAY EPITHELIAL-CELLS; MULTIPLE ORGAN FAILURE; BACTERIAL MURAMYL DIPEPTIDE; AORTIC ENDOTHELIAL-CELLS; NECROSIS-FACTOR-ALPHA; MOBILITY GROUP BOX-1 AB Acute lung injury (ALI) that clinically manifests as acute respiratory distress syndrome is caused by an uncontrolled systemic inflammatory response resulting from clinical events including sepsis, major surgery and trauma. Innate immunity activation plays a central role in the development of ALI. Innate immunity is activated through families of related pattern recognition receptors (PRRs), which recognize conserved microbial motifs or pathogen-associated molecular patterns (PAMPs). Toll-like receptors were the first major family of PRRs discovered in mammals. Recently, NACHT-leucine-rich repeat (LRR) receptors and retinoic acid-inducible gene-like receptors have been added to the list. It is now understood that in addition to recognizing infectious stimuli, both Toll-like receptors and NACHT-LRR receptors can also respond to endogenous molecules released in response to stress, trauma and cell damage. These molecules have been termed damage-associated molecular patterns (DAMPS). It has been clinically observed for a long time that infectious and noninfectious insults initiate inflammation, so confirmation of overlapping receptor-signal pathways of activation between PAMPs and DAMPS is no surprise. This review provides an overview of the PRR-dependent mechanisms of ALI and clinical implication. Modification of PRR pathways is likely to be a logical therapeutic target for ALI/acute respiratory distress syndrome. (C) 2010 The Feinstein Institute for Medical Research, www.feinsteininstitute.org Online address: http://www.molmed.org del: 10.2119/molmed.2009.00097 C1 [Xiang, Meng; Fan, Jie] Univ Pittsburgh & Surg Res, VA Pittsburgh Healthcare Syst, Sch Med, Dept Surg, Pittsburgh, PA 15240 USA. RP Fan, J (reprint author), Univ Pittsburgh & Surg Res, VA Pittsburgh Healthcare Syst, Sch Med, Dept Surg, Pittsburgh, PA 15240 USA. EM jif7@pitt.edu FU National Institutes of Health [R01-HL-079669]; National Institutes of Health Center [P50-GM-53789]; VA Merit Award FX This work was supported by the National Institutes of Health Grant R01-HL-079669, National Institutes of Health Center Grant P50-GM-53789, and a VA Merit Award. NR 173 TC 35 Z9 40 U1 1 U2 4 PU FEINSTEIN INST MED RES PI MANHASSET PA 350 COMMUNITY DR, MANHASSET, NY 11030 USA SN 1076-1551 J9 MOL MED JI Mol. Med. PD JAN-FEB PY 2010 VL 16 IS 1-2 BP 69 EP 82 DI 10.2119/molmed.2009.00097 PG 14 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 575CY UT WOS:000276044100008 PM 19949486 ER PT S AU Hunt, JL AF Hunt, Jennifer L. BE Hunt, JL TI Molecular Oncogenesis SO MOLECULAR PATHOLOGY OF ENDOCRINE DISEASES SE Molecular Pathology Library LA English DT Article; Book Chapter ID CELL LUNG-CANCER; THYROID-CANCER; CHERNOBYL ACCIDENT; RADIATION; TUMOR; IDENTIFICATION; CHILDHOOD; PATHOLOGY; GENETICS; GENES C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Hunt, JL (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. NR 39 TC 2 Z9 2 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1935-987X BN 978-1-4419-1706-5 J9 MOL PATHOL LIB PY 2010 VL 3 BP 3 EP 8 DI 10.1007/978-1-4419-1707-2_1 D2 10.1007/978-1-4419-1707-2 PG 6 WC Biochemistry & Molecular Biology; Pathology SC Biochemistry & Molecular Biology; Pathology GA BOP24 UT WOS:000277202600001 ER PT S AU Hunt, JL AF Hunt, Jennifer L. BE Hunt, JL TI Benign Nodular Thyroid Disease SO MOLECULAR PATHOLOGY OF ENDOCRINE DISEASES SE Molecular Pathology Library LA English DT Article; Book Chapter ID THYROTROPIN RECEPTOR MUTATIONS; TOXIC MULTINODULAR GOITER; CONGENITAL HYPOTHYROIDISM; TSH-RECEPTOR; ACTIVATING MUTATIONS; HIGH-FREQUENCY; ADENOMAS; CARCINOMAS; GENES; NEOPLASMS C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Hunt, JL (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. NR 46 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1935-987X BN 978-1-4419-1706-5 J9 MOL PATHOL LIB PY 2010 VL 3 BP 47 EP 50 DI 10.1007/978-1-4419-1707-2_6 D2 10.1007/978-1-4419-1707-2 PG 4 WC Biochemistry & Molecular Biology; Pathology SC Biochemistry & Molecular Biology; Pathology GA BOP24 UT WOS:000277202600006 ER PT S AU Hunt, JL LiVolsi, VA AF Hunt, Jennifer L. LiVolsi, Virginia A. BE Hunt, JL TI Poorly Differentiated and Undifferentiated Thyroid Carcinomas SO MOLECULAR PATHOLOGY OF ENDOCRINE DISEASES SE Molecular Pathology Library LA English DT Article; Book Chapter ID SPINDLE-CELL METAPLASIA; THYMUS-LIKE DIFFERENTIATION; PROGNOSTIC-FACTORS; ANAPLASTIC CARCINOMA; PAPILLARY CARCINOMA; FOLLICULAR CARCINOMAS; INSULAR COMPONENT; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; CD5 IMMUNOREACTIVITY; GENETIC ALTERATIONS C1 [Hunt, Jennifer L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. [LiVolsi, Virginia A.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. RP Hunt, JL (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. NR 96 TC 1 Z9 1 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1935-987X BN 978-1-4419-1706-5 J9 MOL PATHOL LIB PY 2010 VL 3 BP 95 EP 101 DI 10.1007/978-1-4419-1707-2_10 D2 10.1007/978-1-4419-1707-2 PG 7 WC Biochemistry & Molecular Biology; Pathology SC Biochemistry & Molecular Biology; Pathology GA BOP24 UT WOS:000277202600010 ER PT S AU Hunt, JL AF Hunt, Jennifer L. BE Hunt, JL TI Unusual Thyroid Tumors SO MOLECULAR PATHOLOGY OF ENDOCRINE DISEASES SE Molecular Pathology Library LA English DT Article; Book Chapter ID THYMUS-LIKE DIFFERENTIATION; SPINDLE EPITHELIAL TUMOR; HYALINIZING TRABECULAR ADENOMA; SCLEROSING MUCOEPIDERMOID CARCINOMA; MECT1-MAML2 FUSION ONCOGENE; OF-THE-LITERATURE; PAPILLARY CARCINOMA; MOLECULAR-GENETICS; GLAND; EOSINOPHILIA C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Hunt, JL (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. NR 54 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1935-987X BN 978-1-4419-1706-5 J9 MOL PATHOL LIB PY 2010 VL 3 BP 123 EP 126 DI 10.1007/978-1-4419-1707-2_12 D2 10.1007/978-1-4419-1707-2 PG 4 WC Biochemistry & Molecular Biology; Pathology SC Biochemistry & Molecular Biology; Pathology GA BOP24 UT WOS:000277202600012 ER PT S AU Hasserjian, RP AF Hasserjian, Robert P. BE Dunphy, CH TI Molecular Pathology of Myelodysplastic/Myeloproliferative Neoplasms, Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB, and FGFR1, and Mastocytosis SO MOLECULAR PATHOLOGY OF HEMATOLYMPHOID DISEASES SE Molecular Pathology Library LA English DT Article; Book Chapter ID JUVENILE MYELOMONOCYTIC LEUKEMIA; JAK2 V617F MUTATION; FACTOR-RECEPTOR-BETA; CELL MYELOPROLIFERATIVE DISORDER; CHRONIC MYELOGENOUS LEUKEMIA; PROGNOSTIC SCORING SYSTEM; MYELODYSPLASTIC SYNDROME; FUSION GENE; RINGED SIDEROBLASTS; REFRACTORY-ANEMIA C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02163 USA. RP Hasserjian, RP (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02163 USA. NR 101 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1935-987X BN 978-1-4419-5697-2 J9 MOL PATHOL LIB PY 2010 BP 405 EP 416 DI 10.1007/978-1-4419-5698-9_32 D2 10.1007/978-1-4419-5698-9 PG 12 WC Medical Laboratory Technology; Pathology SC Medical Laboratory Technology; Pathology GA BOR14 UT WOS:000277366500032 ER PT B AU Gutierrez, A Look, AT AF Gutierrez, Alejandro Look, A. Thomas BE Houghton, PJ Arceci, RJ TI Molecular Targeted Therapies in T-Cell Acute Lymphoblastic Leukemia SO MOLECULARLY TARGETED THERAPY FOR CHILDHOOD CANCER LA English DT Article; Book Chapter ID GAMMA-SECRETASE INHIBITORS; C-MYC; GLUCOCORTICOID RESISTANCE; DRUGGABLE GENOME; TYROSINE KINASE; CANCER-CELLS; NOTCH; ACTIVATION; MUTATIONS; PTEN C1 [Look, A. Thomas] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Look, A. Thomas] Childrens Hosp Boston, Boston, MA 02115 USA. [Look, A. Thomas] Harvard Univ, Sch Med, Boston, MA USA. RP Look, AT (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA. EM thomas_look@dfci.harvard.edu OI Gutierrez, Alejandro/0000-0002-0249-9007 NR 54 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-69060-5 PY 2010 BP 19 EP 30 DI 10.1007/978-0-387-69062-9_2 D2 10.1007/978-0-387-69062-9 PG 12 WC Oncology; Pediatrics SC Oncology; Pediatrics GA BQX55 UT WOS:000282063800002 ER PT J AU Neugroschl, J Sano, M AF Neugroschl, Judith Sano, Mary TI Current Treatment and Recent Clinical Research in Alzheimer's Disease SO MOUNT SINAI JOURNAL OF MEDICINE LA English DT Review DE Alzheimer's disease; amyloid; antioxidant; Dimebon; immunotherapy; receptor for advanced glycation end products; research; secretase; tau; treatment ID RANDOMIZED CONTROLLED-TRIAL; NERVE GROWTH-FACTOR; ESTROGEN REPLACEMENT THERAPY; MILD COGNITIVE IMPAIRMENT; PLACEBO-CONTROLLED TRIAL; AMYLOID PRECURSOR PROTEIN; TOTAL HOMOCYSTEINE LEVELS; MRC/BHF HEART PROTECTION; HEALTH INITIATIVE MEMORY; HIGH-RISK INDIVIDUALS AB The transition from either epidemiological observation or the bench to rigorously tested clinical trials in patients with Alzheimer's disease is clinical in understanding which treatments are beneficial to patients. The amyloid hypothesis has undergone scrutiny recently, as many trials aimed at reducing and plaque have been completed or are in the testing phase. Examples include modulation of the secretases involved in beta amyloid formation, anti-aggregation agents, and immunotherapeutic trials. Other therapies targeting hyperphosphorylated tau and novel targets such as enhancement mitochondrial function, serotonin receptors, receptor for advanced glycation end products, and nerve growth factor, as well as other strategies, are discussed. A brief review of the current Food and Drug Administration-approved treatments is included. Mt Sinai J Med 77:3-16, 2010. (C) 2010 Mount Sinai School of Medicine C1 [Neugroschl, Judith; Sano, Mary] Mt Sinai Sch Med, New York, NY 10029 USA. [Sano, Mary] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Neugroschl, J (reprint author), Mt Sinai Sch Med, New York, NY 10029 USA. EM judith.neugroschl@mssm.edu FU [AG005138] FX This work was supported by grant AG005138. NR 127 TC 36 Z9 43 U1 0 U2 7 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0027-2507 J9 MT SINAI J MED JI Mt. Sinai J. Med. PD JAN-FEB PY 2010 VL 77 IS 1 SI SI BP 3 EP 16 DI 10.1002/msj.20165 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA 553LF UT WOS:000274367500002 PM 20101716 ER PT J AU Elder, GA Sosa, MAG De Gasperi, R AF Elder, Gregory A. Sosa, Miguel A. Gama De Gasperi, Rita TI Transgenic Mouse Models of Alzheimer's Disease SO MOUNT SINAI JOURNAL OF MEDICINE LA English DT Review DE Alzheimer's disease; amyloid precursor protein; animal model; presenilins; transgenic mice ID AMYLOID-PRECURSOR-PROTEIN; A-BETA-DEPOSITION; KNOCK-IN MICE; GENE-TARGETED MICE; PLAQUE-FORMATION; NEURONAL LOSS; MUTANT PRESENILIN-1; SYNAPTIC PLASTICITY; HIPPOCAMPAL-NEURONS; COGNITIVE DEFICITS AB Alzheimer's disease is the most common cause of senile dementia in the United States and Europe. At present, there is no effective treatment. Given the disease's prevalence and poor prognosis, the development of animal models has been a high research priority. Transgenic modeling has been pursued oil the basis of the amyloid hypothesis and has taken advantage Of mutations in the amyloid precursor protein and the presenilins that cause familial forms of Alzheimer's disease. Modeling has been most aggressively pursued in mice, for which the techniques of genetic modification are well developed Transgenic mouse models now exist that mimic a range of Alzheimer's disease-related p pathologies. Although none of the models fully replicates the human disease, the models have contributed significant insights into the pathophysiology of beta-amyloid toxicity, particularly with respect to the effects of: different beta-amyloid species and the possible pathogenic role of beta-amyloid oligomers. They have also been widely used in the preclinical testing of potential therapeutic modalities and have played a pivotal role in the development of immunotherapies for Alzheimer's disease that are currently ill clinical trials. These models Will, without a doubt, continue to Play central roles in preclinical testing and be used as tools for developing insights into the biological basis of Alzheimer's disease. Mt Sinai J Med 77:69-81, 2010. (C) 2010 Mount Sinai School of Medicine C1 [Elder, Gregory A.] Vet Affairs Med Ctr, James J Peters Dept, Neurol Serv, Bronx, NY USA. [Sosa, Miguel A. Gama; De Gasperi, Rita] Vet Affairs Med Ctr, James J Peters Dept, Res & Dev Serv, Bronx, NY USA. [Elder, Gregory A.; Sosa, Miguel A. Gama; De Gasperi, Rita] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Elder, Gregory A.] Mt Sinai Sch Med, Dept Neurol, New York, NY USA. RP Elder, GA (reprint author), Vet Affairs Med Ctr, James J Peters Dept, Neurol Serv, Bronx, NY USA. EM gregory.elder@mssm.edu FU National Institute on Aging [AG20139, AG029361, AG02219, AG05138]; Alzheimer's Association [IIRG-07-57318]; Department of Veterans Affairs [1101BX000342] FX Work conducted in the authors' laboratory has been supported by grants from the National Institute on Aging (AG20139, AG029361, AG02219, and AG05138), the Alzheimer's Association (IIRG-07-57318) and a Merit Award from the Department of Veterans Affairs (1101BX000342). NR 103 TC 64 Z9 67 U1 6 U2 40 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0027-2507 J9 MT SINAI J MED JI Mt. Sinai J. Med. PD JAN-FEB PY 2010 VL 77 IS 1 SI SI BP 69 EP 81 DI 10.1002/msj.20159 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA 553LF UT WOS:000274367500008 PM 20101721 ER PT J AU Akbari, O Stock, P Singh, AK Lombardi, V Lee, WL Freeman, GJ Sharpe, AH Umetsu, DT DeKruyff, RH AF Akbari, O. Stock, P. Singh, A. K. Lombardi, V. Lee, W-L Freeman, G. J. Sharpe, A. H. Umetsu, D. T. DeKruyff, R. H. TI PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions SO MUCOSAL IMMUNOLOGY LA English DT Article ID KILLER T-CELLS; V-ALPHA-14 NKT CELLS; DENDRITIC CELLS; CUTTING EDGE; IMMUNE-RESPONSE; MOUSE MODEL; B7 FAMILY; ACTIVATION; B7-DC; ANTIGEN AB Interactions of the inhibitory receptor programmed death-1 (PD-1) with its ligands, programmed death ligand (PD-L) 1 and PD-L2, regulate T-cell activation and tolerance. In this study, we investigated the role of PD-L1 and PD-L2 in regulating invariant natural killer T (iNKT)-cell-mediated airway hyperreactivity (AHR) in a murine model of asthma. We found that the severity of AHR and airway inflammation is significantly greater in PD-L2(-/-) mice compared with wild-type mice after either ovalbumin (OVA) sensitization and challenge or administration of alpha-galactosylceramide (alpha-GalCer). iNKT cells from PD-L2(-/-) mice produced significantly more interleukin (IL)-4 than iNKT cells from control mice. Moreover, blockade of PD-L2 interactions of wild-type iNKT cells in vitro with monoclonal antibodies (mAbs) resulted in significantly enhanced levels of IL-4 production. In contrast, PD-L1(-/-) mice showed significantly reduced AHR and enhanced production of interferon-gamma (IFN-gamma) by iNKT cells. iNKT-deficient J alpha 18(-/-) mice reconstituted with iNKT cells from PD-L2(-/-) mice developed high levels of AHR, whereas mice reconstituted with iNKT cells from PD-L1(-/-) mice developed lower levels of AHR compared with control. As PD-L2 is not expressed on iNKT cells but rather is expressed on lung dendritic cells (DCs), in which its expression is upregulated by allergen challenge or IL-4, these findings suggest an important role of PD-L2 on lung DCs in modulating asthma pathogenesis. These studies also indicate that PD-L1 and PD-L2 have important but opposing roles in the regulation of AHR and iNKT-cell-mediated activation. C1 [Akbari, O.; Singh, A. K.; Lombardi, V.] Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA. [Lee, W-L; Umetsu, D. T.; DeKruyff, R. H.] Harvard Univ, Childrens Hosp, Sch Med, Div Immunol, Boston, MA 02115 USA. [Stock, P.] Univ Hosp Charite, Dept Pediat Pneumol & Immunol, Berlin, Germany. [Freeman, G. J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Freeman, G. J.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Sharpe, A. H.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Akbari, O (reprint author), Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA. EM akbari@usc.edu FU NIH [AI066020, AI56299, HHSN266200500030C]; Grand Challenges in Global Health initiative; NIH/NIAI/DAIT BAA-05-11 [HL062348]; German Research Foundation [ST0467/4-2] FX This study was supported by NIH Grants AI066020 (O. A.), AI56299 (G. J. F., A. H. S., D. T. U., R. D. K.), NIH AI56299, HHSN266200500030C, and the Foundation for the NIH through the Grand Challenges in Global Health initiative (G. J. F. and A. H. S.), NIH/NIAI/DAIT BAA-05-11 (G. J. F.) HL062348 (D. T. U.) and German Research Foundation (DFG) Grant ST0467/4-2 (P. S.). NR 49 TC 44 Z9 45 U1 0 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1933-0219 J9 MUCOSAL IMMUNOL JI Mucosal Immunol. PD JAN PY 2010 VL 3 IS 1 BP 81 EP 91 DI 10.1038/mi.2009.112 PG 11 WC Immunology SC Immunology GA 533CD UT WOS:000272798800011 PM 19741598 ER PT B AU Santo, L Raje, N AF Santo, Loredana Raje, Noopur BE Kumar, S TI The Etiology and Pathophysiology of Multiple Myeloma SO MULTIPLE MYELOMA SE Emerging Cancer Therapeutics LA English DT Article; Book Chapter ID MARROW STROMAL CELLS; NF-KAPPA-B; FIBROBLAST-GROWTH-FACTOR; MEDIATED DRUG-RESISTANCE; DEXAMETHASONE-INDUCED APOPTOSIS; NECROSIS-FACTOR FAMILY; LYTIC BONE-DISEASE; BODY-MASS INDEX; UNDETERMINED SIGNIFICANCE; MONOCLONAL GAMMOPATHY AB Although the introduction of novel agents has changed the landscape of multiple myeloma (MM) outcomes, it remains an incurable malignancy of plasma cells. Its development is associated with dysregulated expression and function of multiple cellular genes controlling apoptosis, proliferation, and cell growth. Understanding the etiology and pathogenesis of MM may provide the framework for identification of novel therapeutic targets. Here, we provide a comprehensive review of the latest advances in the study of MM pathogenesis, including the evolution of MM from monoclonal gammopathy of unclear significance. Bone marrow microenvironmental interactions are highlighted in the context of promoting proliferation, survival, drug resistance, and migration of MM cells, with a focus on signaling cascades and cytokines mediating this interaction. C1 [Raje, Noopur] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Raje, N (reprint author), Massachusetts Gen Hosp, Ctr Canc, POB 216,55 Fruit St, Boston, MA 02114 USA. EM nraje@partners.org NR 143 TC 0 Z9 0 U1 0 U2 1 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-91-4 J9 EMERG CANCER THER PY 2010 VL 1 IS 2 BP 197 EP 214 DI 10.5003/2151-4194.1.2.197 PG 18 WC Oncology; Hematology SC Oncology; Hematology GA BQN14 UT WOS:000281356500001 ER PT B AU Laubach, J Schlossman, R Mitsiades, C Anderson, K Richardson, P AF Laubach, Jacob Schlossman, Robert Mitsiades, Constantine Anderson, Kenneth Richardson, Paul BE Kumar, S TI Initial Treatment of Multiple Myeloma in Transplant-Eligible Patients SO MULTIPLE MYELOMA SE Emerging Cancer Therapeutics LA English DT Article; Book Chapter ID STEM-CELL TRANSPLANTATION; LENALIDOMIDE PLUS DEXAMETHASONE; PROTEASOME INHIBITOR PS-341; NEWLY-DIAGNOSED MYELOMA; DEEP-VEIN THROMBOSIS; AUTOLOGOUS TRANSPLANTATION; EXTRAMEDULLARY DISEASE; PROGNOSTIC-FACTOR; POOR-PROGNOSIS; THALIDOMIDE AB The treatment of multiple myeloma (MM) has changed significantly over the past decade with the introduction of thalidomide, lenalidomide, and bortezomib. These agents are now standard of care for patients with relapsed and newly diagnosed disease. The management of a patient with newly diagnosed multiple myeloma is influenced to a great extent by eligibility for autologous stem cell transplantation (ASCT), which remains a cornerstone of therapy for appropriately selected patients. This chapter focuses on the use of thalidomide, lenalidomide, and bortezomib as part of initial therapy for transplant-eligible MM patients. C1 [Laubach, Jacob; Schlossman, Robert; Mitsiades, Constantine; Anderson, Kenneth; Richardson, Paul] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. RP Laubach, J (reprint author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM jacobp_laubach@dfci.harvard.edu NR 56 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-91-4 J9 EMERG CANCER THER PY 2010 VL 1 IS 2 BP 319 EP 328 DI 10.5003/2151-4194.1.2.319 PG 10 WC Oncology; Hematology SC Oncology; Hematology GA BQN14 UT WOS:000281356500007 ER PT J AU Goyal, N Salameh, JS Baldassari, LE David, WS AF Goyal, Namita Salameh, Johnny S. Baldassari, Laura E. David, William S. TI ADDED SAMPLING IMPROVES REPRODUCIBILITY OF MULTIPOINT MOTOR UNIT ESTIMATES SO MUSCLE & NERVE LA English DT Article DE motor unit number estimation (MUNE); multiple-point stimulation (MPS); surface motor unit action potentials (sMUAPs); test-retest reproducibility; incremental method; sampling; reproducibility ID NUMBER ESTIMATION; POINT STIMULATION; RELIABILITY; MUSCLE AB Motor unit number estimation (MUNE) has been used to track motor unit attrition. Studies have used the modified multiple-point stimulation (MPS) technique, collecting three surface motor unit action potentials (sMUAPs) from 3 sites to calculate MUNE. Factoring additional sMUAPs should theoretically improve reproducibility, but the optimal number has not been defined. We evaluated the effect of increased sMUAP sampling on test-retest reproducibility of the modified MPS MUNE technique and found that MUNE reproducibility increased with additional sampling. Muscle Nerve 41: 114-116, 2010 C1 [Goyal, Namita; Salameh, Johnny S.; David, William S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA. [Baldassari, Laura E.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. RP Goyal, N (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, 165 Cambridge St,Suite 820, Boston, MA 02114 USA. EM nagoyal@partners.org NR 10 TC 2 Z9 3 U1 1 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0148-639X J9 MUSCLE NERVE JI Muscle Nerve PD JAN PY 2010 VL 41 IS 1 BP 114 EP 116 DI 10.1002/mus.21500 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 540FB UT WOS:000273315600015 PM 19813198 ER PT B AU Silbermann, R Roodman, GD AF Silbermann, Rebecca Roodman, G. David BE Roodman, GD TI Clinical Presentation of Myeloma Bone Disease SO MYELOMA BONE DISEASE SE Current Clinical Oncology Series LA English DT Article; Book Chapter DE Multiple myeloma; Myeloma bone disease; Pathologic fracture; Hypercalcemia ID MULTIPLE-MYELOMA; STAGING SYSTEM; PATHOGENESIS; SURVIVAL; OSTEOBLASTS; ACTIVATION; BORTEZOMIB; MARKERS AB Bone disease in multiple myeloma is characterized by lytic lesions that are frequently associated with fracture, hypercalcemia, and severe pain. Bone pain is the most frequent presenting symptom for patients with multiple myeloma. It is estimated that approximately 60% of patients have bone pain at the time of myeloma diagnosis and 90% of patients develop bone lesions during their disease course. In addition to lytic lesions, patients frequently develop diffuse osteopenia, pathologic fractures, and compression fractures of the spine. Bone disease significantly impacts patient morbidity, performance status, and survival. While there is an association between the number of lytic bone lesions in an individual and their disease burden, an individual's degree of bone disease does not appear to have significant utility in predicting outcomes. C1 [Roodman, G. David] Univ Pittsburgh, Med Ctr, VA Pittsburgh Healthcare Syst, Dept Med Hematol Oncol, Pittsburgh, PA 15240 USA. RP Roodman, GD (reprint author), Univ Pittsburgh, Med Ctr, VA Pittsburgh Healthcare Syst, Dept Med Hematol Oncol, Pittsburgh, PA 15240 USA. EM roodmangd@upmc.edu; roodmangd@upmc.edu NR 42 TC 4 Z9 4 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-60761-553-8 J9 CURR CLIN ONCOL PY 2010 BP 1 EP 13 DI 10.1007/978-1-60761-554-5_1 D2 10.1007/978-1-60761-554-5 PG 13 WC Oncology SC Oncology GA BOX84 UT WOS:000277978900001 ER PT B AU Vallet, S Raje, N AF Vallet, Sonia Raje, Noopur BE Roodman, GD TI Osteoclast Activation in Multiple Myeloma SO MYELOMA BONE DISEASE SE Current Clinical Oncology Series LA English DT Article; Book Chapter DE Osteolysis; MM niche; Osteoclast activation; Osteoblasts ID KAPPA-B LIGAND; MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; BONE-MARROW MICROENVIRONMENT; IN-VIVO; RECEPTOR ACTIVATOR; CELL-GROWTH; THERAPEUTIC IMPLICATIONS; BREAST-CANCER; TUMOR BURDEN; SRANKL/OSTEOPROTEGERIN RATIO AB Osteolytic bone disease affects more than 80% of multiple myeloma (MM) patients with a negative impact on both quality of life and overall survival. The pathogenesis of osteolytic disease resides in increased osteoclast (OC) activation along with osteoblast (OB) inhibition resulting in altered bone remodeling. OC number and activity in MM are enhanced mainly via cytokine deregulation within the bone marrow (BM) milieu and an imbalance of the OC/OB axis. Several novel agents are currently under investigation for their positive effect on bone remodeling via OC inhibition or OB activation. In addition to restoring bone remodeling, these drugs may inhibit tumor growth in vivo. Therefore, targeting bone disease is a promising therapeutic strategy not only with the goal of alleviating morbidity from bone disease but also resultant anti-tumor activity. C1 [Vallet, Sonia; Raje, Noopur] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med,Div Hematol Oncol, Boston, MA 02114 USA. RP Raje, N (reprint author), Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med,Div Hematol Oncol, Boston, MA 02114 USA. EM nraje@partners.org NR 82 TC 1 Z9 1 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-60761-553-8 J9 CURR CLIN ONCOL PY 2010 BP 183 EP 198 DI 10.1007/978-1-60761-554-5_10 D2 10.1007/978-1-60761-554-5 PG 16 WC Oncology SC Oncology GA BOX84 UT WOS:000277978900010 ER PT J AU Ostrowski, M Carmo, NB Krumeich, S Fanget, I Raposo, G Savina, A Moita, CF Schauer, K Hume, AN Freitas, RP Goud, B Benaroch, P Hacohen, N Fukuda, M Desnos, C Seabra, MC Darchen, F Amigorena, S Moita, LF Thery, C AF Ostrowski, Matias Carmo, Nuno B. Krumeich, Sophie Fanget, Isabelle Raposo, Graca Savina, Ariel Moita, Catarina F. Schauer, Kristine Hume, Alistair N. Freitas, Rui P. Goud, Bruno Benaroch, Philippe Hacohen, Nir Fukuda, Mitsunori Desnos, Claire Seabra, Miguel C. Darchen, Francois Amigorena, Sebastian Moita, Luis F. Thery, Clotilde TI Rab27a and Rab27b control different steps of the exosome secretion pathway SO NATURE CELL BIOLOGY LA English DT Article ID CELL-DERIVED EXOSOMES; MULTIVESICULAR ENDOSOMES; PLASMA-MEMBRANE; B-LYMPHOCYTES; VESICLES; PROTEINS; GRANULES; RELEASE; GTPASES; ASSOCIATION AB Exosomes are secreted membrane vesicles that share structural and biochemical characteristics with intraluminal vesicles of multivesicular endosomes (MVEs). Exosomes could be involved in intercellular communication and in the pathogenesis of infectious and degenerative diseases. The molecular mechanisms of exosome biogenesis and secretion are, however, poorly understood. Using an RNA interference (RNAi) screen, we identified five Rab GTPases that promote exosome secretion in HeLa cells. Among these, Rab27a and Rab27b were found to function in MVE docking at the plasma membrane. The size of MVEs was strongly increased by Rab27a silencing, whereas MVEs were redistributed towards the perinuclear region upon Rab27b silencing. Thus, the two Rab27 isoforms have different roles in the exosomal pathway. In addition, silencing two known Rab27 effectors, Slp4 (also known as SYTL4, synaptotagmin-like 4) and Slac2b (also known as EXPH5, exophilin 5), inhibited exosome secretion and phenocopied silencing of Rab27a and Rab27b, respectively. Our results therefore strengthen the link between MVEs and exosomes, and introduce ways of manipulating exosome secretion in vivo. C1 [Carmo, Nuno B.; Moita, Catarina F.; Freitas, Rui P.; Moita, Luis F.] Inst Mol Med, Cell Biol Immune Syst Unit, P-1649028 Lisbon, Portugal. [Ostrowski, Matias; Krumeich, Sophie; Savina, Ariel; Benaroch, Philippe; Amigorena, Sebastian; Thery, Clotilde] INSERM, U932, F-75005 Paris, France. [Ostrowski, Matias; Krumeich, Sophie; Raposo, Graca; Savina, Ariel; Schauer, Kristine; Goud, Bruno; Benaroch, Philippe; Amigorena, Sebastian; Thery, Clotilde] Inst Curie, F-75005 Paris, France. [Raposo, Graca; Schauer, Kristine; Goud, Bruno] CNRS, UMR144, F-75005 Paris, France. [Hume, Alistair N.; Seabra, Miguel C.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW7 2AZ, England. [Seabra, Miguel C.] Univ Nova Lisboa, Fac Ciencias Med, CEDOC, P-1169056 Lisbon, Portugal. [Seabra, Miguel C.] Inst Gulbenkian Ciencias, P-2780156 Oeiras, Portugal. [Hacohen, Nir] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Charlestown, MA 02142 USA. [Hacohen, Nir] Harvard & MIT, Broad Inst, Cambridge, MA USA. [Fanget, Isabelle; Desnos, Claire; Darchen, Francois] CNRS, Inst Biol Physicochim, FRE 3146, F-75005 Paris, France. [Fukuda, Mitsunori] Tohoku Univ, Dept Dev Biol & Neurosci, Lab Membrane Trafficking Mech, Sendai, Miyagi 9809578, Japan. RP Moita, LF (reprint author), Inst Mol Med, Cell Biol Immune Syst Unit, Sala P3-B-40,Edificio Egas Moniz,Ave Prof Egas Mo, P-1649028 Lisbon, Portugal. EM lmoita@fm.ul.pt; clotilde.thery@curie.fr RI Moita, Luis/L-1296-2013; thery, clotilde/F-6373-2013; Fukuda, MItsunori/I-1511-2015; Faculdade de Ciencias Medicas, Nova Medical School/K-6209-2013; OI Moita, Luis/0000-0003-0707-315X; thery, clotilde/0000-0001-8294-6884; Ferreira Moita, Catarina/0000-0002-9910-2343; Amigorena, Sebastian/0000-0001-8583-8416; Seabra, Miguel/0000-0002-6404-4892 FU Institut National du Cancer; Institut Curie; Association pour la Recherche sur le Cancer and Fondation de France; Agence Nationale de la Recherche [ANR-06-BLAN-0211-02]; Fundacao Luso-Americana para o Desenvolvimento; Funda ao para a Ciencia e a Tecnologia [PTDC/SAU-MII/69280/2006, PTDC/SAU-MII/78333/2006] FX This work was supported by post-doctoral salaries from Institut National du Cancer and Institut Curie to M. O., grants from Association pour la Recherche sur le Cancer and Fondation de France to C. T., and from the Agence Nationale de la Recherche to F. D. (ANR-06-BLAN-0211-02). L. F. M. is a Young Investigator from the Human Frontier Science Program and receives support from Fundacao Luso-Americana para o Desenvolvimento and Funda ao para a Ciencia e a Tecnologia (PTDC/SAU-MII/69280/2006 and PTDC/SAU-MII/78333/2006). We thank PICT IbiSA Imaging Facility at Curie Institute, V. Racine and J.-B. Sibarita for providing a copy of their multidimensional image analysis program, I. Hurbain for help in electron microscopy quantification, P. Simoes and M. H. Raquel for some of the lentiviral preparations, T. Tolmachova for bones of Rab27-knockout mice, J. Mordoh for providing an anti-CD63 FC-5.01 antibody and R. Allan for critical reading of the manuscript. NR 49 TC 395 Z9 407 U1 11 U2 87 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1465-7392 J9 NAT CELL BIOL JI Nat. Cell Biol. PD JAN PY 2010 VL 12 IS 1 BP 19 EP U61 DI 10.1038/ncb2000 PG 25 WC Cell Biology SC Cell Biology GA 535MS UT WOS:000272973800008 PM 19966785 ER PT J AU Cirstea, IC Kutsche, K Dvorsky, R Gremer, L Carta, C Horn, D Roberts, AE Lepri, F Merbitz-Zahradnik, T Konig, R Kratz, CP Pantaleoni, F Dentici, ML Joshi, VA Kucherlapati, RS Mazzanti, L Mundlos, S Patton, MA Silengo, MC Rossi, C Zampino, G Digilio, C Stuppia, L Seemanova, E Pennacchio, LA Gelb, BD Dallapiccola, B Wittinghofer, A Ahmadian, MR Tartaglia, M Zenker, M AF Cirstea, Ion C. Kutsche, Kerstin Dvorsky, Radovan Gremer, Lothar Carta, Claudio Horn, Denise Roberts, Amy E. Lepri, Francesca Merbitz-Zahradnik, Torsten Koenig, Rainer Kratz, Christian P. Pantaleoni, Francesca Dentici, Maria L. Joshi, Victoria A. Kucherlapati, Raju S. Mazzanti, Laura Mundlos, Stefan Patton, Michael A. Silengo, Margherita Cirillo Rossi, Cesare Zampino, Giuseppe Digilio, Cristina Stuppia, Liborio Seemanova, Eva Pennacchio, Len A. Gelb, Bruce D. Dallapiccola, Bruno Wittinghofer, Alfred Ahmadian, Mohammad R. Tartaglia, Marco Zenker, Martin TI A restricted spectrum of NRAS mutations causes Noonan syndrome SO NATURE GENETICS LA English DT Article ID RAS PROTEINS; DISORDERS; CANCER; SWITCH; KRAS AB Noonan syndrome, a developmental disorder characterized by congenital heart defects, reduced growth, facial dysmorphism and variable cognitive deficits, is caused by constitutional dysregulation of the RAS-MAPK signaling pathway. Here we report that germline NRAS mutations conferring enhanced stimulus-dependent MAPK activation account for some cases of this disorder. These findings provide evidence for an obligate dependency on proper NRAS function in human development and growth. C1 [Wittinghofer, Alfred; Zenker, Martin] Max Planck Inst Mol Physiol, Dept Biol Struct, D-44139 Dortmund, Germany. [Cirstea, Ion C.; Dvorsky, Radovan; Gremer, Lothar; Merbitz-Zahradnik, Torsten; Ahmadian, Mohammad R.] Univ Dusseldorf, Med Ctr, Inst Biochem & Mol Biol 2, Dusseldorf, Germany. [Kutsche, Kerstin] Univ Klinikum Hamburg Eppendorf, Inst Humangenet, Hamburg, Germany. [Carta, Claudio; Pantaleoni, Francesca; Tartaglia, Marco] Ist Super Sanita, Dipartimento Ematol Oncol & Med Mol, I-00161 Rome, Italy. [Horn, Denise; Mundlos, Stefan] Charite, Inst Med Genet, D-13353 Berlin, Germany. [Roberts, Amy E.; Joshi, Victoria A.; Kucherlapati, Raju S.] Harvard Univ, Sch Med, Boston, MA USA. [Roberts, Amy E.] Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA. [Lepri, Francesca; Dentici, Maria L.; Dallapiccola, Bruno] Ist Ricovero & Cura Carattere Sci Casa Sollievo S, San Giovanni Rotondo, Italy. [Lepri, Francesca; Dentici, Maria L.; Dallapiccola, Bruno] Casa Sollievo Sofferenza Ist Mendel, Rome, Italy. [Koenig, Rainer] Goethe Univ Frankfurt, Inst Human Genet, Frankfurt, Germany. [Kratz, Christian P.] NCI, Clin Genet Branch, Div Canc Epidemiol & Genet, Rockville, MD USA. [Kratz, Christian P.] Univ Freiburg, Dept Paediat & Adolescent Med, Freiburg, Germany. [Joshi, Victoria A.] Partners HealthCare Ctr Personalized Genet Med, Boston, MA USA. [Joshi, Victoria A.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Mazzanti, Laura] Univ Bologna, Dipartimento Pediat, Bologna, Italy. [Patton, Michael A.] Univ London St Georges Hosp, Dept Clin Genet, London, England. [Silengo, Margherita Cirillo] Univ Turin, Dipartimento Pediat, Turin, Italy. [Rossi, Cesare] St Orsola Marcello Malpighi Hosp, Unita Operat Genet Med, Bologna, Italy. [Zampino, Giuseppe] Univ Cattolica Sacro Cuore, Ist Clin Pediat, Rome, Italy. [Digilio, Cristina] Bambino Gesu Pediat Hosp, Sez Genet Med, Rome, Italy. [Stuppia, Liborio] Univ G DAnnunzio, Dipartimento Sci Biomed, Chieti, Italy. [Seemanova, Eva] Charles Univ Prague, Univ Hosp Prague, Inst Biol & Med Genet, Prague, Czech Republic. [Pennacchio, Len A.] Univ Calif Berkeley, Lawrence Berkeley Lab, Genom Div, Berkeley, CA 94720 USA. [Pennacchio, Len A.] US DOE, Joint Genome Inst, Walnut Creek, CA USA. [Gelb, Bruce D.] Mt Sinai Sch Med, Ctr Mol Cardiol, New York, NY USA. [Gelb, Bruce D.] Mt Sinai Sch Med, Dept Pediat, New York, NY USA. [Gelb, Bruce D.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY USA. [Zenker, Martin] Univ Erlangen Nurnberg, Inst Human Genet, Univ Hosp Erlangen, D-8520 Erlangen, Germany. [Zenker, Martin] Otto Von Guericke Univ, Univ Hosp Magdeburg, Inst Human Genet, Magdeburg, Germany. RP Zenker, M (reprint author), Max Planck Inst Mol Physiol, Dept Biol Struct, Rheinlanddamm 201, D-44139 Dortmund, Germany. EM reza.ahmadian@uni-duesseldorf.de; mtartaglia@iss.it; martin.zenker@med.ovgu.de RI Carta, Claudio/A-7305-2013; Gremer, Lothar/H-9128-2013; Dallapiccola, Bruno/K-8692-2016; OI Gremer, Lothar/0000-0001-7065-5027; Lepri, Francesca Romana/0000-0001-5331-0473; Dallapiccola, Bruno/0000-0002-5031-1013; Silengo, Margherita/0000-0002-6255-1532; Tartaglia, Marco/0000-0001-7736-9672; Stuppia, Liborio/0000-0002-6232-0996 FU European Research Area Network; German Research Foundation (DFG) [AH 92/5-1, KR 3473/1-1, ZE 524/4-1]; German Ministry of Science and Education [01GS08100]; Telethon-Italy [GGP07115]; Associazione Italiana Sindromi di Costello e Cardiofaciocutanea; Collaborazione Italia-USA/malattie rare FX We are grateful to the subjects and their families for participating in this study. We thank A. Diem and B. Quinger (Institute of Human Genetics, Erlangen, Germany), T. Squatriti and S. Venanzi (Istituto Superiore di Sanita, Rome, Italy) and I. Jantke and S. Lorenz (Institut fur Humangenetik, Hamburg, Germany) for skillful technical assistance. The X-ray diffraction datasets were collected at the Swiss Light Source, beamline X10SA, Paul Scherrer Institut, Villigen, Switzerland. This work was supported by grants from the European Research Area Network for research programs on rare diseases (E-Rare) 2009 to M. T., M. Z. and M. R. A. (European Network on Noonan Syndrome and Related Disorders), German Research Foundation (DFG) to M. R. A. (AH 92/5-1) and C. P. K. and M. Z. (KR 3473/1-1 and ZE 524/4-1), Nationales Genomforschungsnetz Plus program of the German Ministry of Science and Education to M. R. A. (BMBF, grant 01GS08100), and Telethon-Italy (GGP07115), 'Associazione Italiana Sindromi di Costello e Cardiofaciocutanea' and 'Collaborazione Italia-USA/malattie rare' to M. T. NR 14 TC 117 Z9 119 U1 1 U2 10 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 EI 1546-1718 J9 NAT GENET JI Nature Genet. PD JAN PY 2010 VL 42 IS 1 BP 27 EP 29 DI 10.1038/ng.497 PG 3 WC Genetics & Heredity SC Genetics & Heredity GA 536PA UT WOS:000273055100012 PM 19966803 ER PT J AU von Boehmer, H Melchers, F AF von Boehmer, Harald Melchers, Fritz TI Checkpoints in lymphocyte development and autoimmune disease SO NATURE IMMUNOLOGY LA English DT Review ID T-CELL-RECEPTOR; SYSTEMIC-LUPUS-ERYTHEMATOSUS; PROGENITOR B-CELLS; V-H REPLACEMENT; NEGATIVE SELECTION; CLONAL DELETION; ALPHA-BETA; ALLELIC INCLUSION; CD4+8+ THYMOCYTES; CENTRAL TOLERANCE AB Antigen receptor-controlled checkpoints in B lymphocyte development are crucial for the prevention of autoimmune diseases such as systemic lupus erythematosus. Checkpoints at the stage of pre-B cell receptor (pre-BCR) and BCR expression can eliminate certain autoreactive BCRs either by deletion of or anergy induction in cells expressing autoreactive BCRs or by receptor editing. For T cells, the picture is more complex because there are regulatory T (T(reg)) cells that mediate dominant tolerance, which differs from the recessive tolerance mediated by deletion and anergy. Negative selection of thymocytes may be as essential as T(reg) cell generation in preventing autoimmune diseases such as type 1 diabetes, but supporting evidence is scarce. Here we discuss several scenarios in which failures at developmental checkpoints result in autoimmunity. C1 [von Boehmer, Harald] Harvard Univ, Sch Med, Boston, MA 02115 USA. [von Boehmer, Harald] Dana Farber Canc Inst, Boston, MA 02115 USA. [Melchers, Fritz] Max Planck Inst Infect Biol, Berlin, Germany. RP von Boehmer, H (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA. EM harald_von_boehmer@dfci.harvard.edu; fritz.melchers@unibas.ch FU Deutsche Forschungsgesellschaft [ME 2764/1-1]; US National Institutes of Health [ROI AI 045846, R37 AI 053102, ROI AI 051378, POI CA 10990] FX Supported by the Deutsche Forschungsgesellschaft (Koselleck grant P. S. ME 2764/1-1 to F. M.) and the US National Institutes of Health (ROI AI 045846, R37 AI 053102, ROI AI 051378 and POI CA 10990 to H. v. B.). NR 123 TC 124 Z9 125 U1 3 U2 25 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1529-2908 J9 NAT IMMUNOL JI Nat. Immunol. PD JAN PY 2010 VL 11 IS 1 BP 14 EP 20 DI 10.1038/ni.1794 PG 7 WC Immunology SC Immunology GA 533WE UT WOS:000272855300004 PM 20016505 ER PT J AU Krainc, D AF Krainc, Dimitri TI Huntington's disease: tagged for clearance SO NATURE MEDICINE LA English DT Editorial Material ID MUTANT HUNTINGTIN; DEGRADATION; TARGETS AB The neuronal accumulation of mutant huntingtin is a hallmark of Huntington's disease. New research shows that post-translational modifications of the mutant protein promote its clearance, uncovering new therapeutic targets for this disorder. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol,Mass Gen Inst Neurodegenerat, Charlestown, MA USA. RP Krainc, D (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol,Mass Gen Inst Neurodegenerat, Charlestown, MA USA. EM dkrainc@partners.org NR 9 TC 4 Z9 4 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD JAN PY 2010 VL 16 IS 1 BP 32 EP 33 DI 10.1038/nm0110-32 PG 3 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 541EA UT WOS:000273395500030 PM 20057421 ER PT J AU Karumanchi, SA Thadhani, R AF Karumanchi, S. Ananth Thadhani, Ravi TI Why don't statins always work? SO NATURE MEDICINE LA English DT Editorial Material ID CARDIOVASCULAR-DISEASE; CONTROLLED-TRIAL; KIDNEY-DISEASE; BLOOD-PRESSURE; HEMODIALYSIS; UREMIA; ATHEROGENESIS; INFLAMMATION; ASSOCIATION; PREVENTION C1 [Karumanchi, S. Ananth] Beth Israel Deaconess Med Ctr, Howard Hughes Med Inst, Ctr Vasc Biol, Boston, MA 02215 USA. [Karumanchi, S. Ananth; Thadhani, Ravi] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Thadhani, Ravi] Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA. RP Karumanchi, SA (reprint author), Beth Israel Deaconess Med Ctr, Howard Hughes Med Inst, Ctr Vasc Biol, Boston, MA 02215 USA. EM sananth@bidmc.harvard.edu FU NIEHS NIH HHS [P30 ES002109] NR 16 TC 9 Z9 9 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD JAN PY 2010 VL 16 IS 1 BP 38 EP 40 DI 10.1038/nm0110-38 PG 3 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 541EA UT WOS:000273395500033 PM 20057425 ER PT J AU Rask-Madsen, C King, GL AF Rask-Madsen, Christian King, George L. TI Factors that protect the diabetic vasculature SO NATURE MEDICINE LA English DT Editorial Material ID ENDOTHELIAL GROWTH-FACTOR; RETINOPATHY; VEGF; NEPHROPATHY; APOPTOSIS C1 [Rask-Madsen, Christian; King, George L.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. RP Rask-Madsen, C (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. EM george.king@joslin.harvard.edu NR 10 TC 14 Z9 16 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD JAN PY 2010 VL 16 IS 1 BP 40 EP 41 DI 10.1038/nm0110-40 PG 3 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 541EA UT WOS:000273395500034 PM 20057426 ER PT J AU Echtler, K Stark, K Lorenz, M Kerstan, S Walch, A Jennen, L Rudelius, M Seidl, S Kremmer, E Emambokus, NR von Bruehl, ML Frampton, J Isermann, B Genzel-Boroviczeny, O Schreiber, C Mehilli, J Kastrati, A Schwaiger, M Shivdasani, RA Massberg, S AF Echtler, Katrin Stark, Konstantin Lorenz, Michael Kerstan, Sandra Walch, Axel Jennen, Luise Rudelius, Martina Seidl, Stefan Kremmer, Elisabeth Emambokus, Nikla R. von Bruehl, Marie-Luise Frampton, Jon Isermann, Berend Genzel-Boroviczeny, Orsolya Schreiber, Christian Mehilli, Julinda Kastrati, Adnan Schwaiger, Markus Shivdasani, Ramesh A. Massberg, Steffen TI Platelets contribute to postnatal occlusion of the ductus arteriosus SO NATURE MEDICINE LA English DT Article ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; VON-WILLEBRAND-FACTOR; RESPIRATORY-DISTRESS SYNDROME; ACUTE MYOCARDIAL-INFARCTION; PERMANENT ANATOMIC CLOSURE; TRANSCRIPTION FACTOR NF-E2; IN-VIVO; PREMATURE-INFANTS; NITRIC-OXIDE; GLYCOPROTEIN IIB AB The ductus arteriosus (DA) is a fetal shunt vessel between the pulmonary artery and the aorta that closes promptly after birth. Failure of postnatal DA closure is a major cause of morbidity and mortality particularly in preterm neonates. The events leading to DA closure are incompletely understood. Here we show that platelets have an essential role in DA closure. Using intravital microscopy of neonatal mice, we observed that platelets are recruited to the luminal aspect of the DA during closure. DA closure is impaired in neonates with malfunctioning platelet adhesion or aggregation or with defective platelet biogenesis. Defective DA closure resulted in a left-to-right shunt with increased pulmonary perfusion, pulmonary vascular remodeling and right ventricular hypertrophy. Our findings indicate that platelets are crucial for DA closure by promoting thrombotic sealing of the constricted DA and by supporting luminal remodeling. A retrospective clinical study revealed that thrombocytopenia is an independent predictor for failure of DA closure in preterm human newborns, indicating that platelets are likely to contribute to DA closure in humans. C1 [Echtler, Katrin; Stark, Konstantin; Lorenz, Michael; Kerstan, Sandra; von Bruehl, Marie-Luise; Mehilli, Julinda; Kastrati, Adnan; Massberg, Steffen] Tech Univ Munich, Klin Herz & Kreislauferkrankungen, Deutsch Herzzentrum, Munich, Germany. [Walch, Axel; Jennen, Luise] Gesell Strahlen & Umweltforsch MbH, Inst Pathol, Helmholtz Zentrum Munchen, Deutsch Forschungszentrum Umwelt & Gesundheit, D-8042 Neuherberg, Germany. [Rudelius, Martina; Seidl, Stefan] Tech Univ Munich, Inst Allgemeine Pathol & Pathol Anat, Munich, Germany. [Kremmer, Elisabeth] Inst Mol Immunol, Deutsch Forschungszentrum Umwelt & Gesundheit, Helmholtz Zentrum Munchen, Munich, Germany. [Emambokus, Nikla R.] Harvard Univ, Childrens Hosp, Sch Med, Boston, MA 02115 USA. [Frampton, Jon] Univ Birmingham, Inst Biomed Res, Birmingham, W Midlands, England. [Isermann, Berend] Univ Klinikum Heidelberg, Med Klin, Heidelberg, Germany. [Genzel-Boroviczeny, Orsolya] Univ Munich, Perinatalzentrum, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Munich, Germany. [Schreiber, Christian] Tech Univ Munich, Klin Herz & Gefasschirurg, Deutsch Herzzentrum, Munich, Germany. [Schwaiger, Markus] Tech Univ Munich, Nukl Med Klin Klinikums Rechts Isar, Munich, Germany. [Shivdasani, Ramesh A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol & Canc Biol, Boston, MA 02115 USA. [Massberg, Steffen] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA. [Massberg, Steffen] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Massberg, S (reprint author), Tech Univ Munich, Klin Herz & Kreislauferkrankungen, Deutsch Herzzentrum, Munich, Germany. EM massberg@dhm.mhn.de RI Walch, Axel/B-4554-2012; OI Walch, Axel/0000-0001-5578-4023; schwaiger, markus /0000-0002-2305-7144 FU Deutsche Forschungsgemeinschaft; Ernst und Berta-Grimmke Foundation FX We thank M. Shakibaei, S. Reder and J. Schwarz for their support. This work was supported by the Deutsche Forschungsgemeinschaft and the Ernst und Berta-Grimmke Foundation. NR 62 TC 64 Z9 68 U1 1 U2 7 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD JAN PY 2010 VL 16 IS 1 BP 75 EP U111 DI 10.1038/nm.2060 PG 9 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 541EA UT WOS:000273395500039 PM 19966813 ER PT J AU Goren, A Ozsolak, F Shoresh, N Ku, MC Adli, M Hart, C Gymrek, M Zuk, O Regev, A Milos, PM Bernstein, BE AF Goren, Alon Ozsolak, Fatih Shoresh, Noam Ku, Manching Adli, Mazhar Hart, Chris Gymrek, Melissa Zuk, Or Regev, Aviv Milos, Patrice M. Bernstein, Bradley E. TI Chromatin profiling by directly sequencing small quantities of immunoprecipitated DNA SO NATURE METHODS LA English DT Article ID HUMAN GENOME; IN-VIVO AB Chromatin structure and transcription factor localization can be assayed genome-wide by sequencing genomic DNA fractionated by protein occupancy or other properties, but current technologies involve multiple steps that introduce bias and inefficiency. Here we apply a single-molecule approach to directly sequence chromatin immunoprecipitated DNA with minimal sample manipulation. This method is compatible with just 50 pg of DNA and should thus facilitate charting chromatin maps from limited cell populations. C1 [Goren, Alon; Shoresh, Noam; Ku, Manching; Adli, Mazhar; Gymrek, Melissa; Zuk, Or; Regev, Aviv; Bernstein, Bradley E.] Harvard & Massachusetts Inst Technol, Broad Inst, Cambridge, MA USA. [Goren, Alon; Ku, Manching; Adli, Mazhar; Gymrek, Melissa; Regev, Aviv; Bernstein, Bradley E.] Massachusetts Gen Hosp, Howard Hughes Med Inst, Boston, MA 02114 USA. [Goren, Alon; Ku, Manching; Adli, Mazhar; Gymrek, Melissa; Bernstein, Bradley E.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. [Goren, Alon; Ku, Manching; Adli, Mazhar; Gymrek, Melissa; Bernstein, Bradley E.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Goren, Alon; Ku, Manching; Adli, Mazhar; Gymrek, Melissa; Bernstein, Bradley E.] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02114 USA. [Ozsolak, Fatih; Hart, Chris; Milos, Patrice M.] Helicos BioSci Corp, Cambridge, MA USA. [Regev, Aviv] MIT, Dept Biol, Cambridge, MA USA. RP Bernstein, BE (reprint author), Harvard & Massachusetts Inst Technol, Broad Inst, Cambridge, MA USA. EM bernstein.bradley@mgh.harvard.edu OI /0000-0002-6086-3903 FU EMBO; Croucher Foundation; Burroughs Wellcome Fund; Howard Hughes Medical Institute; US National Human Genome Research Institute FX We thank J. Robinson and members of the IGV platform for their help with data presentation. A. G. is supported by an EMBO long-term postdoctoral fellowship. M. K. is supported by a Croucher Foundation fellowship. A. R. is an investigator of the Merkin Foundation for Stem Cell Research at the Broad Institute. This research was supported by funds from the Burroughs Wellcome Fund (to B. E. B. and A. R.), Howard Hughes Medical Institute (to B. E. B. and A. R.), Partnership for Cures Culpeper Scholarship (to B. E. B.) and the US National Human Genome Research Institute. NR 16 TC 69 Z9 69 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1548-7091 J9 NAT METHODS JI Nat. Methods PD JAN PY 2010 VL 7 IS 1 BP 47 EP U7 DI 10.1038/NMETH.1404 PG 5 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 537QL UT WOS:000273128300026 PM 19946276 ER PT J AU Stadtfeld, M Maherali, N Borkent, M Hochedlinger, K AF Stadtfeld, Matthias Maherali, Nimet Borkent, Marti Hochedlinger, Konrad TI A reprogrammable mouse strain from gene-targeted embryonic stem cells SO NATURE METHODS LA English DT Article ID TRANSGENIC MICE; SOMATIC-CELLS; PLURIPOTENCY; GENERATION; SYSTEM; EXPRESSION AB The derivation of induced pluripotent stem cells (iPSCs) usually involves the viral introduction of reprogramming factors into somatic cells. Here we used gene targeting to generate a mouse strain with a single copy of an inducible, polycistronic reprogramming cassette, allowing for the induction of pluripotency in various somatic cell types. As these 'reprogrammable mice' can be easily bred, they are a useful tool to study the mechanisms underlying cellular reprogramming. C1 [Stadtfeld, Matthias; Maherali, Nimet; Borkent, Marti; Hochedlinger, Konrad] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Stadtfeld, Matthias; Maherali, Nimet; Borkent, Marti; Hochedlinger, Konrad] Harvard Stem Cell Inst, Ctr Regenerat Med, Boston, MA USA. [Stadtfeld, Matthias; Maherali, Nimet; Borkent, Marti; Hochedlinger, Konrad] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. [Maherali, Nimet] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA. [Borkent, Marti] Erasmus Univ, Rotterdam, Netherlands. RP Hochedlinger, K (reprint author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. EM khochedlinger@helix.mgh.harvard.edu OI Stadtfeld, Matthias/0000-0002-5852-9906 FU Schering Foundation; US National Institutes of Health Director's Innovator Award; Harvard Stem Cell Institute; Massachusetts General Hospital FX We thank G. Mostoslavsky (Boston University School of Medicine) for the STEMCCA construct and secondary viral MEFs, A. Foudi and S. Eminli for help with hematopoietic cell isolation and culture, A. Khalil for help in cloning the Collagen-OKSM targeting construct, J. Polo for help with cell culture as well as for inspiring discussions, and C. Konrad for advice on tumor histology. M. S. was supported by a postdoctoral fellowship from the Schering Foundation, and K. H. was supported by a US National Institutes of Health Director's Innovator Award as well as by funds provided by the Harvard Stem Cell Institute and Massachusetts General Hospital. NR 15 TC 85 Z9 86 U1 1 U2 14 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1548-7091 J9 NAT METHODS JI Nat. Methods PD JAN PY 2010 VL 7 IS 1 BP 53 EP U10 DI 10.1038/NMETH.1409 PG 4 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 537QL UT WOS:000273128300028 PM 20010832 ER PT J AU Truccolo, W Hochberg, LR Donoghue, JP AF Truccolo, Wilson Hochberg, Leigh R. Donoghue, John P. TI Collective dynamics in human and monkey sensorimotor cortex: predicting single neuron spikes SO NATURE NEUROSCIENCE LA English DT Article ID MOTOR CORTEX; CORTICAL-NEURONS; TETRAPLEGIA; POPULATION; ENSEMBLE; AREA; CELL AB Coordinated spiking activity in neuronal ensembles, in local networks and across multiple cortical areas, is thought to provide the neural basis for cognition and adaptive behavior. Examining such collective dynamics at the level of single neuron spikes has remained, however, a considerable challenge. We found that the spiking history of small and randomly sampled ensembles (similar to 20-200 neurons) could predict subsequent single neuron spiking with substantial accuracy in the sensorimotor cortex of humans and nonhuman behaving primates. Furthermore, spiking was better predicted by the ensemble's history than by the ensemble's instantaneous state (Ising models), emphasizing the role of temporal dynamics leading to spiking. Notably, spiking could be predicted not only by local ensemble spiking histories, but also by spiking histories in different cortical areas. These strong collective dynamics may provide a basis for understanding cognition and adaptive behavior at the level of coordinated spiking in cortical networks. C1 [Truccolo, Wilson; Donoghue, John P.] Brown Univ, Dept Neurosci, Providence, RI 02912 USA. [Truccolo, Wilson; Hochberg, Leigh R.; Donoghue, John P.] Brown Univ, Brown Inst Brain Sci, Providence, RI 02912 USA. [Hochberg, Leigh R.] Brown Univ, Div Engn, Providence, RI 02912 USA. [Hochberg, Leigh R.; Donoghue, John P.] Dept Vet Affairs, Rehabil Res & Dev Serv, Providence, RI USA. [Truccolo, Wilson; Hochberg, Leigh R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA. [Hochberg, Leigh R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Hochberg, Leigh R.] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Boston, MA USA. RP Truccolo, W (reprint author), Brown Univ, Dept Neurosci, Providence, RI 02912 USA. EM wilson_truccolo@brown.edu OI Hochberg, Leigh/0000-0003-0261-2273 FU National Institute of Neurological Disorders and Stroke [5K01NS057389-02, NS-25074]; National Institute of Child Health and Human Development/National Center for Medical Rehabilitation Research [N01-HD53403]; Massachusetts General Hospital Deane Institute; Doris Duke Charitable Foundation; National Institute on Deafness and Other Communication Disorders [R01-DC-009899] FX We thank M. R. Fellows, C. Vargas-Irwin and B. Philip for collecting the nonhuman primate data. We thank our clinical trial participants for their dedication to this research, G. Friehs for his role as surgical investigator for the pilot clinical trial, J. Mukand for his role as clinical investigator for the pilot clinical trial, and A. Caplan, M. Serruya, M. Saleh and other employees of Cyberkinetics Neurotechnology Systems for data collection, manufacturing and clinical trial management. This study was based on work supported in part by the Office of Research and Development, Rehabilitation R&D Service, Department of Veterans Affairs ( L. R. H. and J. P. D.). This work was supported by the National Institute of Neurological Disorders and Stroke (5K01NS057389-02 to W. T. and NS-25074 (Javits Award) to J. P. D.), the National Institute of Child Health and Human Development/National Center for Medical Rehabilitation Research (N01-HD53403, subcontract to L. R. H.), the Massachusetts General Hospital Deane Institute ( L. R. H.), the Doris Duke Charitable Foundation ( L. R. H) and the National Institute on Deafness and Other Communication Disorders (R01-DC-009899 to L. R. H.). NR 39 TC 80 Z9 80 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1097-6256 J9 NAT NEUROSCI JI Nat. Neurosci. PD JAN PY 2010 VL 13 IS 1 BP 105 EP U275 DI 10.1038/nn.2455 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 536PM UT WOS:000273056300020 PM 19966837 ER PT J AU Ford, JM Roach, BJ Mathalon, DH AF Ford, Judith M. Roach, Brian J. Mathalon, Daniel H. TI Assessing corollary discharge in humans using noninvasive neurophysiological methods SO NATURE PROTOCOLS LA English DT Article ID HUMAN AUDITORY-CORTEX; CORTICAL RESPONSIVENESS; INDUCED SUPPRESSION; SPEECH PRODUCTION; SCHIZOPHRENIA; DYSFUNCTION; RESPONSES; SYMPTOMS; HALLUCINATIONS; STIMULATION AB In this paper, we present a vocal production protocol for studying the neurophysiological action of the corollary discharge, a mechanism that allows animals to ignore sensations resulting from their own actions, and tag them as 'self'. electroencephalograms are recorded while subjects say 'ah' about 100 times with minimal throat, jaw and tongue movements (talk condition). this sequence of sounds is recorded and played back during the listen condition. event-related potentials are synchronized to the onset of speech sounds during the talk and listen conditions. neural responses from the auditory cortex to the spoken sound as it is being spoken during the talk condition are compared with neural responses to the same sounds when played back during the listen condition. the successful action of the corollary discharge is seen when the response of the auditory cortex is suppressed during the talk compared with the listen condition. the protocol takes about 5 min to complete. C1 [Ford, Judith M.; Roach, Brian J.; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. RP Ford, JM (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. EM Judith.ford@ucsf.edu OI Roach, Brian/0000-0002-3264-1465; Mathalon, Daniel/0000-0001-6090-4974 FU VA (Merit Review); National Institute of Mental Health [MH40052, MH 58262, MH067967]; National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD); VA Research Service FX We thank S. Guillory for programming the Matlab task. This work was supported by the VA Research Service and grants from the VA (Merit Review), the National Institute of Mental Health (MH40052, MH 58262, MH067967) and the National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD). NR 44 TC 18 Z9 18 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1754-2189 J9 NAT PROTOC JI Nat. Protoc. PY 2010 VL 5 IS 6 BP 1160 EP 1168 DI 10.1038/nprot.2010.67 PG 9 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 605NQ UT WOS:000278354700018 PM 20539291 ER PT J AU O'Donoghue, M Braunwald, E AF O'Donoghue, Michelle Braunwald, Eugene TI Natriuretic peptides in heart failure: should therapy be guided by BNP levels? SO NATURE REVIEWS CARDIOLOGY LA English DT Review ID LEFT-VENTRICULAR DYSFUNCTION; MEDICINE PRACTICE GUIDELINES; TRIAL VAL-HEFT; CARDIAC RESYNCHRONIZATION; CLINICAL UTILIZATION; NATIONAL-ACADEMY; BRAIN; IMPACT; CARVEDILOL; MORTALITY AB Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Testing for natriuretic peptide markers, such as B-type natriuretic peptide (BNP) or N-terminal proBNP (NT-proBNP), has emerged as an important tool for the diagnosis and risk stratification of patients with HF. However, questions remain regarding the potential role for natriuretic peptides to guide therapy in patients with HF. In this Review, we address the underlying assumptions and the existing evidence supporting a natriuretic-peptide-guided approach to the outpatient management of HF. C1 [O'Donoghue, Michelle; Braunwald, Eugene] Harvard Univ, TIMI Study Grp, Div Cardiovasc, Brigham & Womens Hosp,Med Sch, Boston, MA 02115 USA. [O'Donoghue, Michelle; Braunwald, Eugene] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. RP Braunwald, E (reprint author), Harvard Univ, TIMI Study Grp, Div Cardiovasc, Brigham & Womens Hosp,Med Sch, 350 Longwood Ave, Boston, MA 02115 USA. EM ebraunwald@partners.org NR 47 TC 43 Z9 44 U1 0 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-5002 J9 NAT REV CARDIOL JI Nat. Rev. Cardiol. PD JAN PY 2010 VL 7 IS 1 BP 13 EP 20 DI 10.1038/nrcardio.2009.197 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 535ES UT WOS:000272950300005 PM 19935742 ER PT J AU Faris, JE Michaelson, MD AF Faris, Jason E. Michaelson, M. Dror TI TARGETED THERAPIES Sunitinib versus interferon-alpha in metastatic RCC SO NATURE REVIEWS CLINICAL ONCOLOGY LA English DT Editorial Material ID RENAL-CELL CARCINOMA; PHASE-III TRIAL; DOUBLE-BLIND; EFFICACY; SAFETY AB Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-alpha as first-line treatment for patients with metastatic renal-cell carcinoma. The observed improvement in overall survival for patients treated with sunitinib further establishes this agent as the reference standard for first-line treatment of good-risk and intermediate-risk patients with metastatic renal cancer. C1 [Faris, Jason E.; Michaelson, M. Dror] Massachusetts Gen Hosp, Ctr Canc, Claire & John Bertucci Ctr Genitourinary Canc, Boston, MA 02114 USA. RP Michaelson, MD (reprint author), Massachusetts Gen Hosp, Ctr Canc, Claire & John Bertucci Ctr Genitourinary Canc, 55 Fruit St,YAW7, Boston, MA 02114 USA. EM dmichaelson1@partners.org OI Michaelson, Dror/0000-0001-9249-6338 NR 10 TC 4 Z9 5 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-4774 J9 NAT REV CLIN ONCOL JI Nat. Rev. Clin. Oncol. PD JAN PY 2010 VL 7 IS 1 BP 7 EP 8 DI 10.1038/nrclinonc.2009.173 PG 2 WC Oncology SC Oncology GA 535SX UT WOS:000272992200002 PM 20029441 ER PT J AU Durante, M Loeffler, JS AF Durante, Marco Loeffler, Jay S. TI Charged particles in radiation oncology SO NATURE REVIEWS CLINICAL ONCOLOGY LA English DT Review ID CARBON ION RADIOTHERAPY; PROTON-BEAM THERAPY; CELL LUNG-CANCER; SKULL-BASE; IN-VITRO; COST-EFFECTIVENESS; SPACE EXPLORATION; TUMOR-THERAPY; UP-REGULATION; IRRADIATION AB Radiotherapy is one of the most common and effective therapies for cancer. Generally, patients are treated with X-rays produced by electron accelerators. Many years ago, researchers proposed that high-energy charged particles could be used for this purpose, owing to their physical and radiobiological advantages compared with X-rays. Particle therapy is an emerging technique in radiotherapy. Protons and carbon ions have been used for treating many different solid cancers, and several new centers with large accelerators are under construction. Debate continues on the cost: benefit ratio of this technique, that is, on whether the high costs of accelerators and beam delivery in particle therapy are justified by a clear clinical advantage. This Review considers the present clinical results in the field, and identifies and discusses the research questions that have resulted with this technique. C1 [Durante, Marco] Gesell Schwerionenforsch GSI, Helmholtzzentrum Schwerionenforsch, Dept Biophys, D-64291 Darmstadt, Germany. [Loeffler, Jay S.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RP Durante, M (reprint author), Gesell Schwerionenforsch GSI, Helmholtzzentrum Schwerionenforsch, Dept Biophys, Plackstr 1, D-64291 Darmstadt, Germany. EM m.durante@gsi.de RI Durante, Marco/K-1315-2014; OI Durante, Marco/0000-0002-4615-553X NR 62 TC 221 Z9 222 U1 8 U2 73 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-4774 EI 1759-4782 J9 NAT REV CLIN ONCOL JI Nat. Rev. Clin. Oncol. PD JAN PY 2010 VL 7 IS 1 BP 37 EP 43 DI 10.1038/nrclinonc.2009.183 PG 7 WC Oncology SC Oncology GA 535SX UT WOS:000272992200007 PM 19949433 ER PT J AU Utzschneider, KM Kowdley, KV AF Utzschneider, Kristina M. Kowdley, Kris V. TI Hereditary hemochromatosis and diabetes mellitus: implications for clinical practice SO NATURE REVIEWS ENDOCRINOLOGY LA English DT Review ID INSULIN SECRETORY CAPACITY; HFE GENE-MUTATIONS; LONG-TERM SURVIVAL; IRON-OVERLOAD; JUVENILE HEMOCHROMATOSIS; GLUCOSE-TOLERANCE; THALASSEMIA MAJOR; BETA-THALASSEMIA; HIGH PREVALENCE; POPULATION AB Hereditary hemochromatosis (HH) is a genetic condition that can lead to unregulated absorption of iron from the gut with resultant iron overload. The most common form of HH is caused by mutations in the HFE gene, with most cases of HH presenting in patients who are homozygous for the Cys282Tyr mutation. The prevalence of HFE gene mutations in persons of Northern European ancestry is fairly high (0.3-0.7% homozygous and 9-14% heterozygous for the Cys282Tyr mutation), but the penetrance of the disease is considered fairly low and is quite variable. While routine screening of the general population is not recommended, a targeted approach to screening in symptomatic patients and in those with a family member with iron overload is warranted. Untreated, iron overload can lead to considerable morbidity including liver cirrhosis, arthritis and diabetes mellitus, and increased mortality. The pathophysiology of diabetes mellitus in HH is thought to be due primarily to defects in the early insulin response to glucose. An Hfe(-/-) mouse model of HH has demonstrated defects in beta-cell function and beta-cell apoptosis that may be mediated by increased oxidative stress. Fortunately, these defects seem to be reversible if phlebotomy treatment is initiated before the development of cirrhosis or diabetes mellitus in patients. Further research into the long-term effects of treatment on prevention of diabetes mellitus in HH is needed. C1 [Utzschneider, Kristina M.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. [Kowdley, Kris V.] Virginia Mason Med Ctr, Ctr Liver Dis, Seattle, WA 98101 USA. [Kowdley, Kris V.] Benaroya Res Inst, Seattle, WA 98101 USA. RP Utzschneider, KM (reprint author), VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, 1600 S Columbian Way 151, Seattle, WA 98108 USA. EM kutzschn@u.washington.edu FU VA Puget Sound Health Care System, Seattle, WA; Department of Veterans Affairs; NIH [DK02957] FX This work is supported in part by the VA Puget Sound Health Care System, Seattle, WA and the Department of Veterans Affairs (to K. M. U.) and NIH Grant DK02957 (to K. V. K.). NR 57 TC 25 Z9 28 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-5029 EI 1759-5037 J9 NAT REV ENDOCRINOL JI Nat. Rev. Endocrinol. PD JAN PY 2010 VL 6 IS 1 BP 26 EP 33 DI 10.1038/nrendo.2009.241 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 533AN UT WOS:000272794400008 PM 20010968 ER PT J AU Irazoqui, JE Urbach, JM Ausubel, FM AF Irazoqui, Javier E. Urbach, Jonathan M. Ausubel, Frederick M. TI Evolution of host innate defence: insights from Caenorhabditis elegans and primitive invertebrates SO NATURE REVIEWS IMMUNOLOGY LA English DT Review ID NF-KAPPA-B; PSEUDOMONAS-AERUGINOSA VIRULENCE; ILEAL CROHNS-DISEASE; GROWTH-FACTOR-BETA; TOLL-LIKE RECEPTOR; IMMUNE-RESPONSE; C-ELEGANS; SIGNALING PATHWAY; PROTEIN-KINASE; HOMEOBOX GENE AB The genetically tractable model organism Caenorhabditis elegans was first used to model bacterial virulence in vivo a decade ago. Since then, great strides have been made in identifying the host response pathways that are involved in its defence against infection. Strikingly, C. elegans seems to detect, and respond to, infection without the involvement of its homologue of Toll-like receptors, in contrast to the well-established role for these proteins in innate immunity in mammals. What, therefore, do we know about host defence mechanisms in C. elegans and what can they tell us about innate immunity in higher organisms? C1 [Urbach, Jonathan M.; Ausubel, Frederick M.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA. [Urbach, Jonathan M.; Ausubel, Frederick M.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. [Irazoqui, Javier E.] Massachusetts Gen Hosp, Program Dev Immunol, Boston, MA 02114 USA. [Irazoqui, Javier E.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02114 USA. RP Ausubel, FM (reprint author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA. EM Ausubel@molbio.mgh.harvard.edu RI Irazoqui, Javier/A-8028-2013; OI Irazoqui, Javier/0000-0001-6553-1329 FU US National Institutes of Health [R01 AI64332, PO1 AI44220] FX The unpublished observations cited in this review were funded by US National Institutes of Health grants R01 AI64332 and PO1 AI44220 awarded to F.M.A. NR 121 TC 158 Z9 161 U1 3 U2 44 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1474-1733 J9 NAT REV IMMUNOL JI Nat. Rev. Immunol. PD JAN PY 2010 VL 10 IS 1 BP 47 EP 58 DI 10.1038/nri2689 PG 12 WC Immunology SC Immunology GA 535SW UT WOS:000272992100012 PM 20029447 ER PT J AU Bertram, L Tanzi, RE AF Bertram, Lars Tanzi, Rudolph E. TI ALZHEIMER DISEASE New light on an old CLU SO NATURE REVIEWS NEUROLOGY LA English DT Editorial Material ID GENOME-WIDE ASSOCIATION; IDENTIFIES VARIANTS AB Genome-wide association studies (gwas) have uncovered over two dozen candidate Alzheimer disease susceptibility genes; however, the results of these studies showed limited overlap. Two independently performed gwas involving cohorts from Europe and the us have now identified three additional putative Alzheimer disease genes that show modest but remarkably consistent effects across data sets. C1 [Bertram, Lars] Max Planck Inst Mol Genet, Neuropsychiat Genet Grp, D-14195 Berlin, Germany. [Tanzi, Rudolph E.] Massachusetts Gen Hosp, Genet & Aging Res Unit, Dept Neurol, Charlestown, MA 02129 USA. RP Bertram, L (reprint author), Max Planck Inst Mol Genet, Neuropsychiat Genet Grp, Ihnestr 63,Room 204-1, D-14195 Berlin, Germany. EM lbertram@molgen.mpg.de RI Bertram, Lars/K-3889-2015 OI Bertram, Lars/0000-0002-0108-124X FU NIMH NIH HHS [R37 MH060009, R37 MH060009-10] NR 10 TC 29 Z9 29 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-4758 J9 NAT REV NEUROL JI Nat. Rev. Neurol. PD JAN PY 2010 VL 6 IS 1 BP 11 EP 13 DI 10.1038/nrneurol.2009.213 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 541ZU UT WOS:000273461500004 PM 20057494 ER PT J AU Sasaki, Y Nanez, JE Watanabe, T AF Sasaki, Yuka Nanez, Jose E. Watanabe, Takeo TI Advances in visual perceptual learning and plasticity SO NATURE REVIEWS NEUROSCIENCE LA English DT Review ID VERNIER DISCRIMINATION TASK; FEATURE-BASED ATTENTION; SLOW-WAVE SLEEP; MEMORY CONSOLIDATION; TEXTURE-DISCRIMINATION; DEPENDENT PLASTICITY; MOTION DISCRIMINATION; DECLARATIVE MEMORY; PREFRONTAL CORTEX; DEPTH-PERCEPTION AB Visual perceptual learning (VPL) is defined as a long-term improvement in performance on a visual task. In recent years, the idea that conscious effort is necessary for VPL to occur has been challenged by research suggesting the involvement of more implicit processing mechanisms, such as reinforcement-driven processing and consolidation. In addition, we have learnt much about the neural substrates of VPL and it has become evident that changes in visual areas and regions beyond the visual cortex can take place during VPL. C1 [Sasaki, Yuka; Watanabe, Takeo] ATR Computat Neurosci Labs, Kyoto 6190288, Japan. [Sasaki, Yuka] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Sasaki, Yuka] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Nanez, Jose E.] Arizona State Univ, Dept Social & Behav Sci, Phoenix, AZ 85069 USA. [Watanabe, Takeo] Boston Univ, Dept Psychol, Boston, MA 02215 USA. [Watanabe, Takeo] Boston Univ, Ctr Neurosci, Boston, MA 02215 USA. RP Watanabe, T (reprint author), ATR Computat Neurosci Labs, Seika Cho, Kyoto 6190288, Japan. EM takeo@bu.edu FU Sleep Research Society Foundation; Harvard Medical School; Massachusetts General Hospital; ERATO Shimojo Implicit Brain Project (Japan Science Technology); National Centre for Research Resources [P41RR14075]; Mind Institute and the Athinoula A. Martinos Center for Biological Imaging; US National Institutes of Health [R01 EY015980-04A2, R01 EY019466, R01 AG031941, R21 EY018925, R21 EY017737]; National Science Foundation [BCS-0549,036] FX We thank G. Deangelis, B. Dosher, Z.-L. Lu and K. Shibata for valuable comments on an early draft of the paper and N. Ito for technical assistance. This study is supported by grants from the Sleep Research Society Foundation, Harvard Medical School, Massachusetts General Hospital, ERATO Shimojo Implicit Brain Project (Japan Science Technology), the National Centre for Research Resources (P41RR14075) the Mind Institute and the Athinoula A. Martinos Center for Biological Imaging to Y.S. and by grants from the US National Institutes of Health (R01 EY015980-04A2, R01 EY019466, R01 AG031941, R21 EY018925, R21 EY017737) and the National Science Foundation (BCS-0549,036) to T.W. NR 123 TC 133 Z9 135 U1 6 U2 52 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1471-0048 J9 NAT REV NEUROSCI JI Nat. Rev. Neurosci. PD JAN PY 2010 VL 11 IS 1 BP 53 EP 60 DI 10.1038/nrn2737 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 534AJ UT WOS:000272867600012 PM 19953104 ER PT J AU Eisner, BH Kurtz, MP Dretler, SP AF Eisner, Brian H. Kurtz, Michael P. Dretler, Stephen P. TI Ureteroscopy for the management of stone disease SO NATURE REVIEWS UROLOGY LA English DT Review ID SHOCK-WAVE LITHOTRIPSY; URETERAL ACCESS SHEATH; INITIAL CLINICAL-EXPERIENCE; HOLMIUM LASER LITHOTRIPSY; LARGE RENAL-CALCULI; UPPER URINARY-TRACT; PNEUMATIC LITHOTRIPSY; IN-VITRO; SEMIRIGID URETEROSCOPY; STAGHORN CALCULI AB Ureteroscopy is the first-line treatment for urinary stone disease at many institutions. Techniques and indications continue to evolve. This Review covers the most current trends, controversies, and issues in ureteroscopic stone management. We present a summary of the most recent evidence regarding ureteroscopic treatment of ureteral and renal stones, current standard indications, adjunct devices and instruments used during ureteroscopy, and future directions. C1 [Eisner, Brian H.; Kurtz, Michael P.; Dretler, Stephen P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Urol, Boston, MA 02114 USA. RP Eisner, BH (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Urol, 55 Fruit St, Boston, MA 02114 USA. EM beisner@partners.org NR 67 TC 7 Z9 7 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-4812 J9 NAT REV UROL JI Nat. Rev. Urol. PD JAN PY 2010 VL 7 IS 1 BP 40 EP 45 DI 10.1038/nrurol.2009.233 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 542AD UT WOS:000273462600006 PM 19949429 ER PT J AU Zhou, YB Meraner, P Kwon, HT Machnes, D Oh-hora, M Zimmer, J Huang, Y Stura, A Rao, A Hogan, PG AF Zhou, Yubin Meraner, Paul Kwon, Hyoung T. Machnes, Danya Oh-hora, Masatsugu Zimmer, Jochen Huang, Yun Stura, Antonio Rao, Anjana Hogan, Patrick G. TI STIM1 gates the store-operated calcium channel ORAI1 in vitro SO NATURE STRUCTURAL & MOLECULAR BIOLOGY LA English DT Article ID STROMAL INTERACTION MOLECULE-1; ACTIVATES CRAC CHANNELS; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; CA2+ ENTRY; SACCHAROMYCES-CEREVISIAE; SECRETORY VESICLES; CELL-ACTIVATION; WATER CHANNEL; PORE SUBUNIT AB Store-operated Ca(2+) entry through the plasma membrane Ca(2+) release-activated Ca(2+) (CRAC) channel in mammalian T cells and mast cells depends on the sensor protein stromal interaction molecule 1 (STIM1) and the channel subunit ORAI1. To study STIM1-ORAI1 signaling in vitro, we have expressed human ORAI1 in a sec6-4 strain of the yeast Saccharomyces cerevisiae and isolated sealed membrane vesicles carrying ORAI1 from the Golgi compartment to the plasma membrane. We show by in vitro Ca(2+) flux assays that bacterially expressed recombinant STIM1 opens wild-type ORAI1 channels but not channels assembled from the ORAI1 pore mutant E106Q or the ORAI1 severe combined immunodeficiency (SCID) mutant R91W. These experiments show that the STIM1-ORAI1 interaction is sufficient to gate recombinant human ORAI1 channels in the absence of other proteins of the human ORAI1 channel complex, and they set the stage for further biochemical and biophysical dissection of ORAI1 channel gating. C1 [Zhou, Yubin; Meraner, Paul; Kwon, Hyoung T.; Machnes, Danya; Oh-hora, Masatsugu; Huang, Yun; Stura, Antonio; Rao, Anjana; Hogan, Patrick G.] Childrens Hosp, Immune Dis Inst, Boston, MA 02115 USA. [Zhou, Yubin; Meraner, Paul; Kwon, Hyoung T.; Machnes, Danya; Oh-hora, Masatsugu; Huang, Yun; Stura, Antonio; Rao, Anjana; Hogan, Patrick G.] Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA. [Zhou, Yubin; Meraner, Paul; Oh-hora, Masatsugu; Huang, Yun; Rao, Anjana] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Zimmer, Jochen] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. [Zimmer, Jochen] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA. RP Hogan, PG (reprint author), Childrens Hosp, Immune Dis Inst, 300 Longwood Ave, Boston, MA 02115 USA. EM hogan@idi.harvard.edu RI Zhou, Yubin/D-4748-2011; OI Zhou, Yubin/0000-0001-7962-0517; Huang, Yun/0000-0001-5950-9168 FU CCR NIH HHS [RC1 DA028422-02]; Howard Hughes Medical Institute; NIAID NIH HHS [R01 AI040127, AI084167, AI40127, R01 AI040127-20, R01 AI084167, R01 AI084167-07]; NIDA NIH HHS [RC1 DA028422, RC1 DA028422-02]; NIGMS NIH HHS [GM075256, R01 GM075256] NR 59 TC 100 Z9 101 U1 1 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1545-9985 J9 NAT STRUCT MOL BIOL JI Nat. Struct. Mol. Biol. PD JAN PY 2010 VL 17 IS 1 BP 112 EP U137 DI 10.1038/nsmb.1724 PG 6 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA 541CL UT WOS:000273390300019 PM 20037597 ER PT B AU Hasserjian, RP AF Hasserjian, Robert P. BE Jones, D TI Chronic Myelogenous Leukemia SO NEOPLASTIC HEMATOPATHOLOGY: EXPERIMENTAL AND CLINICAL APPROACHES SE Contemporary Hematology LA English DT Article; Book Chapter DE Chronic myelogenous leukemia (CML); Philadelphia chromosome, BCR-ABL, kinase in CML; Chronic myelogenous leukemia, accelerated phase (definition); Chronic myelogenous leukemia, blast phase/crisis; Chronic myelogenous leukemia, prognostic models (Sokol score) Chronic myelogenous leukemia; Use of cytogenetics; Chronic myelogenous leukemia, use of PCR; Chronic myelogenous leukemia; Use of FISH; Imatinib (Gleevec), resistance (definitions); Imatinib, primary resistance; Chronic myelogenous leukemia, BCR-ABL point mutation; Chronic myelogenous leukemia, imatinib (Gleevec) resistance; Chronic myelogenous leukemia, genetic progression ID CHRONIC MYELOID-LEUKEMIA; BCR-ABL FUSION; CHRONIC GRANULOCYTIC-LEUKEMIA; IMATINIB MESYLATE THERAPY; KINASE DOMAIN MUTATIONS; IN-SITU HYBRIDIZATION; ADDITIONAL CYTOGENETIC ABNORMALITIES; DERIVATIVE CHROMOSOME-9 DELETIONS; HARMONIZING CURRENT METHODOLOGY; BONE-MARROW TRANSPLANTATION AB Chronic myelogenous leukemia, BCR-ABL1+ (CML), is a myeloproliferative neoplasm defined by the presence of the BCR-ABL fusion gene produced by the t(9;22) (q32;q11) cytogenetic abnormality. CML manifests clinically as leukocytosis with circulating immature granulocytic precursors and splenomegaly. When untreated, its natural history is that of inexorable progression to an acute leukemia (blast crisis) after a prolonged chronic phase. The recent development of inhibitors of BCR-ABL tyrosine kinase activity have dramatically altered the clinical course of CML, with long-term remissions in most patients treated early in the course of disease. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Hasserjian, RP (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. NR 117 TC 0 Z9 0 U1 0 U2 1 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-60761-383-1 J9 CONTEMP HEMATOL PY 2010 BP 193 EP 211 DI 10.1007/978-1-60761-348-8_10 D2 10.1007/978-1-60761-384-8 PG 19 WC Hematology SC Hematology GA BNI24 UT WOS:000274630100010 ER PT J AU Keller, C Katz, R Sarnak, MJ Fried, LF Kestenbaum, B Cushman, M Shlipak, MG AF Keller, Christopher Katz, Ronit Sarnak, Mark J. Fried, Linda F. Kestenbaum, Bryan Cushman, Mary Shlipak, Michael G. CA CHS Study TI Inflammatory biomarkers and decline in kidney function in the elderly: the Cardiovascular Health Study SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE cystatin C; inflammation; inflammatory biomarkers; kidney ID C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; SERUM CYSTATIN-C; GLOMERULAR-FILTRATION-RATE; RENAL-INSUFFICIENCY; 10-YEAR INCIDENCE; POOLED ANALYSIS; RISK; PROGRESSION; MORTALITY AB Methods. This study included 4128 subjects from the Cardiovascular Health Study. Cystatin C was measured at baseline, 3 years later and 7 years later; eligible subjects had at least two measures. Cystatin C-based estimated glomerular filtration rate (eGFR(cysC)) was estimated, and rapid kidney function decline was defined as an annual loss of eGFR(cysC) > 3 mL/min/1.73 m(2). Predictors included ten inflammatory and procoagulant biomarkers: C-reactive protein, interleukin-6, intercellular adhesion molecule-1, white blood cell count, fibrinogen, factor VII, factor VIII, D-dimer, plasmin-antiplasmin complex and serum albumin. Results. During the study, 1059 subjects (26%) had a rapid decline in kidney function. In contrast to the other nine inflammatory or procoagulant biomarkers, serum albumin had a consistent and inverse association with rapid kidney function decline [final adjusted logistic regression model: 1.14-fold increased odds (95% CI 1.06-1.23) of rapid decline per standard deviation lower albumin]. The lowest quartile of albumin had an odds ratio of 1.55 (95% CI 1.23-1.96) for rapid decline compared with the highest quartile. These associations persisted after adjusting the albumin models for CRP, IL-6 and fibrinogen. Conclusions. In contrast to nine other inflammatory and procoagulant markers, only lower baseline levels of serum albumin were consistently associated with a rapid decline in kidney function, as measured by cystatin C-based eGFR. C1 [Keller, Christopher; Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Keller, Christopher; Shlipak, Michael G.] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. [Katz, Ronit] Univ Washington, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98195 USA. [Sarnak, Mark J.] Tufts Univ New England Med Ctr, Div Nephrol, Boston, MA USA. [Fried, Linda F.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Kestenbaum, Bryan] VA Puget Sound Healthcare Syst, Div Nephrol, Seattle, WA USA. [Cushman, Mary] Univ Vermont, Dept Med, Burlington, VT USA. [Cushman, Mary] Univ Vermont, Dept Pathol, Burlington, VT 05405 USA. RP Shlipak, MG (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. EM michael.shlipak@ucsf.edu FU National Heart, Lung, and Blood Institute [N01-HC-85079, N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, U01 HL080295]; Dr Sarnak's National Institute of Aging (NIA) [R01AG027002]; National Kidney Foundation; NIA; American Heart Association; [R01 DK066488-01] FX The Cardiovascular Health Study was funded by the National Heart, Lung, and Blood Institute by contract numbers N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, grant number U01 HL080295, with additional contributions from the National Institute of Neurological Disorders and Stroke. Cystatin C measurements were funded by Dr Sarnak's National Institute of Aging (NIA) grant no. R01AG027002. Dr C. K. is funded by a fellowship award from the National Kidney Foundation. Drs R. K., L. F. and M. S. are additionally funded by the NIA. Dr M. S. is also funded by R01 DK066488-01, as well as by the American Heart Association Established Investigator Award. A full list of principal CHS investigators and institutions can be found at http://www.chs-nhlbi.org/pi.htm. NR 25 TC 25 Z9 28 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD JAN PY 2010 VL 25 IS 1 BP 119 EP 124 DI 10.1093/ndt/gfp429 PG 6 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA 537KZ UT WOS:000273113100021 PM 19734138 ER PT J AU Delgado, C Johansen, KL AF Delgado, Cynthia Johansen, Kirsten L. TI Deficient Counseling on Physical Activity among Nephrologists SO NEPHRON CLINICAL PRACTICE LA English DT Article DE Deficient counseling; Exercise counseling practices; KDOQI guidelines; Nephrologists' counseling practices; Physical activity, nephrologists ID HEMODIALYSIS-PATIENTS; CARDIAC REHABILITATION; DIALYSIS PATIENTS; CORONARY-BYPASS; EXERCISE; HEALTH; SURVIVAL AB Background: An evaluation of exercise counseling practices among nephrologists in 2001 demonstrated few clinicians assessing patients' levels of physical activity (PA) and counseling to increase activity. Recent Kidney Disease Outcomes Quality Initiative (KDOQI) cardiovascular guidelines recommended that nephrologists counsel patients to increase PA. Our objective was to ascertain whether nephrologists' counseling practices have changed. Methods: We administered a 30-item survey regarding exercise counseling to nephrologists attending the ASN meeting in 2007. Some questions were adapted from a prior survey administered in 2001 to assess differences in practice patterns compared to 6 years earlier. Results: Participants answered questions regarding opinions and practices relevant to PA (n = 198), KDOQI guidelines, self-reported PA, and demographic information (n = 173). Participants were 44 +/- 11 years of age, 48% practicing in the USA, and 76% male. In multivariate analysis, older nephrologists (OR; 95% CI) (3.3; 1.2-9.0) and those more physically active (5.5; 2.0-14) were more likely to ask and counsel patients about PA. Opinions associated with less counseling behavior included lack of confidence in ability to discuss PA (0.2; 0.05-0.5). Multivariate comparison to previous respondents (n = 503) showed current nephrologists were not asking and counseling more (1.2; 0.81-1.8). Conclusion: Despite new guidelines, counseling behavior has not increased. Published guidelines are insufficient to reach younger nephrologists. Copyright (C) 2010 S. Karger AG, Basel C1 [Delgado, Cynthia; Johansen, Kirsten L.] Univ Calif San Francisco, Nephrol Sect, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Delgado, C (reprint author), Univ Calif San Francisco, Vet Affairs Med Ctr, 4150 Clement St,Box 111J, San Francisco, CA 94121 USA. EM cynthia.delgado@ucsf.edu FU NIDDK NIH HHS [T32 DK007219, K24 DK085153] NR 13 TC 19 Z9 21 U1 1 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1660-2110 J9 NEPHRON CLIN PRACT JI Nephron. Clin. Pract. PY 2010 VL 116 IS 4 BP C330 EP C336 DI 10.1159/000319593 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 632XL UT WOS:000280462800015 PM 20664289 ER PT J AU Minev, E Unruh, M Shlipak, MG Simsonick, E Yaffe, K Leak, TS Newman, AB Fried, LF AF Minev, Evgueni Unruh, Mark Shlipak, Michael G. Simsonick, Eleanor Yaffe, Kristine Leak, Tennille S. Newman, Anne B. Fried, Linda F. CA Hlth ABC Study TI Association of Cystatin C and Depression in Healthy Elders: The Health, Aging and Body Composition Study SO NEPHRON CLINICAL PRACTICE LA English DT Article DE Depression, elderly; Cystatin C; Chronic kidney disease ID CHRONIC KIDNEY-DISEASE; RENAL-TRANSPLANTATION; HEMODIALYSIS-PATIENTS; PREVALENCE; DIAGNOSIS; OUTCOMES; DEATH AB Background/Aims: Depression is highly prevalent in individuals with advanced kidney disease, but is less well studied in individuals with milder disease. We evaluated the association between kidney function and depression in the Health, Aging and Body Composition (Health ABC) study. Methods: The study enrolled 3,075 community-dwelling black and white adults aged 70-79 years. Kidney function was measured by cystatin C and estimated glomerular filtration rate (eGFR). The main outcome was incident treated depression. Results: 52% of participants had low (<= 1.0), 33% intermediate (> 1-1.25) and 15% high cystatin C (> 1.25). Kidney function and depression were not associated at baseline. Of 2,731 nondepressed participants at baseline, 95 developed incident depression during follow-up. In unadjusted Cox proportional hazard models, hazard ratios (HR) for incident depression were 1.89 (95% confidence interval (CI) 1.21-2.97) for the intermediate and 2.17 (CI 1.24-3.79) for the high cystatin C group. Intermediate (HR = 1.84) and high (HR = 2.1) serum cystatin C remained associated with incident depression in adjusted models. Chronic kidney disease, defined by an eGFR < 60 ml/min/1.73 m(2), was not associated with depression. Conclusion: Participants with higher cystatin C had an increased likelihood of developing treated depression. Future studies should target this high-risk group. Copyright (C) 2010 S. Karger AG, Basel C1 [Minev, Evgueni; Unruh, Mark; Fried, Linda F.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA 15216 USA. [Newman, Anne B.] Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA 15216 USA. [Leak, Tennille S.; Newman, Anne B.; Fried, Linda F.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15216 USA. [Fried, Linda F.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Gen Internal Med Sect, Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Shlipak, Michael G.; Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Yaffe, Kristine] Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Simsonick, Eleanor] NIA, NIH, Baltimore, MD 21224 USA. RP Minev, E (reprint author), Univ Pittsburgh, Sch Med, Renal Electrolyte Div, 3550 Terrace St, Pittsburgh, PA 15216 USA. EM evgueni.minev@gmail.com RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 FU NIA NIH HHS [P30 AG024827] NR 21 TC 2 Z9 2 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1660-2110 J9 NEPHRON CLIN PRACT JI Nephron. Clin. Pract. PY 2010 VL 116 IS 3 BP C241 EP C246 DI 10.1159/000317205 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 621OI UT WOS:000279588200015 PM 20606485 ER PT J AU Post, JB Jegede, AB Morin, K Spungen, AM Langhoff, E Sano, M AF Post, James B. Jegede, Adejoke B. Morin, Kel Spungen, Ann M. Langhoff, Erik Sano, Mary TI Cognitive Profile of Chronic Kidney Disease and Hemodialysis Patients without Dementia SO NEPHRON CLINICAL PRACTICE LA English DT Article DE Cognition; Mild cognitive impairment; Cerebrovascular disease; Chronic kidney disease; Hemodialysis ID WHITE-MATTER LESIONS; STAGE RENAL-DISEASE; CARDIOVASCULAR-DISEASE; VASCULAR DEMENTIA; IMPAIRMENT; PREVALENCE; PRODUCTS; ADULTS; HEALTH AB Background/Aims: The high risk and prevalence of dementia among patients with chronic kidney disease (CKD) and in those receiving hemodialysis (HD) may be preceded by mild cognitive impairment (MCI). We aimed to assess cognitive function in CKD and HD patients with no history of stroke or dementia, in order to identify and characterize early cognitive deficits. Methods: 24 CKD and 27 HD male outpatients without history of cerebrovascular or neurodegenerative disease underwent comprehensive neuropsychological testing in an observational cross-sectional study. Test results were used to categorize patients into MCI subtypes. Results: All subjects scored >= 28 on the Mini-Mental State Examination. The prevalence of executive function was at least 25% in both groups and memory impairment occurred in 13% of the HD patients and 15% of those with CKD. MCI occurred in 76% of the group and HD patients showed a higher prevalence of MCI compared to CKD patients (89 vs. 63%) with a preponderance (> 70%) of cases across both groups classified as non-amnestic MCI. Conclusion: Predialysis CKD and HD patients have a high prevalence of MCI despite normal global cognitive function. MCI was more prevalent among the HD patients and deficits more frequently resulted in non-amnestic MCI. Copyright (C) 2010 S. Karger AG, Basel C1 [Post, James B.; Langhoff, Erik] James J Peters VA Med Ctr, Div Nephrol, Bronx, NY 10468 USA. [Post, James B.; Jegede, Adejoke B.; Morin, Kel; Spungen, Ann M.] James J Peters VA Med Ctr, VA RR&D, Ctr Excellence Med Consequences, SCI, Bronx, NY USA. [Post, James B.; Langhoff, Erik] Mt Sinai Sch Med, Dept Med, Bronx, NY USA. [Spungen, Ann M.] Mt Sinai Sch Med, Dept Rehabil Med, Bronx, NY USA. [Sano, Mary] Mt Sinai Sch Med, Dept Psychiat, Bronx, NY USA. RP Post, JB (reprint author), James J Peters VA Med Ctr, Div Nephrol, 4C-12 Outpatient Renal Practice,130 W Kingsbridge, Bronx, NY 10468 USA. EM James.Post@va.gov FU VA VISN 3 Seed Grant Program; VARRD CDA 2 [B5050W]; VARR& D Center of Excellence [B4162C]; NIH/NIA [P50AG005138] FX Funding for this project was provided by the VA VISN 3 Seed Grant Program, VARR&D CDA 2 # B5050W, VARR& D Center of Excellence # B4162C and NIH/NIA # P50AG005138. NR 40 TC 18 Z9 22 U1 1 U2 4 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1660-2110 J9 NEPHRON CLIN PRACT JI Nephron. Clin. Pract. PY 2010 VL 116 IS 3 BP C247 EP C255 DI 10.1159/000317206 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 621OI UT WOS:000279588200016 PM 20606486 ER PT J AU Roumelioti, ME Argyropoulos, C Buysse, DJ Nayar, H Weisbord, SD Unruh, ML AF Roumelioti, Maria-Eleni Argyropoulos, Christos Buysse, Daniel J. Nayar, Harry Weisbord, Steven D. Unruh, Mark L. TI Sleep Quality, Mood, Alertness and Their Variability in CKD and ESRD SO NEPHRON CLINICAL PRACTICE LA English DT Article DE Mood; Sleep quality; Alertness; Chronic kidney disease; End-stage renal disease; Pittsburgh Sleep Diary; SF-36 ID CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; OF-LIFE; MAINTENANCE HEMODIALYSIS; HEALTH SURVEY; HEART HEALTH; DIALYSIS; DEPRESSION; SYMPTOMS; OUTCOMES AB Background/Aims: Little is known about the association of chronic kidney disease (CKD) with sleep quality, mood, and alertness. In this report, we assessed these symptoms among patients with advanced CKD (stages 4-5) and those with end-stage renal disease (ESRD) and compared them to healthy controls without known kidney disease. Methods: Patients were recruited from local dialysis units, outpatient nephrology clinics and the Thomas E. Starzl Transplant Institute. Healthy control subjects matched for age, gender and race were drawn from an archival database. Daily symptoms of sleep quality, mood, and alertness were assessed by visual analogue scales of the Pittsburgh Sleep Diary. Health-related quality of life was assessed by the Short Form-36 instrument. Results: Sixty-nine dialysis patients and 23 patients with advanced CKD demonstrated worse scores in sleep quality, mood, and alertness (p < 0.001) than controls. In adjusted analyses, European-American race, dialysis dependency, younger age, and physical performance SF-36 components were significantly associated with poor sleep quality, mood and alertness (p < 0.05). The dialysis population demonstrated higher day-to-day variability in scores than either the advanced CKD patients or the controls. Conclusion: Advanced CKD and dialysis dependency are associated with impaired and highly variable sleep quality, mood, and alertness. Copyright (C) 2010 S. Karger AG, Basel C1 [Roumelioti, Maria-Eleni; Argyropoulos, Christos; Weisbord, Steven D.; Unruh, Mark L.] Univ Pittsburgh, Med Ctr, Renal Electrolyte Div, Pittsburgh, PA 15213 USA. [Buysse, Daniel J.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA. [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Nayar, Harry] Drexel Univ, Sch Med, Pittsburgh, PA USA. RP Unruh, ML (reprint author), Univ Pittsburgh, Med Ctr, Renal Electrolyte Div, 200 Lothrop St,PUH C-1111, Pittsburgh, PA 15213 USA. EM unruh@pitt.edu OI Argyropoulos, Christos/0000-0002-9679-7805 FU Fresenius National Kidney Foundation; Paul Teschan Research Grant; NIH [DK66006, DK77785, MH24652]; NIH/NCRR/CTSA [UL1 RR024153] FX This work was supported by the Fresenius National Kidney Foundation Young Investigator Grant, Paul Teschan Research Grant, NIH DK66006 and DK77785 (M. L. U.) and NIH MH24652 (D. J. B.). This publication was supported by funds received from the NIH/NCRR/CTSA Grant UL1 RR024153. NR 47 TC 11 Z9 11 U1 1 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1660-2110 J9 NEPHRON CLIN PRACT JI Nephron. Clin. Pract. PY 2010 VL 114 IS 4 BP C277 EP C287 DI 10.1159/000276580 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA 546IQ UT WOS:000273804900011 PM 20090370 ER PT J AU Khan, AM Li, M Balamuthusamy, S Maderdrut, JL Simon, EE Batuman, V AF Khan, Altaf-M. Li, Min Balamuthusamy, Saravanan Maderdrut, Jerome L. Simon, Eric E. Batuman, Vecihi TI Myeloma Light Chain-Induced Renal Injury in Mice SO NEPHRON EXPERIMENTAL NEPHROLOGY LA English DT Article DE Protein overload; Kidney failure; Proteinuria; Cytokines; Plasma cell dyscrasias ID PROXIMAL TUBULAR CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; PROGRESSIVE NEPHROPATHIES; GLOMERULAR INJURY; URINARY-EXCRETION; KIDNEY-DISEASE; KAPPA-B; ACTIVATION; PROTEIN-1; OVERLOAD AB We investigated the effects of human light chain (LC) protein-overload in mice kidney to gain further insights into the molecular mechanisms involved in the pathogenesis of myeloma kidney. Intact male C57BL/6, 10- to 12-week-old mice were given daily intraperitoneal (i.p.) injections of 1 ml of human kappa-LCs (1.5 mg/ml, low dose), or (100 mg/ml, high dose) to uninephrectomized mice for 2 weeks. Intact, sham-operated or uninephrectomized control animals were given the same volume (1 ml/day) of saline, human serum albumin (10 mg/ml) or bovine serum albumin (100 mg/ml) i.p. for 2 weeks in place of LCs. The low-dose LC-treated mice had human LCs in their urine and a significant increase in monocyte chemoattractant protein-1 (MCP-1) mRNA in the kidneys. Uninephrectomized mice treated with high-dose kappa-LCs showed tubule casts, and foci of intracytoplasmic rhomboid crystals within the proximal tubules, along with cytoskeletal disruptions and alterations in the brush-border membrane, and high concentrations of human kappa-LC were present in their sera. High-dose LC treatment also led to increases in serum creatinine and tumor necrosis factor-alpha levels, and marked increases in interleukin-6 and MCP-1 expression as well as cellular apoptosis in the kidneys. These studies demonstrate that myeloma LC overload over a range of LC concentrations in mice causes significant functional and morphological kidney injury. The model should be helpful in investigating pathophysiologic mechanisms and exploring therapeutic interventions for myeloma kidney and other LC-associated renal disorders. Copyright (C) 2010 S. Karger AG, Basel C1 [Khan, Altaf-M.; Li, Min; Balamuthusamy, Saravanan; Simon, Eric E.; Batuman, Vecihi] Tulane Univ, Sch Med, Dept Med, Sect Nephrol & Hypertens, New Orleans, LA 70112 USA. [Maderdrut, Jerome L.] Tulane Univ, Sch Med, Dept Med, Peptide Res Lab, New Orleans, LA 70112 USA. [Simon, Eric E.; Batuman, Vecihi] Southeast Louisiana Vet Hlth Care Syst, US Dept Vet Affairs, New Orleans, LA USA. RP Batuman, V (reprint author), Tulane Univ, Sch Med, Dept Med, Sect Nephrol & Hypertens, 1430 Tulane Ave,SL 45, New Orleans, LA 70112 USA. EM vbatuma@tulane.edu OI Batuman, Vecihi/0000-0002-1800-9009 FU Louisiana Board of Regents; Rudolph Matas Memorial Fund; DCI; Louisiana Cancer Research Consortium; Arimura Foundation FX This work was supported in part by research grants from the Research Commercialization and Educational Enhancement Program of the Louisiana Board of Regents (M. L., J.L.M. and V. B.), the Rudolph Matas Memorial Fund (V. B. and M. L.), DCI Research Endowment Fund (V. B.), the Louisiana Cancer Research Consortium (J.L.M.), and the Arimura Foundation (M. L.). We are also thankful to Dr. Solange Abdulnour-Nakhoul in the Department of Medicine, Tulane University School of Medicine, for providing histology facility and helpful discussions. NR 37 TC 9 Z9 9 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1660-2129 J9 NEPHRON EXP NEPHROL JI Nephron Exp. Nephrol PY 2010 VL 116 IS 2 BP E32 EP E41 DI 10.1159/000317129 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 618CV UT WOS:000279329900002 PM 20588062 ER PT J AU Haslinger, R Klinkner, KL Shalizi, CR AF Haslinger, Robert Klinkner, Kristina Lisa Shalizi, Cosma Rohilla TI The Computational Structure of Spike Trains SO NEURAL COMPUTATION LA English DT Article ID LEMPEL-ZIV COMPLEXITY; DYNAMIC-ANALYSIS; ENTROPY; STATES; SEQUENCES AB Neurons perform computations, and convey the results of those computations through the statistical structure of their output spike trains. Here we present a practical method, grounded in the information-theoretic analysis of prediction, for inferring a minimal representation of that structure and for characterizing its complexity. Starting from spike trains, our approach finds their causal state models (CSMs), the minimal hidden Markov models or stochastic automata capable of generating statistically identical time series. We then use these CSMs to objectively quantify both the generalizable structure and the idiosyncratic randomness of the spike train. Specifically, we show that the expected algorithmic information content ( the information needed to describe the spike train exactly) can be split into three parts describing ( 1) the time-invariant structure ( complexity) of the minimal spike-generating process, which describes the spike train statistically; ( 2) the randomness ( internal entropy rate) of the minimal spike-generating process; and ( 3) a residual pure noise term not described by the minimal spike-generating process. We use CSMs to approximate each of these quantities. The CSMs are inferred nonparametrically from the data, making only mild regularity assumptions, via the causal state splitting reconstruction algorithm. The methods presented here complement more traditional spike train analyses by describing not only spiking probability and spike train entropy, but also the complexity of a spike train's structure. We demonstrate our approach using both simulated spike trains and experimental data recorded in rat barrel cortex during vibrissa stimulation. C1 [Haslinger, Robert] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Haslinger, Robert] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA. [Klinkner, Kristina Lisa; Shalizi, Cosma Rohilla] Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15213 USA. [Shalizi, Cosma Rohilla] Santa Fe Inst, Santa Fe, NM 87051 USA. RP Haslinger, R (reprint author), Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. EM robhh@nmr.mgh.harvard.edu; klinkner@stat.cmu.edu; cshalizi@stat.cmu.edu FU NINDS NIH HHS [K25 NS052422, K25 NS052422-03] NR 44 TC 18 Z9 18 U1 0 U2 2 PU MIT PRESS PI CAMBRIDGE PA ONE ROGERS ST, CAMBRIDGE, MA 02142-1209 USA SN 0899-7667 EI 1530-888X J9 NEURAL COMPUT JI Neural Comput. PD JAN PY 2010 VL 22 IS 1 BP 121 EP 157 DI 10.1162/neco.2009.12-07-678 PG 37 WC Computer Science, Artificial Intelligence; Neurosciences SC Computer Science; Neurosciences & Neurology GA 534CP UT WOS:000272873400005 PM 19764880 ER PT J AU Rajaraman, P Hutchinson, A Wichner, S Black, PM Fine, HA Loeffler, JS Selker, RG Shapiro, WR Rothman, N Linet, MS Inskip, PD AF Rajaraman, Preetha Hutchinson, Amy Wichner, Sara Black, Peter M. Fine, Howard A. Loeffler, Jay S. Selker, Robert G. Shapiro, William R. Rothman, Nathaniel Linet, Martha S. Inskip, Peter D. TI DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma SO NEURO-ONCOLOGY LA English DT Article DE acoustic neuroma; brain; case-control; DNA repair; glioma; meningioma; neoplasm; polymorphism; tumor ID BREAST-CANCER RISK; BRAIN-TUMORS; COMPREHENSIVE ANALYSIS; VARIANTS; XRCC1; ERCC1 AB Although the etiology of primary brain tumors is largely unknown, prior studies suggest that DNA repair polymorphisms may influence risk of glioma. Altered DNA repair is also likely to affect the risk of meningioma and acoustic neuroma, but these tumors have not been well studied. We estimated the risk of glioma (n = 362), meningioma (n = 134), and acoustic neuroma (n = 69) in non-Hispanic whites with respect to 36 single nucleotide polymorphisms from 26 genes involved in DNA repair in a hospital-based, case-control study conducted by the National Cancer Institute. We observed significantly increased risk of meningioma with the T variant of GLTSCR1 rs1035938 (OR(CT/TT) = 3.5; 95% confidence interval: 1.8-6.9; P(trend) .0006), which persisted after controlling for multiple comparisons (P = .019). Significantly increased meningioma risk was also observed for the minor allele variants of ERCC4 rs1800067 (P(trend) .01); MUTYH rs3219466 (P(trend) .02), and PCNA rs25406 (P(trend) .03). The NBN rs1805794 minor allele variant was associated with decreased meningioma risk (P(trend) .006). Risk of acoustic neuroma was increased for the ERCC2 rs1799793 (P(trend) .03) and ERCC5 rs17655 (P(trend) .05) variants and decreased for the PARP1 rs1136410 (P(trend) .03). Decreased glioma risk was observed with the XRCC1 rs1799782 variant (P(trend) .04). Our results suggest that common DNA repair variants may affect the risk of adult brain tumors, especially meningioma. C1 [Rajaraman, Preetha; Wichner, Sara; Rothman, Nathaniel; Linet, Martha S.; Inskip, Peter D.] NCI, Div Canc Epidemiol & Genet, NIH, DHHS, Bethesda, MD 20892 USA. [Hutchinson, Amy] NCI, Core Genotyping Facil, Div Canc Epidemiol & Genet, Adv Technol Program,SAIC Frederick Inc, Frederick, MD 21701 USA. [Black, Peter M.] Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA. [Fine, Howard A.] NCI, Neurooncol Branch, NIH, DHHS, Bethesda, MD 20892 USA. [Loeffler, Jay S.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Selker, Robert G.] Western Penn Hosp, Div Neurosurg, Pittsburgh, PA 15224 USA. [Shapiro, William R.] St Josephs Hosp, Barrow Neurol Inst, Phoenix, AZ USA. RP Rajaraman, P (reprint author), NCI, Div Canc Epidemiol & Genet, NIH, DHHS, 6120 Execut Blvd,EPS Room 7085, Bethesda, MD 20892 USA. EM rajarama@mail.nih.gov FU National Cancer Institute, National Institutes of Health, Department of Health and Human Services; National Cancer Institute, National Institutes of Health [N01-CO-12400] FX This research was supported by intramural funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services. This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract N01-CO-12400. NR 25 TC 85 Z9 88 U1 1 U2 8 PU DUKE UNIV PRESS PI DURHAM PA 905 W MAIN ST, STE 18-B, DURHAM, NC 27701 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JAN PY 2010 VL 12 IS 1 BP 37 EP 48 DI 10.1093/neuonc/nop012 PG 12 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 546BE UT WOS:000273781300007 PM 20150366 ER PT J AU Colman, H Zhang, L Sulman, EP McDonald, JM Shooshtari, NL Rivera, A Popoff, S Nutt, CL Louis, DN Cairncross, JG Gilbert, MR Phillips, HS Mehta, MP Chakravarti, A Pelloski, CE Bhat, K Feuerstein, BG Jenkins, RB Aldape, K AF Colman, Howard Zhang, Li Sulman, Erik P. McDonald, J. Matthew Shooshtari, Nasrin Latif Rivera, Andreana Popoff, Sonya Nutt, Catherine L. Louis, David N. Cairncross, J. Gregory Gilbert, Mark R. Phillips, Heidi S. Mehta, Minesh P. Chakravarti, Arnab Pelloski, Christopher E. Bhat, Krishna Feuerstein, Burt G. Jenkins, Robert B. Aldape, Ken TI A multigene predictor of outcome in glioblastoma SO NEURO-ONCOLOGY LA English DT Article DE biomarkers; MGMT promoter; glioblastoma; prognostic genes; temozolomide ID GROWTH-FACTOR RECEPTOR; EPITHELIAL-MESENCHYMAL TRANSITIONS; COMPARATIVE GENOMIC HYBRIDIZATION; TUMOR PROGRESSION; STEM-CELLS; EXPRESSION; SURVIVAL; BRAIN; GLIOMAS; ANGIOGENESIS AB Only a subset of patients with newly diagnosed glioblastoma (GBM) exhibit a response to standard therapy. To date, a biomarker panel with predictive power to distinguish treatment sensitive from treatment refractory GBM tumors does not exist. An analysis was performed using GBM microarray data from 4 independent data sets. An examination of the genes consistently associated with patient outcome, revealed a consensus 38-gene survival set. Worse outcome was associated with increased expression of genes associated with mesenchymal differentiation and angiogenesis. Application to formalin fixed-paraffin embedded (FFPE) samples using real-time reverse-transcriptase polymerase chain reaction assays resulted in a 9-gene subset which appeared robust in these samples. This 9-gene set was then validated in an additional independent sample set. Multivariate analysis confirmed that the 9-gene set was an independent predictor of outcome after adjusting for clinical factors and methylation of the methylguanine methyltransferase promoter. The 9-gene profile was also positively associated with markers of glioma stem-like cells, including CD133 and nestin. In sum, a multigene predictor of outcome in glioblastoma was identified which appears applicable to routinely processed FFPE samples. The profile has potential clinical application both for optimization of therapy in GBM and for the identification of novel therapies targeting tumors refractory to standard therapy. C1 [Colman, Howard; Zhang, Li; Sulman, Erik P.; McDonald, J. Matthew; Shooshtari, Nasrin Latif; Rivera, Andreana; Popoff, Sonya; Gilbert, Mark R.; Pelloski, Christopher E.; Bhat, Krishna; Aldape, Ken] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77401 USA. [Colman, Howard; Zhang, Li; Sulman, Erik P.; McDonald, J. Matthew; Shooshtari, Nasrin Latif; Rivera, Andreana; Popoff, Sonya; Gilbert, Mark R.; Pelloski, Christopher E.; Bhat, Krishna; Aldape, Ken] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77401 USA. [Colman, Howard; Zhang, Li; Sulman, Erik P.; McDonald, J. Matthew; Shooshtari, Nasrin Latif; Rivera, Andreana; Popoff, Sonya; Gilbert, Mark R.; Pelloski, Christopher E.; Bhat, Krishna; Aldape, Ken] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77401 USA. [Colman, Howard; Zhang, Li; Sulman, Erik P.; McDonald, J. Matthew; Shooshtari, Nasrin Latif; Rivera, Andreana; Popoff, Sonya; Gilbert, Mark R.; Pelloski, Christopher E.; Bhat, Krishna; Aldape, Ken] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77401 USA. [Phillips, Heidi S.] Genentech Inc, Dept Tumor Biol & Angiogenesis, San Francisco, CA 94080 USA. [Nutt, Catherine L.; Louis, David N.; Chakravarti, Arnab] Massachusetts Gen Hosp, Dept Pathol & Radiat Oncol, Boston, MA 02114 USA. [Cairncross, J. Gregory] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada. [Mehta, Minesh P.] Univ Wisconsin, Dept Human Oncol, Madison, WI USA. [Feuerstein, Burt G.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA. [Jenkins, Robert B.] Mayo Clin, Dept Lab Genet, Rochester, MN USA. RP Aldape, K (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd, Houston, TX 77401 USA. EM kaldape@mdanderson.org RI Nutt, Catherine/K-8794-2012; Gilbert, Mark/J-7494-2016; OI Gilbert, Mark/0000-0003-2556-9722; mehta, minesh/0000-0002-4812-5713 FU V Foundation; Dr Marnie Rose Foundation; National Institute of Health/National Cancer Institute [P50CA127001] FX Supported by grants from the V Foundation, The Dr Marnie Rose Foundation, and a SPORE grant in Brain Cancer (P50CA127001) from the National Institute of Health/National Cancer Institute. NR 38 TC 173 Z9 177 U1 0 U2 9 PU DUKE UNIV PRESS PI DURHAM PA 905 W MAIN ST, STE 18-B, DURHAM, NC 27701 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JAN PY 2010 VL 12 IS 1 BP 49 EP 57 DI 10.1093/neuonc/nop007 PG 9 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 546BE UT WOS:000273781300008 PM 20150367 ER PT J AU Raizer, JJ Abrey, LE Lassman, AB Chang, SM Lamborn, KR Kuhn, JG Yung, WKA Gilbert, MR Aldape, KD Wen, PY Fine, HA Mehta, M DeAngelis, LM Lieberman, F Cloughesy, TF Robins, HI Dancey, J Prados, MD AF Raizer, Jeffrey J. Abrey, Lauren E. Lassman, Andrew B. Chang, Susan M. Lamborn, Kathleen R. Kuhn, John G. Yung, W. K. Alfred Gilbert, Mark R. Aldape, Kenneth D. Wen, Patrick Y. Fine, Howard A. Mehta, Minesh DeAngelis, Lisa M. Lieberman, Frank Cloughesy, Timothy F. Robins, H. Ian Dancey, Janet Prados, Michael D. CA N Amer Brain Tumor Consortium TI A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas SO NEURO-ONCOLOGY LA English DT Article DE erlotinib; glioblastoma; glioma; meningioma; pharmacokinetics ID CONFERS ENHANCED TUMORIGENICITY; TYROSINE-KINASE INHIBITOR; GROWTH-FACTOR RECEPTORS; BRAIN-TUMOR CONSORTIUM; PHARMACOKINETICS; TEMOZOLOMIDE; COMMON; CELLS AB The objective of this phase I study was to determine the maximal tolerated dose (MTD) of erlotinib in patients with re current malignant gliomas (MGs) or recurrent meningiomas on enzyme-inducing antiepileptic drugs (EIAEDs). Dose escalation was by a standard 3 x 3 design. The initial starting dose of erlotinib was 150 mg daily. If no dose-limiting toxicity (DLT) was observed, then dose escalation occurs as follows: 200 mg/day, 275 mg/day, and then increased in 125 mg increments until the MTD was reached. The MTD was defined as the dose where <= 1 of 6 patients experienced a DLT and the dose above had 2 or more DLTs. The MTD was 650 mg/day; the observed DLTs were grade 3 rash in 2 patients at 775 mg/day. Pharmacokinetic analysis showed a significant influence of EIAEDs on the metabolism of erlotinib when compared with our phase 11 data published separately. Primary toxicities were rash and diarrhea. The MTD of erlotinib in patients receiving EIAEDs is substantially higher than the standard dose of 150 mg. This has important implications for further development of this drug in the treatment of MG as well as the optimal management of patients with other malignancies such as NSCLC who are on enzyme-inducing drugs. C1 [Raizer, Jeffrey J.] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA. [Abrey, Lauren E.; Lassman, Andrew B.; DeAngelis, Lisa M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Chang, Susan M.; Lamborn, Kathleen R.; Prados, Michael D.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA. [Kuhn, John G.] Univ Texas Hlth Sci Ctr San Antonio, Pharmacotherapy Educ & Res Ctr, San Antonio, TX 78229 USA. [Yung, W. K. Alfred; Gilbert, Mark R.] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA. [Aldape, Kenneth D.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA. [Wen, Patrick Y.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Fine, Howard A.] NCI, Neurooncol Branch, NIH, Bethesda, MD 20892 USA. [Mehta, Minesh; Robins, H. Ian] Univ Wisconsin Hosp, Madison, WI USA. [Lieberman, Frank] Univ Pittsburgh, Med Ctr Canc Pavil, Div Neurooncol, Pittsburgh, PA USA. [Cloughesy, Timothy F.] Univ Calif Los Angeles, David Geffen Sch Med, Neurooncol Program, Los Angeles, CA 90095 USA. [Dancey, Janet] Ontario Inst Canc Res, Toronto, ON, Canada. RP Raizer, JJ (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Neurol, 710 N Lake Shore Dr,Abbott Hall 1123, Chicago, IL 60611 USA. EM jraizer@nmff.org RI Gilbert, Mark/J-7494-2016; OI Gilbert, Mark/0000-0003-2556-9722; mehta, minesh/0000-0002-4812-5713 FU NABTC [CA62399, CA62422]; GCRC [M01-RR00079, CA62426, CA62412, CA16672, U01CA62407-08, U01CA6242108, M01 RR03186, U01CA62405, M01-RR00056, U01 CA62399, M01-RR0865]; [5-U01CA62399-09] FX Grant Support: 5-U01CA62399-09 (J.J.R., L.E.A., A.B.L., and L.M.D.); NABTC # CA62399 and Member # CA62422, GCRC Grant # M01-RR00079 (S.M.C., K.R.L., and M.D.P.); CA62426 (J.G.K.); CA62412, GCRC Grant # CA16672 (W.K.A.Y. and M.R.G.); U01CA62407-08 (P.Y.W.), U01CA6242108, GCRC Grant # M01 RR03186 (M.M. and H.I.R.); U01CA62405, GCRC Grant # M01-RR00056 (F.L.); U01 CA62399, GCRC Grant # M01-RR0865 (T.F.C.). NR 16 TC 23 Z9 26 U1 0 U2 5 PU DUKE UNIV PRESS PI DURHAM PA 905 W MAIN ST, STE 18-B, DURHAM, NC 27701 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JAN PY 2010 VL 12 IS 1 BP 87 EP 94 DI 10.1093/neuonc/nop017 PG 8 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 546BE UT WOS:000273781300012 PM 20150371 ER PT J AU Raizer, JJ Abrey, LE Lassman, AB Chang, SM Lamborn, KR Kuhn, JG Yung, WKA Gilbert, MR Aldape, KA Wen, PY Fine, HA Mehta, M DeAngelis, LM Lieberman, F Cloughesy, TF Robins, HI Dancey, J Prados, MD AF Raizer, Jeffrey J. Abrey, Lauren E. Lassman, Andrew B. Chang, Susan M. Lamborn, Kathleen R. Kuhn, John G. Yung, W. K. Alfred Gilbert, Mark R. Aldape, Kenneth A. Wen, Patrick Y. Fine, Howard A. Mehta, Minesh DeAngelis, Lisa M. Lieberman, Frank Cloughesy, Timothy F. Robins, H. Ian Dancey, Janet Prados, Michael D. CA N Amer Brain Tumor Consortium TI A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy SO NEURO-ONCOLOGY LA English DT Article DE erlotinib; glioblastoma; glioma; meningioma; pharmacokinetics ID GROWTH-FACTOR-RECEPTOR; CELL LUNG-CANCER; CONFERS ENHANCED TUMORIGENICITY; RADIATION-THERAPY; KINASE INHIBITORS; PROTEIN-KINASE; I/II TRIAL; GEFITINIB; TEMOZOLOMIDE; BRAIN AB Patients with (a) recurrent malignant glioma (MG): glioblastoma (GBM) or recurrent anaplastic glioma (AG), and (b) nonprogressive (NP) GBM following radiation therapy (RT) were eligible. Primary objective for recurrent MG was progression-free survival at 6 months (PFS-6) and overall survival at 12 months for NP GBM post-RT. Secondary objectives for recurrent MGs were response, survival, assessment of toxicity, and pharmacokinetics (PKs). Treatment with enzyme-inducing antiepileptic drugs was not allowed. Patients received 150 mg/day erlotinib. Patients requiring surgery were treated 7 days prior to tumor removal for PK analysis and effects of erlotinib on epidermal growth factor receptor (EGFR) and intracellular signaling pathways. Ninety-six patients were evaluable (53 recurrent MG and 43 NP GBM); 5 patients were not evaluable for response. PFS-6 in recurrent GBM was 3% with a median PFS of 2 months; PFS-6 in recurrent AG was 27% with a median PFS of 2 months. Twelve-month survival was 57% in NP GBMs post-RT. Primary toxicity was dermatologic. The tissue-to-plasma ratio normalized to nanograms per gram dry weight for erlotinib and OSI-420 ranged from 25% to 44% and 30% to 59%, respectively, for pretreated surgical patients. No effect on EGFR or intratumoral signaling was seen. Patients with NP GBM post-RT who developed rash in cycle 1 had improved survival (P < .001.). Single-agent activity of erlotinib is minimal for recurrent MGs and marginally beneficial following RT for NP GBM patients. Development of rash in cycle 1 correlates with survival in patients with NP GBM after RT. C1 [Raizer, Jeffrey J.] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA. [Abrey, Lauren E.; Lassman, Andrew B.; DeAngelis, Lisa M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Chang, Susan M.; Lamborn, Kathleen R.; Prados, Michael D.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA. [Kuhn, John G.] Univ Texas Hlth Sci Ctr San Antonio, Pharmacotherapy Educ & Res Ctr, San Antonio, TX 78229 USA. [Yung, W. K. Alfred; Gilbert, Mark R.; Aldape, Kenneth A.] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA. [Wen, Patrick Y.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Fine, Howard A.] NCI, Neurooncol Branch, NIH, Bethesda, MD 20892 USA. [Mehta, Minesh; Robins, H. Ian] Univ Wisconsin Hosp, Madison, WI USA. [Lieberman, Frank] Univ Pittsburgh, Med Ctr Canc Pavil, Div Neurooncol, Pittsburgh, PA USA. [Cloughesy, Timothy F.] Univ Calif Los Angeles, David Geffen Sch Med, Neurooncol Program, Los Angeles, CA 90095 USA. [Dancey, Janet] Ontario Inst Canc Res, Toronto, ON, Canada. RP Raizer, JJ (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Neurol, 710 N Lake Shore Dr,Abbott Hall 1123, Chicago, IL 60611 USA. EM jraizer@nmff.org RI Gilbert, Mark/J-7494-2016; OI Gilbert, Mark/0000-0003-2556-9722; mehta, minesh/0000-0002-4812-5713 FU NABTC [CA62399, CA62422]; GCRC [M01-RR00079, CA62426, CA62412,, CA16672, U01CA62407-08, U01CA62421-08, M01 RR03186, U01CA62405, M01-RR00056, U01CA62399, M01-RR0865]; [5-U01CA62399-09] FX Grant Support: 5-U01CA62399-09 (J.J.R., L.E.A., A.B.L., and L.M.D.); NABTC # CA62399 and Member # CA62422, GCRC Grant # M01-RR00079 (S.M.C., K.R.L., and M.D.P.); CA62426 (J.G.K.); CA62412, GCRC Grant # CA16672 (W.K.A.Y. and M.R.G.); U01CA62407-08 (P.Y.W.); U01CA62421-08, GCRC Grant # M01 RR03186 (M.M. and H.I.R.); U01CA62405, GCRC Grant # M01-RR00056 (F.L.); U01CA62399, GCRC Grant # M01-RR0865 (T.F.C.). NR 43 TC 119 Z9 123 U1 0 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JAN PY 2010 VL 12 IS 1 BP 95 EP 103 DI 10.1093/neuonc/nop015 PG 9 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 546BE UT WOS:000273781300013 PM 20150372 ER PT J AU Handratta, V Hsu, E Vento, J Yang, C Tanev, K AF Handratta, Venkatesh Hsu, Ellen Vento, John Yang, Clifford Tanev, Kaloyan TI Neuroimaging findings and brain-behavioral correlates in a former boxer with chronic traumatic brain injury SO NEUROCASE LA English DT Article DE Chronic traumatic brain injury; Dementia; Traumatic brain injury; Dementia pugilistica; Neuroimaging; Neuropsychiatry; Brain behavior relationships ID CAVUM SEPTI PELLUCIDI; NATIONAL-FOOTBALL-LEAGUE; CORTICAL CELL-CULTURE; GLUTAMATE NEUROTOXICITY; BIPOLAR DISORDER; RAT; SCHIZOPHRENIA; PREVALENCE; VERGAE; ENCEPHALOPATHY AB Chronic traumatic brain injury (CTBI) is associated with contact sports such as boxing. CTBI results from repetitive blows to the head rather than from a single impact. CTBI individuals present with motor symptoms (incoordination, spasticity, parkinsonism), cognitive impairment (executive dysfunction, memory deficits) and neuropsychiatric symptoms (irritability, affective disturbances). The structural and functional neuroimaging findings and clinical presentation of a CTBI case are described. We propose hypotheses about the pathophysiology of the observed neuroimaging findings and their relationship to the neuropsychiatric symptoms of the patients. C1 [Handratta, Venkatesh; Hsu, Ellen; Vento, John; Yang, Clifford; Tanev, Kaloyan] Univ Connecticut, Ctr Hlth, Farmington, CT USA. RP Tanev, K (reprint author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA. EM ktanev@partners.org NR 64 TC 11 Z9 11 U1 5 U2 11 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1355-4794 J9 NEUROCASE JI Neurocase PY 2010 VL 16 IS 2 BP 125 EP 134 DI 10.1080/13554790903329166 PG 10 WC Clinical Neurology; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 569LY UT WOS:000275599800004 PM 19967598 ER PT J AU Faber, R Azad, A Reinsvold, R AF Faber, Raymond Azad, Alvi Reinsvold, Richard TI A case of the corpus callosum and alien hand syndrome from a discrete paracallosal lesion SO NEUROCASE LA English DT Article DE Split-brain syndrome; Syndrome of hemisphere disconnection; Paracallosal lesion; Apraxia; Agraphia ID DISEASE IMAGE; APRAXIA; DISCONNECTION; INFARCTION AB Here we present a patient with an isolated paracallosal brain lesion who exhibited behavioral changes associated with the corpus callosum syndrome (CCS) including features of the alien hand syndrome (AHS). The CCS is also known as the split-brain syndrome, the syndrome of hemisphere disconnection, the syndrome of brain bisection and the syndrome of the cerebral commissures. Because most reported cases of CCS were caused by tumors which extended beyond the corpus callosum (CC) and did not always induce a complete disconnection, there was much controversy about the role of the CC and the existence of a specific CCS. Aside from surgically based cases, the full complement of the CCS is infrequently clinically encountered. The patient described has a classic CCS from natural causes. This case report is unique in exhibiting a complete CCS with AHS secondary to an ischemic event affecting the left pericallosal region. To our knowledge this is the first case report of such a combination. C1 [Faber, Raymond] Laurel Ridge Treatment Ctr, San Antonio, TX USA. [Faber, Raymond] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Faber, Raymond; Azad, Alvi] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Azad, Alvi; Reinsvold, Richard] Wilford Hall USAF Med Ctr, San Antonio, TX USA. RP Faber, R (reprint author), 7400 Merton Minter Blvd 116-A, San Antonio, TX 78229 USA. EM faber@uthscsa.edu NR 21 TC 2 Z9 3 U1 1 U2 6 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1355-4794 J9 NEUROCASE JI Neurocase PY 2010 VL 16 IS 4 BP 281 EP 285 AR PII 918511495 DI 10.1080/13554790903456217 PG 5 WC Clinical Neurology; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 626JZ UT WOS:000279963600001 PM 20069502 ER PT S AU Kern, RS Horan, WP AF Kern, Robert S. Horan, William P. BE Roder, V Medalia, A TI Definition and Measurement of Neurocognition and Social Cognition SO NEUROCOGNITION AND SOCIAL COGNITION IN SCHIZOPHRENIA PATIENTS: BASIC CONCEPTS AND TREATMENTS SE Key Issues in Mental Health LA English DT Article; Book Chapter ID CONTINUOUS PERFORMANCE-TEST; IDENTICAL PAIRS VERSION; CHRONIC-SCHIZOPHRENIA; EMOTION RECOGNITION; NEURAL BASIS; TEST BATTERY; 1ST-EPISODE SCHIZOPHRENIA; COMPUTERIZED ASSESSMENT; ATTRIBUTIONAL STYLE; IMPROVE COGNITION AB Disturbances in neurocognition and social cognition are widely recognized as core features of schizophrenia. In this chapter, we provide a critical review of measurement in these 2 areas. For neurocognition, we compare 3 approaches: (a) hybrid batteries, (b) computer-based batteries and (c) the MATRICS Consensus Cognitive Battery. For social cognition, we compare measures used to assess 5 key domains: (a) emotional processing, (b) social perception, (c) social knowledge, (d) attribution bias and (e) theory of mind. We conclude with a section on the promise of developing new treatments in neurocognition and social cognition that will rely, in part, on the advances in measurement within these areas. Copyright (C) 2010 S. Karger AG, Basel C1 [Kern, Robert S.; Horan, William P.] Educ & Clin Ctr, Dept Vet Affairs VISN Mental Illness Res 22, Los Angeles, CA USA. [Kern, Robert S.; Horan, William P.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Kern, RS (reprint author), VA Greater Los Angeles Healthcare Syst MIRECC 210, Bldg 210,Room 116,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM rkern@ucla.edu NR 145 TC 6 Z9 6 U1 2 U2 5 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1662-4874 BN 978-3-8055-9338-0 J9 KEY ISSUES MENT HEAL JI Key Iss. Ment. Health PY 2010 VL 177 BP 1 EP 22 PG 22 WC Psychiatry SC Psychiatry GA BNP90 UT WOS:000275191300001 ER PT J AU Balasubramanian, R Dwyer, A Seminara, SB Pitteloud, N Kaiser, UB Crowley, WF AF Balasubramanian, Ravikumar Dwyer, Andrew Seminara, Stephanie B. Pitteloud, Nelly Kaiser, Ursula B. Crowley, William F., Jr. TI Human GnRH Deficiency: A Unique Disease Model to Unravel the Ontogeny of GnRH Neurons SO NEUROENDOCRINOLOGY LA English DT Article DE Gonadotropin-releasing hormone deficiency; Gonadotropin-releasing hormone neuronal ontogeny; Puberty; Kallmann syndrome; Hypogonadotropic hypogonadism ID GONADOTROPIN-RELEASING-HORMONE; IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM; PROTEIN-COUPLED RECEPTOR; LINKED KALLMANN-SYNDROME; OLFACTORY-BULB; ARCUATE NUCLEUS; HEPARAN-SULFATE; CHARGE-SYNDROME; X-CHROMOSOME; NEUROKININ-B AB Evolutionary survival of a species is largely a function of its reproductive fitness. In mammals, a sparsely populated and widely dispersed network of hypothalamic neurons, the gonadotropin-releasing hormone (GnRH) neurons, serve as the pilot light of reproduction via coordinated secretion of GnRH. Since it first description, human GnRH deficiency has been recognized both clinically and genetically as a heterogeneous disease. A spectrum of different reproductive phenotypes comprised of congenital GnRH deficiency with anosmia (Kallmann syndrome), congenital GnRH deficiency with normal olfaction (normosmic idiopathic hypogonadotropic hypogonadism), and adult-onset hypogonadotropic hypogonadism has been described. In the last two decades, several genes and pathways which govern GnRH ontogeny have been discovered by studying humans with GnRH deficiency. More importantly, detailed study of these patients has highlighted the emerging theme of oligogenicity and genotypic synergism, and also expanded the phenotypic diversity with the documentation of reversal of GnRH deficiency later in adulthood in some patients. The underlying genetic defect has also helped understand the associated nonreproductive phenotypes seen in some of these patients. These insights now provide practicing clinicians with targeted genetic diagnostic strategies and also impact on clinical management. Copyright (C) 2010 S. Karger AG, Basel C1 [Crowley, William F., Jr.] Massachusetts Gen Hosp, Harvard Reprod Endocrine Sci Ctr Excellence, Reprod Endocrine Unit, Dept Med, Boston, MA 02114 USA. Brigham & Womens Hosp, Div Endocrine, Boston, MA 02115 USA. RP Crowley, WF (reprint author), Massachusetts Gen Hosp, Harvard Reprod Endocrine Sci Ctr Excellence, Reprod Endocrine Unit, Dept Med, Bartlett Hall Extens 5th Floor 55,Fruit St, Boston, MA 02114 USA. EM wcrowley@partners.org RI Dwyer, Andrew/D-8099-2012; PITTELOUD, Nelly/K-2709-2014 OI Dwyer, Andrew/0000-0002-7023-6794; FU NICHD NIH HHS [R01 HD043341, R01 HD056264, U54 HD028138] NR 122 TC 29 Z9 30 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0028-3835 EI 1423-0194 J9 NEUROENDOCRINOLOGY JI Neuroendocrinology PY 2010 VL 92 IS 2 BP 81 EP 99 DI 10.1159/000314193 PG 19 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA 642QF UT WOS:000281230300001 PM 20606386 ER PT J AU Kianmanesh, R Ruszniewski, P Rindi, G Kwekkeboom, D Pape, UF Kulke, M Garcia, IS Scoazec, JY Nilsson, O Fazio, N Lesurtel, M Chen, YJ Eriksson, B Cioppi, F O'Toole, D AF Kianmanesh, Reza Ruszniewski, Philippe Rindi, Guido Kwekkeboom, Dik Pape, Ulrich-Frank Kulke, Matthew Garcia, Isabel Sevilla Scoazec, Jean-Yves Nilsson, Ola Fazio, Nicola Lesurtel, Mickael Chen, Yuan-Jia Eriksson, Barbro Cioppi, Federica O'Toole, Dermot CA Palma Mallorca Consensus Conf Part TI ENETS Consensus Guidelines for the Management of Peritoneal Carcinomatosis from Neuroendocrine Tumors SO NEUROENDOCRINOLOGY LA English DT Article ID HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; DIGESTIVE ENDOCRINE TUMORS; LIVER METASTASES; CYTOREDUCTIVE SURGERY; COLORECTAL-CANCER; GASTROINTESTINAL CANCER; SYSTEMIC CHEMOTHERAPY; STAGING LAPAROSCOPY; SURFACE COMPONENT; CARCINOID-TUMORS C1 [Kianmanesh, Reza] Univ Paris 07, Louis Mourier Univ Hosp, APHP, Dept Digest Surg, FR-97201 Colombes, France. [Kianmanesh, Reza] Univ Paris Diderot, Beaujon Louis Mourier Univ Hosp Grp, APHP, Paris, France. [Ruszniewski, Philippe] Beaujon Univ Hosp, APHP, Dept Gastroenterol, Clichy, France. [Rindi, Guido] Univ Parma, Dept Pathol & Lab Med, I-43100 Parma, Italy. [Kwekkeboom, Dik] Erasmus Univ, Med Ctr, Dept Nucl Med, Rotterdam, Netherlands. [Pape, Ulrich-Frank] Charite, Campus Virchow Klinikum, Div Gastroenterol & Hepatol, Dept Internal Med, D-13353 Berlin, Germany. [Kulke, Matthew] Dana Farber Canc Inst, Boston, MA 02115 USA. [Garcia, Isabel Sevilla] Hosp Clin Univ, Malaga, Spain. [Scoazec, Jean-Yves] Hop Edouard Herriot, Lyon, France. [Nilsson, Ola] Sahlgrens Univ Hosp, Gothenburg, Sweden. [Fazio, Nicola] European Inst Oncol, Milan, Italy. [Lesurtel, Mickael] Univ Zurich Hosp, Dept Visceral & Transplant Surg, Swiss HPB Ctr, CH-8091 Zurich, Switzerland. [Chen, Yuan-Jia] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing 100037, Peoples R China. [Eriksson, Barbro] Univ Uppsala Hosp, Endocrine Unit, Dept Med, Uppsala, Sweden. [Cioppi, Federica] Univ Florence, Dept Clin Physiopathol, Florence, Italy. [O'Toole, Dermot] St James Hosp, Dept Clin Med & Gastroenterol, Dublin, Ireland. [O'Toole, Dermot] Trinity Coll Dublin, Dublin, Ireland. RP Kianmanesh, R (reprint author), Univ Paris 07, Louis Mourier Univ Hosp, APHP, Dept Digest Surg, 178 Rue Renouillers, FR-97201 Colombes, France. EM reza.kianmanesh@lmr.aphp.fr RI Lopes, Jose Manuel/J-7428-2013; OI Lopes, Jose Manuel/0000-0001-8597-3474; RINDI, Guido/0000-0003-2996-4404; Perren, Aurel/0000-0002-6819-6092; fazio, nicola/0000-0001-6869-0704 NR 44 TC 12 Z9 12 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0028-3835 J9 NEUROENDOCRINOLOGY JI Neuroendocrinology PY 2010 VL 91 IS 4 BP 333 EP 340 DI 10.1159/000286700 PG 8 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA 613EB UT WOS:000278959700008 PM 20424420 ER PT J AU Okereke, OI Kurth, T Pollak, MN Gaziano, JM Grodstein, F AF Okereke, Olivia I. Kurth, Tobias Pollak, Michael N. Gaziano, J. Michael Grodstein, Francine TI Fasting Plasma Insulin, C-Peptide and Cognitive Change in Older Men without Diabetes: Results from the Physicians' Health Study II SO NEUROEPIDEMIOLOGY LA English DT Article DE Insulin; C-Peptide; Cognitive decline; Dementia; Diabetes ID CORONARY-HEART-DISEASE; RANDOMIZED CONTROLLED-TRIAL; ALZHEIMER-DISEASE; ELDERLY POPULATION; VITAMINS E; WOMEN; DECLINE; RISK; IMPAIRMENT; MELLITUS AB Background: Type 2 diabetes has been associated with diminished late-life cognition; less is known about relations of insulin levels and insulin secretion to cognitive change among persons without diabetes. We examined prospectively relations of fasting insulin levels and insulin secretion to cognitive decline among healthy, community-dwelling older men without diabetes. Methods: Fasting plasma insulin and C-peptide (insulin secretion) levels were measured in 1,353 nondiabetic men, aged 60-92 years (mean = 71.3 years), in the Physicians' Health Study II, who participated in cognitive testing an average of 3.3 years later. Two assessments were administered 2 years apart (range = 1.5-4.0 years) using telephone-based tests (general cognition, verbal memory and category fluency). Primary outcomes were the Telephone Interview for Cognitive Status (TICS), global cognition (averaging all tests) and verbal memory (averaging 4 verbal tests). Multivariable linear regression models were used to estimate the relations of insulin and C-peptide to cognitive decline. Results: Higher fasting insulin was associated with a greater decline on all tests, after adjustment. Findings were statistically significant for the TICS and category fluency, e. g. the multivariable-adjusted mean difference (95% CI) in decline for men with the highest versus lowest insulin levels was -0.62 (-1.15, -0.09) points on the TICS (p for trend = 0.04); this difference was similar to that between men 7 years apart in age. Similarly, there was a greater decline across all tests with increasing C-peptide, but the findings were statistically significant only for the global score (p for trend = 0.03). Conclusions: Higher fasting insulin and greater insulin secretion in older men may be related to overall cognitive decline, even in the absence of diabetes. Copyright (C) 2010 S. Karger AG, Basel C1 [Okereke, Olivia I.; Grodstein, Francine] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA. [Okereke, Olivia I.; Kurth, Tobias; Gaziano, J. Michael; Grodstein, Francine] Brigham & Womens Hosp, Div Aging, Boston, MA 02115 USA. [Kurth, Tobias; Gaziano, J. Michael] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. [Kurth, Tobias; Grodstein, Francine] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Gaziano, J. Michael] VA Boston Healthcare Syst, Jamaica Plain, MA USA. [Pollak, Michael N.] McGill Univ, Jewish Gen Hosp, Dept Med, Lady Davis Res Inst, Montreal, PQ H3T 1E2, Canada. [Pollak, Michael N.] McGill Univ, Jewish Gen Hosp, Dept Oncol, Lady Davis Res Inst, Montreal, PQ H3T 1E2, Canada. [Kurth, Tobias] INSERM, U708, Paris, France. [Kurth, Tobias] Univ Paris 06, Paris, France. RP Okereke, OI (reprint author), Brigham & Womens Hosp, Dept Med, Channing Lab, 3rd Floor,181 Longwood Ave, Boston, MA 02115 USA. EM ookereke@partners.org RI Kurth, Tobias/A-9243-2012; Pollak, Michael/G-9094-2011; Okereke, Olivia/R-9934-2016 OI Kurth, Tobias/0000-0001-7169-2620; Pollak, Michael/0000-0003-3047-0604; FU National Institutes of Health [AG15933, AG24215, CA34944, CA40360, CA42182, CA97193, HL26490, HL34595] FX This work was supported by grants AG15933, AG24215, CA34944, CA40360, CA42182, CA97193, HL26490 and HL34595 from the National Institutes of Health. Dr. Okereke's effort was supported by an R01 Minority Supplement to grant AG24215. NR 43 TC 8 Z9 8 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0251-5350 J9 NEUROEPIDEMIOLOGY JI Neuroepidemiology PY 2010 VL 34 IS 4 BP 200 EP 207 DI 10.1159/000289351 PG 8 WC Public, Environmental & Occupational Health; Clinical Neurology SC Public, Environmental & Occupational Health; Neurosciences & Neurology GA 574CW UT WOS:000275967100002 PM 20197703 ER PT J AU Custo, A Boas, DA Tsuzuki, D Dan, I Mesquita, R Fischl, B Grimson, WEL Wells, W AF Custo, Anna Boas, David A. Tsuzuki, Daisuke Dan, Ippeita Mesquita, Rickson Fischl, Bruce Grimson, W. Eric L. Wells, Williams, III TI Anatomical atlas-guided diffuse optical tomography of brain activation SO NEUROIMAGE LA English DT Article DE Diffuse optical tomography; NIRS; Anatomical atlas; MRI; Segmentation; Registration; Inverse problem; Human study; Somatosensory ID NEAR-INFRARED SPECTROSCOPY; SURFACE-BASED ANALYSIS; CORTICAL SURFACE; COORDINATE SYSTEM; VISUAL-CORTEX; HUMAN HEAD; MR-IMAGES; STIMULATION; FNIRS; LIGHT AB We describe a neuroimaging protocol that utilizes an anatomical atlas of the human head to guide diffuse optical tomography of human brain activation. The protocol is demonstrated by imaging the hemodynamic response to median-nerve stimulation in three healthy subjects, and comparing the images obtained using a head atlas with the images obtained using the subject-specific head anatomy. The results indicate that using the head atlas anatomy it is possible to reconstruct the location of the brain activation to the expected gyrus of the brain, in agreement with the results obtained with the subject-specific head anatomy. The benefits of this novel method derive from eliminating the need for subject-specific head anatomy and thus obviating the need for a subject-specific MRI to improve the anatomical interpretation of diffuse optical tomography images of brain activation. (C) 2009 Elsevier Inc. All rights reserved. C1 [Custo, Anna; Fischl, Bruce; Grimson, W. Eric L.; Wells, Williams, III] MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA. [Custo, Anna; Boas, David A.; Mesquita, Rickson; Fischl, Bruce] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Tsuzuki, Daisuke; Dan, Ippeita] Natl Food Res Inst, Tsukuba, Ibaraki 3058642, Japan. [Mesquita, Rickson] Univ Estadual Campinas, Inst Phys, BR-13083970 Campinas, SP, Brazil. [Wells, Williams, III] Harvard Univ, Sch Med, Brigham Womens Hosp, Boston, MA 02115 USA. RP Custo, A (reprint author), MIT, Comp Sci & Artificial Intelligence Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA. EM custo@csail.mit.edu RI Dan, Ippeita/F-9179-2011; Mesquita, Rickson/N-9119-2013; Inst. of Physics, Gleb Wataghin/A-9780-2017 OI Dan, Ippeita/0000-0002-1779-9205; Mesquita, Rickson/0000-0003-1945-6713; FU NIH [U54-EB-005149, P41-RR14075, P41-RR13218] FX This work was supported by NIH U54-EB-005149, NIH P41-RR14075, and NIH P41-RR13218. NR 46 TC 66 Z9 67 U1 0 U2 9 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 J9 NEUROIMAGE JI Neuroimage PD JAN 1 PY 2010 VL 49 IS 1 BP 561 EP 567 DI 10.1016/j.neuroimage.2009.07.033 PG 7 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 522WV UT WOS:000272031700055 PM 19643185 ER PT B AU Devore, S Schwartz, A Delgutte, B AF Devore, Sasha Schwartz, Andrew Delgutte, Bertrand BE LopezPoveda, EA Palmer, AR TI Effect of Reverberation on Directional Sensitivity of Auditory Neurons: Central and Peripheral Factors SO NEUROPHYSIOLOGICAL BASES OF AUDITORY PERCEPTION LA English DT Proceedings Paper CT 15th International Symposium on Hearing CY JUN 01-05, 2009 CL Salamanca, SPAIN SP Med Elect, Hear Life DE Auditory nerve; Binaural; Inferior colliculus; Reverberation; Sound localization ID INTERAURAL TIME SENSITIVITY; HIGH-FREQUENCY NEURONS; INFERIOR COLLICULUS; SOUND LOCALIZATION; NERVE; DELAYS; CUES AB In reverberant environments, acoustic reflections interfere with the direct sound arriving at a listener's ears, distorting the binaural cues for sound localization. Using virtual auditory space simulation techniques, we investigated the effects of reverberation on the directional rate responses of single neurons in the inferior colliculus (IC) of unanesthetized rabbits. We find that reverberation degrades the directional sensitivity of single neurons, although the amount of degradation depends on the characteristic frequency (CF) and the type of binaural cues available. To investigate the extent to which these midbrain results reflect peripheral processing of the monaural input signals, we extracted directional information from spike trains recorded from auditory nerve (AN) in anesthetized cat for the same VAS stimuli. Our results suggest that the frequency-dependent degradation in ITD-based directional sensitivity in reverberation originates in the auditory periphery. C1 [Devore, Sasha; Schwartz, Andrew; Delgutte, Bertrand] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. RP Devore, S (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. EM sashad@alum.mit.edu NR 17 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-5685-9 PY 2010 BP 273 EP 282 DI 10.1007/978-1-4419-5686-6_26 PG 10 WC Acoustics; Neurosciences SC Acoustics; Neurosciences & Neurology GA BVA26 UT WOS:000290883800026 ER PT J AU Huffman, JC Celano, CM Januzzi, JL AF Huffman, Jeff C. Celano, Christopher M. Januzzi, James L. TI The relationship between depression, anxiety, and cardiovascular outcomes in patients with acute coronary syndromes SO NEUROPSYCHIATRIC DISEASE AND TREATMENT LA English DT Review DE acute coronary syndrome; anxiety; anxiety disorders; depression; myocardial infarction; unstable angina ID ACUTE MYOCARDIAL-INFARCTION; HEART-RATE-VARIABILITY; POSTTRAUMATIC-STRESS-DISORDER; QUALITY-OF-LIFE; HOSPITAL CARDIAC COMPLICATIONS; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; BETA-BLOCKER THERAPY; C-REACTIVE PROTEIN; ARTERY-DISEASE AB Depression and anxiety occur at high rates among patients suffering an acute coronary syndrome (ACS). Both depressive symptoms and anxiety appear to adversely affect in-hospital and long term cardiac outcomes of post-ACS patients, independent of traditional risk factors. Despite their high prevalence and serious impact, mood and anxiety symptoms go unrecognized and untreated in most ACS patients and such symptoms (rather than being transient reactions to ACS) persist for months and beyond. The mechanisms by which depression and anxiety are linked to these negative medical outcomes are likely a combination of the effects of these conditions on inflammation, catecholamines, heart rate variability, and endothelial function, along with effects on health-promoting behavior. Fortunately, standard treatments for these disorders appear to be safe, well-tolerated and efficacious in this population; indeed, selective serotonin reuptake inhibitors may actually improve cardiac outcomes. Future research goals include gaining a better understanding of the combined effects of depression and anxiety, as well as definitive prospective studies of the impact of treatment on cardiac outcomes. Clinically, protocols that allow for efficient and systematic screening, evaluation, and treatment for depression and anxiety in cardiac patients are critical to help patients avoid the devastating effects of these illnesses on quality of life and cardiac health. C1 [Huffman, Jeff C.; Celano, Christopher M.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Januzzi, James L.] Massachusetts Gen Hosp, Dept Cardiol, Boston, MA 02114 USA. RP Huffman, JC (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 55 Fruit St,Blake 11, Boston, MA 02114 USA. EM jhuffman@partners.org NR 157 TC 37 Z9 41 U1 6 U2 11 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1176-6328 J9 NEUROPSYCH DIS TREAT JI Neuropsychiatr. Dis. Treat. PY 2010 VL 6 BP 123 EP 136 PG 14 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 821CV UT WOS:000294953300015 PM 20505844 ER PT J AU Schulze, TG Alda, M Adli, M Akula, N Ardau, R Bui, ET Chillotti, C Cichon, S Czerski, P Del Zompo, M Detera-Wadleigh, SD Grof, P Gruber, O Hashimoto, R Hauser, J Hoban, R Iwata, N Kassem, L Kato, T Kittel-Schneider, S Kliwicki, S Kelsoe, JR Kusumi, I Laje, G Leckband, SG Manchia, M MacQueen, G Masui, T Ozaki, N Perlis, RH Pfennig, A Piccardi, P Richardson, S Rouleau, G Reif, A Rybakowski, JK Sasse, J Schumacher, J Severino, G Smoller, JW Squassina, A Turecki, G Young, LT Yoshikawa, T Bauer, M McMahon, FJ AF Schulze, Thomas G. Alda, Martin Adli, Mazda Akula, Nirmala Ardau, Raffaella Bui, Elise T. Chillotti, Caterina Cichon, Sven Czerski, Piotr Del Zompo, Maria Detera-Wadleigh, Sevilla D. Grof, Paul Gruber, Oliver Hashimoto, Ryota Hauser, Joanna Hoban, Rebecca Iwata, Nakao Kassem, Layla Kato, Tadafumi Kittel-Schneider, Sarah Kliwicki, Sebastian Kelsoe, John R. Kusumi, Ichiro Laje, Gonzalo Leckband, Susan G. Manchia, Mirko MacQueen, Glenda Masui, Takuya Ozaki, Norio Perlis, Roy H. Pfennig, Andrea Piccardi, Paola Richardson, Sara Rouleau, Guy Reif, Andreas Rybakowski, Janusz K. Sasse, Johanna Schumacher, Johannes Severino, Giovanni Smoller, Jordan W. Squassina, Alessio Turecki, Gustavo Young, L. Trevor Yoshikawa, Takeo Bauer, Michael McMahon, Francis J. TI The International Consortium on Lithium Genetics (ConLiGen): An Initiative by the NIMH and IGSLI to Study the Genetic Basis of Response to Lithium Treatment SO NEUROPSYCHOBIOLOGY LA English DT Article DE Manic-depressive illness; Schizoaffective disorder; Mood stabilizer; Antidepressants; Suicidal behavior; Genome-wide association study; Neurogenesis; Neuroplasticity ID STAR-ASTERISK-D; SEQUENCED TREATMENT ALTERNATIVES; BIPOLAR-DISORDER; ANTIDEPRESSANT TREATMENT; SUICIDAL IDEATION; DRUG DISCOVERY; D COHORT; ASSOCIATION; DEPRESSION; PHARMACOGENETICS AB For more than half a decade, lithium has been successfully used to treat bipolar disorder. Worldwide, it is considered the first-line mood stabilizer. Apart from its proven antimanic and prophylactic effects, considerable evidence also suggests an antisuicidal effect in affective disorders. Lithium is also effectively used to augment antidepressant drugs in the treatment of refractory major depressive episodes and prevent relapses in recurrent unipolar depression. In contrast to many psychiatric drugs, lithium has outlasted various pharmacotherapeutic 'fashions', and remains an indispensable element in contemporary psychopharmacology. Nevertheless, data from pharmacogenetic studies of lithium are comparatively sparse, and these studies are generally characterized by small sample sizes and varying definitions of response. Here, we present an international effort to elucidate the genetic underpinnings of lithium response in bipolar disorder. Following an initiative by the International Group for the Study of Lithium-Treated Patients (www.IGSLI.org) and the Unit on the Genetic Basis of Mood and Anxiety Disorders at the National Institute of Mental Health, lithium researchers from around the world have formed the Consortium on Lithium Genetics (www.ConLiGen.org) to establish the largest sample to date for genome-wide studies of lithium response in bipolar disorder, currently comprising more than 1,200 patients characterized for response to lithium treatment. A stringent phenotype definition of response is one of the hallmarks of this collaboration. ConLiGen invites all lithium researchers to join its efforts. Copyright (C) 2010 S. Karger AG, Basel C1 [Schulze, Thomas G.; Akula, Nirmala; Bui, Elise T.; Detera-Wadleigh, Sevilla D.; Kassem, Layla; Laje, Gonzalo; Richardson, Sara; Schumacher, Johannes; McMahon, Francis J.] NIMH, Unit Genet Basis Mood & Anxiety Disorders, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. [Hoban, Rebecca; Kelsoe, John R.; Leckband, Susan G.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Hoban, Rebecca; Kelsoe, John R.] VA San Diego Healthcare Syst, Dept Psychiat, San Diego, CA USA. [Leckband, Susan G.] VA San Diego Healthcare Syst, Dept Pharm, La Jolla, CA USA. [Leckband, Susan G.] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, San Diego, CA 92103 USA. [Perlis, Roy H.; Smoller, Jordan W.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Perlis, Roy H.; Smoller, Jordan W.] Harvard Univ, Sch Med, Boston, MA USA. [Schulze, Thomas G.] Cent Inst Mental Hlth, Dept Genet Epidemiol Psychiat, D-6800 Mannheim, Germany. [Adli, Mazda] Charite, Dept Psychiat & Psychotherapy, D-13353 Berlin, Germany. [Cichon, Sven; Schumacher, Johannes] Univ Bonn, Dept Genom, Life & Brain Ctr, D-5300 Bonn, Germany. [Cichon, Sven; Schumacher, Johannes] Univ Bonn, Inst Human Genet, D-5300 Bonn, Germany. [Gruber, Oliver] Univ Gottingen, Dept Psychiat & Psychotherapy, Gottingen, Germany. [Kittel-Schneider, Sarah; Reif, Andreas] Univ Wurzburg, Dept Psychiat Psychosomat & Psychotherapy, Wurzburg, Germany. [Pfennig, Andrea; Sasse, Johanna; Bauer, Michael] Tech Univ Dresden, Dept Psychiat & Psychotherapy, Univ Hosp Carl Gustav Carus, Dresden, Germany. [Alda, Martin] Dalhousie Univ, Dept Psychiat, Halifax, NS, Canada. [Grof, Paul] Mood Disorders Ctr Ottawa, Ottawa, ON, Canada. [Grof, Paul] Univ Toronto, Dept Psychiat, Toronto, ON, Canada. [MacQueen, Glenda] Univ Calgary, Dept Psychiat, Calgary, AB, Canada. [Rouleau, Guy] Univ Montreal, CHU St Justine Res Ctr, Dept Med, Montreal, PQ H3C 3J7, Canada. [Turecki, Gustavo] McGill Univ, Dept Psychiat, Douglas Hosp, Res Inst, Montreal, PQ, Canada. [Young, L. Trevor] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada. [Del Zompo, Maria; Manchia, Mirko; Piccardi, Paola; Severino, Giovanni; Squassina, Alessio] Univ Cagliari, BB Brodie Dept Neurosci, Cagliari, Italy. [Czerski, Piotr; Hauser, Joanna] Karol Marcinkowski Univ Med Sci, Psychiat Genet Unit, Poznan, Poland. [Kliwicki, Sebastian; Rybakowski, Janusz K.] Karol Marcinkowski Univ Med Sci, Dept Adult Psychiat, Poznan, Poland. [Hashimoto, Ryota] Osaka Univ, Grad Sch Med, Osaka, Japan. [Iwata, Nakao] Fujita Hlth Univ, Sch Med, Dept Psychiat, Toyoake, Aichi 47011, Japan. [Kato, Tadafumi] RIKEN, Brain Sci Inst, Lab Mol Dynam Mental Disorders, Saitama, Japan. [Yoshikawa, Takeo] RIKEN, Brain Sci Inst, Lab Mol Psychiat, Saitama, Japan. [Kusumi, Ichiro; Masui, Takuya] Hokkaido Univ, Dept Psychiat, Grad Sch Med, Sapporo, Hokkaido, Japan. [Ozaki, Norio] Nagoya Univ, Dept Psychiat, Grad Sch Med, Nagoya, Aichi 4648601, Japan. [Cichon, Sven] Res Ctr Juelich, Inst Neurosci & Med INM 1, Julich, Germany. RP Schulze, TG (reprint author), NIMH, Unit Genet Basis Mood & Anxiety Disorders, NIH, Dept Hlth & Human Serv, 35 Convent Dr,Bldg 35,Rm 1A205,MSC 3719, Bethesda, MD 20892 USA. EM schulzet@mail.nih.gov RI Czerski, Piotr/B-8446-2011; Kusumi, Ichiro/A-4067-2012; Laje, Gonzalo/L-2654-2014; Hashimoto, Ryota/P-8572-2014; Ozaki, Norio/M-8908-2014; Schumacher, Johannes/F-4970-2015; Severino, Giovanni/B-2823-2012; Manchia, Mirko/E-8751-2010; Alda, Martin/F-5812-2010; Schulze, Thomas/H-2157-2013; Cichon, Sven/H-8803-2013; Cichon, Sven/B-9618-2014; Kato, Tadafumi/J-3583-2014; OI Czerski, Piotr/0000-0003-0745-5916; Laje, Gonzalo/0000-0003-2763-3329; Hashimoto, Ryota/0000-0002-5941-4238; Ozaki, Norio/0000-0002-7360-4898; Schumacher, Johannes/0000-0001-9217-6457; Alda, Martin/0000-0001-9544-3944; Cichon, Sven/0000-0002-9475-086X; Cichon, Sven/0000-0002-9475-086X; Kato, Tadafumi/0000-0001-7856-3952; Manchia, Mirko/0000-0003-4175-6413; Kittel-Schneider, Sarah/0000-0003-3057-6150; McMahon, Francis/0000-0002-9469-305X; Squassina, Alessio/0000-0001-7415-7607 FU NIMH [MH079799]; NARSAD; Canadian Institutes of Health Research (CIHR) [64410]; Deutsche Forschungsgemeinschaft (DFG) [KFO 125, SFB TRR 58]; German Ministry for Education and Research (BMBF) [IZKF N-4]; Regional Councillorship of Health FX This research was in part supported by the Intramural Program of the NIMH. Dr. Thomas G. Schulze's work is furthermore supported by NARSAD. Dr. Martin Alda's work on the phenotype of lithium response has been supported by grants from the Canadian Institutes of Health Research (CIHR, grant 64410) and by NARSAD. Dr. Smoller's work is supported in part by a grant from the NIMH (MH079799). Dr. Reif is supported by the Deutsche Forschungsgemeinschaft (DFG) (KFO 125 and SFB TRR 58) and the German Ministry for Education and Research (BMBF) (IZKF N-4). The work of the Cagliari group was partly supported by the Regional Councillorship of Health, 'Regione Autonoma della Sardegna'. NR 28 TC 43 Z9 43 U1 0 U2 4 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0302-282X J9 NEUROPSYCHOBIOLOGY JI Neuropsychobiology PY 2010 VL 62 IS 1 BP 72 EP 78 DI 10.1159/000314708 PG 7 WC Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 594ZC UT WOS:000277579200009 PM 20453537 ER PT J AU Weiss, D Infante-Duarte, C Salbach-Andrae, H Burghardt, R Hamann, I Pfeiffer, E Lehmkuhl, U Ehrlich, S AF Weiss, Deike Infante-Duarte, Carmen Salbach-Andrae, Harriet Burghardt, Roland Hamann, Isabell Pfeiffer, Ernst Lehmkuhl, Ulrike Ehrlich, Stefan TI Preproenkephalin Expression in Peripheral Blood Mononuclear Cells of Acutely Underweight and Recovered Patients with Anorexia Nervosa SO NEUROPSYCHOBIOLOGY LA English DT Article DE Preproenkephalin; Anorexia nervosa; Depressive symptoms; Anxious symptoms; Obsessive-compulsive symptoms; Stress; Nicotine; Smoking; Peripheral blood mononuclear cells; Real-time PCR ID MESSENGER-RNA EXPRESSION; EATING-DISORDERS; FEMALE ADOLESCENTS; PROENKEPHALIN-A; IMMUNE-SYSTEM; GENE-EXPRESSION; MET-ENKEPHALIN; FOOD-INTAKE; STRESS; LEPTIN AB Background: The prohormone preproenkephalin (ppE) and its derived peptides are involved in leukocyte functioning as well as in the regulation of hunger and satiety. Various abnormalities of the immune and endocrine systems have been described in states of malnutrition such as anorexia nervosa (AN). We hypothesized that ppE expression in AN patients may vary depending on the state of the disorder and the extent of malnutrition. Methods: Expression of ppE mRNA was analysed in peripheral blood mononuclear cells of 29 underweight and 29 weight-recovered patients with AN and compared to that in 29 healthy control women. The extent of malnutrition was characterized by BMI and plasma leptin. Psychological distress and eating disorder specific-psychopathology was determined with the Symptom Check-list-90-Revised and the Eating Disorders Inventory-2. Results: ppE gene expression was similar in all 3 groups and was not related to nutritional status or eating disorder symptoms. However, a significant negative correlation was found between ppE expression and obsessive-compulsive, depressive and anxious symptoms. In addition, ppE expression was higher in smokers compared to non-smokers. Conclusion: Although malnutrition and hypoleptinaemia as seen in patients with AN were not related to peripheral ppE expression, we demonstrated reduced ppE expression in patients with elevated psychological distress. Similar associations have been shown in animal models of stress. It remains speculative if psychological symptoms and/or stress may augment immune abnormalities in AN patients via a pathway that is independent of nutritional status and involves ppE. Copyright (C) 2010 S. Karger AG, Basel C1 [Ehrlich, Stefan] Harvard Univ, Massachusetts Gen Hosp, Psychiat Neuroimaging Res Program, Med Sch,Dept Psychiat,Gollub Lab, Charlestown, MA 02129 USA. [Weiss, Deike; Salbach-Andrae, Harriet; Burghardt, Roland; Pfeiffer, Ernst; Lehmkuhl, Ulrike; Ehrlich, Stefan] Charite, Dept Child & Adolescent Psychiat Psychosomat & Ps, D-13353 Berlin, Germany. [Ehrlich, Stefan] Charite, Dept Psychiat & Psychotherapy, D-13353 Berlin, Germany. [Infante-Duarte, Carmen; Hamann, Isabell] Charite, Cecilie Vogt Clin, D-13353 Berlin, Germany. RP Ehrlich, S (reprint author), Harvard Univ, Massachusetts Gen Hosp, Psychiat Neuroimaging Res Program, Med Sch,Dept Psychiat,Gollub Lab, CNY Bldg 120,Suite 100, Charlestown, MA 02129 USA. EM stefan@nmr.mgh.harvard.edu OI Ehrlich, Stefan/0000-0003-2132-4445 NR 51 TC 4 Z9 4 U1 1 U2 5 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0302-282X J9 NEUROPSYCHOBIOLOGY JI Neuropsychobiology PY 2010 VL 62 IS 3 BP 151 EP 157 DI 10.1159/000318571 PG 7 WC Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 629VP UT WOS:000280228500002 PM 20628265 ER PT J AU Sahyoun, CP Belliveau, JW Soulieres, I Schwartz, S Mody, M AF Sahyoun, Cherif P. Belliveau, John W. Soulieres, Isabelle Schwartz, Shira Mody, Maria TI Neuroimaging of the functional and structural networks underlying visuospatial vs. linguistic reasoning in high-functioning autism SO NEUROPSYCHOLOGIA LA English DT Article DE Autism; Reasoning; DTI; fMRI; Language; Visuospatial ID MAGNETIC-RESONANCE IMAGES; SURFACE-BASED ANALYSIS; SPECTRUM DISORDERS; WORKING-MEMORY; CORPUS-CALLOSUM; WHITE-MATTER; CORTICAL SURFACE; SENTENCE COMPREHENSION; COORDINATE SYSTEM; MENTAL ROTATION AB High-functioning individuals with autism have been found to favor visuospatial processing in the face of typically poor language abilities. We aimed to examine the neurobiological basis of this difference using functional magnetic resonance imaging and diffusion tensor imaging. We compared 12 children with high functioning autism (HFA) to 12 age- and IQ-matched typically developing controls (CTRL) on a pictorial reasoning paradigm under three conditions: V, requiring visuospatial processing; S, requiring language (i.e., semantic) processing; and V+S, a hybrid condition in which language use could facilitate visuospatial transformations. Activated areas in the brain were chosen as endpoints for probabilistic diffusion tractography to examine tract integrity (FA) within the structural network underlying the activation patterns. The two groups showed similar networks, with linguistic processing activating inferior frontal, superior and middle temporal, ventral visual, and temporo-parietal areas, whereas visuospatial processing activated occipital and inferior parietal cortices. However, HFA appeared to activate occipitoparietal and ventral temporal areas, whereas CTRL relied more on frontal and temporal language regions. The increased reliance on visuospatial abilities in HFA was supported by intact connections between the inferior parietal and the ventral temporal ROIs. In contrast, the inferior frontal region showed reduced connectivity to ventral temporal and middle temporal areas in this group, reflecting impaired activation of frontal language areas in autism. The HFA group's engagement of posterior brain regions along with its weak connections to frontal language areas suggest support for a reliance on visual mediation in autism, even in tasks of higher cognition. (C) 2009 Elsevier Ltd. All rights reserved. C1 [Sahyoun, Cherif P.; Belliveau, John W.; Soulieres, Isabelle; Schwartz, Shira; Mody, Maria] Massachusetts Gen Hosp, MIT, HMS Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Sahyoun, Cherif P.; Belliveau, John W.; Mody, Maria] Harvard MIT, Div Hlth Sci & Technol, Cambridge, MA USA. [Soulieres, Isabelle] Hop Riviere des Prairies, Clin Specialisee Autisme, Montreal, PQ, Canada. RP Sahyoun, CP (reprint author), MGH NMR Ctr, 149 13th St, Charlestown, MA 02129 USA. EM cherif@mit.edu; maria@nmr.mgh.harvard.edu FU National Institutes of Health [NS037462, HD40712]; National Center for Research Resources [P41RR14075] FX This research was supported by funding from the National Institutes of Health (NS037462, HD40712) and in part by the National Center for Research Resources (P41RR14075). We would like to thank all the children and parents for their willingness to participate in the study. We thank Seppo P. Ahlfors, Matthew F. Glasser, Douglas Greve, Saad Jbabdi, David Salat, and Emi Takahashi for various aspects of analysis and interpretation. NR 98 TC 75 Z9 76 U1 3 U2 25 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3932 J9 NEUROPSYCHOLOGIA JI Neuropsychologia PD JAN PY 2010 VL 48 IS 1 BP 86 EP 95 DI 10.1016/j.neuropsychologia.2009.08.013 PG 10 WC Behavioral Sciences; Neurosciences; Psychology, Experimental SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA 550NU UT WOS:000274135500010 PM 19698726 ER PT J AU Luks, TL Oliveira, M Possin, KL Bird, A Miller, BL Weiner, MW Kramer, JH AF Luks, Tracy L. Oliveira, Michael Possin, Katherine L. Bird, Anne Miller, Bruce L. Weiner, Michael W. Kramer, Joel H. TI Atrophy in two attention networks is associated with performance on a Flanker task in neurodegenerative disease SO NEUROPSYCHOLOGIA LA English DT Article DE Neurodegenerative disease; Attentional control; Flanker; Voxel-based morphometry ID ANTERIOR CINGULATE CORTEX; EVENT-RELATED FMRI; RESPONSE CHANNEL ACTIVATION; PRIMARY-PROGRESSIVE-APHASIA; INFERIOR FRONTAL-CORTEX; PREFRONTAL CORTEX; FRONTOTEMPORAL DEMENTIA; SEMANTIC DEMENTIA; ALZHEIMER-DISEASE; CONFLICT AB This study investigated the neurobiological basis of attentional control dysfunction in neurodegenerative disease by determining the effect of regional brain atrophy on Flanker task performance of neurodegenerative patients. We hypothesized that atrophy in DLPFC and ACC would be significantly associated with decreased attentional control performance on the Flanker task. We used voxel-based morphometry (VBM) to measure the relationship between MRI measures of regional grey matter atrophy and performance on a version of the Flanker task, measured by accuracy and response time. Sixty-five subjects participated, including patients with frontotemporal dementia, Alzheimer's disease, mild cognitive impairment, non-fluent progressive aphasia, corticobasal degeneration, progressive supranuclear palsy, semantic dementia, and healthy controls. Accuracy measures of attentional control and response time measures of attentional control were associated with two different patterns of regional atrophy across subjects. First, there was an association between left hemisphere DLPFC and ACC atrophy and poorer attentional control accuracy. Second, right hemisphere temporal-parietal junction (TPJ) and ventrolateral prefrontal cortex (VLPFC) and DLPFC atrophy were associated with slower response times during attentional control on accurate trials, which may reflect emergent involvement due to deficits in the DLPFC-ACC network. (C) 2009 Published by Elsevier Ltd. C1 [Luks, Tracy L.; Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Possin, Katherine L.; Bird, Anne; Miller, Bruce L.; Kramer, Joel H.] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94143 USA. [Weiner, Michael W.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Luks, TL (reprint author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, Box 0628, San Francisco, CA 94143 USA. EM Tracy.Luks@radiology.ucsf.edu FU NIA NIH HHS [K01 AG027369-01A1, K01 AG027369-02, K01 AG027369-05, P01 AG019724, K01 AG027369, K01 AG027369-04, K01 AG027369-03] NR 56 TC 18 Z9 20 U1 1 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3932 J9 NEUROPSYCHOLOGIA JI Neuropsychologia PD JAN PY 2010 VL 48 IS 1 BP 165 EP 170 DI 10.1016/j.neuropsychologia.2009.09.001 PG 6 WC Behavioral Sciences; Neurosciences; Psychology, Experimental SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA 550NU UT WOS:000274135500018 PM 19747928 ER PT J AU Gutchess, AH Kensinger, EA Schacter, DL AF Gutchess, Angela H. Kensinger, Elizabeth A. Schacter, Daniel L. TI Functional neuroimaging of self-referential encoding with age SO NEUROPSYCHOLOGIA LA English DT Article DE Aging; Self; Long-term memory; Prefrontal cortex; Cognition; fMRI ID MEDIAL PREFRONTAL CORTEX; EVENT-RELATED FMRI; SUBSEQUENT MEMORY; BRAIN ACTIVITY; OLDER-ADULTS; COGNITIVE NEUROSCIENCE; LIFE-SPAN; DEACTIVATIONS; RECRUITMENT; RETRIEVAL AB Aging impacts memory formation and the engagement of frontal and medial temporal regions. However, much of the research to date has focused on the encoding of neutral verbal and visual information. The present fMRI study investigated age differences in a social encoding task while participants made judgments about the self or another person. Although previous studies identified an intact self-reference effect with age, subserved by robust engagement of medial prefrontal cortex (mPFC) by both young and older adults, we identified a number of age differences. In regions including superior mPFC, inferior prefrontal cortex, and anterior and posterior cingulate cortex, young and older adults exhibited reversals in the pattern of activity for self and other conditions. Whereas young primarily evidenced subsequent forgetting effects in the self-reference condition, older adults demonstrated subsequent memory effects in the other-reference condition. These results indicate fundamental differences across the age groups in the engagement of elaborative encoding processes. We suggest that older adults may encode information about the self in a more normative manner, whereas young adults focus on encoding the unique aspects of the self and distinguishing the self from others. (C) 2009 Elsevier Ltd. All rights reserved. C1 [Gutchess, Angela H.] Brandeis Univ, Dept Psychol, Waltham, MA 02454 USA. [Gutchess, Angela H.; Kensinger, Elizabeth A.; Schacter, Daniel L.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [Kensinger, Elizabeth A.] Boston Coll, Dept Psychol, Chestnut Hill, MA 02167 USA. [Schacter, Daniel L.] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA. RP Gutchess, AH (reprint author), Brandeis Univ, Dept Psychol, 415 South St,MS 062, Waltham, MA 02454 USA. EM gutchess@brandeis.edu OI Schacter, Daniel/0000-0002-2460-6061 FU National Institutes of Health [AG008441, AG026920, MH070199]; AFAR; National Center for Research Resources [P41 RR14075]; MIND Institute FX The authors gratefully acknowledge support from the National Institutes of Health, grants AG008441 (to D.L.S.), AG026920 (to A.H.G.), and MH070199 (to E.A.K.). Portions of this research were conducted while A.H.G. was an AFAR Research Grant recipient. The Athinoula A. Martinos Center for Biomedical Imaging is supported by the National Center for Research Resources (grant P41 RR14075) and by the MIND Institute. We thank Alana Wong, Gina Gotthilf, and Roee Gilron for experimental assistance, and Moshe Bar, Malia Mason, and Gagan Wig for helpful discussions. NR 54 TC 47 Z9 47 U1 1 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3932 J9 NEUROPSYCHOLOGIA JI Neuropsychologia PD JAN PY 2010 VL 48 IS 1 BP 211 EP 219 DI 10.1016/j.neuropsychologia.2009.09.006 PG 9 WC Behavioral Sciences; Neurosciences; Psychology, Experimental SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA 550NU UT WOS:000274135500024 PM 19765600 ER PT J AU Dickerson, BC Eichenbaum, H AF Dickerson, Bradford C. Eichenbaum, Howard TI The Episodic Memory System: Neurocircuitry and Disorders SO NEUROPSYCHOPHARMACOLOGY LA English DT Review DE medial temporal lobe; hippocampus; episodic memory; neuropsychology; Alzheimer's disease ID MEDIAL TEMPORAL-LOBE; MILD COGNITIVE IMPAIRMENT; TRANSIENT GLOBAL AMNESIA; HIPPOCAMPAL SCLEROSIS DEMENTIA; MONKEY RETROSPLENIAL CORTEX; ALZHEIMERS-DISEASE; RECOGNITION MEMORY; DEVELOPMENTAL AMNESIA; CORTICAL AFFERENTS; FRONTAL-LOBE AB The ability to encode and retrieve our daily personal experiences, called episodic memory, is supported by the circuitry of the medial temporal lobe (MTL), including the hippocampus, which interacts extensively with a number of specific distributed cortical and subcortical structures. In both animals and humans, evidence from anatomical, neuropsychological, and physiological studies indicates that cortical components of this system have key functions in several aspects of perception and cognition, whereas the MTL structures mediate the organization and persistence of the network of memories whose details are stored in those cortical areas. Structures within the MTL, and particularly the hippocampus, have distinct functions in combining information from multiple cortical streams, supporting our ability to encode and retrieve details of events that compose episodic memories. Conversely, selective damage in the hippocampus, MTL, and other structures of the large-scale memory system, or deterioration of these areas in several diseases and disorders, compromises episodic memory. A growing body of evidence is converging on a functional organization of the cortical, subcortical, and MTL structures that support the fundamental features of episodic memory in humans and animals. Neuropsychopharmacology Reviews (2010) 35, 86-104; doi:10.1038/npp.2009.126; published online 23 September 2009 C1 [Dickerson, Bradford C.] Massachusetts Gen Hosp, Dept Neurol, Massachusetts Alzheimers Dis Res Ctr, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [Dickerson, Bradford C.] Harvard Univ, Sch Med, Boston, MA USA. [Eichenbaum, Howard] Boston Univ, Dept Psychol, Ctr Memory & Brain, Boston, MA 02215 USA. RP Dickerson, BC (reprint author), Massachusetts Alzheimers Dis Res Ctr, Dept Neurol, MGH Gerontol Res Unit, 149 13th St,Suite 2691, Charlestown, MA 02129 USA. EM bradd@nmr.mgh.harvard.edu FU National Institute on Aging [R01-AG29411, R21-AG29840]; Alzheimer's Association FX This work was generously supported by the National Institute on Aging (R01-AG29411, R21-AG29840) and the Alzheimer's Association. NR 162 TC 130 Z9 134 U1 3 U2 37 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD JAN PY 2010 VL 35 IS 1 BP 86 EP 104 DI 10.1038/npp.2009.126 PG 19 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 532XV UT WOS:000272784600006 PM 19776728 ER PT J AU Shin, LM Liberzon, I AF Shin, Lisa M. Liberzon, Israel TI The Neurocircuitry of Fear, Stress, and Anxiety Disorders SO NEUROPSYCHOPHARMACOLOGY LA English DT Review DE amygdala; fMRI; PET; anterior cingulate; insula; hippocampus ID OBSESSIVE-COMPULSIVE DISORDER; CEREBRAL-BLOOD-FLOW; MEDIAL PREFRONTAL CORTEX; GENERALIZED SOCIAL PHOBIA; POSITRON-EMISSION-TOMOGRAPHY; ANTERIOR CINGULATE CORTEX; MAGNETIC-RESONANCE SPECTROSCOPY; CHILDHOOD SEXUAL-ABUSE; BENZODIAZEPINE-RECEPTOR-BINDING; COGNITIVE-BEHAVIORAL THERAPY AB Anxiety disorders are a significant problem in the community, and recent neuroimaging research has focused on determining the brain circuits that underlie them. Research on the neurocircuitry of anxiety disorders has its roots in the study of fear circuits in animal models and the study of brain responses to emotional stimuli in healthy humans. We review this research, as well as neuroimaging studies of anxiety disorders. In general, these studies have reported relatively heightened amygdala activation in response to disorder-relevant stimuli in post-traumatic stress disorder, social phobia, and specific phobia. Activation in the insular cortex appears to be heightened in many of the anxiety disorders. Unlike other anxiety disorders, post-traumatic stress disorder is associated with diminished responsivity in the rostral anterior cingulate cortex and adjacent ventral medial prefrontal cortex. Additional research will be needed to (1) clarify the exact role of each component of the fear circuitry in the anxiety disorders, (2) determine whether functional abnormalities identified in the anxiety disorders represent acquired signs of the disorders or vulnerability factors that increase the risk of developing them, (3) link the findings of functional neuroimaging studies with those of neurochemistry studies, and (4) use functional neuroimaging to predict treatment response and assess treatment-related changes in brain function. Neuropsychopharmacology Reviews (2010) 35, 169-191; doi:10.1038/npp.2009.83; published online 22 July 2009 C1 [Shin, Lisa M.] Tufts Univ, Dept Psychol, Medford, MA 02155 USA. [Shin, Lisa M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA USA. [Liberzon, Israel] Ann Arbor Vet Affairs Med Ctr, Psychiat Serv, Ann Arbor, MI USA. [Liberzon, Israel] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. RP Shin, LM (reprint author), Tufts Univ, Dept Psychol, 490 Boston Ave, Medford, MA 02155 USA. EM lisa.shin@tufts.edu RI Frank, David/E-8213-2012; OI Liberzon, Israel/0000-0002-4990-556X NR 387 TC 509 Z9 518 U1 49 U2 200 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD JAN PY 2010 VL 35 IS 1 BP 169 EP 191 DI 10.1038/npp.2009.83 PG 23 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 532XV UT WOS:000272784600010 PM 19625997 ER PT J AU Bush, G AF Bush, George TI Attention-Deficit/Hyperactivity Disorder and Attention Networks SO NEUROPSYCHOPHARMACOLOGY LA English DT Review DE attention; ADHD; imaging; reward; cingulate; prefrontal ID DEFICIT-HYPERACTIVITY DISORDER; ANTERIOR CINGULATE CORTEX; FUNCTIONAL MAGNETIC-RESONANCE; EVENT-RELATED FMRI; POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL-BLOOD-FLOW; ABNORMAL-PSYCHICAL-CONDITIONS; CORPUS-CALLOSUM MORPHOLOGY; MEDIAL PREFRONTAL CORTEX; MULTISOURCE INTERFERENCE TASK AB Research attempting to elucidate the neuropathophysiology of attention-deficit/hyperactivity disorder (ADHD) has not only shed light on the disorder itself, it has simultaneously provided new insights into the mechanisms of normal cognition and attention. This review will highlight and integrate this bidirectional flow of information. Following a brief overview of ADHD clinical phenomenology, ADHD studies will be placed into a wider historical perspective by providing illustrative examples of how major models of attention have influenced the development of neurocircuitry models of ADHD. The review will then identify major components of neural systems potentially relevant to ADHD, including attention networks, reward/feedback-based processing systems, as well as a 'default mode' resting state network. Further, it will suggest ways in which these systems may interact and be influenced by neuromodulatory factors. Recent ADHD imaging data will be selectively provided to both illustrate the field's current level of knowledge and to show how such data can inform our understanding of normal brain functions. The review will conclude by suggesting possible avenues for future research. Neuropsychopharmacology Reviews (2010) 35, 278-300; doi:10.1038/npp.2009.120; published online 16 September 2009 C1 [Bush, George] Massachusetts Gen Hosp E, Psychiat Neurosci Program, Dept Psychiat, Charlestown, MA 02129 USA. [Bush, George] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Bush, George] Massachusetts Gen Hosp, Dept Psychiat, Psychiat Neurosci Div, Boston, MA 02114 USA. [Bush, George] Harvard Univ, Sch Med, MGH MIT HMS Athinoula A Martinos Ctr Funct & Stru, MIT, Charlestown, MA USA. [Bush, George] Massachusetts Gen Hosp, Benson Henry Inst Mind Body Med, Boston, MA 02114 USA. RP Bush, G (reprint author), Massachusetts Gen Hosp E, Psychiat Neurosci Program, Dept Psychiat, CNY 2614,Bldg 149,13th St, Charlestown, MA 02129 USA. EM geo@nmr.mgh.harvard.edu FU NCRR NIH HHS [P41 RR014075] NR 305 TC 122 Z9 126 U1 11 U2 38 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD JAN PY 2010 VL 35 IS 1 BP 278 EP 300 DI 10.1038/npp.2009.120 PG 23 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 532XV UT WOS:000272784600015 PM 19759528 ER PT J AU George, MS Aston-Jones, G AF George, Mark S. Aston-Jones, Gary TI Noninvasive techniques for probing neurocircuitry and treating illness: vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) SO NEUROPSYCHOPHARMACOLOGY LA English DT Review DE TMS; VNS; neuromodulation ID TREATMENT-RESISTANT DEPRESSION; HUMAN MOTOR CORTEX; DEEP BRAIN-REGIONS; LOCUS-COERULEUS; MAJOR DEPRESSION; CORTICAL EXCITABILITY; PARKINSONS-DISEASE; PREFRONTAL CORTEX; BLOOD-FLOW; BOLD FMRI AB Although the preceding chapters discuss much of the new knowledge of neurocircuitry of neuropsychiatric diseases, and an invasive approach to treatment, this chapter describes and reviews the noninvasive methods of testing circuit-based theories and treating neuropsychiatric diseases that do not involve implanting electrodes into the brain or on its surface. These techniques are transcranial magnetic stimulation, vagus nerve stimulation, and transcranial direct current stimulation. Two of these approaches have FDA approval as therapies. Neuropsychopharmacology Reviews (2010) 35, 301-316; doi:10.1038/npp.2009.87; published online 19 August 2009 C1 [George, Mark S.] Med Univ S Carolina, Brain Stimulat Lab, Inst Psychiat, Charleston, SC 29425 USA. [George, Mark S.] Med Univ S Carolina, Dept Psychiat, Inst Psychiat, Ctr Adv Imaging Res, Charleston, SC 29425 USA. [George, Mark S.] Med Univ S Carolina, Dept Radiol, Inst Psychiat, Ctr Adv Imaging Res, Charleston, SC 29425 USA. [George, Mark S.] Med Univ S Carolina, Dept Neurosci, Inst Psychiat, Ctr Adv Imaging Res, Charleston, SC 29425 USA. [George, Mark S.] Med Univ S Carolina, SC Brain Imaging Ctr Econ Excellence, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Aston-Jones, Gary] Med Univ S Carolina, Murray Chair Excellence Neurosci, Charleston, SC 29425 USA. RP George, MS (reprint author), Med Univ S Carolina, Brain Stimulat Lab, Inst Psychiat, 67 President St,Rm 502 N, Charleston, SC 29425 USA. EM georgem@musc.edu NR 184 TC 93 Z9 99 U1 2 U2 22 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD JAN PY 2010 VL 35 IS 1 BP 301 EP 316 DI 10.1038/npp.2009.87 PG 16 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 532XV UT WOS:000272784600016 PM 19693003 ER PT J AU Busl, KM Greer, DM AF Busl, Katharina M. Greer, David M. TI Hypoxic-ischemic brain injury: Pathophysiology, neuropathology and mechanisms SO NEUROREHABILITATION LA English DT Article ID TRANSIENT FOREBRAIN ISCHEMIA; GLOBAL CEREBRAL-ISCHEMIA; RAT HIPPOCAMPAL SLICE; NITRIC-OXIDE SYNTHASE; CARDIAC-ARREST; PROTEIN-SYNTHESIS; CIRCULATORY ARREST; GERBIL HIPPOCAMPUS; CELL-DEATH; CARDIOCIRCULATORY ARREST AB Hypoxic-ischemic brain injury is a well known consequence of cardiac arrest. Variable injuries can occur with purely hypoxic or histotoxic insults such as asphyxiation and carbon monoxide poisoning. The injury may happen at the time of the insult, but there may also be continued damage after circulation and oxygenation are reestablished. The nature and extent of the damage appears to depend on the severity, time course and duration of the oxygen deprivation and lack of blood supply, as well as on the underlying mechanism. This review describes the pathophysiological and molecular basis of hypoxic ischemic brain injury, and differentiates between the mechanisms of injury by cardiac arrest, pure respiratory arrest, and arrest secondary to cytotoxicity (e.g. carbon monoxide poisoning). C1 [Busl, Katharina M.; Greer, David M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA. RP Greer, DM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, ACC 739A,55 Fruit St, Boston, MA 02114 USA. EM dgreer@partners.org NR 72 TC 60 Z9 70 U1 2 U2 7 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1053-8135 J9 NEUROREHABILITATION JI Neurorehabilitation PY 2010 VL 26 IS 1 BP 5 EP 13 DI 10.3233/NRE-2010-0531 PG 9 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 562NQ UT WOS:000275059000002 PM 20130351 ER PT J AU Anderson, CA Arciniegas, DB AF Anderson, C. Alan Arciniegas, David B. TI Cognitive sequelae of hypoxic-ischemic brain injury: A review SO NEUROREHABILITATION LA English DT Review DE Hypoxic-ischemic; anoxic; brain injury; cognition; attention; memory; executive function ID HOSPITAL CARDIAC-ARREST; PERSISTENT VEGETATIVE STATE; MINIMALLY CONSCIOUS STATES; QUALITY-OF-LIFE; EFNS TASK-FORCE; CEREBRAL ANOXIA; CARDIOPULMONARY-RESUSCITATION; NEUROPSYCHOLOGICAL PROFILE; ADULT SURVIVORS; MEDICAL ASPECTS AB Despite improvements in the pre-hospital and critical care management of persons with hypoxic-ischemic brain injury (HI-BI) and the conditions with which it is associated, acute and chronic cognitive impairments remain problems for many survivors of such injuries. Disorders of consciousness, attention, speed of processing, and memory impairments, and executive dysfunction are among the most prominent and common disturbances of cognition after HI-BI. Acute interventions, including therapeutic hypothermia, may improve global outcomes after HI-BI, but their specific effects on post-hypoxic cognitive impairments remain uncertain. Additionally, treatments for cognitive impairments after HI-BI are underdeveloped and are generally arrived at by analogy to the treatment of such problems arising from other neurological conditions, especially traumatic brain injury. In the service of offering a practical approach to the evaluation and care of persons with cognitive impairments after HI-BI, the most common types of post-hypoxic cognitive impairments are reviewed. Cognitive outcomes after HI-BI are discussed and suggestions for the nonpharmacologic and pharmacologic neurorehabilitation of these problems are offered. C1 [Anderson, C. Alan; Arciniegas, David B.] Univ Colorado, Sch Med, Dept Neurol, Behav Neurol Sect, Denver, CO USA. [Anderson, C. Alan; Arciniegas, David B.] Univ Colorado, Sch Med, Dept Psychiat, Neurobehav Disorders Program, Denver, CO 80262 USA. [Anderson, C. Alan; Arciniegas, David B.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Arciniegas, David B.] HealthONE Spalding Rehabil Hosp, Brain Injury Rehabil Unit, Aurora, CO USA. RP Anderson, CA (reprint author), Univ Colorado Denver, Dept Neurol, Mail Stop B182,12700 E 19th Ave,Room 5C03, Aurora, CO 80045 USA. EM al.anderson@ucdenver.edu NR 106 TC 32 Z9 36 U1 2 U2 25 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1053-8135 J9 NEUROREHABILITATION JI Neurorehabilitation PY 2010 VL 26 IS 1 BP 47 EP 63 DI 10.3233/NRE-2010-0535 PG 17 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 562NQ UT WOS:000275059000006 PM 20130355 ER PT J AU Lew, HL Weihing, J Myers, PJ Pogoda, TK Goodrich, GL AF Lew, Henry L. Weihing, Jeffrey Myers, Paula J. Pogoda, Terri K. Goodrich, Gregory L. TI Dual sensory impairment (DSI) in traumatic brain injury (TBI) - An emerging interdisciplinary challenge SO NEUROREHABILITATION LA English DT Article DE Dual sensory impairment; DSI; auditory; hearing; visual; military; blast ID CLOSED-HEAD-INJURY; INFORMATION-PROCESSING DEFICITS; LOW-VISION REHABILITATION; INTRACEREBRAL POTENTIALS; VISUAL-STIMULI; RARE TARGET; AUDITORY DYSFUNCTION; HEARING IMPAIRMENT; NOISE EXPOSURE; CONCUSSION AB The present review characterizes dual sensory impairment (DSI) as co-existing auditory and visual deficits in TBI that can be peripherally or centrally based. Current research investigating DSI in the military population, along with applicable research which focuses on unimodal deficits, is considered. Due to the heterogenous nature of TBI lesions, an important challenge that the clinician faces is ruling out the influence of multiple sensory deficits and/or the influence of cognitive processes on diagnosis and rehabilitation of the patient. Treatment options for DSI involve remediation of the sensory deficits via existing sensory aids or training exercises. C1 [Lew, Henry L.] Virginia Commonwealth Univ, Sch Med, DVBIC, Richmond, VA 23219 USA. [Lew, Henry L.] Virginia Commonwealth Univ, Sch Med, Dept PM&R, Richmond, VA 23219 USA. [Lew, Henry L.] Harvard Univ, Sch Med, Dept PM&R, Boston, MA USA. [Weihing, Jeffrey; Pogoda, Terri K.] VA Boston Healthcare Syst, TBI Res Ctr, Boston, MA USA. [Myers, Paula J.] James A Haley Vet Hosp, Audiol Serv, Tampa, FL 33612 USA. [Pogoda, Terri K.] Boston Healthcare Syst, VA, Ctr Org Leadership & Management Res, Boston, MA USA. [Pogoda, Terri K.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Goodrich, Gregory L.] VA Palo Alto Hlth Care Syst, Psychol Serv, Palo Alto, CA USA. [Goodrich, Gregory L.] VA Palo Alto Hlth Care Syst, Western Blind Rehabil Ctr, Palo Alto, CA USA. RP Lew, HL (reprint author), Virginia Commonwealth Univ, Sch Med, DVBIC, 730 E Broad St, Richmond, VA 23219 USA. EM hlew@dvbic.org NR 87 TC 18 Z9 18 U1 0 U2 7 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1053-8135 EI 1878-6448 J9 NEUROREHABILITATION JI Neurorehabilitation PY 2010 VL 26 IS 3 BP 213 EP 222 DI 10.3233/NRE-2010-0557 PG 10 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 603OQ UT WOS:000278218300005 PM 20448311 ER PT J AU Lew, HL Amick, MM Kraft, M Stein, MB Cifu, DX AF Lew, Henry L. Amick, Melissa M. Kraft, Malissa Stein, Murray B. Cifu, David X. TI Potential driving issues in combat returnees SO NEUROREHABILITATION LA English DT Article DE Traumatic brain injury; post traumatic stress disorder; motor vehicle crashes; deployment; evasive driving skills; veterans ID TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; PERSIAN-GULF-WAR; NEUROCOGNITIVE PERFORMANCE; POSTCONCUSSIVE SYMPTOMS; US VETERANS; CONCUSSION; IRAQ; MORTALITY; SOLDIERS AB The driving abilities of service members returning from Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF) have not been well reported and are an important aspect of their return to normal life. This article reviews the unique risk factors for unsafe driving in this cohort. In particular, the cognitive and psychological symptoms of mild traumatic brain injury and postraumatic stress disorder, two of the most common diagnoses affecting these returning warriors, are specified, and their possible association with impaired driving is examined. The potential negative impact of the "battlemind driving tactics" (i.e., evasive driving skills) acquired by these service members as part of their military tours is also highlighted. The article concludes with comments about the functional consequences of impaired driving in this population, including limits to participation in rehabilitation and community reintegration, as well as recognition of the need for further research in this area. C1 [Lew, Henry L.] VA Boston Hlth Care Syst, PM& R Serv, Polytrauma & TBI Res Ctr, Boston, MA 02130 USA. [Lew, Henry L.] DVBIC, Richmond, VA USA. [Lew, Henry L.] Virginia Commonwealth Univ, Sch Med, Richmond, VA USA. [Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Stein, Murray B.] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA. [Stein, Murray B.] VA San Diego Healthcare Syst, Psychiat Serv, San Diego, CA USA. [Cifu, David X.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA. [Cifu, David X.] Hunter Holmes McGuire VA Healthcare Syst, PM&R Serv, Richmond, VA USA. RP Lew, HL (reprint author), VA Boston Hlth Care Syst, PM& R Serv, Polytrauma & TBI Res Ctr, 150 S Huntington Ave, Boston, MA 02130 USA. EM Henry.Lew@VA.gov NR 50 TC 16 Z9 16 U1 2 U2 5 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1053-8135 J9 NEUROREHABILITATION JI Neurorehabilitation PY 2010 VL 26 IS 3 BP 271 EP 278 DI 10.3233/NRE-2010-0562 PG 8 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 603OQ UT WOS:000278218300010 PM 20448316 ER PT J AU Ando, K Watanabe, K Maesako, M Asada, M Kubota, M Aoyagi, N Kuzuya, A Uemura, K Kawamata, J Takahashi, R Kinoshita, A AF Ando, Koichi Watanabe, Kiwamu Maesako, Masato Asada, Megumi Kubota, Masakazu Aoyagi, Nobuhisa Kuzuya, Akira Uemura, Kengo Kawamata, Jun Takahashi, Ryosuke Kinoshita, Ayae TI Analysis of N-cadherin interacting proteins in Alzheimer's disease SO NEUROSCIENCE RESEARCH LA English DT Meeting Abstract C1 [Ando, Koichi; Watanabe, Kiwamu; Aoyagi, Nobuhisa; Kuzuya, Akira; Kawamata, Jun; Takahashi, Ryosuke] Kyoto Univ, Grad Sch Med, Dept Neurol, Kyoto, Japan. [Uemura, Kengo] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Maesako, Masato; Asada, Megumi; Kubota, Masakazu; Kinoshita, Ayae] Kyoto Univ, Fac Med, Sch Hlth Sci, Kyoto, Japan. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-0102 J9 NEUROSCI RES JI Neurosci. Res. PY 2010 VL 68 SU 1 BP E67 EP E67 DI 10.1016/j.neures.2010.07.064 PG 1 WC Neurosciences SC Neurosciences & Neurology GA V24XS UT WOS:000208443700300 ER PT J AU Asada, M Uemura, K Kuzuya, A Yamada, N Maesako, M Watanabe, K Ando, K Berezovska, O Hyman, BT Takahashi, R Kinoshita, A AF Asada, Megumi Uemura, Kengo Kuzuya, Akira Yamada, Nao Maesako, Masato Watanabe, Kiwamu Ando, Koichi Berezovska, Oksana Hyman, Bradley T. Takahashi, Ryosuke Kinoshita, Ayae TI The effect of N-cadherin/Nectin-1 expression on APP cis-dimerization SO NEUROSCIENCE RESEARCH LA English DT Meeting Abstract C1 [Asada, Megumi; Yamada, Nao; Maesako, Masato; Kinoshita, Ayae] Kyoto Univ, Grad Sch Med, Kyoto 6068501, Japan. [Asada, Megumi; Uemura, Kengo; Kuzuya, Akira; Watanabe, Kiwamu; Ando, Koichi; Takahashi, Ryosuke] Kyoto Univ, Dept Neuro, Kyoto 6068501, Japan. [Asada, Megumi; Uemura, Kengo; Kuzuya, Akira; Yamada, Nao; Maesako, Masato; Watanabe, Kiwamu; Ando, Koichi; Berezovska, Oksana; Hyman, Bradley T.; Takahashi, Ryosuke; Kinoshita, Ayae] Sappro Med Univ, Dept Neurol, Sapporo, Hokkaido, Japan. [Berezovska, Oksana; Hyman, Bradley T.] Massachusetts Gen Hosp, Alzheimer Res Unit, MassGeneral Inst Neurodegenerat Dis, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-0102 J9 NEUROSCI RES JI Neurosci. Res. PY 2010 VL 68 SU 1 BP E189 EP E189 DI 10.1016/j.neures.2010.07.2410 PG 1 WC Neurosciences SC Neurosciences & Neurology GA V24XS UT WOS:000208443701224 ER PT J AU Tamaki, M Huang, TR Lin, FH Hamalainen, M Yotsumoto, Y Watanabe, T Sasaki, Y AF Tamaki, Masako Huang, Tsung-Ren Lin, Fa-Hsuan Hamalainen, Matti Yotsumoto, Yuko Watanabe, Takeo Sasaki, Yuka TI MEG cortical activation during sleep correlated with improvement of a motor sequence learning SO NEUROSCIENCE RESEARCH LA English DT Meeting Abstract C1 [Huang, Tsung-Ren; Watanabe, Takeo] Boston Univ, Boston, MA 02215 USA. [Lin, Fa-Hsuan; Hamalainen, Matti; Sasaki, Yuka] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Yotsumoto, Yuko] Keio Univ, Tokyo 108, Japan. [Sasaki, Yuka] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RI Hamalainen, Matti/C-8507-2013; Lin, Fa-Hsuan/G-6988-2012; OI Lin, Fa-Hsuan/0000-0002-9539-1731; Huang, Tsung-Ren/0000-0003-4396-7943 NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-0102 J9 NEUROSCI RES JI Neurosci. Res. PY 2010 VL 68 SU 1 BP E77 EP E77 DI 10.1016/j.neures.2010.07.107 PG 1 WC Neurosciences SC Neurosciences & Neurology GA V24XS UT WOS:000208443700342 ER PT J AU Connolly, ES Hoh, BL Selden, NR Asher, AL Kondziolka, D Boulis, NM Barker, FG AF Connolly, E. Sander, Jr. Hoh, Brian L. Selden, Nathan R. Asher, Anthony L. Kondziolka, Douglas Boulis, Nicholas M. Barker, Fred G., II TI Clipping Versus Coiling for Ruptured Intracranial Aneurysms: Integrated Medical Learning at CNS 2007 SO NEUROSURGERY LA English DT Article DE Endovascular coiling; Equipose; Medical education; Open surgical clipping; Unruptured intracerebral aneurysm ID RANDOMIZED CONTROLLED-TRIALS; GUGLIELMI DETACHABLE COILS; IN-HOSPITAL MORTALITY; CEREBRAL ANEURYSMS; ENDOVASCULAR TREATMENT; UNITED-STATES; UNRUPTURED ANEURYSMS; CONCEPTUAL-FRAMEWORK; SURGICAL-TREATMENT; CLINICAL-TRIALS AB OBJECTIVE: Patients with intracranial aneurysms, both ruptured and unruptured, are frequently eligible for both open surgery ("clipping") and endovascular repair ("coiling"). Although results of randomized trials have informed this decision, the actual choice of clipping or coiling for individual patients remains complex. At the 2007 Congress of Neurological Surgeons (CNS) Annual Meeting, a novel active learning process called Integrated Medical Learning (IML) was applied to education about this critical treatment choice. METHODS: CNS members received an electronically distributed premeeting survey and educational materials about the clipping versus coiling decision and related topics. At the Annual Meeting, participants used handheld devices to choose clipping or coiling for treatment of individual aneurysms, both before and after expert opinion presentations. After the meeting, members who had answered premeeting surveys received a follow-up questionnaire. RESULTS: In the premeeting poll, respondents with self-described specialties of "vascular," Cerebrovascular Section members, surgeons with active cerebrovascular practices, and surgeons in practice for less than 20 years had higher levels of baseline knowledge of cerebrovascular literature (P < .03). Surgeons' clinical volumes of clipping and coiling strongly influenced their vote for clipping or coiling for a hypothetical patient (P < .01). At the meeting, in 6 of 8 cases of ruptured aneurysms the audience was split 75%:25% or closer to "clinical equipoise" (50:50 split). Surgeons with vascular specialty, academic surgeons, and residents were more likely to recommend clipping for individual cases (P < .05). After experts' presentations, in 6 of 8 cases the audience opinion changed significantly. Vascular specialists and younger surgeons were less likely to change their opinion (P < .03). The 2 cases with no shift in opinion were the most-clippable and most-coilable cases. Postmeeting surveys showed evidence of retained knowledge from the meeting, and respondents thought IML had been helpful. CONCLUSIONS: Using IML, we were able to study baseline knowledge and practice patterns for an important cerebrovascular treatment decision. Evidence suggested that expert presentations were effective in changing audience opinion, at least in cases where preexisting opinion was close to clinical equipoise. C1 [Connolly, E. Sander, Jr.] Columbia Univ, Dept Neurol Surg, New York, NY USA. [Hoh, Brian L.] Univ Florida, Dept Neurosurg, Gainesville, FL USA. [Selden, Nathan R.] Oregon Hlth & Sci Univ, Div Pediat Neurosurg, Dept Neurol Surg, Portland, OR 97201 USA. [Asher, Anthony L.] Carolina Neurosurg & Spine Associates, Charlotte, NC USA. [Kondziolka, Douglas] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15261 USA. [Kondziolka, Douglas] Univ Pittsburgh, Sch Med, Dept Radiat Oncol, Pittsburgh, PA 15261 USA. [Kondziolka, Douglas] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15261 USA. [Boulis, Nicholas M.] Emory Univ, Dept Neurol Surg, Atlanta, GA 30322 USA. [Barker, Fred G., II] Harvard Univ, Sch Med, Dept Surg Neurosurg, Boston, MA USA. RP Barker, FG (reprint author), Massachusetts Gen Hosp, Pappas Ctr Neurooncol, Yawkey 9E,Fruit St, Boston, MA 02114 USA. EM barker@helix.mgh.harvard.edu OI Selden, Nathan/0000-0001-6108-9721 NR 69 TC 4 Z9 4 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-396X J9 NEUROSURGERY JI Neurosurgery PD JAN PY 2010 VL 66 IS 1 BP 19 EP 33 DI 10.1227/01.NEU.0000362005.93515.5B PG 15 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 535KP UT WOS:000272967400003 PM 19935437 ER PT J AU Agarwalla, PK Barnard, ZR Curry, WT AF Agarwalla, Pankaj K. Barnard, Zachary R. Curry, William T., Jr. TI Virally Mediated Immunotherapy for Brain Tumors SO NEUROSURGERY CLINICS OF NORTH AMERICA LA English DT Article DE Glioblastoma; Immunotherapy; Oncolytic virus; Brain cancer; Immunosuppression; Gene therapy ID HERPES-SIMPLEX-VIRUS; RECURRENT GLIOBLASTOMA-MULTIFORME; HUMAN-MALIGNANT GLIOMA; TOLL-LIKE RECEPTORS; HUMAN CYTOMEGALOVIRUS; ANTITUMOR IMMUNITY; ONCOLYTIC VIRUS; GENE-THERAPY; DENDRITIC CELLS; CANCER VACCINE AB Brain tumors are a leading cause of mortality and morbidity in the United States. Malignant brain tumors occur in approximately 80,000 adults. Furthermore, the average 5-year survival rate for malignant brain tumors across all ages and races is approximately 30% and has remained relatively static over the past few decades, showing the need for continued research and progress in brain tumor therapy. Improved techniques in molecular biology have expanded understanding of tumor genetics and permitted viral engineering and the anticancer therapeutic use of viruses as directly cytotoxic agents and as gene vectors. Preclinical models have shown promising antitumor effects, and generation of clinical grade vectors is feasible. In parallel to these developments, better understanding of antitumor immunity has been accompanied by progress in cancer immunotherapy, the goal of which is to stimulate host rejection of a growing tumor. This article reviews the intersection between the use of viral therapy and immunotherapy in the treatment of malignant gliomas. Each approach shows great promise on its own and in combined or integrated forms. C1 [Barnard, Zachary R.; Curry, William T., Jr.] Massachusetts Gen Hosp, Dept Neurosurg, Stephen E & Catherine Pappas Ctr Neurooncol, Boston, MA 02114 USA. [Agarwalla, Pankaj K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Brain Tumor Immunotherapy Lab,Dept Neurosurg, Boston, MA USA. RP Curry, WT (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, Stephen E & Catherine Pappas Ctr Neurooncol, 55 Fruit St Y9E, Boston, MA 02114 USA. EM wcurry@partners.org NR 74 TC 5 Z9 7 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1042-3680 J9 NEUROSURG CLIN N AM JI Neurosurg. Clin. N. Am. PD JAN PY 2010 VL 21 IS 1 BP 167 EP + DI 10.1016/j.nec.2009.08.013 PG 14 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 601LA UT WOS:000278059500015 PM 19944975 ER PT J AU Kahle, KT Kozono, D Ng, K Hsieh, G Zinn, PO Nitta, M Chen, CC AF Kahle, Kristopher T. Kozono, David Ng, Kimberly Hsieh, Grace Zinn, Pascal O. Nitta, Masayuki Chen, Clark C. TI Functional genomics to explore cancer cell vulnerabilities SO NEUROSURGICAL FOCUS LA English DT Article DE functional genomics; RNA interference; short interfering RNA; glioblastoma multiforme; cancer ID SYNTHETIC LETHAL; GLIOBLASTOMA-MULTIFORME; ESSENTIAL GENES; RNAI SCREEN; IDENTIFICATION; ADDICTION; DISCOVERY; ONCOGENE; PATHWAYS; MUTANTS AB Our understanding of glioblastoma multiforme (GBM), the most common form of primary brain cancer, has been significantly advanced by recent efforts to characterize the cancer genome using unbiased high-throughput sequencing analyses. While these studies have documented hundreds of mutations, gene copy alterations, and chromosomal abnormalities, only a subset of these alterations are likely to impact tumor initiation or maintenance. Furthermore, genes that are not altered at the genomic level may play essential roles in tumor initiation and maintenance. Identification of these genes is critical for therapeutic development and investigative methodologies that afford insight into biological function. This requirement has largely been fulfilled with the emergence of RNA interference (RNAi) and high-throughput screening technology. In this article, the authors discuss the application of genome-wide, high-throughput RNAi-based genetic screening as a powerful tool for the rapid and cost-effective identification of genes essential for cancer proliferation and survival. They describe how these technologies have been used to identify genes that are themselves selectively lethal to cancer cells, or synthetically lethal with other oncogenic mutations. The article is intended to provide a platform for how RNAi libraries might contribute to uncovering glioma cell vulnerabilities and provide information that is highly complementary to the structural characterization of the glioblastoma genome. The authors emphasize that unbiased, systems-level structural and functional genetic approaches are complementary efforts that should facilitate the identification of genes involvedin the pathogenesis of GBM and permit the identification of novel drug targets. (DOI: 10.3171/2009.10.FOCUS09212) C1 [Chen, Clark C.] Harvard Univ, Sch Med, Dept Radiat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA. [Kahle, Kristopher T.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Kahle, Kristopher T.] Howard Hughes Med Inst, Boston, MA 02115 USA. [Kahle, Kristopher T.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. [Kahle, Kristopher T.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Kozono, David] Brigham & Womens Hosp, Harvard Radiat Oncol Program, Boston, MA 02115 USA. [Chen, Clark C.] Beth Israel Deaconess Med Ctr, Dept Neurosurg, Boston, MA 02215 USA. RP Chen, CC (reprint author), Harvard Univ, Sch Med, Dept Radiat Oncol, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM clark_chen@dfci.harvard.edu NR 36 TC 3 Z9 3 U1 0 U2 0 PU AMER ASSOC NEUROLOGICAL SURGEONS PI ROLLING MEADOWS PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA SN 1092-0684 J9 NEUROSURG FOCUS JI Neurosurg. Focus PD JAN PY 2010 VL 28 IS 1 AR E5 DI 10.3171/2009.10.FOCUS09212 PG 7 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 539MQ UT WOS:000273259200006 PM 20043720 ER PT J AU Cristofaro, V Lowalekar, S Yalla, SV Sullivan, MP AF Cristofaro, Vivian Lowalekar, Samar Yalla, Subbarao V. Sullivan, Maryrose P. TI CALCIUM SENSING RECEPTOR EXPRESSED IN INTERSTITIAL CELLS MODULATES BLADDER FUNCTION SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT 7th Annual Winter Meeting of the Society-for-Urodynamics-and-Female-Urology CY JAN 23-FEB 27, 2010 CL St Petersburg, FL SP Soc Urodynam & Female Urol C1 [Cristofaro, Vivian; Lowalekar, Samar; Yalla, Subbarao V.; Sullivan, Maryrose P.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, W Roxbury, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0733-2467 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PY 2010 VL 29 IS 2 BP 244 EP 245 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 569JV UT WOS:000275593300005 ER PT J AU Lowalekar, S Cristofaro, V Yalla, SV Sullivan, MP AF Lowalekar, Samar Cristofaro, Vivian Yalla, Subbarao V. Sullivan, Maryrose P. TI OREXIN HAS A DIRECT EFFECT ON BLADDER FUNCTION SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT 7th Annual Winter Meeting of the Society-for-Urodynamics-and-Female-Urology CY JAN 23-FEB 27, 2010 CL St Petersburg, FL SP Soc Urodynam & Female Urol C1 [Lowalekar, Samar; Cristofaro, Vivian; Yalla, Subbarao V.; Sullivan, Maryrose P.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0733-2467 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PY 2010 VL 29 IS 2 BP 246 EP 247 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 569JV UT WOS:000275593300009 ER PT J AU Morrisroe, S Pollard, M Mossanen, M Shekelle, P Anger, J AF Morrisroe, Shelby Pollard, Matthew Mossanen, Matthew Shekelle, Paul Anger, Jennifer TI OUTCOMES OF PREGNANCY FOLLOWING SURGERY FOR STRESS URINARY INCONTINENCE: A SYSTEMATIC REVIEW SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT 7th Annual Winter Meeting of the Society-for-Urodynamics-and-Female-Urology CY JAN 23-FEB 27, 2010 CL St Petersburg, FL SP Soc Urodynam & Female Urol C1 [Morrisroe, Shelby; Pollard, Matthew; Mossanen, Matthew; Anger, Jennifer] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA. [Shekelle, Paul] W Los Angeles VA Med Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0733-2467 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PY 2010 VL 29 IS 2 BP 308 EP 308 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 569JV UT WOS:000275593300145 ER PT J AU Jura, Y Townsend, M Grodstein, F AF Jura, Y. Townsend, M. Grodstein, F. TI CAFFEINE INTAKE AND RISK OF STRESS, URGENCY, AND MIXED URINARY INCONTINENCE SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT Joint Meeting of the International-Continence-Society/International-Urogynecological-Associat ion CY AUG 23-27, 2010 CL Toronto, CANADA SP Int Continence Soc, Int Urogynecol Assoc C1 [Jura, Y.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Townsend, M.] Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA. [Grodstein, F.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0733-2467 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PY 2010 VL 29 IS 6 MA 165 BP 1038 EP 1039 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 638OL UT WOS:000280904100164 ER PT J AU Weinstein, N Pulliam, S Wakamatsu, M AF Weinstein, N. Pulliam, S. Wakamatsu, M. TI MINIMALLY-INVASIVE SACRAL COLPOPEXY: COMPARISON OF OPERATIVE CHARACTERISTICS OF LAPAROSCOPIC AND ROBOTIC APPROACHES SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT Joint Meeting of the International-Continence-Society/International-Urogynecological-Associat ion CY AUG 23-27, 2010 CL Toronto, CANADA SP Int Continence Soc, Int Urogynecol Assoc C1 [Weinstein, N.; Pulliam, S.; Wakamatsu, M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cambridge, MA 02138 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0733-2467 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PY 2010 VL 29 IS 6 BP 1171 EP 1172 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 638OL UT WOS:000280904100255 ER PT J AU Burgio, KL Brubaker, L Richter, HE Wai, CY Litman, HJ France, DB Menefee, SA Sirls, LT Kraus, SR Johnson, HW Tennstedt, SL AF Burgio, Kathryn L. Brubaker, Linda Richter, Holly E. Wai, Clifford Y. Litman, Heather J. France, Diane Borello Menefee, Shawn A. Sirls, Larry T. Kraus, Stephen R. Johnson, Harry W. Tennstedt, Sharon L. TI Patient Satisfaction With Stress Incontinence Surgery SO NEUROUROLOGY AND URODYNAMICS LA English DT Article DE patient outcomes assessment; patient satisfaction; surgery; urinary incontinence ID QUALITY-OF-LIFE; URINARY-INCONTINENCE; SURGICAL-TREATMENT; WOMEN; SEVERITY; IMPROVEMENT; PREDICTORS; PHYSICIAN; OUTCOMES; HEALTH AB Aims: To identify predictors and correlates of patient satisfaction 24 months after Burch colpopexy or autologous fascial sling for treatment of stress urinary incontinence (SUI). Methods: Participants were the 655 randomized subjects in the Stress Incontinence Surgical Treatment Efficacy Trial (SISTEr). Variables potentially associated with satisfaction were tested in bivariate analysis, including demographics, baseline clinical characteristics of incontinence, and outcomes on validated subjective and objective measures. Satisfaction with treatment was defined as a response of "completely satisfied" or "mostly satisfied" on the Patient Satisfaction Questionnaire (PSQ) at 24 months. Variables significantly related to satisfaction were entered into multivariable regression models to test their independent association with satisfaction. Results: At 24 months post-surgery, 480 (73%) participants completed the PSQ. Mean (+/- SD) age of the sample was 52 ( 10) years and 77% were white. Most (82%) were completely or mostly satisfied with their surgery related to urine leakage. In the final multivariable model, patient satisfaction was associated with greater reduction in SUI symptoms (from baseline to 24 months; OR = 1.17, 95% CI: 1.10, 1.24) and greater reductions in symptom distress (OR = 1.16; CI: 1.08, 1.24). Lower odds of satisfaction were associated with greater urge incontinence symptoms at baseline (OR = 0.09, CI: 0.04, 0.22), detrusor overactivity at 24 months (OR = 0.29, CI: 0.12, 0.69), and a positive stress test at 24 months (OR = 0.45, CI: 0.22, 0.91). Conclusions: Stress incontinent women who also have urge incontinence symptoms may benefit from additional preoperative counseling to set realistic expectations about potential surgical outcomes or proactive treatment of urge incontinence symptoms to minimize their post-operative impact. Neurourol. Urodynam. 29:1403-1409, 2010. (C) 2010 Wiley-Liss, Inc. C1 [Burgio, Kathryn L.; Richter, Holly E.] Univ Alabama, Birmingham VA Med Ctr, Birmingham, AL 35233 USA. [Burgio, Kathryn L.] Dept Vet Affairs, Birmingham, AL USA. [Brubaker, Linda] Loyola Univ, Stritch Sch Med, Chicago, IL 60611 USA. [Wai, Clifford Y.] Univ Texas SW, Dallas, TX USA. [Litman, Heather J.; Tennstedt, Sharon L.] New England Res Inst, Watertown, MA 02172 USA. [France, Diane Borello] Duquesne Univ, Pittsburgh, PA 15219 USA. [Menefee, Shawn A.] Kaiser Permanente, San Diego, CA USA. [Sirls, Larry T.] William Beaumont Hosp, Royal Oak, MI 48072 USA. [Kraus, Stephen R.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Johnson, Harry W.] Univ Maryland, Baltimore, MD 21201 USA. RP Burgio, KL (reprint author), Univ Alabama, Birmingham VA Med Ctr, 11G,700 S 19th St, Birmingham, AL 35233 USA. EM kburgio@uab.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [U01 DK 58225, U01 DK58234, U01 DK58229, U01 DK58231, U01 DK60397, U01 DK60401, U01 DK60395, U01 DK60393, U01 DK60380, U01 DK60379]; National Institute of Child Health and Human Development; Office of Research in Women's Health of the National Institutes of Health FX This study was supported by cooperative agreements with the National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK 58225, U01 DK58234, U01 DK58229, U01 DK58231, U01 DK60397, U01 DK60401, U01 DK60395, U01 DK60393, U01 DK60380, U01 DK60379) and by the National Institute of Child Health and Human Development and Office of Research in Women's Health of the National Institutes of Health. NR 25 TC 15 Z9 15 U1 1 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0733-2467 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PY 2010 VL 29 IS 8 BP 1403 EP 1409 DI 10.1002/nau.20877 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 677UI UT WOS:000284016900008 PM 20976815 ER PT B AU Luo, HR Bajrami, B AF Luo, Hongbo R. Bajrami, Besnik BE DeFranco, JE TI REGULATION OF NEUTROPHIL HOMEOSTASIS BY SPONTANEOUS APOPTOTIC DEATH SO NEUTROPHILS: LIFESPAN, FUNCTIONS AND ROLES IN DISEASE SE Cell Biology Research Progress LA English DT Article; Book Chapter ID COLONY-STIMULATING FACTOR; NF-KAPPA-B; PROGRAMMED CELL-DEATH; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE-C; INFLAMMATORY RESPONSE SYNDROME; TNF-ALPHA; FAS LIGAND; IN-VITRO; CONSTITUTIVE APOPTOSIS AB Neutrophils are terminally differentiated and normally have a very short life-span (720 hr) in circulation and in tissue (1-4 days). Neutrophil death is a critical mechanism for modulating neutrophil homeostasis. Accelerated neutrophil death leads to a decrease of neutrophil counts (neutropenia), augments the chance of contracting bacterial or fungal infections, and impairs the resolution of such infections. On the other hand, delayed death and clearance of neutrophils in tissues causes unwanted and exaggerated inflammation. Thus, the death program in neutrophils needs to be well controlled to provide a perfect balance between their immune functions and their safe clearance. In this article, we summarize recent studies on the molecular mechanism of neutrophil spontaneous death. Intracellular factors and extracellular stimuli that can modulate neutrophil lifespan as well as the involvement of neutrophil apoptosis in infectious and inflammatory diseases are also discussed. C1 Dana Farber Harvard Canc Ctr, Boston, MA USA. Childrens Hosp Boston, Joint Program Transfus Med, Stem Cell Program, Dept Lab Med, Boston, MA USA. Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Luo, HR (reprint author), Karp Family Res Bldg,Room 10214,1 Blackfan Circle, Boston, MA 02115 USA. EM Hongbo.Luo@childrens.harvard.edu NR 122 TC 0 Z9 0 U1 1 U2 2 PU NOVA SCIENCE PUBLISHERS, INC PI HAUPPAUGE PA 400 OSER AVE, STE 1600, HAUPPAUGE, NY 11788-3635 USA BN 978-1-61668-666-6 J9 CELL BIO RES PROG PY 2010 BP 255 EP 270 PG 16 WC Cell Biology SC Cell Biology GA BTG01 UT WOS:000286869600008 ER PT S AU Hobson, A Voss, U AF Hobson, Allan Voss, Ursula BE Perry, E Collerton, D LeBeau, F Ashton, H TI Lucid dreaming and the bimodality of consciousness SO NEW HORIZONS IN THE NEUROSCIENCE OF CONSCIOUSNESS SE Advances in Consciousness Research LA English DT Article; Book Chapter ID REM-SLEEP; BRAIN; ORGANIZATION; BEHAVIOR; STATE AB In this essay, we develop our working hypothesis that consciousness in primates and humans is a state-dependent commodity that has at least two expressions. Waking and dreaming are two such states that differ in conscious awareness. In both states, we are perceptive and emotional. Whereas in dreaming, our thoughts are delusional, however, waking consciousness potentiates volition and reflection. We propose that dreaming is a state of primary consciousness, while usually, secondary consciousness is reserved to waking. Lucid dreaming is an extraordinary state with elements of both waking and dreaming and both primary and secondary consciousness. It is a rare but very real condition which is a promising tool in the study of the brain basis of consciousness. C1 [Hobson, Allan] Beth Israel Deaconness Med Ctr, Boston, MA 02215 USA. [Hobson, Allan] Harvard Med Ctr, Boston, MA USA. [Voss, Ursula] JW Goethe Univ Frankfurt, Bonn, Germany. RP Hobson, A (reprint author), Beth Israel Deaconness Med Ctr, Boston, MA 02215 USA. EM allan_hobson@hms.harvard.edu; u.voss@uni-bonn.de NR 21 TC 1 Z9 1 U1 2 U2 8 PU JOHN BENJAMINS B V PUBL PI AMSTERDAM ME PA PO BOX 36224, 1020 AMSTERDAM ME, NETHERLANDS SN 1381-589X BN 978-90-272-8804-2; 978-90-272-5215-9 J9 ADV CONSC RES PY 2010 VL 79 BP 155 EP 165 D2 10.1075/aicr.79 PG 11 WC Psychology, Biological; Neurosciences; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology GA BB5ZO UT WOS:000344249000017 ER PT J AU Zhang, ZD Kolodziej, AF Qi, JF Nair, SA Wang, XF Case, AW Greenfield, MT Graham, PB McMurry, TJ Caravan, P AF Zhang, Zhaoda Kolodziej, Andrew F. Qi, Jianfeng Nair, Shrikumar A. Wang, Xifang Case, April W. Greenfield, Matthew T. Graham, Philip B. McMurry, Thomas J. Caravan, Peter TI Effect of peptide-chelate architecture on the metabolic stability of peptide-based MRI contrast agents SO NEW JOURNAL OF CHEMISTRY LA English DT Article ID IN-VIVO; THROMBUS; COMPLEXES; EP-2104R; BINDING AB A strategy for preparing high relaxivity, metabolically-stable, peptide-based MR contrast agents is described. C1 [Zhang, Zhaoda; Caravan, Peter] Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Zhang, Zhaoda; Caravan, Peter] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. [Kolodziej, Andrew F.; Qi, Jianfeng; Nair, Shrikumar A.; Wang, Xifang; Case, April W.; Greenfield, Matthew T.; Graham, Philip B.; McMurry, Thomas J.] Epix Pharmaceut, Lexington, MA 02140 USA. RP Caravan, P (reprint author), Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, 149 13th St,Suite 2301, Charlestown, MA 02129 USA. EM caravan@nmr.mgh.harvard.edu NR 26 TC 5 Z9 5 U1 0 U2 9 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1144-0546 J9 NEW J CHEM JI New J. Chem. PY 2010 VL 34 IS 4 BP 611 EP 616 DI 10.1039/b9nj00787c PG 6 WC Chemistry, Multidisciplinary SC Chemistry GA 577AC UT WOS:000276190800007 ER PT B AU Thieu, KP Tsao, H AF Thieu, Khanh P. Tsao, Hensin BE Jemec, GBE Kemeny, L Miech, D TI Genetics of Non-Melanoma Skin Cancers and Associated Familial Syndromes SO NON-SURGICAL TREATMENT OF KERATINOCYTE SKIN CANCER LA English DT Article; Book Chapter ID BASAL-CELL CARCINOMA; MUIR-TORRE-SYNDROME; DUPRE-CHRISTOL SYNDROME; SEBACEOUS GLAND TUMORS; HEALING SQUAMOUS EPITHELIOMA; RAS ONCOGENE MUTATIONS; COARSE SPARSE HAIR; XERODERMA-PIGMENTOSUM; DNA-REPAIR; GORLIN-SYNDROME C1 [Tsao, Hensin] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. [Thieu, Khanh P.] Harvard Univ, Sch Med, Boston, MA USA. RP Tsao, H (reprint author), Massachusetts Gen Hosp, Dept Dermatol, Bartlett Hall 622,50 Blossom St, Boston, MA 02114 USA. EM htsao@partners.org NR 109 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-3-540-79340-3 PY 2010 BP 25 EP 38 DI 10.1007/978-3-540-79341-0_4 PG 14 WC Oncology SC Oncology GA BMD15 UT WOS:000271888400004 ER PT S AU Kovall, RA Blacklow, SC AF Kovall, Rhett A. Blacklow, Stephen C. BE Kopan, R TI MECHANISTIC INSIGHTS INTO NOTCH RECEPTOR SIGNALING FROM STRUCTURAL AND BIOCHEMICAL STUDIES SO NOTCH SIGNALING SE Current Topics in Developmental Biology LA English DT Review; Book Chapter ID ANKYRIN REPEAT DOMAIN; O-LINKED FUCOSE; RBP-J-KAPPA; ACTIVE TRANSCRIPTION COMPLEX; ACUTE LYMPHOBLASTIC-LEUKEMIA; LIGAND-BINDING DOMAIN; INHIBITS TUMOR-GROWTH; BARR-VIRUS EBNA2; DNA-BINDING; CRYSTAL-STRUCTURE AB Notch proteins are the receptors in a highly conserved signal transduction system used to communicate signals between cells that contact each other. Studies investigating structure function relationships in Notch signaling have gained substantial momentum in recent years. Here, we summarize the current understanding of the molecular logic of Notch signal transduction, emphasizing structural and biochemical studies of Notch receptors, their ligands, and complexes of intracellular Notch proteins with their target transcription factors. Recent advances in the structure-based modulation of Notch-signaling activity are also discussed. C1 [Kovall, Rhett A.] Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45221 USA. [Blacklow, Stephen C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA. [Blacklow, Stephen C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Blacklow, Stephen C.] Brigham & Womens Hosp, Boston, MA 02115 USA. RP Kovall, RA (reprint author), Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45221 USA. NR 173 TC 79 Z9 82 U1 1 U2 11 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0070-2153 BN 978-0-12-380914-8 J9 CURR TOP DEV BIOL JI Curr. Top. Dev. Biol. PY 2010 VL 92 BP 31 EP 71 DI 10.1016/S0070-2153(10)92002-4 PG 41 WC Developmental Biology SC Developmental Biology GA BQY36 UT WOS:000282103900002 PM 20816392 ER PT S AU Liu, JN Sato, C Cerletti, M Wagers, A AF Liu, Jianing Sato, Chihiro Cerletti, Massimiliano Wagers, Amy BE Kopan, R TI NOTCH SIGNALING IN THE REGULATION OF STEM CELL SELF-RENEWAL AND DIFFERENTIATION SO NOTCH SIGNALING SE Current Topics in Developmental Biology LA English DT Review; Book Chapter ID HEMATOPOIETIC PROGENITOR CELLS; ACUTE LYMPHOBLASTIC-LEUKEMIA; GAMMA-SECRETASE INHIBITORS; HUMAN SOMATIC-CELLS; AMYLOID PRECURSOR PROTEIN; GENE-EXPRESSION PROFILES; MYOGENIC SATELLITE CELLS; BONE-MARROW; IN-VIVO; MYELOID DIFFERENTIATION AB Stem cells are rare and unique precursor cells that participate in the building and rebuilding of tissues and organs during embryogenesis, postnatal growth, and injury repair. Stem cells are distinctively endowed with the ability to both self-renew and differentiate, such that they can replenish the stem cell pool while continuing to produce the differentiated daughter cells that are essential for tissue function. Stem cell self-renewal/differentiation decisions must be carefully controlled during organogenesis, tissue homeostasis, and regeneration, as failure in stem cell maintenance or activation can lead to progressive tissue wasting, while unchecked self-renewal is a hallmark of many cancers. Here, we review evidence implicating the Notch signaling pathway, an evolutionarily conserved cell fate determinant with widespread roles in a variety of tissues and organisms, as a crucial regulator of stem cell behavior. As discussed below, this pathway plays varied and critical roles at multiple stages of organismal development, in lineage-specific differentiation of pluripotent embryonic stem cells, and in controlling stem cell numbers and activity in the context of age-related tissue degeneration, injury-induced tissue repair, and malignancy. C1 [Liu, Jianing; Cerletti, Massimiliano; Wagers, Amy] Joslin Diabet Ctr, Boston, MA 02215 USA. [Sato, Chihiro] Washington Univ, St Louis, MO USA. RP Liu, JN (reprint author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA. NR 231 TC 115 Z9 117 U1 2 U2 20 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0070-2153 BN 978-0-12-380914-8 J9 CURR TOP DEV BIOL JI Curr. Top. Dev. Biol. PY 2010 VL 92 BP 367 EP + DI 10.1016/S0070-2153(10)91012-7 PG 15 WC Developmental Biology SC Developmental Biology GA BQY36 UT WOS:000282103900012 PM 20816402 ER PT S AU Spiegelman, BM AF Spiegelman, Bruce M. BE Clement, K Spiegelman, BM Christen, Y TI Transcriptional Regulation of Brown and White Adipogenesis SO NOVEL INSIGHTS INTO ADIPOSE CELL FUNCTIONS SE Research and Perspectives in Endocrine Interactions LA English DT Proceedings Paper CT 9th Symposium on Endocrine Research and Medicine Interactions CY DEC 04, 2009 CL Paris, FRANCE ID OBESITY; MICE; THERMOGENESIS; ADIPOCYTES; ABLATION; GENE AB There are two types of adipose cells in the mammalian body. White fat, the most common type of fat cell, is specialized for the storage of energy. White adipose tissue makes up 15% or more of the total body weight in healthy individuals, and this number can be very much higher in obese individuals. White adipocytes take up glucose or lipid from the blood and use them to synthesize triglycerides. These can then be released into blood as free fatty acids when the animal is fasting. Brown fat cells play a very different role in the body. These cells function to dissipate chemical energy in the form of heat, in response to cold or certain high-calorie diets. Physiologically, it is clear that brown fat serves as a very important defense against hypothermia and obesity. Brown fat plays its thermogenic function through the expression of UCP-1, a mitochondria! protein that catalyzes a proton leak across the inner membrane of the mitochondrion. Importantly, mice with a genetic reduction in either brown fat tissue or the UCP-1 gene have a greater tendency to develop obesity (Lowell et al. 1993; Feldmann et al. 2009). These data have increased the urgency to determine the transcriptional pathways by which these two types of fat cells develop. C1 Dana Farber Canc Inst, Boston, MA 02115 USA. RP Spiegelman, BM (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA. EM bruce_spiegelman@dfci.harvard.edu; bruce_spiegelman@dfci.harvard.edu NR 18 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 1861-2253 BN 978-3-642-13516-3 J9 RES PERSPECT END INT JI Res. Perspect. End. Int. PY 2010 BP 89 EP 92 DI 10.1007/978-3-642-13517-0_8 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BAP06 UT WOS:000304974600008 ER PT J AU Chen, L Shioda, T Coser, KR Lynch, MC Yang, CW Schmidt, EV AF Chen, Li Shioda, Toshi Coser, Kathryn R. Lynch, Mary C. Yang, Chuanwei Schmidt, Emmett V. TI Genome-wide analysis of YY2 versus YY1 target genes SO NUCLEIC ACIDS RESEARCH LA English DT Article ID TRANSCRIPTION FACTOR YY1; ANGIOGENESIS INHIBITOR THROMBOSPONDIN-1; RIBOSOMAL-PROTEIN PROMOTERS; SET ENRICHMENT ANALYSIS; C-MYC; DNA-BINDING; TRANSGENIC MICE; EXPRESSION; POLYCOMB; YIN-YANG-1 AB Yin Yang 1 (YY1) is a critical transcription factor controlling cell proliferation, development and DNA damage responses. Retrotranspositions have independently generated additional YY family members in multiple species. Although Drosophila YY1 [pleiohomeotic (Pho)] and its homolog [pleiohomeotic-like (Phol)] redundantly control homeotic gene expression, the regulatory contributions of YY1-homologs have not yet been examined in other species. Indeed, targets for the mammalian YY1 homolog YY2 are completely unknown. Using gene set enrichment analysis, we found that lentiviral constructs containing short hairpin loop inhibitory RNAs for human YY1 (shYY1) and its homolog YY2 (shYY2) caused significant changes in both shared and distinguishable gene sets in human cells. Ribosomal protein genes were the most significant gene set upregulated by both shYY1 and shYY2, although combined shYY1/2 knock downs were not additive. In contrast, shYY2 reversed the anti-proliferative effects of shYY1, and shYY2 particularly altered UV damage response, platelet-specific and mitochondrial function genes. We found that decreases in YY1 or YY2 caused inverse changes in UV sensitivity, and that their combined loss reversed their respective individual effects. Our studies show that human YY2 is not redundant to YY1, and YY2 is a significant regulator of genes previously identified as uniquely responding to YY1. C1 [Chen, Li; Shioda, Toshi; Coser, Kathryn R.; Lynch, Mary C.; Yang, Chuanwei; Schmidt, Emmett V.] Massachusetts Gen Hosp, Canc Res Ctr, Boston, MA 02114 USA. [Schmidt, Emmett V.] Harvard Univ, Sch Med, MassGen Hosp Children, Dept Pediat, Boston, MA 02114 USA. RP Schmidt, EV (reprint author), Massachusetts Gen Hosp, Canc Res Ctr, Boston, MA 02114 USA. EM schmidt@helix.mgh.harvard.edu FU PHS [RO1-CA63117, UO1 AI070330, RO1-CA69069]; Susan G. Komen for the Cure [FAS0703860]; AstraZeneca FX PHS RO1-CA63117 and UO1 AI070330; RO1-CA69069 to LC and EVS. The Molecular Profiling Laboratory of the Cancer Research Center at MGH provided service and technological support for microarray processing and data generation. Their support came from the Susan G. Komen for the Cure (FAS0703860) and the AstraZeneca-MGH Infrastructure Key Alliance Fund to TS. Funding for open access charge: UO1 AI070330. NR 74 TC 11 Z9 14 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-1048 J9 NUCLEIC ACIDS RES JI Nucleic Acids Res. PY 2010 VL 38 IS 12 BP 4011 EP 4026 DI 10.1093/nar/gkq112 PG 16 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 634EV UT WOS:000280563400013 PM 20215434 ER PT J AU Culhane, AC Schwarzl, T Sultana, R Picard, KC Picard, SC Lu, TH Franklin, KR French, SJ Papenhausen, G Correll, M Quackenbush, J AF Culhane, Aedin C. Schwarzl, Thomas Sultana, Razvan Picard, Kermshlise C. Picard, Shaita C. Lu, Tim H. Franklin, Katherine R. French, Simon J. Papenhausen, Gerald Correll, Mick Quackenbush, John TI GeneSigDB-a curated database of gene expression signatures SO NUCLEIC ACIDS RESEARCH LA English DT Article ID SET ENRICHMENT ANALYSIS; BREAST-CANCER; ANNOTATION; PREDICTORS; PROFILES AB The primary objective of most gene expression studies is the identification of one or more gene signatures; lists of genes whose transcriptional levels are uniquely associated with a specific biological phenotype. Whilst thousands of experimentally derived gene signatures are published, their potential value to the community is limited by their computational inaccessibility. Gene signatures are embedded in published article figures, tables or in supplementary materials, and are frequently presented using non-standard gene or probeset nomenclature. We present GeneSigDB (http://compbio.dfci.harvard.edu/genesigdb) a manually curated database of gene expression signatures. GeneSigDB release 1.0 focuses on cancer and stem cells gene signatures and was constructed from more than 850 publications from which we manually transcribed 575 gene signatures. Most gene signatures (n = 560) were successfully mapped to the genome to extract standardized lists of EnsEMBL gene identifiers. GeneSigDB provides the original gene signature, the standardized gene list and a fully traceable gene mapping history for each gene from the original transcribed data table through to the standardized list of genes. The GeneSigDB web portal is easy to search, allows users to compare their own gene list to those in the database, and download gene signatures in most common gene identifier formats. C1 [Culhane, Aedin C.] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. RP Culhane, AC (reprint author), Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. EM aedin@jimmy.harvard.edu; johnq@jimmy.harvard.edu FU US National Institutes of Health [R01-CA098522, 1P50HG004233]; Dana-Farber Cancer Institute Women's Cancer Program; Dana-Farber Strategic Plan Initiative FX Funding for open access charge: US National Institutes of Health (grant numbers R01-CA098522 and 1P50HG004233); the Dana-Farber Cancer Institute Women's Cancer Program; and funds provided through the Dana-Farber Strategic Plan Initiative. NR 15 TC 51 Z9 51 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-1048 J9 NUCLEIC ACIDS RES JI Nucleic Acids Res. PD JAN PY 2010 VL 38 SU 1 BP D716 EP D725 DI 10.1093/nar/gkp1015 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 579TV UT WOS:000276399100113 PM 19934259 ER PT J AU Spandidos, A Wang, XW Wang, HJ Seed, B AF Spandidos, Athanasia Wang, Xiaowei Wang, Huajun Seed, Brian TI PrimerBank: a resource of human and mouse PCR primer pairs for gene expression detection and quantification SO NUCLEIC ACIDS RESEARCH LA English DT Article ID REAL-TIME PCR; POLYMERASE-CHAIN-REACTION; OLIGONUCLEOTIDE PROBES; MOLECULAR BEACONS; NUCLEIC-ACID; DNA AMPLIFICATION; QUANTITATIVE PCR; CROSS-PLATFORM; GREEN-I; RT-PCR AB PrimerBank (http://pga. mgh. harvard. edu/primer bank/) is a public resource for the retrieval of human and mouse primer pairs for gene expression analysis by PCR and Quantitative PCR (QPCR). A total of 306 800 primers covering most known human and mouse genes can be accessed from the PrimerBank database, together with information on these primers such as T(m), location on the transcript and amplicon size. For each gene, at least one primer pair has been designed and in many cases alternative primer pairs exist. Primers have been designed to work under the same PCR conditions, thus facilitating high- throughput QPCR. There are several ways to search for primers for the gene(s) of interest, such as by: GenBank accession number, NCBI protein accession number, NCBI gene ID, PrimerBank ID, NCBI gene symbol or gene description (keyword). In all, 26 855 primer pairs covering most known mouse genes have been experimentally validated by QPCR, agarose gel analysis, sequencing and BLAST, and all validation data can be freely accessed from the PrimerBank web site. C1 [Spandidos, Athanasia; Wang, Xiaowei; Wang, Huajun; Seed, Brian] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Computat & Integrat Biol, Boston, MA 02114 USA. [Spandidos, Athanasia; Wang, Xiaowei; Wang, Huajun; Seed, Brian] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA. RP Seed, B (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Computat & Integrat Biol, 185 Cambridge St, Boston, MA 02114 USA. EM bseed@ccib.mgh.harvard.edu FU National Institutes of Health Program for Genomic Applications [U01 HL66678]; Center for Computational and Integrative Biology; Massachusetts General Hospital FX National Institutes of Health Program for Genomic Applications (grant U01 HL66678). Funding for open access charge: Center for Computational and Integrative Biology, Massachusetts General Hospital. NR 70 TC 199 Z9 200 U1 1 U2 20 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-1048 J9 NUCLEIC ACIDS RES JI Nucleic Acids Res. PD JAN PY 2010 VL 38 SU 1 BP D792 EP D799 DI 10.1093/nar/gkp1005 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 579TV UT WOS:000276399100124 ER PT J AU Melchior, L Carter, B Helsley, A Ernest, JK Friesner, D AF Melchior, Lynne Carter, Becky Helsley, Anne Ernest, Janice K. Friesner, Dan TI The Diabetes Disease State Management Exemplar SO NURSING ECONOMICS LA English DT Article ID SELF-MANAGEMENT; PROGRAM; METAANALYSIS AB One relatively new method of providing care to patients with chronic disease is disease state management (DSM). Diabetes is particularly interesting to study because it is not only one of the most prevalent chronic diseases, but it is also a disease for which DSM is highly cost effective. Similarly, registered nurses represent the group of practitioners most likely to provide a comprehensive set of DSM activities. This experiment was conducted in fall 2005 at a nationally recognized diabetes center which is affiliated with a large, full service medical center The results suggest at least three forms of content delivery - in-class, at-home study packets, and online modules are all equally effective at enhancing diabetes DSM knowledge. C1 [Melchior, Lynne; Carter, Becky] St Marys Hosp, Joslin Diabet Ctr, Evansville, IN USA. [Ernest, Janice K.] St Marys Hosp, Cardiovasc Serv, Evansville, IN USA. [Friesner, Dan] N Dakota State Univ, Fargo, ND 58105 USA. RP Melchior, L (reprint author), St Marys Hosp, Joslin Diabet Ctr, Evansville, IN USA. NR 15 TC 0 Z9 0 U1 0 U2 0 PU JANNETTI PUBLICATIONS, INC PI PITMAN PA EAST HOLLY AVENUE, BOX 56, PITMAN, NJ 08071-0056 USA SN 0746-1739 J9 NURS ECON JI Nurs. Econ. PD JAN-FEB PY 2010 VL 28 IS 1 BP 7 EP + PG 12 WC Nursing SC Nursing GA 554II UT WOS:000274428300003 PM 20306874 ER PT J AU Reynolds, MA Branch-Mays, GL Dawson, DR Novak, KF Ebersole, JL Novak, MJ Gunsolley, JC Holt, SC Mattison, JA Ingram, DK AF Reynolds, Mark A. Branch-Mays, Grishondra L. Dawson, Dolphus R. Novak, Karen F. Ebersole, Jeffrey L. Novak, M. John Gunsolley, John C. Holt, Stanley C. Mattison, Julie A. Ingram, Donald K. TI Differential sex effects of nutritional status on inflammatory periodontal disease in non-human primates Response SO NUTRITION LA English DT Letter C1 [Dawson, Dolphus R.; Novak, Karen F.; Ebersole, Jeffrey L.; Novak, M. John] Univ Kentucky, Coll Dent, Ctr Oral Hlth Res, Lexington, KY USA. [Gunsolley, John C.] Virginia Commonwealth Univ, Sch Dent, Richmond, VA USA. [Holt, Stanley C.] Forsyth Inst, Boston, MA USA. [Mattison, Julie A.] NIA, Lab Expt Gerontol, Intramural Res Program, NIH, Baltimore, MD 21224 USA. [Ingram, Donald K.] Louisiana State Univ Syst, Pennington Biomed Res Ctr, Nutr Neurosci & Aging Lab, Baton Rouge, LA USA. [Reynolds, Mark A.; Branch-Mays, Grishondra L.] Univ Maryland, Sch Dent, Dept Periodont, Baltimore, MD 21201 USA. RP Reynolds, MA (reprint author), Univ Maryland, Sch Dent, Dept Periodont, Baltimore, MD 21201 USA. NR 5 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0899-9007 J9 NUTRITION JI Nutrition PD JAN PY 2010 VL 26 IS 1 BP 140 EP 140 DI 10.1016/j.nut.2009.09.019 PG 1 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 578XZ UT WOS:000276331800020 ER PT J AU Fang, SC Eisen, EA Cavallari, JM Mittleman, MA Christiani, DC AF Fang, S. C. Eisen, E. A. Cavallari, J. M. Mittleman, M. A. Christiani, D. C. TI Circulating adhesion molecules after short-term exposure to particulate matter among welders SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID CORONARY-HEART-DISEASE; DIESEL-EXHAUST INHALATION; AIR-POLLUTION; ENDOTHELIAL DYSFUNCTION; MYOCARDIAL-INFARCTION; FINE PARTICLES; HEALTHY-ADULTS; MORTALITY; INFLAMMATION; MARKERS AB Background: Studies from several countries indicate that welders experience increased risk of mortality and morbidity from ischaemic heart disease. Although the underlying mechanisms are unclear, vascular responses to particulate matter contained in welding fumes may play a role. To investigate this, we studied the acute effects of welding fume exposure on the endothelial component of vascular function, as measured by circulating adhesion molecules involved in leukocyte adhesion (sICAM-1 and sVCAM-1) and coagulation (vWF). Methods: A panel of 26 male welders was studied repeatedly across a 6 h work-shift on a high exposure welding day and/or a low exposure non-welding day. Personal PM(2.5) exposure was measured throughout the work-shift. Blood samples were collected in the morning (baseline) prior to the exposure period, immediately after the exposure period, and the following morning. To account for the repeated measurements, we used linear mixed models to evaluate the effects of welding (binary) and PM(2.5) (continuous) exposure on each blood marker, adjusting for baseline blood marker concentration, smoking, age and time of day. Results: Welding and PM(2.5) exposure were significantly associated with a decrease in sVCAM-1 in the afternoon and the following morning and an increase in vWF in the afternoon. Conclusions: The data suggest that welding and short-term occupational exposure to PM(2.5) may acutely affect the endothelial component of vascular function. C1 [Fang, S. C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Environm & Occupat Med & Epidemiol Program, Boston, MA 02115 USA. [Eisen, E. A.] Univ Calif Berkeley, Sch Publ Hlth, Dept Environm Hlth Sci, Berkeley, CA 94720 USA. [Mittleman, M. A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Mittleman, M. A.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA. [Christiani, D. C.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP Fang, SC (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Environm & Occupat Med & Epidemiol Program, 665 Huntington Ave,FXB 103, Boston, MA 02115 USA. EM sfang@hsph.harvard.edu FU National Institute for Environmental Health Sciences (NIEHS) [ES009860, ES00002]; National Institute for Occupational Safety and Health (NIOSH) [T42 OH008416]; NIOSH and NIEHS [T42 OH008416, T32 ES07069] FX The National Institute for Environmental Health Sciences (NIEHS) (grant numbers ES009860 and ES00002) supported this work. SF was supported by National Institute for Occupational Safety and Health (NIOSH) training grant T42 OH008416 and JC was supported by NIOSH and NIEHS training grants T42 OH008416 and T32 ES07069. NR 35 TC 8 Z9 8 U1 0 U2 2 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1351-0711 J9 OCCUP ENVIRON MED JI Occup. Environ. Med. PD JAN PY 2010 VL 67 IS 1 BP 11 EP 16 DI 10.1136/oem.2008.043794 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 535TR UT WOS:000272994700003 PM 19736177 ER PT B AU Applebaum, A Brennan, M AF Applebaum, Allison Brennan, Mark BE Brennan, M Karpiak, SE Shippy, RA Cantor, MH TI MENTAL HEALTH AND DEPRESSION SO OLDER ADULTS WITH HIV: AN IN-DEPTH EXAMINATION OF AN EMERGING POPULATION SE HIV AIDS-Medical Social and Psychological Aspects LA English DT Article; Book Chapter ID FACTORS AFFECTING ADHERENCE; SUBSTANCE USE DISORDERS; ANTIRETROVIRAL THERAPY; HIV DISEASE; UNITED-STATES; OLDER-ADULTS; DRUG-USE; HIV/AIDS; WOMEN; PREVALENCE C1 [Brennan, Mark] New York City Dept Aging, New York, NY USA. [Applebaum, Allison] Boston Univ, Dept Clin Psychol, Boston, MA 02215 USA. [Applebaum, Allison] Massachusetts Gen Hosp, Behav Med Serv, Boston, MA 02114 USA. RP Applebaum, A (reprint author), Boston Univ, Dept Clin Psychol, Boston, MA 02215 USA. NR 43 TC 1 Z9 1 U1 2 U2 3 PU NOVA SCIENCE PUBLISHERS, INC PI HAUPPAUGE PA 400 OSER AVE, STE 1600, HAUPPAUGE, NY 11788-3635 USA BN 978-1-60876-054-1 J9 HIV AIDS-MED SOC PSY PY 2010 BP 27 EP 34 PG 8 WC Gerontology; Public, Environmental & Occupational Health SC Geriatrics & Gerontology; Public, Environmental & Occupational Health GA BQO41 UT WOS:000281447100003 ER PT B AU Applebaum, A Brennan, M AF Applebaum, Allison Brennan, Mark BE Brennan, M Karpiak, SE Shippy, RA Cantor, MH TI SUBSTANCE AND ALCOHOL USE SO OLDER ADULTS WITH HIV: AN IN-DEPTH EXAMINATION OF AN EMERGING POPULATION SE HIV AIDS-Medical Social and Psychological Aspects LA English DT Article; Book Chapter ID SEXUAL RISK BEHAVIORS; DRUG-USERS; ANTIRETROVIRAL THERAPY; BISEXUAL MEN; PSYCHOLOGICAL DISTRESS; HIV-INFECTION; UNITED-STATES; ADHERENCE; GENDER; GAY C1 [Applebaum, Allison] Boston Univ, Dept Clin Psychol, Boston, MA 02215 USA. [Brennan, Mark] New York City Dept Aging, New York, NY USA. [Applebaum, Allison] Massachusetts Gen Hosp, Behav Med Serv, Boston, MA 02114 USA. RP Applebaum, A (reprint author), Boston Univ, Dept Clin Psychol, Boston, MA 02215 USA. NR 21 TC 0 Z9 0 U1 1 U2 1 PU NOVA SCIENCE PUBLISHERS, INC PI HAUPPAUGE PA 400 OSER AVE, STE 1600, HAUPPAUGE, NY 11788-3635 USA BN 978-1-60876-054-1 J9 HIV AIDS-MED SOC PSY PY 2010 BP 35 EP 42 PG 8 WC Gerontology; Public, Environmental & Occupational Health SC Geriatrics & Gerontology; Public, Environmental & Occupational Health GA BQO41 UT WOS:000281447100004 ER PT B AU Brennan, M Applebaum, A AF Brennan, Mark Applebaum, Allison BE Brennan, M Karpiak, SE Shippy, RA Cantor, MH TI LONELINESS AMONG OLDER ADULTS WITH HIV SO OLDER ADULTS WITH HIV: AN IN-DEPTH EXAMINATION OF AN EMERGING POPULATION SE HIV AIDS-Medical Social and Psychological Aspects LA English DT Article; Book Chapter ID POSITIVE MEN; RISK; COMMUNITY; HIV/AIDS; SUPPORT; SEX C1 [Brennan, Mark] New York City Dept Aging, New York, NY USA. [Applebaum, Allison] Massachusetts Gen Hosp, Behav Med Serv, Boston, MA 02114 USA. [Applebaum, Allison] Boston Univ, Dept Clin Psychol, Boston, MA 02215 USA. RP Brennan, M (reprint author), State Soc Aging New York, New York, NY USA. NR 17 TC 0 Z9 0 U1 0 U2 0 PU NOVA SCIENCE PUBLISHERS, INC PI HAUPPAUGE PA 400 OSER AVE, STE 1600, HAUPPAUGE, NY 11788-3635 USA BN 978-1-60876-054-1 J9 HIV AIDS-MED SOC PSY PY 2010 BP 75 EP 78 PG 4 WC Gerontology; Public, Environmental & Occupational Health SC Geriatrics & Gerontology; Public, Environmental & Occupational Health GA BQO41 UT WOS:000281447100008 ER PT J AU Chabner, BA AF Chabner, Bruce A. TI Academia-Pharma Intersect: Providing a Broader Perspective on Drug Development Synergies between Academia and Industry SO ONCOLOGIST LA English DT Editorial Material C1 [Chabner, Bruce A.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Chabner, Bruce A.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. RP Chabner, BA (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 J9 ONCOLOGIST JI Oncologist PY 2010 VL 15 IS 1 BP 1 EP 1 DI 10.1634/theoncologist.2009-0338 PG 1 WC Oncology SC Oncology GA 550SF UT WOS:000274149000001 PM 20086167 ER PT J AU Neal, JW AF Neal, Joel W. TI Histology Matters: Individualizing Treatment in Non-Small Cell Lung Cancer SO ONCOLOGIST LA English DT Editorial Material ID PHASE-III; KRAS MUTATION; CHEMOTHERAPY; METAANALYSIS; CARBOPLATIN; PACLITAXEL; GEFITINIB; TRIALS C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. RP Neal, JW (reprint author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St,Lawrence House 221, Boston, MA 02114 USA. EM jwneal@partners.org NR 15 TC 19 Z9 20 U1 0 U2 0 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 J9 ONCOLOGIST JI Oncologist PY 2010 VL 15 IS 1 BP 3 EP 5 DI 10.1634/theoncologist.2009-0306 PG 3 WC Oncology SC Oncology GA 550SF UT WOS:000274149000002 PM 20086166 ER PT J AU Zhu, AX Hong, TS Hezel, AF Kooby, DA AF Zhu, Andrew X. Hong, Theodore S. Hezel, Aram F. Kooby, David A. TI Current Management of Gallbladder Carcinoma SO ONCOLOGIST LA English DT Article ID ADVANCED BILIARY-TRACT; PHASE-II TRIAL; GROWTH-FACTOR-RECEPTOR; EXTERNAL-BEAM RADIOTHERAPY; FINDING RESIDUAL DISEASE; EXTRAHEPATIC BILE-DUCT; SURGICAL-TREATMENT; RADIATION-THERAPY; RADICAL RESECTION; LAPAROSCOPIC CHOLECYSTECTOMY AB Gallbladder cancer (GBC) represents the most common and aggressive type among the biliary tree cancers (BTCs). Complete surgical resection offers the only chance for cure; however, only 10% of patients with GBC present with early-stage disease and are considered surgical candidates. Among those patients who do undergo "curative" resection, recurrence rates are high. There are no established adjuvant treatments in this setting. Patients with unresectable or metastatic GBC have a poor prognosis. There has been a paucity of randomized phase III data in this field. A recent report demonstrated longer overall survival with gemcitabine in combination with cisplatin than with gemcitabine alone in patients with advanced or metastatic BTCs. Molecularly targeted agents are under development. In this review, we attempt to discuss the current status and key issues involved in the management of GBC. The Oncologist 2010;15:168-181 C1 [Zhu, Andrew X.] Harvard Univ, Ctr Canc, Tucker Gosnell Ctr Gastrointestinal Canc, Massachusetts Gen Hosp,Med Sch, Boston, MA 02114 USA. [Hezel, Aram F.] Univ Rochester, Sch Med, James P Wilmot Canc Ctr, Rochester, NY USA. [Kooby, David A.] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA. RP Zhu, AX (reprint author), Harvard Univ, Ctr Canc, Tucker Gosnell Ctr Gastrointestinal Canc, Massachusetts Gen Hosp,Med Sch, LH-POB 232,55 Fruit St, Boston, MA 02114 USA. EM azhu@partners.org NR 110 TC 86 Z9 106 U1 0 U2 6 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 EI 1549-490X J9 ONCOLOGIST JI Oncologist PY 2010 VL 15 IS 2 BP 168 EP 181 DI 10.1634/theoncologist.2009-0302 PG 14 WC Oncology SC Oncology GA 561SH UT WOS:000274998700007 PM 20147507 ER PT J AU Chabner, BA AF Chabner, Bruce A. TI A tribute to Eli Glatstein - About Eli SO ONCOLOGIST LA English DT Biographical-Item C1 [Chabner, Bruce A.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Chabner, Bruce A.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP Chabner, BA (reprint author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St,LH 214, Boston, MA 02114 USA. EM bchabner@partners.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 J9 ONCOLOGIST JI Oncologist PY 2010 VL 15 IS 4 BP 329 EP 331 DI 10.1634/theoncologist.2009-S108 PG 3 WC Oncology SC Oncology GA 587AD UT WOS:000276957400001 PM 20413637 ER PT J AU Tejpar, S Bertagnolli, M Bosman, F Lenz, HJ Garraway, L Waldman, F Warren, R Bild, A Collins-Brennan, D Hahn, H Harkin, DP Kennedy, R Ilyas, M Morreau, H Proutski, V Swanton, C Tomlinson, I Delorenzi, M Fiocca, R Van Cutsem, E Roth, A AF Tejpar, Sabine Bertagnolli, Monica Bosman, Fred Lenz, Heinz-Joseph Garraway, Levi Waldman, Frederic Warren, Robert Bild, Andrea Collins-Brennan, Denise Hahn, Hejin Harkin, D. Paul Kennedy, Richard Ilyas, Mohammad Morreau, Hans Proutski, Vitali Swanton, Charles Tomlinson, Ian Delorenzi, Mauro Fiocca, Roberto Van Cutsem, Eric Roth, Arnaud TI Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery SO ONCOLOGIST LA English DT Article ID THYMIDYLATE SYNTHASE EXPRESSION; METASTATIC COLORECTAL-CANCER; SURGICAL ADJUVANT BREAST; MICROSATELLITE-INSTABILITY STATUS; ISLAND METHYLATOR PHENOTYPE; MISMATCH-REPAIR STATUS; KIRSTEN RAS MUTATIONS; MESSENGER-RNA LEVELS; 18Q ALLELIC LOSS; GENE-EXPRESSION AB The number of agents that are potentially effective in the adjuvant treatment of locally advanced resectable colon cancer is increasing. Consequently, it is important to ascertain which subgroups of patients will benefit from a specific treatment. Despite more than two decades of research into the molecular genetics of colon cancer, there is a lack of prognostic and predictive molecular biomarkers with proven utility in this setting. A secondary objective of the Pan European Trials in Adjuvant Colon Cancer-3 trial, which compared irinotecan in combination with 5-fluorouracil and leucovorin in the postoperative treatment of stage III and stage II colon cancer patients, was to undertake a translational research study to assess a panel of putative prognostic and predictive markers in a large colon cancer patient cohort. The Cancer and Leukemia Group B 89803 trial, in a similar design, also investigated the use of prognostic and predictive biomarkers in this setting. In this article, the authors, who are coinvestigators from these trials and performed similar investigations of biomarker discovery in the adjuvant treatment of colon cancer, review the current status of biomarker research in this field, drawing on their experiences and considering future strategies for biomarker discovery in the postgenomic era. The Oncologist 2010; 15: 390-404 C1 [Tejpar, Sabine; Van Cutsem, Eric] Univ Hosp Gasthuisberg, Digest Oncol Unit, B-3000 Louvain, Belgium. [Bertagnolli, Monica; Collins-Brennan, Denise] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. [Bosman, Fred] Univ Lausanne, Dept Pathol, Lausanne, Switzerland. [Lenz, Heinz-Joseph] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Garraway, Levi] Dana Farber Canc Inst, Boston, MA 02115 USA. [Waldman, Frederic] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA. [Warren, Robert] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. [Bild, Andrea] Univ Utah, Dept Pharmacol & Toxicol, Salt Lake City, UT 84112 USA. [Hahn, Hejin] Virginia Mason Med Ctr, Dept Pathol, Seattle, WA 98101 USA. [Harkin, D. Paul; Kennedy, Richard; Proutski, Vitali] Almac Diagnost, Cambridge, MA USA. [Ilyas, Mohammad] Univ Nottingham, Sch Mol Med Sci, Nottingham NG7 2RD, England. [Morreau, Hans] Leiden Univ, Dept Pathol, Med Ctr, Leiden, Netherlands. [Swanton, Charles] Royal Marsden Hosp, London Res Inst, Canc Res UK, London SW3 6JJ, England. [Tomlinson, Ian] Canc Res UK, London Res Inst, Mol & Populat Genet Lab, London, England. [Delorenzi, Mauro] Swiss Inst Bioinformat, Lausanne, Switzerland. [Fiocca, Roberto] Univ Genoa, Dept Surg & Morphol Sci, Genoa, Italy. [Roth, Arnaud] Univ Hosp Geneva, Geneva, Switzerland. RP Tejpar, S (reprint author), Univ Hosp Gasthuisberg, Digest Oncol Unit, Herestr 49, B-3000 Louvain, Belgium. EM sabine.tejpar@uz.kuleuven.ac.be RI Kennedy, Richard/J-3489-2012; Fiocca, Roberto/K-9705-2016 OI Kennedy, Richard/0000-0003-4737-6163; Fiocca, Roberto/0000-0002-8856-6185 FU Pfizer; Genentech; ImClone; Roche; BMS; Merck; Novartis; NCCN FX Disclosures: Sabine Tejpar: None; Monica Bertagnolli: Honoraria: Pfizer; Fred Bosman: Research funding/contracted research: Pfizer; Heinz-Joseph Lenz: Intellectual property rights/inventor/patent holder: Abraxis; Research funding/contracted research: Genentech, ImClone, Roche, BMS, Merck, Pfizer; Ownership interest: Responsegenetics; Levi Garraway: Consultant/advisory role: Novartis; Research funding/contracted research: Novartis; Frederic Waldman: None; Robert Warren: Research funding/contracted research: NCCN; Andrea Bild: None; Denise Collins-Brennan: None; Hejin Hahn: None; D. Paul Harkin: Employment/leadership position: Almac Diagnostics; Ownership interest: Almac Diagnostics; Richard Kennedy: Employment/leadership position: Almac Diagnostics; Mohammad Ilyas: None; Hans Morreau: None; Vitali Proutski: None; Charles Swanton: None; Ian Tomlinson: None; Mauro Delorenzi: None; Roberto Fiocca: Research funding/contracted research: Pfizer; Eric Van Cutsem: Research funding/contracted research: Pfizer; Arnaud Roth: Honoraria: Pfizer. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers. NR 155 TC 88 Z9 89 U1 1 U2 9 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 J9 ONCOLOGIST JI Oncologist PY 2010 VL 15 IS 4 BP 390 EP 404 DI 10.1634/theoncologist.2009-0233 PG 15 WC Oncology SC Oncology GA 587AD UT WOS:000276957400009 PM 20350999 ER PT J AU Duda, DG Willett, CG Ancukiewicz, M di Tomaso, E Shah, M Czito, BG Bentley, R Poleski, M Lauwers, GY Carroll, M Tyler, D Mantyh, C Shellito, P Clark, JW Jain, RK AF Duda, Dan G. Willett, Christopher G. Ancukiewicz, Marek di Tomaso, Emmanuelle Shah, Mira Czito, Brian G. Bentley, Rex Poleski, Martin Lauwers, Gregory Y. Carroll, Madeline Tyler, Douglas Mantyh, Christopher Shellito, Paul Clark, Jeffrey W. Jain, Rakesh K. TI Plasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer SO ONCOLOGIST LA English DT Article DE Bevacizumab; sVEGFR-1; Biomarker; Rectal cancer; Chemoradiation; Toxicity ID METASTATIC COLORECTAL-CANCER; ENDOTHELIAL GROWTH-FACTOR; ANTIANGIOGENIC THERAPY; CHEMOTHERAPY; CHEMORADIOTHERAPY; FLUOROURACIL; LEUCOVORIN; REGRESSION; RADIATION; CETUXIMAB AB We explored plasma and urinary concentrations of two members of the vascular endothelial growth factor (VEGF) family and their receptors as potential response and toxicity biomarkers of bevacizumab with neoadjuvant chemoradiation in patients with localized rectal cancer. The concentrations of VEGF, placental growth factor (PlGF), soluble VEGF receptor 1 (sVEGFR-1), and sVEGFR-2 were measured in plasma and urine at baseline and during treatment. Pretreatment values and changes over time were analyzed as potential biomarkers of pathological response to treatment as well as for acute toxicity in patients with locally advanced rectal cancer treated prospectively in 2002-2008 with neoadjuvant bevacizumab, 5-fluorouracil, radiation therapy, and surgery in a phase I/II trial. Of all biomarkers, pretreatment plasma sVEGFR-1-an endogenous blocker of VEGF and PlGF, and a factor linked with "vascular normalization"-was associated with both primary tumor regression and the development of adverse events after neoadjuvant bevacizumab and chemoradiation. Based on the findings in this exploratory study, we propose that plasma sVEGFR-1 should be further studied as a potential biomarker to stratify patients in future studies of bevacizumab and/or cytotoxics in the neoadjuvant setting. The Oncologist 2010;15:577-583 C1 [Willett, Christopher G.; Shah, Mira; Czito, Brian G.; Carroll, Madeline] Duke Univ, Dept Radiat Oncol, Med Ctr, Durham, NC 27710 USA. [Bentley, Rex] Duke Univ, Dept Pathol, Med Ctr, Durham, NC 27710 USA. [Poleski, Martin; Tyler, Douglas; Mantyh, Christopher] Duke Univ, Dept Med & Surg, Med Ctr, Durham, NC 27710 USA. [Jain, Rakesh K.] Massachusetts Gen Hosp, Steele Lab, Dept Radiat Oncol, Boston, MA 02114 USA. [Lauwers, Gregory Y.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Shellito, Paul] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Clark, Jeffrey W.] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA. RP Willett, CG (reprint author), Duke Univ, Dept Radiat Oncol, Med Ctr, Box 3085, Durham, NC 27710 USA. EM christopher.willett@duke.edu; jain@steele.mgh.harvard.edu FU NIH [R21-CA99237, P01-CA80124, R01-CA115767, R01-CA85140, R01-CA126642]; Federal Share/NCI Proton Beam Program Income; National Foundation for Cancer Research FX We thank Kathryn Kinzel for technical support. This study was partially supported by NIH grants R21-CA99237, P01-CA80124, R01-CA115767, R01-CA85140, and R01-CA126642 and Federal Share/NCI Proton Beam Program Income grants, and by the National Foundation for Cancer Research. NR 25 TC 37 Z9 37 U1 1 U2 1 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 J9 ONCOLOGIST JI Oncologist PY 2010 VL 15 IS 6 BP 577 EP 583 DI 10.1634/theoncologist.2010-0029 PG 7 WC Oncology SC Oncology GA 615DQ UT WOS:000279113300006 PM 20484123 ER PT J AU Lannen, P Wolfe, J Mack, J Onelov, E Nyberg, U Kreicbergs, U AF Lannen, Patrizia Wolfe, Joanne Mack, Jennifer Onelov, Erik Nyberg, Ullakarin Kreicbergs, Ulrika TI Absorbing Information about a Child's Incurable Cancer SO ONCOLOGY LA English DT Article DE Prognostic information; Childhood cancer; Communication ID INTENSIVE-CARE-UNIT; OF-LIFE CARE; PEDIATRIC PALLIATIVE CARE; FAMILY PERSPECTIVES; BAD-NEWS; COMMUNICATION; PROGNOSIS; QUALITY; PARENTS; END AB Purpose: To assess parents' ability to absorb information that their child's cancer was incurable and to identify factors associated with parents' ability to absorb this information. Patients and Methods: An anonymous mail-in questionnaire study was performed as a population-based investigation in Sweden between August and October of 2001. 449 parents who lost a child to cancer 4-9 years earlier (response rate 80%) completed the survey. 191 (43%) of the bereaved parents were fathers and 251 (56%) were mothers. Results: Sixty percent of parents (n = 258) reported that they were able to absorb the information that their child's illness was incurable. Parents were better able to absorb this information when the information was given in an appropriate manner (RR 1.6; CI 1.3-2.0), when they shared their problems with others during the child's illness course (RR 1.4; CI 1.1-1.8) and when they had no history of depression (RR 1.3; CI 1.0-1.8). Parents who reported that they were able to absorb the information were more likely to have expressed their farewells to the child in their desired manner (RR 1.3; CI 1.0-1.5). Conclusions: Parents who received information that their child's illness was incurable in an appropriate manner are more likely to absorb that information. Whether or not parents are able to absorb the information that their child's cancer is incurable has implications in terms of preparation for the child's impending death. Copyright (C) 2010 S. Karger AG, Basel C1 [Lannen, Patrizia; Kreicbergs, Ulrika] Childrens Hosp, Phyllis F Cantor Ctr, Boston, MA 02115 USA. [Wolfe, Joanne; Mack, Jennifer] Childrens Hosp, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA. [Wolfe, Joanne; Mack, Jennifer] Childrens Hosp, Ctr Outcomes & Policy Res, Dana Farber Canc Inst, Boston, MA 02115 USA. [Wolfe, Joanne; Mack, Jennifer] Childrens Hosp, Dept Med, Boston, MA 02115 USA. [Lannen, Patrizia] Univ Bern, Inst Social & Prevent Med, Bern, Switzerland. [Onelov, Erik; Nyberg, Ullakarin] Karolinska Inst, Div Clin Canc Epidemiol, SE-17176 Stockholm, Sweden. [Kreicbergs, Ulrika] Karolinska Inst, Dept Women & Childs Hlth, SE-17176 Stockholm, Sweden. [Nyberg, Ullakarin] Karolinska Inst, St Gorans Hosp, Dept Clin Neurosci, SE-17176 Stockholm, Sweden. RP Kreicbergs, U (reprint author), Karolinska Inst, Dept Women & Childs Hlth Q6 05, SE-17176 Stockholm, Sweden. EM ulrika.kreicbergs@ki.se FU Swedish Children's Cancer Foundation; Swedish Society for Medical Research; Swiss Cancer League [KLS-01645-02-2005]; National Cancer Institute [NCI 5 K07 CA 096746]; American Cancer Society FX We thank the parents who made this study possible by bravely sharing their experiences with us. The study was supported by grants from the Swedish Children's Cancer Foundation, the Swedish Society for Medical Research, the Swiss Cancer League (KLS-01645-02-2005), the National Cancer Institute (No. NCI 5 K07 CA 096746), and the American Cancer Society. NR 38 TC 12 Z9 13 U1 1 U2 6 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0030-2414 J9 ONCOLOGY-BASEL JI Oncology PY 2010 VL 78 IS 3-4 BP 259 EP 266 DI 10.1159/000315732 PG 8 WC Oncology SC Oncology GA 618CZ UT WOS:000279330300013 PM 20523086 ER PT B AU Dahlberg, SE Gray, RJ AF Dahlberg, Suzanne E. Gray, Robert J. BE Kelly, WK Halabi, S TI Noninferiority Trials in Oncology SO ONCOLOGY CLINICAL TRIALS LA English DT Article; Book Chapter ID CELL LUNG-CANCER; EQUIVALENCE RANDOMIZED-TRIALS; CLINICAL-TRIALS; NON-INFERIORITY; BREAST-CANCER; SAMPLE-SIZE; PHASE-III; CHEMOTHERAPY; GEMCITABINE; CISPLATIN C1 [Dahlberg, Suzanne E.; Gray, Robert J.] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. RP Dahlberg, SE (reprint author), Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, 665 Huntington Ave, Boston, MA 02115 USA. NR 22 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-38-9 PY 2010 BP 101 EP 107 PG 7 WC Oncology; Medicine, Research & Experimental; Pharmacology & Pharmacy SC Oncology; Research & Experimental Medicine; Pharmacology & Pharmacy GA BMU36 UT WOS:000273577900013 ER PT J AU McCleary, NJ Meyerhardt, JA AF McCleary, Nadine Jackson Meyerhardt, Jeffrey A. TI New Developments in the Adjuvant Therapy of Stage II Colon Cancer Risk Assessments in the Older Patient SO ONCOLOGY-NEW YORK LA English DT Article ID COLORECTAL-CANCER; GERIATRIC ASSESSMENT; ELDERLY-PATIENTS; TREATMENT TRIALS; POOLED ANALYSIS; FOLINIC ACID; CHEMOTHERAPY USE; CLINICAL-TRIALS; DUKES B; FLUOROURACIL AB While adjuvant chemotherapy has proven benefit in stage III colon cancer, its role for stage II colon cancer remains unclear. This article reviews data regarding adjuvant therapy in stage II colon cancer. We will discuss factors to consider in assessing the risk of recurrence in stage II disease. We will also outline considerations regarding adjuvant therapy in older patients. C1 [McCleary, Nadine Jackson; Meyerhardt, Jeffrey A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [McCleary, Nadine Jackson] Harvard Univ, Sch Med, Dept Med Oncol, Gastrointestinal Canc Ctr, Boston, MA 02115 USA. RP McCleary, NJ (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM najackson@partners.org NR 57 TC 0 Z9 0 U1 0 U2 0 PU UBM MEDICA PI NORWALK PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA SN 0890-9091 J9 ONCOLOGY-NY JI Oncology-NY PD JAN PY 2010 VL 24 IS 1 SU 1 BP 3 EP 8 PG 6 WC Oncology SC Oncology GA 800PC UT WOS:000293374400002 PM 20225605 ER PT J AU Doran, E Jackman, D AF Doran, Elizabeth Jackman, David TI Fire Without Smoke: Lung Cancer in 'Never-Smokers' The Subramanian/Govindan Article Reviewed SO ONCOLOGY-NEW YORK LA English DT Editorial Material ID PULMONARY ADENOCARCINOMA; KRAS MUTATIONS; CARBOPLATIN; PACLITAXEL; STATISTICS; SURVIVAL C1 [Doran, Elizabeth; Jackman, David] Harvard Univ, Sch Med, Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA. RP Doran, E (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, 44 Binney St, Boston, MA 02115 USA. NR 14 TC 2 Z9 2 U1 0 U2 1 PU UBM MEDICA PI NORWALK PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA SN 0890-9091 J9 ONCOLOGY-NY JI Oncology-NY PD JAN PY 2010 VL 24 IS 1 BP 40 EP 43 PG 2 WC Oncology SC Oncology GA 800AZ UT WOS:000293330700003 PM 20187320 ER PT B AU Baehring, JM Schlegel, U Hochberg, FH AF Baehring, Joachim M. Schlegel, Uwe Hochberg, Fred H. BE Tonn, JC Westphal, M Rutka, JT TI Primary CNS Lymphoma SO ONCOLOGY OF CNS TUMORS, SECOND EDITION LA English DT Article; Book Chapter ID CENTRAL-NERVOUS-SYSTEM; HIGH-DOSE METHOTREXATE; STEM-CELL RESCUE; ABERRANT SOMATIC HYPERMUTATION; ACTIVE ANTIRETROVIRAL THERAPY; RECURRENT PRIMARY CNS; NON-HODGKIN-LYMPHOMA; EPSTEIN-BARR VIRUS; QUALITY-OF-LIFE; CENTER B-CELLS C1 [Baehring, Joachim M.] Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT 06510 USA. [Hochberg, Fred H.] Massachusetts Gen Hosp, Brain Tumor Oncol Ctr, Boston, MA 02114 USA. [Schlegel, Uwe] Knappschaftskrankenhaus, Neurol Klin, D-44892 Bochum, Germany. RP Baehring, JM (reprint author), Yale Univ, Sch Med, Dept Neurosurg, 333 Cedar St,TMP 412, New Haven, CT 06510 USA. EM joachim.baehring@yale.edu; uwe.schlegel@kk-bochum.de; fhochberg@partners.org NR 96 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-3-642-02873-1 PY 2010 BP 331 EP 344 DI 10.1007/978-3-642-02874-8_19 D2 10.1007/978-3-642-02874-8 PG 14 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA BNV40 UT WOS:000275666300019 ER PT J AU Igdem, S Spiegel, DY Efstathiou, J Miller, RC Poortmans, PMP Koca, S Kilic-Unsal, D Okkan, S Zietman, A AF Igdem, Sefik Spiegel, Daphna Y. Efstathiou, Jason Miller, Robert C. Poortmans, Philip M. P. Koca, Sedat Kilic-Unsal, Diclehan Okkan, Sait Zietman, Anthony TI Prostatic Duct Adenocarcinoma: Clinical Characteristics, Treatment Options, and Outcomes - a Rare Cancer Network Study SO ONKOLOGIE LA English DT Article DE Prostate cancer; Duct adenocarcinoma; Endocrine management; Radiotherapy ID RADICAL PROSTATECTOMY; CARCINOMA; FEATURES; RADIOTHERAPY AB Background: To evaluate the clinical characteristics, contemporary treatment options, and outcome of prostatic duct adenocarcinoma (PDA), we initiated a Rare Cancer Network (RCN) study. Materials and Methods: Six member institutions of the RCN collected clinical data on 31 patients. Treatment consisted of definitive radiotherapy in 14 patients and radical prostatectomy in 16 patients. One patient was treated with androgen deprivation alone. The mean follow-up period was 56 months. Results: Of the 14 patients managed with radiotherapy, 1 patient developed bone metastases and died of prostate cancer, and 1 patient had a biochemical relapse 8 years after definitive radiotherapy. Of the 16 patients who underwent radical prostatectomy, 2 patients developed bone metastases, one of who died of disease. Three patients that relapsed after prostatectomy were successfully salvaged with radiotherapy. The patient that was treated with androgen deprivation alone developed bone metastases at 10 months, was treated with chemotherapy, and was alive after 22 months. Conclusions: Our results suggest that PDA is a cancer with a behavior similar to that of high Gleason grade acinar carcinoma. Good local control can be achieved by either radiation or surgery. Postoperative radiotherapy seems to work as an adjuvant or salvage treatment, and most tumors appear to respond to androgen deprivation. C1 [Igdem, Sefik; Okkan, Sait] Istanbul Bilim Univ, Dept Radiat Oncol, Sch Med, TR-34340 Istanbul, Turkey. [Spiegel, Daphna Y.; Efstathiou, Jason; Zietman, Anthony] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Miller, Robert C.] Mayo Clin, Dept Radiat Oncol, Rochester, MN USA. [Poortmans, Philip M. P.] Inst Verbeeten, Dept Radiat Oncol, Tilburg, Netherlands. [Koca, Sedat] Istanbul Univ, Dept Radiat Oncol, Cerrahpasa Med Sch, Istanbul, Turkey. [Kilic-Unsal, Diclehan] Gazi Univ, Dept Radiat Oncol, Ankara, Turkey. RP Igdem, S (reprint author), Istanbul Bilim Univ, Dept Radiat Oncol, Sch Med, Cemil Aslan Guder Sok 8, TR-34340 Istanbul, Turkey. EM sefikigdem@gmail.com RI Poortmans, P.M.P./L-4581-2015 NR 15 TC 6 Z9 6 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0378-584X J9 ONKOLOGIE JI Onkologie PY 2010 VL 33 IS 4 BP 169 EP 173 DI 10.1159/000288710 PG 5 GA 577TC UT WOS:000276245900004 PM 20389142 ER PT J AU Rueda, BR Tilly, JL Schorge, JO AF Rueda, Bo R. Tilly, Jonathan L. Schorge, John O. TI Surgical Debulking Before or After Chemotherapy: Stemming the Tide on Ovarian Cancer Recurrence SO ONKOLOGIE LA English DT Editorial Material ID NEOADJUVANT CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; SURVIVAL; CELLS; CARCINOMA; DISEASE; CD133 C1 [Rueda, Bo R.; Tilly, Jonathan L.] Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Boston, MA 02114 USA. [Rueda, Bo R.; Schorge, John O.] Massachusetts Gen Hosp, Div Gynecol Oncol, Vincent Obstet & Gynecol Serv, Boston, MA 02114 USA. [Rueda, Bo R.; Tilly, Jonathan L.; Schorge, John O.] Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA. [Rueda, Bo R.; Schorge, John O.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. RP Rueda, BR (reprint author), Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, 55 Fruit St, Boston, MA 02114 USA. EM brueda@partners.org NR 22 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0378-584X J9 ONKOLOGIE JI Onkologie PY 2010 VL 33 IS 6 BP 286 EP 287 DI 10.1159/000314637 PG 2 GA 606AR UT WOS:000278393100001 PM 20523089 ER PT S AU Alt, C Biss, DP Tajouri, N Jakobs, TC Lin, CP AF Alt, Clemens Biss, David P. Tajouri, Nadja Jakobs, Tatjana C. Lin, Charles P. BE Manns, F Soderberg, PG Arthur, HO TI An adaptive-optics scanning laser ophthalmoscope for imaging murine retinal microstructure SO OPHTHALMIC TECHNOLOGIES XX SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Ophthalmic Technologies XX CY JAN 23-25, 2010 CL San Francisco, CA SP SPIE, Topcon Advanced Biomed Imaging Lab & Swedish Ophthalmol Soc DE scanning laser ophthalmoscope; adaptive optics; retinal ganglion cells; retinal microglia; retinal blood flow; retinal vasculature; neurodegeneration ID IN-VIVO; GANGLION-CELLS; MICROGLIAL CELLS; SCHEMATIC EYE; MOUSE; MODEL; RAT; DISEASE; MICE; NEURODEGENERATION AB In vivo retinal imaging is an outstanding tool to observe biological processes unfold in real-time. The ability to image microstructure in vivo can greatly enhance our understanding of function in retinal microanatomy under normal conditions and in disease. Transgenic mice are frequently used for mouse models of retinal diseases. However, commercially available retinal imaging instruments lack the optical resolution and spectral flexibility necessary to visualize detail comprehensively. We developed an adaptive optics scanning laser ophthalmoscope (AO-SLO) specifically for mouse eyes. Our SLO is a sensor-less adaptive optics system (no Shack Hartmann sensor) that employs a stochastic parallel gradient descent algorithm to modulate a deformable mirror, ultimately aiming to correct wavefront aberrations by optimizing confocal image sharpness. The resulting resolution allows detailed observation of retinal microstructure. The AO-SLO can resolve retinal microglia and their moving processes, demonstrating that microglia processes are highly motile, constantly probing their immediate environment. Similarly, retinal ganglion cells are imaged along with their axons and sprouting dendrites. Retinal blood vessels are imaged both using evans blue fluorescence and backscattering contrast. C1 [Alt, Clemens; Biss, David P.; Lin, Charles P.] Harvard Univ, Massachusetts Gen Hosp, Wellman Ctr Photomed, Adv Microscopy Program,Med Sch, Boston, MA 02114 USA. RP Alt, C (reprint author), Harvard Univ, Massachusetts Gen Hosp, Wellman Ctr Photomed, Adv Microscopy Program,Med Sch, 185 Cambridge St, Boston, MA 02114 USA. NR 43 TC 6 Z9 6 U1 1 U2 4 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-7946-4 J9 PROC SPIE PY 2010 VL 7550 AR 755019 DI 10.1117/12.840583 PG 11 WC Ophthalmology; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging SC Ophthalmology; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging GA BRY95 UT WOS:000283928200029 ER PT J AU Chan, RVP Yonekawa, Y Lane, AM Skondra, D Munzenrider, JE Collier, JM Gragoudas, ES Kim, IK AF Chan, R. V. Paul Yonekawa, Yoshihiro Lane, Anne Marie Skondra, Dimitra Munzenrider, John E. Collier, J. Michael Gragoudas, Evangelos S. Kim, Ivana K. TI Proton Beam Irradiation Using a Light-Field Technique for the Treatment of Choroidal Hemangiomas SO OPHTHALMOLOGICA LA English DT Article DE Proton beam irradiation; Light field technique; Choroidal hemangiomas ID SEROUS RETINAL-DETACHMENT; PHOTODYNAMIC THERAPY; VERTEPORFIN; MELANOMA AB Background/Aims: To describe the clinical outcomes of patients with circumscribed and diffuse choroidal hemangiomas treated by proton beam irradiation using a nonsurgical light-field technique. Methods: A retrospective chart review was performed on a series of 19 patients (19 eyes) with choroidal hemangiomas treated with proton beam therapy between July 1988 and August 2005. Choroidal hemangiomas were treated with proton beam irradiation using a light-field technique and doses ranging from 15 to 30 cobalt Gray equivalents (CGE; CGE = proton Gy X relative biological effectiveness 1.1) in 4 fractions. Patients with at least 6 months' follow-up were included in the study. Tumor regression, visual acuity, absorption of subretinal fluid, and treatment-associated complications were evaluated by clinical examination and ultrasonography. Results: Visual acuity improved or remained stable in 14 of 18 eyes (78%). Subretinal fluid was initially present in 16 of 19 eyes (84%), and completely resolved in all 16 eyes. Tumor height, as measured by B-scan ultrasonography, decreased in 18 of 19 eyes and remained stable in 1 of 19, as of the last examination. Complications of radiation developed in 9 of 19 eyes (47%) with the total applied dose ranging from 15 to 30 CGE for these 9 eyes. Conclusions: Proton beam irradiation using a light-field technique without surgical tumor localization is an effective treatment option in managing both circumscribed choroidal hemangiomas and diffuse hemangiomas associated with Sturge-Weber syndrome. A total proton dose as low as 15 CGE applied in 4 fractions appears to be sufficient to reduce tumor size, promote absorption of subretinal fluid, and improve or stabilize vision in most patients. Copyright (C) 2009 S. Karger AG, Basel C1 [Lane, Anne Marie; Skondra, Dimitra; Gragoudas, Evangelos S.; Kim, Ivana K.] Harvard Univ, Massachusetts Eye & Ear Infirm, Massachusetts Gen Hosp, Retina Serv,Med Sch, Boston, MA 02114 USA. [Munzenrider, John E.; Collier, J. Michael] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Chan, R. V. Paul; Yonekawa, Yoshihiro] Weill Cornell Med Coll, New York Presbyterian Hosp, Retina Serv, New York, NY USA. RP Kim, IK (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Massachusetts Gen Hosp, Retina Serv,Med Sch, 243 Charles St, Boston, MA 02114 USA. EM ivana_kim@meei.harvard.edu NR 21 TC 4 Z9 4 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0030-3755 J9 OPHTHALMOLOGICA JI Ophthalmologica PY 2010 VL 224 IS 4 BP 209 EP 216 DI 10.1159/000260226 PG 8 WC Ophthalmology SC Ophthalmology GA 557UX UT WOS:000274696700003 PM 19940527 ER PT S AU Celli, JP Rizvi, I Evans, CL Abu-Yousif, A Hasan, T AF Celli, Jonathan P. Rizvi, Imran Evans, Conor L. Abu-Yousif, Adnan Hasan, Tayyaba BE Kessel, DH TI 3D Ovarian Cancer Models: Imaging and Therapeutic Combinations SO OPTICAL METHODS FOR TUMOR TREATMENT AND DETECTION: MECHANISMS AND TECHNIQUES IN PHOTODYNAMIC THERAPY XIX SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Methods for Tumor Treatment and Detection - Mechanisms and Techniques in Photodynamic Therapy XIX CY JAN 23-25, 2010 CL San Francisco, CA SP SPIE DE Image Processing; Photodynamic Therapy; PDT; Carboplatin; Combination Treatment; in vitro model ID PHASE-II TRIAL; PHOTODYNAMIC THERAPY; IN-VIVO; CULTURES; TUMORS AB We introduce a new platform to study treatment response in adherent micrometastatic ovarian cancer, combining an in vitro 3D model, with custom quantitative analysis routines to report growth and cytotoxic response in large sets of image data. OVCAR-5 human ovarian cancer cells were grown on a bed of Growth Factor Reduced Matrigel (TM) (GFR Matrigel (TM)). Using batch analysis routines to analyze longitudinal image data we show that in vitro tumor growth leads to a reproducible log-normal size distribution with two well-defined peaks. These distinct growth modes correspond to a population with approximately constant diameter of 20 mu m over the time probed, while the other peak corresponds to a more rapidly assembling sub-distribution of micronodules which shifts towards larger peak center positions with mean equivalent diameters of 92 mu m, 120 mu m and 150 mu m at days 7, 10 and 17 following plating. At day 10, 3D and monolayer cultures were treated with a regimen of either carboplatin or photodynamic therapy. Using a quantitative fluorescence imaging approach we report dose response curves and demonstrate that 3D nodules are significantly less sensitive to treatment than the same cells grown in monolayer. 3D cultures subject to 5J/cm(2) PDT (250nM BPD-MA) exhibited a mean viability of 80% (95% CI = 73% to 82%) relative to no treatment control. 3D cultures subject to carboplatin treatment at 100uM concentration exhibited a mean viability of 92% (95% CI = 86% to 97%). A combination treatment of 5J/cm(2) PDT followed by 100 mu M carboplatin yielded an enhanced cytotoxic effect with mean viability of 46%, 95% confidence interval (CI) = (35% to 46%). C1 [Celli, Jonathan P.; Rizvi, Imran; Evans, Conor L.; Abu-Yousif, Adnan; Hasan, Tayyaba] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02115 USA. RP Celli, JP (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02115 USA. EM thasan@partners.org NR 12 TC 1 Z9 1 U1 1 U2 3 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-7947-1 J9 PROC SPIE PY 2010 VL 7551 AR 75510I DI 10.1117/12.843279 PG 10 WC Oncology; Optics; Physics, Applied SC Oncology; Optics; Physics GA BRY90 UT WOS:000283927200012 ER PT S AU Evans, CL Rizvi, I Celli, J Abu-Yousif, A de Boer, J Hasan, T AF Evans, Conor L. Rizvi, Imran Celli, Jonathan Abu-Yousif, Adnan de Boer, Johannes Hasan, Tayyaba BE Kessel, DH TI Visualizing Photodynamic Therapy Response with Time-Lapse OCT in an in vitro Model of Metastatic Ovarian Cancer SO OPTICAL METHODS FOR TUMOR TREATMENT AND DETECTION: MECHANISMS AND TECHNIQUES IN PHOTODYNAMIC THERAPY XIX SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Methods for Tumor Treatment and Detection - Mechanisms and Techniques in Photodynamic Therapy XIX CY JAN 23-25, 2010 CL San Francisco, CA SP SPIE DE Optical coherence tomography; photodynamic therapy; ovarian cancer; time-lapse microscopy ID GROWTH; VIVO AB Ovarian epithelial cancer has a high morbidity due to its propensity to metastasize onto surfaces in the abdomen. In order to effectively treat these metastatic lesions with photodynamic therapy (PDT), it is critical to understand the detailed dynamics of the PDT response. 3D in vitro models of ovarian cancer are a promising system for studying the response to PDT of these lesions, as they replicate the size, appearance, and characteristics of metastatic disease observed in the clinic. An ideal approach capable of non-purturbative, 3D imaging of this model is optical coherence tomography (OCT). An ultrahigh resolution time-lapse OCT (TL-OCT) system was used to visualize the photodynamic therapeutic response in the hours and days following treatment. Tumor nodules were observed to experience rapid cell death within the first 24 hours post-treatment using benzophorphyrin derivative monoacid A (BPD), characterized by structural breakdown of the model nodules. Highly scattering bodies were observed with OCT contrast to form at the periphery of the tumor nodules. These highly scattering moieties were identified as apoptotic bodies, indicating that OCT is capable of tracking the PDT-induced apoptosis in real-time without the need for labels. C1 [Evans, Conor L.; Rizvi, Imran; Celli, Jonathan; Abu-Yousif, Adnan; Hasan, Tayyaba] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Evans, CL (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, 40 Blossom St, Boston, MA 02114 USA. EM thasan@partners.org NR 11 TC 2 Z9 2 U1 0 U2 3 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-7947-1 J9 PROC SPIE PY 2010 VL 7551 AR 75510J DI 10.1117/12.843271 PG 5 WC Oncology; Optics; Physics, Applied SC Oncology; Optics; Physics GA BRY90 UT WOS:000283927200013 ER PT S AU Spring, B Mai, ZM Rai, P Chang, S Hasan, T AF Spring, Bryan Mai, Zhiming Rai, Prakash Chang, Sung Hasan, Tayyaba BE Kessel, DH TI Theranostic Nanocells for Simultaneous Imaging and Photodynamic therapy of Pancreatic Cancer SO OPTICAL METHODS FOR TUMOR TREATMENT AND DETECTION: MECHANISMS AND TECHNIQUES IN PHOTODYNAMIC THERAPY XIX SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Methods for Tumor Treatment and Detection - Mechanisms and Techniques in Photodynamic Therapy XIX CY JAN 23-25, 2010 CL San Francisco, CA SP SPIE DE Photodynamic Therapy; nanocell; nanoparticles; liposomes; anti-VEGF therapy; pancreatic cancer ID ENDOTHELIAL GROWTH-FACTOR; COMBINATION THERAPY; NANOTECHNOLOGY; VEGF; NANOPARTICLES; ANGIOGENESIS; BEVACIZUMAB; EXPRESSION; SURVIVAL; DELIVERY AB Nanotechnology has the potential to deliver multiple imaging and therapeutic agents to the "right place at the right time". This could dramatically improve treatment responses in cancer which have been so far, dismal as well as allow us to monitor this response online. Pancreatic cancer (PanCa) has a poor prognosis with a 5-year survival rate of only 5% and there is a desperate need for effective treatments. Photodynamic therapy (PDT) has shown promising results in treating PanCa. Mechanism-based combinations with PDT have enhanced treatment outcome. Agents tested with PDT include Avastin, an antibody against vascular endothelial growth factor (VEGF) which is approved for treating various cancers. Here, we investigate the effect of neutralizing intracellular VEGF using nanotechnology for the delivery of Avastin in combination with PDT. For this we used a construct called "nanocells" in which the photosensitizer was trapped inside polymer nanoparticles and these, with Avastin, were then encapsulated inside liposomes. Simultaneous delivery of drugs in nano-constructs could improve the treatment response of mechanism based combination therapies against cancer. Our studies demonstrate significant enhancement in treatment outcomes when nanocell-based PDT is combined with Avastin in orthotopic PanCa mouse models. We propose a new paradigm for Avastin-based therapy by combining intracellular delivery of the antibody and PDT using nanotechnology for treating PanCa. C1 [Spring, Bryan; Mai, Zhiming; Rai, Prakash; Chang, Sung; Hasan, Tayyaba] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Spring, B (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. EM thasan@partners.org NR 48 TC 3 Z9 3 U1 0 U2 1 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-7947-1 J9 PROC SPIE PY 2010 VL 7551 AR 755104 DI 10.1117/12.843725 PG 11 WC Oncology; Optics; Physics, Applied SC Oncology; Optics; Physics GA BRY90 UT WOS:000283927200003 ER PT J AU Srinivasan, VJ Jiang, JY Yaseen, MA Radhakrishnan, H Wu, WC Barry, S Cable, AE Boas, DA AF Srinivasan, Vivek J. Jiang, James Y. Yaseen, Mohammed A. Radhakrishnan, Harsha Wu, Weicheng Barry, Scott Cable, Alex E. Boas, David A. TI Rapid volumetric angiography of cortical microvasculature with optical coherence tomography SO OPTICS LETTERS LA English DT Article AB We describe methods and algorithms for rapid volumetric imaging of cortical vasculature with optical coherence tomography (OCT). By optimizing system design, scanning protocols, and algorithms for visualization of capillary flow, comprehensive imaging of the surface pial vasculature and capillary bed is performed in approximately 12 s. By imaging during hypercapnia and comparing with simultaneous CCD imaging, the sources of contrast of OCT angiography are investigated. (C) 2009 Optical Society of America C1 [Srinivasan, Vivek J.; Yaseen, Mohammed A.; Radhakrishnan, Harsha; Wu, Weicheng; Boas, David A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp,Photon Migrat Imaging Lab, Athinoula A Martinos Ctr Biomed Imaging,MIT, Charlestown, MA 02129 USA. [Jiang, James Y.; Barry, Scott; Cable, Alex E.] Thorlabs Inc, Newton, NJ 07860 USA. RP Srinivasan, VJ (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp,Photon Migrat Imaging Lab, Athinoula A Martinos Ctr Biomed Imaging,MIT, Charlestown, MA 02129 USA. EM vjsriniv@nmr.mgh.harvard.edu RI Radhakrishnan, Harsha/K-5557-2012 FU National Institutes of Health (NIH) [R01-NS057476, P01NS055104, P50NS010828, K99NS067050]; Air Force Office of Scientific Research (AFOSR) [MFEL FA9550-07-1-0101] FX We acknowledge support by the National Institutes of Health (NIH) (R01-NS057476, P01NS055104, P50NS010828, and K99NS067050) and the Air Force Office of Scientific Research (AFOSR) (MFEL FA9550-07-1-0101). NR 9 TC 77 Z9 77 U1 0 U2 3 PU OPTICAL SOC AMER PI WASHINGTON PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA SN 0146-9592 J9 OPT LETT JI Opt. Lett. PD JAN 1 PY 2010 VL 35 IS 1 BP 43 EP 45 PG 3 WC Optics SC Optics GA 547HN UT WOS:000273877700015 PM 20664667 ER PT J AU Gennari, L Klein, R Ferrari, S AF Gennari, Luigi Klein, Robert Ferrari, Serge BE Orwoll, ES Bilezikian, JP Vanderschueren, D TI The Genetics of Peak Bone Mass SO OSTEOPOROSIS IN MEN: THE EFFECTS OF GENDER ON SKELETAL HEALTH, 2ND EDITION LA English DT Article; Book Chapter ID QUANTITATIVE TRAIT LOCI; RECEPTOR-RELATED PROTEIN-5; VITAMIN-D-RECEPTOR; LDL-RECEPTOR-RELATED-PROTEIN-5 LRP5 GENE; GENOME LINKAGE SCAN; MINERAL DENSITY; IDIOPATHIC OSTEOPOROSIS; FRACTURE RISK; ALPHA GENE; LOW BMD C1 [Gennari, Luigi] Univ Siena, Deparment Internal Med Endocrine Metab Sci & Bioc, I-53100 Siena, Italy. [Klein, Robert] Oregon Hlth & Sci Univ, Bone & Mineral Unit, Portland, OR 97201 USA. [Klein, Robert] Portland VA Med Ctr, Portland, OR USA. [Ferrari, Serge] Univ Hosp Geneva, Serv Bone Dis, Dept Rehabil & Geriatr, WHO Collaborating Ctr Osteoporosis Prevent, Geneva, Switzerland. RP Gennari, L (reprint author), Univ Siena, Deparment Internal Med Endocrine Metab Sci & Bioc, I-53100 Siena, Italy. RI Gennari, Luigi/J-7013-2016 OI Gennari, Luigi/0000-0001-6833-4232 NR 92 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-08-092346-8 PY 2010 BP 149 EP 163 DI 10.1016/B978-0-12-374602-3.00012-2 PG 15 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BFC98 UT WOS:000319219700014 ER PT B AU Wiren, KM Orwoll, ES AF Wiren, Kristine M. Orwoll, Eric S. BE Orwoll, ES Bilezikian, JP Vanderschueren, D TI Androgens and Bone: Basic Aspects SO OSTEOPOROSIS IN MEN: THE EFFECTS OF GENDER ON SKELETAL HEALTH, 2ND EDITION LA English DT Article; Book Chapter ID OSTEOBLASTIC CELL-LINE; GROWTH-FACTOR-BETA; RECEPTOR MODULATOR SARM; ADULT MALE-MICE; AGED MALE-RATS; MINERAL DENSITY; OVARIECTOMIZED RATS; CORTICAL BONE; BIOCHEMICAL MARKERS; PARATHYROID-HORMONE C1 [Wiren, Kristine M.; Orwoll, Eric S.] Oregon Hlth & Sci Univ, Bone & Mineral Unit, Portland, OR 97201 USA. [Wiren, Kristine M.] Portland VA Med Ctr, Portland, OR USA. RP Wiren, KM (reprint author), Oregon Hlth & Sci Univ, Bone & Mineral Unit, Portland, OR 97201 USA. OI Wiren, Kristine/0000-0002-6159-4450 NR 173 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-08-092346-8; 978-0-12-374602-3 PY 2010 BP 295 EP 317 DI 10.1016/B978-0-12-374602-3.00025-0 PG 23 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BFC98 UT WOS:000319219700027 ER PT B AU Leder, BZ AF Leder, Benjamin Z. BE Orwoll, ES Bilezikian, JP Vanderschueren, D TI Androgens and the Skeleton - Humans SO OSTEOPOROSIS IN MEN: THE EFFECTS OF GENDER ON SKELETAL HEALTH, 2ND EDITION LA English DT Article; Book Chapter ID BONE-MINERAL DENSITY; HORMONE-BINDING GLOBULIN; PREDICTED ADULT HEIGHT; SEX STEROID-LEVELS; IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM; CONGENITAL AROMATASE DEFICIENCY; ESTROGEN REPLACEMENT THERAPY; SERUM TESTOSTERONE LEVELS; PLACEBO-CONTROLLED TRIAL; COMMUNITY-DWELLING MEN C1 [Leder, Benjamin Z.] Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02114 USA. [Leder, Benjamin Z.] Harvard Univ, Sch Med, Boston, MA USA. RP Leder, BZ (reprint author), Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02114 USA. NR 148 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-08-092346-8; 978-0-12-374602-3 PY 2010 BP 319 EP 334 DI 10.1016/B978-0-12-374602-3.00026-2 PG 16 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BFC98 UT WOS:000319219700028 ER PT B AU Wiren, KM AF Wiren, Kristine M. BE Adler, RA TI Androgen Action in Bone: Basic Cellular and Molecular Aspects SO OSTEOPOROSIS: PATHOPHYSIOLOGY AND CLINICAL MANAGEMENT, SECOND EDITION SE Contemporary Endocrinology LA English DT Article; Book Chapter DE Androgen; androgen receptor; osteoblast; osteoclast; bone ID OSTEOBLAST-LIKE CELLS; GROWTH-FACTOR-BETA; MESSENGER-RIBONUCLEIC-ACID; THYROID-HORMONE RECEPTOR; MINERAL DENSITY; IN-VITRO; MALE-RATS; POSTMENOPAUSAL WOMEN; PARATHYROID-HORMONE; AROMATASE-ACTIVITY AB The impact of the menopause on skeletal health is obvious, but there remains confusion interpreting the skeletal actions of sex steroids. Thus, the mechanisms by which androgens affect bone homeostasis are becoming the focus of intensified research. As a classic steroid hormone, the biological cellular signaling responses to androgen are mediated through the androgen receptor (AR), a ligand-inducible transcription factor. Androgen effects on bone may also be indirectly modulated and/or mediated by other autocrine and paracrine factors in the bone microenvironment or through steroid metabolic enzymatic activity. ARs have been identified in a variety of cells found in bone, thus clearly identifying bone as a target tissue for androgen action. The direct effects of androgen that influence the complex processes of proliferation, differentiation, mineralization, and gene expression in the osteoblast are being characterized, but much remains controversial. This chapter will review recent progress on characterization of the molecular and cellular mechanisms that underlie androgen action in bone. C1 Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Bone & Mineral Unit, Portland, OR 97201 USA. RP Wiren, KM (reprint author), Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Bone & Mineral Unit, Portland, OR 97201 USA. NR 158 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-934115-19-0 J9 CONTEMP ENDOCRINOL S PY 2010 SI 2 BP 359 EP 383 DI 10.1007/978-1-59745-459-9_16 D2 10.1007/978-1-59745-459-9 PG 25 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BMR67 UT WOS:000273414500016 ER PT J AU Nicoucar, K Giger, R Jaecklin, T Pope, HG Dulguerov, P AF Nicoucar, Keyvan Giger, Roland Jaecklin, Thomas Pope, Harrison G., Jr. Dulguerov, Pavel TI Management of congenital third branchial arch anomalies: A systematic review SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article; Proceedings Paper CT 110th Annual Meeting of the American-Academy-of-Otolaryngology-Head-and-Neck-Surgery-Foundation CY SEP 17-20, 2006 CL Toronto, CANADA SP Amer Acad Otolaryngol Head & Neck Surg Fdn ID PYRIFORM SINUS FISTULA; ACUTE SUPPURATIVE THYROIDITIS; THYMOPHARYNGEAL DUCT CYST; CERVICAL THYMIC CYSTS; NECK INFECTION; SURGICAL-MANAGEMENT; IMAGING FINDINGS; POUCH ANOMALIES; CLEFT SINUS; CHILDREN AB OBJECTIVE: To systematically review the existing literature on third branchial arch anomalies and suggest guidelines for their management. DATA SOURCES: We searched PubMed, Medline, and Embase using Scopus, and collected additional publications cited in bibliographies. We included all English-language articles and all foreign-language articles with an English abstract. REVIEW METHODS: Two investigators reviewed all cases explicitly identified as third arch anomalies or meeting anatomical criteria for third arch anomalies; they assessed presentation, diagnostic methods, intervention, and outcome. RESULTS: We found 202 cases of third arch anomalies; they presented primarily on the left side (89%), usually as neck abscess (39%) or acute suppurative thyroiditis (33%). Barium swallow, direct laryngoscopy. and magnetic resonance imaging were the most useful diagnostic tools. The recurrence rate varied among the treatment options: incision and drainage, 94 percent; endoscopic cauterization of the sinus tract opening, 18 percent; open-neck surgery and tract excision, 15 percent: and partial thyroidectomy during open-neck surgery, 14 percent. Complications after surgery appeared somewhat more frequently in children eight years of age or younger. CONCLUSION: Third arch anomalies are more common than previously reported. They appear to be best treated by complete excision of the cyst, sinus, or fistula during a quiescent period. Repeated incision and drainage yields high rates of recurrence and should be avoided. Complications might be minimized by first initiating antibiotic treatment, delaying surgical treatment until the inflammatory process is maximally resolved, and by using endoscopic cauterization. (C) 2010 American Academy of Otolaryngology Head and Neck Surgery Foundation. All rights reserved. C1 [Nicoucar, Keyvan; Giger, Roland; Dulguerov, Pavel] Univ Hosp, Dept Otolaryngol Head & Neck Surg, Geneva, Switzerland. [Jaecklin, Thomas] Univ Hosp, Pediat Intens Care Unit, Geneva, Switzerland. [Pope, Harrison G., Jr.] Harvard Univ, McLean Hosp, Sch Med, Belmont, MA 02178 USA. RP Nicoucar, K (reprint author), Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, 243 Charles St,Room 421, Boston, MA 02114 USA. EM Keyvan_Nicoucar@meei.harvard.edu RI Dulguerov, Pavel/I-7325-2015 OI Dulguerov, Pavel/0000-0001-5863-3933 NR 88 TC 19 Z9 29 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD JAN PY 2010 VL 142 IS 1 BP 21 EP 28 DI 10.1016/j.otohns.2009.09.001 PG 8 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 582CW UT WOS:000276574200005 PM 20096218 ER PT J AU Benoit, MM North, PE McKenna, MJ Mihm, MC Johnson, MM Cunningham, MJ AF Benoit, Margo McKenna North, Paula E. McKenna, Michael J. Mihm, Martin C. Johnson, Matthew M. Cunningham, Michael J. TI Facial nerve hemangiomas: Vascular tumors or malformations? SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Academy-of-Otolaryngology-Head-and-Neck-Surgery-Foundation CY OCT 04-07, 2009 CL San Diego, CA SP Amer Acad Otolaryngol Head & Neck Surg Fdn ID TEMPORAL BONE HEMANGIOMAS; JUVENILE HEMANGIOMAS; MANAGEMENT; MARKER AB OBJECTIVE: To reclassify facial nerve hemangiomas in the context of presently accepted vascular lesion nomenclature by examining histology and immunohistochemical markers. STUDY DESIGN: Cohort analysis of patients diagnosed with a facial nerve hemangioma between 1990 and 2008. SETTING: Collaborative analysis at a specialty hospital and a major academic hospital. SUBJECTS AND METHODS: Seven subjects were identified on composite review of office charts, a pathology database spanning both institutions, and an encrypted patient registry. Clinical data were compiled, and hematoxylin-eosin-stained specimens were reviewed. For six patients, archived pathological tissue was available for immunohistochemical evaluation of markers specific for infantile hemangioma (glucose transporter protein isoform 1 [GLUT1] and Lewis Y antigen) and for lymphatic endothelial cells (podoplanin). RESULTS: All patients clinically presented with slowly progressive facial weakness at a mean age of 45 years without prior symptomatology. Hemotoxylin-eosin-stained histopathological slides showed irregularly shaped, dilated lesional vessels with flattened endothelial cells, scant smooth muscle, and no internal elastic lamina. Both podoplanin staining for lymphatic endothelial cells and GLUT1 and LewisY antigen staining for infantile hemangioma endothelial cells were negative in lesional vessels in all specimens for which immunohistochemical analysis was performed. CONCLUSION: Lesions of the geniculate ganglion historically referred to as "hemangiomas" do not demonstrate clinical, histopathological, or immunohistochemical features consistent with a benign vascular tumor, but instead are consistent with venous malformation. We propose that these lesions be classified as "venous vascular malformations of the facial nerve." This nomenclature should more accurately predict clinical behavior and guide therapeutic interventions. (C) 2010 American Academy of Otolaryngology-Head and Neck Surgery Foundation. All rights reserved. C1 [Benoit, Margo McKenna; McKenna, Michael J.; Cunningham, Michael J.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. [Benoit, Margo McKenna; McKenna, Michael J.; Cunningham, Michael J.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [North, Paula E.] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA. [Mihm, Martin C.; Johnson, Matthew M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Benoit, MM (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. EM Margo_Benoit@meei.harvard.edu NR 19 TC 13 Z9 16 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD JAN PY 2010 VL 142 IS 1 BP 108 EP 114 DI 10.1016/j.otohns.2009.10.007 PG 7 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 582CW UT WOS:000276574200020 PM 20096233 ER PT J AU Vakharia, KT Durand, ML Hamilos, DL Geyer, JT Holbrook, EH AF Vakharia, Kalpesh T. Durand, Marlene L. Hamilos, Daniel L. Geyer, Julia T. Holbrook, Eric H. TI An atypical case of chronic invasive fungal sinusitis and its management SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article C1 [Vakharia, Kalpesh T.; Durand, Marlene L.; Holbrook, Eric H.] Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Boston, MA 02114 USA. [Durand, Marlene L.] Massachusetts Eye & Ear Infirm, Div Infect Dis, Boston, MA 02114 USA. [Hamilos, Daniel L.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA. [Geyer, Julia T.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Vakharia, KT (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, 243 Charles St, Boston, MA 02114 USA. EM kalpesh_vakharia@meei.harvard.edu NR 5 TC 2 Z9 2 U1 1 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD JAN PY 2010 VL 142 IS 1 BP 150 EP 151 DI 10.1016/j.otohns.2009.06.743 PG 2 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 582CW UT WOS:000276574200033 PM 20096246 ER PT J AU Kapural, L Stojanovic, M Bensitel, T Zovkic, P AF Kapural, Leonardo Stojanovic, Milan Bensitel, Toula Zovkic, Paulina TI Cooled Radiofrequency (RF) of L5 Dorsal Ramus for RF Denervation of the Sacroiliac Joint: Technical Report SO PAIN MEDICINE LA English DT Article DE Sacroiliitis; Radiofrequency Denervation; Chronic Lower Back Pain ID LOW-BACK-PAIN; NEUROTOMY; ELECTRODE; ABLATION AB Background and Objectives. The sacroiliac joint is a common source of chronic low back pain. We recently described the use of cooled radiofrequency (RF) electrodes for performing lateral branch neurotomy to treat sacroiliac joint pain. The procedure involves lesioning the lateral branches of the posterior primary rami at S1-S3, and the L5 dorsal ramus (L5DR). While the cooled RF electrode has been adopted as a means for lesioning the lateral branches, conventional RF electrodes are used to lesion the L5DR. The objective of this technical report is to evaluate the acute safety of denervating the L5DR using cooled RF electrode. Methods. Electronic chart review was conducted on 100 consecutive RF procedures. Data collected included age, sex, years of pain, body mass index, post-procedural pain, numbness, weakness, and other complications. Results. Of 100 procedures 82 were completed using cooled electrode for sacral lateral branches and L5DR. Of the 82 procedures completed using cooled RF to L5DR, 24 were reported to be of high difficulty and 19 with poor visualization (bowel gas). There were no major complications related to the procedure. Four patients reported increased pain: two from the conventional RF of L5DR group and two from the cooled RF group. All of the pains were transient and returned to the baseline within 6 weeks. There were two patients experiencing localized numbness over the upper medial quadrant of the buttock, both in cooled RF group. There was no reported weakness of the lower extremity. Two patients complained of increased lower back pain and two of prolonged itching. Conclusions. This review demonstrates the acute safety of using cooled RF for L5DR denervation with no report of significant or unusual patient complications. To establish frequency of complication associated with the treatment, a larger registry is required. C1 [Kapural, Leonardo; Bensitel, Toula; Zovkic, Paulina] Cleveland Clin, Dept Pain Management, Cleveland, OH 44195 USA. [Stojanovic, Milan] Massachusetts Gen Hosp, Pain Management Dept, Boston, MA 02114 USA. RP Kapural, L (reprint author), Cleveland Clin, Dept Pain Management, 9500 Euclid Ave Desk C25, Cleveland, OH 44195 USA. EM Kapural@ccf.org NR 22 TC 7 Z9 11 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PD JAN PY 2010 VL 11 IS 1 BP 53 EP 57 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 543TL UT WOS:000273601400009 PM 20030745 ER PT J AU Mao, JR AF Mao, Jianren TI N-type Calcium Channel Blocker for Pain Treatment SO PAIN MEDICINE LA English DT Editorial Material C1 [Mao, Jianren] MGH Ctr Translat Pain Res, Boston, MA USA. [Mao, Jianren] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia & Crit Care, Boston, MA USA. RP Mao, JR (reprint author), MGH Ctr Translat Pain Res, Boston, MA USA. NR 1 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PY 2010 VL 11 IS 2 BP 153 EP 153 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 548VR UT WOS:000273997600001 PM 20447299 ER PT J AU Christo, PJ Christo, DK Carinci, AJ Freischlag, JA AF Christo, Paul J. Christo, Dana K. Carinci, Adam J. Freischlag, Julie A. TI Single CT-Guided Chemodenervation of the Anterior Scalene Muscle with Botulinum Toxin for Neurogenic Thoracic Outlet Syndrome SO PAIN MEDICINE LA English DT Article DE Thoracic Outlet Syndrome; Anterior Scalene Muscle; Botulinum Toxin (Botox); Computed Tomographic Imaging (CT); Pain Relief; McGill Pain Questionnaire ID CONSERVATIVELY TREATED PATIENTS; MCGILL PAIN QUESTIONNAIRE; COMPRESSION SYNDROME; ABNORMALITIES; OPERATIONS; DIAGNOSIS; ANATOMY; MODEL AB Objective. To examine pain relief in patients with neurogenic thoracic outlet syndrome (NTOS) after a single, low dose injection of botulinum toxin A (Botox) into the anterior scalene muscle (ASM) under computed tomographic (CT) guidance. Design. Prospective longitudinal study. Setting. Academic medical institution. Patients. Patients 18 years of age and older were evaluated for potential scalenectomy and first rib resection using the transaxillary approach at the study institution between 2005 and 2008. All patients had failed physical therapy. A total of 29 procedures on 27 participants were studied. Interventions. A single, 20-unit injection of Botox into the ASM under CT-guidance. Outcome Measures. Short-form McGill Pain Questionnaire (SF-MPQ) prior to and at 1, 2, and 3 months post-Botox toxin injection. Results. There was a decline in pain during the 3 months subsequent to Botox injection as noted by the following components of the SF-MPQ: sensory (P = 0.02), total (P = 0.05), visual analog scale (VAS [P = 0.04]), and present pain intensity (PPI) score (P = 0.06). The proportion of patients reporting more intense pain scores did not return to the pre-intervention level at 3 months post-Botox injection. Conclusion. Patients experienced substantial pain relief in months 1 and 2 following a single Botox injection into the ASM under CT guidance. Significant pain reduction was noted for 3 months after Botox injection with respect to both sensory and VAS scores, and the total and PPI scores approximated statistical significance. After 3 months, patients experienced a 29% decrease in the sensory component of their pain as well as an approximate 15% reduction in their VAS score. A single, CT-guided Botox injection into the ASM may offer an effective, minimally invasive treatment for NTOS. C1 [Christo, Paul J.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Div Pain Med, Baltimore, MD 21205 USA. [Christo, Dana K.] Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Baltimore, MD 21205 USA. [Freischlag, Julie A.] Johns Hopkins Univ, Sch Med, Dept Surg, Div Vasc Surg, Baltimore, MD 21205 USA. [Carinci, Adam J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care Med & Pain Med,Div Pain, Boston, MA USA. RP Christo, PJ (reprint author), Johns Hopkins Univ Hosp, 550 North Broadway,Suite 301, Baltimore, MD 21205 USA. EM pchristo@jhmi.edu NR 52 TC 16 Z9 16 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PY 2010 VL 11 IS 4 BP 504 EP 511 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 577LB UT WOS:000276223500006 PM 20202146 ER PT J AU Chen, L Houghton, M Seefeld, L Malarick, C Mao, JR AF Chen, Lucy Houghton, Mary Seefeld, Lindsey Malarick, Charlene Mao, Jianren TI A Survey of Selected Physician Views on Acupuncture in Pain Management SO PAIN MEDICINE LA English DT Article DE Acupuncture; Pain Management; Survey; Pain Medicine; Alternative Medicine ID ALTERNATIVE MEDICINE; GENERAL-PRACTITIONERS; COMPLEMENTARY MEDICINE; ATTITUDES; DOCTORS AB Objectives. To collect information on the role of acupuncture in pain management from pain physicians and referral physicians who manage clinical pain conditions. Methods. The survey was conducted between 2007 and 2008 through nationwide direct mail or e-mail to 1083 physicians who are currently practicing in the United States. We divided our 16 survey questions into five categories: 1) physician's attitude toward acupuncture as a modality of pain management; 2) physician's preference or belief with regard to the type of pain condition suitable for acupuncture referrals; 3) timing for making acupuncture referrals (e.g., acupuncture as a first line pain treatment option or a last approach after failed conventional pain management); 4) clinical assessment criteria for the effectiveness of acupuncture therapy; and 5) barriers to making acupuncture referrals (e.g., physician's personal view, insurance issues, patient refusal, etc.). The survey results were calculated and interpreted as the percentage rate of response. Result. The results indicate that an overwhelming majority of survey responders have a positive attitude and favorable experience with using acupuncture as an alternative modality for chronic pain management. However, our survey responders are mostly from teaching hospitals, suggesting a possible gap between teaching hospitals and other medical facilities (private practice and community hospitals) in utilizing acupuncture for pain management. The lack of insurance coverage and facility for acupuncture treatment are two primary barriers to making acupuncture referrals. Conclusions. The survey results indicate that acupuncture is considered by many physicians to be a useful alternative modality for chronic pain management. C1 [Chen, Lucy; Houghton, Mary; Seefeld, Lindsey; Malarick, Charlene; Mao, Jianren] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med,MGH Ctr Tran, Boston, MA 02114 USA. RP Chen, L (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med,MGH Ctr Tran, WACC 324, Boston, MA 02114 USA. EM llchen@partners.org FU NIH [DA22576] FX This study is partially supported by NIH RO1 grant DA22576. NR 11 TC 6 Z9 6 U1 3 U2 9 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PY 2010 VL 11 IS 4 BP 530 EP 534 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 577LB UT WOS:000276223500010 PM 20202145 ER PT J AU Tsao, JCI Stein, JA Dobalian, A AF Tsao, Jennie C. I. Stein, Judith A. Dobalian, Aram TI Sex Differences in Pain and Misuse of Prescription Analgesics Among Persons with HIV SO PAIN MEDICINE LA English DT Article DE Pain; Substance Abuse; Opioid Misuse; Women; Gender Differences; AIDS ID AMBULATORY AIDS PATIENTS; QUALITY-OF-LIFE; NATIONAL PROBABILITY SAMPLES; LOW-PREVALENCE DISEASES; DRUG-USE; INFECTED PATIENTS; SERVICES UTILIZATION; UNITED-STATES; HEALTH; UNDERESTIMATION AB Objective. Women represent the largest percentage of new HIV infections globally. Yet, no large-scale studies have examined the experience of pain and its treatment in women living with HIV. Design. This study used structural equation modeling to examine sex differences in pain and the use and misuse of prescription analgesics in a representative sample of HIV+ persons in the United Stated within a prospective, longitudinal design. Outcome Measures. Bodily pain subscale of the Short-Form 36 and Modified Short Form of the World Health Organization's Composite International Diagnostic Interview (opioid misuse). Results. Women reported more pain than men over a roughly 6-month period regardless of mode of HIV transmission or prior drug use history. Men acknowledged more misuse of prescription analgesics over an approximate 1-year period compared with women, after taking into account pain, use of analgesics specifically for pain, and drug use history. Weaker associations between pain and use of analgesics specifically for pain that persisted over time were found among women compared with men. For both men and women, pain was stable over time. Problem drug use history exerted significant direct and indirect effects on pain, opioid misuse, and pain-specific analgesic use across sex. Conclusion. The current findings are consistent with prior evidence indicating female pain predominance as well as the undertreatment of pain among women with HIV. Efforts should be made to improve the assessment and long-term management of pain in HIV+ persons. C1 [Tsao, Jennie C. I.] Univ Calif Los Angeles, David Geffen Sch Med, Pediat Pain Program, Dept Pediat, Los Angeles, CA 90024 USA. [Stein, Judith A.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Dobalian, Aram] Univ Calif Los Angeles, Sch Publ Hlth, VA Greater Los Angeles Healthcare Syst HSR&D, Ctr Excellence Study Healthcare Provider Behav, Los Angeles, CA 90024 USA. [Dobalian, Aram] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. RP Tsao, JCI (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Pediat Pain Program, Dept Pediat, 1072 Gayley Ave, Los Angeles, CA 90024 USA. EM jtsao@mednet.ucla.edu FU National Institute on Drug Abuse [DA017026, DA01070-35]; RAND [U01HS08578]; Agency for Healthcare Research and Quality [U01HS08578]; Health Resources and Services Administration; National Institute of Mental Health; National Institute on Drug Abuse; Office of Research on Minority Health through the National Institute for Dental Research; Robert Wood Johnson Foundation; Merck and Company; Glaxo-Wellcome; National Institute on Aging FX Support for this research was provided by DA017026 awarded to the first author and by DA01070-35 awarded to the second author by the National Institute on Drug Abuse. The HIV Cost and Services Utilization Study (HCSUS) was supported by a cooperative agreement (U01HS08578) between RAND and the Agency for Healthcare Research and Quality. Substantial additional support for this agreement was provided by the Health Resources and Services Administration, the National Institute of Mental Health, the National Institute on Drug Abuse, and the Office of Research on Minority Health through the National Institute for Dental Research. Additional support was provided by the Robert Wood Johnson Foundation, Merck and Company, Glaxo-Wellcome, and the National Institute on Aging. The authors thank Gisele Pham for her secretarial and administrative contributions to this research project, and the participants in this study. NR 36 TC 7 Z9 7 U1 3 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PY 2010 VL 11 IS 6 BP 815 EP 824 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 604YK UT WOS:000278314200004 PM 20456074 ER PT J AU Scrivani, S Wallin, D Moulton, EA Cole, S Wasan, AD Lockerman, L Bajwa, Z Upadhyay, J Becerra, L Borsook, D AF Scrivani, Steven Wallin, Diana Moulton, Eric A. Cole, Sadie Wasan, Ajay D. Lockerman, Larry Bajwa, Zahid Upadhyay, Jaymin Becerra, Lino Borsook, David TI A fMRI Evaluation of Lamotrigine for the Treatment of Trigeminal Neuropathic Pain: Pilot Study SO PAIN MEDICINE LA English DT Article DE Neuropathy; Chronic Pain; Pain Medicine ID PLACEBO-CONTROLLED TRIAL; NOXIOUS THERMAL STIMULI; DOUBLE-BLIND; ANTIEPILEPTIC DRUGS; DIABETIC-NEUROPATHY; HEALTHY-VOLUNTEERS; OROFACIAL PAIN; NEURALGIA; MECHANISMS; SCALE AB Using functional magnetic resonance imaging (fMRI) methods, we evaluated the effects of lamotrigine vs placebo in a double-blind 1:1 randomized trial. Six patients with neuropathic pain were recruited for the study. All subjects had baseline pain > 4/10 on a visual analog scale (VAS) and allodynia to brush as inclusion criteria for the study. Patients underwent two fMRI sessions, with half of the subjects receiving placebo first and half receiving drug first (based on the blinding protocol). Lamotrigine decreased their average pain intensity level from 5.6 to 3.5 on a VAS. All subjects had brush, cold, and heat applied to the affected and mirror-unaffected sides of their face. The results show: 1) in a small cohort, lamotrigine had a significant effect on heat VAS but not on the other stimuli; and 2) contrast analysis of fMRI results for heat stimuli applied to the affected face for lamotrigine vs placebo produced an overall decrease in blood oxygen dependent level signal, suggesting a potential inhibitory effect of the drug on predominantly cortical regions (frontal, parietal, and temporal). C1 [Scrivani, Steven; Wallin, Diana; Moulton, Eric A.; Cole, Sadie; Upadhyay, Jaymin; Becerra, Lino; Borsook, David] McLean Hosp, PAIN Grp, Brain Imaging Ctr, Belmont, MA 02478 USA. [Wasan, Ajay D.] Brigham & Womens Hosp, Dept Anesthesiol & Psychiat, Boston, MA 02115 USA. [Lockerman, Larry] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Belmont, MA 02178 USA. [Scrivani, Steven] Tufts Univ, Tufts Med Ctr, Craniofacial Pain & Headache Ctr, Boston, MA 02111 USA. [Bajwa, Zahid] UMass Mem Med Ctr, TMJ Headache Ctr, Worcester, MA USA. [Becerra, Lino; Borsook, David] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Becerra, Lino; Borsook, David] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Scrivani, S (reprint author), McLean Hosp, PAIN Grp, Brain Imaging Ctr, 115 Mill St, Belmont, MA 02478 USA. EM rmaciewicz@pbsmedicalconsulting.com OI Wallin, Diana/0000-0003-4244-0314 FU GlaxoSmithKline FX This work was supported by an investigator-initiated grant from GlaxoSmithKline. NR 58 TC 11 Z9 12 U1 1 U2 8 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PY 2010 VL 11 IS 6 BP 920 EP 941 PG 22 WC Medicine, General & Internal SC General & Internal Medicine GA 604YK UT WOS:000278314200016 PM 20492571 ER PT J AU Buckalew, N Haut, MW Aizenstein, H Morrow, L Perera, S Kuwabara, H Weiner, DK AF Buckalew, Neilly Haut, Marc W. Aizenstein, Howard Morrow, Lisa Perera, Subashan Kuwabara, Hiroto Weiner, Debra K. TI Differences in Brain Structure and Function in Older Adults with Self-Reported Disabling and Nondisabling Chronic Low Back Pain SO PAIN MEDICINE LA English DT Article DE Chronic Pain; Older Adults; Structural MRI; Functional MRI; Disability ID POSITRON-EMISSION-TOMOGRAPHY; WHITE-MATTER MICROSTRUCTURE; SUPPLEMENTARY MOTOR AREA; HUMAN CEREBRAL-CORTEX; ILLNESS RATING-SCALE; MINI-MENTAL STATE; GRAY-MATTER; PHYSICAL PERFORMANCE; BODY-COMPOSITION; GAIT SPEED AB Objective. The primary aim of this pilot study was to identify structural and functional brain differences in older adults with self-reported disabling chronic low back pain (CLBP) compared with those who reported nondisabling CLBP. Design. Cross-sectional. Participants. Sixteen cognitively intact older adults, eight with disabling CLBP and eight with nondisabling CLBP. Exclusions were psychiatric or neurological disorders, substance abuse, opioid use, or diabetes mellitus. Methods. Participants underwent: structural and functional brain MRI; neuropsychological assessment using the Repeatable Battery for the Assessment of Neuropsychological Status, Trail Making Tests A and B; and physical performance assessment using the Short Physical Performance Battery. Results. In the disabled group, there was significantly lower white matter (WM) integrity (P < 0.05) of the splenium of the corpus callosum. This group also demonstrated activation of the right medial prefrontal cortex at rest whereas the nondisabled demonstrated activation of the left lateral prefrontal cortex. Combined groups analysis revealed a strong positive correlation (r(s) = 0.80, P < 0.0002) between WM integrity of the left centrum semiovale with gait-speed. Secondary analysis revealed a strong negative correlation between total months of CLBP and WM integrity of the SCC (r(s) = -0.59, P < 0.02). Conclusions. Brain structure and function is different in older adults with disabling CLBP compared with those with nondisabling CLBP. Deficits in brain morphology combining groups are associated with pain duration and poor physical function. Our findings suggest brain structure and function may play a key role in chronic pain related disability and may be important treatment targets. C1 [Morrow, Lisa; Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Sch Med, Pittsburgh, PA 15213 USA. [Perera, Subashan] Univ Pittsburgh, Dept Med, Sch Med, Pittsburgh, PA 15213 USA. [Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15213 USA. [Aizenstein, Howard] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15213 USA. [Aizenstein, Howard] Univ Pittsburgh, Adv Ctr Intervent & Serv Res Late life Mood Disor, Pittsburgh, PA 15213 USA. [Aizenstein, Howard] Univ Pittsburgh, John Hartford Ctr Excellence Geriatr Psychiat, Pittsburgh, PA 15213 USA. [Haut, Marc W.] Univ Pittsburgh, Dept Behav Med & Psychiat, Pittsburgh, PA 15213 USA. [Haut, Marc W.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. [Haut, Marc W.] Univ Pittsburgh, Dept Radiol, Pittsburgh, PA 15213 USA. [Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Kuwabara, Hiroto] Johns Hopkins, Dept Radiol, Baltimore, MD USA. RP Buckalew, N (reprint author), Univ Pittsburgh, MSEL, Sch Med, Clin Scientist Training Program, Suite 500,Kaufmann Bldg,3471 5th Ave, Pittsburgh, PA 15213 USA. EM neilly.buckalew@gmail.com RI Perera, Subashan/D-7603-2014; OI Haut, Marc/0000-0003-0235-362X FU National Institute on Aging [T32 AG021885]; NIA; University of Pittsburgh's Claude Pepper Older Americans Independence Center [AG024827] FX The authors would like to generously thank the following people for their assistance and hard work in completing this study: Denise Davis at the University of Pittsburgh Medical Center, Presbyterian MR Research Center; Kate Dunfee and Meg Nable research assistants to Dr. Howard Aizenstein; and Dr. R. P. Detwiler. We would also like to thank Dr. Stephanie Studenski for sponsoring Neilly Buckalew under a National Institute on Aging grant (T32 AG021885) and thank you to Dr. Amber Barnato of the CSTP and Dr. Michael Boninger of the Department of Physical Medicne and Rehabilitation for their added mentorship. We also extend our gratitude to the NIA for funding Ms. Buckalew's training as well as to Dr. Arthur Levine, Senior Vice Chancellor for the Health Sciences and Dean of the School of Medicine at the University of Pittsburgh. This work was also supported by a grant from the University of Pittsburgh's Claude Pepper Older Americans Independence Center AG024827. NR 127 TC 16 Z9 16 U1 2 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PY 2010 VL 11 IS 8 BP 1183 EP 1197 PG 15 WC Medicine, General & Internal SC General & Internal Medicine GA 632WL UT WOS:000280459900008 PM 20609128 ER PT J AU Oaklander, AL AF Oaklander, Anne Louise TI Role of Minimal Distal Nerve Injury in Complex Regional Pain Syndrome-I SO PAIN MEDICINE LA English DT Article DE Nerve Injury; Chronic Pain; Allodynia; Animal Model; Reflex Sympathetic Dystrophy ID REFLEX SYMPATHETIC DYSTROPHY; DORSAL-HORN NEURONS; PERIPHERAL-NERVE; NEUROPATHIC PAIN; SAPHENOUS NERVE; RAT; INNERVATION; CELLS; REORGANIZATION; INHIBITION C1 [Oaklander, Anne Louise] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA. [Oaklander, Anne Louise] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA. RP Oaklander, AL (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, 275 Charles St,Warren Bldg 310, Boston, MA 02114 USA. EM aoaklander@partners.org FU Public Health Service [R01NS 42866, K24NS059892]; family foundations FX Supported in part by the Public Health Service (R01NS 42866, K24NS059892) and family foundations. NR 39 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PY 2010 VL 11 IS 8 BP 1251 EP 1256 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 632WL UT WOS:000280459900015 PM 20704673 ER PT J AU Caraway, DL Kloth, D Hirsch, JA Deer, TE Datta, S Falco, FJE Helm, S AF Caraway, David L. Kloth, David Hirsch, Joshua A. Deer, Timothy E. Datta, Sukdeb Falco, Frank J. E. Helm, Standiford TI In Response To: Are We Lemmings Going Off a Cliff? The Case Against the "Interventional" Pain Medicine Label SO PAIN MEDICINE LA English DT Letter C1 [Caraway, David L.] Tri State LLC, Ctr Pain Relief, St Marys Reg Med Ctr, Huntington, WV USA. [Deer, Timothy E.] W Virginia Univ Med, Charleston, WV USA. [Kloth, David] Connecticut Pain Care, Danbury, CT USA. [Hirsch, Joshua A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Datta, Sukdeb] Vanderbilt Univ, Intervent Pain Program, Nashville, TN USA. [Falco, Frank J. E.] Temple Univ, Sch Med, Newark, DE USA. [Helm, Standiford] Pacific Coast Pain Management Ctr, Laguna Hills, CA USA. RP Caraway, DL (reprint author), Tri State LLC, Ctr Pain Relief, St Marys Reg Med Ctr, Huntington, WV USA. NR 7 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PY 2010 VL 11 IS 8 BP 1303 EP 1304 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 632WL UT WOS:000280459900023 PM 20704679 ER PT J AU Shugarman, LR Asch, SM Meredith, LS Sherbourne, CD Hagenmeier, E Wen, L Cohen, A Rubenstein, LV Goebel, J Lanto, A Lorenz, KA AF Shugarman, Lisa R. Asch, Steven M. Meredith, Lisa S. Sherbourne, Cathy D. Hagenmeier, Emily Wen, Li Cohen, Angela Rubenstein, Lisa V. Goebel, Joy Lanto, Andy Lorenz, Karl A. TI Factors Associated with Clinician Intention to Address Diverse Aspects of Pain in Seriously III Outpatients SO PAIN MEDICINE LA English DT Article DE Pain; Depression; Mental Health; Opioids; Antidepressants; Existential Pain; Spiritual Pain ID 5TH VITAL SIGN; PRIMARY-CARE; PERSISTENT PAIN; MEDICAL VISITS; CANCER PAIN; QUALITY; DEPRESSION; COMMUNICATION; VIGNETTES; BEHAVIOR AB Background. Pain is a common, often undertreated problem among patients with palliative needs. Objectives. To evaluate clinician factors associated with intention to address diverse aspects of pain. Design. Clinicians reviewed a clinical vignette describing a frail elderly patient with advanced hormone-refractory metastatic prostate cancer, depression, and pain not on analgesic therapy. Clinicians were surveyed about their intentions for treatment. Participants. All 280 primary care and specialist clinicians working in 19 hospital and community-based primary care, oncology, and cardiology clinics at eight geographically dispersed sites in two large VA hospital systems. Main Measures. Endpoints were clinician intention to deliver guideline-concordant care: prescribe opioids/antidepressants, assess existential wellbeing, and offer mental health referral. Demographic and behavioral measures were evaluated in association with endpoints. Key Results. Of 208 (74%) responding practitioners, 189 were responsible for prescribing decisions. Of those, 86, 77, 75, and 69 were "very"/"somewhat likely" to prescribe opioids, antidepressants, refer to a mental health specialist, or assess existential wellbeing, respectively. Factors associated with greater intent to prescribe an opioid or antidepressant included female gender, being an attending physician, being a primary care clinician, and greater confidence in pain management skills. Greater trust in the validity of pain ratings was associated with intent to prescribe an antidepressant and assess existential wellbeing. Prescribing opioids was less likely if perceived as an administrative burden. Assessing existential wellbeing was less likely if time constraints were perceived a barrier to evaluating pain. Female gender was the only factor associated with intent to refer to a mental health specialist. Conclusions. Our findings suggest useful targets for improving pain management include bolstering clinician confidence in pain management and their trust in pain ratings. C1 [Asch, Steven M.; Rubenstein, Lisa V.; Lorenz, Karl A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Wen, Li] Vet Adm Long Beach Healthcare Syst, Long Beach, CA USA. [Goebel, Joy] Calif State Univ Long Beach, Sch Nursing, Long Beach, CA 90840 USA. [Asch, Steven M.; Hagenmeier, Emily; Cohen, Angela; Rubenstein, Lisa V.; Lanto, Andy; Lorenz, Karl A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Asch, Steven M.; Meredith, Lisa S.; Sherbourne, Cathy D.; Rubenstein, Lisa V.; Lorenz, Karl A.] RAND Corp, Santa Monica, CA USA. [Shugarman, Lisa R.] SCAN Fdn, Long Beach, CA USA. RP Lorenz, KA (reprint author), VA Greater Los Angeles Healthcare Syst, 113101 Wilshire Blvd, Los Angeles, CA 90073 USA. EM karl.lorenz@va.gov FU The Veterans Administration [IIR-030150]; VA HSRD FX Dr Karl Lorenz was supported by a VA HSR&D, Career Development Award. This study was funded by The Veterans Administration (IIR-030150). NR 29 TC 6 Z9 6 U1 1 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PY 2010 VL 11 IS 9 BP 1365 EP 1372 DI 10.1111/j.1526-4637.2010.00931.x PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 647SA UT WOS:000281638100008 PM 20807347 ER PT J AU Manchikanti, L Falco, FJE Boswell, MV Hirsch, JA AF Manchikanti, Laxmaiah Falco, Frank J. E. Boswell, Mark V. Hirsch, Joshua A. TI Facts, Fallacies, and Politics of Comparative Effectiveness Research: Part I. Basic Considerations SO PAIN PHYSICIAN LA English DT Review DE Comparative effectiveness research; evidence-based medicine; Institute of Medicine; National Institute for Health and Clinical Excellence; interventional pain management; interventional techniques; geographic variations; inappropriate care ID LOW-BACK-PAIN; EVIDENCE-BASED MEDICINE; CAUDAL EPIDURAL INJECTIONS; CLINICAL-PRACTICE GUIDELINES; MEDIAL BRANCH BLOCKS; FACET JOINT PAIN; DEGENERATIVE SPINAL-DISORDERS; HEALTH TECHNOLOGY ASSESSMENTS; RANDOMIZED CONTROLLED-TRIALS; ACUTE MYOCARDIAL-INFARCTION AB While the United States leads the world in many measures of health care innovation, it has been suggested that it lags behind many developed nations in a variety of health outcomes. It has also been stated that the United States continues to outspend all other Organisation for Economic Co-operation and Development (OECD) countries by a wide margin. Spending on health goods and services per person in the United States, in 2007, increased to $7,290 - almost 21/2 times the average of all OECD countries. Rising health care costs in the United States have been estimated to increase to 19.1% of gross domestic product (GDP) or $4.4 trillion by 2018. The increases are illustrated in both public and private sectors. Higher health care costs in the United States are implied from the variations in the medical care from area to area around the country, with almost 50% of medical care being not evidence-based, and finally as much as 30% of spending reflecting medical care of uncertain or questionable value. Thus, comparative effectiveness research (CER) has been touted by supporters with high expectations to resolve most ill effects of health care in the United States and provide high quality, less expensive, universal health care. CER is defined as the generation and synthesis of evidence that compares the benefits and harms of alternate methods to prevent, diagnose, treat, and monitor a clinical condition or to improve the delivery of care. The efforts of CER in the United States date back to the late 1970's even though it was officially born with the Medicare Modernization Act (MMA) and has been rejuvenated with the American Recovery and Reinvestment Act (ARRA) of 2009 with an allocation of $1.1 billion. CER has been the basis for health care decision-making in many other countries. According to the International Network of Agencies for Health Technology Assessments (INAHTA), many industrialized countries have bodies that are charged with health technology assessments (HTAs) or comparative effectiveness studies. Of all the available agencies, the National Institute for Health and Clinical Excellence (NICE) of the United Kingdom is the most advanced, stable, and has provided significant evidence, though based on rigid and proscriptive economic and clinical formulas. While CER is making a rapid surge in the United States, supporters and opponents are expressing their views. Part I of this comprehensive review will describe facts, fallacies, and politics of CER with discussions to understand basic concepts of CER. C1 [Manchikanti, Laxmaiah] Pain Management Ctr Paducah, Paducah, KY USA. [Falco, Frank J. E.] Mid Atlantic Spine & Pain Specialists Newark, Newark, DE USA. [Boswell, Mark V.] Texas Tech Univ, Hlth Sci Ctr, Int Pain Ctr, Lubbock, TX 79430 USA. [Hirsch, Joshua A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Hirsch, Joshua A.] Harvard Univ, Sch Med, Boston, MA USA. [Hirsch, Joshua A.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. RP Manchikanti, L (reprint author), 2831 Lone Oak Rd, Paducah, KY 42003 USA. EM drlm@thepainmd.com NR 217 TC 109 Z9 109 U1 2 U2 15 PU AM SOC INTERVENTIONAL PAIN PHYSICIANS PI PADUCAH PA 81 LAKEVIEW DR, PADUCAH, KY 42001 USA SN 1533-3159 J9 PAIN PHYSICIAN JI Pain Physician PD JAN-FEB PY 2010 VL 13 IS 1 BP E23 EP E54 PG 32 WC Anesthesiology; Clinical Neurology SC Anesthesiology; Neurosciences & Neurology GA 857IT UT WOS:000297712500002 PM 20119474 ER PT J AU Manchikanti, L Falco, FJE Boswell, MV Hirsch, JA AF Manchikanti, Laxmaiah Falco, Frank J. E. Boswell, Mark V. Hirsch, Joshua A. TI Facts, Fallacies, and Politics of Comparative Effectiveness Research: Part 2-Implications for Interventional Pain Management SO PAIN PHYSICIAN LA English DT Review DE Comparative effectiveness research; evidence-based medicine; Institute of Medicine; National Institute for Health and Clinical Excellence; interventional pain management; interventional techniques; geographic variations; inappropriate care ID LOW-BACK-PAIN; EVIDENCE-BASED MEDICINE; CAUDAL EPIDURAL INJECTIONS; SPINAL-CORD STIMULATION; CLINICAL-PRACTICE GUIDELINE; TECHNOLOGY-ASSESSMENT-SUBCOMMITTEE; PHARMACEUTICAL BENEFITS SCHEME; CONGRESSIONAL BUDGET OFFICE; RADICULAR LUMBOSACRAL PAIN; FACET JOINT INTERVENTIONS AB The United States leads the world in many measures of health care innovation. However, it has been criticized to lag behind many developed nations in important health outcomes including mortality rates and higher health care costs. The surveys have shown the United States to outspend all other Organisation for Economic Co-operation and Development (OECD) countries with spending on health goods and services per person of $7,290 - almost 21/2 times the average of all OECD countries in 2007. Rising health care costs in the United States have been estimated to increase to 19.1% of gross domestic product (GDP) or $4.4 trillion by 2018. CER is defined as the generation and synthesis of evidence that compares the benefits and harms of alternate methods to prevent, diagnose, treat, and monitor a clinical condition or to improve the delivery of care. The, comparative effectiveness research (CER) has been touted by supporters with high expectations to resolve most ill effects of health care in the United States providing high quality, less expensive, universal health care. The efforts of CER in the United States date back to the late 1970s and it was officially inaugurated with the enactment of the Medicare Modernization Act (MMA). It has been rejuvenated with the American Recovery and Reinvestment Act (ARRA) of 2009 with an allocation of $1.1 billion. CER has been the basis of decision for health care in many other countries. Of all the available agencies, the National Institute for Health and Clinical Excellence (NICE) of the United Kingdom is the most advanced, stable, and has provided significant evidence, though based on rigid and proscriptive economic and clinical formulas. While CER is taking a rapid surge in the United States, supporters and opponents are emerging expressing their views. Since interventional pain management is a new and evolving specialty, with ownership claimed by numerous organizations, at times it is felt as if it has many fathers and other times it becomes an orphan. Part 2 of this comprehensive review will provide facts, fallacies, and politics of CER along with discussion of potential outcomes, impact of CER on health care delivery, and implications for interventional pain management in the United States. C1 [Manchikanti, Laxmaiah] Pain Management Ctr Paducah, Paducah, KY USA. [Falco, Frank J. E.] Mid Atlantic Spine & Pain Specialists Newark, Newark, DE USA. [Boswell, Mark V.] Texas Tech Univ, Hlth Sci Ctr, Dept Anesthesiol, Lubbock, TX 79430 USA. [Hirsch, Joshua A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Hirsch, Joshua A.] Harvard Univ, Sch Med, Boston, MA USA. [Boswell, Mark V.] Texas Tech Univ, Hlth Sci Ctr, Int Pain Ctr, Lubbock, TX 79430 USA. [Hirsch, Joshua A.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. RP Manchikanti, L (reprint author), 2831 Lone Oak Rd, Paducah, KY 42003 USA. EM drlm@thepainmd.com NR 180 TC 93 Z9 93 U1 1 U2 9 PU AM SOC INTERVENTIONAL PAIN PHYSICIANS PI PADUCAH PA 81 LAKEVIEW DR, PADUCAH, KY 42001 USA SN 1533-3159 J9 PAIN PHYSICIAN JI Pain Physician PD JAN-FEB PY 2010 VL 13 IS 1 BP E55 EP E79 PG 25 WC Anesthesiology; Clinical Neurology SC Anesthesiology; Neurosciences & Neurology GA 857IT UT WOS:000297712500003 PM 20119475 ER PT J AU Correa-Gallego, C Ferrone, CR Thayer, SP Wargo, JA Warshaw, AL Fernandez-del Castillo, C AF Correa-Gallego, Camilo Ferrone, Cristina R. Thayer, Sarah P. Wargo, Jennifer A. Warshaw, Andrew L. Fernandez-del Castillo, Carlos TI Incidental Pancreatic Cysts: Do We Really Know What We Are Watching? SO PANCREATOLOGY LA English DT Article DE Branch-duct IPMNs; Cystic neoplasms; Incidental pancreatic cysts; Intraductal papillary mucinous neoplasms; Main-duct IPMNs; Mucinous cystic neoplasms; Pancreas, cystic neoplasms; Pancreatic cysts ID PAPILLARY MUCINOUS NEOPLASMS; RESECTION AB Background: Most cystic neoplasms of the pancreas (CNPs) are incidentally discovered. Their management continues to be debated and preoperative diagnosis is often inaccurate. Methods: Retrospective review of 330 patients with incidentally discovered CNPs. Preoperative and final histological diagnoses were correlated. Results: 41% (136/330) of patients were operated on at diagnosis. 50 patients underwent resection for a presumed branch-duct (Bd) intraductal papillary mucinous neoplasm (IPMN), which was confirmed in only 64% (32/50); of the remaining patients, 20% had main-duct involvement. Mucinous cystic neoplasm was the preoperative diagnosis in 30/136 patients, histologic examination was confirmatory in only 60% (18/30). Most lesions presumed to be main-duct or combined IPMNs or serous cystadenomas were confirmed as such after resection (15/16 and 11/12, respectively). Multifocality was not only associated with Bd-IPMN, and 5% of all cysts were non-neoplastic. Overall, in only 68% of cases did the preoperative and histological diagnoses match. Conclusions: In an experienced, high-volume center, preoperative diagnosis was incorrect in one-third of incidentally discovered CNPs who underwent resection. Of particular concern, 20% of presumed Bd-IPMN had a main-duct component. Conversely, 5% of resected cysts were not even neoplastic. Clearly, better diagnostic methods are needed to aid in formulating appropriate treatment strategies. Copyright (C) 2010 S. Karger AG, Basel and IAP C1 [Correa-Gallego, Camilo; Ferrone, Cristina R.; Thayer, Sarah P.; Wargo, Jennifer A.; Warshaw, Andrew L.; Fernandez-del Castillo, Carlos] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. RP Fernandez-del Castillo, C (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg, 15 Parkman St,WAC 460, Boston, MA 02114 USA. EM cfernandez@partners.org FU NCI NIH HHS [P01 CA117969, P01 CA117969-03, P50 CA127003, P50 CA127003-02, P50 CA127003-04] NR 11 TC 94 Z9 96 U1 1 U2 5 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1424-3903 J9 PANCREATOLOGY JI Pancreatology PY 2010 VL 10 IS 2-3 BP 144 EP 150 DI 10.1159/000243733 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 621MO UT WOS:000279583200007 PM 20484954 ER PT J AU Vesterhus, M Raeder, H Kurpad, AJ Kawamori, D Molven, A Kulkarni, RN Kahn, CR Njolstad, PR AF Vesterhus, Mette Raeder, Helge Kurpad, Amarnath J. Kawamori, Dan Molven, Anders Kulkarni, Rohit N. Kahn, C. Ronald Njolstad, Pal Rasmus TI Pancreatic Function in Carboxyl-Ester Lipase Knockout Mice SO PANCREATOLOGY LA English DT Article DE Carboxyl-ester lipase; MODY; Exocrine dysfunction ID DIET-INDUCED OBESITY; CHOLESTERYL ESTER; RETINYL ESTER; MUTATIONS; DEFICIENCY; INSULIN; MOUSE; GENE; ABSORPTION; RECEPTOR AB Background/Aims: CEL-MODY is a monogenic form of diabetes and exocrine pancreatic insufficiency due to mutations in the carboxyl-ester lipase (CEL) gene. We aimed to investigate endocrine and exocrine pancreatic function in CEL knockout mice (CELKO). Methods: A knockout mouse model with global targeted deletion of CEL was investigated physiologically and histopathologically, and compared to littermate control CEL+/+ mice at 7 and 12 months on normal chow and high-fat diets (HFD), i.e. 42 and 60% fat by calories. Results: CELKO+/+ and -/- mice showed normal growth and development and normal glucose metabolism on a chow diet. Female CEL-/- mice on 60% HFD, on the other hand, had increased random blood glucose compared to littermate controls (p = 0.02), and this was accompanied by a reduction in glucose tolerance that did not reach statistical significance. In these mice there was also islet hyperplasia, however, alpha- and beta-islet cells appeared morphologically normal and pancreatic exocrine function was also normal. Conclusion: Although we observed mild glucose intolerance in female mice with whole-body knockout of CEL, the full phenotype of human CEL-MODY was not reproduced, suggesting that the pathogenic mechanisms involved are more complex than a simple loss of CEL function. Copyright (C) 2010 S. Karger AG, Basel and IAP C1 [Njolstad, Pal Rasmus] Univ Bergen, Dept Clin Med, Sect Pediat, NO-5020 Bergen, Norway. [Vesterhus, Mette; Raeder, Helge; Njolstad, Pal Rasmus] Haukeland Hosp, Dept Pediat, N-5021 Bergen, Norway. [Molven, Anders] Haukeland Hosp, Dept Pathol, N-5021 Bergen, Norway. [Molven, Anders] Univ Bergen, Gade Inst, NO-5020 Bergen, Norway. [Kurpad, Amarnath J.; Kawamori, Dan; Kulkarni, Rohit N.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Cell & Mol Physiol, Boston, MA 02115 USA. [Vesterhus, Mette; Raeder, Helge; Kahn, C. Ronald; Njolstad, Pal Rasmus] Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Obes, Boston, MA 02115 USA. RP Njolstad, PR (reprint author), Univ Bergen, Dept Clin Med, Sect Pediat, NO-5020 Bergen, Norway. EM pal.njolstad@uib.no OI Njolstad, Pal R./0000-0003-0304-6728 FU Haukeland University Hospital; Innovest; Research Council of Norway; University of Bergen, Norway; Fulbright Foundation; ESPE; Norwegian Research Council; Manpei Suzuki Diabetes Foundation, Japan; JDRF; National Institutes of Health [DK33201, DK55545]; Joslin Diabetes and Endocrinology Research Center [5P30 DK36836]; Joslin Diabetes Center [DK34834, RO1 DK 67536] FX We want to thank Dr. Laurence Panicot, Beth Israel Deaconess Medical Center, Boston, Mass., USA, for kindly rederiving and providing us with the CELKO mice, Heike Immervoll for assisting with the assessment of histological sections, and Anita Nordboe, Liv Aasmul and Michael Rourk for practical assistance. This study was supported in part by funds from Haukeland University Hospital, Innovest, The Research Council of Norway, and University of Bergen, Norway, the Fulbright Foundation (to P.R.N.) and an ESPE Sabbatical Leave Programme (to P.R.N.), a Leiv Eiriksson Mobility Grant from The Norwegian Research Council (to M. V.), a Research Fellowship (Manpei Suzuki Diabetes Foundation, Japan; to D. K.), a JDRF Post-doctoral Fellowship (to D. K.) and by National Institutes of Health Grants DK33201 and DK55545, Joslin Diabetes and Endocrinology Research Center, Grant 5P30 DK36836 Specialized Assay Core, the Joslin Diabetes Center, Grant DK34834 (to C.R.K.) and RO1 DK 67536 (to R.N.K.). NR 34 TC 12 Z9 14 U1 1 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1424-3903 J9 PANCREATOLOGY JI Pancreatology PY 2010 VL 10 IS 4 BP 467 EP 476 DI 10.1159/000266284 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 661TO UT WOS:000282751200009 PM 20720448 ER PT J AU Sepucha, K Ozanne, EM AF Sepucha, Karen Ozanne, Elissa M. TI How to define and measure concordance between patients' preferences and medical treatments: A systematic review of approaches and recommendations for standardization SO PATIENT EDUCATION AND COUNSELING LA English DT Review DE Quality; Decisions; Decision making; Measurement; Patient-centered ID RANDOMIZED CONTROLLED-TRIAL; LIFE-SUSTAINING TREATMENT; DECISION-MAKING; BREAST-CANCER; PATIENTS CHOICES; HORMONE-THERAPY; PATIENTS VALUES; PRIMARY-CARE; WOMEN; AID AB Objective: The purpose is to systematically review the methods used to calculate the association between patients' preferences and treatment choices and to present a set of recommendations for definition and measurement of this concept. Methods: A systematic review of the literature from 1967 to 2007 identified articles that reported a relationship between patients' preferences and their treatment choices. Potential citations were identified from electronic databases, the Cochrane Collaborative review, and identified experts. Relevant articles were abstracted by two reviewers independently using standard forms. Results: The search identified 3114 unique citations, the full text of 180 articles was examined, and 49 articles were included. These 49 studies used a variety of definitions of preferences and choices, and calculated concordance in different ways. Half of the studies tied their method to a theoretical framework. There were problems with many of the studies that limit the ability to generalize or make comparisons across studies. Conclusion: There is no consistent method for defining or calculating the match between patients' preferences and treatment choices. There is a need for more clarity in the definition and reporting of this type of concordance in measures of decision quality. Practice Implications: The match between an informed patient's preferences and treatment choices is a key component of patient-centered care. Valid and reliable measures of the level of concordance are needed. (C) 2009 Elsevier Ireland Ltd. All rights reserved. C1 [Sepucha, Karen] Harvard Univ, Hlth Decis Res Unit, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. [Ozanne, Elissa M.] HMS, MGH, Inst Technol Assessment, Boston, MA USA. RP Sepucha, K (reprint author), Harvard Univ, Hlth Decis Res Unit, Massachusetts Gen Hosp, Sch Med, 50 Staniford St,Suite 936, Boston, MA 02114 USA. EM ksepucha@partners.org FU Foundation for informed Medical Decision Making; American Cancer Society [MRSG112037] FX Financial support for this study was provided by a contract to Massachusetts General Hospital from the Foundation for informed Medical Decision Making. The funding agreement ensured the authors' independence in designing the study. interpreting the data, writing, and publishing the report. Dr. Ozanne was also supported in part by grant number MRSG112037 from the American Cancer Society. NR 71 TC 21 Z9 21 U1 2 U2 12 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD JAN PY 2010 VL 78 IS 1 BP 12 EP 23 DI 10.1016/j.pec.2009.05.011 PG 12 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 549MJ UT WOS:000274053300003 PM 19570647 ER PT J AU DeMarco, TA Nusbaum, RH Peshkin, BN Patenaude, AF Schneider, KA Garber, JE Valdimarsdottir, HB Tercyak, KP AF DeMarco, Tiffani A. Nusbaum, Rachel H. Peshkin, Beth N. Patenaude, Andrea F. Schneider, Katherine A. Garber, Judy E. Valdimarsdottir, Heiddis B. Tercyak, Kenneth P. TI Prevalence and correlates of mothers and fathers attending pretest cancer genetic counseling together SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Cancer; Breast cancer; Genetic counseling; BRCA1/2 testing; Parents ID FAMILY SYSTEM CHARACTERISTICS; PARENTING ALLIANCE; HEREDITARY BREAST; OVARIAN-CANCER; BRCA1/2; CHILDREN; SUSCEPTIBILITY; WOMEN; NEEDS; COMMUNICATION AB Objective: To determine the prevalence of fathers' attendance at pretest cancer genetic Counseling sessions with mothers undergoing BRCA1/2 genetic testing for hereditary breast/ovarian cancer (HBOC) risk, and to identify psychosocial and other correlates of fathers' attendance. Methods: One hundred and twenty-one fathers of minor-age children who were spouses/partners of women (mothers) undergoing such counseling and testing were recruited, completed a behavioral self-report survey, and provided data about their sociodemographic backgrounds, father-child cancer communication histories, parenting relationship quality, and information-seeking and perceived knowledge. Results: A total of 27.3% of fathers attended pretest cancer genetic Counseling with mothers. Compared to fathers who did not attend pretest cancer genetic counseling, those who did had stronger parenting alliances with mothers, were more likely to have sought out information about BRCA1/2 testing, and felt more informed about testing. In an adjusted logistic regression model of session attendance, the strength of the parenting alliance was associated with a 6% increase in the likelihood of attending genetic counseling (odds ratio [OR] = 1.06, 95% confidence interval [CI] = 1.01, 1.12, p < .05) and greater perceived knowledge about BRCA1/2 testing was associated with a four-fold increase in the likelihood of session attendance (OR = 4.03, CI = 1.77, 9.37, p < .001). Conclusion: One in three fathers attend pretest cancer genetic counseling with mothers undergoing BRCA1/2 testing; those who do have closer parenting relationships and are more informed about BRCA1/2 testing. Practice implications: When possible, providers should discuss mothers including fathers in cancer genetic counseling sessions as this may affect outcomes of HBOC genetic counseling and testing. (C) 2009 Elsevier Ireland Ltd. All rights reserved. C1 [DeMarco, Tiffani A.; Nusbaum, Rachel H.; Peshkin, Beth N.; Tercyak, Kenneth P.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA. [Patenaude, Andrea F.; Schneider, Katherine A.; Garber, Judy E.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Valdimarsdottir, Heiddis B.] Mt Sinai Sch Med, New York, NY USA. RP Tercyak, KP (reprint author), Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, 3300 Whitehaven St NW,Suite 4100, Washington, DC 20007 USA. EM tercyakk@georgetown.edu FU National Institutes of Health's National Human Genome Research Institute [HG002686]; National Cancer Institute [CA091831]; Jess and Mildred Fisher Center for Familial Cancer Research at the Lombardi Comprehensive Cancer Center FX The authors would like to thank Marilyn Sampilo, Lara Wilson, Lauren Wine Grella, Clinton Finch, and Scott Kelly for their contributions to this research. We are also grateful to McKinsey Goodenberger for assistance with the literature review, and to the participants who took part in this study.; This research was supported by grants from the National Institutes of Health's National Human Genome Research Institute (HG002686) and National Cancer Institute (CA091831) to Dr. Tercyak with additional support from the Jess and Mildred Fisher Center for Familial Cancer Research at the Lombardi Comprehensive Cancer Center. NR 39 TC 5 Z9 5 U1 0 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD JAN PY 2010 VL 78 IS 1 BP 29 EP 33 DI 10.1016/j.pec.2009.05.013 PG 5 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 549MJ UT WOS:000274053300005 PM 19545972 ER PT J AU Trivedi, RB Ayotte, BJ Thorpe, CT Edelman, D Bosworth, HB AF Trivedi, Ranak B. Ayotte, Brian J. Thorpe, Carolyn T. Edelman, David Bosworth, Hayden B. TI Is there a nonadherent subtype of hypertensive patient? A latent class analysis approach SO PATIENT PREFERENCE AND ADHERENCE LA English DT Article DE adherence; hypertension; latent class analysis; self-management AB To determine subtypes of adherence, 636 hypertensive patients (48% White, 34% male) reported adherence to medications, diet, exercise, smoking, and home blood pressure monitoring. A latent class analysis approach was used to identify subgroups that adhere to these five self-management behaviors. Fit statistics suggested two latent classes. The first class (labeled "more adherent") included patients with greater probability of adhering to recommendations compared with the second class (labeled "less adherent") with regard to nonsmoking (97.7% versus 76.3%), medications (75.5% versus 49.5%), diet (70.7% versus 46.9%), exercise (63.4% versus 27.2%), and blood pressure monitoring (32% versus 3.4%). Logistic regression analyses used to characterize the two classes showed that "more adherent" participants were more likely to report full-time employment, adequate income, and better emotional and physical well-being. Results suggest the presence of a less adherent subtype of hypertensive patients. Behavioral interventions designed to improve adherence might best target these at-risk patients for greater treatment efficiency. C1 [Trivedi, Ranak B.] VA Puget Sound Hlth Care Syst, NW Hlth Serv Res & Dev Serv Ctr Excellence, Seattle, WA USA. [Ayotte, Brian J.] Boston VA Hlth Care Syst, Boston, MA USA. [Thorpe, Carolyn T.] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI USA. [Edelman, David; Bosworth, Hayden B.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. RP Trivedi, RB (reprint author), 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM ranak.trivedi@va.gov FU NHLBI [R01 HL070713]; Pfizer; American Heart Association; VA Puget Sound Health Care System FX This study was supported by NHLBI Grant R01 HL070713, a Pfizer Health Communication Initiative Award, and an American Heart Association Established Investigator Award, awarded to HBB, the principal investigator, who has full access to all of the data in the study and takes responsibility for the integrity of the data and its analysis. Results were initially presented at the 67th Annual Meeting of the American Psychosomatic Society. This work was supported in part by the facilities provided by the VA Puget Sound Health Care System where RBT is a core investigator. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government. We would like to thank Dr Joshua Thorpe for his suggestions regarding presentation of the analytic approach and results. NR 41 TC 3 Z9 3 U1 2 U2 4 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1177-889X J9 PATIENT PREFER ADHER JI Patient Prefer. Adherence PY 2010 VL 4 BP 255 EP 262 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA V21NV UT WOS:000208215200031 PM 20694185 ER PT J AU Hausmann, LRM Ren, DX Sevick, MA AF Hausmann, Leslie R. M. Ren, Dianxu Sevick, Mary Ann TI Racial differences in diabetes-related psychosocial factors and glycemic control in patients with type 2 diabetes SO PATIENT PREFERENCE AND ADHERENCE LA English DT Article DE diabetes mellitus; type 2; minority health; health status disparities; psychosocial factors; disease management AB Background: We examined whether diabetes-related psychosocial factors differ between African American and white patients with type 2 diabetes. We also tested whether racial differences in glycemic control are independent of such factors. Methods: Baseline glycosylated hemoglobin (HbA(1c)) and survey measures from 79 African American and 203 white adult participants in a diabetes self-management clinical trial were analyzed. Results: Several psychosocial characteristics varied by race. Perceived interference of diabetes with daily life, perceived diabetes severity, and diabetes-related emotional distress were higher for African Americans than for whites, as were access to illness-management resources and social support. Mean HbA(1c) levels were higher among African Americans than whites (8.14 vs 7.40, beta = 0.17). This difference persisted after adjusting for demographic, clinical, and diabetes-related psychosocial characteristics that differed by race (beta = 0.18). Less access to illness-management resources (beta = -0.25) and greater perceived severity of diabetes (beta = 0.21) also predicted higher HbA(1c). Discussion: Although racial differences in diabetes-related psychosocial factors were observed, African Americans continued to have poorer glycemic control than whites even after such differences were taken into account. Interventions that target psychosocial factors related to diabetes management, particularly illness-management resources, may be a promising way to improve glycemic control for all patients. C1 [Hausmann, Leslie R. M.; Sevick, Mary Ann] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Sevick, Mary Ann] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15206 USA. [Ren, Dianxu] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA. [Sevick, Mary Ann] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15261 USA. [Sevick, Mary Ann] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA. RP Hausmann, LRM (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr,151C-H, Pittsburgh, PA 15206 USA. EM leslie.hausmann@va.gov FU Veterans Affairs Pittsburgh Healthcare System in Pittsburgh, PA; VA Health Services Research and Development Career Development Awards [RCD 06-287, ER 0280-1]; [NIH/NINR/NR-R01008792]; [NIH/NCRR/CTSA-UL1-RR024153]; [NIH/NCRR/GCRC-M01-RR000056] FX The work of this paper was supported by the following grants: NIH/NINR/NR-R01008792, NIH/NCRR/CTSA-UL1-RR024153, and NIH/NCRR/GCRC-M01-RR000056. This material is also the result of work supported by resources and the use of facilities at the Veterans Affairs Pittsburgh Healthcare System in Pittsburgh, PA. Dr Hausmann was supported by VA Health Services Research and Development Career Development Awards (RCD 06-287 and ER 0280-1). The authors take full responsibility for the contents of this paper, which do not represent the views of the Department of Veterans Affairs or the United States Government. The authors would like to acknowledge the individual contributions of: Rita Marsh, RN, MSN; Deborah Klinvex, BA; Tienna Luster; Beth Hall, RD; and Kathleen O'Malley, BA, BPhil. NR 66 TC 10 Z9 10 U1 0 U2 6 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1177-889X J9 PATIENT PREFER ADHER JI Patient Prefer. Adherence PY 2010 VL 4 BP 291 EP 299 DI 10.2147/PPA.S12353 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA V21NV UT WOS:000208215200035 PM 20859456 ER PT B AU Wenk, JF Zhang, ZH Cheng, GM Sun, K Walker, JC Saloner, DA Ratcliffe, MB Guccione, JM AF Wenk, Jonathan F. Zhang, Zhihong Cheng, Guangming Sun, Kay Walker, Joseph C. Saloner, David A. Ratcliffe, Mark B. Guccione, Julius M. BE Kerckhoffs, RCP TI In Vivo Myocardial Material Properties and Stress Distributions in Normal and Failing Human Hearts SO PATIENT -SPECIFIC MODELING OF THE CARDIOVASCULAR SYSTEM: TECHNOLOGY-DRIVEN PERSONALIZED MEDICINE LA English DT Article; Book Chapter ID LEFT-VENTRICULAR ANEURYSM; FINITE-ELEMENT-ANALYSIS; TAGGED MR-IMAGES; CANINE LEFT-VENTRICLE; WALL STRESS; DOPPLER-ECHOCARDIOGRAPHY; DILATED CARDIOMYOPATHY; 3-DIMENSIONAL STRAIN; DIASTOLIC FUNCTION; MODEL C1 [Wenk, Jonathan F.; Guccione, Julius M.] Univ Calif San Francisco, Dept Vet Affairs Med Ctr, Div Surg Serv 112D, San Francisco, CA 94121 USA. [Cheng, Guangming] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94121 USA. [Ratcliffe, Mark B.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Wenk, JF (reprint author), Univ Calif San Francisco, Dept Vet Affairs Med Ctr, Div Surg Serv 112D, Bldg 2,Room 106,4150 Clement St, San Francisco, CA 94121 USA. EM jonathan.wenk@va.gov NR 49 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-6690-2 PY 2010 BP 131 EP 144 DI 10.1007/978-1-4419-6691-9_8 D2 10.1007/978-1-4419-6691-9 PG 14 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical SC Cardiovascular System & Cardiology; Engineering GA BQY34 UT WOS:000282103700008 ER PT B AU Wiggs, JL AF Wiggs, Janey L. BE Giaconi, JA Law, SK Coleman, AL Caprioli, J TI Other Tests in Glaucoma: Genetic Testing SO PEARLS OF GLAUCOMA MANAGEMENT LA English DT Article; Book Chapter ID OPEN-ANGLE GLAUCOMA; PRIMARY CONGENITAL GLAUCOMA; DNA-SEQUENCE VARIANTS; CYP1B1 MUTATIONS; UNITED-STATES; LOXL1 GENE; POPULATION; PSEUDOEXFOLIATION; SUSCEPTIBILITY; ASSOCIATION C1 Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA. RP Wiggs, JL (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA. EM janey_wiggs@meei.harvard.edu NR 22 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-3-540-68238-7 PY 2010 BP 149 EP 156 DI 10.1007/978-3-540-68240-0_18 D2 10.1007/978-3-540-68240-0 PG 8 WC Ophthalmology SC Ophthalmology GA BNL12 UT WOS:000274840900018 ER PT B AU Walton, DS AF Walton, David S. BE Giaconi, JA Law, SK Coleman, AL Caprioli, J TI Pediatric Glaucoma: Angle Surgery and Glaucoma Drainage Devices SO PEARLS OF GLAUCOMA MANAGEMENT LA English DT Article; Book Chapter ID OUTCOMES C1 [Walton, David S.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. RP Walton, DS (reprint author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, 2 Longfellow Pl,Suite 201, Boston, MA 02114 USA. EM blacki@att.net NR 9 TC 2 Z9 2 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-3-540-68238-7 PY 2010 BP 403 EP 408 DI 10.1007/978-3-540-68240-0_52 D2 10.1007/978-3-540-68240-0 PG 6 WC Ophthalmology SC Ophthalmology GA BNL12 UT WOS:000274840900052 ER PT B AU Rhee, DJ AF Rhee, Douglas J. BE Giaconi, JA Law, SK Coleman, AL Caprioli, J TI Complications: Blebitis SO PEARLS OF GLAUCOMA MANAGEMENT LA English DT Article; Book Chapter ID VITREOUS PENETRATION; LEVOFLOXACIN C1 [Rhee, Douglas J.] Childrens Hosp, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Rhee, Douglas J.] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Rhee, DJ (reprint author), Childrens Hosp, Massachusetts Eye & Ear Infirm, 243Charles St, Boston, MA 02114 USA. EM DouaRhee@aol.com NR 7 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-3-540-68238-7 PY 2010 BP 457 EP 459 DI 10.1007/978-3-540-68240-0_61 D2 10.1007/978-3-540-68240-0 PG 3 WC Ophthalmology SC Ophthalmology GA BNL12 UT WOS:000274840900061 ER PT B AU McBride, SM Haas-Kogan, D AF McBride, Sean M. Haas-Kogan, Daphne BE Gupta, N Banerjee, A HaasKogan, D TI Intracranial Germ Cell Tumors SO PEDIATRIC CNS TUMORS, SECOND EDITION SE Pediatric Oncology LA English DT Article; Book Chapter ID CENTRAL-NERVOUS-SYSTEM; PINEAL REGION TUMORS; INVOLVED-FIELD RADIOTHERAPY; RESIDUAL MATURE TERATOMA; RADIATION-THERAPY; PRIMARY CHEMOTHERAPY; CEREBROSPINAL-FLUID; COMBINATION CHEMOTHERAPY; PATIENT POPULATIONS; SFOP EXPERIENCE C1 [McBride, Sean M.] Massachusetts Gen Hosp, Harvard Radiat Oncol Program, Dept Radiat Oncol, Boston, MA 02215 USA. [Haas-Kogan, Daphne] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Radiat Oncol, San Francisco, CA 94115 USA. [Haas-Kogan, Daphne] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Neurol Surg, San Francisco, CA 94115 USA. RP McBride, SM (reprint author), Massachusetts Gen Hosp, Harvard Radiat Oncol Program, Dept Radiat Oncol, 100 Blossom St, Boston, MA 02215 USA. EM seanmatthewmcbride@gmail.com; dhaaskogan@radonc.ucsf.edu NR 94 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-3-540-87976-3 J9 PEDIATR ONCOL-BERLIN PY 2010 BP 115 EP 133 DI 10.1007/978-3-540-87979-4_6 D2 10.1007/978-3-540-87979-4 PG 19 WC Oncology; Pediatrics SC Oncology; Pediatrics GA BMQ46 UT WOS:000273348100006 ER PT B AU McBride, SM Haas-Kogan, DA AF McBride, Sean M. Haas-Kogan, Daphne A. BE Gupta, N Banerjee, A HaasKogan, D TI Advances in Radiation Therapy SO PEDIATRIC CNS TUMORS, SECOND EDITION SE Pediatric Oncology LA English DT Article; Book Chapter ID GROWTH-FACTOR RECEPTOR; PEDIATRIC BRAIN-TUMORS; CENTRAL-NERVOUS-SYSTEM; RECURRENT GLIOBLASTOMA-MULTIFORME; GASTROINTESTINAL STROMAL TUMORS; ACUTE LYMPHOBLASTIC-LEUKEMIA; EXTERNAL-BEAM RADIOTHERAPY; SENSORINEURAL HEARING-LOSS; CHILDHOOD-CANCER SURVIVOR; PRIOR CRANIAL IRRADIATION C1 [McBride, Sean M.] Massachusetts Gen Hosp, Dept Radiat Oncol, Harvard Radiat Oncol Program, Boston, MA 02215 USA. [Haas-Kogan, Daphne A.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Radiat Oncol, San Francisco, CA 94115 USA. [Haas-Kogan, Daphne A.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Neurol Surg, San Francisco, CA 94115 USA. RP McBride, SM (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Harvard Radiat Oncol Program, 100 Blossom St, Boston, MA 02215 USA. EM seanmatthewmcbride@gmail.com; dhaaskogan@radonc.ucsf.edu NR 118 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-3-540-87976-3 J9 PEDIATR ONCOL-BERLIN PY 2010 BP 313 EP 334 DI 10.1007/978-3-540-87979-4_16 D2 10.1007/978-3-540-87979-4 PG 22 WC Oncology; Pediatrics SC Oncology; Pediatrics GA BMQ46 UT WOS:000273348100016 ER PT S AU Misra, M Klibanski, A AF Misra, Madhusmita Klibanski, Anne BA Maghnie, M BF Maghnie, M BE Loche, S Cappa, M Ghizzoni, L TI Neuroendocrine Consequences of Anorexia Nervosa in Adolescents SO PEDIATRIC NEUROENDOCRINOLOGY SE Endocrine Development LA English DT Proceedings Paper CT Workshop on Pediatric Neuroendocrinology CY MAY 17-19, 2009 CL Cagliari, ITALY ID BONE-MINERAL DENSITY; REGIONAL BODY-COMPOSITION; GROWTH-HORMONE; HEALTHY ADOLESCENTS; SECRETORY DYNAMICS; LUTEINIZING-HORMONE; WEIGHT-GAIN; FEMALE ADOLESCENTS; BINDING-PROTEIN; BULIMIA-NERVOSA AB Anorexia nervosa (AN) is a condition of severe undernutrition characterized by alterations in multiple neuroendocrine axes and peptides that signal or regulate energy intake. These alterations include a state of hypogonadotropic hypogonadism, a nutritionally acquired resistance to growth hormone (GH) with low IGF-1 levels, relative hypercortisolemia, low total T3 despite normal TSH, low levels of leptin and insulin, and elevated levels of ghrelin, peptide YY (PYY) and possibly adiponectin. Although many of these changes are adaptive to low weight, they can impact bone metabolism, body composition, reproductive function and statural growth. Low bone mass is characteristic of AN in both adolescent boys and girls. In girls, sites of trabecular bone are more likely to be affected than sites of cortical bone, whereas in boys with AN, sites of cortical bone are more commonly affected. Bone microarchitecture is also affected in adolescent girls with AN, with a decrease in trabecular thickness and bone trabecular volume, and an increase in trabecular separation. Important predictors of low bone density include nutritional factors, body composition, hypogonadism, low IGF-1, elevated cortisol and PYY levels, with possible contributions of low insulin. Weight gain is associated with a stabilization of bone density, although residual deficits persist in the short term, and in some cases, long term. Copyright (C) 2010 S. Karger AG, Basel C1 [Misra, Madhusmita] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA. RP Misra, M (reprint author), Massachusetts Gen Hosp, Neuroendocrine Unit, BUL 457,55 Fruit St, Boston, MA 02114 USA. EM mmisra@partners.org FU NCRR NIH HHS [K23 RR018851] NR 65 TC 29 Z9 29 U1 1 U2 6 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1421-7082 BN 978-3-8055-9302-1 J9 ENDOCR DEV JI Endocr. Dev. PY 2010 VL 17 BP 197 EP 214 PG 18 WC Endocrinology & Metabolism; Neurosciences; Pediatrics SC Endocrinology & Metabolism; Neurosciences & Neurology; Pediatrics GA BOE77 UT WOS:000276397500018 PM 19955768 ER PT B AU Shin, L Henderson, DC AF Shin, Lauren Henderson, David C. BE Freemark, M TI Obesity and Metabolic Dysfunction in the Child with a Major Behavioral Disorder: Atypical Antipsychotics SO PEDIATRIC OBESITY: ETIOLOGY, PATHOGENESIS, AND TREATMENT SE Contemporary Endocrinology LA English DT Article; Book Chapter DE Psychotropic; psychiatric; orlistat; metformin ID RANDOMIZED CONTROLLED-TRIAL; SCHOOL-AGED CHILDREN; INDUCED WEIGHT-GAIN; DOUBLE-BLIND; PEDIATRIC-PATIENTS; DIABETES-MELLITUS; ADVERSE EVENTS; ADOLESCENTS; SCHIZOPHRENIA; RISPERIDONE C1 [Shin, Lauren] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Shin, Lauren] Maryville Acad, Scott Nolan Ctr, Des Plaines, IL 60016 USA. [Henderson, David C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Freedom Trail Clin, Boston, MA 02114 USA. RP Shin, L (reprint author), Rush Univ, Med Ctr, Chicago, IL 60612 USA. NR 50 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-60327-873-7 J9 CONTEMP ENDOCRINOL S PY 2010 BP 369 EP 376 DI 10.1007/978-1-60327-874-4_25 D2 10.1007/978-1-60327-874-4 PG 8 WC Endocrinology & Metabolism; Medicine, General & Internal; Pediatrics SC Endocrinology & Metabolism; General & Internal Medicine; Pediatrics GA BQT26 UT WOS:000281780600025 ER PT J AU Shah, SS Ten Have, TR Metlay, JP AF Shah, Samir S. Ten Have, Thomas R. Metlay, Joshua P. TI Costs of Treating Children With Complicated Pneumonia: A Comparison of Primary Video-Assisted Thoracoscopic Surgery and Chest Tube Placement SO PEDIATRIC PULMONOLOGY LA English DT Article DE pleural effusion; empyema; thoracoscopy; resource utilization ID PEDIATRIC PARAPNEUMONIC EMPYEMA; COMMUNITY-ACQUIRED PNEUMONIA; PROPENSITY SCORES; MANAGEMENT; EFFUSIONS; DRAINAGE; OUTCOMES; THERAPY; CARE; DECORTICATION AB Objectives: To describe charges associated with primary video-assisted thoracoscopic surgery (VATS) and primary chest tube placement in a multicenter cohort of children with empyema and to determine whether pleural fluid drainage by primary VATS was associated with cost-savings compared with primary chest tube placement. Study Design: Retrospective cohort study Setting and Participants Administrative database containing inpatient resource utilization data from 27 tertiary care children's hospitals. Patients between 12 months and 18 years of age diagnosed with complicated pneumonia were eligible if they were discharged between 2001 and 2005 and underwent early (within 2 days of index hospitalization) pleural fluid drainage. Main Exposure: Method of pleural fluid drainage, categorized as VATS or chest tube placement. Results: Pleural drainage in the 764 patients was performed by VATS (n = 50) or chest tube placement (n = 714). There were 521 (54%) males. Median hospital charges were $36,320 [interquartile range (IQR), $24,814-$62,269]. The median pharmacy and radiologic imaging charges were $5,884 (IQR, $3,142-$11,357) and $2,875 (IQR, $1,703-$4,950), respectively Adjusting for propensity score matching, patients undergoing primary VATS did not have higher charges than patients undergoing primary chest tube placement. Conclusions: In this multicenter study, we found that the charges incurred in caring for children with empyema were substantial. However, primary VATS was not associated with higher total or pharmacy charges than primary chest tube placement, suggesting that the additional costs of performing VATS are offset by reductions in length of stay (LOS) and requirement for additional procedures. Pediatr Pulmonol. 2010; 45:71-77. (C) 2009 Wiley-Liss, Inc. C1 [Shah, Samir S.] Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA. [Shah, Samir S.] Childrens Hosp Philadelphia, Div Gen Pediat, Philadelphia, PA 19104 USA. [Shah, Samir S.; Ten Have, Thomas R.; Metlay, Joshua P.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Shah, Samir S.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. [Metlay, Joshua P.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Shah, Samir S.; Ten Have, Thomas R.; Metlay, Joshua P.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Metlay, Joshua P.] Vet Affairs Med Ctr, Philadelphia, PA USA. RP Shah, SS (reprint author), Childrens Hosp Philadelphia, Div Infect Dis, Room 1526,North Campus,34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM shahs@email.chop.edu FU National Institute of Allergy and Infectious Diseases [K01 AI73729, K24 AI073957]; Robert Wood Johnson Foundation FX Grant sponsor: National Institute of Allergy and Infectious Diseases; Grant number: K01 AI73729; Grant number: K24 AI073957. Grant sponsor: Robert Wood Johnson Foundation. NR 33 TC 13 Z9 13 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 8755-6863 J9 PEDIATR PULM JI Pediatr. Pulmonol. PD JAN PY 2010 VL 45 IS 1 BP 71 EP 77 DI 10.1002/ppul.21143 PG 7 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA 544BA UT WOS:000273625000010 PM 19953659 ER PT J AU Misra, M AF Misra, Madhusmita TI LESSONS LEARNED FROM METABOLIC BONE DISEASE ASSOCIATED WITH DISORDERED EATING SO PEDIATRIC PULMONOLOGY LA English DT Meeting Abstract ID ANOREXIA-NERVOSA; ADOLESCENT GIRLS; MINERAL DENSITY; DOUBLE-BLIND C1 [Misra, Madhusmita] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 7 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 8755-6863 J9 PEDIATR PULM JI Pediatr. Pulmonol. PY 2010 SU 33 BP 152 EP 154 PG 3 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA 664UQ UT WOS:000282988800036 ER PT J AU Thiagarajah, J Song, Y Derichs, N Verkman, A AF Thiagarajah, J. Song, Y. Derichs, N. Verkman, A. TI AIRWAY SURFACE LIQUID THICKNESS AND DYNAMICS IMAGED BY SURFACE LASER REFLECTANCE MICROSCOPY SO PEDIATRIC PULMONOLOGY LA English DT Meeting Abstract C1 [Thiagarajah, J.; Song, Y.; Derichs, N.; Verkman, A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Thiagarajah, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 8755-6863 J9 PEDIATR PULM JI Pediatr. Pulmonol. PY 2010 SU 33 BP 254 EP 254 PG 1 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA 664UQ UT WOS:000282988800183 ER PT J AU Liu, L Shastry, S Sloane, PA Mazur, M Parker, SB Bouma, BE Tearney, GJ Rowe, SM AF Liu, L. Shastry, S. Sloane, P. A. Mazur, M. Parker, S. B. Bouma, B. E. Tearney, G. J. Rowe, S. M. TI MODULATION OF ION TRANSPORT & MUCUS CLEARANCE IN CELLS & TISSUES: NEW INSIGHTS FROM VIDEO-RATE REFLECTANCE TOMOGRAPHY IMAGING SO PEDIATRIC PULMONOLOGY LA English DT Meeting Abstract C1 [Liu, L.; Bouma, B. E.; Tearney, G. J.] Harvard Univ, Sch Med, Boston, MA USA. [Liu, L.; Bouma, B. E.; Tearney, G. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Shastry, S.; Sloane, P. A.; Mazur, M.; Parker, S. B.; Rowe, S. M.] Univ Alabama, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 8755-6863 J9 PEDIATR PULM JI Pediatr. Pulmonol. PY 2010 SU 33 BP 297 EP 298 PG 2 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA 664UQ UT WOS:000282988800305 ER PT J AU Aitken, ML Flume, PA Geller, DE Lapey, A Zuckerman, J Fox, H Charlton, B AF Aitken, M. L. Flume, P. A. Geller, D. E. Lapey, A. Zuckerman, J. Fox, H. Charlton, B. TI SIX-MONTH ADMINISTRATION OF INHALED MANNITOL IN CYSTIC FIBROSIS - A SAFETY AND EFFICACY STUDY SO PEDIATRIC PULMONOLOGY LA English DT Meeting Abstract C1 [Aitken, M. L.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [Flume, P. A.] Med Univ S Carolina, Charleston, SC 29425 USA. [Geller, D. E.] Nemours Childrens Clin, Orlando, FL USA. [Lapey, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Zuckerman, J.] Maine Med Grp, Portland, ME USA. [Fox, H.; Charlton, B.] Pharmaxis Ltd, Sydney, NSW, Australia. NR 3 TC 1 Z9 1 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 8755-6863 J9 PEDIATR PULM JI Pediatr. Pulmonol. PY 2010 SU 33 BP 299 EP 299 PG 1 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA 664UQ UT WOS:000282988800308 ER PT J AU Hoffman, LR Moskowitz, SM Foster, JM Emerson, J Burns, JL Gibson, RL AF Hoffman, L. R. Moskowitz, S. M. Foster, J. M. Emerson, J. Burns, J. L. Gibson, R. L. TI TOBRAMYCIN SUSCEPTIBILITY OF PSEUDOMONAS AERUGINOSA CYSTIC FIBROSIS ISOLATES USING STANDARD & BIOFILM METHODS: RELATIONSHIP WITH ERADICATION & INFLAMMATION SO PEDIATRIC PULMONOLOGY LA English DT Meeting Abstract C1 [Hoffman, L. R.; Moskowitz, S. M.; Foster, J. M.; Emerson, J.; Burns, J. L.; Gibson, R. L.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. [Moskowitz, S. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 4 TC 0 Z9 0 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 8755-6863 J9 PEDIATR PULM JI Pediatr. Pulmonol. PY 2010 SU 33 BP 336 EP 337 PG 2 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA 664UQ UT WOS:000282988800413 ER PT J AU Dellon, EP Sawicki, GS Wolfe, J Hanson, LC AF Dellon, E. P. Sawicki, G. S. Wolfe, J. Hanson, L. C. TI PHYSICIANS' VIEWS ON COMMUNICATION ABOUT LIFE-SUSTAINING TREATMENTS IN CYSTIC FIBROSIS SO PEDIATRIC PULMONOLOGY LA English DT Meeting Abstract C1 [Dellon, E. P.; Hanson, L. C.] Univ N Carolina, Chapel Hill, NC USA. [Sawicki, G. S.] Childrens Hosp Boston, Boston, MA USA. [Wolfe, J.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 8755-6863 J9 PEDIATR PULM JI Pediatr. Pulmonol. PY 2010 SU 33 BP 388 EP 389 PG 2 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA 664UQ UT WOS:000282988800553 ER PT B AU Kwolek, CJ Patel, R AF Kwolek, Christopher J. Patel, Rajendra BE Fogarty, TJ White, RA TI The Current Status of Hybrid Repair of Thoracoabdominal Aortic Aneurysms SO PERIPHERAL ENDOVASCULAR INTERVENTIONS, THIRD EDITION LA English DT Article; Book Chapter ID OPEN-SURGICAL REPAIR; HIGH-RISK PATIENTS; ENDOVASCULAR TREATMENT; STENT-GRAFT; EXPERIENCE; OUTCOMES; TRIAL; REVASCULARIZATION; OPERATIONS; EXCLUSION C1 [Kwolek, Christopher J.; Patel, Rajendra] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Vasc & Endovasc Surg,Dept Surg, Boston, MA 02115 USA. RP Kwolek, CJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Vasc & Endovasc Surg,Dept Surg, Boston, MA 02115 USA. EM ckwolek@partners.org NR 35 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-1386-9 PY 2010 BP 389 EP 396 DI 10.1007/978-1-4419-1387-6_26 D2 10.1007/978-1-4419-1387-6 PG 8 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging; Surgery SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging; Surgery GA BPI61 UT WOS:000278928400026 ER PT J AU Kapoor, A Chuang, W Radhakrishnan, N Smith, KJ Berlowitz, D Segal, JB Katz, JN Losina, E AF Kapoor, Alok Chuang, Warren Radhakrishnan, Nila Smith, Kenneth J. Berlowitz, Dan Segal, Jodi B. Katz, Jeffrey N. Losina, Elena TI Cost Effectiveness of Venous Thromboembolism Pharmacological Prophylaxis in Total Hip and Knee Replacement A Systematic Review SO PHARMACOECONOMICS LA English DT Review ID DEEP-VEIN THROMBOSIS; MAJOR ORTHOPEDIC-SURGERY; MOLECULAR-WEIGHT HEPARIN; RANDOMIZED DOUBLE-BLIND; PROLONGED ENOXAPARIN THERAPY; ELECTIVE HIP; ANTITHROMBOTIC PROPHYLAXIS; POSTOPERATIVE FONDAPARINUX; DABIGATRAN ETEXILATE; UTILITY ANALYSIS AB Total hip and knee replacements (THR and TKR) are high-risk settings for venous thromboembolism (VTE). This review summarizes the cost effectiveness of VTE prophylaxis regimens for THR and TKR. We searched MEDLINE (January 1997 to October 2009), EMBASE (January 1997 to June 2009) and the UK NHS Economic Evaluation Database (1997 to October 2009). We analysed recent cost-effectiveness studies examining five categories of comparisons: (i) anticoagulants (warfarin, low-molecular-weight heparin [LMWH] or fondaparinux) versus acetylsalicylic acid (aspirin); (ii) LMWH versus warfarin; (iii) fondaparinux versus LMWH; (iv) comparisons with new oral anticoagulants; and (v) extended-duration (>= 3 weeks) versus short-duration (<3 weeks) prophylaxis. We abstracted information on cost and effectiveness for each prophylaxis regimen in order to calculate an incremental cost-effectiveness ratio. Because of variations in effectiveness units reported and horizon length analysed, we calculated two cost-effectiveness ratios, one for the number of symptomatic VTE events avoided at 90 days and the other for QALYs at the 1-year mark or beyond. Our search identified 33 studies with 67 comparisons. After standardization, comparisons between LMWH and warfarin were inconclusive, whereas fondaparinux dominated LMWH in nearly every comparison. The latter results were derived from radiographic VTE rates. Extended-duration prophylaxis after THR was generally cost effective. Small numbers prohibit conclusions about aspirin, new oral anticoagulants or extended-duration prophylaxis after TKR. Fondaparinux after both THR and TKR and extended-duration LMWH after THR appear to be cost-effective prophylaxis regimens. Small numbers for other comparisons and absence of trials reporting symptomatic endpoints prohibit comprehensive conclusions. C1 [Kapoor, Alok; Radhakrishnan, Nila] Boston Univ, Sch Med, Hosp Med Unit, Boston, MA 02118 USA. [Chuang, Warren] Massachusetts Gen Hosp, Hospitalist Med Grp, Boston, MA 02114 USA. [Smith, Kenneth J.] Univ Pittsburgh, Sch Med, Sect Decis Sci & Clin Syst Modelling, Pittsburgh, PA USA. [Berlowitz, Dan] Edith Nourse Rogers Mem Vet Adm Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA. [Berlowitz, Dan] Boston Univ, Sch Med, Boston, MA 02215 USA. [Segal, Jodi B.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Katz, Jeffrey N.; Losina, Elena] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Orthopaed Surg, Boston, MA 02115 USA. [Katz, Jeffrey N.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA. [Katz, Jeffrey N.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Orthopaed & Arthrit Ctr Outcomes Res, Boston, MA 02115 USA. [Losina, Elena] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA. RP Kapoor, A (reprint author), Boston Univ, Sch Med, Hosp Med Unit, Boston, MA 02118 USA. EM alok.kapoor@bmc.org RI Segal, Jodi/A-2863-2009 OI Segal, Jodi/0000-0003-3978-9662 FU NIAMS NIH HHS [K24 AR002123, K24 AR002123-10, K24 AR057827, K24 AR057827-03, P60 AR047782, P60 AR047782-10] NR 73 TC 11 Z9 11 U1 0 U2 6 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 1170-7690 J9 PHARMACOECONOMICS JI Pharmacoeconomics PY 2010 VL 28 IS 7 BP 521 EP 538 PG 18 WC Economics; Health Care Sciences & Services; Health Policy & Services; Pharmacology & Pharmacy SC Business & Economics; Health Care Sciences & Services; Pharmacology & Pharmacy GA 626SL UT WOS:000279987100001 PM 20550220 ER PT J AU Purschke, M Rubio, N Held, KD Redmond, RW AF Purschke, Martin Rubio, Noemi Held, Kathryn D. Redmond, Robert W. TI Phototoxicity of Hoechst 33342 in time-lapse fluorescence microscopy SO PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES LA English DT Article ID REC-MYC CELLS; CULTURED-CELLS; APOPTOSIS; CYCLE; CINEMATOGRAPHY; LINES AB Dyes that bind to DNA, such as Hoechst 33342, are commonly used to visualize chromatin in live cells by fluorescence microscopy. A caveat is that the probes themselves should not perturb cellular responses and under normal conditions the dyes are generally non-toxic. However, researchers are increasingly using computerized time-lapse microscopy (CTLM), where cells stained with fluorescent dyes are often imaged frequently over a period of several days, to follow cellular responses in real time. Little is currently known about possible toxicity of fluorescent DNA dyes under CTLM conditions. In this study we demonstrate that the common live-cell DNA stain Hoechst 33342 can cause apoptosis under CTLM conditions. Although toxicity is evident at long times in the absence of imaging at high dye concentrations, phototoxicity from repeated excitation of the dye in the imaging process is dominant. We show that phototoxicity is a function of the product of light fluence and dye concentration, irrespective of irradiance, frequency and total number of scans. Thus, phototoxicity can be prevented by a combination of dye concentration and imaging procedure that is below this threshold. These quantitative data can be used as a guide to others performing time-lapse microscopy studies with this common live-cell DNA stain and serves as a caution for researchers when using other fluorescent stains under CTLM conditions. C1 [Rubio, Noemi; Redmond, Robert W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA. [Purschke, Martin; Held, Kathryn D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02114 USA. RP Redmond, RW (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA. EM Redmond@helix.mgh.harvard.edu FU [NIH-P01 CA095227] FX This work was supported by NIH-P01 CA095227. We thank Dr William Dewey for the REC:myc cells and his advice with the CTLM, Ms Yulya Spantchak for assisting with CTLM analysis, Dr Yin-Chu Chen for assistance in setting up the CTML and Drs Howard Liber and Kevin Prise for helpful discussions. This paper is subject to NIH Public Access Policy. NR 18 TC 22 Z9 22 U1 0 U2 9 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1474-905X J9 PHOTOCH PHOTOBIO SCI JI Photochem. Photobiol. Sci. PY 2010 VL 9 IS 12 BP 1634 EP 1639 DI 10.1039/c0pp00234h PG 6 WC Biochemistry & Molecular Biology; Biophysics; Chemistry, Physical SC Biochemistry & Molecular Biology; Biophysics; Chemistry GA 684YA UT WOS:000284590000012 PM 20931137 ER PT S AU Huang, LY Dai, TH Hamblin, MR AF Huang, Liyi Dai, Tianhong Hamblin, Michael R. BE Gomer, CJ TI Antimicrobial Photodynamic Inactivation and Photodynamic Therapy for Infections SO PHOTODYNAMIC THERAPY: METHODS AND PROTOCOLS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Bacteria; fungus; microbiology; colony-forming units; Photorhabdus luminescens luciferase; bioluminescence imaging; mouse model of localized infection; antibiotic; wound healing ID MESOSUBSTITUTED CATIONIC PORPHYRINS; GRAM-NEGATIVE BACTERIA; PSEUDOMONAS-AERUGINOSA; ESCHERICHIA-COLI; ZINC PHTHALOCYANINE; WOUND INFECTIONS; BURNED MICE; IN-VIVO; PHOTOINACTIVATION; MICROORGANISMS AB Photodynamic therapy (PDT) was initially discovered over 100 years ago by its ability to kill microorganisms, but its use to treat infections clinically has not been much developed. However, the present relentless increase in antibiotic resistance worldwide and the emergence of strains that are resistant to all known antibiotics has stimulated research into novel antimicrobial strategies such as PDT that are thought to be unlikely to lead to the development of resistance. In this chapter we will cover the use of PDT to kill pathogenic microbial cells in vitro and describe a mouse model of localized infection and its treatment by PDT without causing excessive damage to the host tissue. C1 [Huang, Liyi; Dai, Tianhong; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Huang, Liyi; Dai, Tianhong; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Huang, Liyi] Guangxi Med Univ, Affiliated Coll & Hosp 1, Dept Infect Dis, Nanning, Peoples R China. [Hamblin, Michael R.] Harvard Mit Div Hlth Sci & Technol, Cambridge, MD USA. RP Huang, LY (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. OI Hamblin, Michael/0000-0001-6431-4605 FU NIAID NIH HHS [R01 AI050875, R01 AI050875-06] NR 36 TC 43 Z9 44 U1 1 U2 4 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-60761-696-2 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2010 VL 635 BP 155 EP 173 DI 10.1007/978-1-60761-697-9_12 D2 10.1007/978-1-60761-697-9 PG 19 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Radiology, Nuclear Medicine & Medical Imaging GA BOY59 UT WOS:000278067700012 PM 20552347 ER PT S AU Yaseen, MA Srinivasan, VJ Sakadzic, S Vinogradov, SA Boas, DA AF Yaseen, Mohammad A. Srinivasan, Vivek J. Sakadzic, Sava Vinogradov, Sergei A. Boas, David A. BE Kollias, N Choi, B Zeng, H Malek, RS Wong, BJF IIgner, JFR Gregory, KW Guillermo, JT Marcu, L Hirschberg, H Madsen, SJ Mandelis, A MahadevanJansen, A Jansen ED TI Optically based quantification of absolute cerebral metabolic rate of oxygen (CMRO2) with high spatial resolution in rodents SO PHOTONIC THERAPEUTICS AND DIAGNOSTICS VI SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Photonic Therapeutics and Diagnostics VI CY JAN 23-25, 2010 CL San Francisco, CA SP SPIE DE oxygen partial pressure; blood flow; cerebral metabolism; lifetime imaging microscopy; OCT ID BLOOD-FLOW; FUNCTIONAL ACTIVATION; PHOSPHORESCENCE; MICROSCOPY; DEPRESSION; TENSION AB Measuring oxygen delivery in brain tissue is important for identifying the pathophysiological changes associated with brain injury and various diseases such as cancer, stroke, and Alzheimer's disease. We have developed a multi-modal imaging system for minimally invasive measurement of cerebral oxygenation and blood flow in small animals with high spatial resolution. The system allows for simultaneous measurement of blood flow using Fourier-domain optical coherence tomography, and oxygen partial pressure (pO(2)) using either confocal or multiphoton phosphorescence lifetime imaging with exogenous porphyrin-based dyes sensitive to dissolved oxygen. Here we present the changes in pO(2) and blood flow in superficial cortical vessels of Sprague Dawley rats in response to conditions such as hypoxia, hyperoxia, and functional stimulation. pO(2) measurements display considerable heterogeneity over distances that cannot be resolved with more widely used oxygen-monitoring techniques such as BOLD-fMRI. Large increases in blood flow are observed in response to functional stimulation and hypoxia. Our system allows for quantification of cerebral metabolic rate of oxygen (CMRO2) with high spatial resolution, providing a better understanding of metabolic dynamics during functional stimulation and under various neuropathologies. Ultimately, better insight into the underlying mechanisms of neuropathologies will facilitate the development of improved therapeutic strategies to minimize damage to brain tissue. C1 [Yaseen, Mohammad A.; Srinivasan, Vivek J.; Sakadzic, Sava; Boas, David A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Radiol, MGH MIT HMS Athinuola A Martinos Ctr Biomed Imagi, Charlestown, MA 02129 USA. RP Yaseen, MA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Radiol, MGH MIT HMS Athinuola A Martinos Ctr Biomed Imagi, Charlestown, MA 02129 USA. EM dboas@nmr.mgh.harvard.edu NR 20 TC 1 Z9 1 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-7944-0 J9 PROC SPIE PY 2010 VL 7548 AR 75483R DI 10.1117/12.842904 PG 9 WC Biophysics; Optics SC Biophysics; Optics GA BRY80 UT WOS:000283924300073 ER PT J AU Lisitza, N Huang, XD Hatabu, H Patz, S AF Lisitza, Natalia Huang, Xudong Hatabu, Hiroto Patz, Samuel TI Exploring collagen self-assembly by NMR SO PHYSICAL CHEMISTRY CHEMICAL PHYSICS LA English DT Article ID ATOMIC-FORCE MICROSCOPE; TRIPLE-HELICAL PEPTIDE; MAGNETIC-RESONANCE; I COLLAGEN; FIBRILLOGENESIS; WATER; (PRO-HYP-GLY)(10); RELAXATION; DYNAMICS; TENDON AB The time-dependence of the NMR signal intensity of collagen type I is representative of protein aggregation. It is pH sensitive and can be related to aggregation mechanism. C1 [Lisitza, Natalia; Huang, Xudong; Hatabu, Hiroto; Patz, Samuel] Harvard Univ, Brigham & Womens Hosp, Dept Radiol, Sch Med, Boston, MA 02115 USA. [Huang, Xudong] Harvard Univ, Dept Psychiat, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. RP Lisitza, N (reprint author), Harvard Univ, Brigham & Womens Hosp, Dept Radiol, Sch Med, Boston, MA 02115 USA. EM nlisitza@partners.org RI Patz, Samuel/I-2879-2012; OI Patz, Samuel/0000-0002-4500-1918 FU Center for Pulmonary Imaging; Department of Radiology at Brigham and Women's Hospital FX We thankfully acknowledge funding from Center for Pulmonary Imaging and Department of Radiology at Brigham and Women's Hospital. We also thank Dr Yi-Qiao Song (Schlumberger Doll Research) for reviewing the manuscript and helpful discussions. NR 23 TC 3 Z9 3 U1 0 U2 9 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1463-9076 J9 PHYS CHEM CHEM PHYS JI Phys. Chem. Chem. Phys. PY 2010 VL 12 IS 42 BP 14169 EP 14171 DI 10.1039/c0cp00651c PG 3 WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical SC Chemistry; Physics GA 668IS UT WOS:000283262400035 PM 20877840 ER PT J AU Melhorn, SJ Krause, EG Scott, KA Mooney, MR Johnson, JD Woods, SC Sakai, RR AF Melhorn, Susan J. Krause, Eric G. Scott, Karen A. Mooney, Marie R. Johnson, Jeffrey D. Woods, Stephen C. Sakai, Randall R. TI Acute exposure to a high-fat diet alters meal patterns and body composition SO PHYSIOLOGY & BEHAVIOR LA English DT Article DE Meal patterns; High-fat diet; Body weight; Body composition ID OBESE ZUCKER RAT; FOOD-INTAKE; POSTPRANDIAL SATIETY; MACRONUTRIENT INTAKE; FEEDING PATTERNS; RESISTANT RATS; ENERGY-BALANCE; FEMALE RATS; OLETF RATS; SIZE AB Weight gain and adiposity are often attributed to the overconsumption of unbalanced, high-fat diets however, the pattern of consumption can also contribute to associated body weight and compositional changes. The present Study explored the rapid alterations in meal patterns of normal-weight rats given continuous access to high-fat diet and examined body weight and composition changes compared to chow fed controls. Ten Long-Evans rats were implanted with Subcutaneous microchips for meal pattern analysis. Animals were body weight matched and separated into two groups: high-fat or chow fed. Each group was maintained on their assigned diet for nine days and monitored for 22 h each day for meal pattern behavior. Body weight was evaluated every other day, and body composition measures were taken prior and following diet exposure. High-fat fed animals gained more weight and adipose tissue than chow fed controls and displayed a reduced meal frequency and increased meal size. Furthermore, meal size was significantly correlated with the gain of adipose tissue. Together, these results Suggest that consumption of a high-fat diet can rapidly alter meal patterns, which in turn contribute to the development of adiposity. Published by Elsevier Inc. C1 [Melhorn, Susan J.; Krause, Eric G.; Scott, Karen A.; Woods, Stephen C.; Sakai, Randall R.] Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45237 USA. [Melhorn, Susan J.; Scott, Karen A.] Univ Cincinnati, Coll Med, Program Neurosci, Cincinnati, OH 45237 USA. [Mooney, Marie R.; Johnson, Jeffrey D.] Univ Cincinnati, Dept Biomed Engn, Cincinnati, OH 45221 USA. RP Melhorn, SJ (reprint author), VA Puget Sound Hlth Care Syst, Lattemann Lab 151S, 1660 So Columbian Way, Seattle, WA 98108 USA. EM smelhorn@u.washington.edu FU NIDDK NIH HHS [R01 DK066596, R01 DK066596-06] NR 60 TC 25 Z9 25 U1 0 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0031-9384 J9 PHYSIOL BEHAV JI Physiol. Behav. PD JAN PY 2010 VL 99 IS 1 BP 33 EP 39 DI 10.1016/j.physbeh.2009.10.004 PG 7 WC Psychology, Biological; Behavioral Sciences SC Psychology; Behavioral Sciences GA 553NL UT WOS:000274374000005 PM 19835896 ER PT J AU Claypool, BM Yoder, SC Citron, DM Finegold, SM Goldstein, EJC Haake, SK AF Claypool, Brianna M. Yoder, Sean C. Citron, Diane M. Finegold, Sydney M. Goldstein, Ellie J. C. Haake, Susan Kinder TI Mobilization and prevalence of a fusobacterial plasmid SO PLASMID LA English DT Article DE Fusobacterium nucleatum; Mobilization; Conjugation; Plasmid; pFN1 ID ENDODONTIC INFECTIONS; NUCLEATUM; PROTEIN; BACTERIA; GENE; IDENTIFICATION; MUTAGENESIS; RELAXOSOME; ABSCESSES; SEQUENCE AB Fusobacterium nucleatum is a Gram-negative anaerobic rod found in dental plaque biofilms, and is an opportunistic pathogen implicated in periodontitis as well as a wide range of systemic abscesses and infections. Genomic analyses of F. nucleatum indicate considerable genetic diversity and a prominent role for horizontal gene transfer in the evolution of the species. Several plasmids isolated from F nucleatum, including pFN1, harbor relaxase gene homologs that may function in plasmid mobilization. In this investigation we examined the RP4-mediated mobilization properties of pFN1 and the prevalence of pFN1-related sequences in a panel of F. nucleatum clinical isolates. The fusobacterial plasmid pFN1 was mobilized by RP4 at a high frequency. Deletion analyses were used to delineate the core mobilon of pFN1, which consisted of the relaxase gene (rlx), an upstream open reading frame ORF4 and a region of DNA upstream of ORF4 with potential nic sites. To examine the prevalence of pFN1 in a panel of clinical isolates, total DNA isolated from the strains was hybridized with pFN1 replication (repA) and rlx gene probes. DNA from strains harboring plasmids known to be homologous to pFN1 hybridized with both the repA and rlx probes. Five additional strains were rlx-positive but repA-negative, indicating a greater prevalence of rlx-related genes in comparison with repA-related genes. Plasmid or plasmid-related sequences were identified in 11.5% of the strains examined. These findings demonstrate mobilization properties of a fusobacterial plasmid that may be important in horizontal gene transfer. (C) 2009 Elsevier Inc. All rights reserved. C1 [Claypool, Brianna M.; Yoder, Sean C.; Haake, Susan Kinder] Univ Calif Los Angeles, Sch Dent, Sect Periodont, Los Angeles, CA 90095 USA. [Haake, Susan Kinder] Univ Calif Los Angeles, Sch Dent, Dent Res Inst, Los Angeles, CA 90095 USA. [Citron, Diane M.; Goldstein, Ellie J. C.] RM Alden Lab, Culver City, CA USA. [Finegold, Sydney M.] W Los Angeles Vet Adm, Wadsworth Anaerobe Lab, Los Angeles, CA USA. RP Haake, SK (reprint author), Univ Calif Los Angeles, Sch Dent, Sect Periodont, 10833 Conte Ave, Los Angeles, CA 90095 USA. EM shaake@ucla.edu FU NIH/NIDCR PHS [DE015348] FX We thank Dr. David Haake for his review of this manuscript. We additional acknowledge Dr. Sharon Hunt Gerardo and Ms. Anna Kreymer for suggestions and technical assistance, respectively. This investigation was supported by NIH/NIDCR PHS Grant No. DE015348 (S.K.H.). NR 36 TC 3 Z9 3 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0147-619X J9 PLASMID JI Plasmid PD JAN PY 2010 VL 63 IS 1 BP 11 EP 19 DI 10.1016/j.plasmid.2009.09.001 PG 9 WC Genetics & Heredity; Microbiology SC Genetics & Heredity; Microbiology GA 544YA UT WOS:000273695400002 PM 19761790 ER PT J AU Hadlock, TA Kowaleski, J Lo, D Mackinnon, SE Heaton, JT AF Hadlock, Tessa A. Kowaleski, Jeffrey Lo, David Mackinnon, Susan E. Heaton, James T. TI Rodent Facial Nerve Recovery after Selected Lesions and Repair Techniques SO PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Society-for-Peripheral-Nerve CY JAN 09-11, 2009 CL Maui, HI SP Amer Soc Peripheral Nerve ID QUALITY-OF-LIFE; FUNCTIONAL RECOVERY; GRADING SYSTEMS; ELECTRICAL-STIMULATION; WHISKER MOVEMENTS; HOUSE-BRACKMANN; CRUSH INJURY; BELLS-PALSY; RAT; PARALYSIS AB Background: Measuring rodent facial movements is a reliable method for studying recovery from facial nerve manipulation and for examining the behavioral correlates of aberrant regeneration. The authors quantitatively compared recovery of vibrissal and ocular function following three types of clinically relevant nerve injury. Methods: One hundred seventy-eight adult rats underwent facial nerve manipulation and testing. In the experimental groups, the left facial nerve was either crushed, transected, and repaired epineurially, or transected and the stumps suture-secured into a tube with a 2-mm gap between them. Facial recovery was measured for the ensuing 1 to 4 months. Data were analyzed for whisking recovery. Previously developed markers of co-contraction of the upper and midfacial zones (possible synkinesis markers) were also examined. Results: Animals in the crush groups recovered nearly normal whisking parameters within 25 days. The distal branch crush group showed improved recovery over the main trunk crush group for several days during early recovery. By week 9, the transection/repair groups showed evidence of recovery that trended further upward throughout the study period. The entubulation groups followed a similar recovery pattern, although they did not maintain significant recovery levels by the study conclusion. Markers of potential synkinesis increased in selected groups following facial nerve injury. Conclusions: Rodent vibrissal function recovers in a predictable fashion following manipulation. Generalized co-contraction of the upper and midfacial zones emerges following facial nerve manipulation, possibly related to aberrant regeneration, polyterminal axons, or hypersensitivity of the rodent to sensory stimuli following nerve manipulation. (Plast. Reconstr. Surg. 125: 99, 2010.) C1 Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg, Cambridge, MA 02138 USA. Washington Univ, Sch Med, Div Plast & Reconstruct Surg, St Louis, MO 63130 USA. RP Hadlock, TA (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA. EM tessa_hadlock@meei.harvard.edu FU NIDCR NIH HHS [K-08 DE015665-01A2, K08 DE015665]; NINDS NIH HHS [R01 NS071067] NR 44 TC 21 Z9 21 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0032-1052 J9 PLAST RECONSTR SURG JI Plast. Reconstr. Surg. PD JAN PY 2010 VL 125 IS 1 BP 99 EP 109 DI 10.1097/PRS.0b013e3181c2a5ea PG 11 WC Surgery SC Surgery GA 541LK UT WOS:000273417000013 PM 20048604 ER PT S AU McLoud, TC Abbott, GF Malagari, K AF McLoud, Theresa C. Abbott, Gerald F. Malagari, Katerina BE Bouros, D TI Imaging of the Pleura SO PLEURAL DISEASE, 2ND EDITION SE Lung Biology in Health and Disease LA English DT Article; Book Chapter ID SOLITARY FIBROUS TUMOR; TNM STAGING SYSTEM; COMPUTED-TOMOGRAPHY; MALIGNANT MESOTHELIOMA; CHEST RADIOGRAPHS; EPITHELIOID HEMANGIOENDOTHELIOMA; DIFFERENTIAL-DIAGNOSIS; TENSION PNEUMOTHORAX; RADIOLOGIC FEATURES; ASBESTOS EXPOSURE C1 [McLoud, Theresa C.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Abbott, Gerald F.] Rhode Isl Hosp, Providence, RI USA. [Malagari, Katerina] Univ Athens, Sch Med, GR-11527 Athens, Greece. [Malagari, Katerina] Attikon Univ Hosp, Dept Radiol, Athens, Greece. RP McLoud, TC (reprint author), Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. NR 115 TC 0 Z9 0 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL ST, LONDON, EC2A 4LQ, ENGLAND SN 0362-3181 BN 978-1-4200-7739-1; 978-1-4200-7738-4 J9 LUNG BIOL HEALTH DIS PY 2010 VL 229 BP 30 EP 64 PG 35 WC Respiratory System SC Respiratory System GA BC9UL UT WOS:000356890800006 ER PT S AU Donahue, DM Mathisen, DJ AF Donahue, Dean M. Mathisen, Douglas J. BE Bouros, D TI Surgical Management of Empyema SO PLEURAL DISEASE, 2ND EDITION SE Lung Biology in Health and Disease LA English DT Article; Book Chapter ID POSTPNEUMONECTOMY EMPYEMA; PLEURAL EMPYEMA; BRONCHOPLEURAL FISTULA; PULMONARY RESECTION; FLAP; CLOSURE; OMENTUM C1 [Donahue, Dean M.; Mathisen, Douglas J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Thorac Surg, Boston, MA 02138 USA. RP Donahue, DM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Thorac Surg, Boston, MA 02138 USA. NR 22 TC 0 Z9 0 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL ST, LONDON, EC2A 4LQ, ENGLAND SN 0362-3181 BN 978-1-4200-7739-1; 978-1-4200-7738-4 J9 LUNG BIOL HEALTH DIS PY 2010 VL 229 BP 357 EP 366 PG 10 WC Respiratory System SC Respiratory System GA BC9UL UT WOS:000356890800023 ER PT S AU Wright, CD Mark, EJ AF Wright, Cameron D. Mark, Eugene J. BE Bouros, D TI Benign Tumors of the Pleura SO PLEURAL DISEASE, 2ND EDITION SE Lung Biology in Health and Disease LA English DT Article; Book Chapter ID SOLITARY FIBROUS TUMORS; PATHOLOGICAL CORRELATION; MALIGNANT VARIANTS; SURGICAL-TREATMENT; LOCALIZED BENIGN; MESOTHELIOMA; DIAGNOSIS; MR; PSEUDOTUMOR; EXPRESSION C1 [Wright, Cameron D.; Mark, Eugene J.] Harvard Univ, Sch Med, Boston, MA 02138 USA. [Wright, Cameron D.; Mark, Eugene J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Wright, CD (reprint author), Harvard Univ, Sch Med, Boston, MA 02138 USA. NR 42 TC 0 Z9 0 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL ST, LONDON, EC2A 4LQ, ENGLAND SN 0362-3181 BN 978-1-4200-7739-1; 978-1-4200-7738-4 J9 LUNG BIOL HEALTH DIS PY 2010 VL 229 BP 448 EP 467 PG 20 WC Respiratory System SC Respiratory System GA BC9UL UT WOS:000356890800028 ER PT J AU Lim, SY Rogers, T Chan, T Whitney, JB Kim, J Sodroski, J Letvin, NL AF Lim, So-Yon Rogers, Thomas Chan, Tiffany Whitney, James B. Kim, Jonghwa Sodroski, Joseph Letvin, Norman L. TI TRIM5 alpha Modulates Immunodeficiency Virus Control in Rhesus Monkeys SO PLOS PATHOGENS LA English DT Article ID RESTRICTION FACTOR TRIM5-ALPHA; MURINE LEUKEMIA-VIRUS; SIMIAN IMMUNODEFICIENCY; HIV-1 INFECTION; DISEASE PROGRESSION; T-CELLS; MACAQUES; REPLICATION; ASSOCIATION; VARIANTS AB The cytoplasmic TRIM5 alpha proteins of certain mammalian lineages efficiently recognize the incoming capsids of particular retroviruses and potently restrict infection in a species-specific manner. Successful retroviruses have evolved capsids that are less efficiently recognized by the TRIM5 alpha proteins of the natural hosts. To address whether TRIM5 alpha contributes to the outcome of retroviral infection in a susceptible host species, we investigated the impact of TRIM5 polymorphisms in rhesus monkeys on the course of a simian immunodeficiency virus (SIV) infection. Full-length TRIM5 alpha cDNAs were derived from each of 79 outbred monkeys and sequenced. Associations were explored between the expression of particular TRIM5 alleles and both the permissiveness of cells to SIV infection in vitro and clinical sequelae of SIV infection in vivo. Natural variation in the TRIM5 alpha B30.2(SPRY) domain influenced the efficiency of SIVmac capsid binding and the in vitro susceptibility of cells from the monkeys to SIVmac infection. We also show the importance in vivo of the interaction of SIVmac with different allelic forms of TRIM5, demonstrating that particular alleles are associated with as much as 1.3 median log difference in set-point viral loads in SIVmac-infected rhesus monkeys. Moreover, these allelic forms of TRIM5 were associated with the extent of loss of central memory (CM) CD4+ T cells and the rate of progression to AIDS in the infected monkeys. These findings demonstrate a central role for TRIM5 alpha in limiting the replication of an immunodeficiency virus infection in a primate host. C1 [Lim, So-Yon; Rogers, Thomas; Chan, Tiffany; Whitney, James B.; Letvin, Norman L.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Kim, Jonghwa; Sodroski, Joseph] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. RP Lim, SY (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. EM nletvin@bidmc.harvard.edu FU NIAID Center for HIV/AIDS Vaccine Immunology [AI067854] FX This work was supported by the NIAID Center for HIV/AIDS Vaccine Immunology grant AI067854. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 46 TC 86 Z9 86 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7366 J9 PLOS PATHOG JI PLoS Pathog. PD JAN PY 2010 VL 6 IS 1 AR e1000738 DI 10.1371/journal.ppat.1000738 PG 11 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA 551RQ UT WOS:000274227100029 PM 20107597 ER PT J AU Qin, ZQ Freitas, E Sullivan, R Mohan, S Bacelieri, R Branch, D Romano, M Kearney, P Oates, J Plaisance, K Renne, R Kaleeba, J Parsons, C AF Qin, Zhiqiang Freitas, Eduardo Sullivan, Roger Mohan, Sarumathi Bacelieri, Rocky Branch, Drake Romano, Margaret Kearney, Patricia Oates, Jim Plaisance, Karlie Renne, Rolf Kaleeba, Johnan Parsons, Chris TI Upregulation of xCT by KSHV-Encoded microRNAs Facilitates KSHV Dissemination and Persistence in an Environment of Oxidative Stress SO PLOS PATHOGENS LA English DT Article ID SARCOMA-ASSOCIATED HERPESVIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; MULTICENTRIC CASTLEMANS-DISEASE; PRIMARY EFFUSION LYMPHOMA; LATENTLY INFECTED-CELLS; KAPOSIS-SARCOMA; ENDOTHELIAL-CELLS; REACTIVE OXYGEN; PERIPHERAL-BLOOD; GENE-EXPRESSION AB Upregulation of xCT, the inducible subunit of a membrane-bound amino acid transporter, replenishes intracellular glutathione stores to maintain cell viability in an environment of oxidative stress. xCT also serves as a fusion-entry receptor for the Kaposi's sarcoma-associated herpesvirus (KSHV), the causative agent of Kaposi's sarcoma (KS). Ongoing KSHV replication and infection of new cell targets is important for KS progression, but whether xCT regulation within the tumor microenvironment plays a role in KS pathogenesis has not been determined. Using gene transfer and whole virus infection experiments, we found that KSHV-encoded microRNAs (KSHV miRNAs) upregulate xCT expression by macrophages and endothelial cells, largely through miR-K12-11 suppression of BACH-1-a negative regulator of transcription recognizing antioxidant response elements within gene promoters. Correlative functional studies reveal that upregulation of xCT by KSHV miRNAs increases cell permissiveness for KSHV infection and protects infected cells from death induced by reactive nitrogen species (RNS). Interestingly, KSHV miRNAs simultaneously upregulate macrophage secretion of RNS, and biochemical inhibition of RNS secretion by macrophages significantly reduces their permissiveness for KSHV infection. The clinical relevance of these findings is supported by our demonstration of increased xCT expression within more advanced human KS tumors containing a larger number of KSHV-infected cells. Collectively, these data support a role for KSHV itself in promoting de novo KSHV infection and the survival of KSHV-infected, RNS-secreting cells in the tumor microenvironment through the induction of xCT. C1 [Qin, Zhiqiang; Freitas, Eduardo; Sullivan, Roger; Mohan, Sarumathi; Kearney, Patricia; Oates, Jim; Parsons, Chris] Med Univ S Carolina, Dept Med, Hollings Canc Ctr, Charleston, SC 29425 USA. [Qin, Zhiqiang; Parsons, Chris] Med Univ S Carolina, Hollings Canc Ctr, Dept Craniofacial Biol, Charleston, SC 29425 USA. [Bacelieri, Rocky; Branch, Drake] Med Univ S Carolina, Hollings Canc Ctr, Dept Dermatol, Charleston, SC 29425 USA. [Romano, Margaret] Med Univ S Carolina, Hollings Canc Ctr, Dept Pathol, Charleston, SC 29425 USA. [Oates, Jim] Ralph H Johnson VA Med Ctr, Med Serv, Charleston, SC USA. [Plaisance, Karlie; Renne, Rolf] Univ Florida, Dept Mol Genet & Microbiol, Shands Canc Ctr, Gainesville, FL USA. [Kaleeba, Johnan] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Microbiol & Immunol, Bethesda, MD 20814 USA. [Kaleeba, Johnan] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Mol Cell Biol, Bethesda, MD 20814 USA. RP Qin, ZQ (reprint author), Med Univ S Carolina, Dept Med, Hollings Canc Ctr, Charleston, SC 29425 USA. EM jkaleeba@usuhs.mil; parsonch@musc.edu FU National Institutes of Health [K08-1CA103858]; South Carolina COBRE for Oral Health [P20-RR017696]; MUSC Hollings Cancer Center Translational Pilot Award; USUHS [R073NS]; MUSC Hollings Cancer Center [P30-CA-138313] FX This work was supported by grants from the National Institutes of Health (K08-1CA103858 to CP), the South Carolina COBRE for Oral Health (P20-RR017696; CP is subproject investigator), an MUSC Hollings Cancer Center Translational Pilot Award (CP), a USUHS grant (R073NS to JK), and the MUSC Hollings Cancer Center (core grant P30-CA-138313 to the HCC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 71 TC 53 Z9 55 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7366 J9 PLOS PATHOG JI PLoS Pathog. PD JAN PY 2010 VL 6 IS 1 AR e1000742 DI 10.1371/journal.ppat.1000742 PG 14 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA 551RQ UT WOS:000274227100032 PM 20126446 ER PT J AU Kim, JK Oh, K AF Kim, Jun Ki Oh, Kyunghwan BE Hashim, AA TI Micro/nano scale phase front inscription on polymer thin layer for flexible beam shaping SO POLYMER THIN FILMS LA English DT Article; Book Chapter ID SURFACE-RELIEF GRATINGS; SINGLE-MODE FIBERS; FILMS; LASER; AZOBENZENE; MICROLENSES; LIGHT C1 [Kim, Jun Ki] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. [Oh, Kyunghwan] Yonsei Univ, Dept Phys, Seoul 120749, South Korea. RP Kim, JK (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. NR 32 TC 1 Z9 1 U1 0 U2 0 PU INTECH EUROPE PI RIJEKA PA JANEZA TRDINE9, RIJEKA, 51000, CROATIA BN 978-953-307-059-9 PY 2010 BP 239 EP 252 PG 14 WC Materials Science, Coatings & Films; Polymer Science SC Materials Science; Polymer Science GA BD7WD UT WOS:000363637600015 ER PT J AU Adler, LD Nierenberg, AA AF Adler, Lisa D. Nierenberg, Andrew A. TI Review of Medication Adherence in Children and Adults with ADHD SO POSTGRADUATE MEDICINE LA English DT Review DE ADHD; medication adherence; continuity; discontinuity; psychostimulants ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; PHARMACOLOGICAL-TREATMENT; METHYLPHENIDATE TREATMENT; ADOLESCENTS; CONTINUITY; MANAGEMENT AB Objective: To review the literature on the prevalence, potential causes, and consequences of medication nonadherence in adult attention-deficit/hyperactivity disorder (ADHD). Background: Attention-deficit/hyperactivity, disorder is a common, chronic, and impairing neuropsychiatric disorder, affecting 4.4% of the US adult Population. Medications alleviate many aspects of the disorder, but associated difficulties with disorganization and planning can lead patients to have poor adherence and subsequent treatment failure. This review will examine the scope and consequences of medication nonadherence in children and adults With ADHD. Methods: Comprehensive literature reviews via PubMed searches were conducted for continuity of medication and medication adherence (and related terms) in ADHD (and ADD). The Studies were reviewed and classified regarding prevalence, measure of adherence Or continuity, etiology. and consequences of medication nonadherence in childhood/adolescent and adult ADHD. Results: Studies of pharmacy claims databases and treatment Studies have shown that the prevalence of medication discontinuation or nonadherence is between 13.2% to 64%. More studies have focused on medication adherence in children/adolescents than in adult ADHD. Medication nonadherence is more prevalent in immediate-release versus extended-release psychostimulants in childhood/adolescent ADHD, but differences in the formulations have not been studied extensively in adults. Current studies have almost exclusively relied on patient reports. Possible etiologies of medication nonadherence have not been examined with formal rating instruments in adult ADHD. The long-term consequences of medication nonadherence, in terms of impairments, have not been examined. Conclusions: Studies have documented that medication nonadherence is common in childhood/adolescent ADHD. Further prospective studies are necessary to document the scope of the problem in adult ADHD and to examine the potential benefits of utilizing extended-re I case medications in adult ADHD. Studies correlating the impact of medication nonadherence on symptoms and impairments in adult ADHD are needed. Future Studies should consider utilizing technology to document medication nonadherence, such as MEMS caps. C1 [Nierenberg, Andrew A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Adler, Lisa D.] Cornell Univ, Ithaca, NY USA. RP Nierenberg, AA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Suite 580,50 Staniford St, Boston, MA 02114 USA. EM anierenberg@partners.org FU NIMH; PamLabs; Pfizer Pharmaceuticals; Shire; Astra Zeneca; Eli Lilly; Janssen Pharmaceuticals; Bristol-Myers Squibb FX Lisa D. Adler, BA discloses no conflicts of interest. Andrew A. Nierenberg, MD discloses conflicts of interest with the American Psychiatric Association, Appliance Computing Inc. (Mindsite), Brain Cells, Inc., Brandeis University, Eli Lilly and Company, Novartis, PGx Health, Shire, Schering-Plough, Targacept, and Takeda Pharmaceuticals. He received grant/research Support through MGH from NIMH, PamLabs, Pfizer Pharmaceuticals, and Shire. He received honoraria from Belvoir Publishing, University of Texas Southwestern Dallas, Hillside Hospital, American Drug Utilization Review, American Society for Clinical Psychopharmacology, Baystate Medical Center, Columbia University, Imedex, MJ Consulting, New York State, MBL Publishing, Physicians Postgraduate Press, SUNY Buffalo, University of Wisconsin, and the University of Pisa. Dr. Nierenberg is a presenter for the Massachusetts General Hospital Psychiatry Academy (MGHPA). The education programs conducted by the MGHPA were Supported through Independent Medical Education (IME) grants from the following pharmaceutical companies in 2008: Astra Zeneca, Eli Lilly, and Janssen Pharmaceuticals; in 2009 Astra Zeneca, Eli Lilly, and Bristol-Myers Squibb. Dr. Nierenberg owns stock options in Appliance Computing, Inc. and Brain Cells, Inc. Through MGH, he is named for copyrights to the Clinical Positive Affect Scale and the MGH Structured Clinical Interview for the Montgomery Asberg Depression Scale exclusively licensed to the MGH Clinical Trials Network and Institute (CTNI). Also, through NIGH, Dr. Nierenberg has a patent extension application for the combination of buspirone, bupropion, and melatonin for the treatment of depression. NR 19 TC 82 Z9 82 U1 5 U2 23 PU JTE MULTIMEDIA PI BERWYN PA 1235 WESTLAKES DR, STE 220, BERWYN, PA 19312 USA SN 0032-5481 J9 POSTGRAD MED JI Postgrad. Med. PD JAN PY 2010 VL 122 IS 1 BP 184 EP 191 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 559GJ UT WOS:000274811000020 PM 20107302 ER PT J AU Robbins, MEC Linard, C Panigrahy, D AF Robbins, Michael E. C. Linard, Christine Panigrahy, Dipak TI PPARs and Anticancer Therapies SO PPAR RESEARCH LA English DT Editorial Material C1 [Robbins, Michael E. C.] Wake Forest Univ, Bowman Gray Sch Med, Ctr Comprehens Canc, Brain Tumor Ctr Excellence,Dept Radiat Oncol, Winston Salem, NC 27157 USA. [Linard, Christine] Inst Radioprotect & Nucl Safety, F-92262 Fontenay Aux Roses, France. [Panigrahy, Dipak] Harvard Univ, Med Ctr, Childrens Hosp, Vasc Biol Program, Boston, MA 02115 USA. [Panigrahy, Dipak] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. RP Robbins, MEC (reprint author), Wake Forest Univ, Bowman Gray Sch Med, Ctr Comprehens Canc, Brain Tumor Ctr Excellence,Dept Radiat Oncol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA. EM mrobbins@wfubmc.edu NR 0 TC 3 Z9 3 U1 0 U2 0 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1687-4757 J9 PPAR RES JI PPAR Res. PY 2010 AR 536415 DI 10.1155/2010/536415 PG 2 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 670LL UT WOS:000283423100001 ER PT J AU Lesnik, DJ O'Leary, MA Noordzij, JP Randolph, GW AF Lesnik, David J. O'Leary, Miriam A. Noordzij, J. Pieter Randolph, Gregory W. BE Arora, A Tolley, NS Tuttle, MR TI Surgical management of benign thyroid disease SO PRACTICAL MANUAL OF THYROID AND PARATHYROID DISEASE LA English DT Article; Book Chapter ID RECURRENT LARYNGEAL NERVE; PARATHYROID-HORMONE ASSAY; GRAVES-DISEASE; HYPERTHYROIDISM; HYPOCALCEMIA; SURGERY; THYROTOXICOSIS; COMPLICATIONS; THERAPY; GOITER C1 [Lesnik, David J.; Randolph, Gregory W.] Harvard Univ, Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Sch Med,Div Thyroid & Parathyroid Surg, Boston, MA 02115 USA. [O'Leary, Miriam A.; Noordzij, J. Pieter] Boston Med Ctr, Dept Otolaryngol, Boston, MA USA. [Randolph, Gregory W.] Massachusetts Gen Hosp, Massachusetts Eye & Ear Infirm, Member Endocrine Surg Serv, Boston, MA 02114 USA. RP Lesnik, DJ (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Sch Med,Div Thyroid & Parathyroid Surg, Boston, MA 02115 USA. NR 37 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-1-405-17034-5 PY 2010 BP 77 EP 86 DI 10.1002/9781444307641.ch8 D2 10.1002/9781444307641 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BUP71 UT WOS:000289977300010 ER PT J AU Stack, BC Randolph, G AF Stack, Brendan C. Randolph, Gregory BE Arora, A Tolley, NS Tuttle, MR TI Investigations SO PRACTICAL MANUAL OF THYROID AND PARATHYROID DISEASE LA English DT Article; Book Chapter ID INVASIVE RADIOGUIDED PARATHYROIDECTOMY; POSITRON-EMISSION-TOMOGRAPHY; HIGH-RESOLUTION ULTRASOUND; 99M SESTAMIBI SCANS; PRIMARY HYPERPARATHYROIDISM; PREOPERATIVE LOCALIZATION; DOUBLE-PHASE; COMPUTED-TOMOGRAPHY; TC-99M METHOXYISOBUTYLISONITRILE; TECHNETIUM-99M-SESTAMIBI SPECT C1 [Stack, Brendan C.] Univ Arkansas Med Sci, Dept Otolaryngol HNS, Little Rock, AR 72205 USA. [Randolph, Gregory] Harvard Univ, Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Sch Med,Div Thyroid & Parathyroid Surg, Boston, MA USA. [Randolph, Gregory] Massachusetts Gen Hosp, Massachusetts Eye & Ear Infirm, Member Endocrine Surg Serv, Boston, MA 02114 USA. RP Stack, BC (reprint author), Univ Arkansas Med Sci, Dept Otolaryngol HNS, Little Rock, AR 72205 USA. NR 89 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-1-405-17034-5 PY 2010 BP 162 EP 172 D2 10.1002/9781444307641 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BUP71 UT WOS:000289977300016 ER PT J AU Lemon, SC Prout, MN Barnett, JB Flynn, MS AF Lemon, Stephenie C. Prout, Marianne N. Barnett, Junaidah B. Flynn, Maureen Sullivan TI Developing and Implementing the Massachusetts Comprehensive Cancer Control Coalition Survivorship Summit SO PREVENTING CHRONIC DISEASE LA English DT Article AB Cancer survivors face numerous medical and psychosocial challenges, which the medical and public health systems are ill-equipped to deal with. In May 2008, the Massachusetts Comprehensive Cancer Control Coalition conducted a Cancer Survivorship Summit to elicit input from cancer survivors and professionals on developing system-level action plans for cancer survivorship issues. We describe how health care and public health professionals can implement similar events. Our results suggest that a cancer survivorship summit can be a valuable tool for cancer coalitions and advocacy organizations in determining survivorship agendas and action plans. C1 [Prout, Marianne N.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Barnett, Junaidah B.] Tufts Univ, Sch Med, Boston, MA 02111 USA. [Barnett, Junaidah B.] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA. [Flynn, Maureen Sullivan] Lance Armstrong Fdn, Dana Farber Canc Inst, Adult Survivorship Clin, Boston, MA USA. RP Lemon, SC (reprint author), Univ Massachusetts, Div Prevent & Behav Med, Sch Med, 55 Lake Ave N, Worcester, MA 01655 USA. EM stephenie.lemon@umassmed.edu FU Centers for Disease Control and Prevention, National Cancer Prevention and Control; American Cancer Society; Massachusetts Department of Public Health Women's Health Network and Men's Health; Bureau of Communicable Disease Control; Bayer HealthCare; Dana-Farber Cancer Institute; Lance Armstrong Foundation; Massachusetts Cancer Prevention Community Research Network; New England Coalition for Cancer Survivorship; Pfizer Oncology FX Funding for the MCCCC Survivorship Summit was provided in part by a cooperative agreement from Centers for Disease Control and Prevention, National Cancer Prevention and Control Program grant to the Massachusetts Comprehensive Cancer Prevention and Control Program. Funding was also provided by the American Cancer Society, Massachusetts Department of Public Health Women's Health Network and Men's Health Partnership and Bureau of Communicable Disease Control, Bayer HealthCare, Dana-Farber Cancer Institute, Lance Armstrong Foundation, Massachusetts Cancer Prevention Community Research Network, New England Coalition for Cancer Survivorship, and Pfizer Oncology. NR 11 TC 1 Z9 1 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD JAN PY 2010 VL 7 IS 1 AR A22 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V20RZ UT WOS:000208158400022 PM 20040237 ER PT S AU Madihally, SV AF Madihally, Sundararajan V. BA Madihally, SV BF Madihally, SV TI Principles of Biomedical Engineering Introduction SO PRINCIPLES OF BIOMEDICAL ENGINEERING SE Engineering in Medicine and Biology LA English DT Editorial Material; Book Chapter C1 [Madihally, Sundararajan V.] Oklahoma State Univ, Sch Chem Engn, Stillwater, OK 74078 USA. [Madihally, Sundararajan V.] Shriners Hosp Children, Sacramento, CA USA. [Madihally, Sundararajan V.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Madihally, Sundararajan V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Madihally, Sundararajan V.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08855 USA. RP Madihally, SV (reprint author), Oklahoma State Univ, Sch Chem Engn, Stillwater, OK 74078 USA. NR 8 TC 0 Z9 0 U1 0 U2 0 PU ARTECH HOUSE PI NORWOOD PA 685 CANTON ST, NORWOOD, MA 02062 USA SN 0278-0054 BN 978-1-60807-055-8 J9 ENG MED BIOL JI Eng. Med. Biol. PY 2010 BP 1 EP 20 PG 20 WC Engineering, Biomedical SC Engineering GA BOR26 UT WOS:000277375500001 ER PT S AU Madihally, SV AF Madihally, Sundararajan V. BA Madihally, SV BF Madihally, SV TI Biotransport SO PRINCIPLES OF BIOMEDICAL ENGINEERING SE Engineering in Medicine and Biology LA English DT Article; Book Chapter ID GROWTH-FACTOR; DIFFUSION; SEVOFLURANE C1 [Madihally, Sundararajan V.] Oklahoma State Univ, Sch Chem Engn, Stillwater, OK 74078 USA. [Madihally, Sundararajan V.] Shriners Hosp Children, Sacramento, CA USA. [Madihally, Sundararajan V.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Madihally, Sundararajan V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Madihally, Sundararajan V.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08855 USA. RP Madihally, SV (reprint author), Oklahoma State Univ, Sch Chem Engn, Stillwater, OK 74078 USA. NR 17 TC 0 Z9 0 U1 0 U2 1 PU ARTECH HOUSE PI NORWOOD PA 685 CANTON ST, NORWOOD, MA 02062 USA SN 0278-0054 BN 978-1-60807-055-8 J9 ENG MED BIOL JI Eng. Med. Biol. PY 2010 BP 21 EP 62 PG 42 WC Engineering, Biomedical SC Engineering GA BOR26 UT WOS:000277375500002 ER PT S AU Madihally, SV AF Madihally, Sundararajan V. BA Madihally, SV BF Madihally, SV TI Bioelectrical Phenomena SO PRINCIPLES OF BIOMEDICAL ENGINEERING SE Engineering in Medicine and Biology LA English DT Article; Book Chapter C1 [Madihally, Sundararajan V.] Oklahoma State Univ, Sch Chem Engn, Stillwater, OK 74078 USA. [Madihally, Sundararajan V.] Shriners Hosp Children, Sacramento, CA USA. [Madihally, Sundararajan V.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Madihally, Sundararajan V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Madihally, Sundararajan V.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08855 USA. RP Madihally, SV (reprint author), Oklahoma State Univ, Sch Chem Engn, Stillwater, OK 74078 USA. NR 11 TC 0 Z9 0 U1 0 U2 0 PU ARTECH HOUSE PI NORWOOD PA 685 CANTON ST, NORWOOD, MA 02062 USA SN 0278-0054 BN 978-1-60807-055-8 J9 ENG MED BIOL JI Eng. Med. Biol. PY 2010 BP 63 EP 107 PG 45 WC Engineering, Biomedical SC Engineering GA BOR26 UT WOS:000277375500003 ER PT S AU Madihally, SV AF Madihally, Sundararajan V. BA Madihally, SV BF Madihally, SV TI Biofluid Flow SO PRINCIPLES OF BIOMEDICAL ENGINEERING SE Engineering in Medicine and Biology LA English DT Article; Book Chapter ID VENTRICULAR ASSIST DEVICE; BLOOD; PRINCIPLE C1 [Madihally, Sundararajan V.] Oklahoma State Univ, Sch Chem Engn, Stillwater, OK 74078 USA. [Madihally, Sundararajan V.] Shriners Hosp Children, Sacramento, CA USA. [Madihally, Sundararajan V.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Madihally, Sundararajan V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Madihally, Sundararajan V.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08855 USA. RP Madihally, SV (reprint author), Oklahoma State Univ, Sch Chem Engn, Stillwater, OK 74078 USA. NR 23 TC 0 Z9 0 U1 0 U2 0 PU ARTECH HOUSE PI NORWOOD PA 685 CANTON ST, NORWOOD, MA 02062 USA SN 0278-0054 BN 978-1-60807-055-8 J9 ENG MED BIOL JI Eng. Med. Biol. PY 2010 BP 109 EP 155 PG 47 WC Engineering, Biomedical SC Engineering GA BOR26 UT WOS:000277375500004 ER PT S AU Madihally, SV AF Madihally, Sundararajan V. BA Madihally, SV BF Madihally, SV TI Biomechanics SO PRINCIPLES OF BIOMEDICAL ENGINEERING SE Engineering in Medicine and Biology LA English DT Article; Book Chapter C1 [Madihally, Sundararajan V.] Oklahoma State Univ, Sch Chem Engn, Stillwater, OK 74078 USA. [Madihally, Sundararajan V.] Shriners Hosp Children, Sacramento, CA USA. [Madihally, Sundararajan V.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Madihally, Sundararajan V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Madihally, Sundararajan V.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08855 USA. RP Madihally, SV (reprint author), Oklahoma State Univ, Sch Chem Engn, Stillwater, OK 74078 USA. NR 20 TC 0 Z9 0 U1 0 U2 0 PU ARTECH HOUSE PI NORWOOD PA 685 CANTON ST, NORWOOD, MA 02062 USA SN 0278-0054 BN 978-1-60807-055-8 J9 ENG MED BIOL JI Eng. Med. Biol. PY 2010 BP 157 EP 211 PG 55 WC Engineering, Biomedical SC Engineering GA BOR26 UT WOS:000277375500005 ER PT S AU Madihally, SV AF Madihally, Sundararajan V. BA Madihally, SV BF Madihally, SV TI Biomaterials SO PRINCIPLES OF BIOMEDICAL ENGINEERING SE Engineering in Medicine and Biology LA English DT Article; Book Chapter ID HEART-VALVES; LASER C1 [Madihally, Sundararajan V.] Oklahoma State Univ, Sch Chem Engn, Stillwater, OK 74078 USA. [Madihally, Sundararajan V.] Shriners Hosp Children, Sacramento, CA USA. [Madihally, Sundararajan V.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Madihally, Sundararajan V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Madihally, Sundararajan V.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08855 USA. RP Madihally, SV (reprint author), Oklahoma State Univ, Sch Chem Engn, Stillwater, OK 74078 USA. NR 21 TC 0 Z9 0 U1 0 U2 0 PU ARTECH HOUSE PI NORWOOD PA 685 CANTON ST, NORWOOD, MA 02062 USA SN 0278-0054 BN 978-1-60807-055-8 J9 ENG MED BIOL JI Eng. Med. Biol. PY 2010 BP 213 EP 254 PG 42 WC Engineering, Biomedical SC Engineering GA BOR26 UT WOS:000277375500006 ER PT S AU Madihally, SV AF Madihally, Sundararajan V. BA Madihally, SV BF Madihally, SV TI Cellular Engineering SO PRINCIPLES OF BIOMEDICAL ENGINEERING SE Engineering in Medicine and Biology LA English DT Article; Book Chapter ID RECEPTOR; BINDING; ADHESION; CELLS C1 [Madihally, Sundararajan V.] Oklahoma State Univ, Sch Chem Engn, Stillwater, OK 74078 USA. [Madihally, Sundararajan V.] Shriners Hosp Children, Sacramento, CA USA. [Madihally, Sundararajan V.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Madihally, Sundararajan V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Madihally, Sundararajan V.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08855 USA. RP Madihally, SV (reprint author), Oklahoma State Univ, Sch Chem Engn, Stillwater, OK 74078 USA. NR 22 TC 0 Z9 0 U1 0 U2 0 PU ARTECH HOUSE PI NORWOOD PA 685 CANTON ST, NORWOOD, MA 02062 USA SN 0278-0054 BN 978-1-60807-055-8 J9 ENG MED BIOL JI Eng. Med. Biol. PY 2010 BP 255 EP 303 PG 49 WC Engineering, Biomedical SC Engineering GA BOR26 UT WOS:000277375500007 ER PT S AU Madihally, SV AF Madihally, Sundararajan V. BA Madihally, SV BF Madihally, SV TI Biomedical Imaging SO PRINCIPLES OF BIOMEDICAL ENGINEERING SE Engineering in Medicine and Biology LA English DT Article; Book Chapter C1 [Madihally, Sundararajan V.] Oklahoma State Univ, Sch Chem Engn, Stillwater, OK 74078 USA. [Madihally, Sundararajan V.] Shriners Hosp Children, Sacramento, CA USA. [Madihally, Sundararajan V.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Madihally, Sundararajan V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Madihally, Sundararajan V.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08855 USA. RP Madihally, SV (reprint author), Oklahoma State Univ, Sch Chem Engn, Stillwater, OK 74078 USA. NR 8 TC 0 Z9 0 U1 0 U2 0 PU ARTECH HOUSE PI NORWOOD PA 685 CANTON ST, NORWOOD, MA 02062 USA SN 0278-0054 BN 978-1-60807-055-8 J9 ENG MED BIOL JI Eng. Med. Biol. PY 2010 BP 305 EP 351 PG 47 WC Engineering, Biomedical SC Engineering GA BOR26 UT WOS:000277375500008 ER PT S AU Madihally, SV AF Madihally, Sundararajan V. BA Madihally, SV BF Madihally, SV TI Biosensors SO PRINCIPLES OF BIOMEDICAL ENGINEERING SE Engineering in Medicine and Biology LA English DT Article; Book Chapter C1 [Madihally, Sundararajan V.] Oklahoma State Univ, Sch Chem Engn, Stillwater, OK 74078 USA. [Madihally, Sundararajan V.] Shriners Hosp Children, Sacramento, CA USA. [Madihally, Sundararajan V.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Madihally, Sundararajan V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Madihally, Sundararajan V.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08855 USA. RP Madihally, SV (reprint author), Oklahoma State Univ, Sch Chem Engn, Stillwater, OK 74078 USA. NR 12 TC 0 Z9 0 U1 0 U2 0 PU ARTECH HOUSE PI NORWOOD PA 685 CANTON ST, NORWOOD, MA 02062 USA SN 0278-0054 BN 978-1-60807-055-8 J9 ENG MED BIOL JI Eng. Med. Biol. PY 2010 BP 353 EP 397 PG 45 WC Engineering, Biomedical SC Engineering GA BOR26 UT WOS:000277375500009 ER PT S AU Madihally, SV AF Madihally, Sundararajan V. BA Madihally, SV BF Madihally, SV TI Physiological Modeling SO PRINCIPLES OF BIOMEDICAL ENGINEERING SE Engineering in Medicine and Biology LA English DT Article; Book Chapter C1 [Madihally, Sundararajan V.] Oklahoma State Univ, Sch Chem Engn, Stillwater, OK 74078 USA. [Madihally, Sundararajan V.] Shriners Hosp Children, Sacramento, CA USA. [Madihally, Sundararajan V.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Madihally, Sundararajan V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Madihally, Sundararajan V.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08855 USA. RP Madihally, SV (reprint author), Oklahoma State Univ, Sch Chem Engn, Stillwater, OK 74078 USA. NR 14 TC 0 Z9 0 U1 0 U2 0 PU ARTECH HOUSE PI NORWOOD PA 685 CANTON ST, NORWOOD, MA 02062 USA SN 0278-0054 BN 978-1-60807-055-8 J9 ENG MED BIOL JI Eng. Med. Biol. PY 2010 BP 399 EP 444 PG 46 WC Engineering, Biomedical SC Engineering GA BOR26 UT WOS:000277375500010 ER PT S AU Madihally, SV AF Madihally, Sundararajan V. BA Madihally, SV BF Madihally, SV TI Ethical, Legal, and Societal Aspects SO PRINCIPLES OF BIOMEDICAL ENGINEERING SE Engineering in Medicine and Biology LA English DT Article; Book Chapter C1 [Madihally, Sundararajan V.] Oklahoma State Univ, Sch Chem Engn, Stillwater, OK 74078 USA. [Madihally, Sundararajan V.] Shriners Hosp Children, Sacramento, CA USA. [Madihally, Sundararajan V.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Madihally, Sundararajan V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Madihally, Sundararajan V.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08855 USA. RP Madihally, SV (reprint author), Oklahoma State Univ, Sch Chem Engn, Stillwater, OK 74078 USA. NR 12 TC 0 Z9 0 U1 0 U2 0 PU ARTECH HOUSE PI NORWOOD PA 685 CANTON ST, NORWOOD, MA 02062 USA SN 0278-0054 BN 978-1-60807-055-8 J9 ENG MED BIOL JI Eng. Med. Biol. PY 2010 BP 445 EP 466 PG 22 WC Engineering, Biomedical SC Engineering GA BOR26 UT WOS:000277375500011 ER PT B AU Ellisen, LW Haber, DA AF Ellisen, Leif W. Haber, Daniel A. BE Chung, DC Haber, DA TI Basic Principles of Cancer Genetics SO PRINCIPLES OF CLINICAL CANCER GENETICS: A HANDBOOK FROM THE MASSACHUSETTS GENERAL HOSPITAL LA English DT Article; Book Chapter DE Oncogene; Tumor suppressor gene; DNA repair; Cell cycle; Apoptosis; Telomerase; Genetic instability; Epigenetics; MicroRNA ID CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; TUMOR-SUPPRESSOR GENE; LI-FRAUMENI-SYNDROME; BREAST-CANCER; COLORECTAL-CANCER; CHROMOSOMAL TRANSLOCATIONS; PHILADELPHIA-CHROMOSOME; MOLECULAR-GENETICS; CLINICAL-RELEVANCE C1 [Ellisen, Leif W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02115 USA. [Haber, Daniel A.] Howard Hughes Med Inst, Boston, MA 02115 USA. [Ellisen, Leif W.; Haber, Daniel A.] Harvard Univ, Sch Med, Boston, MA USA. RP Ellisen, LW (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02115 USA. EM ellisen@helix.mgh.harvard.edu NR 99 TC 2 Z9 2 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-93844-8 PY 2010 BP 1 EP 22 DI 10.1007/978-0-387-93846-2_1 D2 10.1007/978-0-387-93846-2 PG 22 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA BPC93 UT WOS:000278549600001 ER PT B AU Shannon, KM Patel, D AF Shannon, Kristen M. Patel, Devanshi BE Chung, DC Haber, DA TI Principles of Cancer Genetic Counseling and Genetic Testing SO PRINCIPLES OF CLINICAL CANCER GENETICS: A HANDBOOK FROM THE MASSACHUSETTS GENERAL HOSPITAL LA English DT Article; Book Chapter DE Genetic testing; Informed consent; Autosomal dominant; Autosomal recessive; DNA banking; Germline mutations; Risk assessment; Confidentiality ID NONPOLYPOSIS COLORECTAL-CANCER; FAMILIAL ADENOMATOUS POLYPOSIS; LI-FRAUMENI-SYNDROME; BREAST-CANCER; OVARIAN-CANCER; HEREDITARY BREAST; EMOTIONAL-REACTIONS; GERMLINE MUTATIONS; DISTANT RELATIVES; AMERICAN-SOCIETY C1 [Shannon, Kristen M.; Patel, Devanshi] Massachusetts Gen Hosp, Ctr Canc Risk Assessment, Boston, MA 02114 USA. RP Shannon, KM (reprint author), Massachusetts Gen Hosp, Ctr Canc Risk Assessment, Boston, MA 02114 USA. EM keshannon@partners.org NR 111 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-93844-8 PY 2010 BP 23 EP 40 DI 10.1007/978-0-387-93846-2_2 D2 10.1007/978-0-387-93846-2 PG 18 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA BPC93 UT WOS:000278549600002 ER PT B AU Ryan, PD AF Ryan, Paula D. BE Chung, DC Haber, DA TI Genetics of Hereditary Breast Cancer SO PRINCIPLES OF CLINICAL CANCER GENETICS: A HANDBOOK FROM THE MASSACHUSETTS GENERAL HOSPITAL LA English DT Article; Book Chapter DE Breast cancer; Hereditary Breast Ovarian Cancer (HBOC); BRCA1; BRCA2; p53; Li-Fraumeni syndrome; Cowden's disease; PTEN gene; PARP inhibitor; Mammography ID BRCA2 MUTATION CARRIERS; DIFFUSE GASTRIC-CANCER; GENOME-WIDE ASSOCIATION; POLY(ADP-RIBOSE) POLYMERASE INHIBITION; BILATERAL PROPHYLACTIC MASTECTOMY; P53 GERMLINE MUTATIONS; OVARIAN-CANCER; SUSCEPTIBILITY GENE; ORAL-CONTRACEPTIVES; ESTROGEN-RECEPTOR C1 Massachusetts Gen Hosp, Breast & Ovarian Canc Genet & Risk Assessment Cli, Boston, MA 02114 USA. RP Ryan, PD (reprint author), Massachusetts Gen Hosp, Breast & Ovarian Canc Genet & Risk Assessment Cli, Boston, MA 02114 USA. EM pdryan@partners.org NR 116 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-93844-8 PY 2010 BP 41 EP 51 DI 10.1007/978-0-387-93846-2_3 D2 10.1007/978-0-387-93846-2 PG 11 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA BPC93 UT WOS:000278549600003 ER PT B AU Specht, MC del Carmen, MG Smith, BL AF Specht, Michelle C. del Carmen, Marcela G. Smith, Barbara L. BE Chung, DC Haber, DA TI Surgical Management of Hereditary Breast and Ovarian Cancer SO PRINCIPLES OF CLINICAL CANCER GENETICS: A HANDBOOK FROM THE MASSACHUSETTS GENERAL HOSPITAL LA English DT Article; Book Chapter DE Breast cancer; Ovarian cancer; Mastectomy; Reconstructive surgery; Prophylactic surgery; Salpingooophorectomy; Breast cancer screening ID SKIN-SPARING MASTECTOMY; BILATERAL PROPHYLACTIC MASTECTOMY; REDUCING SALPINGO-OOPHORECTOMY; BRCA2 MUTATION CARRIERS; SEROUS PAPILLARY CARCINOMA; DIFFUSE GASTRIC-CANCER; RISK-REDUCTION; GERMLINE MUTATIONS; FOLLOW-UP; CONSERVING TREATMENT C1 [Smith, Barbara L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc,Breast Program, Boston, MA 02115 USA. [Specht, Michelle C.] Massachusetts Gen Hosp, Dept Surg Oncol, Boston, MA 02114 USA. [del Carmen, Marcela G.] Massachusetts Gen Hosp, Dept Obstet, Boston, MA 02114 USA. [del Carmen, Marcela G.] Massachusetts Gen Hosp, Gynecol Serv, Boston, MA 02114 USA. RP Smith, BL (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc,Breast Program, Boston, MA 02115 USA. NR 89 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-93844-8 PY 2010 BP 53 EP 62 DI 10.1007/978-0-387-93846-2_4 D2 10.1007/978-0-387-93846-2 PG 10 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA BPC93 UT WOS:000278549600004 ER PT B AU Chan, AT Chung, DC AF Chan, Andrew T. Chung, Daniel C. BE Chung, DC Haber, DA TI Hereditary Colon Cancer: Colonic Polyposis Syndromes SO PRINCIPLES OF CLINICAL CANCER GENETICS: A HANDBOOK FROM THE MASSACHUSETTS GENERAL HOSPITAL LA English DT Article; Book Chapter DE Familial Adenomatous Polyposis; MYH-Associated Polyposis; Juvenile Polyposis; Peutz-Jeghers Syndrome; PTEN-Hamartoma Syndrome; Hyperplastic Polyposis; APC; MYH; LKB1; MADH4; BMPR1A; PTEN ID FAMILIAL ADENOMATOUS POLYPOSIS; PEUTZ-JEGHERS-SYNDROME; GENOTYPE-PHENOTYPE CORRELATIONS; MULTIPLE COLORECTAL ADENOMAS; MUTYH-ASSOCIATED POLYPOSIS; MYH-ASSOCIATED POLYPOSIS; GERM-LINE MUTATIONS; JUVENILE POLYPOSIS; DESMOID TUMORS; HYPERPLASTIC POLYPOSIS C1 [Chan, Andrew T.; Chung, Daniel C.] GI Canc Genet Program, Ctr Canc, Boston, MA USA. [Chan, Andrew T.; Chung, Daniel C.] Harvard Univ, Sch Med, Boston, MA USA. [Chan, Andrew T.] Massachusetts Gen Hosp, Dept Gastroenterol, Boston, MA 02114 USA. EM achan@partners.org; dchung@partners.org; dchung@partners.org NR 116 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-93844-8 PY 2010 BP 63 EP 76 DI 10.1007/978-0-387-93846-2_5 D2 10.1007/978-0-387-93846-2 PG 14 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA BPC93 UT WOS:000278549600005 ER PT B AU Kwak, EL Chung, DC AF Kwak, Eunice L. Chung, Daniel C. BE Chung, DC Haber, DA TI Hereditary Colon Cancer: Lynch Syndrome SO PRINCIPLES OF CLINICAL CANCER GENETICS: A HANDBOOK FROM THE MASSACHUSETTS GENERAL HOSPITAL LA English DT Article; Book Chapter DE Lynch syndrome; Hereditary nonpolyposis colon cancer syndrome; DNA mismatch repair; Microsatellite instability; MSH2 gene; MLH1 gene; MSH6 gene; PMS2 gene; Endometrial cancer; Immunohistochemistry; Amsterdam criteria; Bethesda guidelines; Muir-Torre syndrome ID NONPOLYPOSIS COLORECTAL-CANCER; TUMOR MICROSATELLITE-INSTABILITY; DNA MISMATCH-REPAIR; MUIR-TORRE-SYNDROME; REVISED BETHESDA GUIDELINES; MSH2 MUTATION CARRIERS; SERVICES-TASK-FORCE; ENDOMETRIAL CANCER; GERMLINE EPIMUTATION; AMSTERDAM CRITERIA C1 [Kwak, Eunice L.] Massachusetts Gen Hosp, Ctr Canc, Dept Hematol & Oncol, Boston, MA 02114 USA. [Chung, Daniel C.] Massachusetts Gen Hosp, Gastrointestinal Unit, GI Canc Genet Program, Boston, MA 02114 USA. [Chung, Daniel C.] Massachusetts Gen Hosp, Ctr Canc, GI Canc Genet Program, Boston, MA 02114 USA. [Chung, Daniel C.] Harvard Univ, Sch Med, Boston, MA USA. RP Kwak, EL (reprint author), Massachusetts Gen Hosp, Ctr Canc, Dept Hematol & Oncol, Boston, MA 02114 USA. EM ekwak@partners.org; dchung@partners.org; dchung@partners.org NR 72 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-93844-8 PY 2010 BP 77 EP 88 DI 10.1007/978-0-387-93846-2_6 D2 10.1007/978-0-387-93846-2 PG 12 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA BPC93 UT WOS:000278549600006 ER PT B AU Alsina, J Thayer, SP AF Alsina, Janivette Thayer, Sarah P. BE Chung, DC Haber, DA TI Hereditary Pancreatic Cancer SO PRINCIPLES OF CLINICAL CANCER GENETICS: A HANDBOOK FROM THE MASSACHUSETTS GENERAL HOSPITAL LA English DT Article; Book Chapter DE Pancreatic cancer; PANIN; BRCA2; p16 gene; Endoscopic ultrasound; MRI; ERCP; Hereditary pancreatitis; Pancreatic endocrine tumor ID CATIONIC TRYPSINOGEN; BRCA2 MUTATIONS; GENE; RISK; KINDREDS; SURVEILLANCE; ADENOCARCINOMA; MANAGEMENT; DIAGNOSIS; FAMILIES C1 [Thayer, Sarah P.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA. [Thayer, Sarah P.] Massachusetts Gen Hosp, Pancreat Biol Lab, Boston, MA 02114 USA. [Alsina, Janivette] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. RP Thayer, SP (reprint author), Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA. EM sthayer@partners.org NR 47 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-93844-8 PY 2010 BP 89 EP 96 DI 10.1007/978-0-387-93846-2_7 D2 10.1007/978-0-387-93846-2 PG 8 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA BPC93 UT WOS:000278549600007 ER PT B AU Pandalai, PK Yoon, SS AF Pandalai, Prakash K. Yoon, Sam S. BE Chung, DC Haber, DA TI Hereditary Diffuse Gastric Cancer SO PRINCIPLES OF CLINICAL CANCER GENETICS: A HANDBOOK FROM THE MASSACHUSETTS GENERAL HOSPITAL LA English DT Article; Book Chapter DE Diffuse gastric cancer; CDH1 gene; E-cadherin; Gastrectomy; Lobular breast cancer; Signet ring cells; Endoscopy ID E-CADHERIN GENE; PROPHYLACTIC TOTAL GASTRECTOMY; POSITRON-EMISSION-TOMOGRAPHY; LOBULAR BREAST-CARCINOMA; INVASION SUPPRESSOR GENE; ENDOSCOPIC CONGO RED; RING-CELL-CARCINOMA; METHYLENE-BLUE TEST; GERMLINE MUTATIONS; PROMOTER HYPERMETHYLATION C1 [Yoon, Sam S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA. [Yoon, Sam S.] Harvard Univ, Sch Med, Boston, MA USA. RP Yoon, SS (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA. NR 76 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-93844-8 PY 2010 BP 97 EP 107 DI 10.1007/978-0-387-93846-2_8 D2 10.1007/978-0-387-93846-2 PG 11 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA BPC93 UT WOS:000278549600008 ER PT B AU Chan-Smutko, G Iliopoulos, O AF Chan-Smutko, Gayun Iliopoulos, Othon BE Chung, DC Haber, DA TI Familial Renal Cell Cancers and Pheochromocytomas SO PRINCIPLES OF CLINICAL CANCER GENETICS: A HANDBOOK FROM THE MASSACHUSETTS GENERAL HOSPITAL LA English DT Article; Book Chapter DE Von Hippel Lindau (VHL) syndrome; Renal cell cancer; Pheochromocytoma; Hemangioblastoma; VHL gene; mTOR; Hypoxia inducible factor (HIF); Tuberous sclerosis; TSC1; TSC2; Paraganglioma; SDH ID HIPPEL-LINDAU-DISEASE; TUBEROUS SCLEROSIS COMPLEX; TUMOR-SUPPRESSOR GENE; BIRT-HOGG-DUBE; ENDOCRINE NEOPLASIA TYPE-2; HEREDITARY KIDNEY CANCER; HEPATOCYTE GROWTH-FACTOR; SPINAL-CORD HEMANGIOBLASTOMAS; FUMARATE HYDRATASE MUTATIONS; RECEPTOR INHIBITOR SU5416 C1 [Iliopoulos, Othon] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Iliopoulos, Othon] Massachusetts Gen Hosp, Ctr Canc, Familial Renal Carcinoma Clin, Boston, MA USA. [Chan-Smutko, Gayun] Massachusetts Gen Hosp, Ctr Canc Risk Assessment, Boston, MA 02114 USA. RP Iliopoulos, O (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA. EM oiliopoulos@partners.org NR 179 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-93844-8 PY 2010 BP 109 EP 128 DI 10.1007/978-0-387-93846-2_9 D2 10.1007/978-0-387-93846-2 PG 20 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA BPC93 UT WOS:000278549600009 ER PT B AU Chao, ED Gabree, MJ Tsao, H AF Chao, Elizabeth D. Gabree, Michele J. Tsao, Hensin BE Chung, DC Haber, DA TI Familial Atypical Mole Melanoma (FAMM) Syndrome SO PRINCIPLES OF CLINICAL CANCER GENETICS: A HANDBOOK FROM THE MASSACHUSETTS GENERAL HOSPITAL LA English DT Article; Book Chapter DE Melanoma; Atypical mole; p16 gene; CDKN2 gene; Cell cycle ID DYSPLASTIC NEVUS SYNDROME; CUTANEOUS MALIGNANT-MELANOMA; MULTIPLE PRIMARY MELANOMAS; CDKN2A GERMLINE MUTATIONS; POPULATION-BASED PREVALENCE; PANCREATIC-CANCER KINDREDS; ACQUIRED MELANOCYTIC NEVI; SKIN SELF-EXAMINATION; PRONE FAMILIES; UVEAL MELANOMA C1 [Tsao, Hensin] Massachusetts Gen Hosp, MGH Melanoma & Pigmented Les Ctr, MGH Melanoma Genet Program, Wellman Ctr Photomed, Boston, MA 02114 USA. [Chao, Elizabeth D.] Harvard Univ, Sch Med, Boston, MA USA. [Gabree, Michele J.] Massachusetts Gen Hosp, Ctr Canc Risk Assessment, Boston, MA 02114 USA. RP Tsao, H (reprint author), Massachusetts Gen Hosp, MGH Melanoma & Pigmented Les Ctr, MGH Melanoma Genet Program, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 189 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-93844-8 PY 2010 BP 129 EP 144 DI 10.1007/978-0-387-93846-2_10 D2 10.1007/978-0-387-93846-2 PG 16 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA BPC93 UT WOS:000278549600010 ER PT B AU Houvras, YJ Daniels, GH AF Houvras, Yariv J. Daniels, Gilbert H. BE Chung, DC Haber, DA TI Multiple Endocrine Neoplasia SO PRINCIPLES OF CLINICAL CANCER GENETICS: A HANDBOOK FROM THE MASSACHUSETTS GENERAL HOSPITAL LA English DT Article; Book Chapter DE Multiple endocrine neoplasia; Medullary thyroid cancer; Pheochromocytoma; Hyperparathyroidism; RET; MENIN; Gastrinoma; Insulinoma; Pituitary adenoma ID MEDULLARY-THYROID CARCINOMA; ZOLLINGER-ELLISON-SYNDROME; CUTANEOUS LICHEN-AMYLOIDOSIS; EARLY MALIGNANT PROGRESSION; LONG-TERM SURVIVAL; TYPE-1 MEN1; RET PROTOONCOGENE; TYROSINE KINASE; PRIMARY HYPERPARATHYROIDISM; FOLLOW-UP C1 [Houvras, Yariv J.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Daniels, Gilbert H.] Massachusetts Gen Hosp, Endocrine Tumor Genet Clin, Boston, MA 02114 USA. [Daniels, Gilbert H.] Massachusetts Gen Hosp, Thyroid Clin, Boston, MA 02114 USA. [Daniels, Gilbert H.] Harvard Univ, Sch Med, Boston, MA USA. RP Houvras, YJ (reprint author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. EM yhouvras@partners.org NR 138 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-93844-8 PY 2010 BP 145 EP 162 DI 10.1007/978-0-387-93846-2_11 D2 10.1007/978-0-387-93846-2 PG 18 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA BPC93 UT WOS:000278549600011 ER PT B AU Sweetser, DA Grabowski, EF AF Sweetser, David A. Grabowski, Eric F. BE Chung, DC Haber, DA TI Pediatric Malignancies: Retinoblastoma and Wilms' Tumor SO PRINCIPLES OF CLINICAL CANCER GENETICS: A HANDBOOK FROM THE MASSACHUSETTS GENERAL HOSPITAL LA English DT Article; Book Chapter DE Retinoblastoma; Wilms tumor; WTI gene; RB1 gene; Cell cycle; Beckwith Wiedemann syndrome; WTX gene; Knudsen hypothesis ID BECKWITH-WIEDEMANN-SYNDROME; GOLABI-BEHMEL-SYNDROME; ISOLATED UNILATERAL RETINOBLASTOMA; LOW-PENETRANCE RETINOBLASTOMA; CHILDRENS ONCOLOGY GROUP; ACUTE MYELOID-LEUKEMIA; P53 GENE-MUTATIONS; SUSCEPTIBILITY GENE; HEREDITARY RETINOBLASTOMA; HISTONE DEACETYLASE C1 [Sweetser, David A.; Grabowski, Eric F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat Hematol Oncol, Boston, MA 02115 USA. [Grabowski, Eric F.] Harvard Univ, Sch Med, Boston, MA USA. RP Sweetser, DA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat Hematol Oncol, Boston, MA 02115 USA. EM dsweetser@partners.org; EGrabowski@partners.org NR 188 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-93844-8 PY 2010 BP 163 EP 180 DI 10.1007/978-0-387-93846-2_12 D2 10.1007/978-0-387-93846-2 PG 18 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA BPC93 UT WOS:000278549600012 ER PT B AU Smith, MJ Plotkin, SR AF Smith, Miriam J. Plotkin, Scott R. BE Chung, DC Haber, DA TI Neurofibromatosis and Schwannomatosis SO PRINCIPLES OF CLINICAL CANCER GENETICS: A HANDBOOK FROM THE MASSACHUSETTS GENERAL HOSPITAL LA English DT Article; Book Chapter DE Neurofibromatosis; Schwannomatosis; NF1; NF2; Neurofibroma; Cafe-au-lait spot; Mosaicism; Schwannoma ID GASTROINTESTINAL STROMAL TUMORS; NERVE SHEATH TUMORS; BILATERAL ACOUSTIC NEUROFIBROMATOSIS; STEREOTACTIC RADIOTHERAPY FSRT; GENOTYPE-PHENOTYPE CORRELATION; NF1 GENE; FAMILIAL SCHWANNOMATOSIS; VESTIBULAR-SCHWANNOMA; SUPPRESSOR GENE; TYPE-1 NEUROFIBROMATOSIS C1 [Smith, Miriam J.; Plotkin, Scott R.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Plotkin, Scott R.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Plotkin, Scott R.] Harvard Univ, Sch Med, Boston, MA USA. RP Plotkin, SR (reprint author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. EM splotkin@partners.org RI Smith, Miriam/J-4001-2015 OI Smith, Miriam/0000-0002-3184-0817 NR 111 TC 1 Z9 1 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-93844-8 PY 2010 BP 181 EP 193 DI 10.1007/978-0-387-93846-2_13 D2 10.1007/978-0-387-93846-2 PG 13 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA BPC93 UT WOS:000278549600013 ER PT B AU Choy, E Altshuler, D AF Choy, Edwin Altshuler, David BE Chung, DC Haber, DA TI The HapMap Project and Low-Penetrance Cancer Susceptibility Alleles SO PRINCIPLES OF CLINICAL CANCER GENETICS: A HANDBOOK FROM THE MASSACHUSETTS GENERAL HOSPITAL LA English DT Article; Book Chapter DE Haplotype; HapMap; Single-nucleotide polymorphism; Genome-wide association study; Allele; Linkage ID GENOME-WIDE ASSOCIATION; BREAST-CANCER; GENETIC ASSOCIATION; PROSTATE-CANCER; MOLECULAR-ORIGINS; HAPLOTYPE MAP; HUMAN-DISEASE; POPULATION; RISK; LOCI C1 [Choy, Edwin] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Altshuler, David] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. [Altshuler, David] Harvard Univ, Sch Med, Boston, MA USA. RP Choy, E (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. EM echoy@partners.org NR 31 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-93844-8 PY 2010 BP 195 EP 204 DI 10.1007/978-0-387-93846-2_14 D2 10.1007/978-0-387-93846-2 PG 10 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA BPC93 UT WOS:000278549600014 ER PT B AU Shaw, AT Attar, EC Choy, E Engelman, J AF Shaw, Alice T. Attar, Eyal C. Choy, Edwin Engelman, Jeffrey BE Chung, DC Haber, DA TI Somatic Genetic Alterations and Implications for Targeted Therapies in Cancer (GIST, CML, Lung Cancer) SO PRINCIPLES OF CLINICAL CANCER GENETICS: A HANDBOOK FROM THE MASSACHUSETTS GENERAL HOSPITAL LA English DT Article; Book Chapter DE Tyrosine kinase; Tyrosine kinase inhibitor; Gastrointestinal stromal tumor; Chronic myelogenous leukemia; Lung cancer; Imatinib; EGFR inhibitor; Philadelphia chromosome; c-KIT; Stem cell factor; Fluorescence in situ hybridization ID EPIDERMAL-GROWTH-FACTOR; GASTROINTESTINAL STROMAL TUMORS; CHRONIC MYELOID-LEUKEMIA; NONSMALL CELL LUNG; TYROSINE KINASE INHIBITOR; CHRONIC MYELOGENOUS LEUKEMIA; FACTOR-RECEPTOR GENE; EML4-ALK FUSION GENE; PREVIOUSLY TREATED PATIENTS; ANAPLASTIC LYMPHOMA KINASE C1 [Shaw, Alice T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02115 USA. [Attar, Eyal C.] Harvard Univ, Sch Med, Boston, MA USA. [Choy, Edwin] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP Shaw, AT (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02115 USA. EM ashaw1@partners.org NR 150 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-93844-8 PY 2010 BP 205 EP 220 DI 10.1007/978-0-387-93846-2_15 D2 10.1007/978-0-387-93846-2 PG 16 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA BPC93 UT WOS:000278549600015 ER PT B AU Caballero, AE AF Caballero, A. Enrique BE Poretsky, L TI Diabetes in Culturally Diverse Populations: From Biology to Culture SO PRINCIPLES OF DIABETES MELLITUS, SECOND EDITION LA English DT Article; Book Chapter ID NUTRITION EXAMINATION SURVEY; IMPAIRED GLUCOSE-TOLERANCE; SELF-MANAGEMENT; INSULIN-RESISTANCE; HEALTH LITERACY; UNITED-STATES; MEXICAN-AMERICANS; DISEASE MANAGEMENT; AFRICAN-AMERICAN; THRIFTY GENOTYPE C1 Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA. RP Caballero, AE (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA. EM enrique.caballero@joslin.harvard.edu NR 90 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS BN 978-0-387-09840-1 PY 2010 BP 129 EP 144 DI 10.1007/978-0-387-09841-8_9 D2 10.1007/978-0-387-09841-8 PG 16 WC Endocrinology & Metabolism; Medicine, General & Internal SC Endocrinology & Metabolism; General & Internal Medicine GA BNP93 UT WOS:000275191900009 ER PT B AU Ganda, OP AF Ganda, Om P. BE Poretsky, L TI Dyslipidemia: Pathogenesis and Management SO PRINCIPLES OF DIABETES MELLITUS, SECOND EDITION LA English DT Article; Book Chapter ID CORONARY-HEART-DISEASE; HIGH-DENSITY-LIPOPROTEIN; RANDOMIZED CONTROLLED-TRIAL; REVERSE CHOLESTEROL TRANSPORT; HEALED MYOCARDIAL-INFARCTION; PLACEBO-CONTROLLED TRIAL; EXTENDED-RELEASE NIACIN; TRANSFER PROTEIN GENE; TREATMENT PANEL-III; NON-HDL CHOLESTEROL C1 Harvard Univ, Sch Med, Joslin Diabet Ctr, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA. RP Ganda, OP (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA. EM om.ganda@joslin.harvard.edu NR 110 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS BN 978-0-387-09840-1 PY 2010 BP 435 EP 456 DI 10.1007/978-0-387-09841-8_28 D2 10.1007/978-0-387-09841-8 PG 22 WC Endocrinology & Metabolism; Medicine, General & Internal SC Endocrinology & Metabolism; General & Internal Medicine GA BNP93 UT WOS:000275191900028 ER PT B AU Hsu, WC Arampatzi, KM Mantzoros, CS AF Hsu, William C. Arampatzi, Kalliopi M. Mantzoros, Christos S. BE Poretsky, L TI Obesity - Genetics, Pathogenesis, Therapy SO PRINCIPLES OF DIABETES MELLITUS, SECOND EDITION LA English DT Article; Book Chapter ID WEIGHT-LOSS SURGERY; UNITED-STATES; BARIATRIC SURGERY; NATIONAL COHORT; LEPTIN; GAIN; METAANALYSIS; OVERWEIGHT; ORLISTAT; INSIGHT C1 [Hsu, William C.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. [Mantzoros, Christos S.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Boston, MA 02115 USA. RP Hsu, WC (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. EM cmantzor@bidmc.harvard.edu NR 43 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS BN 978-0-387-09840-1 PY 2010 BP 475 EP 488 DI 10.1007/978-0-387-09841-8_30 D2 10.1007/978-0-387-09841-8 PG 14 WC Endocrinology & Metabolism; Medicine, General & Internal SC Endocrinology & Metabolism; General & Internal Medicine GA BNP93 UT WOS:000275191900030 ER PT B AU Herzlinger, S Abrahamson, MJ AF Herzlinger, Susan Abrahamson, Martin J. BE Poretsky, L TI Treating Type 2 Diabetes Mellitus SO PRINCIPLES OF DIABETES MELLITUS, SECOND EDITION LA English DT Article; Book Chapter ID GLUCAGON-LIKE PEPTIDE-1; INSULIN-RESISTANCE ATHEROSCLEROSIS; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; IMPAIRED GLUCOSE-TOLERANCE; MEDICAL NUTRITION THERAPY; IMPROVES GLYCEMIC CONTROL; CONTROLLED CLINICAL-TRIAL; RISK-FACTORS; CARDIOVASCULAR EVENTS; EXENATIDE EXENDIN-4 C1 [Herzlinger, Susan; Abrahamson, Martin J.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. RP Abrahamson, MJ (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. EM martin.abrahamson@joslin.harvard.edu NR 93 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS BN 978-0-387-09840-1 PY 2010 BP 731 EP 747 DI 10.1007/978-0-387-09841-8_44 D2 10.1007/978-0-387-09841-8 PG 17 WC Endocrinology & Metabolism; Medicine, General & Internal SC Endocrinology & Metabolism; General & Internal Medicine GA BNP93 UT WOS:000275191900044 ER PT B AU Horton, ES AF Horton, Edward S. BE Poretsky, L TI Prevention of Type 2 Diabetes Mellitus SO PRINCIPLES OF DIABETES MELLITUS, SECOND EDITION LA English DT Article; Book Chapter ID IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE INTERVENTION; RANDOMIZED CONTROLLED-TRIAL; 10-YEAR FOLLOW-UP; CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME; PHYSICAL-ACTIVITY; RISK-FACTORS; WEIGHT-GAIN; INSULIN-RESISTANCE C1 [Horton, Edward S.] Joslin Diabet Ctr, Boston, MA 02215 USA. [Horton, Edward S.] Harvard Univ, Sch Med, Boston, MA USA. RP Horton, ES (reprint author), Joslin Diabet Ctr, Boston, MA 02215 USA. EM edward.horton@joslin.harvard.edu NR 50 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS BN 978-0-387-09840-1 PY 2010 BP 821 EP 832 DI 10.1007/978-0-387-09841-8_50 D2 10.1007/978-0-387-09841-8 PG 12 WC Endocrinology & Metabolism; Medicine, General & Internal SC Endocrinology & Metabolism; General & Internal Medicine GA BNP93 UT WOS:000275191900050 ER PT B AU Sano, M Jacobs, D Gaynor, K AF Sano, Mary Jacobs, Diane Gaynor, Katya BE Legato, MJ TI Hormone Replacement Therapy and Cognitive Function SO PRINCIPLES OF GENDER-SPECIFIC MEDICINE, 2ND EDITION LA English DT Article; Book Chapter ID HEALTH INITIATIVE MEMORY; RANDOMIZED CONTROLLED-TRIAL; CONJUGATED EQUINE ESTROGENS; SURGICALLY MENOPAUSAL WOMEN; QUALITY-OF-LIFE; RADIAL-ARM MAZE; POSTMENOPAUSAL WOMEN; ALZHEIMERS-DISEASE; BREAST-CANCER; DOUBLE-BLIND C1 [Sano, Mary] Alzheimer Dis Res Ctr, New York, NY USA. [Sano, Mary; Gaynor, Katya] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Sano, Mary] James J Peters VAMC, New York, NY USA. RP Sano, M (reprint author), Alzheimer Dis Res Ctr, New York, NY USA. NR 57 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND BN 978-0-08-092150-1; 978-0-12-374271-1 PY 2010 BP 142 EP 148 DI 10.1016/B978-0-12-374271-1.00013-7 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA BEO92 UT WOS:000317610700017 ER PT B AU Pearlman, J Cooper, R Chhabra, HS Jefferds, A Anbarasan, I AF Pearlman, Jon Cooper, Rory Chhabra, H. S. Jefferds, Alexandra Anbarasan, Ilanagai GP ASME TI A LOW-COST TOOL FOR GATHERING AND INTERPRETING THE MOBILITY NEEDS OF WHEELCHAIR USERS IN INDIA SO PROCEEDINGS OF THE ASME INTERNATIONAL DESIGN ENGINEERING TECHNICAL CONFERENCES AND COMPUTERS AND INFORMATION IN ENGINEERING CONFERENCE, VOL 8, PTS A AND B LA English DT Proceedings Paper CT ASME International Design Engineering Technical Conferences/Computers and Information in Engineering Conference CY AUG 30-SEP 02, 2009 CL San Diego, CA SP ASME, Design Engn Div, ASME, Computers & Info Engn Div ID REHABILITATION; DISABILITIES; WOMEN; DEVICE AB Collecting and interpreting customer needs using traditional product development tools can be difficult or impossible when there is a large geographic, cultural, or social gap between the customer and product designer. As part of a project to design an electric powered wheelchair (EPW) for Indians with disabilities, we piloted a new approach to gather and interpret customer needs. First, we distributed cameras to manual wheelchair users at the Indian Spinal Injury Center in New Delhi, India, and asked subjects take photos and write descriptions of accessibility barriers in and around their homes. The film was then processed; photos were de-identified and integrated into an internet-based questionnaire. Individuals with expertise in wheelchair use and design, and home modifications were recruited to participate in the questionnaire where they identified and ranked the accessibility barriers in each of 50 images which were randomly selected from the full database. Thirty cameras were received, yielding approximately 500 photos which were integrated into the questionnaire. A total of 72 subjects from 8 countries participated in the questionnaire. Using cluster analysis, we developed unique groupings for accessibility barriers based on their severity and prevalence. These groupings provided valuable and relevant information to develop and prioritize the design specifications of the EPW. C1 [Pearlman, Jon; Cooper, Rory] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Pearlman, J (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. NR 45 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC MECHANICAL ENGINEERS PI NEW YORK PA THREE PARK AVENUE, NEW YORK, NY 10016-5990 USA BN 978-0-7918-4905-7 PY 2010 BP 531 EP 540 PG 10 WC Computer Science, Interdisciplinary Applications; Engineering, Manufacturing; Engineering, Mechanical SC Computer Science; Engineering GA BUU86 UT WOS:000290416800052 ER PT B AU Wang, SB Kozanek, M Wood, KB Li, GA AF Wang, Shaobai Kozanek, Michal Wood, Kirkham B. Li, Guoan GP ASME TI LUMBAR DEGENERATIVE DISC DISEASE INCREASES DEFORMATIONS AT CEPHALAD ADJACENT LEVELS IN VIVO SO PROCEEDINGS OF THE ASME SUMMER BIOENGINEERING CONFERENCE, 2010 LA English DT Proceedings Paper CT 12th ASME Summer Bioengineering Conference CY JUN 16-19, 2010 CL Naples, FL SP ASME, Bioengineer Div, Natl Inst Health, Natl Sci Fdn C1 [Wang, Shaobai; Kozanek, Michal; Wood, Kirkham B.; Li, Guoan] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Bioengn Lab,Dept Orthopaed, Boston, MA 02115 USA. RP Wang, SB (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Bioengn Lab,Dept Orthopaed, Boston, MA 02115 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC MECHANICAL ENGINEERS PI NEW YORK PA THREE PARK AVENUE, NEW YORK, NY 10016-5990 USA BN 978-0-7918-4403-8 PY 2010 BP 915 EP 916 PG 2 WC Engineering, Biomedical SC Engineering GA BUY47 UT WOS:000290705300458 ER PT B AU Chakraborty, N Menze, MA Elmoazzen, H Hand, SC Toner, M AF Chakraborty, Nilay Menze, Michael A. Elmoazzen, Heidi Hand, Steve C. Toner, Mehmet GP ASME TI CHOLINE CHLORIDE IMPROVES THE DESICCATION TOLERANCE OF CHINESE HAMSTER OVARY CELLS SO PROCEEDINGS OF THE ASME SUMMER BIOENGINEERING CONFERENCE, 2010 LA English DT Proceedings Paper CT 12th ASME Summer Bioengineering Conference CY JUN 16-19, 2010 CL Naples, FL SP ASME, Bioengineer Div, Natl Inst Health (NIH), Natl Sci Fdn ID MAMMALIAN-CELLS; PRESERVATION C1 [Chakraborty, Nilay; Elmoazzen, Heidi; Toner, Mehmet] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med & Surg Serv, Boston, MA 02114 USA. RP Chakraborty, N (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med & Surg Serv, Boston, MA 02114 USA. RI Chakraborty, Nilay/C-3118-2009 NR 9 TC 0 Z9 0 U1 1 U2 3 PU AMER SOC MECHANICAL ENGINEERS PI NEW YORK PA THREE PARK AVENUE, NEW YORK, NY 10016-5990 USA BN 978-0-7918-4403-8 PY 2010 BP 993 EP 994 PG 2 WC Engineering, Biomedical SC Engineering GA BUY47 UT WOS:000290705300497 ER PT J AU Wang, JH AF Wang, Jia-huai TI The CHINA CONNECTION: Michael Rossmann and his first encounter with me SO PROTEIN & CELL LA English DT Editorial Material C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Wang, JH (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM jwang@red.dfci.harvard.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU HIGHER EDUCATION PRESS PI BEIJING PA SHATANHOU ST 55, BEIJING 100009, PEOPLES R CHINA SN 1674-800X J9 PROTEIN CELL JI Protein Cell PD JAN PY 2010 VL 1 IS 1 BP 6 EP 8 DI 10.1007/s13238-010-0001-6 PG 3 WC Cell Biology SC Cell Biology GA V25XI UT WOS:000208510300004 PM 21203992 ER PT S AU Conboy, MJ Cerletti, M Wagers, AJ Conboy, IM AF Conboy, Michael J. Cerletti, Massimiliano Wagers, Amy J. Conboy, Irina M. BE Conboy, IM Schaffer, DV BarcellosHoff, MH Li, S TI Immuno-Analysis and FACS Sorting of Adult Muscle Fiber-Associated Stem/Precursor Cells SO PROTOCOLS FOR ADULT STEM CELLS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Satellite cell; Myoblast; Myogenic; Renewal ID SKELETAL-MUSCLE; HETEROGENEITY AB We describe the immunostaining methods we commonly use to detect the more robust cell markers identifying the various cell populations obtained by the enzymatic and or mechanical dissociation of muscle satellite cells: CD34, m-Cadherin, and Pax7, self-renewing muscle stem cells expressing CXCR4 and beta 1-integrin, populations of proliferative myogenic progenitor cells expressing, Pax3, Pax7, Myf5, MyoD1, and desmin, differentiating myoblasts expressing myogenin and cMHC, and the CD45 expressing leukocyte lineage cells that infiltrate injured and regenerating skeletal muscle. C1 [Conboy, Michael J.; Conboy, Irina M.] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA. [Cerletti, Massimiliano; Wagers, Amy J.] Joslin Diabet Ctr, Sect Dev & Stem Cell Biol, Boston, MA 02215 USA. [Cerletti, Massimiliano; Wagers, Amy J.] Joslin Diabet Ctr, Dept Pathol, Boston, MA 02215 USA. [Cerletti, Massimiliano; Wagers, Amy J.] Harvard Stem Cell Inst, Boston, MA USA. RP Conboy, MJ (reprint author), Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA. EM iconboy@berkeley.edu; iconboy@berkeley.edu FU NIA NIH HHS [R01 AG027252]; NIAMS NIH HHS [K01 AR050515] NR 4 TC 25 Z9 25 U1 0 U2 4 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-60761-062-5 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2010 VL 621 BP 165 EP 173 DI 10.1007/978-1-60761-063-2_11 D2 10.1007/978-1-60761-063-2 PG 9 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BOU18 UT WOS:000277616500011 PM 20405366 ER PT S AU McBride, SM Yock, TI AF McBride, Sean M. Yock, Torunn I. BE Metz, JM TI Proton Radiotherapy in Pediatric Malignancies SO PROTON THERAPY SE Radiation Medicine Rounds LA English DT Article; Book Chapter ID CHILDRENS ONCOLOGY GROUP; EXTERNAL-BEAM RADIATION; CHILDHOOD-CANCER; CRANIOSPINAL IRRADIATION; BRAIN-TUMORS; ORBITAL RHABDOMYOSARCOMA; ADJUVANT CHEMOTHERAPY; PHOTON RADIOTHERAPY; CRANIAL RADIATION; CLINICAL-OUTCOMES AB Proton radiotherapy is a critical new treatment modality in the world of pediatric malignancies. The ability of proton radiotherapy to reduce significant dose to normal structures brings with it the promise of reduced long-term side effects. This is increasingly important in the pediatric population, where long-term survivors are quite common. A variety of data argues for the benefits of proton radiotherapy in the treatment of ependymoma, medulloblastoma, glioma, craniopharyngioma, germ cell tumors, retinoblastoma, rhabdomyosarcoma, and Ewing's sarcoma. C1 [McBride, Sean M.; Yock, Torunn I.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RP McBride, SM (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. EM smcbride@lroc.harvard.edu NR 75 TC 1 Z9 1 U1 1 U2 1 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA SN 2151-4208 BN 978-1-617050-44-2 J9 RADIAT MED ROUNDS PY 2010 VL 1 IS 3 BP 491 EP 510 DI 10.5003/2151-4208.1.3.491 PG 20 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA BSV92 UT WOS:000285941700005 ER PT B AU Jacobson, CC Kimball, AB AF Jacobson, Christine C. Kimball, Alexa B. BE Gordon, KB Ruderman, EM TI Psoriasis SO PSORIASIS AND PSORIATIC ARTHRITIS: AN INTEGRATED APPROACH LA English DT Article; Book Chapter ID QUALITY-OF-LIFE; TUMOR-NECROSIS-FACTOR; GENERALIZED PUSTULAR PSORIASIS; CHRONIC PLAQUE PSORIASIS; INFLAMMATORY-BOWEL-DISEASE; POPULATION-BASED COHORT; TRIOXSALEN BATH PUVA; FOLLOW-UP; MALIGNANT-TUMORS; SUSCEPTIBILITY LOCUS C1 [Jacobson, Christine C.] Stanford Univ, Sch Med, Dept Dermatol, Stanford, CA 94305 USA. [Kimball, Alexa B.] Massachusetts Gen Hosp, Dermatol Clin Studies Unit, Boston, MA 02114 USA. [Kimball, Alexa B.] Brigham & Womens Hosp, Dermatol Clin Studies Unit, Boston, MA 02115 USA. RP Jacobson, CC (reprint author), Stanford Univ, Sch Med, Dept Dermatol, Stanford, CA 94305 USA. NR 144 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-1-907673-05-4 PY 2010 BP 47 EP 56 PG 10 WC Dermatology; Rheumatology SC Dermatology; Rheumatology GA BQA85 UT WOS:000280527100006 ER PT S AU Yehuda, R Bierer, LM Pratchett, LC Pelcovitz, M AF Yehuda, Rachel Bierer, Linda M. Pratchett, Laura C. Pelcovitz, Michelle BE Barchas, JD Difede, J TI Using biological markers to inform a clinically meaningful treatment response SO PSYCHIATRIC AND NEUROLOGIC ASPECTS OF WAR SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT 89th Annual Conference of the Association for Research in Nervous and Mental Disease CY DEC 16, 2009 CL Rockefeller Univ, New York, NY HO Rockefeller Univ DE PTSD; treatment response; combat trauma; neuroendocrinology ID POSTTRAUMATIC-STRESS-DISORDER; EXPOSURE THERAPY; VETERANS; CORTISOL; PTSD; PSYCHOTHERAPY; SERTRALINE; VICTIMS; PLACEBO; TRAUMA AB Combat veterans with posttraumatic stress disorder (PTSD) demonstrate less robust improvement following treatments than do civilians with PTSD. This paper discusses a theoretical model for evaluating treatment response based on the extent of change in biological markers of symptom severity or resilience between treatment initiation and termination. Such analysis permits a determination of biological change associated with the liberal criteria commonly used to determine treatment response in combat PTSD, and a comparison of this to the biological change associated with clinical response determined according to the conservative definition more appropriate to civilian PTSD. Interim data supporting the utility of this approach is presented based on preliminary analyses from our work in progress. We propose that future studies consider the unique consequences of combat trauma and develop treatments that incorporate the complex nature of the exposure and response characteristic of a veteran population. C1 [Yehuda, Rachel; Bierer, Linda M.; Pratchett, Laura C.] James J Peters VAMC, Dept Psychiat, Bronx, NY USA. [Yehuda, Rachel; Bierer, Linda M.; Pelcovitz, Michelle] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. RP Yehuda, R (reprint author), James J Peters VAMC, Dept Psychiat, 526 OOMH,130 W Kingsbridge Rd, Bronx, NY USA. EM rachel.yehuda@va.gov FU NIMH [MH088101]; DOD [PT073577, 10164894]; VA Merit Review FX This work was supported by the following funding: NIMH MH088101, DOD PT073577 and 10164894, and VA Merit Review to R.Y. NR 36 TC 13 Z9 13 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 BN 978-1-57331-804-4 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2010 VL 1208 BP 158 EP 163 DI 10.1111/j.1749-6632.2010.05698.x PG 6 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA BSK28 UT WOS:000284742000020 PM 20955338 ER PT J AU Salzer, MS Kundra, LB AF Salzer, Mark S. Kundra, Loran B. TI Liability Issues Associated With Referrals to Self-Help Groups SO PSYCHIATRIC SERVICES LA English DT Article AB Self-help groups, which are also referred to as mutual aid groups, are widely recognized as an important component of a comprehensive public mental health system that promotes recovery. Nonetheless, some psychiatrists and other providers have expressed concerns about these consumer-run groups and fear potential liability if they make referrals and something harmful occurs. This column reviews potential liability claims that could be made pertaining to referrals to self-help groups. The authors conclude that the likelihood of success of a plaintiff's claim is small. Recommendations are given for further lowering the likelihood of a successful suit. (Psychiatric Services 61: 6-8, 2010) C1 [Salzer, Mark S.] Univ Penn, Sch Med, Dept Psychiat, Ctr Mental Hlth Policy & Serv Res, Philadelphia, PA 19104 USA. [Salzer, Mark S.] Philadelphia Dept Veter Affairs Med Ctr, Vet Integrated Serv Network 4, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. [Kundra, Loran B.] UPenn Collaborat Community Integrat, Wayne, PA USA. RP Salzer, MS (reprint author), Univ Penn, Sch Med, Dept Psychiat, Ctr Mental Hlth Policy & Serv Res, 3535 Market St,3rd Floor, Philadelphia, PA 19104 USA. EM mark.salzer@uphs.upenn.edu FU Federal Department of Education, National Institute on Disability and Rehabilitation Research [H133B031109] FX The contents of this legal summary were developed under a grant to the University of Pennsylvania from the Federal Department of Education, National Institute on Disability and Rehabilitation Research grant H133B031109 (Dr. Salzer, principal investigator). However, the contents do not necessarily represent the policy of the Department of Education and do not imply endorsement by the federal government. NR 9 TC 0 Z9 0 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JAN PY 2010 VL 61 IS 1 BP 6 EP 8 PG 3 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 539DX UT WOS:000273234800002 PM 20044410 ER PT J AU Kilbourne, AM Greenwald, DE Hermann, RC Charns, MP McCarthy, JF Yano, EM AF Kilbourne, Amy M. Greenwald, Devra E. Hermann, Richard C. Charns, Martin P. McCarthy, John F. Yano, Elizabeth M. TI Financial Incentives and Accountability for Integrated Medical Care in Department of Veterans Affairs Mental Health Programs SO PSYCHIATRIC SERVICES LA English DT Article ID CARDIOVASCULAR-DISEASE; OLDER PATIENTS; GLOBAL BURDEN; QUALITY; PERFORMANCE; DISORDERS; ILLNESS; SCHIZOPHRENIA; SYSTEM; PAY AB Objective: This study assessed the extent to which mental health leaders perceive their programs as being primarily accountable for monitoring general medical conditions among patients with serious mental illness, and it assessed associations with modifiable health system factors. Methods: As part of the Department of Veterans Affairs (VA) 2007 national Mental Health Program Survey, 108 mental health program directors were queried regarding program characteristics. Perceived accountability was defined as whether their providers, as opposed to external general medical providers, were primarily responsible for specific clinical tasks related to serious mental illness treatment or high-risk behaviors. Multivariable logistic regression was used to determine whether financial incentives or other system factors were associated with accountability. Results: Thirty-six percent of programs reported primary accountability for monitoring diabetes and cardiovascular risk after prescription of second-generation antipsychotics, 10% for hepatitis C screening, and 17% for obesity screening and weight management. In addition, 18% and 27% of program leaders, respectively, received financial bonuses for high performance for screening for risk of diabetes and cardiovascular disease and for alcohol misuse. Financial bonuses for diabetes and cardiovascular screening were associated with primary accountability for such screening (odds ratio = 5.01, p < .05). Co-location of general medical providers was associated with greater accountability for high-risk behavior screening or treatment. Conclusions: Financial incentives to improve quality performance may promote accountability in monitoring diabetes and cardiovascular risk assessment within mental health programs. Integrated care strategies (co-location) might be needed to promote management of high-risk behaviors among patients with serious mental illness. (Psychiatric Services 61: 38-44, 2010) C1 [Kilbourne, Amy M.; McCarthy, John F.] Dept Vet Affairs, HSR&D, Serious Mental Illness Treatment Res & Evaluat Ct, Ann Arbor, MI 48105 USA. [Greenwald, Devra E.] VA Pittsburgh Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Hermann, Richard C.; Charns, Martin P.] VA Boston Healthcare Syst, Ctr Org Leadership & Management Syst, Boston, MA USA. [Yano, Elizabeth M.] VA HSR&D Ctr Excellence Study Healthcare Provider, Los Angeles, CA USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. RP Kilbourne, AM (reprint author), Dept Vet Affairs, HSR&D, Serious Mental Illness Treatment Res & Evaluat Ct, 2215 Fuller Rd, Ann Arbor, MI 48105 USA. EM amykilbo@umich.edu FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [IIR05-195, IIR 07-115] FX This research was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service ( grants IIR05-195 and IIR 07-115). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. The authors thank the following individuals for providing a critical review of the Mental Health Program Survey: Mark Bauer, M. D., Stephen Cavicchia, Psy.D., Joseph Conigliaro, M. D., M. P. H., Larry Drill, M. S. W., M. P. H., Joanne Kirchner, M. D., David Oslin, M. D., Linda McBride, R.N., Kathleen Schutte, Ph.D., and Marcia Valenstein, M. D. NR 33 TC 14 Z9 14 U1 1 U2 4 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JAN PY 2010 VL 61 IS 1 BP 38 EP 44 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 539DX UT WOS:000273234800008 PM 20044416 ER PT J AU McInnes, DK Hyun, JK Trafton, JA Asch, SM Gifford, AL AF McInnes, D. Keith Hyun, Jenny K. Trafton, Jodie A. Asch, Steven M. Gifford, Allen L. TI Program Characteristics Associated With Testing for HIV and Hepatitis C in Veterans Substance Use Disorder Clinics SO PSYCHIATRIC SERVICES LA English DT Article ID VA PATIENTS; DRUG-USERS; INFECTION; RISK; CARE AB Objective: This study examined whether organizational characteristics and quality improvement initiatives were related to HIV and hepatitis C (HCV) testing rates in veterans' substance use disorders programs. Methods: Data were collected by surveying 232 program directors at all U. S. Department of Veterans Affairs (VA) substance use disorder programs. Results: Program directors (N = 223) reported that, on average, 35% of their patients were tested for HIV (median = 10%) and 57% were tested for HCV (median = 80%). Of the quality improvement initiatives examined, computerized reminders to clinicians (p = .02) and a designated clinician for screening (p = .01) were positively associated with HCV testing, and computerized templates that guide clinicians through ordering of testing were positively associated with HIV testing (p = .06). Conclusions: Despite national emphasis on HIV testing, rates of testing were lower for HIV than for HCV in programs serving veterans with substance use disorders and at risk of both illnesses. System-level quality improvement initiatives may be effective at increasing rates of infectious disease screening. (Psychiatric Services 61: 90-94, 2010) C1 [McInnes, D. Keith] Edith Nourse Rogers Mem Vet Adm Hosp, CHQOER, Bedford, MA 01730 USA. [McInnes, D. Keith] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Hyun, Jenny K.] Dept Vet Affairs, Natl Ctr PTSD, Palo Alto, CA USA. [Trafton, Jodie A.] VA Ctr Hlth Care Evaluat, Menlo Pk, CA USA. [Asch, Steven M.] VA Greater Los Angeles Hlth Care Syst, HIV Hepatitis Qual Enhancement Res Initiat, Los Angeles, CA USA. [Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Gifford, Allen L.] VA New England Hlth Care Syst, HIV Hepatitis Qual Enhancement Res Initiat, Bedford, MA USA. [Gifford, Allen L.] Boston Univ, Sch Med, Boston, MA 02118 USA. RP McInnes, DK (reprint author), Edith Nourse Rogers Mem Vet Adm Hosp, CHQOER, 200 Springs Rd 152,Bldg 70, Bedford, MA 01730 USA. EM keith.mcinnes@va.gov NR 12 TC 1 Z9 1 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JAN PY 2010 VL 61 IS 1 BP 90 EP 94 PG 5 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 539DX UT WOS:000273234800018 PM 20044426 ER PT J AU Even, C Weintraub, D AF Even, Christian Weintraub, Daniel TI Case for and against specificity of depression in Alzheimer's disease SO PSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Review DE aged; Alzheimer's disease; dementia; depression; mood disorders ID LATE-ONSET DEPRESSION; PROVISIONAL DIAGNOSTIC-CRITERIA; DEFINED VASCULAR DEPRESSION; MAJOR DEPRESSION; DOUBLE-BLIND; GERIATRIC DEPRESSION; PSYCHIATRIC-SYMPTOMS; GLUCOSE-METABOLISM; PRIMARY DEMENTIA; CACHE COUNTY AB Aims: The aims of this study were to assess the epidemiological, phenomenological, and pathophysiological evidence that suggests the specificity of depression associated with Alzheimer's disease (AD). Methods: We reviewed the English-language literature. Results: Depression occurs significantly more often in patients with AD than in the general elderly population. While development of depression in response to the disability and emotional stress of AD may be a contributory factor in some patients, several studies showed that depression was not, or was only seldom, related to self-awareness of AD and these studies could not explain the high prevalence figures. To overcome the overlapping phenomenology of the two diseases, specific diagnostic criteria have been developed for depression in this context. Mixed findings have come from neuropathological and neuroimaging studies, with some evidence linking the underlying neural substrate of AD and depression, suggesting an overlapping cause of primary depression and depression comorbid with AD. Few randomized controlled trials for depression associated with AD have been conducted, with rather poor results for the use of antidepressants. Conclusions: Currently, depression associated with AD is not considered a separate disorder by regulatory authorities and is unlikely to be considered as such in the near future. Several obstacles remain to support such a specific position, including the heterogenous nature of depression in general and within AD itself, the lack of a distinct set of symptoms, and limited treatment. C1 [Even, Christian] Univ Paris 05, Ctr Hosp St Anne, Clin Malad Mentales & Encephale, INSERM,U675,Ctr Psychiat & Neurosci, F-75674 Paris 14, France. [Weintraub, Daniel] Univ Penn, PADRECC, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, MIRECC, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Even, C (reprint author), Univ Paris 05, Ctr Hosp St Anne, Clin Malad Mentales & Encephale, INSERM,U675,Ctr Psychiat & Neurosci, 100 Rue Sante, F-75674 Paris 14, France. EM c.even@ch-sainte-anne.fr NR 85 TC 9 Z9 10 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1323-1316 EI 1440-1819 J9 PSYCHIAT CLIN NEUROS JI Psychiatry Clin. Neurosci. PY 2010 VL 64 IS 4 BP 358 EP 366 DI 10.1111/j.1440-1819.2010.02108.x PG 9 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 631OA UT WOS:000280355800002 PM 20573052 ER PT J AU Reimherr, F Amsterdam, J Dunner, D Adler, L Zhang, SY Williams, D Marchant, B Michelson, D Nierenberg, A Schatzberg, A Feldman, P AF Reimherr, Frederick Amsterdam, Jay Dunner, David Adler, Lenard Zhang, Shuyu Williams, David Marchant, Barrie Michelson, David Nierenberg, Andrew Schatzberg, Alan Feldman, Peter TI Genetic polymorphisms in the treatment of depression: Speculations from an augmentation study using atomoxetine SO PSYCHIATRY RESEARCH LA English DT Article DE 5-HTTLPR; Atomoxetine; Depression; Genetic polymorphism; Sertraline; SSRI ID SEROTONIN TRANSPORTER GENE; ANTIDEPRESSANT RESPONSE; FUNCTIONAL POLYMORPHISM; PROMOTER POLYMORPHISM; ALLELIC VARIATION; DOUBLE-BLIND; DISORDER; PAROXETINE; FLUVOXAMINE; SERTRALINE AB Treatment-resistant depression may be related to polymorphisms in the promoter region of the serotonin transporter gene (5-HTTLPR) or dysregulation of noradrenergic systems. To examine 5-HTTLPR genotypes and responses to treatment, adult patients (N=261) with current major depression and a symptom severity rating 2:18 on the 17-item Hamilton Depression Rating Scale (HAMD(17)) were treated for 8 weeks with open-label sertraline (100-200 mg/d). Patients remaining symptomatic (total score >4, or> 1 on any item of the HAMD17 Maier-Philipp subscale) were randomly assigned to double-blind therapy with sertraline plus either atomoxetine (40-120 mg/d) or placebo for 8 additional weeks. 5-HTTLPR genotype did not predict responses to sertraline monotherapy or discontinuation rates. Among the 138 patients remaining symptomatic after sertraline monotherapy (L/L = 21%, S/L = 50%, S/S = 29%), significantly more S/S-genotype patients achieved remission under combined sertraline/atomoxetine treatment relative to the other genotypes (S/S = 81.8%; non-S/S=32.7%), but not under sertraline/placebo treatment (S/S=35.7%; non-S/S=37.7%). Minor genotypic differences were noted in adverse event profiles. In patients with poor responses to sertraline monotherapy for depression, addition of atomoxetine may improve responses to treatment of depression in S/S-genotyped patients. Although this study is speculative, it represents a pharmacologically and genotypically well-defined patient population. Clinical Trials Registry #: NCT00485862. URL where available: http://www.clinicaltrials.gov/ct/show/ NCT00485862?order = 1. (C) 2009 Published by Elsevier Ireland Ltd. C1 [Reimherr, Frederick; Marchant, Barrie] Univ Utah, Hlth Sci Ctr, Dept Psychiat, Salt Lake City, UT 84132 USA. [Amsterdam, Jay] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Dunner, David] Univ Washington, Dept Psychiat & Behav Sci, Mercer Isl, WA USA. [Dunner, David] Univ Washington, Ctr Anxiety & Depress, Mercer Isl, WA USA. [Adler, Lenard] NYU, Sch Med, Dept Psychiat, New York, NY USA. [Zhang, Shuyu; Williams, David; Feldman, Peter] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA. [Michelson, David] Merck & Co Inc, Merck Res Labs, N Wales, PA USA. [Nierenberg, Andrew] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA USA. [Schatzberg, Alan] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. RP Reimherr, F (reprint author), Univ Utah, Hlth Sci Ctr, Dept Psychiat, 50 N Med Dr, Salt Lake City, UT 84132 USA. EM fred.reimherr@hsc.utah.edu OI Adler, Len/0000-0002-9812-8234 FU Eli Lilly and Company FX This research was supported by Eli Lilly and Company. Appreciation is expressed to Dr. Patrick McGrath of Columbia University for his insightful comments regarding the data. NR 40 TC 12 Z9 12 U1 3 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD JAN PY 2010 VL 175 IS 1-2 BP 67 EP 73 DI 10.1016/j.psychres.2009.01.005 PG 7 WC Psychiatry SC Psychiatry GA 553NT UT WOS:000274374800013 PM 19969374 ER PT J AU Haggerty, GD Siefert, CJ Weinberger, J AF Haggerty, Greg D. Siefert, Caleb J. Weinberger, Joel TI EXAMINING THE RELATIONSHIP BETWEEN CURRENT ATTACHMENT STATUS AND FREELY RECALLED AUTOBIOGRAPHICAL MEMORIES OF CHILDHOOD SO PSYCHOANALYTIC PSYCHOLOGY LA English DT Article DE attachment; attachment anxiety; attachment avoidance; childhood memories; memory recall ID ADULT ATTACHMENT; CONSTRUCT ACCESSIBILITY; INDIVIDUAL-DIFFERENCES; EMOTIONAL MEMORY; NEGATIVE AFFECT; REPRESENTATIONS; INFORMATION; PERSONALITY; MOOD; ACTIVATION AB This study investigated the relationship between individual differences in attachment and the free recall of childhood memories. Specifically, it focuses oil how attachment anxiety and attachment avoidance, using the Experiences in Close Relationship Scale self-report, relate to the affective quality and the presence of caregivers in memories from childhood. Participants were 79 undergraduate and masters students attending a northeast university. Participants completed a memory task designed to elicit freely recalled memories from childhood. They then rated the affective valence (positive/negative) and intensity of each memory, and identified memories in which caretakers were present. Attachment avoidance was related to recalling more negative memories involving caretakers and was negatively related to the average intensity of memories involving caretakers. The results support and extend previous research suggesting that affect regulation strategies employed by individuals high in attachment anxiety and high in attachment avoidance are linked to differences in how information about the past is recalled. C1 [Haggerty, Greg D.] Nassau Univ, Med Ctr, Syosset, NY 11791 USA. [Siefert, Caleb J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. [Weinberger, Joel] Adelphi Univ, Derner Inst Adv Psychol Studies, Garden City, NY 11530 USA. RP Haggerty, GD (reprint author), Nassau Univ, Med Ctr, 18 Sexton Rd, Syosset, NY 11791 USA. EM ghag541@aol.com NR 49 TC 6 Z9 7 U1 4 U2 15 PU EDUCATIONAL PUBLISHING FOUNDATION PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0736-9735 J9 PSYCHOANAL PSYCHOL JI Psychoanal. Psychol. PD JAN PY 2010 VL 27 IS 1 BP 27 EP 41 DI 10.1037/a0018638 PG 15 WC Psychology, Clinical; Psychology, Psychoanalysis SC Psychology GA 565AH UT WOS:000275259900004 ER PT J AU Nierenberg, AA Husain, MM Trivedi, MH Fava, M Warden, D Wisniewski, SR Miyahara, S Rush, AJ AF Nierenberg, A. A. Husain, M. M. Trivedi, M. H. Fava, M. Warden, D. Wisniewski, S. R. Miyahara, S. Rush, A. J. TI Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR(star)D report SO PSYCHOLOGICAL MEDICINE LA English DT Article DE Major depression; remission; residual symptoms ID SEQUENCED TREATMENT ALTERNATIVES; STAR-ASTERISK-D; REPORT QIDS-SR; QUICK INVENTORY; PSYCHOMETRIC EVALUATION; MODAFINIL AUGMENTATION; RATING-SCALE; FATIGUE; ANTIDEPRESSANTS; SYMPTOMATOLOGY AB Background. Many patients with major depressive disorder (MDD) who experience full symptomatic remission after antidepressant treatment still have residual depressive symptoms. We describe the types and frequency of residual depressive symptoms and their relationship to subsequent depressive relapse after treatment with citalopram in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Method. Participants in primary (n=18) and psychiatric (n=23) practice settings were openly treated with citalopram, using measurement-based care for up to 14 weeks and follow-up for up to I year. We assessed 943 (32.8% of 2876) participants who met criteria for remission to determine the proportions with individual residual symptoms and any of the nine DSM-IV criterion symptom domains to define a major depressive episode. At each visit, the 16-itern Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR16) and the self-report Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) scale were used to assessed depressive symptoms and side-effects respectively. Results. More than 90% of remitters had at least one residual depressive symptom (median = 3). The most common were weight increase (71.3%) and mid-nocturnal insomnia (54.9%). The most common residual symptom domains were sleep disturbance (71.7%) and appetite/weight disturbance (35.9%). Those who remitted before 6 weeks had fewer residual symptoms at study exit than did later remitters. Residual sleep disturbance did not predict relapse during follow-up. Having a greater number of residual symptom domains was associated with a higher probability of relapse. Conclusions. Patients with remission of MDD after treatment with citalopram continue to experience selected residual depressive symptoms, which increase the risk of relapse. C1 [Nierenberg, A. A.; Fava, M.] Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA. [Husain, M. M.; Trivedi, M. H.; Warden, D.; Rush, A. J.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA. [Wisniewski, S. R.; Miyahara, S.] Univ Pittsburgh, Grad Sch Publ Hlth, Epidemiol Data Ctr, Pittsburgh, PA USA. [Rush, A. J.] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA. RP Nierenberg, AA (reprint author), Massachusetts Gen Hosp, Depress Clin & Res Program, Suite 580,50 Staniford St, Boston, MA 02114 USA. EM anierenberg@partners.org FU NIMH NIH HHS [N01MH90003] NR 30 TC 133 Z9 143 U1 0 U2 8 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0033-2917 J9 PSYCHOL MED JI Psychol. Med. PD JAN PY 2010 VL 40 IS 1 BP 41 EP 50 DI 10.1017/S0033291709006011 PG 10 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 535IW UT WOS:000272962300006 PM 19460188 ER PT J AU Pischke, CR Frenda, S Ornish, D Weidner, G AF Pischke, Claudia Ruth Frenda, Steven Ornish, Dean Weidner, Gerdi TI Lifestyle changes are related to reductions in depression in persons with elevated coronary risk factors SO PSYCHOLOGY & HEALTH LA English DT Article DE elevated coronary risk factors; depressive symptoms; lifestyle changes ID TYPE-2 DIABETES-MELLITUS; IMPAIRED GLUCOSE-TOLERANCE; HEART-DISEASE; METABOLIC SYNDROME; PHYSICAL-ACTIVITY; MAJOR DEPRESSION; RANDOMIZED-TRIAL; GLYCEMIC CONTROL; FOLLOW-UP; PREVENTION AB This observational study investigates whether persons with elevated coronary risk factors (CRFs 3 and/or diabetes) and depression [i.e., epsilon 16 on the Center for Epidemiological Scale - Depression (CES-D)] can make changes in health behaviours over 3 months and improve depressive symptoms and other CRFs. Analyses were based on data from 310 men and 687 women enrolled in the high-risk arm of the Multisite Cardiac Lifestyle Intervention Program, targeting diet (10% fat), exercise (3 h per week) and stress management (7 h per week). As expected, at study entry, depressed persons had a more adverse medical status, consumed more dietary fat and practiced less stress management than non-depressed persons. To examine 3-month changes, participants were grouped into (1) depressed persons who became non-depressed (CES-D 16, n = 248; 73%), (2) persons who remained or became depressed (CES-D 16, n = 76) and (3) non-depressed persons who remained non-depressed (n = 597). All persons, regardless of group, met program goals. The greatest improvements (i.e., diet, exercise, perceived stress, hostility and mental health) were observed in Group 1 relative to Groups 2 and 3, which did not differ from each other. Comprehensive lifestyle changes appear to be feasible and beneficial for initially depressed persons with elevated CRFs. C1 [Weidner, Gerdi] San Francisco State Univ, Tiburon, CA 94920 USA. [Weidner, Gerdi] Johannes Gutenberg Univ Mainz, D-55122 Mainz, Germany. [Pischke, Claudia Ruth] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Boston, MA 02130 USA. [Frenda, Steven; Ornish, Dean] Res Inst Prevent Med, Sausalito, CA 94965 USA. RP Weidner, G (reprint author), San Francisco State Univ, 3150 Paradise Dr, Tiburon, CA 94920 USA. EM gweidner@sfsu.edu NR 67 TC 5 Z9 5 U1 3 U2 10 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0887-0446 J9 PSYCHOL HEALTH JI Psychol. Health PY 2010 VL 25 IS 9 BP 1077 EP 1100 AR PII 917229765 DI 10.1080/08870440903002986 PG 24 WC Public, Environmental & Occupational Health; Psychology, Multidisciplinary SC Public, Environmental & Occupational Health; Psychology GA 676BI UT WOS:000283884700004 PM 20204946 ER PT J AU Boeka, AG Prentice-Dunn, S Lokken, KL AF Boeka, Abbe G. Prentice-Dunn, Steven Lokken, Kristine L. TI Psychosocial predictors of intentions to comply with bariatric surgery guidelines SO PSYCHOLOGY HEALTH & MEDICINE LA English DT Article DE protection motivation theory; health behavior model; post-surgical compliance; bariatric surgery outcome ID PROTECTION MOTIVATION THEORY; GASTRIC BYPASS-SURGERY; SKIN-CANCER RISK; EATING DISTURBANCES; WEIGHT-LOSS; BEHAVIOR; OBESITY; INTERVENTION; GASTROPLASTY; METAANALYSIS AB An increasing body of research suggests that many patients have difficulty adopting the eating guidelines after weight-loss surgery, thereby reducing the long-term success of the procedure. Given such difficulties, it is possible that the typical preoperative education regarding post-surgical eating behavior guidelines is ineffective in motivating some individuals to comply. Presently, no accurate predictors of intentions to comply with post-bariatric surgery guidelines have been identified. In the present pilot study, a psychosocial intervention based on protection motivation theory (PMT) was presented to patients undergoing bariatric surgery. PMT is a well-established preventive health model that has been utilized in a variety of health domains. Participants for this study were recruited before undergoing bariatric surgery, and were randomly assigned to one of two groups: PMT group vs. control. In addition to routine messages from the bariatric surgeon, participants in the PMT group received an intervention based in PMT that focused on the importance of adhering to post-surgical eating behavior guidelines and how best to adhere to these guidelines. Participants in the control group received standard of care information from the bariatric surgeon. Results indicated that the PMT intervention did not have a significant impact. However, follow-up analyses revealed that two aspects of PMT, perceived self-efficacy and perceived threat of not following the guidelines, predicted patients' intentions to comply with post-surgical guidelines. Findings are discussed in terms of the methodological compromises that resulted from the applied research setting as well as promising avenues for future investigation. C1 [Boeka, Abbe G.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA. [Boeka, Abbe G.; Prentice-Dunn, Steven] Univ Alabama, Dept Psychol, Tuscaloosa, AL 35487 USA. [Lokken, Kristine L.] Univ Alabama, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA. [Lokken, Kristine L.] Birmingham VA Med Ctr, Dept Phys Med & Rehabil, Birmingham, AL USA. RP Boeka, AG (reprint author), Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA. EM abbe.boeka@yale.edu OI Brooks, Steven/0000-0002-4592-4974 NR 26 TC 8 Z9 8 U1 0 U2 14 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1354-8506 J9 PSYCHOL HEALTH MED JI Psychol. Health Med. PY 2010 VL 15 IS 2 BP 188 EP 197 DI 10.1080/13548501003615282 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 583ZO UT WOS:000276720000008 PM 20391236 ER PT J AU Cohn, AM Jakupcak, M Seibert, LA Hildebrandt, TB Zeichner, A AF Cohn, Amy M. Jakupcak, Matthew Seibert, L. Alana Hildebrandt, Thomas B. Zeichner, Amos TI The Role of Emotion Dysregulation in the Association Between Men's Restrictive Emotionality and Use of Physical Aggression SO PSYCHOLOGY OF MEN & MASCULINITY LA English DT Article DE aggression; restrictive emotionality; emotion dysregulation; gender role conflict ID POSTTRAUMATIC-STRESS-DISORDER; GENDER-ROLE STRESS; LABORATORY AGGRESSION; EXPERIENTIAL AVOIDANCE; CHILD CONVERSATIONS; SAMPLE-SIZE; BEHAVIOR; EXPRESSION; VIOLENCE; SCALE AB To test the mediating effect of emotional dysregulation on the association between men's restrictive emotionality and the use of aggression toward another, 128 undergraduate men were asked to complete a Response Choice Aggression Paradigm (RCAP), a competitive reaction time task in which participants were given the choice to shock or refrain from shocking an ostensible opponent. Aggression was measured as the average intensity of shocks delivered by the participant throughout the task, restrictive emotionality was measured using a subscale of the Gender Role Conflict Scale (O'Neil, Helms, Gable, David, & Wrightman, 1986), and emotional dysregulation was measured by the Difficulties in Emotion Regulation Scale (Gratz & Roemer, 2004). Findings from a structural equation model showed that emotional dysregulation does mediate the association between restrictive emotionality and aggression. Specifically, this relationship appeared to be largely driven by a lack of acceptance and inability to tolerate emotional experiences, rather than by overall inability to regulate internal experiences. Conceptual and clinical implications for addressing men's aggressive behavior are discussed. C1 [Cohn, Amy M.] Rutgers State Univ, Ctr Alcohol Studies, Piscataway, NJ 08854 USA. [Jakupcak, Matthew] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, VA Puget Sound Hlth Care Syst,MIRECC, Washington, DC USA. [Seibert, L. Alana; Zeichner, Amos] Univ Georgia, Dept Psychol, Athens, GA 30602 USA. [Hildebrandt, Thomas B.] Mt Sinai Sch Med, New York, NY USA. RP Cohn, AM (reprint author), Rutgers State Univ, Ctr Alcohol Studies, 607 Allison Rd, Piscataway, NJ 08854 USA. EM amycohn@rci.rutgers.edu OI Hildebrandt, Thomas/0000-0001-7054-9590 NR 74 TC 28 Z9 28 U1 0 U2 10 PU EDUCATIONAL PUBLISHING FOUNDATION PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1524-9220 J9 PSYCHOL MEN MASCULIN JI Psychol. Men Masculinity PD JAN PY 2010 VL 11 IS 1 BP 53 EP 64 DI 10.1037/a0018090 PG 12 WC Psychology, Social SC Psychology GA 586HF UT WOS:000276896400005 ER PT B AU Thompson, BL AF Thompson, Brian L. BE Jackson, RG TI WHY NEUROTICISM MAY BE RELEVANT TO UNDERSTANDING RESPONSE TO MEDITATION-BASED INTERVENTIONS: A REVIEW OF SOME FORGOTTEN LITERATURE SO PSYCHOLOGY OF NEUROTICISM AND SHAME SE Psychology of Emotions Motivations and Actions LA English DT Article; Book Chapter ID COGNITIVE THERAPY; MINDFULNESS MEDITATION; DEPRESSED-PATIENTS; ANXIETY DISORDERS; MAJOR DEPRESSION; 5-FACTOR MODEL; SELF-REPORT; PERSONALITY; METAANALYSIS; POPULATION AB Before the explosion of interest in mindfulness-based interventions (e.g. Hayes, Follette, & Linehan, 2004), early meditation researchers explored the impact of personality traits on response to sitting meditation practice, particularly with Transcendental Meditation. The purpose of this chapter is to provide a brief overview of that early research and explore how some of the findings of these often forgotten studies may be incorporated into contemporary research on meditation-based treatments. Given the incidence of depression in individuals high in neuroticism, particular emphasis is placed on understanding how neuroticism might impact and be impacted by Mindfulness-Based Cognitive Therapy for depression (Segal, Williams, & Teasdale, 2002). C1 Portland VA Med Ctr, Portland, OR USA. RP Thompson, BL (reprint author), Portland VA Med Ctr, Portland, OR USA. NR 51 TC 0 Z9 0 U1 2 U2 3 PU NOVA SCIENCE PUBLISHERS, INC PI HAUPPAUGE PA 400 OSER AVE, STE 1600, HAUPPAUGE, NY 11788-3635 USA BN 978-1-60876-870-7 J9 PSYCHOL EMOT MOTIV A PY 2010 BP 225 EP 234 PG 10 WC Psychology, Multidisciplinary SC Psychology GA BPM62 UT WOS:000279304400012 ER PT J AU Lovallo, WR Robinson, JL Glahn, DC Fox, PT AF Lovallo, William R. Robinson, Jennifer L. Glahn, David C. Fox, Peter T. TI Acute effects of hydrocortisone on the human brain: An fMRI study SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE Cortisol; Hydrocortisone; Human; Brain; Magnetic resonance imaging; Amygdala; Hippocampus; Thalamus ID HIPPOCAMPAL-FORMATION VOLUME; MEMORY RETRIEVAL; RAT-BRAIN; PREFRONTAL CORTEX; CORTISOL; STRESS; RECEPTOR; GLUCOCORTICOIDS; CORTICOSTERONE; PERFORMANCE AB Cortisol is essential for regulating all cell types in the body, including those in the brain. Most information concerning cortisol's cerebral effects comes from work in nonhumans. This is a first effort to use functional magnetic resonance imaging (fMRI) to study the time course and locus of cortisol's effects on selected brain structures in resting humans. We repeatedly scanned 21 healthy young adults over 45 min to examine changes in the brain's activity 5 min before, and for 40 min after, an IV injection of 10 mg of hydrocortisone (N = 11) or saline placebo (N = 10). At 15-18 min postinjection we observed in the hydrocortisone group reduced activity in the hippocampus and amygdala that reached a peak response minimum at 25-30 min postinjection (-1 Standard Deviation) relative to placebo. No such effect was seen in the thalamus. Functional MRI appears to be a safe, noninvasive method to study the time course and anatomical effects of glucocorticoids in the human brain. Published by Elsevier Ltd. C1 [Lovallo, William R.] Univ Oklahoma, Hlth Sci Ctr, Vet Affairs Med Ctr, Behav Sci Labs, Oklahoma City, OK 73104 USA. [Lovallo, William R.] Univ Oklahoma, Hlth Sci Ctr, Dept Psychiat & Behav Sci, Oklahoma City, OK 73104 USA. [Robinson, Jennifer L.; Glahn, David C.; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Robinson, Jennifer L.; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, San Antonio, TX 78229 USA. [Robinson, Jennifer L.; Fox, Peter T.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Lovallo, WR (reprint author), Vet Affairs Med Ctr, Behav Sci Labs 151A, 921 NE 13th St, Oklahoma City, OK 73104 USA. EM bill@mindbody1.org RI Fox, Peter/B-4725-2010; Robinson, Jennifer/B-7893-2010 OI Fox, Peter/0000-0002-0465-2028; FU Medical Research Service of the Department of Veterans Affairs; National Institutes of Health, NIAAA [AA12207]; NARSAD; UTHSCSA GCRC [M01-RR-01346] FX This work was supported by the Medical Research Service of the Department of Veterans Affairs (W.R.L.), the National Institutes of Health, NIAAA (AA12207) (W.R.L.), NARSAD (Esset Young Investigator, D.C.G.), and the UTHSCSA GCRC (M01-RR-01346). NR 39 TC 52 Z9 52 U1 2 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD JAN PY 2010 VL 35 IS 1 SI SI BP 15 EP 20 DI 10.1016/j.psyneuen.2009.09.010 PG 6 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA 546WG UT WOS:000273844100003 PM 19836143 ER PT J AU Birk, JL Dennis, TA Shin, LM Urry, HL AF Birk, Jeffrey L. Dennis, Tracy A. Shin, Lisa M. Urry, Heather L. TI UNIQUE AND OPPOSING CONTRIBUTIONS OF TRAIT AND STATE ANXIETY TO THE EXECUTIVE CONTROL OF ATTENTION SO PSYCHOPHYSIOLOGY LA English DT Meeting Abstract CT 15th Annual Meeting Portland Marriott Downtown Waterfront CY SEP 29-OCT 03, 2010 CL Portland, OR SP Soc Psychophysiolog C1 [Birk, Jeffrey L.; Shin, Lisa M.; Urry, Heather L.] Tufts Univ, Medford, MA 02155 USA. [Shin, Lisa M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cambridge, MA 02138 USA. [Dennis, Tracy A.] CUNY Hunter Coll, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 1 U2 4 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0048-5772 J9 PSYCHOPHYSIOLOGY JI Psychophysiology PY 2010 VL 47 SU 1 BP S32 EP S32 PG 1 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 635NI UT WOS:000280662000178 ER PT J AU Condray, R Siegle, GJ Steinhauer, SR AF Condray, Ruth Siegle, Greg J. Steinhauer, Stuart R. TI SEMANTIC MEMORY AND WORD FREQUENCY MODULATE N400 IN THE FAMILY MEMBERS OF SCHIZOPHRENIA PATIENTS SO PSYCHOPHYSIOLOGY LA English DT Meeting Abstract CT 15th Annual Meeting Portland Marriott Downtown Waterfront CY SEP 29-OCT 03, 2010 CL Portland, OR SP Soc Psychophysiolog C1 [Condray, Ruth; Siegle, Greg J.; Steinhauer, Stuart R.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. [Steinhauer, Stuart R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0048-5772 J9 PSYCHOPHYSIOLOGY JI Psychophysiology PY 2010 VL 47 SU 1 BP S10 EP S10 PG 1 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 635NI UT WOS:000280662000056 ER PT J AU Ford, JM Perez, V Roach, BJ Vinogradov, S Loewy, R Stuart, BK Mathalon, DH AF Ford, Judith M. Perez, Veronica Roach, Brian J. Vinogradov, Sophia Loewy, Rachel Stuart, Barbara K. Mathalon, Daniel H. TI SPEECH-INDUCED SUPPRESSION OF AUDITORY CORTEX: COROLLARY DISCHARGE DYSFUNCTION IN THE PRODROMAL STAGE OF SCHIZOPHRENIA SO PSYCHOPHYSIOLOGY LA English DT Meeting Abstract CT 50th Annual Meeting of the Society-for-Psychophysiological-Research CY SEP 29-OCT 03, 2010 CL Portland, OR SP Soc Psychophysiol Res C1 [Ford, Judith M.; Perez, Veronica; Roach, Brian J.; Vinogradov, Sophia; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA. [Ford, Judith M.; Perez, Veronica; Roach, Brian J.; Vinogradov, Sophia; Loewy, Rachel; Stuart, Barbara K.; Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0048-5772 J9 PSYCHOPHYSIOLOGY JI Psychophysiology PY 2010 VL 47 SU 1 BP S10 EP S10 PG 1 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 635NI UT WOS:000280662000054 ER PT J AU Mathalon, DH AF Mathalon, Daniel H. TI BEYOND THE ODDBALL IN SCHIZOPHRENIA RESEARCH: NEUROPHYSIOLOGIC STUDIES OF MEMORY AND LANGUAGE PROCESSING SO PSYCHOPHYSIOLOGY LA English DT Meeting Abstract CT 50th Annual Meeting of the Society-for-Psychophysiological-Research CY SEP 29-OCT 03, 2010 CL Portland, OR SP Soc Psychophysiol Res C1 [Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0048-5772 J9 PSYCHOPHYSIOLOGY JI Psychophysiology PY 2010 VL 47 SU 1 BP S10 EP S10 PG 1 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 635NI UT WOS:000280662000053 ER PT J AU Niznikiewicz, M Bobrow, L Wible, C Whitman-Gabrieli, S Nestor, PG Shenton, ME Kubicki, M AF Niznikiewicz, Margaret Bobrow, Laurel Wible, Cynthia Whitman-Gabrieli, Susan Nestor, Paul G. Shenton, Martha E. Kubicki, Marek TI DIFFERENCES IN BRAIN ACTIVATION AS A FUNCTION OF RELATIONSHIP TYPE AND TEMPORAL DISTANCE BETWEEN PRIMES AND TARGETS IN NORMAL CONTROL AND SCHIZOPHRENIA INDIVIDUALS SO PSYCHOPHYSIOLOGY LA English DT Meeting Abstract CT 15th Annual Meeting Portland Marriott Downtown Waterfront CY SEP 29-OCT 03, 2010 CL Portland, OR SP Soc Psychophysiolog C1 [Niznikiewicz, Margaret; Shenton, Martha E.] Boston VA Healthcare Syst, Boston, MA USA. [Niznikiewicz, Margaret; Wible, Cynthia; Shenton, Martha E.; Kubicki, Marek] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Niznikiewicz, Margaret; Bobrow, Laurel; Wible, Cynthia; Shenton, Martha E.; Kubicki, Marek] Brigham & Womens Hosp, Boston, MA 02115 USA. [Whitman-Gabrieli, Susan; Nestor, Paul G.] MIT, Cambridge, MA 02139 USA. [Nestor, Paul G.] Univ Massachusetts, Boston, MA 02125 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0048-5772 J9 PSYCHOPHYSIOLOGY JI Psychophysiology PY 2010 VL 47 SU 1 BP S11 EP S11 PG 1 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 635NI UT WOS:000280662000057 ER PT J AU Pineles, SL Rasmusson, AM Yehuda, R Lasko, NB Macklin, ML Orr, SP AF Pineles, Suzanne L. Rasmusson, Ann M. Yehuda, Rachel Lasko, Natasha B. Macklin, Michael L. Orr, Scott P. TI CORTISOL AND PTSD: SOME INSIGHT INTO THE DIVERGENT FINDINGS IN THE LITERATURE SO PSYCHOPHYSIOLOGY LA English DT Meeting Abstract CT 15th Annual Meeting Portland Marriott Downtown Waterfront CY SEP 29-OCT 03, 2010 CL Portland, OR SP Soc Psychophysiolog C1 [Pineles, Suzanne L.; Rasmusson, Ann M.] Boston Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA 02215 USA. [Yehuda, Rachel] Bronx VA Med Ctr, Mt Sinai Sch Med, Bronx, NY USA. [Lasko, Natasha B.; Macklin, Michael L.; Orr, Scott P.] Harvard Univ, Sch Med, VA Manchester, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 2 U2 5 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0048-5772 J9 PSYCHOPHYSIOLOGY JI Psychophysiology PY 2010 VL 47 SU 1 BP S96 EP S96 PG 1 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 635NI UT WOS:000280662000526 ER PT J AU Silverman, BC Kim, AY Freudenreich, O AF Silverman, Benjamin C. Kim, Arthur Y. Freudenreich, Oliver TI Interferon-Induced Psychosis as a "Psychiatric Contraindication" to Hepatitis C Treatment: A Review and Case-Based Discussion SO PSYCHOSOMATICS LA English DT Review ID CHRONIC VIRAL-HEPATITIS; QUALITY-OF-LIFE; ALPHA TREATMENT; RIBAVIRIN TREATMENT; INDUCED DEPRESSION; PLUS RIBAVIRIN; PEGYLATED INTERFERON-ALPHA-2B; VIROLOGICAL RESPONSE; SUICIDAL IDEATION; VIRUS-INFECTION AB Background: Hepatitis C (HCV) infection is a major cause of liver disease, cirrhosis, and hepatocellular carcinoma. Interferon-based treatments have the potential to decrease the burden of disease, but are complicated by side effects, including neuropsychiatric symptoms. Objective: The authors described a case of interferon-induced psychosis as a framework to review the literature and discuss the decision to pursue antiviral treatment in psychiatrically ill patients with hepatitis C. Method: The authors followed a patient with chronic HCV who received interferon and ribavirin and who developed hallucinations ultimately requiring psychiatric hospitalization. Results: Despite treatment with various neuroleptics, the psychosis resolved only when the interferon/ribavirin were discontinued. Conclusion: Psychiatric illness should not rule out the possibility of interferon-based therapy, but it calls for close integration of psychiatric and medical care and individualized decision-making based on the biological and psychosocial circumstances of each case. (Psychosomatics 2010; 51: 1-7) C1 [Silverman, Benjamin C.] Massachusetts Gen Hosp, Wang Ambulatory Care Ctr, Dept Psychiat, Boston, MA 02114 USA. Massachusetts Gen Hosp, Schizophrenia Program, Dept Psychiat, Boston, MA 02114 USA. Harvard Univ, Sch Med, Div Infect Dis, MGH, Cambridge, MA 02138 USA. RP Silverman, BC (reprint author), Massachusetts Gen Hosp, Wang Ambulatory Care Ctr, Dept Psychiat, Rm 812,15 Parkman St, Boston, MA 02114 USA. EM bcsilverman@partners.org NR 75 TC 7 Z9 9 U1 0 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0033-3182 J9 PSYCHOSOMATICS JI Psychosomatics PD JAN-FEB PY 2010 VL 51 IS 1 BP 1 EP 7 PG 7 WC Psychiatry; Psychology SC Psychiatry; Psychology GA 550SC UT WOS:000274148500001 PM 20118434 ER PT J AU Prowler, ML Weiss, D Caroff, SN AF Prowler, Matthew L. Weiss, David Caroff, Stanley N. TI Treatment of Catatonia With Methylphenidate in an Elderly Patient With Depression SO PSYCHOSOMATICS LA English DT Article AB Background: Catatonia is especially common among patients with mood disorders. Objective: The authors evaluated the effects of methylphenidate as an augmentation strategy in an elderly patient with catatonia and depression. Method: Methylphenidate was administered to a catatonic patient who had not responded to lorazepam. Results: The patient showed an acute and marked response to methylphenidate. Discussion: Methylphenidate may be effective as an adjunct in elderly depression patients with catatonia, as well as in medically ill, apathetic patients. However, there have been few attempts to study the role of psychostimulants in alleviating catatonia in general, or catatonia associated specifically with an underlying depressive disorder, even though catatonia is frequently associated with mood disorders. (Psychosomatics 2010; 51: 74-76) C1 [Prowler, Matthew L.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Prowler, ML (reprint author), Univ Penn, Sch Med, Dept Psychiat, 3535 Market St,2nd Fl, Philadelphia, PA 19104 USA. EM matthew.prowler@uphs.upenn.edu NR 17 TC 6 Z9 6 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0033-3182 J9 PSYCHOSOMATICS JI Psychosomatics PD JAN-FEB PY 2010 VL 51 IS 1 BP 74 EP 76 PG 3 WC Psychiatry; Psychology SC Psychiatry; Psychology GA 550SC UT WOS:000274148500011 PM 20118444 ER PT J AU Kontos, N AF Kontos, Nicholas TI Trusting Doctors: The Decline of Moral Authority in American Medicine SO PSYCHOSOMATICS LA English DT Book Review C1 [Kontos, Nicholas] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Kontos, Nicholas] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Kontos, N (reprint author), Harvard Univ, Sch Med, Cambridge, MA 02138 USA. NR 1 TC 0 Z9 0 U1 2 U2 3 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0033-3182 J9 PSYCHOSOMATICS JI Psychosomatics PD JAN-FEB PY 2010 VL 51 IS 1 BP 91 EP 92 PG 3 WC Psychiatry; Psychology SC Psychiatry; Psychology GA 550SC UT WOS:000274148500016 ER PT J AU Sylvia, LG Ametrano, RM Nierenberg, AA AF Sylvia, Louisa G. Ametrano, Rebecca M. Nierenberg, Andrew A. TI Exercise Treatment for Bipolar Disorder: Potential Mechanisms of Action Mediated through Increased Neurogenesis and Decreased Allostatic Load SO PSYCHOTHERAPY AND PSYCHOSOMATICS LA English DT Review DE Exercise; Brain-derived neurotrophic factor; Allostatic load; Bipolar disorder ID NEUROTROPHIC FACTOR BDNF; LITHIUM-TREATED PATIENTS; MAJOR DEPRESSION; METABOLIC SYNDROME; PHYSICAL-ACTIVITY; VAL66MET POLYMORPHISM; SYNAPTIC-PLASTICITY; UNIPOLAR DEPRESSION; RAT HIPPOCAMPUS; LIFE EVENTS AB Outcomes are frequently suboptimal for patients with bipolar disorder who are treated with pharmacotherapy alone. Adjunct exercise has the potential to substantially improve acute and long-term outcomes, although how exercise would improve the course of bipolar disorder needs to be elucidated. We propose that exercise may improve mood and functioning by increasing neurogenesis and reducing allostatic load. We review data suggesting that exercise increases levels of brain-derived neurotrophic factor, which in turn increases neurogenesis and decreases allostatic load. Exercise as a psychosocial adjunct for bipolar disorder should be assessed with rigorous randomized clinical trials. Copyright (C) 2009 S. Karger AG, Basel C1 [Sylvia, Louisa G.; Ametrano, Rebecca M.; Nierenberg, Andrew A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Sylvia, LG (reprint author), 50 Staniford St,Suite 580, Boston, MA 02114 USA. EM lsylvia2@partners.org NR 124 TC 23 Z9 23 U1 4 U2 21 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0033-3190 J9 PSYCHOTHER PSYCHOSOM JI Psychother. Psychosom. PY 2010 VL 79 IS 2 BP 87 EP 96 DI 10.1159/000270916 PG 10 WC Psychiatry; Psychology SC Psychiatry; Psychology GA 555PW UT WOS:000274526600003 PM 20051706 ER PT J AU Fava, M AF Fava, Maurizio TI The Possible Antianxiety and Mood-Stabilizing Effects of Rufinamide SO PSYCHOTHERAPY AND PSYCHOSOMATICS LA English DT Letter ID ANTIEPILEPTIC DRUGS C1 Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA. RP Fava, M (reprint author), Massachusetts Gen Hosp, Depress Clin & Res Program, 55 Fruit St,Bulfinch 351, Boston, MA 02114 USA. EM mfava@partners.org NR 4 TC 4 Z9 4 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0033-3190 J9 PSYCHOTHER PSYCHOSOM JI Psychother. Psychosom. PY 2010 VL 79 IS 3 BP 194 EP 195 DI 10.1159/000296139 PG 2 WC Psychiatry; Psychology SC Psychiatry; Psychology GA 587WJ UT WOS:000277026200010 PM 20234151 ER PT J AU Arar, N Seo, J Lee, S Abboud, HE Copeland, LA Noel, P Parchman, M AF Arar, N. Seo, J. Lee, S. Abboud, H. E. Copeland, L. A. Noel, P. Parchman, M. TI Preferences regarding Genetic Research Results: Comparing Veterans and Nonveterans Responses SO PUBLIC HEALTH GENOMICS LA English DT Article DE Common complex diseases; Ethics; Genetic family studies; Research results ID RESEARCH PARTICIPANTS; CANCER; INFORMATION; ETHICS; POPULATION; DISCLOSURE; ATTITUDES; GENOMICS; RETURN; ADOLESCENTS AB Objective: Communicating genetic research results to participants presents ethical challenges. Our objectives were to examine participants' preferences in receiving future genetic research results and to compare preferences reported by veteran and nonveterans participants. Methods: Secondary analysis was performed on data collected in 2000-2004 from 1,575 consent forms signed by Mexican-American participants enrolled in 2 genetic family studies (GFS) in San Antonio: The Family Investigation of Nephropathy and Diabetes (FIND) and the Extended FIND (EFIND). The consent forms for these studies contained multiple-choice questions to examine participants' preferences about receiving their (1) clinical lab results and (2) future genetic research results. The FIND and EFIND databases had information on subjects' demographic characteristics and some selected clinical variables. We identified veterans using the Veterans Health Administration's (VHA's) centralized data repository. We compared veterans' and nonveterans' preferences using Student's t test for continuous variables and chi(2) test for discrete variables. A logistic regression analyzed subjects' preference for receiving their research results, controlling for other socio-demographic and clinical variables. Results: The sample included 275 (18%) veterans and 1,247 (82%) nonveterans. Our results indicated a strong desire among the majority of participants 1,445 (95%) in getting their clinical lab research results. Likewise, 93% expressed interest in being informed about their future genetic results. There was no significant difference in veterans' and nonveterans' preference to disclosure of the research results (chi(2) test; p > 0.05). Regression analysis showed no significant relationship (p = 0.449) between the outcome (receiving research results) and veterans' responses after controlling for demographics and educational levels. Conclusion: Participants believed they would prefer receiving their genetic research results. Veterans are similar to nonveterans in their preferences. Offering genetic research results to participants should be based on well defined and structured plans to enhance interpretation of genetic data. Copyright (C) 2010 S. Karger AG, Basel C1 [Arar, N.; Seo, J.; Lee, S.; Abboud, H. E.; Copeland, L. A.; Noel, P.; Parchman, M.] Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, Dept Med, Audie L Murphy Mem Vet Hosp, San Antonio, TX 78229 USA. RP Arar, N (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med Nephrol, S Texas Hlth Care Syst, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM ararn@uthscsa.edu OI Copeland, Laurel/0000-0002-9478-0209 FU NIH/NIDDK [P50 DK061597]; VHA-HSRD [PPO 09-241, DNA 08-129] FX We wish to thank all participants of the FIND and EFIND Studies for their cooperation and generous participation. This study was supported by funds from NIH/NIDDK (P50 DK061597). This work was also supported by the VHA-HSR&D (PPO 09-241 and DNA 08-129: Nedal Arar PhD). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 40 TC 8 Z9 8 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1662-4246 J9 PUBLIC HEALTH GENOM JI Pub. Health Genomics PY 2010 VL 13 IS 7-8 BP 431 EP 439 DI 10.1159/000317099 PG 9 WC Genetics & Heredity; Public, Environmental & Occupational Health SC Genetics & Heredity; Public, Environmental & Occupational Health GA 690NQ UT WOS:000285011900006 PM 20829581 ER PT J AU Dolan, SM Hollegaard, MV Merialdi, M Betran, AP Allen, T Abelow, C Nace, J Lin, BK Khoury, MJ Ioannidis, JPA Bagade, S Zheng, X Dubin, RA Bertram, L Edwards, DRV Menon, R AF Dolan, S. M. Hollegaard, M. V. Merialdi, M. Betran, A. P. Allen, T. Abelow, C. Nace, J. Lin, B. K. Khoury, M. J. Ioannidis, J. P. A. Bagade, S. Zheng, X. Dubin, R. A. Bertram, L. Edwards, D. R. Velez Menon, R. TI Synopsis of Preterm Birth Genetic Association Studies: The Preterm Birth Genetics Knowledge Base (PTBGene) SO PUBLIC HEALTH GENOMICS LA English DT Article DE HuGE review; Meta-analysis; Prematurity; Preterm birth; Systematic review ID HUMAN GENOME EPIDEMIOLOGY; FACTOR-V-LEIDEN; THROMBOPHILIC POLYMORPHISMS; BETA-2-ADRENERGIC RECEPTOR; SYSTEMATIC METAANALYSES; ETHNIC-DIFFERENCES; DELIVERY; PREGNANCY; OUTCOMES; RISK AB Aim: Our goal was to produce a field synopsis of genetic associations with preterm birth and to set up a publicly available online database summarizing the data. Methods: We performed a systematic review and meta-analyses to identify genetic associations with preterm birth. We have set up a publicly available online database of genetic association data on preterm birth called PTBGene (http://ric.einstein.yu.edu/ptbgene/index.html) and report on a structured synopsis thereof as of December 1, 2008. Results: Data on 189 polymorphisms in 84 genes have been included and 36 meta-analyses have been performed. Five gene variants (4 in maternal DNA, one in newborn DNA) have shown nominally significant associations, but all have weak epidemiological credibility. Conclusion: After publishing this field synopsis, the PTBGene database will be regularly updated to keep track of the evolving evidence base of genetic factors in pre-term birth with the goal of promoting knowledge sharing and multicenter collaboration among preterm birth research groups. Copyright (C) 2010 S. Karger AG, Basel C1 [Dolan, S. M.; Abelow, C.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Obstet & Gynecol & Womens Hlth, Bronx, NY 10461 USA. [Hollegaard, M. V.] Statens Serum Inst, Sect Neonatal Screening & Hormones, DK-2300 Copenhagen, Denmark. [Merialdi, M.; Betran, A. P.; Menon, R.] WHO, Dept Reprod Hlth & Res, CH-1211 Geneva, Switzerland. [Allen, T.] WHO, Dept Knowledge Management & Sharing, CH-1211 Geneva, Switzerland. [Lin, B. K.] March Dimes, Off Med Director, White Plains, NY USA. [Nace, J.; Menon, R.] Perinatal Res Ctr, Nashville, TN USA. [Khoury, M. J.] Lab Ctr Dis Control, Natl Off Publ Hlth Genom, Atlanta, GA USA. [Ioannidis, J. P. A.] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece. [Ioannidis, J. P. A.] Fdn Res & Technol Hellas, Biomed Res Inst, Ioannina, Greece. [Ioannidis, J. P. A.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA. [Ioannidis, J. P. A.] Tufts Univ, Sch Med, Tufts Med Ctr, Ctr Genet Epidemiol & Modeling, Boston, MA 02111 USA. [Bagade, S.; Bertram, L.] Massachusetts Gen Hosp, Dept Neurol, MassGen Inst Neurodegenerat Dis MIND, Genet & Aging Res Unit, Charlestown, MA USA. [Zheng, X.; Dubin, R. A.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Bertram, L.] Max Planck Inst Mol Genet, Neuropsychiat Genet Grp, Dept Vertebrate Genom, Berlin, Germany. [Edwards, D. R. Velez] Vanderbilt Univ, Dept Obstet & Gynecol, Vanderbilt Epidemiol Ctr, Inst Med & Publ Hlth, Nashville, TN USA. [Menon, R.] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Dolan, SM (reprint author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Obstet & Gynecol & Womens Hlth, Belfer 501,1300 Morris Pk Ave, Bronx, NY 10461 USA. EM siobhanmdolan@yahoo.com RI Ioannidis, John/G-9836-2011; Velez Edwards, Digna/C-1090-2012; Bertram, Lars/K-3889-2015; OI Bertram, Lars/0000-0002-0108-124X; Hollegaard, Mads Vilhelm/0000-0003-1061-0091 FU World Health Organization; Preterm Birth International Collaborative; Albert Einstein College of Medicine; March of Dimes; Cure Alzheimer's Fund FX Funding for this project has been provided by the World Health Organization, Preterm Birth International Collaborative, Albert Einstein College of Medicine, March of Dimes, and the Cure Alzheimer's Fund. NR 59 TC 36 Z9 37 U1 0 U2 6 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1662-4246 J9 PUBLIC HEALTH GENOM JI Pub. Health Genomics PY 2010 VL 13 IS 7-8 BP 514 EP 523 DI 10.1159/000294202 PG 10 WC Genetics & Heredity; Public, Environmental & Occupational Health SC Genetics & Heredity; Public, Environmental & Occupational Health GA 690NQ UT WOS:000285011900015 PM 20484876 ER PT J AU Xu, XG Paganetti, H AF Xu, X. George Paganetti, Harald TI Better radiation weighting factors for neutrons generated from proton treatment are needed SO RADIATION PROTECTION DOSIMETRY LA English DT Editorial Material ID CONVERSION COEFFICIENTS; INDUCTION; DOSIMETRY; FLUENCE C1 [Xu, X. George] Rensselaer Polytech Inst, Troy, NY 12181 USA. [Paganetti, Harald] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Xu, XG (reprint author), Rensselaer Polytech Inst, Troy, NY 12181 USA. EM xug2@rpi.edu NR 23 TC 6 Z9 6 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0144-8420 J9 RADIAT PROT DOSIM JI Radiat. Prot. Dosim. PY 2010 VL 138 IS 4 BP 291 EP 294 DI 10.1093/rpd/ncq028 PG 4 WC Environmental Sciences; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging GA 586FW UT WOS:000276892500001 PM 20172937 ER PT J AU Thornton, E Morrin, MM Yee, J AF Thornton, Eavan Morrin, Martina M. Yee, Judy TI Current Status of MR Colonography SO RADIOGRAPHICS LA English DT Article ID MAGNETIC-RESONANCE COLONOGRAPHY; INITIAL CLINICAL-EXPERIENCE; LIMITED BOWEL PREPARATION; CT COLONOGRAPHY; CONVENTIONAL COLONOSCOPY; COLORECTAL-CANCER; COLONIC DISTENSION; DIAGNOSTIC-ACCURACY; PATIENT ACCEPTANCE; CONTRAST MATERIAL AB The search for an acceptable colorectal cancer screening examination has led to the development of virtual colonoscopy, which includes both computed tomographic (CT) colonography and magnetic resonance (MR) colonography. As indicated by the much larger number of published studies on CT colonography than on MR colonography, multidetector CT appears to be more suitable for colorectal screening than does MR colonography, in part reflecting the ease and speed of performing CT, as well as the increased spatial resolution, decreased cost, and wider availability of CT colonography. The main advantage of MR colonography over CT colonography is that it does not use ionizing radiation, which has important implications for colorectal cancer screening. The use of dark-lumen MR colonography to screen patients for colorectal cancer as well as other abdominopelvic disease could make it more attractive than CT. With the integration of 3.0-T MR colonography, fecal tagging, and parallel imaging into research and clinical settings, new MR colonography protocols must be optimized. Future MR colonography research should address issues such as image characteristics, presence of artifacts, management of specific absorption rate, and hardware-related modifications. (c) RSNA, 2010 . radiographics.rsna.org C1 [Thornton, Eavan; Morrin, Martina M.] Beaumont Hosp, Dept Radiol, Dublin 9, Ireland. [Yee, Judy] San Francisco VA Med Ctr, Dept Radiol, San Francisco, CA USA. RP Thornton, E (reprint author), Beaumont Hosp, Dept Radiol, Dublin 9, Ireland. EM eavanthornton@gmail.com RI Morrin, Maureen/F-2010-2011 NR 60 TC 21 Z9 21 U1 0 U2 0 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0271-5333 J9 RADIOGRAPHICS JI Radiographics PD JAN PY 2010 VL 30 IS 1 BP 201 EP U229 DI 10.1148/rg.301095519 PG 19 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 544IO UT WOS:000273649000014 PM 20083594 ER PT J AU Nishino, M Washko, GR Hatabu, H AF Nishino, Mizuki Washko, George R. Hatabu, Hiroto TI Volumetric Expiratory HRCT of the Lung: Clinical Applications SO RADIOLOGIC CLINICS OF NORTH AMERICA LA English DT Article DE Computed tomography (CT); Lung; High-resolution CT; Expiratory high-resolution CT; Volumetric ID HIGH-RESOLUTION CT; PULMONARY-FUNCTION TESTS; AIR-FLOW OBSTRUCTION; THIN-SECTION CT; COMPUTED-TOMOGRAPHY; SARCOIDOSIS; BRONCHIECTASIS; EMPHYSEMA; DENSITY; SCANS AB Expiratory high-resolution CT (HRCT) of the chest offers a powerful adjunct to inspiratory HRCT in the detection of lung diseases involving the small airways. In 2003 a clinical HRCT scan protocol was developed. It has since been used for evaluation of diffuse lung disease with suspected airway abnormalities. It provides volumetric assessment of the entire thorax at end-inspiration and at end-expiration, and allows for detailed analysis of the airway and parenchyma. It offers a powerful adjunct to inspiratory HRCT in the detection of lung diseases involving the small airways. This article explores its clinical applications for chronic obstructive pulmonary disease, bronchiectasis, and sarcoidosis. It concludes that standardization of image acquisition and post-processing in CT examinations will be necessary for the real application of quantitative data derived from volumetric expiratory HRCT to daily clinical medical practice. C1 [Nishino, Mizuki] Harvard Univ, Sch Med, Dept Radiol, Dana Farber Canc Inst, Boston, MA 02215 USA. [Washko, George R.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02215 USA. [Washko, George R.] Harvard Univ, Sch Med, Boston, MA USA. [Hatabu, Hiroto] Brigham & Womens Hosp, MRI Program, Ctr Pulm Funct Imaging, Boston, MA 02215 USA. [Hatabu, Hiroto] Harvard Univ, Sch Med, Dept Radiol, Ctr Pulm Funct Imaging,Brigham & Womens Hosp, Boston, MA 02215 USA. RP Nishino, M (reprint author), Harvard Univ, Sch Med, Dept Radiol, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02215 USA. EM Mizuki_Nishino@dfci.harvard.edu NR 29 TC 7 Z9 8 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0033-8389 J9 RADIOL CLIN N AM JI Radiol. Clin. N. Am. PD JAN PY 2010 VL 48 IS 1 BP 177 EP + DI 10.1016/j.rcl.2009.09.003 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 604LZ UT WOS:000278281800011 PM 19995635 ER PT J AU Konstas, AA Lev, MH AF Konstas, Angelos A. Lev, Michael H. TI CT Perfusion Imaging of Acute Stroke: The Need for Arrival Time, Delay Insensitive, and Standardized Postprocessing Algorithms? SO RADIOLOGY LA English DT Editorial Material ID SINGULAR-VALUE DECOMPOSITION; ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; MRI; DIFFUSION; MISMATCH; THERAPY; BRAIN; FLOW C1 [Konstas, Angelos A.; Lev, Michael H.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Konstas, AA (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA. EM akonstas@partners.org NR 28 TC 29 Z9 29 U1 0 U2 1 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD JAN PY 2010 VL 254 IS 1 BP 22 EP 25 DI 10.1148/radiol.09091610 PG 4 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 546OP UT WOS:000273820400007 PM 20032139 ER PT J AU Catalano, OA Choy, G Zhu, A Hahn, PF Sahani, DV AF Catalano, Onofrio A. Choy, Garry Zhu, Andrew Hahn, Peter F. Sahani, Dushyant V. TI Differentiation of Malignant Thrombus from Bland Thrombus of the Portal Vein in Patients with Hepatocellular Carcinoma: Application of Diffusion-weighted MR Imaging SO RADIOLOGY LA English DT Article ID FINE-NEEDLE ASPIRATION; FOCAL HEPATIC-LESIONS; T2 SHINE-THROUGH; TUMOR THROMBUS; ABDOMINAL ORGANS; LIVER-LESIONS; RISK-FACTORS; BENIGN; DIAGNOSIS; BIOPSY AB Purpose: To investigate the utility of diffusion-weighted (DW) imaging in distinguishing bland thrombus from neoplastic thrombus in the portal vein in patients with hepatocellular carcinoma (HCC). Materials and Methods: In this retrospective institutional review board-approved HIPAA-complaint study, the imaging results in 25 patients (16 men [average age, 62.3 years; range, 35-75 years] and nine women [average age, 58.4 years; range, 32-69 years]; overall average age, 60.1 years; range, 32-75 years) with HCC and portal vein thrombosis who were examined with both contrast material-enhanced computed tomography (CT) and 1.5-T magnetic resonance (MR) imaging were reviewed. Axial echo-planar two-dimensional DW imaging was performed by using b values of 50, 400, and 800 sec/mm(2). A thrombus was considered neoplastic if it expanded the vessel or enhanced on the dynamic CT and MR images; otherwise it was considered bland. The signal intensity (SI) of the thrombus and HCC lesions in the same patients was compared on DW images. The results were evaluated by using the Fisher exact test. The apparent diffusion coefficients (ADCs) of HCC and thrombus were used to compute the ratio of the ADC of the thrombus to the ADC of the tumor. Results: On DW images, 15 of 19 neoplastic thrombi demonstrated same SI and four showed lower SI than the primary HCC. Each of the six bland thrombi had lower SI than the primary HCC (P<.001). The mean ADC of HCC and thrombus in the neoplastic thrombus group was 0.87 x 10(-3) mm(2)/sec and 0.88 x 10(-3) mm(2)/sec, respectively (P=.45). The ADC of the bland thrombus was 2.89 x 10(-3) mm(2)/sec, significantly higher than the ADC of the HCC (1.0 x 10(-3) mm(2)/sec, P<.0003). The ratio of the ADC of the thrombus to the ADC of the tumor in the bland thrombus group was 2.9 compared with 0.998 in the neoplastic group (P=.0003). Conclusion: DW imaging enables discrimination between bland and neoplastic portal vein thrombi when the ratio of the ADC of the thrombus to the ADC of HCC was lower than 2 and when the thrombi showed similar SI as the primary HCC when qualitative analysis was performed. (C) RSNA, 2010 C1 [Catalano, Onofrio A.; Choy, Garry; Hahn, Peter F.; Sahani, Dushyant V.] Massachusetts Gen Hosp, Dept Abdominal & Intervent Radiol, Boston, MA 02114 USA. [Zhu, Andrew] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. RP Sahani, DV (reprint author), Massachusetts Gen Hosp, Dept Abdominal & Intervent Radiol, 55 Fruit St,WHT 270, Boston, MA 02114 USA. EM dsahani@partners.org NR 43 TC 54 Z9 56 U1 0 U2 3 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD JAN PY 2010 VL 254 IS 1 BP 154 EP 162 DI 10.1148/radiol.09090304 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 546OP UT WOS:000273820400020 PM 20032150 ER PT J AU Almandoz, JED Schaefer, PW Kelly, HR Lev, MH Gonzalez, RG Romero, JM AF Almandoz, Josser E. Delgado Schaefer, Pamela W. Kelly, Hillary R. Lev, Michael H. Gonzalez, R. Gilberto Romero, Javier M. TI Multidetector CT Angiography in the Evaluation of Acute Blunt Head and Neck Trauma: A Proposed Acute Craniocervical Trauma Scoring System SO RADIOLOGY LA English DT Article ID COMPUTED TOMOGRAPHIC ANGIOGRAPHY; VERTEBRAL ARTERY INJURIES; CEREBROVASCULAR INJURIES; SCREENING-TEST; DIAGNOSIS; ACCURACY AB Purpose: To determine the diagnostic yield of multidetector computed tomographic (CT) angiography in the evaluation of patients presenting to the emergency department with acute blunt head and neck trauma to assess for arterial injury and to propose a practical scoring system for the identification of patients at highest risk of arterial injury. Materials and Methods: With institutional review board approval, Health Insurance Portability and Accountability Act compliance, and waived informed consent, a retrospective study was conducted of 830 consecutive patients who presented to the emergency department with acute blunt head and neck trauma over 9 years and were evaluated with multidetector CT angiography. Unenhanced CT scans and CT angiograms were reviewed for the presence of cervical interfacetal subluxations and/or dislocations, fractures, intracranial hemorrhage, and arterial injury. Medical records were reviewed for mechanism of injury (MOI). Multivariate logistic regression analysis was performed to identify independent predictors of an increased risk of arterial injury. Results: Multidetector CT angiographic results showed injury to 118 arterial structures in 106 (12.8%) patients. Multivariate logistic regression analysis showed that the presence of cervical interfacetal subluxation/dislocations (44.4%; odds ratio [OR], 6.3; P < .0001), fracture lines reaching an arterial structure (22.1%; OR, 4.4; P < .0001), and high-impact MOIs (16.5%; OR, 3.1; P < .0001) were independent predictors of an increased risk of arterial injury and were used to construct a scoring system. Patients with scores of 2 and 3 (21.9% and 52.2%, respectively) were at highest risk of arterial injury. Conclusion: The proposed acute craniocervical trauma scoring system could be used as a guide to select blunt trauma patients for multidetector CT angiographic evaluation. Future validation of this scoring system is necessary. (C) RSNA, 2009 C1 [Almandoz, Josser E. Delgado; Schaefer, Pamela W.; Kelly, Hillary R.; Lev, Michael H.; Gonzalez, R. Gilberto; Romero, Javier M.] Massachusetts Gen Hosp, Dept Radiol, Div Neuroradiol, Boston, MA 02114 USA. RP Almandoz, JED (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Neuroradiol, Gray 2 Room 273A,55 Fruit St, Boston, MA 02114 USA. EM delgadoj@mir.wustl.edu NR 22 TC 14 Z9 14 U1 0 U2 0 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD JAN PY 2010 VL 254 IS 1 BP 236 EP 244 DI 10.1148/radiol.09090693 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 546OP UT WOS:000273820400029 ER PT S AU Chen, CC Hochberg, F Batchelor, T Shih, HA Chakravarti, A Chapman, P Loeffler, J AF Chen, Clark C. Hochberg, Fred Batchelor, Tracy Shih, Helen A. Chakravarti, Arnab Chapman, Paul Loeffler, Jay BE McDermott, MW TI Radiosurgery as Salvage Therapy for Primary Central Nervous System Lymphoma SO RADIOSURGERY, VOL 7 SE RADIOSURGERY (SERIES) LA English DT Proceedings Paper CT 8th Meeting of the International-Stereotactic-Radiosurgery-Society CY JUN 23-27, 2007 CL San Francisco, CA SP Int Stereotact Radiosurg Soc ID PRIMARY CNS LYMPHOMA; NON-HODGKINS-LYMPHOMA; RADIATION-THERAPY; STEREOTACTIC RADIOSURGERY; BRAIN; CHEMOTHERAPY; RADIOTHERAPY; SURVIVAL; CYCLOPHOSPHAMIDE; DEXAMETHASONE AB Background and Aims: 40-50% of patients with primary central nervous system lymphoma (PCNSL) suffer treatment failure after methotrexate (MTX)-based chemotherapy. While whole brain radiation therapy (WBRT) has been reported as an effective salvage modality in this context, the combination of MTX and WBRT causes synergistic neurotoxic effects. Here we investigated the use of radiosurgery as an alternate salvage modality. Methods: We reviewed the records of immunocompetent adults with pathology-confirmed PCNSL who underwent radiosurgery as salvage therapy at the Massachusetts General Hospital between 1993 and 2007. Thirteen salvage radiosurgeries were performed in 7 PCNSL patients. Results: Lesion size ranged from 0.2 to 3.1 (median 0.31) cm(3). Doses were prescribed to the periphery of the lesion and normalized to the 90% isodose line (12-16, median 15 Gy). Follow-up ranged from 18 to 103 (median 29) months. According to the Macdonald criteria, complete radiographic response was observed in 11/13 lesions, stable disease in 1 lesion and disease progression in another lesion. 3/7 patients required multiple radiosurgeries for relapse outside the initial radiosurgery volume. Focal FLAIR signal abnormalities outside the irradiated volume were seen in all cases, though only 2/7 patients developed the type of diffuse leukoencephalopathy that is associated with MTX WBRT therapy. Conclusion: This series suggests that radiosurgery is an effective and well-tolerated salvage therapy for patients with small recurrent PCNSL lesions. Copyright (C) 2010 S. Karger AG, Basel C1 [Chen, Clark C.] Beth Israel Deaconess Med Ctr, Dept Neurosurg, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Chen, CC (reprint author), Beth Israel Deaconess Med Ctr, Dept Neurosurg, Dana Farber Canc Inst, Jimmy Fund 521,44 Binney St, Boston, MA 02115 USA. EM cchen1@partners.org NR 27 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1024-2651 BN 978-3-8055-9364-9 J9 RADIOSURG PY 2010 VL 7 BP 276 EP 287 DI 10.1159/000288739 PG 12 WC Radiology, Nuclear Medicine & Medical Imaging; Surgery SC Radiology, Nuclear Medicine & Medical Imaging; Surgery GA BTZ43 UT WOS:000288517800025 ER PT S AU Morelli, M Carta, AR Kachroo, A Schwarzschild, MA AF Morelli, Micaela Carta, Anna R. Kachroo, Anil Schwarzschild, Michael A. BE Bjorklund, A Cenci, MA TI Pathophysiological roles for purines: adenosine, caffeine and urate SO RECENT ADVANCES IN PARKINSONS DISEASE: BASIC RESEARCH SE Progress in Brain Research LA English DT Review; Book Chapter DE A(2A) receptors; neuroprotection; neurodegeneration; Parkinson's disease ID A(2A) RECEPTOR ANTAGONIST; IDIOPATHIC PARKINSONS-DISEASE; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CANNABINOID CB1 RECEPTORS; DOPAMINE D2 RECEPTORS; ISCHEMIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; URIC-ACID LEVELS; IN-VIVO AB The motor symptoms of Parkinson's disease (PD) are primarily due to the degeneration of the dopaminergic neurons in the nigrostriatal pathway. However, several other brain areas and neurotransmitters other than dopamine such as noradrenaline, 5-hydroxytryptamine and acetylcholine are affected in the disease. Moreover, adenosine because of the extensive interaction of its receptors with the dopaminergic system has been implicated in the pathophysiology of the disease. Based on the involvement of these non-dopaminergic neurotransmitters in PD and the sometimes severe adverse effects that limit the mainstay use of dopamine-based anti-parkinsonian treatments, recent assessments have called for a broadening of therapeutic options beyond the traditional dopaminergic drug arsenal. In this review we describe the interactions between dopamine and adenosine receptors that underpin the pre-clinical and clinical rationale for pursuing adenosine A(2A) receptor antagonists as symptomatic and potentially neuroprotective treatment of PD. The review will pay particular attention to recent results regarding specific A(2A) receptor-receptor interactions and recent findings identifying urate, the end product of purine metabolism, as a novel prognostic biomarker and candidate neuroprotectant in PD. C1 [Morelli, Micaela; Carta, Anna R.] Univ Cagliari, Dept Toxicol, Cagliari, Italy. [Kachroo, Anil; Schwarzschild, Michael A.] Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Boston, MA 02114 USA. RP Morelli, M (reprint author), Univ Cagliari, Dept Toxicol, Cagliari, Italy. EM morelli@unica.it OI morelli, micaela/0000-0003-0394-5782 FU NINDS NIH HHS [K24 NS060991, K24NS060991, R01 NS054978, R01 NS054978-01, R01NS054978, K24 NS060991-02] NR 183 TC 37 Z9 37 U1 0 U2 14 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0079-6123 BN 978-0-444-53614-3 J9 PROG BRAIN RES JI Prog. Brain Res. PY 2010 VL 183 BP 183 EP 208 DI 10.1016/S0079-6123(10)83010-9 PG 26 WC Medicine, Research & Experimental; Clinical Neurology; Neurosciences SC Research & Experimental Medicine; Neurosciences & Neurology GA BTR42 UT WOS:000287859500010 PM 20696321 ER PT J AU Fleischmann, KH Kuter, DJ Coley, CM Rathmell, JP AF Fleischmann, Katharine H. Kuter, David J. Coley, Christopher M. Rathmell, James P. TI Practice Guidelines Often Fail to Keep Pace With the Rapid Evolution of Medicine A Call for Clinicians to Remain Vigilant and Revisit Their Own Practice Patterns SO REGIONAL ANESTHESIA AND PAIN MEDICINE LA English DT Editorial Material ID ENOXAPARIN; DALTEPARIN; SURGERY; RISKS C1 [Fleischmann, Katharine H.; Rathmell, James P.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Kuter, David J.] Massachusetts Gen Hosp, Dept Med, Div Hematol, Boston, MA 02114 USA. [Coley, Christopher M.] Massachusetts Gen Hosp, Dept Risk Management, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Rathmell, JP (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St,GRB 444, Boston, MA 02114 USA. EM jrathmell@partners.org NR 10 TC 5 Z9 5 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1098-7339 J9 REGION ANESTH PAIN M JI Region. Anesth. Pain Med. PD JAN-FEB PY 2010 VL 35 IS 1 BP 4 EP 7 DI 10.1097/AAP.0b013e3181c966bf PG 4 WC Anesthesiology SC Anesthesiology GA 545EY UT WOS:000273716500002 PM 20048651 ER PT S AU Rahmanzadeh, R Rai, P Gerdes, J Hasan, T AF Rahmanzadeh, Ramtin Rai, Prakash Gerdes, Johannes Hasan, Tayyaba BE Achilefu, S Raghavachari, R TI Targeted light-inactivation of the Ki-67 protein using theranostic liposomes leads to death of proliferating cells SO REPORTERS, MARKERS, DYES, NANOPARTICLES, AND MOLECULAR PROBES FOR BIOMEDICAL APPLICATIONS II SE Proceedings of SPIE-The International Society for Optical Engineering LA English DT Proceedings Paper CT Conference on Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications II CY JAN 25-27, 2010 CL San Francisco, CA SP SPIE DE Nanotechnology; Ovarian Cancer; Proliferative Index; Photodynamic Therapy; Antibody ID PHOTODYNAMIC THERAPY; CANCER AB Nanomedicine is beginning to impact the treatment of several diseases and current research efforts include development of integrated nano-constructs (theranostics) which serve as probes for imaging and therapy in addition to delivering macromolecules intracellularly. In cancer, there is a vital unmet need for effective alternative treatments with high specificity and low systemic toxicity. This can be achieved by targeting key molecular markers associated with cancer cells with reduced effective drug doses. Here, we show an innovative proof-of-principle approach for efficient killing of proliferating ovarian cancer cells by inactivating a protein associated with cell proliferation namely, the nuclear Ki-67 protein (pKi-67), using nanotechnology-based photodynamic therapy (PDT). Antibodies against pKi-67 are widely used as prognostic tools for tumor diagnosis. In this work, anti pKi-67 antibodies were first conjugated to fluorescein isothiocyanate (FITC) and then encapsulated inside liposomes. After incubation of OVCAR-5 ovarian cancer cells with these liposomes, confocal microscopy confirmed the localization of the antibodies to the nucleoli of the cells. Irradiation with a 488 nm laser led to a significant loss of cell viability. The specificity of this approach for pKi-67 positive cells was demonstrated in confluent human lung fibroblasts (MRC-5) where only a small population of cells stain positive for pKi-67 and only minimal cell death was observed. Taken together, our findings suggest that pKi-67 targeted with nano-platform is an attractive therapeutic target in cancer therapy. C1 [Rahmanzadeh, Ramtin; Rai, Prakash; Hasan, Tayyaba] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Rahmanzadeh, R (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA. EM thasan@partners.org NR 14 TC 0 Z9 0 U1 0 U2 1 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-7972-3 J9 P SOC PHOTO-OPT INS PY 2010 VL 7576 AR 757602 DI 10.1117/12.843850 PG 5 WC Engineering, Biomedical; Nanoscience & Nanotechnology; Optics SC Engineering; Science & Technology - Other Topics; Optics GA BSS16 UT WOS:000285580600001 ER PT J AU Perota, A Brunetti, D Charreau, B Chatelais, M Lagutina, I Lazzari, G Anegon, I Sachs, DH Cozzi, E Lucchini, F Galli, C AF Perota, A. Brunetti, D. Charreau, B. Chatelais, M. Lagutina, I. Lazzari, G. Anegon, I. Sachs, D. H. Cozzi, E. Lucchini, F. Galli, C. TI GENERATION OF CLONED CD55-CD39 TRANSGENIC alpha 1,3-GALACTOSYLTRANSFERASE DEPLETED (GAL-/-) PIGLETS SO REPRODUCTION FERTILITY AND DEVELOPMENT LA English DT Meeting Abstract C1 [Perota, A.; Brunetti, D.; Lagutina, I.; Lazzari, G.; Galli, C.] AVANTEA Srl, Lab Tecnol Riprod, Cremona, Italy. [Galli, C.] Univ Bologna, Dipartimento Clin Vet, Ozzano Dell Emilia, Italy. [Lucchini, F.] Univ Cattolica Sacro Cuore, Ctr Ric Biotecnol, Cremona, Italy. [Charreau, B.; Chatelais, M.; Anegon, I.] CHU Nantes, INSERM, UMR 643, Inst Transplantat & Rech Transplantat, F-44035 Nantes 01, France. [Cozzi, E.] Osped Gen Padova, Direz Sanit, Padua, Italy. [Sachs, D. H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Sachs, D. H.] Harvard Univ, Sch Med, Transplantat Biol Res Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU CSIRO PUBLISHING PI COLLINGWOOD PA 150 OXFORD ST, PO BOX 1139, COLLINGWOOD, VICTORIA 3066, AUSTRALIA SN 1031-3613 J9 REPROD FERT DEVELOP JI Reprod. Fertil. Dev. PY 2010 VL 22 IS 1 MA 431 BP 372 EP 373 PG 2 WC Developmental Biology; Reproductive Biology; Zoology SC Developmental Biology; Reproductive Biology; Zoology GA 529CF UT WOS:000272492600452 ER PT B AU Tanrikut, C Schlegel, PN AF Tanrikut, Cigdem Schlegel, Peter N. BE Carrell, DT Peterson, CM TI Varicocele and Male Infertility SO REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY: INTEGRATING MODERN CLINICAL AND LABORATORY PRACTICE LA English DT Article; Book Chapter DE Varicocele; Varicocelectomy; Infertility; Hypogonadism; Male ID MICROSURGICAL VARICOCELECTOMY; SEMEN PARAMETERS; SPERMATIC VEIN; TESTICULAR TEMPERATURE; BALLOON OCCLUSION; SURGICAL LIGATION; AZOOSPERMIC MEN; SUBFERTILE MEN; DNA-DAMAGE; REPAIR AB Varicocele is the most common treatable issue in male factor infertility. Although varicocele is also detected in the general population, it is more prevalent in the infertile male, and treatment may be of benefit for some infertile couples. Corrective techniques that optimize testicular function and minimize potential morbidities are important. Future research endeavors should focus on elucidating the mechanism of varicocele effects on spermatogenesis to better identify men who will benefit from treatment and to refine treatment approaches. C1 [Tanrikut, Cigdem] Massachusetts Gen Hosp, MGH Fertil Ctr, Dept Urol, Boston, MA 02114 USA. [Schlegel, Peter N.] Cornell Univ, Weill Med Coll, Dept Urol, New York, NY 10021 USA. [Schlegel, Peter N.] Cornell Univ, Weill Med Coll, Dept Reprod Med, New York, NY 10021 USA. RP Tanrikut, C (reprint author), Massachusetts Gen Hosp, MGH Fertil Ctr, Dept Urol, 55 Fruit St,YAW 10A, Boston, MA 02114 USA. EM ctanrikut@partners.org OI Schlegel, Peter/0000-0002-7129-8137 NR 67 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-1-4419-1435-4 PY 2010 BP 445 EP 451 DI 10.1007/978-1-4419-1436-1_28 D2 10.1007/978-1-4419-1436-1 PG 7 WC Andrology; Obstetrics & Gynecology; Reproductive Biology SC Endocrinology & Metabolism; Obstetrics & Gynecology; Reproductive Biology GA BOL94 UT WOS:000276968200028 ER PT J AU Tak, SH Benefield, LE Mahoney, DF AF Tak, Sunghee H. Benefield, Lazelle E. Mahoney, Diane Feeney TI Technology for Long-Term Care SO RESEARCH IN GERONTOLOGICAL NURSING LA English DT Review ID ALZHEIMERS-DISEASE; CAREGIVERS; INTERVENTION; HOME AB Severe staff shortages in long-term care (LTC) make it difficult to meet the demands of the growing aging population. Further, technology-savvy Baby Boomers are expected to reshape the current institutional environments toward gaining more freedom and control in their care and lives. Voices from business, academia, research, advocacy organizations, and government bodies suggest that innovative technological approaches are the linchpin that may prepare society to cope with these projected demands. In this article, we review the current state of aging-related technology, identify potential areas for efficacy testing on improving the quality of life of LTC residents in future research, and discuss barriers to implementation of LTC technology. Finally, we present a vision of future technology use that could transform current care practices. C1 [Tak, Sunghee H.] Univ Arkansas Med Sci, Coll Nursing, Little Rock, AR 72205 USA. [Benefield, Lazelle E.] Univ Oklahoma, Hlth Sci Ctr, Coll Nursing, Oklahoma City, OK USA. [Mahoney, Diane Feeney] Massachusetts Gen Hosp, Inst Hlth Profess, Sch Nursing, Boston, MA 02114 USA. RP Tak, SH (reprint author), Univ Arkansas Med Sci, Coll Nursing, 4301 W Markham,529, Little Rock, AR 72205 USA. EM taksunghee@uams.edu OI Mahoney, Diane/0000-0002-6415-475X FU John A. Hartford Foundation; Atlantic Philanthropies; National Institutes of Health; National Institute on Aging; Alzheimer's Disease Centers [5 P 30 AG 19606]; Beverly Healthcare, Inc. FX The authors disclose that they have no significant financial interests in any product or class of products discussed directly or indirectly in this activity. Dr. Tak and Dr. Benefield are fellows in the Building Academic Geriatric Nursing Capacity (BAGNC) program, supported by the John A. Hartford Foundation and Atlantic Philanthropies. This work was supported in part by the National Institutes of Health, National Institute on Aging, Alzheimer's Disease Centers (grant 5 P 30 AG 19606) and Beverly Healthcare, Inc. The authors thank Cornelia Beck, PhD, RN, FAAN, for consultation. NR 47 TC 4 Z9 4 U1 1 U2 4 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1940-4921 J9 RES GERONTOL NURS JI Res. Gerontol. Nurs. PD JAN PY 2010 VL 3 IS 1 BP 61 EP 72 DI 10.3928/19404921-20091103-01 PG 12 WC Nursing SC Nursing GA 864DX UT WOS:000298218300008 PM 20128544 ER PT J AU Waldinger, RJ Schulz, MS AF Waldinger, Robert J. Schulz, Marc S. TI Facing the Music or Burying Our Heads in the Sand?: Adaptive Emotion Regulation in Midlife and Late Life SO RESEARCH IN HUMAN DEVELOPMENT LA English DT Article ID PHYSICAL HEALTH; PSYCHOLOGICAL HEALTH; POSITIVE-PSYCHOLOGY; NATURAL-HISTORY; EGO MECHANISMS; OLDER-ADULTS; EXPERIENCE; VULNERABILITY; SATISFACTION; DEPRESSION AB Defenses that keep threatening information out of awareness are posited to reduce anxiety at the cost of longer-term dysfunction. By contrast, socioemotional selectivity theory suggests that preference for positively-valenced information is a late-life manifestation of adaptive emotion regulation. Using longitudinal data on 61 men, we examined links between emotion regulation indices informed by these distinct conceptualizations: defenses in earlier adulthood and selective memory for positively-valenced images in late-life. Use of avoidant defenses in midlife predicted poorer memory for positive, negative, and neutral images nearly 4 decades later. Late-life satisfaction was positively linked with midlife engaging defenses but negatively linked at the trend level with concurrent positive memory bias. C1 [Waldinger, Robert J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02114 USA. [Schulz, Marc S.] Bryn Mawr Coll, Bryn Mawr, PA 19010 USA. RP Waldinger, RJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, 55 Fruit St, Boston, MA 02114 USA. EM rwaldinger@partners.org FU NIA NIH HHS [R01 AG034554-02, R01 AG034554]; NIMH NIH HHS [R01 MH042248] NR 51 TC 4 Z9 4 U1 0 U2 10 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1542-7609 J9 RES HUM DEV JI Res. Hum. Dev. PY 2010 VL 7 IS 4 BP 292 EP 306 AR PII 929904260 DI 10.1080/15427609.2010.526527 PG 15 WC Psychology, Developmental SC Psychology GA 684HA UT WOS:000284539800005 PM 21544264 ER PT J AU Lee, CJ Hoo, GWS Barack, BM AF Lee, C. Joyce Hoo, Guy W. Soo Barack, Bruce M. TI The Subpleural Radiolucent Rim: A Sign of Alveolar Filling and Tachypnea SO RESPIRATION LA English DT Editorial Material C1 Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Angeles Healthcare Syst, Pulm & Crit Care Sect, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Angeles Healthcare Syst, Imaging Serv, Los Angeles, CA 90095 USA. RP Hoo, GWS (reprint author), W Angeles VA Healthcare Ctr, Pulm & Crit Care Sect 111Q, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Guy.Soohoo@va.gov NR 1 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0025-7931 J9 RESPIRATION JI Respiration PY 2010 VL 80 IS 4 BP 347 EP 347 DI 10.1159/000295922 PG 1 WC Respiratory System SC Respiratory System GA 642OB UT WOS:000281224000012 PM 20224252 ER PT J AU Naeser, MA Martin, PI Treglia, E Ho, M Kaplan, E Bashir, S Hamilton, R Coslett, HB Pascual-Leone, A AF Naeser, Margaret A. Martin, Paula I. Treglia, Ethan Ho, Michael Kaplan, Elina Bashir, Shahid Hamilton, Roy Coslett, H. Branch Pascual-Leone, Alvaro TI Research with rTMS in the treatment of aphasia SO RESTORATIVE NEUROLOGY AND NEUROSCIENCE LA English DT Article ID TRANSCRANIAL MAGNETIC STIMULATION; HUMAN MOTOR CORTEX; INFERIOR PREFRONTAL CORTEX; CONSTRAINT-INDUCED APHASIA; POSTSTROKE APHASIA; BRAIN PLASTICITY; RIGHT-HEMISPHERE; FRONTAL-CORTEX; NONFLUENT APHASIA; PREMOTOR CORTEX AB This review of our research with rTMS to treat aphasia contains four parts: Part 1 reviews functional brain imaging studies related to recovery of language in aphasia with emphasis on nonfluent aphasia. Part 2 presents the rationale for using rTMS to treat nonfluent aphasia patients (based on results from functional imaging studies). Part 2 also reviews our current rTMS treatment protocol used with nonfluent aphasia patients, and our functional imaging results from overt naming fMRI scans, obtained pre- and post-a series of rTMS treatments. Part 3 presents results from a pilot study where rTMS treatments were followed immediately by constraint-induced language therapy (CILT). Part 4 reviews our diffusion tensor imaging (DTI) study that examined white matter connections between the horizontal, midportion of the arcuate fasciculus (hAF) to different parts within Broca's area (pars triangularis, PTr; pars opercularis, POp), and the ventral premotor cortex (vPMC) in the RH and in the LH. Part 4 also addresses some of the possible mechanisms involved with improved naming and speech, following rTMS with nonfluent aphasia patients. C1 [Naeser, Margaret A.] VA Boston Healthcare Syst, Aphasia Res Ctr 12A, Boston, MA 02130 USA. [Naeser, Margaret A.; Martin, Paula I.; Treglia, Ethan; Ho, Michael; Kaplan, Elina] Boston Univ, Sch Med, Dept Neurol, Harold Goodglass Boston Univ Aphasia Res Ctr, Boston, MA 02118 USA. [Bashir, Shahid; Pascual-Leone, Alvaro] Harvard Univ, Sch Med, Dept Neurol, Berenson Allen Ctr Noninvas Brain Stimulat, Cambridge, MA 02138 USA. [Bashir, Shahid; Pascual-Leone, Alvaro] Beth Israel Deaconess Med Ctr, Cambridge, MA USA. [Hamilton, Roy; Coslett, H. Branch] Univ Penn, Dept Neurol, Lab Cognit & Neural Stimulat, Ctr Cognit Neurosci,Moss Rehabil Res Inst, Philadelphia, PA 19104 USA. [Pascual-Leone, Alvaro] Inst Univ Neurorehabil Guttmann UAB, Badalona, Spain. RP Naeser, MA (reprint author), VA Boston Healthcare Syst, Aphasia Res Ctr 12A, JP,150 So Huntington Ave, Boston, MA 02130 USA. EM mnaeser@bu.edu RI Bashir, Shahid/E-7212-2014 FU National Institute on Deafness and Other Communication Disorders (NIDCD), Bethesda, MD [RO1 DC05672, P30 DC05207]; Medical Research Service, Department of Veterans Affairs, Washington; NIH [RRO18875]; BBVA Chair in Translational Medicine; Harvard-Thorndike General Clinical Research Center at BIDMC [NCRR MO1 RR01032]; Harvard Clinical and Translational Science Center [UL1 RR025758] FX Research supported by NIH grant RO1 DC05672 from the National Institute on Deafness and Other Communication Disorders (NIDCD), Bethesda, MD, and a grant from the Medical Research Service, Department of Veterans Affairs, Washington, D. C. (to M.A.N.); a K24 NIH award (RRO18875, to A. P.-L); BBVA Chair in Translational Medicine (to A. P.-L.); the Harvard-Thorndike General Clinical Research Center at BIDMC (NCRR MO1 RR01032) and Harvard Clinical and Translational Science Center (UL1 RR025758); and a P30 DC05207 NIDCD grant to the Harold Goodglass BU Aphasia Research Center. NR 120 TC 55 Z9 62 U1 3 U2 12 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0922-6028 J9 RESTOR NEUROL NEUROS JI Restor. Neurol. Neurosci. PY 2010 VL 28 IS 4 BP 511 EP 529 DI 10.3233/RNN-2010-0559 PG 19 WC Neurosciences SC Neurosciences & Neurology GA 639KZ UT WOS:000280975000012 PM 20714075 ER PT B AU Rodriguez-Galindo, C AF Rodriguez-Galindo, C. BE RodriguezGalindo, C Wilson, MW TI Chemotherapy in the Management of Retinoblastoma SO RETINOBLASTOMA SE Pediatric Oncology LA English DT Article; Book Chapter ID EXTERNAL-BEAM RADIOTHERAPY; HIGH-RISK RETINOBLASTOMA; ACUTE MYELOID-LEUKEMIA; HIGH-DOSE CHEMOTHERAPY; TRANSGENIC MURINE RETINOBLASTOMA; ACUTE LYMPHOBLASTIC-LEUKEMIA; STEM-CELL RESCUE; INTRAOCULAR RETINOBLASTOMA; EXTRAOCULAR RETINOBLASTOMA; METASTATIC RETINOBLASTOMA C1 [Rodriguez-Galindo, C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Rodriguez-Galindo, C.] Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA. RP Rodriguez-Galindo, C (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM Carlos_Rodriguez-Galindo@dfci.harvard.edu NR 120 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-0-387-89071-5 J9 PEDIATR ONCOL-BERLIN PY 2010 BP 67 EP 90 DI 10.1007/978-0-387-89072-2_6 PG 24 WC Oncology; Pediatrics SC Oncology; Pediatrics GA BOO60 UT WOS:000277154800006 ER PT B AU Rodriguez-Galindo, C AF Rodriguez-Galindo, C. BE RodriguezGalindo, C Wilson, MW TI Second Malignancies and Other Long Term Effects in Retinoblastoma Survivors SO RETINOBLASTOMA SE Pediatric Oncology LA English DT Article; Book Chapter ID INTRACRANIAL TUMOR IMPORTANT; RADIATION-RELATED RISK; ACUTE MYELOID-LEUKEMIA; TRILATERAL RETINOBLASTOMA; HEREDITARY RETINOBLASTOMA; BILATERAL RETINOBLASTOMA; NONOCULAR TUMORS; SOFT-TISSUE; SUPERIOR INTELLIGENCE; CHILDHOOD-CANCER C1 [Rodriguez-Galindo, C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Rodriguez-Galindo, C.] Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA. RP Rodriguez-Galindo, C (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM Carlos_Rodriguez-Galindo@dfci.harvard.edu NR 64 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-0-387-89071-5 J9 PEDIATR ONCOL-BERLIN PY 2010 BP 115 EP 126 DI 10.1007/978-0-387-89072-2_9 PG 12 WC Oncology; Pediatrics SC Oncology; Pediatrics GA BOO60 UT WOS:000277154800009 ER PT B AU Engelman, A AF Engelman, Alan BE Kurth, R Bannert, N TI Reverse Transcription and Integration SO RETROVIRUSES: MOLECULAR BIOLOGY, GENOMICS AND PATHOGENESIS LA English DT Article; Book Chapter ID HUMAN-IMMUNODEFICIENCY-VIRUS; MURINE LEUKEMIA-VIRUS; AVIAN-SARCOMA VIRUS; NUCLEAR-LOCALIZATION SIGNAL; RETROVIRAL DNA INTEGRATION; HUMAN FOAMY VIRUS; TYPE-1 PREINTEGRATION COMPLEXES; PRIMER TRANSFER-RNA; SITE-DIRECTED MUTAGENESIS; INFECTIOUS-ANEMIA VIRUS AB Retroviruses are unique among animal viruses in that their replication requires the recombination of their own genetic material with that of the infected host cell. Two virus-encapsulated enzymes, reverse transcriptase and integrase, are dedicated to provirus formation. Reverse transcriptase, using a packaged cellular tRNA primer to initiate DNA synthesis from the viral RNA template, generates linear double-stranded DNA within the context of the reverse transcription nucleoprotein complex. The integrase enzyme processes the neo-synthesized DNA ends as the preintegration complex moves toward the cell nucleus. After finding a suitable chromatin acceptor site, the integrase recombines the processed DNA ends with a cell chromosome. This chapter focuses on the mechanisms of viral DNA synthesis, its transport to the nucleus, and the resulting chromosomal DNA integration. C1 Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. RP Engelman, A (reprint author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. EM alan_engelman@dfci.harvard.edu NR 414 TC 16 Z9 16 U1 0 U2 2 PU CAISTER ACADEMIC PRESS PI WYMONDHAM PA 32 HEWITTS LANE, WYMONDHAM NR 18 0JA, ENGLAND BN 978-1-904455-55-4 PY 2010 BP 129 EP 159 PG 31 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA BND77 UT WOS:000274240500005 ER PT J AU Greyson, CR AF Greyson, Clifford R. TI The Right Ventricle and Pulmonary Circulation: Basic Concepts SO REVISTA ESPANOLA DE CARDIOLOGIA LA Spanish DT Article DE Right ventricle; Hypertension; Pulmonary arterial; Heart failure; Physiology ID CANINE RIGHT VENTRICLE; PRESSURE-VOLUME; ARTERIAL-HYPERTENSION; CONTRACTILE PERFORMANCE; CLINICAL-IMPLICATIONS; VASCULAR IMPEDANCE; SYSTOLIC PRESSURE; CONSCIOUS DOGS; HEART-DISEASE; STROKE WORK AB The primary purpose of the right ventricle and pulmonary circulation is gas exchange. Because gas exchange occurs in thin, highly permeable alveolar membranes, pulmonary pressure must remain low to avoid pulmonary edema; because the right ventricle and the lungs are in series with the left ventricle and the systemic circulation, the entire cardiac output must pass through the lungs. This low pressure, high volume system, makes dramatically different demands on the right ventricle compared with the demands made on the left ventricle by the systemic circulation. Moreover, the right ventricle and pulmonary circulation must buffer dynamic changes in blood volume and flow resulting from respiration, positional changes, and changes in left ventricular cardiac output. The optimizations needed to meet these conflicting demands result in reduced capacity to compensate for increased afterload or pressure. Unfortunately, a large number of pathologic processes can result in acute and or chronic increases in afterload stress. As afterload stress rises, right heart failure may develop, and hemodynamic instability and death can occur abruptly. Several biochemical pathways have been identified that may participate in adaptation or maladaptation to excessive pressure loads. C1 [Greyson, Clifford R.] Dept Vet Affairs Med Ctr, Denver, CO USA. [Greyson, Clifford R.] Univ Colorado, Denver, CO 80202 USA. RP Greyson, CR (reprint author), Denver VAMC, 1055 Clermont St, Denver, CO 80220 USA. EM Clifford.Greyson@UCDenver.edu FU NHLBI NIH HHS [R01-HL49444, R01-HL068606] NR 95 TC 20 Z9 21 U1 0 U2 4 PU EDICIONES DOYMA S A PI BARCELONA PA TRAV DE GRACIA 17-21, 08021 BARCELONA, SPAIN SN 0300-8932 EI 1579-2242 J9 REV ESP CARDIOL JI Rev. Esp. Cardiol. PD JAN PY 2010 VL 63 IS 1 BP 81 EP 95 DI 10.1016/S0300-8932(10)70012-9 PG 15 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 566WN UT WOS:000275404200012 PM 20089229 ER PT J AU Khan, AI Chowdhury, F Harris, JB Larocque, RC Faruque, ASG Ryan, ET Calderwood, SB Qadri, F AF Khan, Ashraful I. Chowdhury, Fahima Harris, Jason B. Larocque, Regina C. Faruque, Abu S. G. Ryan, Edward T. Calderwood, Stephen B. Qadri, Firdausi TI Comparison of clinical features and immunological parameters of patients with dehydrating diarrhoea infected with Inaba or Ogawa serotypes of Vibrio cholerae O1 SO SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID SINGLE-DOSE AZITHROMYCIN; EL-TOR; IMMUNE-RESPONSES; CELL RESPONSES; DOUBLE-BLIND; CVD 103-HGR; BANGLADESH; VACCINE; STRAINS; LIPOPOLYSACCHARIDE AB Vibrio cholerae O1, Ogawa and Inaba serotypes, both cause severe cholera. We compared clinical and immunological features in patients in Bangladesh infected with these 2 serotypes. Blood was collected from hospitalized Ogawa (N = 146) or Inaba (N = 191) patients at the acute stage (day 2) and 5 and 19 days later. Ogawa patients were younger than Inaba, presented with shorter duration of diarrhoea, and had more frequent abdominal pain, vomiting and need for intravenous fluids (p < 0.05). Inaba patients more frequently had dark-field positive stools (p < 0.01). Inaba strains were more susceptible to tetracycline and erythromycin than Ogawa strains (p < 0.001). Ogawa infection produced higher plasma vibriocidal as well as IgG responses to cholera toxin B subunit, toxin-coregulated pilus subunit and lipopolysaccharide (LPS); higher IgA responses to LPS in 'antibody in lymphocyte supernatant' (ALS) specimens were also seen. These results suggest that a cholera vaccine based on the Ogawa serotype needs to be further investigated. C1 [Qadri, Firdausi] Int Ctr Diarrhoeal Dis Res, Div Sci Lab, Dhaka 1000, Bangladesh. [Harris, Jason B.; Larocque, Regina C.; Ryan, Edward T.; Calderwood, Stephen B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Harris, Jason B.; Larocque, Regina C.; Ryan, Edward T.; Calderwood, Stephen B.] Harvard Univ, Sch Med, Boston, MA USA. [Harris, Jason B.; Larocque, Regina C.; Ryan, Edward T.; Calderwood, Stephen B.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. RP Qadri, F (reprint author), Int Ctr Diarrhoeal Dis Res, Div Sci Lab, GPO Box 128, Dhaka 1000, Bangladesh. EM fqadri@icddrb.org FU ICDDR, B: Centre for Health and Population Research; Fogarty International Center [D43 TW05572, R24TW007988, K01 TW007144, K01 TW007409]; National Institute of Allergy and Infectious Diseases [U01 A1058935, AI40725] FX We wish to thank the study participants as well as the dedicated field and laboratory workers of the Cholera Immune Response Study at the ICDDR, B. This research was supported by ICDDR, B: Centre for Health and Population Research; grants D43 TW05572 and R24TW007988 from the Fogarty International Center (E.T.R. and S.B.C.); grant U01 A1058935 from the National Institute of Allergy and Infectious Diseases (S.B.C.); grant AI40725 from the National Institute of Allergy and Infectious Diseases (E.T.R.); grant K01 TW007144 from the Fogarty International Center (R.C.L.); and grant K01 TW007409 from the Fogarty International Center U.B.H.) NR 46 TC 3 Z9 3 U1 0 U2 0 PU TAYLOR & FRANCIS AS PI OSLO PA KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY SN 0036-5548 J9 SCAND J INFECT DIS JI Scand. J. Infect. Dis. PY 2010 VL 42 IS 1 BP 48 EP 56 DI 10.3109/00365540903289688 PG 9 WC Infectious Diseases SC Infectious Diseases GA 551LJ UT WOS:000274210500007 PM 19883159 ER PT J AU Velmahos, GC Alam, HB AF Velmahos, G. C. Alam, H. B. TI ACUTE CARE SURGERY: THE NATURAL EVOLUTION OF TRAUMA SURGERY SO SCANDINAVIAN JOURNAL OF SURGERY LA English DT Editorial Material DE Trauma; wounds; injuries; emergency surgery; acute care surgery C1 [Velmahos, G. C.; Alam, H. B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA USA. RP Velmahos, GC (reprint author), 165 Cambridge St,Suite 810, Boston, MA 02114 USA. EM gvelmahos@partners.org NR 0 TC 1 Z9 1 U1 0 U2 0 PU FINNISH SURGICAL SOC PI HELSINKI PA MAKELANKATU 2 C, PO BOX 49, SF-00501 HELSINKI, FINLAND SN 1457-4969 J9 SCAND J SURG JI Scand. J. Surg. PY 2010 VL 99 IS 2 BP 59 EP 60 PG 2 WC Surgery SC Surgery GA 613DK UT WOS:000278957600001 PM 20684113 ER PT J AU Wilson, CT de Moya, MA AF Wilson, C. T. de Moya, M. A. TI CHOLECYSTECTOMY FOR ACUTE GALLSTONE PANCREATITIS: EARLY VS DELAYED APPROACH SO SCANDINAVIAN JOURNAL OF SURGERY LA English DT Review DE Gallstone pancreatitis; cholecystectomy; review; standard of care; length of stay; sphincterotomy; patient safety ID ACUTE BILIARY PANCREATITIS; MAGNETIC-RESONANCE CHOLANGIOPANCREATOGRAPHY; LAPAROSCOPIC CHOLECYSTECTOMY; ENDOSCOPIC SPHINCTEROTOMY; HOSPITAL STAY; MILD; MANAGEMENT; MODERATE; DISEASE; SURGERY AB Background and Aims: The management of gallstone pancreatitis, in particular timing of cholecystectomy, has evolved substantially over the last decade. The trend has been toward earlier cholecystectomy. We review current literature regarding the timing of cholecystectomy in the context of gallstone pancreatitis. Materials and Methods: The authors performed a literature search in PubMed for relevant articles in the English language with greatest weight given to prospective trials compared to observational studies and previous reviews. Results: The literature search yielded 59 articles discussing cholecystectomy in the context of gallstone pancreatitis. Most were retrospective studies or reviews, but there were nine prospective observational studies and two randomized control trials. For mild gallstone pancreatitis, laparoscopic cholecystectomy within 48 hours of presentation (without normalization of pancreatic enzymes or absence of abdominal pain) has been shown to shorten hospital stay without increased morbidity or mortality. Routine preoperative ERCP is unnecessary for patients with mild disease. For more severe disease, timing of cholecystectomy is governed by clinical status. Interval cholecystectomy (>2 weeks after index admission) can be safely done with low risk of recurrence if the patient has had ERCP and sphincterotomy at index admission. Conclusion: Patients with mild gallstone pancreatitis should have cholecystectomy during index admission within 48 hours of arrival, but patients with more severe disease will require cholecystectomy at a later time, depending on the clinical circumstances. Sphincterotomy should be done as soon as possible if cholecystectomy is not feasible early in course. C1 [Wilson, C. T.; de Moya, M. A.] Massachusetts Gen Hosp, Dept Trauma Emergency Surg & Crit Care, Boston, MA 02114 USA. RP de Moya, MA (reprint author), 165 Cambridge St,Suite 810, Boston, MA 02114 USA. EM mdemoya@partners.org NR 33 TC 12 Z9 15 U1 1 U2 3 PU FINNISH SURGICAL SOC PI HELSINKI PA MAKELANKATU 2 C, PO BOX 49, SF-00501 HELSINKI, FINLAND SN 1457-4969 J9 SCAND J SURG JI Scand. J. Surg. PY 2010 VL 99 IS 2 BP 81 EP 85 PG 5 WC Surgery SC Surgery GA 613DK UT WOS:000278957600007 PM 20679042 ER PT J AU Huckans, M Mitchell, A Ruimy, S Loftis, J Hauser, P AF Huckans, Marilyn Mitchell, Alex Ruimy, Samantha Loftis, Jennifer Hauser, Peter TI Antiviral Therapy Completion and Response Rates Among Hepatitis C Patients With and Without Schizophrenia SO SCHIZOPHRENIA BULLETIN LA English DT Article DE interferon; mental disorders; psychotic disorders; adverse effects ID SEVERE MENTAL-ILLNESS; SUBSTANCE USE DISORDERS; INTERFERON-ALPHA; VIRUS-INFECTION; RIBAVIRIN; VETERANS; PREVALENCE; MANAGEMENT; PEOPLE AB Background: Despite disproportionately high rates of hepatitis C (HCV) among patients with severe mental illness, to date, there is scant empirical data available regarding antiviral therapy outcomes within this population. Objective: To compare antiviral therapy completion and response rates between HCV patients with vs those without schizophrenia (SCHZ). Methods: A regional Veterans Healthcare Administration database was used to identify veterans meeting criteria for this retrospective chart review. All patients confirmed to have SCHZ and to have received antiviral therapy between 1998 and 2006 (n = 30) were compared with a control group of demographically matched (HCV genotype, age, race, gender) patients with no history of SCHZ (n = 30). Results: For HCV patients with genotype 1, antiviral completion, end of treatment response (ETR), and sustained viral response (SVR) rates did not significantly differ between groups. For those with genotypes 2 and 3 combined, antiviral therapy completion rates did not significantly differ between groups; however, the SCHZ group was significantly (P < 0.050) more likely to achieve an ETR and an SVR. For all genotypes combined, the SCHZ patients were no more likely than controls to discontinue therapy early for psychiatric symptoms, medical complications, or other adverse events, and groups did not significantly differ in terms of hospitalization rates during antiviral therapy. Conclusion: Our retrospective chart review suggests that patients with SCHZ complete and respond to antiviral therapy for HCV at rates comparable with those without SCHZ. Based on these data, SCHZ should not be considered a contraindication to antiviral therapy for HCV. C1 [Huckans, Marilyn; Mitchell, Alex; Ruimy, Samantha; Loftis, Jennifer; Hauser, Peter] Oregon Hlth & Sci Univ, NW Hepatitis Resource Ctr C, Portland, OR 97239 USA. [Huckans, Marilyn; Mitchell, Alex; Ruimy, Samantha; Hauser, Peter] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR 97239 USA. [Huckans, Marilyn; Loftis, Jennifer; Hauser, Peter] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA. [Loftis, Jennifer; Hauser, Peter] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. [Loftis, Jennifer; Hauser, Peter] Oregon Hlth & Sci Univ, Portland VA Med Ctr, JENS Lab, Portland, OR 97239 USA. [Hauser, Peter] Oregon Hlth & Sci Univ, Dept Internal Med, Portland, OR 97239 USA. RP Huckans, M (reprint author), Portland VA Med Ctr P3MHDC, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM marilyn.huckans@va.gov FU Stanley Medical Research Institute [05R-981] FX Stanley Medical Research Institute (05R-981). NR 23 TC 13 Z9 13 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD JAN PY 2010 VL 36 IS 1 BP 165 EP 172 DI 10.1093/schbul/sbn065 PG 8 WC Psychiatry SC Psychiatry GA 539CR UT WOS:000273231500022 PM 18562341 ER PT S AU Gvilia, I AF Gvilia, Irma BE Clow, A Thorn, L TI UNDERLYING BRAIN MECHANISMS THAT REGULATE SLEEP-WAKEFULNESS CYCLES SO SCIENCE OF AWAKENING SE International Review of Neurobiology LA English DT Review; Book Chapter ID VENTROLATERAL PREOPTIC NUCLEUS; BASAL FOREBRAIN NEURONS; DORSAL RAPHE NUCLEUS; PERIFORNICAL LATERAL HYPOTHALAMUS; EYE-MOVEMENT SLEEP; SEROTONIN-CONTAINING NEURONS; WAKING DISCHARGE PATTERNS; MONOAMINERGIC CELL GROUPS; FREELY MOVING CATS; LOCUS-COERULEUS C1 [Gvilia, Irma] Ilia State Univ, GE-0162 Tbilisi, Rep of Georgia. [Gvilia, Irma] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, North Hills, CA 91343 USA. [Gvilia, Irma] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. RP Gvilia, I (reprint author), Ilia State Univ, GE-0162 Tbilisi, Rep of Georgia. RI Sanguansri, Luz/B-6630-2011 OI Sanguansri, Luz/0000-0003-1908-7604 FU NIMH NIH HHS [MH63323] NR 107 TC 12 Z9 13 U1 0 U2 14 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0074-7742 BN 978-0-12-381324-4 J9 INT REV NEUROBIOL JI Int. Rev. Neurobiol. PY 2010 VL 93 BP 1 EP 21 DI 10.1016/S0074-7742(10)93001-8 PG 21 WC Neurosciences SC Neurosciences & Neurology GA BSH98 UT WOS:000284504400001 PM 20969999 ER PT J AU Ghasemi, M Shafaroodi, H Karimollah, AR Gholipour, T Nezami, BG Ebrahimi, F Dehpour, AR AF Ghasemi, Mehdi Shafaroodi, Hamed Karimollah, Ali Reza Gholipour, Taha Nezami, Behtash Ghazi Ebrahimi, Farzad Dehpour, Ahmad Reza TI ATP-sensitive potassium channels contribute to the time-dependent alteration in the pentylenetetrazole-induced seizure threshold in diabetic mice SO SEIZURE-EUROPEAN JOURNAL OF EPILEPSY LA English DT Article DE Diabetes mellitus; Seizure; ATP-sensitive potassium channel; Pentylenetetrazole; Clonic seizure threshold; Mice ID CROMAKALIM-INDUCED RELAXATION; INSULIN-RESISTANT RATS; K-ATP; NONKETOTIC HYPERGLYCEMIA; CEREBRAL-ARTERIES; METABOLIC SENSORS; BASILAR ARTERY; EXPRESSION; MELLITUS; OPENERS AB Although there is evidence that diabetes affects seizure susceptibility, the underlying mechanism has not been completely understood. Several studies also suggest a pivotal role for K(ATP) channels in the seizure modulation. The aim of the present study was to evaluate the seizure threshold induced by pentylenetetrazole in diabetic mice at different times (3 days, 1-8 weeks) after induction of diabetes with streptozocin and to examine the possible role of ATP-sensitive potassium (K(ATP)) channels in this manner. Our data showed a time-dependent alteration in the threshold in diabetic mice, reaching a peak on week 2 after streptozocin injection and declining significantly afterwards. The seizure threshold in 8-week diabetic mice was even lower than control levels, though the difference was not significant. The K(ATP) channel opener cromakalim (0.1-30 mu g/kg, i.p.) significantly increased the seizure threshold in control mice. Although the K(ATP) channel blocker glibenclamide (0.5, 1 mg/kg) had no effect, it prevented the effects of the potent dose of cromakalim (30 mu g/kg) on seizure threshold in control mice. Glibenclamide (1 mg/kg, i.p.) also decreased the seizure threshold in 2-week diabetic mice to the control levels which was blocked by pre-treatment with cromakalim (10 mu g/kg, i.p.). Cromakalim (10 mu g/kg, i.p.) significantly increased the seizure threshold in 8-week diabetic mice which was inhibited by pretreatment with glibenclamide (1 mg/kg, i.p.). We demonstrated a time-dependent alteration in the pentylenetetrazole-induced seizure threshold in diabetic mice. This phenomenon might be due to the probable alteration in the K(ATP) channel functioning during the diabetic condition. (C) 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved. C1 [Ghasemi, Mehdi; Karimollah, Ali Reza; Gholipour, Taha; Nezami, Behtash Ghazi; Ebrahimi, Farzad; Dehpour, Ahmad Reza] Univ Tehran Med Sci, Sch Med, Dept Pharmacol, Tehran, Iran. [Shafaroodi, Hamed] Islamic Azad Univ Med Sci, Tehran Med Branch, Dept Pharmacol, Tehran, Iran. [Karimollah, Ali Reza] Yazd Univ Med Sci, Sch Med, Dept Pharmacol, Yazd, Iran. [Ebrahimi, Farzad] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. RP Dehpour, AR (reprint author), Univ Tehran Med Sci, Sch Med, Dept Pharmacol, POB 13145-784, Tehran, Iran. EM m82_ghasemi@yahoo.com; dehpour@yahoo.com OI dehpour, ahmad reza/0000-0002-8001-5565 NR 64 TC 7 Z9 8 U1 0 U2 1 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 1059-1311 J9 SEIZURE-EUR J EPILEP JI Seizure PD JAN PY 2010 VL 19 IS 1 BP 53 EP 58 DI 10.1016/j.seizure.2009.11.003 PG 6 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 558SI UT WOS:000274765700009 PM 20004596 ER PT J AU Marcus, KJ Tishler, RB AF Marcus, Karen J. Tishler, Roy B. TI Head and Neck Carcinomas Across the Age Spectrum: Epidemiology, Therapy, and Late Effects SO SEMINARS IN RADIATION ONCOLOGY LA English DT Article ID ADVANCED NASOPHARYNGEAL CARCINOMA; EPSTEIN-BARR-VIRUS; CONCURRENT CISPLATIN-RADIOTHERAPY; RANDOMIZED TRIAL; CHILDHOOD; CANCER; CHEMOTHERAPY; CHILDREN; EXPERIENCE; SURVIVAL AB Carcinomas of the head and neck occur in both children and adults, but notable differences exist in their relative frequency, pathologic subtypes, etiologies, presenting symptoms, and late effects. In contrast, treatment strategies are similar depending on the disease type and distribution at the time of diagnosis. Thus, in adult patients, squamous cell carcinomas or one of its variants are the most common malignancies in the head and neck. However, in children, cancers of the head/neck are most commonly rhabdomyosarcomas, lymphomas, including Hodgkin's lymphoma, lymphoblastic lymphomas, and Burkitt's lymphoma or neuroblastoma. Epithelial cancers are unusual in the pediatric population, with the exception of nasopharyngeal carcinoma. Although nasopharyngeal carcinoma is a rare disease in children, representing less than 1% of childhood cancers, it does constitute 20%-50% of pediatric malignancies of the nasopharynx. This is one of the few malignant tumors in children that arise from the epithelium. Despite the differences between the diseases in children from that in adults, the management strategy has been based largely on the experience in adults. This review will describe the epidemiology, etiology, management, and late effects in children and adults, and offer explanations for both the similarities and differences. Semin Radiat Oncol 20:52-57 (C) 2010 Elsevier Inc. All rights reserved. C1 [Marcus, Karen J.] Childrens Hosp Boston, Div Radiat Oncol, Boston, MA 02115 USA. [Tishler, Roy B.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. RP Marcus, KJ (reprint author), Childrens Hosp Boston, Div Radiat Oncol, 300 Longwood Ave, Boston, MA 02115 USA. EM kmarcus@lroc.harvard.edu NR 31 TC 22 Z9 25 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1053-4296 J9 SEMIN RADIAT ONCOL JI Semin. Radiat. Oncol. PD JAN PY 2010 VL 20 IS 1 BP 52 EP 57 DI 10.1016/j.semradonc.2009.09.004 PG 6 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 619EM UT WOS:000279412000007 PM 19959031 ER PT J AU Merchant, TE Pollack, IF Loeffler, JS AF Merchant, Thomas E. Pollack, Ian F. Loeffler, Jay S. TI Brain Tumors Across the Age Spectrum: Biology, Therapy, and Late Effects SO SEMINARS IN RADIATION ONCOLOGY LA English DT Article ID CONFORMAL RADIATION-THERAPY; LOW-GRADE GLIOMA; AVERAGE-RISK MEDULLOBLASTOMA; PROGNOSTIC-FACTORS; PILOCYTIC ASTROCYTOMAS; POSTERIOR-FOSSA; POSTOPERATIVE CHEMOTHERAPY; INTRACRANIAL EPENDYMOMAS; LOCALIZED EPENDYMOMA; MULTICENTRIC FRENCH AB The clinical difference between brain tumors in adults and children is striking. Compared with adults, pediatric tumor types (mostly glial and neuronal) are more sensitive to adjuvant irradiation and chemotherapy. Pediatric tumors more often require craniospinal irradiation based on their propensity to disseminate within the neuraxis. The spectrum of side effects is broader in the child based on age and extent of treatment: radiation therapy brings increased risk of severe long-term sequelae affecting neurologic, endocrine, and cognitive function. In this review of glioma, ependymoma, and medulloblastoma, we highlight the differences between adults and children, including the higher incidence of spinal cord ependymoma and supratentorial high-grade glioma in the adult and a higher incidence of medulloblastoma in the child. With the exception of completely resected low-grade glioma, radiation therapy remains a standard of care for most patients. In some settings, the radiation oncologist should suggest further surgery or additional adjuvant therapy in an effort to optimize local tumor control. An effort is underway to better characterize adult and pediatric brain tumors biologically with an emphasis on improving our understanding of tumor genesis, malignant transformation, and some of the similarities and differences between tumor types and their response to conventional therapy. Semin Radiat Oncol 20:58-66 (C) 2010 Elsevier Inc. All rights reserved. C1 [Merchant, Thomas E.] St Jude Childrens Hosp, Div Radiat Oncol, Memphis, TN 38105 USA. [Pollack, Ian F.] Childrens Hosp Pittsburgh, Dept Pediat Neurosurg, Pittsburgh, PA USA. [Pollack, Ian F.] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15261 USA. [Loeffler, Jay S.] Harvard Univ, Sch Med, Dept Radiat Oncol, Boston, MA USA. [Loeffler, Jay S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Merchant, TE (reprint author), St Jude Childrens Hosp, Div Radiat Oncol, 262 Danny Thomas Pl,Mail Stop 220, Memphis, TN 38105 USA. EM thomas.merchant@stjude.org FU NCI NIH HHS [P30 CA021765] NR 40 TC 52 Z9 52 U1 0 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1053-4296 J9 SEMIN RADIAT ONCOL JI Semin. Radiat. Oncol. PD JAN PY 2010 VL 20 IS 1 BP 58 EP 66 DI 10.1016/j.semradonc.2009.09.005 PG 9 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 619EM UT WOS:000279412000008 PM 19959032 ER PT J AU Ng, AK Kenney, LB Gilbert, ES Travis, LB AF Ng, Andrea K. Kenney, Lisa B. Gilbert, Ethel S. Travis, Lois B. TI Secondary Malignancies Across the Age Spectrum SO SEMINARS IN RADIATION ONCOLOGY LA English DT Article ID CHILDHOOD-CANCER SURVIVOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; SURGICAL ADJUVANT BREAST; ACUTE MYELOID-LEUKEMIA; LONG-TERM SURVIVORS; CAUSE-SPECIFIC MORTALITY; STAGE HODGKINS-DISEASE; SOFT-TISSUE SARCOMA; NESTED CASE-CONTROL; EXTENDED FOLLOW-UP AB Development of a second malignancy is one of the most serious late effects in survivors of both childhood and adult-onset cancers. Patterns of second malignancy risk across the age spectrum can differ in terms of the types of second malignancies observed, magnitude of the risks, the latency period, associated risk factors, and modifying influences. Potential explanations for the varying risk patterns by age include differences in susceptibility of individual tissue/organ to carcinogenesis based on stage of development and level of tissue maturity, microenvironment, attained age, and lifestyle factors. A thorough understanding of these differences is essential when considering treatment modifications in newly diagnosed cancer patients who are aimed at reducing the risk of second malignancy and other late effects without compromising cure. Moreover, an understanding of the variations in second cancer risk according to age at treatment is important in customizing patient follow-up. Semin Radiat Oncol 20:67-78 (C) 2010 Elsevier Inc. All rights reserved. C1 [Ng, Andrea K.; Kenney, Lisa B.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Ng, Andrea K.; Kenney, Lisa B.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Gilbert, Ethel S.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Travis, Lois B.] Univ Rochester, Med Ctr, Dept Radiat Oncol, Rochester, NY 14642 USA. RP Ng, AK (reprint author), Dana Farber Canc Inst, Dept Radiat Oncol, 75 Francis St,ASBI L2, Boston, MA 02115 USA. EM ang@lroc.harvard.edu FU Intramural NIH HHS [ZIA CP010131-17] NR 120 TC 41 Z9 41 U1 1 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1053-4296 EI 1532-9461 J9 SEMIN RADIAT ONCOL JI Semin. Radiat. Oncol. PD JAN PY 2010 VL 20 IS 1 BP 67 EP 78 DI 10.1016/j.semradonc.2009.09.002 PG 12 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 619EM UT WOS:000279412000009 PM 19959033 ER PT J AU Chung, JH Kanne, JP AF Chung, Jonathan H. Kanne, Jeffrey P. TI Smoking-Related Interstitial Lung Diseases SO SEMINARS IN ROENTGENOLOGY LA English DT Article ID ACUTE EOSINOPHILIC PNEUMONIA; LANGERHANS CELL HISTIOCYTOSIS; RESPIRATORY BRONCHIOLITIS; CIGARETTE-SMOKING; PATHOLOGICAL CORRELATION; NATURAL-HISTORY; CT; NEUTROPHILIA; FEATURES; SMOKERS C1 [Kanne, Jeffrey P.] Univ Wisconsin, Div Cardiothorac Imaging, Dept Radiol, Madison, WI 53572 USA. [Chung, Jonathan H.] Massachusetts Gen Hosp, Dept Radiol, Div Thorac Imaging, Boston, MA 02114 USA. RP Kanne, JP (reprint author), Univ Wisconsin, Div Cardiothorac Imaging, Dept Radiol, MC 3235,600 Highland Ave, Madison, WI 53572 USA. EM jkanne@uwhealth.org NR 46 TC 3 Z9 3 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0037-198X J9 SEMIN ROENTGENOL JI Semin. Roentgenology PD JAN PY 2010 VL 45 IS 1 BP 29 EP 35 DI 10.1053/j.ro.2009.07.006 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 613BD UT WOS:000278950000006 PM 19944250 ER PT J AU Katz, IT Ware, NC Gray, G Haberer, JE Mellins, CA Bangsberg, DR AF Katz, Ingrid T. Ware, Norma C. Gray, Glenda Haberer, Jessica E. Mellins, Claude A. Bangsberg, David R. TI Scaling up human papillomavirus vaccination: a conceptual framework of vaccine adherence SO SEXUAL HEALTH LA English DT Review DE adolescents; development; sexually transmissible infection ID HEPATITIS-B-VACCINE; CERVICAL-CANCER PREVENTION; HPV VACCINATION; DEVELOPING-COUNTRIES; LATIN-AMERICA; YOUNG-WOMEN; COST-EFFECTIVENESS; KEY CHALLENGES; HIV-INFECTION; IMMUNIZATION AB This review article provides a conceptual framework for human papillomavirus (HPV) vaccine acceptance and adherence, with a focus on improving understanding of the sociocultural factors impacting vaccine adherence behaviour. We include a systematic review of the slowly expanding literature on HPV vaccine acceptability and uptake in developed nations, as well as the relatively few publications from poorer nations, where more than 80% of global cervical cancer related deaths occur and where the vaccine will probably have the largest impact. We suggest that this conceptual framework will not only improve our understanding of HPV vaccine uptake and adherence, but it may also guide future sociobehavioural research geared towards improving adherence to the HPV vaccine and other multi-step vaccines in a young population at risk for sexually transmissible infections. C1 [Katz, Ingrid T.] Brigham & Womens Hosp, Div Womens Hlth, Boston, MA 02120 USA. [Katz, Ingrid T.; Ware, Norma C.; Haberer, Jessica E.; Bangsberg, David R.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Gray, Glenda] Univ Witwatersrand, Perinatal HIV Res Unit, Johannesburg, Soweto, South Africa. [Haberer, Jessica E.; Bangsberg, David R.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA. [Bangsberg, David R.] MGH MIT & Harvard, Ragon Inst, Charlestown, MA 02129 USA. [Mellins, Claude A.] Columbia Univ, HIV Ctr Clin & Behav Studies, New York State Psychiat Inst, New York, NY 10032 USA. [Haberer, Jessica E.; Bangsberg, David R.] Harvard Inst Global Hlth, Cambridge, MA 02138 USA. RP Katz, IT (reprint author), Brigham & Womens Hosp, Div Womens Hlth, Boston, MA 02120 USA. EM ikatz2@partners.org FU NIH [1KL2RR025757-01]; Harvard University and its affiliated academic health care centres; National Institute of Mental Health [R21MH085557-01A1] FX Grant Support: Dr Katz received grant support from a KL2 Medical Research Investigator Training (MeRIT) grant awarded via Harvard Catalyst, The Harvard Clinical and Translational Science Center (NIH grant # 1KL2RR025757-01, and financial contributions from Harvard University and its affiliated academic health care centres). Dr Ware received grant support from National Institute of Mental Health R21MH085557-01A1. Dr Gray received grant support from National Institute of Mental Health R21MH083308-02. Dr Haberer received grant support from National Institute of Mental Health K-23 087228 and R21 083306. Dr Mellins received support from National Institute of Mental Health R01MH069133-06A1 and 3R01MH069133-06A1S1, and National Institute of Nursing Research 5R21NR010474-02. Dr Bangsberg received grant support from National Institute of Mental Health K-24 87227, and The Mark and Lisa Schwartz Family Foundation. NR 84 TC 14 Z9 15 U1 2 U2 8 PU CSIRO PUBLISHING PI COLLINGWOOD PA 150 OXFORD ST, PO BOX 1139, COLLINGWOOD, VICTORIA 3066, AUSTRALIA SN 1448-5028 J9 SEX HEALTH JI Sex Health PY 2010 VL 7 IS 3 BP 279 EP 286 DI 10.1071/SH09130 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 640EA UT WOS:000281029900010 PM 20719215 ER PT J AU Reisner, SL Mimiaga, MJ Case, P Grasso, C O'Brien, CT Harigopal, P Skeer, M Mayer, KH AF Reisner, Sari L. Mimiaga, Matthew J. Case, Patricia Grasso, Chris O'Brien, Casey T. Harigopal, Padmini Skeer, Margie Mayer, Kenneth H. TI Sexually Transmitted Disease (STD) Diagnoses and Mental Health Disparities Among Women Who Have Sex With Women Screened at an Urban Community Health Center, Boston, MA, 2007 SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID HOMOSEXUALLY ACTIVE MEN; PSYCHIATRIC-DISORDERS; US POPULATION; UNITED-STATES; HETEROSEXUAL WOMEN; AFRICAN-AMERICAN; RISK BEHAVIORS; NURSES HEALTH; YOUNG-ADULTS; DRUG-USE AB Background: A growing body of research documents mental health disparities among women who have sex with women (WSW) compared with women who have sex with men only (WSM). However, there remains a dearth of research exploring these indicators alongside sexually transmitted diseases (STDs) and WSW sexual health. Methods: A retrospective chart review was conducted of all female patients (n = 368) screened for STDs between July 2007 and December 2007 at an urban community health center in Boston, MA. Deidentified electronic medical record data (e.g., demographics, psychosocial, sexual health) were analyzed and linked to STD positivity. Women who did not have sexual behavior documented in their medical chart (n = 58) were excluded from this analysis. Bivariate and multivariable logistic regression procedures examined sexual and psychosocial health indicators, including sexual preference. Results: Twenty-seven percent of participants were WSW (17% WSW only and 10% WSW/M). Overall, 5% of WSW were diagnosed with a new STD (human papillomavirus, anogenital warts, genital herpes, pelvic inflammatory disease) and 17% had a history of a prior STD. In multivariable models adjusting for demographics, WSW were disproportionately more likely to have mental health and psychosocial issues noted in their medical records, including: a clinical diagnosis of depression, anxiety, and posttraumatic stress disorder, history of suicide attempts, and inpatient psychiatric/mental health treatment. However, WSW were significantly less likely than WSM to engage in "high risk" HIV/STD sexual behavior. In a final multivariable model, same sex behavior was not associated with a different likelihood of being diagnosed with an STD, compared with opposite sex behavior. However, WSW diagnosed with STDs were at increased odds of having bipolar disorder and utilizing outpatient mental health counseling services compared with WSW without STDs. WSW with a history of STDs were at increased odds of having attempted suicide in the past, utilizing both outpatient and inpatient mental health treatment services, and having a history of injection drug use compared with WSW without a history of STDs. Conclusions: WSW with STDs may have presenting psychosocial problems. Further research is warranted to better understand the relationship between sexual behavior and health, as well as to guide the development of interventions to ameliorate health disparities among WSW, particularly in the psychosocial domain. C1 [Reisner, Sari L.; Mimiaga, Matthew J.; Case, Patricia; Grasso, Chris; O'Brien, Casey T.; Harigopal, Padmini; Skeer, Margie; Mayer, Kenneth H.] Fenway Hlth, Fenway Inst, Boston, MA 02215 USA. [Mimiaga, Matthew J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Case, Patricia] Boston Univ, Sch Publ Hlth, Boston, MA USA. [O'Brien, Casey T.] Tufts Univ, Medford, MA 02155 USA. [Skeer, Margie] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Mayer, Kenneth H.] Miriam Hosp, Brown Med Sch, Providence, RI 02906 USA. RP Reisner, SL (reprint author), Fenway Hlth, Fenway Inst, 1340 Boylston St,8th Floor, Boston, MA 02215 USA. EM sreisner@fenwayhealth.org FU Center for Population Research in LGBT Health at The Fenway Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) [R21HD051178]; National Institute on Drug Abuse (NIDA) [R03DA023393] FX Supported by the Center for Population Research in LGBT Health at The Fenway Institute and by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under Award Number R21HD051178: and The National Institute on Drug Abuse (NIDA) grant number R03DA023393 (to M.M.: PI). NR 67 TC 11 Z9 11 U1 2 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD JAN PY 2010 VL 37 IS 1 BP 5 EP 12 DI 10.1097/OLQ.0b013e3181b41314 PG 8 WC Infectious Diseases SC Infectious Diseases GA 538BP UT WOS:000273159400002 PM 20118673 ER PT J AU Tambaca, J Kosor, M Canic, S Paniagua, D AF Tambaca, J. Kosor, M. Canic, S. Paniagua, D. TI MATHEMATICAL MODELING OF VASCULAR STENTS SO SIAM JOURNAL ON APPLIED MATHEMATICS LA English DT Article DE stents; mathematical modeling; theory of elasticity; curved rod model ID CURVED ROD MODEL; MECHANICAL-BEHAVIOR; CORONARY STENTS; DESIGN; FLUID; VALVE; FLOW AB We present a mathematical model for a study of the mechanical properties of endovascular stents in their expanded state. The model is based on the theory of slender curved rods. Stent struts are modeled as linearly elastic curved rods that satisfy the kinematic and dynamic contact conditions at the "vertices" where the struts meet. This defines a stent as a mesh of curved rods. A weak formulation for the stent problem is defined and a finite element method for a numerical computation of its solution was developed. Numerical simulations showing the pressure-displacement (axial and radial) relationship for the entire stent are presented. From the numerical data and from the energy of the problem we deduced an "effective" pressure-displacement relationship of the law of Laplace-type for the mechanical behavior of stents, where the proportionality constant in the Laplace law was expressed explicitly in terms of the geometric and mechanic properties of a stent. C1 [Tambaca, J.] Univ Zagreb, Dept Math, Zagreb 10000, Croatia. [Kosor, M.; Canic, S.] Univ Houston, Dept Math, Houston, TX 77204 USA. [Paniagua, D.] Michael E DeBakey Vet Med Ctr, Cardiac Catheterizat Labs, Houston, TX 77030 USA. [Paniagua, D.] St Lukes Episcopal Hosp, Texas Heart Inst, Med Baylor Coll Med, Houston, TX 77030 USA. RP Tambaca, J (reprint author), Univ Zagreb, Dept Math, Bijenicka 30, Zagreb 10000, Croatia. EM tambaca@math.hr; mate.kosor@gmail.com; canic@math.uh.edu RI Kosor, Mate/H-3404-2012 FU MZOS-Croatia [037-0693014-2765]; NSF/NIH [DMS-0443826]; NSF [DMS-0337355]; Texas Higher Education Board [ARP 003652-0051-2006]; UH [GEAR-2007] FX Research supported in part by MZOS-Croatia under grant 037-0693014-2765 and by the NSF/NIH under grant DMS-0443826.; The work of the second author was supported through NSF/NIH under grant DMS-0443826. The work of the third author was partially supported by the NSF under grant DMS-0337355, Texas Higher Education Board ARP 003652-0051-2006, NSF/NIH under grant DMS-0443826, and UH GEAR-2007 grant. NR 21 TC 12 Z9 12 U1 0 U2 10 PU SIAM PUBLICATIONS PI PHILADELPHIA PA 3600 UNIV CITY SCIENCE CENTER, PHILADELPHIA, PA 19104-2688 USA SN 0036-1399 J9 SIAM J APPL MATH JI SIAM J. Appl. Math. PY 2010 VL 70 IS 6 BP 1922 EP 1952 DI 10.1137/080722618 PG 31 WC Mathematics, Applied SC Mathematics GA 595AV UT WOS:000277584000010 ER PT S AU Potts, JT AF Potts, John T., Jr. BE Zaidi, M TI The early days at the National Institutes of Health SO SKELETAL BIOLOGY AND MEDICINE SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT New York Skeletal Biology and Medicine Conference CY APR 29-MAY 02, 2009 CL Mt Sinai Sch Med, New York, NY HO Mt Sinai Sch Med C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. RP Potts, JT (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Endocrine Unit, 55 Fruit St,BAR 516, Boston, MA 02114 USA. EM potts.john@mgh.harvard.edu NR 2 TC 1 Z9 1 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 BN 978-1-57331-785-6 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2010 VL 1192 BP 1 EP 4 DI 10.1111/j.1749-6632.2009.05250.x PG 4 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA BOV34 UT WOS:000277762400001 PM 20392210 ER PT S AU Lymperi, S Ferraro, F Scadden, DT AF Lymperi, Stefania Ferraro, Francesca Scadden, David T. BE Zaidi, M TI The HSC niche concept has turned 31 Has our knowledge matured? SO SKELETAL BIOLOGY AND MEDICINE SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT New York Skeletal Biology and Medicine Conference CY APR 29-MAY 02, 2009 CL Mt Sinai Sch Med, New York, NY HO Mt Sinai Sch Med DE HSC niche; stem cells; microenvironment; osteoblastic cells; perivascular cells; regeneration ID HEMATOPOIETIC STEM-CELL; BONE-MARROW; PROGENITOR CELLS; G-CSF; MOBILIZATION; MICROENVIRONMENT; OSTEOBLASTS; RECEPTOR; TISSUE; IDENTIFICATION AB The hematopoietic stem cell (HSC) niche is currently defined as the specific microenvironment in the bone marrow (BM) which anatomically harbors HSCs and governs their fate. It plays a pivotal role in regulating the survival and self-renewal ability of HSCs, protecting them from exhaustion while preventing their excessive proliferation. Many different stromal cell types have been proposed as putative constituents of the niche, but their integrated function is still unrevealed. Mechanisms by which stem/progenitor cell behavior is regulated in the niche include cell-to-cell interaction and the production of growth factors, cytokines, and extracellular matrix proteins. The HSC niche is a dynamic entity reflecting and responding to the needs of the organism. An understanding of how the niche participates in the maintenance of tissue homeostasis and repair offers new opportunities for the development of novel therapeutic tools. C1 [Scadden, David T.] Harvard Univ, Harvard Stem Cell Inst, Massachusetts Gen Hosp, Ctr Regenerat Med,Med Sch, Boston, MA 02114 USA. Harvard Univ, Dept Stem Cell & Regenerat Biol, Boston, MA 02114 USA. RP Scadden, DT (reprint author), Harvard Univ, Harvard Stem Cell Inst, Massachusetts Gen Hosp, Ctr Regenerat Med,Med Sch, 185 Cambridge St, Boston, MA 02114 USA. EM dscadden@mgh.harvard.edu FU NHLBI NIH HHS [R01 HL044851, R01 HL097794, U01 HL100402]; NIDDK NIH HHS [R01 DK050234] NR 40 TC 56 Z9 58 U1 2 U2 10 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 BN 978-1-57331-785-6 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2010 VL 1192 BP 12 EP 18 DI 10.1111/j.1749-6632.2009.05223.x PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA BOV34 UT WOS:000277762400003 PM 20392212 ER PT S AU Neer, RM AF Neer, Robert M. CA Investigators, S BE Zaidi, M TI Bone loss across the menopausal transition SO SKELETAL BIOLOGY AND MEDICINE SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT New York Skeletal Biology and Medicine Conference CY APR 29-MAY 02, 2009 CL Mt Sinai Sch Med, New York, NY HO Mt Sinai Sch Med DE epidemiology; women's health; hormones; bone remodeling; osteoporosis; weight; menopause ID EARLY PERIMENOPAUSAL WOMEN; MINERAL DENSITY CHANGES; LIFE-STYLE FACTORS; ETHNIC VARIATION; PREMENOPAUSAL; INACCURACIES; TURNOVER; SWAN AB The Study of Women's Health Across the Nation (SWAN) is an NIH-funded, multidisciplinary, longitudinal observational study of middle-aged U.S. women of multiple ethnicities in or near Boston, Newark, Pittsburgh, Detroit, Chicago, Oakland, and Los Angeles. SWAN measures multiple variables annually, including spine and hip areal bone mineral density (aBMD), serum and urine indices of bone remodeling, and pituitary, ovarian, and adrenal hormones. This chapter outlines the findings of the SWAN study so far. C1 [Neer, Robert M.; Investigators, S] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. RP Neer, RM (reprint author), Massachusetts Gen Hosp, Endocrine Unit, Thier 1051, Boston, MA 02114 USA. EM rneer@partners.org FU NIA NIH HHS [AG012554, AG012495, AG012505, AG012531, AG012535, AG012539, AG012546, AG012553, U01 AG012495, U01 AG012505, U01 AG012531, U01 AG012535, U01 AG012539, U01 AG012546, U01 AG012553, U01 AG012554]; NINR NIH HHS [NR004061, U01 NR004061] NR 10 TC 16 Z9 16 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 BN 978-1-57331-785-6 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2010 VL 1192 BP 66 EP 71 DI 10.1111/j.1749-6632.2009.05233.x PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA BOV34 UT WOS:000277762400010 PM 20392219 ER PT S AU Roodman, GD AF Roodman, G. David BE Zaidi, M TI Insights into the pathogenesis of Paget's disease SO SKELETAL BIOLOGY AND MEDICINE SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT New York Skeletal Biology and Medicine Conference CY APR 29-MAY 02, 2009 CL Mt Sinai Sch Med, New York, NY HO Mt Sinai Sch Med DE Paget's disease; sequestosome-1; measles virus ID KAPPA-B ACTIVATION; INTERACTING PROTEIN P62; CANINE-DISTEMPER VIRUS; MEASLES-VIRUS; BINDING-PROTEIN; SH2 DOMAIN; BONE; KINASE; MUTATION; OSTEOCLASTS AB Paget's disease (PD) affects approximately 1.5 million persons in the United States and is characterized by grossly distorted bone remodeling, with increases in bone resorption and formation. Both environmental and genetic factors may contribute to the pathogenesis of PD. Mutations in sequestosome-1 (p62) occur in 25-30% of patients with familial PD, and in similar to 10% of patients with sporadic PD. Preclinical studies suggest that the p62(P392L) mutation predisposes patients to developing PD rather than causing it. Other studies have suggested that PD results from a chronic paramyxoviral infection. Transgenic mice expressing the measles virus nucleocapsid gene (MVNP) in osteoclasts (OCLs) develop pagetic bone lesions. Further, approximately 70% of patients harboring the p62(P392L). mutation we studied have detectable MVNP transcripts, and inhibiting MVNP expression in bone marrow cultures from those patients blocked pagetic OCL formation. These studies suggest that both genetic and environmental factors contribute to PD. C1 Univ Pittsburgh, Sch Med Hematol Oncol, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Roodman, GD (reprint author), Univ Pittsburgh, Sch Med Hematol Oncol, VA Pittsburgh Healthcare Syst, R&D 151-U,Room 2E-113,Univ Dr C, Pittsburgh, PA 15240 USA. EM roodmangd@upmc.edu NR 33 TC 17 Z9 17 U1 1 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 BN 978-1-57331-785-6 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2010 VL 1192 BP 176 EP 180 DI 10.1111/j.1749-6632.2009.05214.x PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA BOV34 UT WOS:000277762400025 PM 20392234 ER PT S AU Cardozo, CP Qin, WP Peng, YZ Liu, X Wu, Y Pan, JP Bauman, WA Zaidi, M Sun, L AF Cardozo, Christopher P. Qin, Weiping Peng, Yuanzhen Liu, Xuan Wu, Yong Pan, Jiangping Bauman, William A. Zaidi, Mone Sun, Li BE Zaidi, M TI Nandrolone slows hindlimb bone loss in a rat model of bone loss due to denervation SO SKELETAL BIOLOGY AND MEDICINE SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT New York Skeletal Biology and Medicine Conference CY APR 29-MAY 02, 2009 CL Mt Sinai Sch Med, New York, NY HO Mt Sinai Sch Med DE nandrolone; osteoporosis; bone loss ID SPINAL-CORD-INJURY; IMMOBILIZATION; TESTOSTERONE; DENSITY AB Nandrolone is an anabolic steroid that has been demonstrated to reduce the loss of bone and muscle from hindlimb unweighting and to slow muscle atrophy after nerve transection. To determine whether nandrolone has the ability to protect bone against loss due to disuse after denervation, male rats underwent sciatic nerve transaction, followed 28 days later by treatment with nandrolone or vehicle for 28 days. Bone mineral density (BMD) was determined 28 days later or 56 days after nerve transection. Denervation led to reductions in BMD of 7% and 12% for femur and tibia, respectively. Nandrolone preserved 80% and 60% of BMD in femur and tibia, respectively, demonstrating that nandrolone administration significantly reduced loss of BMD from denervation. This study offers a potential novel pharmacological strategy for use of nandrolone to reduce bone loss in severe disuse- and denervation-related bone loss, such as that which occurs after spinal cord injury. C1 [Cardozo, Christopher P.; Qin, Weiping; Wu, Yong; Pan, Jiangping; Bauman, William A.] James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY 10468 USA. [Cardozo, Christopher P.; Qin, Weiping; Wu, Yong; Pan, Jiangping; Bauman, William A.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Peng, Yuanzhen; Liu, Xuan; Zaidi, Mone; Sun, Li] Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY USA. RP Qin, WP (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM weiping.qin@mssm.edu FU Veterans Health Administration, Rehabilitation Research and Development Service [B4162C, B3347K]; National Institutes of Health [AG2317b, DK70525, DK80459] FX C.C. and W.A.B. wish to acknowledge grant support from the Veterans Health Administration, Rehabilitation Research and Development Service (B4162C, B3347K). M.Z. and S.L. acknowledge the National Institutes of Health for support (AG2317b, DK70525, and DK80459). NR 14 TC 13 Z9 13 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA SN 0077-8923 BN 978-1-57331-785-6 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2010 VL 1192 BP 303 EP 306 DI 10.1111/j.1749-6632.2009.05313.x PG 4 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA BOV34 UT WOS:000277762400042 PM 20392251 ER PT S AU Schipani, E AF Schipani, Ernestina BE Zaidi, M TI Posttranslational modifications of collagens as targets of hypoxia and Hif-1 alpha in endochondral bone development SO SKELETAL BIOLOGY AND MEDICINE SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT New York Skeletal Biology and Medicine Conference CY APR 29-MAY 02, 2009 CL Mt Sinai Sch Med, New York, NY HO Mt Sinai Sch Med DE hypoxia; Hif-1 alpha; VHL; chondrocytes; matrix; collagen ID GENE-EXPRESSION; INDUCIBLE FACTOR; STEM-CELLS; DIFFERENTIATION; OXYGEN; HIF-1; MICROENVIRONMENT; FACTOR-1-ALPHA; CARTILAGE; MAINTAIN AB recent years, it has been proposed that oxygen is not only art indispensable metabolic substrate, but also a regulatory signal, and that gradients of oxygenation turn on a specific genetic program. A crucial mediator of the adaptive response of cells to hypoxia is the transcription factor hypoxia-inducible factor 1 alpha (Hif-1 alpha). The fetal growth plate, which is an avascular structure of mesenchymal origin, has a unique out-in gradient of oxygenation. Hif-1 alpha is required for chondrogenesis in vivo by controlling a complex homeostatic response that allows chondrocytes to survive and differentiate in an hypoxic environment. Preliminary evidence suggests that regulation of posttranslational modifications of collagens could be an important component of this adaptive response. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. RP Schipani, E (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Endocrine Unit, Thier Res Bldg,Room 1101,50 Blossom St, Boston, MA 02114 USA. EM schipani@helix.mgh.harvard.edu FU NIH [AR048191] FX This work was supported by the NIH Grant AR048191 (to E.S.). NR 40 TC 9 Z9 9 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 BN 978-1-57331-785-6 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2010 VL 1192 BP 317 EP 321 DI 10.1111/j.1749-6632.2009.05236.x PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA BOV34 UT WOS:000277762400044 PM 20392253 ER PT S AU Wan, C Shao, J Gilbert, SR Riddle, RC Long, FX Johnson, RS Schipani, E Clemens, TL AF Wan, Chao Shao, Jin Gilbert, Shawn R. Riddle, Ryan C. Long, Fanxin Johnson, Randall S. Schipani, Ernestina Clemens, Thomas L. BE Zaidi, M TI Role of HIF-1 alpha in skeletal development SO SKELETAL BIOLOGY AND MEDICINE SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT New York Skeletal Biology and Medicine Conference CY APR 29-MAY 02, 2009 CL Mt Sinai Sch Med, New York, NY HO Mt Sinai Sch Med DE knockout mice; osteoblasts; hypoxia-inducible factor; angiogenesis ID HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; ENDOCHONDRAL BONE-FORMATION; VASCULAR CONTRIBUTION; EPIPHYSIAL CARTILAGE; MULTIPLE ROLES; FACTOR-I; GROWTH; ANGIOGENESIS; PATHWAY; DIFFERENTIATION AB Angiogenesis and osteogenesis are tightly coupled during bone development and regeneration. Mesenchymal cells in the developing stroma elicit angiogenic signals to recruit new blood vessels into bone. Reciprocal signals, likely emanating from the incoming vascular endothelium, stimulate mesenchymal cell specification through additional interactions with cells within the vascular stem cell niche. The hypoxia-inducible factor-1 alpha (HIF-1) pathway has been identified as a key component in this process. We demonstrated that overexpression of HIF-1 in mature osteoblasts through disruption of the von Hippel-Lindau protein profoundly increases angiogenesis and osteogenesis; these processes appear to be coupled by cell nonautonomous mechanisms involving the action of vascular endothelial growth factor (VEGF) on the endothelial cells. The same occurred in the model of injury-mediated bone regeneration (distraction osteogenesis). Surprisingly, manipulation of HIF-1 does not influence angiogenesis of the skull bones, where earlier activation of HIF-1 in the condensing mesenchyme upregulates osterix during cranial bone formation. C1 [Wan, Chao; Riddle, Ryan C.; Clemens, Thomas L.] Johns Hopkins Univ, Sch Med, Dept Orthopaed Surg, Baltimore, MD 21205 USA. [Shao, Jin] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai Inst Traumatol & Orthopaed, Shanghai 200030, Peoples R China. [Gilbert, Shawn R.] Univ Alabama, Dept Surg, Birmingham, AL 35294 USA. [Long, Fanxin] Washington Univ, Sch Med, Dept Med, Dept Dev Biol, St Louis, MO 63110 USA. [Johnson, Randall S.] Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, La Jolla, CA 92093 USA. [Schipani, Ernestina] Harvard Univ, Sch Med, Boston, MA USA. [Schipani, Ernestina] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. RP Wan, C (reprint author), Johns Hopkins Univ, Sch Med, Dept Orthopaed Surg, 1721 E Madison St,Ross Bldg 232, Baltimore, MD 21205 USA. EM cwan6@jhmi.edu OI Johnson, Randall/0000-0002-4084-6639 FU NIH [AR049410] FX This work was supported in part by NIH Grant AR049410. NR 36 TC 51 Z9 62 U1 0 U2 10 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 BN 978-1-57331-785-6 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2010 VL 1192 BP 322 EP 326 DI 10.1111/j.1749-6632.2009.05238.x PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA BOV34 UT WOS:000277762400045 PM 20392254 ER PT S AU Kronenberg, HM AF Kronenberg, Henry M. BE Zaidi, M TI Gs signaling in osteoblasts and hematopoietic stem cells SO SKELETAL BIOLOGY AND MEDICINE SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT New York Skeletal Biology and Medicine Conference CY APR 29-MAY 02, 2009 CL Mt Sinai Sch Med, New York, NY HO Mt Sinai Sch Med DE osteoblast; hematopoietic stem cell; Gs; bone AB The heterotrimeric G protein Gs is a major mediator of the actions of several G protein-coupled receptors that target cells of the osteoblast lineage. For this reason, we generated chimeric mice with normal host cells and cells derived from embryonic stem cells missing the gene encoding the a subunit of Gs. While the mutant cells contributed to cortical osteoblasts and to hematopoietic cells in the liver, the marrow space contained few if any osteoblasts or hematopoietic cells missing Gs. Subsequent studies using the Cre-lox approach to delete Gs alpha from early cells of the osteoblast lineage and from hematopoietic stem cells were performed. These studies demonstrated the crucial roles of Gsa in osteoblastic cells in regulating the differentiation of osteoblasts and in supporting B-cell development as well as the essential role for Gsa in hematopoietic stem cells in allowing the homing of these cells to the marrow. C1 [Kronenberg, Henry M.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. [Kronenberg, Henry M.] Harvard Univ, Sch Med, Boston, MA USA. RP Kronenberg, HM (reprint author), Massachusetts Gen Hosp, Endocrine Unit, Thier 1101,50 Blossom St, Boston, MA 02114 USA. EM hkronenberg@partners.org NR 4 TC 8 Z9 9 U1 1 U2 6 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 BN 978-1-57331-785-6 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2010 VL 1192 BP 327 EP 329 DI 10.1111/j.1749-6632.2009.05251.x PG 3 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA BOV34 UT WOS:000277762400046 PM 20392255 ER PT J AU Gao, X Schwarzschild, MA O'Reilly, EJ Wang, H Ascherio, A AF Gao, Xiang Schwarzschild, Michael A. O'Reilly, Eilis J. Wang, Hao Ascherio, Alberto TI Restless Legs Syndrome and Erectile Dysfunction SO SLEEP LA English DT Article DE Restless legs syndrome; erectile function; men ID PERIODIC LIMB MOVEMENTS; CORONARY-HEART-DISEASE; PARAVENTRICULAR NUCLEUS; PARKINSONS-DISEASE; PENILE ERECTION; SEXUAL FUNCTION; PHOBIC ANXIETY; SLEEP; MEN; ASSOCIATION AB Study Objectives: Dopaminergic hypofunction in the central nervous system may contribute to restless legs syndrome (RLS) and erectile dysfunction (ED). We therefore examined whether men with RLS have higher prevalences of ED. Design: RLS was assessed using a set of standardized questions. Men were considered to have RLS if they met 4 RLS diagnostic criteria recommended by the International RLS Study Group, and had restless legs >= 5 times/month. Erectile function was assessed by a questionnaire. Setting: Community-based. Participants: 23,119 men who participated in the Health Professional Follow-up Study free of diabetes and arthritis. Results: Multivariate-adjusted odds ratios for ED were 1.16 and 1.78 (95% confidence interval: 1.4, 2.3; P trend < 0.0001) for men with RLS symptoms 5-14 times/mo, and 15+ times/mo, respectively, relative to those without RLS, after adjusting for age, smoking, BMI, antidepressant use, and other covariates. The associations between RLS and ED persisted in subgroup analysis according to age, obesity, and smoking status. Conclusions: Men with RLS had a higher likelihood of concurrent ED, and the magnitude of the observed association was increased with a higher frequency of RLS symptoms. These results suggest that ED and RLS share common determinants. C1 [Gao, Xiang; Ascherio, Alberto] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA. [Gao, Xiang; Ascherio, Alberto] Harvard Univ, Sch Med, Boston, MA USA. [Gao, Xiang; O'Reilly, Eilis J.; Wang, Hao; Ascherio, Alberto] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Schwarzschild, Michael A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Gao, X (reprint author), Brigham & Womens Hosp, Dept Med, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA. EM xiang.gao@channing.harvard.edu FU NIH/NINDS [R01 NS062879-01A2] FX Finding/Support: The study was supported by NIH/NINDS grant R01 NS062879-01A2. None of the sponsors participated in the design of study or in the collection, analysis, or interpretation of the data. NR 39 TC 12 Z9 14 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD JAN 1 PY 2010 VL 33 IS 1 BP 75 EP 79 PG 5 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 541KA UT WOS:000273412500013 PM 20120623 ER PT J AU Bianchi, MT AF Bianchi, M. T. TI PROMISCUOUS MODULATION OF ION CHANNELS BY SLEEP-RELATED SUBSTANCES SO SLEEP LA English DT Meeting Abstract C1 [Bianchi, M. T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0016 BP A8 EP A9 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000018 ER PT J AU Chen, L Bolortuya, Y Leonard, M Perry, R Winston, S McKenna, JT Brown, RE McCarley, RW AF Chen, L. Bolortuya, Y. Leonard, M. Perry, R. Winston, S. McKenna, J. T. Brown, R. E. McCarley, R. W. TI REM SLEEP IS DIFFERENTIALLY MODULATED BY OREXIN TYPE 2 RECEPTORS IN LATERAL PONTINE TEGMENTUM (LPT) AND VENTRAL SUBCOERULEUS (vSubC) SO SLEEP LA English DT Meeting Abstract C1 [Chen, L.; Bolortuya, Y.; Winston, S.; McKenna, J. T.; Brown, R. E.; McCarley, R. W.] VA Boston Healthcare Syst, Psychiat, Brockton, MA USA. [Chen, L.; Bolortuya, Y.; Winston, S.; McKenna, J. T.; Brown, R. E.; McCarley, R. W.] Harvard Univ, Sch Med, Brockton, MA 02401 USA. [Leonard, M.; Perry, R.] Stonehill Coll, Easton, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0022 BP A11 EP A11 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000024 ER PT J AU Christie, MA McCarley, RW Strecker, RE AF Christie, M. A. McCarley, R. W. Strecker, R. E. TI SLEEP DEPRIVATION (SD) DOES NOT ALTER WATER CONSUMPTION OR THIRST IN RATS SO SLEEP LA English DT Meeting Abstract C1 Harvard Univ, Sch Med, Brockton, MA 02401 USA. VA Boston Healthcare Syst, Brockton, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0249 BP A87 EP A87 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000252 ER PT J AU Dang-Vu, T McKinney, S Buxton, OM Solet, JM Ellenbogen, JM AF Dang-Vu, T. McKinney, S. Buxton, O. M. Solet, J. M. Ellenbogen, J. M. TI PREDICTING THE INFLUENCE OF SOUND ON SLEEP SO SLEEP LA English DT Meeting Abstract C1 [Dang-Vu, T.; McKinney, S.; Ellenbogen, J. M.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Dang-Vu, T.] Univ Liege, Cyclotron Res Ctr, Liege, Belgium. [Buxton, O. M.] Harvard Univ, Brigham & Womens Hosp, Dept Med, Sch Med, Boston, MA 02115 USA. [Solet, J. M.] Harvard Univ, Dept Psychol, Sch Med, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0129 BP A46 EP A46 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000131 ER PT J AU Ellenbogen, JM Buxton, OM Merlino, MM Sorenson, PG Solet, JM AF Ellenbogen, J. M. Buxton, O. M. Merlino, M. M. Sorenson, P. G. Solet, J. M. TI AROUSALS IN REM SLEEP WITHOUT EMG CHANGES SO SLEEP LA English DT Meeting Abstract C1 [Ellenbogen, J. M.; Buxton, O. M.; Solet, J. M.] Harvard Univ, Sch Med, Div Sleep Med, Boston, MA USA. [Ellenbogen, J. M.; Merlino, M. M.; Sorenson, P. G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Buxton, O. M.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Solet, J. M.] Cambridge Hlth Alliance, Dept Psychiat, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0929 BP A311 EP A311 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208001412 ER PT J AU Fung, CH Martin, JL Fiorentino, L Josephson, KR Chung, C Jouldjian, S Alessi, CA AF Fung, C. H. Martin, J. L. Fiorentino, L. Josephson, K. R. Chung, C. Jouldjian, S. Alessi, C. A. TI THE RELATIONSHIP BETWEEN SEDATIVE HYPNOTICS USE AND FUNCTIONAL RECOVERY IN OLDER PATIENTS UNDERGOING INPATIENT POST-ACUTE REHABILITATION SO SLEEP LA English DT Meeting Abstract C1 [Fung, C. H.; Chung, C.; Alessi, C. A.] Univ Calif Los Angeles, Multicampus Program Geriatr Med & Gerontol, Los Angeles, CA USA. [Martin, J. L.; Fiorentino, L.; Josephson, K. R.; Jouldjian, S.; Alessi, C. A.] VA Greater Los Angeles Healthcare Syst, GRECC, North Hills, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0846 BP A282 EP A283 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208001331 ER PT J AU Gottlieb, DJ AF Gottlieb, D. J. TI OBSTRUCTIVE SLEEP APNEA WITHOUT SELF-REPORTED SLEEPINESS IS ASSOCIATED WITH INCREASED RISK OF MOTOR VEHICLE ACCIDENTS: AN EPIDEMIOLOGIC STUDY SO SLEEP LA English DT Meeting Abstract C1 [Gottlieb, D. J.] VA Boston Healthcare Syst, Boston, MA USA. [Gottlieb, D. J.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Gottlieb, D. J.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0533 BP A180 EP A180 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208001020 ER PT J AU Grandner, MA Perlis, ML Martin, JL Gehrman, P Patel, NP Xie, D Sha, D Weaver, TE Gooneratne, N AF Grandner, M. A. Perlis, M. L. Martin, J. L. Gehrman, P. Patel, N. P. Xie, D. Sha, D. Weaver, T. E. Gooneratne, N. TI SLEEP COMPLAINTS AND FATIGUE DECLINE ACROSS THE LIFESPAN: GETTING OLDER DOES NOT NECESSARILY MEAN POOR SUBJECTIVE SLEEP AND DAYTIME FATIGUE SO SLEEP LA English DT Meeting Abstract C1 [Xie, D.; Sha, D.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Weaver, T. E.] Univ Penn, Sch Nursing, Biobehav & Hlth Sci Div, Philadelphia, PA 19104 USA. [Gooneratne, N.] Univ Penn, Div Geriatr Med, Philadelphia, PA 19104 USA. [Martin, J. L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Martin, J. L.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Patel, N. P.] Reading Hosp Med Ctr, Reading, PA USA. NR 0 TC 1 Z9 1 U1 0 U2 6 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 1033 BP A345 EP A345 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208001516 ER PT J AU Gvilia, I Angara, B McGinty, DJ Szymusiak, RS AF Gvilia, I Angara, B. McGinty, D. J. Szymusiak, R. S. TI MATURATION OF SLEEP HOMEOSTASIS IN RATS DURING THE FOURTH POSTNATAL WEEK SO SLEEP LA English DT Meeting Abstract C1 [Gvilia, I; Angara, B.; McGinty, D. J.; Szymusiak, R. S.] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, North Hills, CA USA. [Szymusiak, R. S.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [McGinty, D. J.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Gvilia, I] Chavchavadze State Univ, Tbilisi, Rep of Georgia. [Gvilia, I] I Beritashvili Inst Physiol, Tbilisi, Rep of Georgia. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0142 BP A51 EP A51 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000144 ER PT J AU John, J Kodama, T Siegel, J AF John, J. Kodama, T. Siegel, J. TI ROLE OF HISTAMINE IN DISRUPTED SLEEP SO SLEEP LA English DT Meeting Abstract C1 [John, J.; Kodama, T.; Siegel, J.] VA Greater Los Angeles Healthcare Syst, North Hills, CA USA. [John, J.; Siegel, J.] Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0155 BP A55 EP A55 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000157 ER PT J AU Kim, Y Bolortuya, Y Chen, L Basheer, R McCarley, RW Strecker, RE AF Kim, Y. Bolortuya, Y. Chen, L. Basheer, R. McCarley, R. W. Strecker, R. E. TI ALTERATIONS IN ADENOSINERGIC AND ADRENERGIC RECEPTOR mRNA LEVELS OBSERVED IN RESPONSE TO CHRONIC SLEEP RESTRICTION IN RATS SO SLEEP LA English DT Meeting Abstract C1 [Kim, Y.; Bolortuya, Y.; Chen, L.; Basheer, R.; McCarley, R. W.; Strecker, R. E.] VA Boston Healthcare Syst, Brockton, MA USA. [Kim, Y.; Bolortuya, Y.; Chen, L.; Basheer, R.; McCarley, R. W.; Strecker, R. E.] Harvard Univ, Sch Med, Brockton, MA 02401 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0150 BP A53 EP A53 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000152 ER PT J AU Kostin, A Rai, S Kumar, S Szymusiak, RS McGinty, DJ Alam, M AF Kostin, A. Rai, S. Kumar, S. Szymusiak, R. S. McGinty, D. J. Alam, M. TI ROLE OF NITRIC OXIDE IN THE PERIFORNICAL-LATERAL HYPOTHALAMIC AREA IN THE REGULATION OF SLEEP AND WAKEFULNESS SO SLEEP LA English DT Meeting Abstract C1 [Kostin, A.; Rai, S.; Kumar, S.; Szymusiak, R. S.; McGinty, D. J.; Alam, M.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, North Hills, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0247 BP A86 EP A87 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000250 ER PT J AU Kouskov, OS Boudreau, EA O'Hearn, DJ AF Kouskov, O. S. Boudreau, E. A. O'Hearn, D. J. TI EFFECTIVENESS OF ADAPTIVE SERVOVENTILATION IN PATIENTS ON OPIOIDS RESISTANT TO STANDARD POSITIVE AIRWAY PRESSURE THERAPY SO SLEEP LA English DT Meeting Abstract C1 [Kouskov, O. S.; Boudreau, E. A.; O'Hearn, D. J.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 043 BP A145 EP A145 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000426 ER PT J AU Krenzer, M Anaclet, C Lu, J AF Krenzer, M. Anaclet, C. Lu, J. TI PONTINE GLUTAMATERGIC CIRCUIT CONTROLS RAPID-EYE-MOVEMENT SLEEP SO SLEEP LA English DT Meeting Abstract C1 BIDMC, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0148 BP A52 EP A53 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000150 ER PT J AU Lyamin, O Pryaslova, J Mukhametov, L Siegel, J AF Lyamin, O. Pryaslova, J. Mukhametov, L. Siegel, J. TI CIRCADIAN ACTIVITY OF NORTHERN FUR SEALS UNDER THE CONTROLLED LIGHT-DARK CYCLE SO SLEEP LA English DT Meeting Abstract C1 [Lyamin, O.; Siegel, J.] Univ Calif Los Angeles, North Hills, CA USA. [Lyamin, O.; Siegel, J.] VA GLAHS Sepulveda, North Hills, CA USA. [Lyamin, O.; Pryaslova, J.; Mukhametov, L.] Dolphin & I Ltd, Moscow, Russia. [Lyamin, O.; Mukhametov, L.] Severtsov Inst Ecol & Evolut, Moscow, Russia. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0211 BP A73 EP A73 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000213 ER PT J AU Lyamin, O Kibalnikov, A Kosenko, P Mukhametov, L Siegel, J AF Lyamin, O. Kibalnikov, A. Kosenko, P. Mukhametov, L. Siegel, J. TI CARDIO-RESPIRATORY PATTERN OF NORTHERN FUR SEALS DURING SLEEP AND WAKING SO SLEEP LA English DT Meeting Abstract C1 [Lyamin, O.; Siegel, J.] Univ Calif Los Angeles, North Hills, CA USA. [Lyamin, O.; Siegel, J.] VA GLAHS Sepulveda, North Hills, CA USA. [Lyamin, O.; Kosenko, P.; Mukhametov, L.] Dolphin & I Ltd, Moscow, Russia. [Lyamin, O.; Mukhametov, L.] Severtsov Inst Ecol & Evolut, Moscow, Russia. [Kibalnikov, A.] So Sci Ctr, Rostov Na Donu, Russia. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0058 BP A23 EP A23 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000060 ER PT J AU Martin, JL Fiorentino, L Jouldjian, S Josephson, KR Fung, CH Alessi, CA AF Martin, J. L. Fiorentino, L. Jouldjian, S. Josephson, K. R. Fung, C. H. Alessi, C. A. TI RATES AND RISK FACTORS FOR INSOMNIA AMONG OLDER PATIENTS UNDERGOING REHABILITATION SO SLEEP LA English DT Meeting Abstract C1 [Martin, J. L.; Fung, C. H.; Alessi, C. A.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Martin, J. L.; Jouldjian, S.; Josephson, K. R.; Fung, C. H.; Alessi, C. A.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Fiorentino, L.] Univ Calif Los Angeles, Cousins Ctr Psychoneuroimmunol, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 1054 BP A352 EP A352 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208001537 ER PT J AU McKenna, JT Rigby, MS Chen, L Winston, S Yanagawa, Y McCarley, RW Brown, RE AF McKenna, J. T. Rigby, M. S. Chen, L. Winston, S. Yanagawa, Y. McCarley, R. W. Brown, R. E. TI GAD67-GFP KNOCK-IN MICE AS A MODEL SYSTEM FOR INVESTIGATION OF GABAergic NEURONS INVOLVED IN BEHAVIORAL STATE CONTROL SO SLEEP LA English DT Meeting Abstract C1 [McKenna, J. T.; Rigby, M. S.; Chen, L.; Winston, S.; McCarley, R. W.; Brown, R. E.] Harvard Univ, VA Boston Healthcare Syst, Sch Med, Brockton, MA 02401 USA. [Rigby, M. S.] Stonehill Coll, Easton, MA USA. [Yanagawa, Y.] Gunma Univ, Grad Sch Med, Maebashi, Gumma 371, Japan. [Yanagawa, Y.] Japan Sci & Technol Agcy, CREST, Chiyoda Ku, Tokyo, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0137 BP A49 EP A49 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000139 ER PT J AU McKenna, JT Albu, SM Winston, S Yanagawa, Y McCarley, RW Brown, RE AF McKenna, J. T. Albu, S. M. Winston, S. Yanagawa, Y. McCarley, R. W. Brown, R. E. TI GABAergic BRAINSTEM PROJECTIONS TO THE DORSAL RAPHE NUCLEUS IN GAD67-GFP KNOCK-IN MICE: IMPLICATIONS FOR REM SLEEP REGULATION SO SLEEP LA English DT Meeting Abstract C1 [McKenna, J. T.; Albu, S. M.; Winston, S.; McCarley, R. W.; Brown, R. E.] Harvard Univ, VA Boston Healthcare Syst, Sch Med, Brockton, MA 02401 USA. [Albu, S. M.] Wheaton Coll, Norton, MA 02766 USA. [Yanagawa, Y.] Gunma Univ, Grad Sch Med, Maebashi, Gumma 371, Japan. [Yanagawa, Y.] Japan Sci & Technol Agcy, CREST, Chiyoda Ku, Tokyo, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0136 BP A49 EP A49 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000138 ER PT J AU McNally, JM Yanagawa, Y McCarley, RW Brown, RE AF McNally, J. M. Yanagawa, Y. McCarley, R. W. Brown, R. E. TI GAMMA OSCILLATIONS IN MOUSE PREFRONTAL CORTEX SLICES: DEVELOPMENTAL CHANGES SO SLEEP LA English DT Meeting Abstract C1 [McNally, J. M.; McCarley, R. W.; Brown, R. E.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Div Sleep Med, Brockton, MA 02401 USA. [Yanagawa, Y.] Gunma Univ, Grad Sch Med, Maebashi, Gumma 371, Japan. [Yanagawa, Y.] Japan Sci & Technol Agcy, CREST, Tokyo, Japan. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0039 BP A17 EP A17 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000041 ER PT J AU Naeim, D Becker, K Poon, C Hakim, A Santiago, S Zeidler, MR AF Naeim, D. Becker, K. Poon, C. Hakim, A. Santiago, S. Zeidler, M. R. TI GREATER LOS ANGELES VETERANS ASSOCIATION EXPERIENCE WITH MANDIBULAR ADVANCEMENT DEVICES FOR THE TREATMENT OF OBSTRUCTIVE SLEEP APNEA SO SLEEP LA English DT Meeting Abstract C1 [Naeim, D.; Becker, K.; Poon, C.; Hakim, A.; Santiago, S.; Zeidler, M. R.] W Los Angeles VA, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0484 BP A164 EP A164 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000487 ER PT J AU Neylan, TC Mon, A Lenoci, M Metzler, T Meyerhoff, DJ AF Neylan, T. C. Mon, A. Lenoci, M. Metzler, T. Meyerhoff, D. J. TI LOW CORTICAL GABA LEVELS IN PTSD ARE MEDIATED BY POOR SLEEP QUALITY SO SLEEP LA English DT Meeting Abstract C1 [Neylan, T. C.; Mon, A.; Metzler, T.; Meyerhoff, D. J.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Neylan, T. C.; Mon, A.; Lenoci, M.; Metzler, T.; Meyerhoff, D. J.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0695 BP A233 EP A234 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208001181 ER PT J AU Patel, SR Goodloe, R Larkin, EK Gottlieb, DJ Li, Y Buxbaum, S Punjabi, NM Zee, P Zhu, X Redline, S AF Patel, S. R. Goodloe, R. Larkin, E. K. Gottlieb, D. J. Li, Y. Buxbaum, S. Punjabi, N. M. Zee, P. Zhu, X. Redline, S. TI CANDIDATE GENE ANALYSIS FOR OBSTRUCTIVE SLEEP APNEA SO SLEEP LA English DT Meeting Abstract C1 [Patel, S. R.; Goodloe, R.; Larkin, E. K.; Li, Y.; Zhu, X.; Redline, S.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Patel, S. R.] Univ Hosp Case Med Ctr, Cleveland, OH USA. [Larkin, E. K.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Gottlieb, D. J.] Boston Univ, Boston, MA 02215 USA. [Gottlieb, D. J.] VA Boston Hlth Care Syst, Boston, MA USA. [Buxbaum, S.] Jackson State Univ, Jackson, MS USA. [Punjabi, N. M.] Johns Hopkins Univ, Baltimore, MD USA. [Zee, P.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0353 BP A124 EP A124 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000356 ER PT J AU Poeta, DL Christie, M Kim, Y McCarley, RW Strecker, RE McCoy, JG AF Poeta, D. L. Christie, M. Kim, Y. McCarley, R. W. Strecker, R. E. McCoy, J. G. TI EFFECTS OF CHRONIC SLEEP RESTRICTION ON SPATIAL LEARNING AND MEMORY IN RATS SO SLEEP LA English DT Meeting Abstract C1 [Christie, M.; Kim, Y.; McCarley, R. W.; Strecker, R. E.; McCoy, J. G.] Harvard Univ, Sch Med, Brockton, MA 02401 USA. [Christie, M.; Kim, Y.; McCarley, R. W.; Strecker, R. E.; McCoy, J. G.] VA Boston Healthcare Syst, Brockton, MA USA. [Poeta, D. L.; Strecker, R. E.; McCoy, J. G.] Stonehill Coll, Easton, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0117 BP A42 EP A42 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000119 ER PT J AU Ramey, DB Storzbach, D Tun, S Huckans, M O'Hearn, DJ Boudreau, EA AF Ramey, D. B. Storzbach, D. Tun, S. Huckans, M. O'Hearn, D. J. Boudreau, E. A. TI EVALUATION OF SLEEP QUALITY IN OIF/OEF VETERANS WITH A HISTORY OF BLAST EXPOSURE SO SLEEP LA English DT Meeting Abstract C1 [Ramey, D. B.; Storzbach, D.; Tun, S.; Huckans, M.; O'Hearn, D. J.; Boudreau, E. A.] Portland VA Med Ctr, Portland, OR USA. [Ramey, D. B.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0849 BP A283 EP A284 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208001334 ER PT J AU Sasaki, Y Tamaki, M Huang, T Lin, F Hamalainen, M Watanabe, T AF Sasaki, Y. Tamaki, M. Huang, T. Lin, F. Haemaelaeinen, M. Watanabe, T. TI SLOW WAVE ACTIVITY IN MOTOR AREAS DURING SLEEP AFTER TRAINING ON A MOTOR SEQUENCE TASK REVEALED BY A TECHNIQUE OF COMBINING MEG AND MRI SO SLEEP LA English DT Meeting Abstract C1 [Sasaki, Y.; Lin, F.; Haemaelaeinen, M.] Massachusetts Gen Hosp, Charlestown, MA USA. [Tamaki, M.] Waseda Univ, Tokorozawa, Saitama, Japan. [Huang, T.; Watanabe, T.] Boston Univ, Boston, MA 02215 USA. [Tamaki, M.] JSPS, Bunkyo, Japan. [Sasaki, Y.; Lin, F.; Haemaelaeinen, M.] Harvard Univ, Sch Med, Boston, MA USA. RI Hamalainen, Matti/C-8507-2013; Lin, Fa-Hsuan/G-6988-2012 OI Lin, Fa-Hsuan/0000-0002-9539-1731 NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0090 BP A34 EP A34 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000092 ER PT J AU Strecker, RE McKenna, JT Bolortuya, Y Kocsis, B McCarley, RW AF Strecker, R. E. McKenna, J. T. Bolortuya, Y. Kocsis, B. McCarley, R. W. TI MUSCIMOL INACTIVATION OF THE PARABRACHIAL/PRECOERELEAN REGION INCREASES SLEEP IN THE RAT SO SLEEP LA English DT Meeting Abstract C1 [Strecker, R. E.; McKenna, J. T.; Bolortuya, Y.; McCarley, R. W.] Harvard Univ, VA Boston Healthcare Syst, Sch Med, Brockton, MA 02401 USA. [Kocsis, B.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0141 BP A50 EP A50 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000143 ER PT J AU Xi, M Fung, SJ Chase, MH AF Xi, M. Fung, S. J. Chase, M. H. TI PROJECTIONS FROM THE CENTRAL NUCLEUS OF THE AMYGDALA TO NEURONS IN THE NUCLEUS PONTIS ORALIS: AN INTRACELLULAR STUDY SO SLEEP LA English DT Meeting Abstract C1 [Xi, M.; Fung, S. J.; Chase, M. H.] WebSci Int, Los Angeles, CA USA. [Chase, M. H.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Xi, M.; Fung, S. J.; Chase, M. H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0156 BP A55 EP A55 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000158 ER PT J AU Zhang, J Xi, M Fung, SJ Sampogna, S Lim, V Chase, MH AF Zhang, J. Xi, M. Fung, S. J. Sampogna, S. Lim, V Chase, M. H. TI GLUTAMATERGIC NEURONS IN THE CENTRAL NUCLEUS OF THE AMYGDALA PROJECT DIRECTLY TO THE NPO SO SLEEP LA English DT Meeting Abstract C1 [Zhang, J.; Xi, M.; Fung, S. J.; Sampogna, S.; Lim, V; Chase, M. H.] Websci Int, Los Angeles, CA USA. [Zhang, J.; Xi, M.; Fung, S. J.; Lim, V; Chase, M. H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Chase, M. H.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0157 BP A55 EP A56 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000159 ER PT S AU Hirshfeld-Becker, DR AF Hirshfeld-Becker, Dina R. BE Gazelle, H Rubin, KH TI Familial and Temperamental Risk Factors for Social Anxiety Disorder SO SOCIAL ANXIETY IN CHILDHOOD: BRIDGING DEVELOPMENTAL AND CLINICAL PERSPECTIVES SE NEW DIRECTIONS FOR CHILD AND ADOLESCENT DEVELOPMENT LA English DT Article; Book Chapter ID 5-YEAR FOLLOW-UP; 1ST 3 DECADES; BEHAVIORAL-INHIBITION; PANIC DISORDER; PARENTAL PSYCHOPATHOLOGY; PRESCHOOL-CHILDREN; CHILDHOOD SHYNESS; MAJOR DEPRESSION; PHOBIA; LIFE AB Social anxiety disorder (SAD) is a common disorder that can lead to significant impairment. In this chapter, the author provides background on the disorder and reviews hypothesized familial and temperamental risk factors. In particular, it highlights the Massachusetts General Hospital (MGH) Longitudinal Study of Children at Risk for Anxiety, now in its fifteenth year, and describes how this study has identified some factors that contribute to risk for SAD. (C) Wiley Periodicals, Inc. C1 [Hirshfeld-Becker, Dina R.] Massachusetts Gen Hosp, Pediat Psychopharmacol Unit, Boston, MA 02114 USA. [Hirshfeld-Becker, Dina R.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Hirshfeld-Becker, DR (reprint author), Massachusetts Gen Hosp, Pediat Psychopharmacol Unit, Boston, MA 02114 USA. NR 62 TC 5 Z9 5 U1 4 U2 10 PU WILEY PERIODICALS PI SAN FRANCISCO PA 989 MARKET STREET, SAN FRANCISCO, CA 94103-1741 USA SN 1534-8687 BN 978-0-470-61805-9 J9 NEW DIR CHILD ADOLES PY 2010 VL 127 BP 51 EP 65 DI 10.1002/cd.262 PG 15 WC Psychology, Developmental SC Psychology GA BXI21 UT WOS:000296163600004 ER PT J AU Chiu, CJ Wray, LA Beverly, EA Dominic, OG AF Chiu, Ching-Ju Wray, Linda A. Beverly, Elizabeth A. Dominic, Oralia G. TI The role of health behaviors in mediating the relationship between depressive symptoms and glycemic control in type 2 diabetes: a structural equation modeling approach SO SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY LA English DT Article DE Depressive symptoms; Health behaviors; Type 2 diabetes; HbA1c; Structural equation models (SEM) ID CONFIRMATORY FACTOR-ANALYSIS; PLACEBO-CONTROLLED TRIAL; OF-FIT INDEXES; SELF-CARE; MEDICATION ADHERENCE; MAJOR DEPRESSION; DOUBLE-BLIND; SAMPLE-SIZE; WEIGHT-LOSS; BODY-MASS AB Objectives We investigated the longitudinal association between depressive symptoms and glycemic control (HbA1c) in adults with type 2 diabetes, and the extent to which that association was explained by health behaviors. Methods This study assessed data on 998 adults (aged 51 and above) with type 2 diabetes in the US nationally representative Health and Retirement Study and its diabetes-specific mail survey. Participants' depressive symptoms and baseline health behaviors (exercise, body weight control, and smoking status) were collected in 1998. Follow-up health behaviors and the glycemic control outcome were measured at a 2- and 5-year intervals, respectively. Results Nearly one in four of participants (23%) reported moderate or high levels of depressive symptoms at baseline (CES-D score >= 3). Adults with higher levels of depressive symptoms at baseline showed lower scores on baseline and follow-up health behaviors as well as higher HbA1c levels at a 5-year follow-up. Structural equation models (SEM) reveal that health behaviors accounted for 13% of the link between depressive symptoms and glycemic control. Conclusions The long-term relationship between depressive symptoms and glycemic control was supported in the present study. Health behaviors, including exercise, body weight control, and smoking status, explained a sizable amount of the association between depressive symptoms and glycemic control. More comprehensive diabetes selfcare behaviors should be examined with available data. Other competing explicators for the link, such as endocrinological process and antidepressant effects, also warrant further examination. C1 [Chiu, Ching-Ju; Wray, Linda A.] Penn State Univ, Dept Biobehav Hlth, University Pk, PA 16802 USA. [Beverly, Elizabeth A.] Harvard Univ, Sch Med, Joslin Diabet Med Ctr, Boston, MA 02215 USA. [Dominic, Oralia G.] Penn State Univ, Hershey Med Ctr, Hershey, PA 17033 USA. RP Chiu, CJ (reprint author), Penn State Univ, Dept Biobehav Hlth, University Pk, PA 16802 USA. EM cuc197@psu.edu FU National Institute on Diabetes and Digestive and Kidney Disorders [DK078894] FX The authors acknowledge the grant support of National Institute on Diabetes and Digestive and Kidney Disorders. Grant number DK078894 (Linda A. Wray, PI). We acknowledge the valuable statistical consulting help provided by John W. Graham on an earlier version of this paper. The earlier version of this paper was presented at the Society of Behavioral Medicine's 29th annual meeting on March 26-29, 2008 in San Diego, CA. NR 62 TC 19 Z9 19 U1 4 U2 17 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0933-7954 EI 1433-9285 J9 SOC PSYCH PSYCH EPID JI Soc. Psychiatry Psychiatr. Epidemiol. PD JAN PY 2010 VL 45 IS 1 BP 67 EP 76 DI 10.1007/s00127-009-0043-3 PG 10 WC Psychiatry SC Psychiatry GA 547JU UT WOS:000273884200008 PM 19343264 ER PT J AU Tucker, J Ren, X Sapio, F AF Tucker, Joseph Ren, Xin Sapio, Flora TI Incarcerated sex workers and HIV prevention in China: Social suffering and social justice countermeasures SO SOCIAL SCIENCE & MEDICINE LA English DT Article DE Syphilis; HIV; China; Suffering; Stigma; Detention; Prison; Sex workers; Women ID REPUBLIC-OF-CHINA; SEXUALLY-TRANSMITTED-DISEASES; HUMAN-RIGHTS; SYPHILIS INFECTIONS; PUBLIC-HEALTH; DRUG-USERS; HIGH-RISK; PROSTITUTION; VIOLENCE; INTERVENTION AB Sex workers in China are routinely coercively detained through administrative mechanisms outside of legal procedures, but very little is known about the anthropologic and public health context of these policies. This biosocial analysis of female Chinese sex worker detention uses ethnographic, legal, and public health data to describe social suffering and countervailing social justice responses among incarcerated sex workers (ISW) in China. Compared to sex workers not detained in China, ISW face substantive inequalities inscribed in physical and psychological suffering. Chinese sex worker detention camp practices may not only systematically increase HIV/syphilis risk among ISW, but also work to narrow women's social spheres of influence, a particularly cruel tragedy in a Chinese social system that highly values social and personal connections. A limited empiric analysis of Guangxi Province STI clinic data shows that cities detaining sex workers have higher mean HIV prevalence compared to cities that do not detain sex workers. While incipient medical and legal movements in China have generated momentum for expanding ISW services and resources, there is still substantial variation in the implementation of laws that ensure basic life-saving medical treatments. Post-incarceration social justice programs for sex workers linking women to essential STI/HIV resources, reconnecting broken social lives, and helping restore interpersonal relationships are urgently needed. (C) 2009 Elsevier Ltd. All rights reserved. C1 [Tucker, Joseph; Ren, Xin; Sapio, Flora] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. RP Tucker, J (reprint author), Massachusetts Gen Hosp, Div Infect Dis, GRJ 504,55 Fruit St, Boston, MA 02114 USA. EM jtucker4@partners.org NR 94 TC 32 Z9 32 U1 2 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0277-9536 J9 SOC SCI MED JI Soc. Sci. Med. PD JAN PY 2010 VL 70 IS 1 SI SI BP 121 EP 129 DI 10.1016/j.socscimed.2009.10.010 PG 9 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 537QB UT WOS:000273127100015 PM 19880233 ER PT J AU Khan, F Hazin, R Han, Y AF Khan, Faisal Hazin, Ribhi Han, Yuchi TI Apneic Disorders Associated with Heart Failure: Pathophysiology and Clinical Management SO SOUTHERN MEDICAL JOURNAL LA English DT Article DE central sleep apnea; heart failure; obstructive sleep apnea; polysomnogram ID OBSTRUCTIVE SLEEP-APNEA; POSITIVE AIRWAY PRESSURE; CHEYNE-STOKES RESPIRATION; NOCTURNAL OXYGEN-THERAPY; CARDIOVASCULAR-DISEASE; BREATHING DISORDERS; CONTROLLED-TRIAL; RISK-FACTOR; PREVALENCE; WOMEN AB Cardiovascular diseases remain the most common cause of both morbidity and mortality in the industrialized world. The frequency of sleep-related breathing disorders (SRBD) is significantly increased in individuals with cardiovascular diseases such as heart failure. Given the co-morbidities associated with SRBD coexisting with HF, prompt recognition and early management of SRBD is critical to improving the overall prognosis and quality of life in heart failure patients with concomitant SRBD. C1 [Khan, Faisal] Gulf Coast Med Ctr, Neurodiagnost & Sleep Ctr, Wharton, TX USA. Harvard Univ, Dept Arts & Sci, Cambridge, MA 02138 USA. Beth Israel Deaconness Med Ctr, Dept Med, Div Cardiovasc Dis, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. RP Khan, F (reprint author), Gulf Coast Med Ctr, Neurodiagnost & Sleep Ctr, Wharton, TX USA. EM fskhan786@gmail.com NR 69 TC 3 Z9 4 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0038-4348 J9 SOUTH MED J JI South.Med.J. PD JAN PY 2010 VL 103 IS 1 BP 44 EP 50 DI 10.1097/SMJ.0b013e3181c3cd64 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 604OP UT WOS:000278288700011 PM 19996838 ER PT J AU Hess, MJ Foo, DK AF Hess, M. J. Foo, D. K. TI Percutaneous enterogastric tube dislodgement in tetraplegics SO SPINAL CORD LA English DT Article DE enteral feeding; spinal cord injury; acute abdomen; treatment complications ID ENDOSCOPIC GASTROSTOMY; EXPERIENCE; ABDOMEN AB Study design: Case reports describing abdominal complications following percutaneous enteral gastric (PEG) tube placement in three tetraplegics. Objectives: The aim was to increase provider awareness of PEG tube dislodgement as a complication in tetraplegics. Setting: Spinal cord injury center, Veteran's Administration hospital. Methods: The charts of three spinal cord injured veterans with tetraplegia were reviewed for clinical presentation and radiographic findings supporting the diagnosis of acute abdominal complications following PEG tube dislodgement. Results: PEG tube dislodgement in tetraplegics can present with occult findings and lead to disastrous outcomes if the diagnosis is delayed. Conclusion: PEG tube dislodgement should be considered in tetraplegics who develop even subtle abdominal complaints, especially if the injury is complete. Further assessment with computed tomography (CT) scans or fistulograms should be considered to help with decision making. Spinal Cord (2010) 48, 83-84; doi:10.1038/sc.2009.66; published online 30 June 2009 C1 [Hess, M. J.; Foo, D. K.] VA Boston Hlth Care Syst, Spinal Cord Injury Serv, W Roxbury, MA USA. RP Hess, MJ (reprint author), VA Boston Hlth Care, Spinal Cord Injury Serv, 1400 VFW Pkwy, W Roxbury, MA 02132 USA. EM marika.hess@va.gov NR 10 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 J9 SPINAL CORD JI Spinal Cord PD JAN PY 2010 VL 48 IS 1 BP 83 EP 84 DI 10.1038/sc.2009.66 PG 2 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 540QB UT WOS:000273349400016 PM 19564881 ER PT J AU Johnson, T Velez, KA Zhan, E AF Johnson, T. Velez, K. A. Zhan, E. TI Buried bumper syndrome causing rectus abdominis necrosis in a man with tetraplegia SO SPINAL CORD LA English DT Article DE buried bumper syndrome; percutaneous endoscopic gastrostomy; complications; tetraplegia ID PERCUTANEOUS ENDOSCOPIC GASTROSTOMY AB Study design: Case report. Objectives: To enhance the early recognition of buried bumper syndrome in patients with tetraplegia requiring percutaneous endoscopic gastrostomy (PEG). Setting: Inpatient unit, Massachusetts, USA. Methods: A 44 year-old man with C2 American Spinal Injury Association grade A tetraplegia with a relatively recent PEG insertion secondary to poor nutritional intake. Results: Several months after PEG placement, patient became febrile, hypotensive and complained of abdominal pain. Plain films showed a dilated bowel suggestive of ileus. Abdominal and pelvic computed tomography with and without contrast revealed PEG tube dislodgement, and a 21cm x 2.8cm left anterior abdominal wall collection consisting of air and contrast. Upon surgical intervention, the left rectus abdominis sheath and muscle were found to be necrotic. Conclusion: Buried bumper syndrome is a serious complication related to PEG tubes. For many people with tetraplegia, PEG is a life-saving procedure with minimal risks. However, emergencies do occur, making prompt recognition imperative to prevent a fatal sequela. Spinal Cord (2010) 48, 85-86; doi:10.1038/sc.2009.67; published online 16 June 2009 C1 [Johnson, T.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Spinal Cord Injury, W Roxbury, MA 02132 USA. [Johnson, T.; Zhan, E.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA. [Velez, K. A.] Tufts Med Ctr, Dept Phys Med & Rehabil, Boston, MA USA. RP Johnson, T (reprint author), Harvard Univ, Sch Med, VA Boston Healthcare Syst, Spinal Cord Injury, 1400 VFW Pkwy,SCI-128, W Roxbury, MA 02132 USA. EM tova.johnson@va.gov NR 5 TC 2 Z9 2 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 J9 SPINAL CORD JI Spinal Cord PD JAN PY 2010 VL 48 IS 1 BP 85 EP 86 DI 10.1038/sc.2009.67 PG 2 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 540QB UT WOS:000273349400017 PM 19528999 ER PT B AU Simpson, AK Whang, PG Hong, J Ploumis, A Vaccaro, AR AF Simpson, Andrew K. Whang, Peter G. Hong, Joseph Ploumis, Avraam Vaccaro, Alexander R. BE Lin, VW TI Thoracolumbar Fractures SO SPINAL CORD MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION LA English DT Article; Book Chapter ID SPINAL-CORD-INJURY; UPPER THORACIC SPINE; BURST FRACTURES; LUMBAR SPINE; NONOPERATIVE TREATMENT; CLASSIFICATION SYSTEMS; NEUROLOGICAL DEFICIT; SURGICAL-MANAGEMENT; POSTERIOR FIXATION; CONTROLLED-TRIAL C1 [Simpson, Andrew K.] Massachusetts Gen Hosp, Harvard Combined Orthopaed Surg, Boston, MA 02114 USA. [Whang, Peter G.] Yale Univ, Sch Med, Dept Orthopaed & Rehabil, Spine Serv, New Haven, CT 06510 USA. [Vaccaro, Alexander R.] Rothman Inst, Dept Orthopaed, Philadelphia, PA USA. [Ploumis, Avraam] Univ Ioannina, Sch Med, Div Orthopaed & Rehabil, Dept Surg, Ioannia, Greece. RP Simpson, AK (reprint author), Massachusetts Gen Hosp, Harvard Combined Orthopaed Surg, Boston, MA 02114 USA. NR 72 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-19-8 PY 2010 BP 202 EP 211 PG 10 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA BOJ93 UT WOS:000276871800015 ER PT B AU Epstein, LJ Brown, R AF Epstein, Lawrence J. Brown, Robert BE Lin, VW TI Sleep Disorders in Spinal Cord Injury SO SPINAL CORD MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION LA English DT Article; Book Chapter ID PERIODIC LEG MOVEMENTS; APNEA SYNDROME; RESTLESS LEGS; INTRATHECAL BACLOFEN; CIRCADIAN PACEMAKER; NOCTURNAL MYOCLONUS; MELATONIN SECRETION; OXYGEN-SATURATION; PHYSICAL-EXERCISE; LESIONS C1 [Epstein, Lawrence J.] Harvard Univ, Sch Med, Div Sleep Med, Boston, MA 02115 USA. [Epstein, Lawrence J.] Sleep HealthCtr, Boston, MA USA. [Brown, Robert] Massachusetts Gen Hosp, Pulm & Crit Care Med Unit, Pulm Funct Lab, Resp Acute Care Unit, Boston, MA 02114 USA. RP Epstein, LJ (reprint author), Harvard Univ, Sch Med, Div Sleep Med, Boston, MA 02115 USA. NR 82 TC 0 Z9 0 U1 0 U2 3 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-19-8 PY 2010 BP 230 EP 240 PG 11 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA BOJ93 UT WOS:000276871800017 ER PT B AU Stiens, SA Singal, AK Korsten, MA AF Stiens, Steven A. Singal, Ashwani K. Korsten, Mark Allen BE Lin, VW TI The Gastrointestinal System after Spinal Cord Injury: Assessment and Intervention SO SPINAL CORD MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION LA English DT Article; Book Chapter ID ANTEGRADE CONTINENCE ENEMA; GASTROESOPHAGEAL-REFLUX DISEASE; NEUROGENIC BOWEL DYSFUNCTION; MESENTERIC-ARTERY SYNDROME; GASTRIC STRESS ULCERATION; COLONIC TRANSIT-TIME; QUALITY-OF-LIFE; ANORECTAL FUNCTION; ELECTRICAL-STIMULATION; QUADRIPLEGIC PATIENTS C1 [Stiens, Steven A.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Stiens, Steven A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Singal, Ashwani K.] Univ Texas Med Branch, Dept Internal Med, Div Gastroenterol, Galveston, TX USA. [Korsten, Mark Allen] Mt Sinai Sch Med, JJP VA Med Ctr, Dept Internal Med & Gastroenterol, Bronx, NY USA. RP Stiens, SA (reprint author), Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. NR 184 TC 1 Z9 1 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-19-8 PY 2010 BP 382 EP 408 PG 27 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA BOJ93 UT WOS:000276871800031 ER PT B AU Svircev, JN Little, JW AF Svircev, Jelena N. Little, James W. BE Lin, VW TI Syringomyelia SO SPINAL CORD MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION LA English DT Article; Book Chapter ID SPINAL-CORD-INJURY; CHIARI-I MALFORMATION; POST-TRAUMATIC SYRINGOMYELIA; OF-THE-LITERATURE; TERM-FOLLOW-UP; POSTTRAUMATIC SYRINGOMYELIA; SYRINGOPERITONEAL SHUNT; CLINICAL PRESENTATION; SURGICAL-TREATMENT; CYSTIC MYELOPATHY C1 [Svircev, Jelena N.; Little, James W.] Univ Washington, Dept Rehabil Med, Spinal Cord Injury Serv, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Svircev, JN (reprint author), Univ Washington, Dept Rehabil Med, Spinal Cord Injury Serv, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NR 99 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-19-8 PY 2010 BP 569 EP 575 PG 7 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA BOJ93 UT WOS:000276871800042 ER PT B AU Ayyoub, Z Aragaki, DLR AF Ayyoub, Ziyad Aragaki, Dixie Lynne Reiko BE Lin, VW TI Dual Diagnosis: Spinal Cord Injury and Brain Injury SO SPINAL CORD MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION LA English DT Article; Book Chapter ID CLOSED HEAD-INJURY; FATAL TRAFFIC ACCIDENTS; NEUROPSYCHOLOGICAL DEFICITS; INTRACRANIAL-PRESSURE; CERVICAL-SPINE; RISK-FACTORS; TRAUMA; REHABILITATION; COMPLICATIONS; PERSPECTIVE C1 [Ayyoub, Ziyad] Univ Calif Los Angeles, David Geffen Sch Med, Ranchos Los Amigos Natl Rehabil Ctr, Adult Brain Injury Rehabil Program, Los Angeles, CA 90095 USA. [Ayyoub, Ziyad; Aragaki, Dixie Lynne Reiko] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Aragaki, Dixie Lynne Reiko] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. RP Ayyoub, Z (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ranchos Los Amigos Natl Rehabil Ctr, Adult Brain Injury Rehabil Program, Los Angeles, CA 90095 USA. NR 72 TC 0 Z9 0 U1 0 U2 1 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-19-8 PY 2010 BP 580 EP 594 PG 15 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA BOJ93 UT WOS:000276871800044 ER PT J AU Atlas, SJ Tosteson, TD Blood, EA Skinner, JS Pransky, GS Weinstein, JN AF Atlas, Steven J. Tosteson, Tor D. Blood, Emily A. Skinner, Jonathan S. Pransky, Glenn S. Weinstein, James N. TI The Impact of Workers' Compensation on Outcomes of Surgical and Nonoperative Therapy for Patients With a Lumbar Disc Herniation SPORT SO SPINE LA English DT Article DE workers'; compensation; disability; lumbar disc herniation; sciatica; outcomes; treatment; predictors; SPORT ID RESEARCH TRIAL SPORT; LOW-BACK-PAIN; RETURN-TO-WORK; RISK-FACTORS; DISABILITY COMPENSATION; RANDOMIZED-TRIAL; TERM DISABILITY; MONEY MATTERS; SURGERY; SPINE AB Study Design. Prospective randomized and observational cohorts. Objective. To compare outcomes of patients with and without workers' compensation who had surgical and nonoperative treatment for a lumbar intervertebral disc herniation (IDH). Summary of Background Data. Few studies have examined the association between worker's compensation and outcomes of surgical and nonoperative treatment. Methods. Patients with at least 6 weeks of sciatica and a lumbar IDH were enrolled in either a randomized trial or observational cohort at 13 US spine centers. Patients were categorized as workers' compensation or nonworkers' compensation based on baseline disability compensation and work status. Treatment was usual nonoperative care or surgical discectomy. Outcomes included pain, functional impairment, satisfaction and work/disability status at 6 weeks, 3, 6, 12, and 24 months. Results. Combining randomized and observational cohorts, 113 patients with workers' compensation and 811 patients without were followed for 2 years. There were significant improvements in pain, function, and satisfaction with both surgical and nonoperative treatment in both groups. In the nonworkers' compensation group, there was a clinically and statistically significant advantage for surgery at 3 months that remained significant at 2 years. However, in the workers' compensation group, the benefit of surgery diminished with time; at 2 years no significant advantage was seen for surgery in any outcome (treatment difference for SF-36 bodily pain [-5.9; 95% CI: -16.7-4.9] and physical function [5.0; 95% CI: -4.9-15]). Surgical treatment was not associated with better work or disability outcomes in either group. Conclusion. Patients with a lumbar IDH improved substantially with both surgical and nonoperative treatment. However, there was no added benefit associated with surgical treatment for patients with workers' compensation at 2 years while those in the nonworkers' compensation group had significantly greater improvement with surgical treatment. C1 [Atlas, Steven J.] Harvard Univ, Sch Med, Med Serv, Gen Med Div,MA General Hosp, Boston, MA USA. [Tosteson, Tor D.; Blood, Emily A.; Skinner, Jonathan S.; Weinstein, James N.] Dartmouth Med Sch, Lebanon, NH USA. [Pransky, Glenn S.] Liberty Mutual Res Inst, Hopkinton, MA USA. [Weinstein, James N.] Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH USA. RP Atlas, SJ (reprint author), Massachusetts Gen Hosp, Div Gen Med, 50 Staniford St, Boston, MA 02114 USA. EM satlas@partners.org FU Federal and institutional funds; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [P60 AR048094, U01-AR45444]; Office of Women's Health, the National Institutes of Health; National Institute of Occupational Safety and Health, The Centers for Disease Control and Prevention FX Federal and institutional funds were received in support of this work.; The Multidisciplinary Clinical Research Center in Musculoskeletal Diseases is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (P60 AR048094). SPORT (U01-AR45444) was supported by NIAMS, and the Office of Women's Health, the National Institutes of Health, and the National Institute of Occupational Safety and Health, The Centers for Disease Control and Prevention. Address correspondence and reprint requests to Steven J. Atlas, MD, MPH, General Medicine Division, Massachusetts General Hospital, 50 Staniford St, Boston, MA 02114; E-mail: satlas@partners.org NR 40 TC 43 Z9 45 U1 7 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0362-2436 J9 SPINE JI SPINE PD JAN 1 PY 2010 VL 35 IS 1 BP 89 EP 97 DI 10.1097/BRS.0b013e3181c68047 PG 9 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA 551WX UT WOS:000274245200015 PM 20023603 ER PT J AU Atlas, SJ AF Atlas, Steven J. TI In the Eye of the Beholder Preferences of Patients, Family Physicians, and Surgeons for Lumbar Spinal Surgery - Point of View SO SPINE LA English DT Editorial Material ID BACK-PAIN C1 Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA. RP Atlas, SJ (reprint author), Massachusetts Gen Hosp, Div Gen Med, 50 Staniford St,9th Floor, Boston, MA 02114 USA. EM satlas@partners.org FU NIAMS NIH HHS [P60 AR048094-01A10003, P60 AR048094] NR 6 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0362-2436 J9 SPINE JI SPINE PD JAN 1 PY 2010 VL 35 IS 1 BP 116 EP 116 DI 10.1097/BRS.0b013e3181b666f8 PG 1 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA 551WX UT WOS:000274245200020 PM 20824182 ER PT J AU Strasser, B Siebert, U Schobersberger, W AF Strasser, Barbara Siebert, Uwe Schobersberger, Wolfgang TI Resistance Training in the Treatment of the Metabolic Syndrome SO SPORTS MEDICINE LA English DT Review ID IMPAIRED GLUCOSE-TOLERANCE; IMPROVES GLYCEMIC CONTROL; TYPE-2 DIABETES-MELLITUS; RESTING BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE MORTALITY; INTRAABDOMINAL ADIPOSE-TISSUE; LOW CARDIORESPIRATORY FITNESS; RANDOMIZED CONTROLLED-TRIAL; AMERICAN-HEART-ASSOCIATION; LIFE-STYLE INTERVENTION AB Over the last decade, investigators have given increased attention to the effects of resistance training (RT) on several metabolic syndrome variables. The metabolic consequences of reduced muscle mass, as a result of normal aging or decreased physical activity, lead to a high prevalence of metabolic disorders. The purpose of this review is: (i) to perform a meta-analysis of randomized controlled trials (RCTs) regarding the effect of RT on obesity-related impaired glucose tolerance and type 2 diabetes mellitus; and (ii) to investigate the existence of a dose-response relationship between intensity, duration and frequency of RT and the metabolic clustering. Thirteen RCTs were identified through a systematic literature search in MEDLINE ranging from January 1990 to September 2007. We included all RCTs comparing RI with a control group in patients with abnormal glucose regulation. For data analysis, we performed random effects meta-analyses to determine weighted mean differences (WMD) with 95% confidence intervals (CIs) for each end-point. All data were analysed with the software package Review Manager 4.2.10 of the Cochrane Collaboration. In the 13 RCTs included in our analysis, RT reduced glycosylated haemoglobin (HbA(1c)) by 0.48% (95% CI -0.76, -0.21; p = 0.0005), fat mass by 2.33 kg (95% CI -4.71, 0.04; p = 0.05) and systolic blood pressure by 6.19 mmHg (95% CI 1.00, 11.38; p = 0.02). There was no statistically significant effect of RT on total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglyceride and diastolic blood pressure. Based on our meta-analysis, RI has a clinically and statistically significant effect on metabolic syndrome risk factors such as obesity, HbA(1c) levels and systolic blood pressure, and therefore should be recommended in the management of type 2 diabetes and metabolic disorders. C1 [Strasser, Barbara] Univ Hlth Sci Med Informat & Technol, Inst Sport Med Alpine Med & Hlth Tourism, Eduard Wallnofer Zentrum 1, A-6060 Innsbruck, Austria. [Siebert, Uwe] UMIT Univ Hlth Sci Med Informat & Technol, Dept Publ Hlth Med Decis Making & Hlth Technol As, Innsbruck, Austria. [Siebert, Uwe] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Siebert, Uwe] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Program,Inst Technol Assessment, Boston, MA 02115 USA. [Siebert, Uwe] Harvard Univ, Sch Med, Dept Hlth Policy & Management, Program Hlth Decis Sci, Boston, MA 02115 USA. RP Strasser, B (reprint author), Univ Hlth Sci Med Informat & Technol, Inst Sport Med Alpine Med & Hlth Tourism, Eduard Wallnofer Zentrum 1, Hall IT, A-6060 Innsbruck, Austria. EM barbara.strasser@umit.at NR 151 TC 75 Z9 81 U1 4 U2 21 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 0112-1642 J9 SPORTS MED JI Sports Med. PY 2010 VL 40 IS 5 BP 397 EP 415 PG 19 WC Sport Sciences SC Sport Sciences GA 610FQ UT WOS:000278717500004 PM 20433212 ER PT S AU Dzik, W AF (Sunny) Dzik, W. BE Mayr, WR TI Three respiratory gases and the red cell: oxygen, carbon dioxide and nitric oxide SO STATE OF THE ART PRESENTATIONS SE ISBT Science Series LA English DT Proceedings Paper CT 31st International Congress of the International-Society-of-Blood-Transfusion/43rd Congress of the DGTI CY JUN 26-JUL 01, 2010 CL Berlin, GERMANY SP Int Soc Blood Transfus ID HEMOGLOBIN; BLOOD; TRANSPORT; BIOAVAILABILITY; ERYTHROCYTES; DISEASE AB Three vital gases - oxygen, carbon dioxide and nitrogen - intersect at the level of the human red blood cell. The delivery of oxygen to all tissues by red cells is essential to human life. Evolution has created a complex molecule, haemoglobin, designed for efficient uptake and off-loading of oxygen. Iron rests at the centre of the haeme moiety and is critical for oxygen exchange. Although studied for over a century, some details of oxygen transport by the red cell remain uncertain. Recent research has focused on the interaction of haemoglobin with a complex of cell-membrane proteins centred on band 3. In addition, there is renewed interest in the question of whether or not stored red cells deliver oxygen to tissues as well as fresh red cells. The interactions of CO(2) with the red cell have drawn far less research attention. Plasma CO(2) released by tissues serves as an essential trigger for oxygen release by haemoglobin via the Bohr effect. CO(2) transport depends on conversion of CO(2) to bicarbonate via red cell carbonic anhydrase in conjunction with chloride exchange across the red cell membrane. There is very little research on the effect of blood storage on CO(2) excretion although this aspect of respiratory physiology is every bit as important as oxygen delivery. Nitric oxide (NO) physiology is directly related to oxygen delivery by the red cell. NO serves a local vasodilator to increase blood flow to hypoxic tissue beds. NO binds strongly to haemoglobin which serves as an NO sink. Under normal conditions, plasma NO synthesized by endothelial cells is not consumed by red cell haemoglobin because of a diffusion blockade across the red cell membrane that results from membrane structures not fully identified. Under conditions of red cell lysis, free haemoglobin scavenges NO reducing local vasodilation. Scavenging of NO is now recognized as an important component of the physiologic response to chronic haemolysis and is very likely to play an important role in the renal lesion of acute haemolysis. The three RBC gases are also the three principal gases of the Earth's atmosphere. While CO(2) is the least abundant of the three by far, it is also likely to be the most critical to the future survival of life on Earth because small further increases in the concentration of CO(2) will result in continued climate change, and large increases will be deadly. Thus, the management of three vital gases by the collection of red cells found within us has broad similarities to the collective management of our atmosphere. Just as the survival of individual tissue cells depends upon proper balance of these three respiratory gases, so too will their proper balance be the key to survival of life on Earth. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Blood Transfus Serv, Boston, MA 02114 USA. RP Dzik, W (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Blood Transfus Serv, Boston, MA 02114 USA. EM sdzik@partners.org NR 15 TC 0 Z9 0 U1 3 U2 5 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 1751-2816 J9 ISBT SCI SERIES PY 2010 VL 5 IS 1 BP 234 EP 238 PG 5 WC Hematology; Immunology SC Hematology; Immunology GA BSN15 UT WOS:000284993800041 ER PT S AU Depa, M Sabuncu, MR Holmvang, G Nezafat, R Schmidt, EJ Golland, P AF Depa, Michal Sabuncu, Mert R. Holmvang, Godtfred Nezafat, Reza Schmidt, Ehud J. Golland, Polina BE Camara, O Pop, M Rhode, K Sermesant, M Smith, N Young, A TI Robust Atlas-Based Segmentation of Highly Variable Anatomy: Left Atrium Segmentation SO STATISTICAL ATLASES AND COMPUTATIONAL MODELS OF THE HEART SE Lecture Notes in Computer Science LA English DT Proceedings Paper CT 1st International Workshop on Statistical Atlases and Computational Models of the Heart CY SEP 20, 2010 CL Beijing, PEOPLES R CHINA SP Siemens, Siemens Corp Res, Scimedia Brainvision DE Atlas-based segmentation; left atrium segmentation; cardiac segmentation; label fusion; non-rigid registration ID BRAIN; FIBRILLATION; IMAGES; HEART; MODEL AB Automatic segmentation of the heart's left atrium offers great benefits for planning and outcome evaluation of atrial ablation procedures. However, the high anatomical variability of the left atrium presents significant challenges for atlas-guided segmentation. In this paper, we demonstrate an automatic method for left atrium segmentation using weighted voting label fusion and a variant of the demons registration algorithm adapted to handle images with different intensity distributions. We achieve accurate automatic segmentation that is robust to the high anatomical variations in the shape of the left atrium in a clinical dataset of MRA images. C1 [Depa, Michal; Golland, Polina] MIT, Comp Sci & Artificial Intelligence Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA. [Sabuncu, Mert R.] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [Holmvang, Godtfred] Massachusetts Gen Hosp, Cardiac MRI Unit, Boston, MA 02114 USA. [Nezafat, Reza] Beth Israel Deaconess Med Ctr, Dept Med, Div Cardiovasc, Boston, MA 02114 USA. [Schmidt, Ehud J.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA. RP Depa, M (reprint author), MIT, Comp Sci & Artificial Intelligence Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA. FU NAMIC [NIH NIBIB NAMIC U54-EB005149]; NAC [NIH NCRR NAC P41-RR13218]; NSF CAREER [0642971]; Irwin Mark Jacobs and Joan Klein Jacobs Presidential Fellowship; Julie Payette NSERC Research Scholarship; [NIH NINDS R01-NS051826]; [NIH R01EB008743-01A2] FX This research was supported in part by NAMIC (NIH NIBIB NAMIC U54-EB005149), the NAC (NIH NCRR NAC P41-RR13218), the NIH NINDS R01-NS051826 grant, the NSF CAREER 0642971 grant, and the NIH R01EB008743-01A2 grant. Michal Depa was supported by the Irwin Mark Jacobs and Joan Klein Jacobs Presidential Fellowship and the Julie Payette NSERC Research Scholarship. NR 22 TC 14 Z9 14 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0302-9743 BN 978-3-642-15834-6 J9 LECT NOTES COMPUT SC PY 2010 VL 6364 BP 85 EP + PG 3 WC Cardiac & Cardiovascular Systems; Computer Science, Theory & Methods; Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Computer Science; Engineering; Radiology, Nuclear Medicine & Medical Imaging GA BUB44 UT WOS:000288721700009 ER PT J AU Chen, Z Barbieri, R Brown, EN AF Chen, Zhe Barbieri, Riccardo Brown, Emery N. BE Oweiss, KG TI State Space Modeling of Neural Spike Train and Behavioral Data SO STATISTICAL SIGNAL PROCESSING FOR NEUROSCIENCE AND NEUROTECHNOLOGY LA English DT Article; Book Chapter ID SEQUENTIAL MONTE-CARLO; HIPPOCAMPAL PLACE CELLS; KALMAN-FILTER; TIME-SERIES; SENSORY STIMULATION; SOURCE LOCALIZATION; PROSTHETIC DEVICES; DYNAMIC-ANALYSIS; BINARY MEASURES; VISUAL-CORTEX C1 [Chen, Zhe] MIT, Dept Brain & Cognit Sci, Neurosci Stat Res Lab, Cambridge, MA 02139 USA. MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Chen, Z (reprint author), MIT, Dept Brain & Cognit Sci, Neurosci Stat Res Lab, E25-618, Cambridge, MA 02139 USA. OI Barbieri, Riccardo/0000-0001-9381-3833; Chen, Zhe/0000-0002-6483-6056 NR 105 TC 3 Z9 3 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-08-096296-2 PY 2010 BP 175 EP 218 DI 10.1016/B978-0-12-375027-3.00006-5 PG 44 WC Engineering, Biomedical; Engineering, Electrical & Electronic SC Engineering GA BEP80 UT WOS:000317654400007 ER PT J AU Weir, GC Bonner-Weir, S AF Weir, Gordon C. Bonner-Weir, Susan BE Efrat, S TI What Does It Take to Make a Beta Cell? SO STEM CELL THERAPY FOR DIABETES SE Stem Cell Biology and Regenerative Medicine LA English DT Article; Book Chapter ID STIMULATED INSULIN-SECRETION; PANCREATIC-ISLETS; GLUCOSE-CONCENTRATION; DIABETES-MELLITUS; GLUCAGON-RELEASE; PROGENITOR CELLS; IN-VIVO; RAT; LANGERHANS; HUMANS AB As diabetes with its devastating complications results from beta-cell deficiency, there is a compelling need to know more about the culprit. Whereas type 1 diabetes has a near complete loss of beta cells owing to autoimmune destruction, type 2 diabetes is associated with a 40-60% reduction in beta-cell mass. Insulin resistance, brought on by our Western lifestyle coupled with genetic factors, is clearly of major importance, but diabetes only develops when beta-cell deficiency with its associated dysfunctional insulin secretion occurs. Replenishment of beta cells by transplantation or by stimulating regeneration of endogenous islets would eliminate the diabetic state. Improving the dysfunctional insulin secretion of diabetes could also provide help. This chapter is written with an eye toward how beta cells, or some kind of beta-cell surrogate, might function when transplanted. It is important to understand beta cells in their normal pancreatic environment to fully appreciate the compromises that will necessarily accompany beta-cell replacement therapy. C1 [Weir, Gordon C.; Bonner-Weir, Susan] Harvard Univ, Sect Islet Transplantat & Cell Biol, Harvard Stem Cell Inst, Dept Med,Joslin Diabet Ctr,Res Div,Med Sch, Boston, MA 02215 USA. RP Weir, GC (reprint author), Harvard Univ, Sect Islet Transplantat & Cell Biol, Harvard Stem Cell Inst, Dept Med,Joslin Diabet Ctr,Res Div,Med Sch, Boston, MA 02215 USA. EM gordon.weir@joslin.harvard.edu; susan.bonner-weir@joslin.harvard.edu OI Bonner-Weir, Susan/0000-0003-4682-0656 NR 66 TC 1 Z9 1 U1 0 U2 1 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-60761-365-7 J9 STEM CELLS BIOL REG JI Stem Cell Biol. Regen. Med. PY 2010 BP 137 EP 152 DI 10.1007/978-1-60761-366-4_6 D2 10.1007/978-1-60761-366-4 PG 16 WC Developmental Biology SC Developmental Biology GA BMQ39 UT WOS:000273345700006 ER PT J AU Bonner-Weir, S Sharma, A AF Bonner-Weir, Susan Sharma, Arun BE Efrat, S TI Generation of Beta Cells from Pancreatic Duct Cells and/or Stem Cells SO STEM CELL THERAPY FOR DIABETES SE Stem Cell Biology and Regenerative Medicine LA English DT Article; Book Chapter ID INSULIN-SECRETING CELLS; 60-PERCENT PARTIAL-PANCREATECTOMY; ENDOCRINE PROGENITOR CELLS; TYPE-2 DIABETES-MELLITUS; CARBONIC-ANHYDRASE-II; ADULT-MOUSE PANCREAS; GROWTH-FACTOR ALPHA; EXOCRINE PANCREAS; IN-VITRO; TRANSCRIPTION FACTORS AB Since diabetes is caused by the loss of the insulin-producing beta cells, its reversal by replacement of these cells by transplantation or by replenishment from endogenous sources seems straightforward. In the pancreas, two mechanisms for beta-cell growth are replication of preexisting beta cells and neogenesis or the differentiation of new beta cells from progenitor/stem cells that were not beta cells. Replication and neogenesis are not mutually exclusive, and there is no biological reason for there to be only one mechanism for replenishment of the islet cells. This chapter focuses on the renewed interest in the identification, expansion, and differentiation of adult pancreatic progenitor/stem cells that can lead to more beta cells, either in vivo or in vitro. C1 [Bonner-Weir, Susan] Harvard Univ, Sect Islet Transplantat & Cell Biol, Harvard Stem Cell Inst, Joslin Diabet Ctr,Res Div,Med Sch,Dept Med, Boston, MA 02215 USA. RP Bonner-Weir, S (reprint author), Harvard Univ, Sect Islet Transplantat & Cell Biol, Harvard Stem Cell Inst, Joslin Diabet Ctr,Res Div,Med Sch,Dept Med, Boston, MA 02215 USA. EM susan.bonner-weir@joslin.harvard.edu; arun.sharma@joslin.harvard.edu OI Bonner-Weir, Susan/0000-0003-4682-0656 NR 80 TC 1 Z9 1 U1 0 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-60761-365-7 J9 STEM CELLS BIOL REG JI Stem Cell Biol. Regen. Med. PY 2010 BP 167 EP 182 DI 10.1007/978-1-60761-366-4_8 D2 10.1007/978-1-60761-366-4 PG 16 WC Developmental Biology SC Developmental Biology GA BMQ39 UT WOS:000273345700008 ER PT J AU Almandoz, JED Yoo, AJ Stone, MJ Schaefer, PW Oleinik, A Brouwers, HB Goldstein, JN Rosand, J Lev, MH Gonzalez, RG Romero, JM AF Almandoz, Josser E. Delgado Yoo, Albert J. Stone, Michael J. Schaefer, Pamela W. Oleinik, Alexandra Brouwers, H. Bart Goldstein, Joshua N. Rosand, Jonathan Lev, Michael H. Gonzalez, R. Gilberto Romero, Javier M. TI The Spot Sign Score in Primary Intracerebral Hemorrhage Identifies Patients at Highest Risk of In-Hospital Mortality and Poor Outcome Among Survivors SO STROKE LA English DT Article DE CTA spot sign; intracerebral hemorrhage; emergency medicine; outcome ID PREDICTS HEMATOMA EXPANSION; ACTIVATED FACTOR-VII; CT ANGIOGRAPHY; CONTRAST EXTRAVASATION; SAFETY AB Background and Purpose-The spot sign score is a potent predictor of hematoma expansion in patients with primary intracerebral hemorrhage (ICH). We aim to determine the accuracy of this scoring system for the prediction of in-hospital mortality and poor outcome among survivors in patients with primary ICH. Methods-Three neuroradiologists retrospectively reviewed CT angiograms (CTAs) performed in 573 consecutive patients who presented to our Emergency Department with primary ICH over a 9-year period to determine the presence and scoring of spot signs according to strict criteria. Baseline ICH and intraventricular hemorrhage volumes were independently determined by computer-assisted volumetric analysis. Medical records were independently reviewed for baseline clinical characteristics and modified Rankin Scale (mRS) at hospital discharge and 3-month follow-up. Poor outcome among survivors was defined as a mRS >= 4 at 3-month follow-up. Results-We identified spot signs in 133 of 573 CTAs (23.2%), 11 of which were delayed spot signs (8.3%). The presence of any spot sign increased the risk of in-hospital mortality (55.6%, OR 4.0, 95% CI 2.6 to 5.9, P < 0.0001) and poor outcome among survivors at 3-month follow-up (50.8%, OR 2.5, 95% CI 1.4 to 4.3, P < 0.0014). The spot sign score successfully predicted an escalating risk of both outcome measures. In multivariate analysis, the spot sign score was an independent predictor of in-hospital mortality (OR 1.5, 95% CI 1.2 to 1.9, P < 0.0002) and poor outcome among survivors at 3-month follow-up (OR 1.6, 95% CI 1.1 to 2.1, P < 0.0065). Conclusion-The spot sign score is an independent predictor of in-hospital mortality and poor outcome among survivors in primary ICH. (Stroke. 2010;41:54-60.) C1 [Almandoz, Josser E. Delgado; Yoo, Albert J.; Stone, Michael J.; Schaefer, Pamela W.; Lev, Michael H.; Gonzalez, R. Gilberto; Romero, Javier M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Neuroradiol,Dept Radiol, Boston, MA USA. [Oleinik, Alexandra; Brouwers, H. Bart; Rosand, Jonathan] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA. [Oleinik, Alexandra; Brouwers, H. Bart; Rosand, Jonathan] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Human Genet Res, Boston, MA USA. [Goldstein, Joshua N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA. RP Almandoz, JED (reprint author), Washington Univ, Sch Med, Div Neuroradiol, Mallinckrodt Inst Radiol, Campus Box 8131,510 S Kingshighway Blvd, St Louis, MO 63110 USA. EM delgadoj@mir.wustl.edu RI Goldstein, Joshua/H-8953-2016 FU NINDS NIH HHS [K23 NS059774, K23NS059774] NR 18 TC 83 Z9 83 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD JAN PY 2010 VL 41 IS 1 BP 54 EP 60 DI 10.1161/STROKEAHA.109.565382 PG 7 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 537DO UT WOS:000273093400010 PM 19910545 ER PT J AU Pervez, MA Silva, G Masrur, S Betensky, RA Furie, KL Hidalgo, R Lima, F Rosenthal, ES Rost, N Viswanathan, A Schwamm, LH AF Pervez, Muhammad A. Silva, Gisele Masrur, Shihab Betensky, Rebecca A. Furie, Karen L. Hidalgo, Renzo Lima, Fabricio Rosenthal, Eric S. Rost, Natalia Viswanathan, Anand Schwamm, Lee H. TI Remote Supervision of IV-tPA for Acute Ischemic Stroke by Telemedicine or Telephone Before Transfer to a Regional Stroke Center Is Feasible and Safe SO STROKE LA English DT Article DE stroke; telemedicine; thrombolysis ID TISSUE-PLASMINOGEN ACTIVATOR; RT-PA STROKE; CARE; ASSOCIATION; RELIABILITY; SYSTEMS; RECOMMENDATIONS; THROMBOLYSIS; TELESTROKE; EMERGENCY AB Background and Purpose-Because of a shortage of stroke specialists, many outlying or "spoke" hospitals initiate intravenous (IV) thrombolysis using telemedicine or telephone consultation before transferring patients to a regional stroke center (RSC) hub. We analyzed complications and outcomes of patients treated with IV tissue plasminogen activator (tPA) using the "drip and ship" approach compared to those treated directly at the RSC. Methods-A retrospective review of our Get With the Guidelines Stroke (GWTG-Stroke) database from 01/2003 to 03/2008 identified 296 patients who received IV tPA within 3 hours of symptom onset without catheter-based reperfusion. GWTG-Stroke definitions for symptomatic intracranial (sICH), systemic hemorrhage, discharge functional status, and destination were applied. Follow-up modified Rankin Score was recorded when available. Results-Of 296 patients, 181 (61.1%) had tPA infusion started at an outside spoke hospital (OSH) and 115 (38.9%) at the RSC hub. OSH patients were younger with fewer severe strokes than RSC patients. Patients treated based on telestroke were more frequently octogenarians than patients treated based on a telephone consult. Mortality, sICH, and functional outcomes were not different between OSH versus RSC and telephone versus telestroke patients. Among survivors, mean length of stay was shorter for OSH patients but discharge status was similar and 75% of patients walked independently at discharge. Conclusions-Outcomes in OSH "drip and ship" patients treated in a hub-and-spoke network were comparable to those treated directly at an RSC. These data suggest that "drip and ship" is a safe and effective method to shorten time to treatment with IV tPA. (Stroke. 2010;41:e18-e24.) C1 [Schwamm, Lee H.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Betensky, Rebecca A.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. RP Schwamm, LH (reprint author), Massachusetts Gen Hosp, Dept Neurol, WACC 720,55 Fruit St, Boston, MA 02114 USA. EM lschwamm@partners.org OI Schwamm, Lee/0000-0003-0592-9145; Rosenthal, Eric/0000-0003-3900-356X FU AHRQ HHS [R01 HS011392, R01HS011392]; NCI NIH HHS [R01 CA075971, R01 CA075971-11]; NINDS NIH HHS [P50 NS051343, P50 NS051343-01A2] NR 38 TC 78 Z9 78 U1 2 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD JAN PY 2010 VL 41 IS 1 BP E18 EP E24 DI 10.1161/STROKEAHA.109.560169 PG 7 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 537DO UT WOS:000273093400040 PM 19910552 ER PT J AU Broyles, LM Gordon, AJ AF Broyles, Lauren M. Gordon, Adam J. TI SBIRT Implementation: Moving Beyond the Interdisciplinary Rhetoric SO SUBSTANCE ABUSE LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; EMERGENCY-DEPARTMENT; BRIEF INTERVENTIONS; COST-EFFECTIVENESS; PROBLEM DRINKERS; PRIMARY-CARE; ALCOHOL; NURSES C1 [Broyles, Lauren M.; Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Broyles, Lauren M.; Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. [Broyles, Lauren M.; Gordon, Adam J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Gordon, Adam J.] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA USA. RP Broyles, LM (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. NR 12 TC 13 Z9 13 U1 0 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 J9 SUBST ABUS JI Subst. Abus. PY 2010 VL 31 IS 4 BP 221 EP 223 AR PII 928725868 DI 10.1080/08897077.2010.514238 PG 3 WC Substance Abuse SC Substance Abuse GA 674KU UT WOS:000283742600001 PM 21038175 ER PT J AU Lalla, RV Pilbeam, CC Walsh, SJ Sonis, ST Keefe, DMK Peterson, DE AF Lalla, Rajesh V. Pilbeam, Carol C. Walsh, Stephen J. Sonis, Stephen T. Keefe, Dorothy M. K. Peterson, Douglas E. TI Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study SO SUPPORTIVE CARE IN CANCER LA English DT Article DE Mucositis; Chemotherapy; Hematopoetic stem cell transplant; Cyclooxygenase; Prostaglandin ID BONE-MARROW-TRANSPLANTATION; ECONOMIC OUTCOMES; COX-2 EXPRESSION; CANCER-THERAPY; HOST-DISEASE; RADIATION; IRRADIATION; ALPHA; INDEX; LUNG AB Oral mucositis can be a significant and dose-limiting complication of high-dose cancer therapy. Mucositis is a particularly severe problem in patients receiving myeloablative chemotherapy prior to bone marrow or hematopoetic stem cell transplant (HSCT). The cyclooxygenase (COX) pathway mediates tissue injury and pain through upregulation of pro-inflammatory prostaglandins, including prostaglandin E2 (PGE2) and prostacyclin (PGI2). The objective of this small (n = 3) pilot study was to examine the role of the COX pathway in causing mucosal injury and pain in chemotherapy-induced oral mucositis. We collected blood, saliva, and oral mucosal biopsy specimens from three autologous HSCT patients at the following time-points before and after administration of conditioning chemotherapy: Day -10, +10, +28, and +100, where day 0 is day of transplant. RNA extracted from full-thickness tissue samples was measured by RT-PCR for the following: COX-1, COX-2, microsomal prostaglandin E synthase (mPGES), IL-1 beta, and TNF-alpha. Blood and saliva samples were measured by ELISA for PGE2 and PGI2, which are markers of COX activity. Severity of oral mucositis was determined using the Oral Mucositis Index. Severity of pain due to oral mucositis was measured using a Visual Analog Scale. Relationships between the different variables were examined using Spearman rank correlation coefficients. Mean mucositis and pain scores increased significantly after administration of chemotherapy and then gradually declined. The correlation between changes in mucositis and pain scores was strong and statistically significant. The following additional correlations were statistically significant: between tissue COX-1 and pain; between tissue mPGES and pain; between salivary PGE1 and pain; between salivary PGI2 and pain. Other relationships were not statistically significant. Our finding of significant associations of pain scores with tissue COX-1 and mPGES, as well as salivary prostaglandins, is suggestive of a role for the cyclooxygenase pathway in mucositis, possibly via upregulation of pro-inflammatory prostaglandins. However, our small sample size may have contributed to the lack of significant associations between COX-2 and other inflammatory mediators with mucosal injury and pain. Thus, additional studies with larger numbers of subjects are warranted to confirm the involvement of the cyclooxygenase pathway in chemotherapy-induced mucositis. C1 [Lalla, Rajesh V.; Peterson, Douglas E.] Univ Connecticut, Ctr Hlth, Neag Comprehens Canc Ctr,Sect Oral Med, Head & Neck Oral Oncol Program,Dept Oral Hlth & D, Farmington, CT 06030 USA. [Pilbeam, Carol C.] Univ Connecticut, Ctr Hlth, Dept Med, Div Endocrinol & Metab, Farmington, CT 06030 USA. [Walsh, Stephen J.] Univ Connecticut, Sch Nursing, Storrs, CT 06269 USA. [Sonis, Stephen T.] Harvard Univ, Sch Dent Med, Brigham & Womens Hosp,Dept Oral Med, Dana Farber Canc Inst,Div Oral Med & Dent, Boston, MA 02115 USA. [Keefe, Dorothy M. K.] Univ Adelaide, Dept Med, Fac Hlth Sci, Adelaide, SA 5001, Australia. RP Lalla, RV (reprint author), Univ Connecticut, Ctr Hlth, Neag Comprehens Canc Ctr,Sect Oral Med, Head & Neck Oral Oncol Program,Dept Oral Hlth & D, MC 1605,Room L6062,263 Farmington Ave, Farmington, CT 06030 USA. EM Lalla@uchc.edu FU NIH [T32DE007302, K23DE016946, M01RR06192] FX Dr. Lalla's effort on this research was supported by grants T32DE007302 and K23DE016946 from the NIH. This research was supported in part by a General Clinical Research Center (GCRC) grant (M01RR06192) from the NIH awarded to the University of Connecticut Health Center. We thank Ms. Pamela Fall, Ms. Christine Abreu and Dr. Jonathan Covault of the GCRC Core Laboratory for implementation of the quantitative RT-PCR and ELISA analyses. We thank Ms. Kim Jennings of the GCRC Clinical Core for study coordination and data entry. NR 31 TC 17 Z9 17 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0941-4355 J9 SUPPORT CARE CANCER JI Support. Care Cancer PD JAN PY 2010 VL 18 IS 1 BP 95 EP 103 DI 10.1007/s00520-009-0635-1 PG 9 WC Oncology; Health Care Sciences & Services; Rehabilitation SC Oncology; Health Care Sciences & Services; Rehabilitation GA 521YR UT WOS:000271963100013 PM 19404685 ER PT J AU Wielgus, J Sarr, MG Warshaw, AL Harken, AH AF Wielgus, Jamie Sarr, Michael G. Warshaw, Andrew L. Harken, Alden H. TI Words, words, words SO SURGERY LA English DT Editorial Material C1 [Wielgus, Jamie] Editorial Off Journal Surg, Plymouth, MA 02360 USA. [Wielgus, Jamie] Dept Surg, Plymouth, MA 02360 USA. [Sarr, Michael G.] Mayo Clin, Rochester, MN USA. [Warshaw, Andrew L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Harken, Alden H.] Univ Calif San Francisco E Bay, Oakland, CA USA. RP Wielgus, J (reprint author), Editorial Off Journal Surg, 20 North St,Suite 1, Plymouth, MA 02360 USA. EM jwielgus@stellarmed.com NR 3 TC 3 Z9 3 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-6060 J9 SURGERY JI Surgery PD JAN PY 2010 VL 147 IS 1 BP 138 EP 139 DI 10.1016/j.surg.2009.08.014 PG 2 WC Surgery SC Surgery GA 543AC UT WOS:000273540500019 PM 20082799 ER PT J AU Sogg, S AF Sogg, Stephanie TI Comprehensive interview assessment of eating behavior 18-35 months after gastric bypass surgery for morbid obesity SO SURGERY FOR OBESITY AND RELATED DISEASES LA English DT Editorial Material C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Weight Ctr, Boston, MA 02114 USA. RP Sogg, S (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Weight Ctr, Boston, MA 02114 USA. NR 19 TC 2 Z9 2 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1550-7289 EI 1878-7533 J9 SURG OBES RELAT DIS JI Surg. Obes. Relat. Dis. PD JAN-FEB PY 2010 VL 6 IS 1 BP 85 EP 87 PG 3 WC Surgery SC Surgery GA V30LF UT WOS:000208816800018 PM 19889583 ER PT J AU Jakobiec, FA Pineda, R Rivera, R Hsu-Winges, C Cherwek, D AF Jakobiec, Frederick A. Pineda, Roberto Rivera, Roxana Hsu-Winges, Charlene Cherwek, David TI Epicorneal Polypoidal Lipodermoid: Lack of Association of Central Corneal Lesions with Goldenhar Syndrome Verified with a Review of the Literature SO SURVEY OF OPHTHALMOLOGY LA English DT Review DE arrector pili; cornea; epibulbar choristoma; Fishman syndrome; Goldenhar syndrome; lacrimal choristoma; limbus; lipodermid; Proteus syndrome ID ENCEPHALOCRANIOCUTANEOUS LIPOMATOSIS; DERMOIDS; CHORISTOMAS; MANIFESTATIONS; EXTENSION; SPECTRUM; NEVUS AB It is remarkable to uncover a new aspect of congenital epibulbar solid dermoids and lipodermoids. We describe a dramatic central epicorneal polypoidal lipodermoid colobonia accompanied by an upper eyelid colobonia that was not associated with Goldenhar syndrome. Histopathologically the excised lesion displayed superficial layers of epidermis and a thin dermis with eccrine glands, vestigial hair structures, and bundles of arrector pili smooth muscle that extended from the undersurface of the epidermis to the bulge area of the primitive hairs. This last feature is not present in normal eyelid skin nor in the conjunctiva, and has not been previously documented to occur in epibulbar dermoids and lipodermoids. S-100-positive dendritic melanocytes and CD1a-positive Langerhans cells were both observed intraepidermally, indicating a complete complement of normal cells in this layer. Beneath the dermis was a massive collection of lobules of mature adipose tissue that fused with the corneal stroma. A virtually identical pedunculated limbal tumor has been previously reported that was associated with Goldenhar syndrome. Review of earlier published cases of epibulbar dermoids and lipodermoids establishes that central corneal lesions are not a stigma of Goldenhar syndrome, in contrast to limbal masses. Other epibulbar choristomas that can be confused with lipodermoids are described. (Surv Ophthalmol 55:78-84, 2010. (C) 2010 Elsevier Inc. All rights reserved.) C1 [Jakobiec, Frederick A.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Eye Pathol Lab,Dept Ophthalmol, Boston, MA 02114 USA. [Rivera, Roxana; Cherwek, David] ORBIS Int, New York, NY USA. [Hsu-Winges, Charlene] Kaiser Permanente, Dept Ophthalmol, San Francisco, CA USA. RP Jakobiec, FA (reprint author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Eye Pathol Lab,Dept Ophthalmol, 243 Charles St,Room 321, Boston, MA 02114 USA. EM Jakobiec@meei.harvard.edu NR 31 TC 6 Z9 6 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-6257 J9 SURV OPHTHALMOL JI Surv. Ophthalmol. PD JAN-FEB PY 2010 VL 55 IS 1 BP 78 EP 84 DI 10.1016/j.survophthal.2009.05.002 PG 7 WC Ophthalmology SC Ophthalmology GA 543AG UT WOS:000273541000005 PM 19783022 ER PT S AU Vianello, F Righi, E Poznansky, MC AF Vianello, Fabrizio Righi, Elda Poznansky, Mark C. BE MarelliBerg, FM Nourshargh, S TI Methods for Quantitation of Leukocyte Chemotaxis and Fugetaxis SO T-CELL TRAFFICKING: METHODS AND PROTOCOLS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Chemotaxis; fugetaxis; in vivo imaging; lymphocyte trafficking ID IN-VIVO; ACTIVE MOVEMENT; T-CELLS; CHEMOKINES; SEMAPHORINS; MIGRATION; CHEMOREPELLENT; CHEMOREPULSION; GRADIENTS; CYTOKINES AB Chemoattraction and chemorepulsion are complex directional responses of a cell to external chemotactic stimuli. The decision of a cell to move towards or away from a chemokinetic source includes detection and quantitation of the gradient of the chemotactic agent, biochemical transmission of the stimulus, and translation into a directional migration. This chapter describes a number of in vitro and in vivo assays that can be used to generate and measure both chemoattraction and chemorepulsion of leucocytes. These tools may eventually allow the further characterisation of the mechanism of this complex-and physiologically and pathologically important phenomenon. C1 [Vianello, Fabrizio] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Haematol, London, England. [Righi, Elda; Poznansky, Mark C.] Harvard Univ, Infect Dis Unit, Massachusetts Gen Hosp, Sch Med, Charlestown, MA USA. [Righi, Elda; Poznansky, Mark C.] Harvard Univ, DFCI Harvard Canc Ctr, Massachusetts Gen Hosp, Sch Med, Charlestown, MA USA. RP Vianello, F (reprint author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Haematol, London, England. RI Vianello, Fabrizio/M-5211-2016 OI Vianello, Fabrizio/0000-0002-7174-4651 NR 23 TC 0 Z9 0 U1 0 U2 3 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-60761-460-9 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2010 VL 616 BP 115 EP 124 DI 10.1007/978-1-60761-461-6_8 PG 10 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BRC25 UT WOS:000282336200008 PM 20379872 ER PT S AU Mempel, TR AF Mempel, Thorsten R. BE MarelliBerg, FM Nourshargh, S TI Single-Cell Analysis of Cytotoxic T Cell Function by Intravital Multiphoton Microscopy SO T-CELL TRAFFICKING: METHODS AND PROTOCOLS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Cytotoxic T lymphocytes; T cell receptor; cytotoxicity; multiphoton intravital microscopy; in vivo imaging; popliteal lymph node; tumor; surrogate target cells AB Novel nonlinear optical imaging modalities, most prominently multiphoton microscopy, allow for the direct in vivo visualization of dynamic biological processes in experimental animals at high spatial and temporal resolution. This has led to important new insights into the orchestration of adaptive immune responses. Here we describe in detail a technique that allows for the monitoring of the cytotoxic function of CD8(+) effector T cells in tumor-draining lymph nodes of mice at the single-cell level in vivo using multiphoton intravital microscopy. C1 [Mempel, Thorsten R.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Charlestown, MA USA. [Mempel, Thorsten R.] Massachusetts Gen Hosp, Ctr Syst Biol, Charlestown, MA USA. [Mempel, Thorsten R.] Harvard Univ, Sch Med, Charlestown, MA USA. RP Mempel, TR (reprint author), Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Charlestown, MA USA. NR 8 TC 2 Z9 2 U1 0 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-60761-460-9 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2010 VL 616 BP 181 EP 192 DI 10.1007/978-1-60761-461-6_12 PG 12 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BRC25 UT WOS:000282336200012 PM 20379876 ER PT J AU An, PG Ashburner, JM Fosburgh, BW Atlas, SJ AF An, Perry G. Ashburner, Jeffrey M. Fosburgh, Blair W. Atlas, Steven J. TI Performance on Preventive Cancer Screening Tests in the Ambulatory Setting by Internal Medicine Resident Physicians SO TEACHING AND LEARNING IN MEDICINE LA English DT Article ID PRIMARY-CARE; OUTCOMES AB Background: Limited information exists about the quality and determinants of ambulatory care by resident physicians. Description: This study investigated whether year of training and primary care versus traditional categorical status for internal medicine residents influenced preventive cancer screening rates. Ambulatory patients cared for by 143 internal medicine residents in one program over a 1-year period were assessed. Patients eligible for breast, cervical, and colorectal cancer screening were identified and test completion status was assessed. Patients who had not yet completed screening and had a visit with the resident physician were prospectively followed for subsequent test completion. Cancer screening rates, overall and among those overdue, were compared controlling for baseline patient characteristics. Evaluation: Among 3,729 patients, overall test completion rates for breast (72%), cervical (75%), and colorectal cancer screening (56%) did not differ by year of training or type of training (primary care vs. categorical). Among patients overdue for a screening test, no association was found by resident year of training or primary care versus categorical status: 22% vs. 12% for colorectal (p = .08), 46% versus 28% for breast (p = .69), and 24% versus 19% for cervical cancer (p = .61), respectively. Conclusions: Neither resident physician type of training nor year of training were found to be associated with cancer screening rates in the ambulatory setting. Future research should seek to identify physician factors and educational strategies to augment system-based efforts to improve the quality of outpatient care by resident physicians. C1 [An, Perry G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Med Serv, Boston, MA USA. [Ashburner, Jeffrey M.; Fosburgh, Blair W.; Atlas, Steven J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gen Med, Boston, MA USA. RP An, PG (reprint author), 107 Charlesbank Rd, Newton, MA 02458 USA. EM perryan@post.harvard.edu FU Massachusetts General Hospital Primary Care Operations Improvement program FX This article was presented in part at the annual meeting of the Society of General Internal Medicine, Toronto, Ontario in April 2007. This work was supported by institutional funding through the Massachusetts General Hospital Primary Care Operations Improvement program. We are grateful to Nancy Wong for her assistance in data acquisition and statistical analysis. NR 16 TC 1 Z9 1 U1 0 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1040-1334 J9 TEACH LEARN MED JI Teach. Learn. Med. PY 2010 VL 22 IS 1 BP 45 EP 49 DI 10.1080/10401330903446362 PG 5 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 575EH UT WOS:000276049000008 PM 20391283 ER PT J AU McLean, CP Miller, NA AF McLean, Carmen P. Miller, Nathan A. TI Changes in Critical Thinking Skills Following a Course on Science and Pseudoscience: A Quasi-Experimental Study SO TEACHING OF PSYCHOLOGY LA English DT Article ID PSYCHOLOGICAL CRITICAL THINKING; PARANORMAL PHENOMENA; IMPROVE; BELIEF AB We assessed changes in paranormal beliefs and general critical thinking skills among students (n = 23) enrolled in an experimental course designed to teach distinguishing science from pseudoscience and a comparison group of students (n = 30) in an advanced research methods course. On average, both courses were successful in reducing paranormal beliefs and increasing both abstract and psychology-specific critical thinking skills. However, the only difference that emerged between the courses was that the experimental course was superior with regard to reducing specific paranormal beliefs. C1 [McLean, Carmen P.; Miller, Nathan A.] Univ Nebraska, Lincoln, NE 68583 USA. RP McLean, CP (reprint author), Boston VA Healthcare Syst, Natl Ctr PTSD, 150 S Huntington Ave,116B-5, Boston, MA 02130 USA. EM Carmen.McLean@va.gov NR 25 TC 14 Z9 14 U1 2 U2 11 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0098-6283 J9 TEACH PSYCHOL JI Teach. Psychol. PY 2010 VL 37 IS 2 BP 85 EP 90 DI 10.1080/00986281003626714 PG 6 WC Education & Educational Research; Psychology, Multidisciplinary SC Education & Educational Research; Psychology GA 575VX UT WOS:000276098600002 ER PT J AU Dolinsky, B Kelley, JM AF Dolinsky, Beverly Kelley, John M. TI For Better or for Worse: Using an Objective Program Assessment Measure to Enhance an Undergraduate Psychology Program SO TEACHING OF PSYCHOLOGY LA English DT Article AB We describe how an objective form of measurement can be used to promote curriculum review, resulting in enhancements to curriculum and pedagogy. During a 4-year period, senior psychology majors took the ETS Major Field Test, and we systematically compared these results to SAT scores, grade point averages, and credits completed. Although diligent, honest, and sometimes frustrating analysis of the comparative results of our students' performance was necessary, the positive outcomes included a more structured curriculum within the psychology major, increased collaboration among faculty, and enhanced student learning experiences. C1 [Dolinsky, Beverly] Endicott Coll, Dept Psychol, Beverly, MA 01915 USA. [Kelley, John M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cambridge, MA 02138 USA. RP Dolinsky, B (reprint author), Endicott Coll, Dept Psychol, 376 Hale St, Beverly, MA 01915 USA. EM bdolinsk@endicott.edu NR 17 TC 1 Z9 1 U1 0 U2 1 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0098-6283 J9 TEACH PSYCHOL JI Teach. Psychol. PY 2010 VL 37 IS 4 BP 252 EP 256 AR PII 927940059 DI 10.1080/00986283.2010.510978 PG 5 WC Education & Educational Research; Psychology, Multidisciplinary SC Education & Educational Research; Psychology GA 662MX UT WOS:000282812500003 ER PT J AU Lowman, J Judge, AM Wiss, C AF Lowman, Joseph Judge, Abigail M. Wiss, Charles TI Lurking on the Internet: A Small-Group Assignment That Puts a Human Face on Psychopathology SO TEACHING OF PSYCHOLOGY LA English DT Editorial Material ID PSYCHOLOGICAL DISORDERS; ABNORMAL-PSYCHOLOGY; STUDENTS AB Lurking on the Internet aims to put a human face on psychopathology for the abnormal psychology course. Student groups are assigned major diagnostic categories and instructed to search the Internet for discussion forums, individual blogs, or YouTube videos where affected individuals discuss their symptoms and lives. After discussing the ethics of passively observing public sites, students monitor relevant sites throughout the term and evaluate what they are learning in class from the perspective of affected individuals. At the end of the term, students submit individual papers based on their observations. Periodically, individual groups are given opportunities to share their findings and, depending on the size of the class, to make formal presentations. C1 [Lowman, Joseph; Wiss, Charles] Univ N Carolina, Chapel Hill, NC 27599 USA. [Judge, Abigail M.] Massachusetts Gen Hosp, Children & Law Program, Boston, MA 02114 USA. RP Lowman, J (reprint author), Univ N Carolina, CB 3270,Davie Hall, Chapel Hill, NC 27599 USA. EM jclow-man@unc.edu NR 8 TC 1 Z9 1 U1 0 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0098-6283 J9 TEACH PSYCHOL JI Teach. Psychol. PY 2010 VL 37 IS 4 BP 267 EP 270 AR PII 927941197 DI 10.1080/00986283.2010.510960 PG 4 WC Education & Educational Research; Psychology, Multidisciplinary SC Education & Educational Research; Psychology GA 662MX UT WOS:000282812500006 ER PT J AU Tuerk, PW Fortney, J Bosworth, HB Wakefield, B Ruggiero, KJ Acierno, R Frueh, BC AF Tuerk, Peter W. Fortney, John Bosworth, Hayden B. Wakefield, Bonnie Ruggiero, Kenneth J. Acierno, Ron Frueh, B. Christopher TI Toward the Development of National Telehealth Services: The Role of Veterans Health Administration and Future Directions for Research SO TELEMEDICINE JOURNAL AND E-HEALTH LA English DT Editorial Material DE telehealth technology; Veterans Health Administration; National Institutes of Health; national telehealth services ID RANDOMIZED-TRIAL; HOME TELEHEALTH; DEPRESSION; CARE AB The Veterans Health Administration (VHA) in the Department of Veteran Affairs (VA) has emerged as a national and international leader in the delivery and research of telehealth-based treatment. Several unique characteristics of care in VA settings intersect to create an ideal environment for telehealth modalities and research. However, the value of telehealth experience and initiatives in VA settings is limited if telehealth strategies cannot be widely exported to other public or private systems. Whereas a hierarchical organization, such as VA, can innovate and fund change relatively quickly based on provider and patient preferences and a growing knowledge base, other health provider organizations and third-party payers may likely require replicable scientific findings over time before incremental investments will be made to create infrastructure, reform regulatory barriers, and amend laws to accommodate expansion of telehealth modalities. Accordingly, large-scale scientifically rigorous telehealth research in VHA settings is essential not only to investigate the efficacy of existing and future telehealth practices in VHA, but also to hasten the development of telehealth infrastructure in private and other public health settings. We propose an expanded partnership between the VA, NIH, and other funding agencies to investigate creative and pragmatic uses of telehealth technology. To this end, we identify six specific areas of research we believe to be particularly relevant to the efficient development of telehealth modalities in civilian and military contexts outside VHA. C1 [Tuerk, Peter W.; Ruggiero, Kenneth J.; Acierno, Ron] Med Ctr, Ralph H Johnson Vet Adm, Charleston, SC 29401 USA. [Tuerk, Peter W.; Ruggiero, Kenneth J.; Acierno, Ron] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Fortney, John] Cent Arkansas Vet Healthcare Syst, VA S Cent Mental Illness Res Educ & Clin Ctr MIRE, N Little Rock, AR USA. [Fortney, John] Univ Arkansas Med Sci, Div Hlth Serv Res, Dept Psychiat, Coll Med, Little Rock, AR 72205 USA. [Bosworth, Hayden B.] Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA. [Bosworth, Hayden B.] Duke Univ, Dept Med, Durham, NC USA. [Bosworth, Hayden B.] Duke Univ, Dept Psychiat, Durham, NC 27706 USA. [Bosworth, Hayden B.] Duke Univ, Dept Nursing, Durham, NC 27706 USA. [Wakefield, Bonnie] Iowa City VA Med Ctr, Ctr Implementat Innovat Strategies Practice, Iowa City, IA USA. [Frueh, B. Christopher] Univ Hawaii, Dept Psychol, Hilo, HI 96720 USA. RP Tuerk, PW (reprint author), Med Ctr, Ralph H Johnson Vet Adm, 109 Bee St, Charleston, SC 29401 USA. EM Peter.Tuerk@VA.GOV NR 8 TC 12 Z9 12 U1 1 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-5627 J9 TELEMED J E-HEALTH JI Telemed. J. e-Health PD JAN-FEB PY 2010 VL 16 IS 1 BP 115 EP 117 DI 10.1089/tmj.2009.0144 PG 3 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 551BV UT WOS:000274181600020 PM 20043704 ER PT B AU Marneros, AG Bickers, DR AF Marneros, Alexander G. Bickers, David R. BE Krieg, T Bickers, DR Miyachi, Y TI Nonmelanoma Skin Cancer SO THERAPY OF SKIN DISEASES: A WORLDWIDE PERSPECTIVE APPROACHES AND THEIR MOLECULAR BASIS LA English DT Article; Book Chapter ID BASAL-CELL-CARCINOMA; IMIQUIMOD 5-PERCENT CREAM; MOHS MICROGRAPHIC SURGERY; AMINOLEVULINATE-PHOTODYNAMIC THERAPY; ORGAN TRANSPLANT RECIPIENTS; 5-YEAR FOLLOW-UP; HUMAN-PAPILLOMAVIRUS INFECTION; MULTIPLE ACTINIC KERATOSES; INDUCED P53 MUTATIONS; SITU BOWENS-DISEASE C1 [Marneros, Alexander G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol,Cutaneous Biol Res Ctr, Boston, MA 02129 USA. [Bickers, David R.] New York Presbyterian Hosp, New York, NY 10032 USA. RP Marneros, AG (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol,Cutaneous Biol Res Ctr, Bldg 149,Room 3-216,13th St, Boston, MA 02129 USA. EM amarneros@partners.org; drb25@columbia.edu; drb25@columbia.edu NR 134 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-3-540-78813-3 PY 2010 BP 599 EP 620 DI 10.1007/978-3-540-78814-0_11.1 D2 10.1007/978-3-540-78814-0 PG 22 WC Dermatology SC Dermatology GA BNK93 UT WOS:000274824900053 ER PT J AU Halassa, MM Dal Maschio, M Beltramo, R Haydon, PG Benfenati, F Fellin, T AF Halassa, Michael M. Dal Maschio, Marco Beltramo, Riccardo Haydon, Philip G. Benfenati, Fabio Fellin, Tommaso TI Integrated Brain Circuits: Neuron-Astrocyte Interaction in Sleep-Related Rhythmogenesis SO THESCIENTIFICWORLDJOURNAL LA English DT Article DE glia; sleep; slow oscillations; adenosine; A1 receptors; cortical rhythms AB Although astrocytes are increasingly recognized as important modulators of neuronal excitability and information transfer at the synapse, whether these cells regulate neuronal network activity has only recently started to be investigated. In this article, we highlight the role of astrocytes in the modulation of circuit function with particular focus on sleep-related rhythmogenesis. We discuss recent data showing that these glial cells regulate slow oscillations, a specific thalamocortical activity that characterizes non-REM sleep, and sleep-associated behaviors. Based on these findings, we predict that our understanding of the genesis and tuning of thalamocortical rhythms will necessarily go through an integrated view of brain circuits in which non-neuronal cells can play important neuromodulatory roles. C1 [Halassa, Michael M.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Halassa, Michael M.] McLean Hosp, Dept Psychiat, Belmont, MA 02178 USA. [Halassa, Michael M.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA. [Dal Maschio, Marco; Beltramo, Riccardo; Benfenati, Fabio; Fellin, Tommaso] Italian Inst Technol, Dept Neurosci & Brain Technol, Genoa, Italy. [Haydon, Philip G.] Tufts Univ, Dept Neurosci, Boston, MA 02111 USA. RP Halassa, MM (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. EM mhalassa@partners.org; marco.dalmaschio@iit.it; riccardo.beltramo@iit.it; philip.haydon@tufts.edu; fabio.benfenati@iit.it; tommaso.fellin@iit.it FU MIUR PRIN program; Telethon-Italy [GGP09134]; San Paolo grants [R01-NS037585]; San Paolo "Programma in Neuroscienze" FX We thank V. Tucci for critical reading of the manuscript and helpful comments. This work was supported by the MIUR PRIN program, Telethon-Italy (GGP09134), San Paolo grants to FB, grant # R01-NS037585 to PGH, and the San Paolo "Programma in Neuroscienze" to TF. NR 126 TC 11 Z9 11 U1 2 U2 2 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1537-744X J9 THESCIENTIFICWORLDJO JI TheScientificWorldJOURNAL PY 2010 VL 10 BP 1634 EP 1645 DI 10.1100/tsw.2010.130 PG 12 WC Environmental Sciences; Multidisciplinary Sciences SC Environmental Sciences & Ecology; Science & Technology - Other Topics GA V25RS UT WOS:000208495700007 PM 20730381 ER PT J AU Marcinkowska, M Wong, KK Kwiatkowski, DJ Kozlowski, P AF Marcinkowska, Malgorzata Wong, Kwok-Kin Kwiatkowski, David J. Kozlowski, Piotr TI Design and Generation of MLPA Probe Sets for Combined Copy Number and Small-Mutation Analysis of Human Genes: EGFR as an Example SO THESCIENTIFICWORLDJOURNAL LA English DT Article DE multiplex ligation-dependent probe amplification; MLPA; copy number variation; CNV; EGFR; large deletion; amplification; mutation detection ID CELL LUNG-CANCER; GROWTH-FACTOR RECEPTOR; GENOMIC REARRANGEMENTS; CLINICAL-RESPONSE; AMPLIFICATION; RESISTANCE; GEFITINIB; DELETIONS; ASSAY; INHIBITOR AB Multiplex ligation-dependent probe amplification (MLPA) is a multiplex copy number analysis method that is routinely used to identify large mutations in many clinical and research labs. One of the most important drawbacks of the standard MLPA setup is a complicated, and therefore expensive, procedure of generating long MLPA probes. This drawback substantially limits the applicability of MLPA to those genomic regions for which ready-to-use commercial kits are available. Here we present a simple protocol for designing MLPA probe sets that are composed entirely of short oligonucleotide half-probes generated through chemical synthesis. As an example, we present the design and generation of an MLPA assay for parallel copy number and small-mutation analysis of the EGFR gene. C1 [Marcinkowska, Malgorzata; Kozlowski, Piotr] Polish Acad Sci, Inst Bioorgan Chem, Canc Genet Lab, Poznan, Poland. [Wong, Kwok-Kin] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Wong, Kwok-Kin] Dana Farber Harvard Canc Ctr, Ludwig Ctr, Boston, MA USA. [Kwiatkowski, David J.] Harvard Univ, Brigham & Womens Hosp, Div Translat Med, Sch Med,Dept Med, Boston, MA 02115 USA. RP Kozlowski, P (reprint author), Polish Acad Sci, Inst Bioorgan Chem, Canc Genet Lab, Poznan, Poland. EM marcinkm@man.poznan.pl; kwong1@partners.org; dk@rics.bwh.harvard.edu; kozlowp@yahoo.com OI wong, kwok kin/0000-0001-6323-235X FU Ministry of Science and Higher Education [N N302-278937]; Dana-Farber-Harvard Cancer Center [P50 CA090578, U01 CA141576, R01 AG2400401, R01 CA122794, R01 CA140594, 1RC2CA147940-01]; Uniting Against Lung Cancer FX This work was supported by the Ministry of Science and Higher Education, Grant No. N N302-278937 (PK and MM); Uniting Against Lung Cancer grant (DJK and K-KW); and Dana-Farber-Harvard Cancer Center Lung Cancer Specialized Program of Research Excellence (SPORE) grants P50 CA090578 (DJK, K-KW), U01 CA141576 (K-KW), R01 AG2400401 (K-KW), R01 CA122794 (K-KW), R01 CA140594 (K-KW), and 1RC2CA147940-01 (K-KW). NR 38 TC 11 Z9 12 U1 0 U2 9 PU THESCIENTIFICWORLD LTD PI NEWBURY PA 29-34, VENTURE WEST, NEW GREENHAM PARK, NEWBURY, BERKSHIRE RG19 6HX, ENGLAND SN 1537-744X J9 THESCIENTIFICWORLDJO JI TheScientificWorldJOURNAL PY 2010 VL 10 BP 2003 EP 2018 DI 10.1100/tsw.2010.195 PG 16 WC Environmental Sciences; Multidisciplinary Sciences SC Environmental Sciences & Ecology; Science & Technology - Other Topics GA 665XW UT WOS:000283072200005 PM 20953551 ER PT S AU Brownell, AL AF Brownell, A. L. BE Toi, VV Khoa, TQD TI Current Development of Neuroimaging Using PET Techniques SO THIRD INTERNATIONAL CONFERENCE ON THE DEVELOPMENT OF BIOMEDICAL ENGINEERING IN VIETNAM SE IFMBE Proceedings LA English DT Proceedings Paper CT 3rd International Conference on the Development of Biomedical Engineering in Vietnam CY JAN 11-14, 2010 CL Ho Chi Minh City, VIETNAM DE PET; blood flow; metabolism; receptor; dopamine ID POSITRON-EMISSION-TOMOGRAPHY; AXIAL SCANNING TOMOGRAPHY; BLOOD-FLOW; METABOLISM; RECEPTORS; DISEASE; BRAIN AB Positron emission imaging was developed more than 50 yrs ago, when Dr. Gordon Brownell did the first clinical brain imaging with his scanner in 1951 on 8-year old girl to detect a brain tumor. Detection and localization of brain tumors was the main application area of the positron emission imaging for the following 20 years. The isotopes like 72As, 64Cu and 68Ga were used as imaging agents. When the cyclotrons came available in the hospital environment in 1970s, 150 and 11C labeled gases replaced the long-lived isotopes. These studies were based on blood flow and oxygen metabolism and are still used in a variety of neurological applications. New area of neuroimaging started, when radiolabeling techniques developed to produce compounds to investigate metabolic and specific biochemical (receptor and/or enzyme) functions in the brain. This development established in vivo neurochemistry, which is presently one of the most active research areas in neuroimaging. Presently the mostly used radiolabels in PET imaging are 11C and 18F, which can be detached to the imaging ligand through radiosyntheses. The main application areas of PET imaging for diagnosis and research include neurodegeneration, stroke, drug addiction, brain activation, epilepsy, inflammation, cancer, and drug development. The application area is continuously increasing based on radiopharmaceutical development. The first significant breakthrough in in vivo neuroimaging happened after introducing of radioligands to image dopamine transporters. Even these ligands are not generally approved for clinical diagnosis; they are used world wide as research tools in neurodegenerative disorders, especially in Parkinson's diseases (PD) as well as drug abuse. Presently world wide interest is to develop specific ligands for diagnosis of Alzheimer's disease and several imaging ligands are in clinical trials. Other active radiopharmaceutical developments include ligands for serotonergic and metabotropic glutamate receptor systems. C1 Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Brownell, AL (reprint author), Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 23 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1680-0737 BN 978-3-642-12019-0 J9 IFMBE PROC PY 2010 VL 27 BP 27 EP 30 PG 4 WC Engineering, Biomedical SC Engineering GA BBO19 UT WOS:000307677500007 ER PT J AU Gong, MN Bajwa, EK Thompson, BT Christiani, DC AF Gong, M. N. Bajwa, E. K. Thompson, B. T. Christiani, D. C. TI Body mass index is associated with the development of acute respiratory distress syndrome SO THORAX LA English DT Article ID ACUTE LUNG INJURY; MECHANICALLY VENTILATED PATIENTS; COLONY-ENHANCING FACTOR; BLUNT TRAUMA PATIENTS; RISK-FACTORS; OBESITY; MORTALITY; OUTCOMES; OVERWEIGHT; IMPACT AB Background: The relationship between body mass index (BMI) and development of acute respiratory distress syndrome (ARDS) is unknown. Methods: A cohort study of critically ill patients at risk for ARDS was carried out. BMI was calculated from admission height and weight. Patients were screened daily for AECC (American European Consensus Committee)-defined ARDS and 60-day ARDS mortality. Results: Of 1795 patients, 83 (5%) patients were underweight (BMI <18.5 kg/m(2)), 627 (35%) normal (BMI 18.5-24.9), 605 (34%) overweight (BMI 25-29.9), 364 (20%) obese (BMI 30-39.9) and 116 (6%) severely obese (BMI >= 40). Increasing weight was associated with younger age (p<0.001), diabetes (p<0.0001), higher blood glucose (p<0.0001), lower prevalence of direct pulmonary injury (p<0.0001) and later development of ARDS (p = 0.01). BMI was associated with ARDS on multivariate analysis (OR(adj) 1.24 per SD increase; 95% CI 1.11 to 1.39). Similarly, obesity was associated with ARDS compared with normal weight (OR(adj) 1.66; 95% CI 1.21 to 2.28 for obese; OR(adj) 1.78; 95% CI 1.12 to 2.92 for severely obese). Exploratory analysis in a subgroup of intubated patients without ARDS on admission (n = 1045) found that obese patients received higher peak (p = 0.0001) and positive end-expiratory pressures (p, 0.0001) than non-obese patients. Among patients with ARDS, increasing BMI was associated with increased length of stay (p = 0.007) but not with mortality (OR(adj) 0.89 per SD increase; 95% CI 0.71 to 1.12). Conclusion: BMI was associated with increased risk of ARDS in a weight-dependent manner and with increased length of stay, but not with mortality. Additional studies are needed to determine whether differences in initial ventilator settings may contribute to ARDS development in the obese. C1 [Christiani, D. C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Environm & Occupat Med & Epidemiol Program, Boston, MA 02115 USA. [Gong, M. N.] Montefiore Med Ctr, Dept Med, Div Crit Care Med, Bronx, NY 10467 USA. [Bajwa, E. K.; Thompson, B. T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Pulm & Crit Care Unit,Dept Med, Boston, MA 02115 USA. RP Christiani, DC (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Environm & Occupat Med & Epidemiol Program, 665 Huntington Ave, Boston, MA 02115 USA. EM dchris@hsph.harvard.edu FU NHLBI [HL60197, HL084060, HL086667] FX The present work is supported by research grants HL60197, HL084060 and HL086667 from NHLBI. NR 36 TC 85 Z9 89 U1 1 U2 2 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0040-6376 J9 THORAX JI Thorax PD JAN PY 2010 VL 65 IS 1 BP 44 EP 50 DI 10.1136/thx.2009.117572 PG 7 WC Respiratory System SC Respiratory System GA 535SV UT WOS:000272991900011 PM 19770169 ER PT B AU Lipinski, B AF Lipinski, Boguslaw BE Macri, DG Procaccini, LD TI SIGNIFICANCE OF FREE RADICAL-MODIFIED FIBRINOGEN IN THROMBOSIS AND RELATED DISEASES SO THROMBOSIS: CAUSES, TREATMENT AND PREVENTION SE Cardiology Research and Clinical Developments LA English DT Article; Book Chapter ID GENERALIZED SHWARTZMAN REACTION; IDIOPATHIC PULMONARY-FIBROSIS; TISSUE-PLASMINOGEN ACTIVATOR; HUMAN ATHEROSCLEROTIC PLAQUE; OXYGEN SPECIES GENERATION; STAGE RENAL-DISEASE; ACUTE LUNG INJURY; OXIDATIVE STRESS; ALZHEIMERS-DISEASE; DIABETES-MELLITUS AB Conversion of a soluble fibrinogen into insoluble fibrin with thrombin leads to the formation of a hemostatic plug that under physiological conditions is degraded by plasmin. Thrombosis is considered to be a result of an imbalance between procoagulant and anticoagulant activities of blood and the persistent presence of fibrin clots in the coronary, pulmonary or cerebral circulations. The main component of a thrombus is fibrin formed from fibrinogen by the action of thrombin. Human plasma fibrinogen is one of the largest plasma proteins composed of three pairs of polypeptide chains linked together by means of disulfide bonds. It had been observed over a century ago that fibrin-like deposits present in atherosclerotic plaques were morphologically different from those in thrombi formed in the blood circulation system. In experimental models, it has been documented that atherosclerotic fibrin deposits are not readily preventable by anticoagulation and are resistant to fibrinolytic degradation. Therefore, the mechanism of atherogenesis cannot be completely explained in terms of activation of classic blood coagulation cascade. More recent studies indicated, however, a link between atherosclerosis and inflammation that is known to be associated with the excessive production of free radicals. Reactive oxygen species are generally recognized to cause oxidative stress resulting in an undesirable oxidation of carbohydrates, fatty acids, nucleic acids and particularly proteins. However, as recently shown by this author, treatment of fibrinogen with non-oxidizing hydroxyl radicals resulted in a limited reduction of its disulfides. As a consequence, fibrinogen polypeptide chains become unfolded with the exposure of buried hydrophobic epitopes and the formation of insoluble intermolecularly bonded aggregates. In human plasma hydroxyl radicals cause the formation of insoluble aggregates composed of fibrinogen and albumin that cannot be degraded either by plasmin or by other active proteolytic enzymes. In vitro prepared fibrinogen-albumin complex, when converted with thrombin to a clot is also refractory to proteolytic degradation. In vivo fibrinogen-albumin complexes are present in patients with congenital abnormalities associated with thromboses, in which an extra cystein is present in the fibrinogen molecule. A characteristic feature of such a complex is its resistance to fibrinolytic degradation of a fibrin clot induced with thrombin. Apparently, this extra cystein causes reductive unfolding of polypeptide chains similar to that induced with hydroxyl radicals making fibrin clots resistant to fibrinolysis. In this Chapter, it is argued that the hypoxia-induced reductive conditions associated with coronary and/or cerebral thrombosis generate hydroxyl radicals causing, in turn, the formation of fibrin(ogen)-albumin complex refractory to proteolysis. This phenomenon may explain why thrombolytic therapy is ineffective when installed 3-4 hours after the onset of thombosis. It has been recently found that such insoluble complexes can be dissolved by the action of singlet oxygen. The non-radical species oxidizes side chains of certain amino acids involved in the hydrophobic interactions between fibrinogen and albumin resulting in the solubilization of insoluble aggregates. In conclusion, the Chapter will present new ideas on the importance of maintaining proper redox balance in the circulation to prevent and reverse the undesirable effects of hydroxyl radicals generated under the reducing conditions of hypoxia observed in atherosclerosis, cancer, neurological and other chronic diseases. C1 Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA. RP Lipinski, B (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA. EM boguslaw_lipinski@joslin.harvard.edu NR 355 TC 0 Z9 0 U1 0 U2 0 PU NOVA SCIENCE PUBLISHERS, INC PI HAUPPAUGE PA 400 OSER AVE, STE 1600, HAUPPAUGE, NY 11788-3635 USA BN 978-1-61668-696-3 J9 CARDIOL RES CLIN DEV PY 2010 BP 1 EP 52 PG 52 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA BSF53 UT WOS:000284337200002 ER PT J AU Lin, RY Davies, TF AF Lin, Reigh-Yi Davies, Terry F. TI Differentiating Thyroid Cells SO THYROID LA English DT Editorial Material ID EMBRYONIC STEM-CELLS; MOUSE EMBRYOS; THYROCYTES C1 [Lin, Reigh-Yi; Davies, Terry F.] Mt Sinai Sch Med, Dept Med, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA. [Davies, Terry F.] James J Peters VA Med Ctr, Thyroid Res Unit, New York, NY USA. RP Lin, RY (reprint author), Mt Sinai Sch Med, Dept Med, Div Endocrinol Diabet & Bone Dis, Box 1055,1 Gustave L Levy Pl, New York, NY 10029 USA. EM reigh-yi.lin@mssm.edu NR 11 TC 4 Z9 4 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1050-7256 J9 THYROID JI Thyroid PD JAN PY 2010 VL 20 IS 1 BP 1 EP 2 DI 10.1089/thy.2009.1613 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 543FI UT WOS:000273556500001 PM 20067376 ER PT J AU Lubitz, CC Faquin, WC Yang, JY Mekel, M Gaz, RD Parangi, S Randolph, GW Hodin, RA Stephen, AE AF Lubitz, Carrie C. Faquin, William C. Yang, Jingyun Mekel, Michal Gaz, Randall D. Parangi, Sareh Randolph, Gregory W. Hodin, Richard A. Stephen, Antonia E. TI Clinical and Cytological Features Predictive of Malignancy in Thyroid Follicular Neoplasms SO THYROID LA English DT Article ID FINE-NEEDLE-ASPIRATION; FROZEN-SECTION; NODULES; LESIONS; RISK; CANCER; BIOPSY; ULTRASONOGRAPHY; EPIDEMIOLOGY; EXPERIENCE AB Background: The preoperative diagnosis of malignancy in nodules suspicious for a follicular neoplasm remains challenging. A number of clinical and cytological parameters have been previously studied; however, none have significantly impacted clinical practice. The aim of this study was to determine predictive characteristics of follicular neoplasms useful for clinical application. Methods: Four clinical (age, sex, nodule size, solitary nodule) and 17 cytological variables were retrospectively reviewed for 144 patients with a nodule suspicious for follicular neoplasm, diagnosed preoperatively by fine-needle aspiration (FNA), from a single institution over a 2-year period (January 2006 to December 2007). The FNAs were examined by a single, blinded pathologist and compared with final surgical pathology. Significance of clinical and cytological variables was determined by univariate analysis and backward stepwise logistic regression. Odds ratios (ORs) for malignancy, a receiver operating characteristic curve, and predicted probabilities of combined features were determined. Results: There was an 11% incidence of malignancy (16/144). On univariate analysis, nodule size >= 4.0 cm nears significance (p = 0.054) and 9 of 17 cytological features examined were significantly associated with malignancy. Three variables stay in the final model after performing backward stepwise selection in logistic regression: nodule size (OR = 0.25, p = 0.05), presence of a transgressing vessel (OR = 23, p < 0.0001), and nuclear grooves (OR = 4.3, p = 0.03). The predicted probability of malignancy was 88.4% with the presence of all three variables on preoperative FNA. When the two papillary carcinomas were excluded from the analysis, the presence of nuclear grooves was no longer significant, and anisokaryosis (OR = 12.74, p = 0.005) and presence of nucleolus (OR = 0.11, p = 0.04) were significantly associated with malignancy. Excluding the two papillary thyroid carcinomas, a nodule size >= 4 cm, with a transgressing vessel and anisokaryosis and lacking a nucleolus, has a predicted probability of malignancy of 96.5%. Conclusions: A combination of larger nodule size, transgressing vessels, and specific nuclear features are predictive of malignancy in patients with follicular neoplasms. These findings enhance our current limited predictive armamentarium and can be used to guide surgical decision making. Further study may result in the inclusion of these variables to the systematic evaluation of follicular neoplasms. C1 [Lubitz, Carrie C.; Mekel, Michal; Gaz, Randall D.; Parangi, Sareh; Randolph, Gregory W.; Hodin, Richard A.; Stephen, Antonia E.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Faquin, William C.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Yang, Jingyun] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. RP Lubitz, CC (reprint author), Massachusetts Gen Hosp, Dept Surg, 15 Parkman,WACC 460, Boston, MA 02114 USA. EM clubitz@partners.org FU Massachusetts General Hospital FX This study was supported by the Claflin Award of the Massachusetts General Hospital. NR 26 TC 31 Z9 32 U1 0 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1050-7256 EI 1557-9077 J9 THYROID JI Thyroid PD JAN PY 2010 VL 20 IS 1 BP 25 EP 31 DI 10.1089/thy.2009.0208 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 543FI UT WOS:000273556500005 PM 20025540 ER PT S AU Clark, DP Faquin, WC AF Clark, Douglas P. Faquin, William C. BA Clark, DP Faquin, WC BF Clark, DP Faquin, WC TI Thyroid Cytopathology Second Edition Introduction and Clinical Aspects SO THYROID CYTOPATHOLOGY, SECOND EDITION SE Essentials in Cytopathology LA English DT Editorial Material; Book Chapter ID NEEDLE ASPIRATION BIOPSY; CARCINOMA; MANAGEMENT; PAPILLARY; CRITERIA; NODULES C1 [Clark, Douglas P.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA. [Faquin, William C.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Clark, DP (reprint author), Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA. NR 10 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1574-9053 BN 978-1-4419-5952-2 J9 ESSENT CYTOPATHOL PY 2010 VL 8 BP 1 EP 7 DI 10.1007/978-1-4419-5954-6_1 D2 10.1007/978-1-4419-5954-6 PG 7 WC Pathology SC Pathology GA BPK05 UT WOS:000279025300001 ER PT S AU Clark, DP Faquin, WC AF Clark, Douglas P. Faquin, William C. BA Clark, DP Faquin, WC BF Clark, DP Faquin, WC TI How to Perform and Process a Thyroid FNA SO THYROID CYTOPATHOLOGY, SECOND EDITION SE Essentials in Cytopathology LA English DT Article; Book Chapter C1 [Clark, Douglas P.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA. [Faquin, William C.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Clark, DP (reprint author), Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1574-9053 BN 978-1-4419-5952-2 J9 ESSENT CYTOPATHOL PY 2010 VL 8 BP 9 EP 22 DI 10.1007/978-1-4419-5954-6_2 D2 10.1007/978-1-4419-5954-6 PG 14 WC Pathology SC Pathology GA BPK05 UT WOS:000279025300002 ER PT S AU Clark, DP Faquin, WC AF Clark, Douglas P. Faquin, William C. BA Clark, DP Faquin, WC BF Clark, DP Faquin, WC TI Approach to Thyroid FNA Cytopathology: An Overview SO THYROID CYTOPATHOLOGY, SECOND EDITION SE Essentials in Cytopathology LA English DT Article; Book Chapter ID NODULES C1 [Clark, Douglas P.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA. [Faquin, William C.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Clark, DP (reprint author), Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA. NR 8 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1574-9053 BN 978-1-4419-5952-2 J9 ESSENT CYTOPATHOL PY 2010 VL 8 BP 23 EP 32 DI 10.1007/978-1-4419-5954-6_3 D2 10.1007/978-1-4419-5954-6 PG 10 WC Pathology SC Pathology GA BPK05 UT WOS:000279025300003 ER PT S AU Clark, DP Faquin, WC AF Clark, Douglas P. Faquin, William C. BA Clark, DP Faquin, WC BF Clark, DP Faquin, WC TI Inflammatory Lesions and Lymphoma SO THYROID CYTOPATHOLOGY, SECOND EDITION SE Essentials in Cytopathology LA English DT Article; Book Chapter ID HASHIMOTO THYROIDITIS; MALIGNANT-LYMPHOMA; DISORDERS; GLAND C1 [Clark, Douglas P.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA. [Faquin, William C.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Clark, DP (reprint author), Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA. NR 9 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1574-9053 BN 978-1-4419-5952-2 J9 ESSENT CYTOPATHOL PY 2010 VL 8 BP 33 EP 53 DI 10.1007/978-1-4419-5954-6_4 D2 10.1007/978-1-4419-5954-6 PG 21 WC Pathology SC Pathology GA BPK05 UT WOS:000279025300004 ER PT S AU Clark, DP Faquin, WC AF Clark, Douglas P. Faquin, William C. BA Clark, DP Faquin, WC BF Clark, DP Faquin, WC TI Colloid-Predominant Lesions SO THYROID CYTOPATHOLOGY, SECOND EDITION SE Essentials in Cytopathology LA English DT Article; Book Chapter C1 [Clark, Douglas P.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA. [Faquin, William C.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Clark, DP (reprint author), Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1574-9053 BN 978-1-4419-5952-2 J9 ESSENT CYTOPATHOL PY 2010 VL 8 BP 55 EP 67 DI 10.1007/978-1-4419-5954-6_5 D2 10.1007/978-1-4419-5954-6 PG 13 WC Pathology SC Pathology GA BPK05 UT WOS:000279025300005 ER PT S AU Clark, DP Faquin, WC AF Clark, Douglas P. Faquin, William C. BA Clark, DP Faquin, WC BF Clark, DP Faquin, WC TI Follicular Lesions SO THYROID CYTOPATHOLOGY, SECOND EDITION SE Essentials in Cytopathology LA English DT Article; Book Chapter ID FINE-NEEDLE-ASPIRATION; THYROID-CARCINOMA; CANCER C1 [Clark, Douglas P.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA. [Faquin, William C.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Clark, DP (reprint author), Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA. NR 10 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1574-9053 BN 978-1-4419-5952-2 J9 ESSENT CYTOPATHOL PY 2010 VL 8 BP 69 EP 92 DI 10.1007/978-1-4419-5954-6_6 D2 10.1007/978-1-4419-5954-6 PG 24 WC Pathology SC Pathology GA BPK05 UT WOS:000279025300006 ER PT S AU Clark, DP Faquin, WC AF Clark, Douglas P. Faquin, William C. BA Clark, DP Faquin, WC BF Clark, DP Faquin, WC TI Hurthle Cell Lesions SO THYROID CYTOPATHOLOGY, SECOND EDITION SE Essentials in Cytopathology LA English DT Article; Book Chapter ID FINE-NEEDLE-ASPIRATION; THYROID-GLAND; CARCINOMA C1 [Clark, Douglas P.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA. [Faquin, William C.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Clark, DP (reprint author), Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA. NR 6 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1574-9053 BN 978-1-4419-5952-2 J9 ESSENT CYTOPATHOL PY 2010 VL 8 BP 93 EP 107 DI 10.1007/978-1-4419-5954-6_7 D2 10.1007/978-1-4419-5954-6 PG 15 WC Pathology SC Pathology GA BPK05 UT WOS:000279025300007 ER PT S AU Clark, DP Faquin, WC AF Clark, Douglas P. Faquin, William C. BA Clark, DP Faquin, WC BF Clark, DP Faquin, WC TI Cystic Lesions of the Thyroid SO THYROID CYTOPATHOLOGY, SECOND EDITION SE Essentials in Cytopathology LA English DT Article; Book Chapter ID NODULES C1 [Clark, Douglas P.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA. [Faquin, William C.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Clark, DP (reprint author), Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1574-9053 BN 978-1-4419-5952-2 J9 ESSENT CYTOPATHOL PY 2010 VL 8 BP 109 EP 124 DI 10.1007/978-1-4419-5954-6_8 D2 10.1007/978-1-4419-5954-6 PG 16 WC Pathology SC Pathology GA BPK05 UT WOS:000279025300008 ER PT S AU Clark, DP Faquin, WC AF Clark, Douglas P. Faquin, William C. BA Clark, DP Faquin, WC BF Clark, DP Faquin, WC TI Papillary Thyroid Carcinoma SO THYROID CYTOPATHOLOGY, SECOND EDITION SE Essentials in Cytopathology LA English DT Article; Book Chapter ID FINE-NEEDLE-ASPIRATION C1 [Clark, Douglas P.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA. [Faquin, William C.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Clark, DP (reprint author), Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA. NR 7 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1574-9053 BN 978-1-4419-5952-2 J9 ESSENT CYTOPATHOL PY 2010 VL 8 BP 125 EP 150 DI 10.1007/978-1-4419-5954-6_9 D2 10.1007/978-1-4419-5954-6 PG 26 WC Pathology SC Pathology GA BPK05 UT WOS:000279025300009 ER PT S AU Clark, DP Faquin, WC AF Clark, Douglas P. Faquin, William C. BA Clark, DP Faquin, WC BF Clark, DP Faquin, WC TI Medullary Thyroid Carcinoma SO THYROID CYTOPATHOLOGY, SECOND EDITION SE Essentials in Cytopathology LA English DT Article; Book Chapter ID CALCITONIN; MUTATIONS; DIAGNOSIS C1 [Clark, Douglas P.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA. [Faquin, William C.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Clark, DP (reprint author), Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA. NR 9 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1574-9053 BN 978-1-4419-5952-2 J9 ESSENT CYTOPATHOL PY 2010 VL 8 BP 151 EP 166 DI 10.1007/978-1-4419-5954-6_10 D2 10.1007/978-1-4419-5954-6 PG 16 WC Pathology SC Pathology GA BPK05 UT WOS:000279025300010 ER PT S AU Clark, DP Faquin, WC AF Clark, Douglas P. Faquin, William C. BA Clark, DP Faquin, WC BF Clark, DP Faquin, WC TI Undifferentiated (Anaplastic) Carcinoma and Secondary Tumors SO THYROID CYTOPATHOLOGY, SECOND EDITION SE Essentials in Cytopathology LA English DT Article; Book Chapter C1 [Clark, Douglas P.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA. [Faquin, William C.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Clark, DP (reprint author), Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1574-9053 BN 978-1-4419-5952-2 J9 ESSENT CYTOPATHOL PY 2010 VL 8 BP 167 EP 181 DI 10.1007/978-1-4419-5954-6_11 D2 10.1007/978-1-4419-5954-6 PG 15 WC Pathology SC Pathology GA BPK05 UT WOS:000279025300011 ER PT J AU Sales, VL Mettler, BA Engelmayr, GC Aikawa, E Bischoff, J Martin, DP Exarhopoulos, A Moses, MA Schoen, FJ Sacks, MS Mayer, JE AF Sales, Virna L. Mettler, Bret A. Engelmayr, George C., Jr. Aikawa, Elena Bischoff, Joyce Martin, David P. Exarhopoulos, Alexis Moses, Marsha A. Schoen, Frederick J. Sacks, Michael S. Mayer, John E., Jr. TI Endothelial Progenitor Cells as a Sole Source for Ex Vivo Seeding of Tissue-Engineered Heart Valves SO TISSUE ENGINEERING PART A LA English DT Article ID IN-VITRO MATURATION; EXTRACELLULAR-MATRIX; GROWTH-FACTOR; DEVELOPMENTAL BIOLOGY; DISEASE; PHENOTYPE; LOCALIZATION; SCAFFOLDS; EVOLUTION; COMPLEX AB Purposes: We investigated whether circulating endothelial progenitor cells (EPCs) can be used as a cell source for the creation of a tissue-engineered heart valve (TEHV). Methods: Trileaflet valved conduits were fabricated using nonwoven polyglycolic acid/poly-4-hydroxybutyrate polymer. Ovine peripheral blood EPCs were dynamically seeded onto a valved conduit and incubated for 7, 14, and 21 days. Results: Before seeding, EPCs were shown to express CD31(+), eNOS(+), and VE-Cadherin(+) but not a-smooth muscle actin. Histological analysis demonstrated relatively homogenous cellular ingrowth throughout the valved conduit. TEHV constructs revealed the presence of endothelial cell (EC) markers and alpha-smooth muscle actin(+) cells comparable with native valves. Protein levels were comparable with native valves and exceeded those in unseeded controls. EPC-TEHV demonstrated a temporal pattern of matrix metalloproteinases-2/9 expression and tissue inhibitors of metalloproteinase activities comparable to that of native valves. Mechanical properties of EPC-TEHV demonstrated significantly greater stiffness than that of the unseeded scaffolds and native valves. Conclusions: Circulating EPC appears to have the potential to provide both interstitial and endothelial functions and could potentially serve as a single-cell source for construction of autologous heart valves. C1 [Sales, Virna L.; Mettler, Bret A.; Mayer, John E., Jr.] Childrens Hosp Boston, Dept Cardiac Surg, Boston, MA 02115 USA. [Sales, Virna L.; Mettler, Bret A.; Aikawa, Elena; Bischoff, Joyce; Moses, Marsha A.; Schoen, Frederick J.; Mayer, John E., Jr.] Harvard Univ, Sch Med, Boston, MA USA. [Engelmayr, George C., Jr.; Sacks, Michael S.] Univ Pittsburgh, Dept Bioengn, Engineered Tissue Mech Lab, McGowan Inst Regenerat Med, Pittsburgh, PA USA. [Engelmayr, George C., Jr.; Schoen, Frederick J.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Aikawa, Elena; Schoen, Frederick J.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Aikawa, Elena] Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA USA. [Bischoff, Joyce; Exarhopoulos, Alexis; Moses, Marsha A.] Childrens Hosp Boston, Dept Surg, Boston, MA 02115 USA. [Bischoff, Joyce; Exarhopoulos, Alexis; Moses, Marsha A.] Childrens Hosp Boston, Vasc Biol Program, Boston, MA 02115 USA. [Martin, David P.] Tepha Inc, Lexington, MA USA. RP Sales, VL (reprint author), Childrens Hosp Boston, Dept Cardiac Surg, 300 Longwood Ave, Boston, MA 02115 USA. EM virna.sales@cardio.chboston.org; john.mayer@cardio.chboston.org RI Engelmayr, George/I-4368-2012; Sacks, Michael/F-3703-2011; OI Bischoff, Joyce/0000-0002-6367-1974 FU NIH [HL-06490, HL-60463, HL-68816, HL-CA83106, P01CA45548, P50DK065298]; National Institute of Standards and Technology [NANB2H3053]; Gross Cardiovascular Fund; Center for Integration of Medicine and Innovative Technology; American Heart Association Scientist Development [0635620T]; National Research Service Award/National Institute of Biomedical Imaging and Bioengineering [F32 EB003353-01]; American Heart Association Predoctoral Fellowship [0415406U] FX We thank Jill Wylie-Sears, M. S., Gwendolyn Louis, B. S. (Children's Hospital, Boston, MA), and Mark Faber, M. S. (Brigham and Women's Hospital, Boston, MA) for excellent technical assistance, and Michael Blaze, Ph. D., for editorial expertise. This work was supported by NIH grants HL-06490 (J. B.), HL-60463 (J. E. M.), HL-68816 (M. S. S.), HL-CA83106, P01CA45548, P50DK065298 (M. A. M.), National Institute of Standards and Technology grant NANB2H3053 (D. P. M./J. E. M.); Gross Cardiovascular Fund and Center for Integration of Medicine and Innovative Technology (J. E. M.). V. L. S. is the recipient of American Heart Association Scientist Development Grant 0635620T. B. A. M. is the recipient of a National Research Service Award/National Institute of Biomedical Imaging and Bioengineering grant F32 EB003353-01. G. C. E. was supported by American Heart Association Predoctoral Fellowship 0415406U. All authors report no conflict of interest. NR 32 TC 30 Z9 32 U1 1 U2 14 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1937-3341 J9 TISSUE ENG PT A JI Tissue Eng. Part A PD JAN PY 2010 VL 16 IS 1 BP 257 EP 267 DI 10.1089/ten.tea.2009.0424 PG 11 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology SC Cell Biology; Biotechnology & Applied Microbiology GA 541QD UT WOS:000273432300023 PM 19698056 ER PT S AU Falvo, JV Tsytsykova, AV Goldfeld, AE AF Falvo, James V. Tsytsykova, Alla V. Goldfeld, Anne E. BE Kollias, G Sfikakis, PP TI Transcriptional Control of the TNF Gene SO TNF PATHOPHYSIOLOGY: MOLECULAR AND CELLULAR MECHANISMS SE Current Directions in Autoimmunity LA English DT Article; Book Chapter ID TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; FACTOR-ALPHA GENE; BETA-GLOBIN LOCUS; HUMAN MONOCYTIC CELLS; CREB-BINDING-PROTEIN; ACTIVATED T-CELLS; SINGLE NUCLEOTIDE POLYMORPHISMS; PERIPHERAL-BLOOD LYMPHOCYTES; MESSENGER-RNA ACCUMULATION AB The cytokine TNF is a critical mediator of immune and inflammatory responses. The TNF gene is an immediate early gene, rapidly transcribed in a variety of cell types following exposure to a broad range of pathogens and signals of inflammation and stress. Regulation of TNF gene expression at the transcriptional level is cell type- and stimulus-specific, involving the recruitment of distinct sets of transcription factors to a compact and modular promoter region. In this review, we describe our current understanding of the mechanisms through which TNF transcription is specifically activated by a variety of extracellular stimuli in multiple cell types, including T cells, B cells, macrophages, mast cells, dendritic cells, and fibroblasts. We discuss the role of nuclear factor of activated T cells and other transcription factors and coactivators in enhanceosome formation, as well as the contradictory evidence for a role for nuclear factor kappa B as a classical activator of the TNF gene. We describe the impact of evolutionarily conserved cis-regulatory DNA motifs in the TNF locus upon TNF gene transcription, in contrast to the neutral effect of single nucleotide polymorphisms. We also assess the regulatory role of chromatin organization, epigenetic modifications, and long-range chromosomal interactions at the TNF locus. Copyright (C) 2010 S. Karger AG, Basel C1 [Falvo, James V.] Immune Dis Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Falvo, JV (reprint author), Immune Dis Inst, 200 Longwood Ave, Boston, MA 02115 USA. EM falvo@idi.harvard.edu; goldfeld@idi.harvard.edu FU NIGMS NIH HHS [R01 GM 076685, R01 GM076685] NR 262 TC 61 Z9 62 U1 0 U2 7 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1422-2132 BN 978-3-8055-9383-0 J9 CURR DIR AUTOIMMUN JI Curr. DIr Autoimmun. PY 2010 VL 11 BP 27 EP 60 PG 34 WC Immunology SC Immunology GA BNW18 UT WOS:000275723900002 PM 20173386 ER PT S AU Kaelin, WG AF Kaelin, William G., Jr. BE Braaten, D TI New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein SO TOWARD PERSONALIZED MEDICINE FOR CANCER SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT Conference on Towards Personalized Cancer Medicine CY MAY 19-21, 2010 CL Barcelona, SPAIN SP Mushett Family Fdn, Roche, Amgen SA, Life Technol, MedImmune, Ramon Areces Pharmaceut, Takeda Oncol Co, Novartis DE cancer; tumor suppressor protein; transcription factor ID RENAL-CELL CARCINOMA; HYPOXIA-INDUCIBLE FACTOR; COPY-NUMBER ALTERATIONS; PHASE-III TRIAL; PROLYL HYDROXYLASE; GENE-EXPRESSION; INTERFERON-ALPHA; BREAST-CANCER; DOUBLE-BLIND; CYCLIN D1 AB Inactivation of the von Hippel-Lindau tumor-suppressor protein (pVHL) causes the most common form of kidney cancer. pVHL is part of a complex that polyubiquitinates the alpha subunit of the heterodimetric transcription factor HIF. In the presence of oxygen, HIF1 alpha is prolyl hydroxylated by EglN1 (also called PHD2); this modification recruits pVHL, which then targets HIF1 alpha for proteasomal degradation. In hypoxic or pVHL-defective cells, HIF1 alpha accumulates, binds to HIF1 beta, and transcriptionally activates genes such as VEGF. VEGF inhibitors and mTOR inhibitors, which indirectly affect HIF, are now approved for the treatment of kidney cancer. EglN1 is a 2-oxoglutarate-dependent dioxygenase; such enzymes can be inhibited with drug-like small molecules and EglN1 inhibitors are currently being tested for the treatment of anemia. EglN2 (PHD1) and EglN3 (PHD3), which are EglN1 paralogs, appear to play HIF-independent roles in cell proliferation and apoptosis, respectively, and are garnering interest as potential cancer targets. A number of JmjC-Containing proteins, including RBP2 and PLU-1, are 2-oxoglutarate-dependent dioxygenases that demethylate histones. Preclinical data suggest that inhibition of RBP2 or PLU-1 would suppress tumor growth. C1 [Kaelin, William G., Jr.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Howard Hughes Med Inst, Boston, MA 02115 USA. [Kaelin, William G., Jr.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA. RP Kaelin, WG (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Howard Hughes Med Inst, 44 Binney St,Mayer 457, Boston, MA 02115 USA. EM william_kaelin@dfci.harvard.edu FU Howard Hughes Medical Institute; NCI NIH HHS [R01 CA076120, P50 CA101942, R01 CA068490] NR 86 TC 4 Z9 4 U1 1 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA SN 0077-8923 BN 978-1-57331-815-0 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2010 VL 1210 BP 1 EP 7 DI 10.1111/j.1749-6632.2010.05781.x PG 7 WC Oncology; Medicine, Research & Experimental; Multidisciplinary Sciences SC Oncology; Research & Experimental Medicine; Science & Technology - Other Topics GA BTH92 UT WOS:000286950200001 PM 20973793 ER PT B AU Uomoto, JM Williams, RM Randa, LA AF Uomoto, Jay M. Williams, Rhonda M. Randa, Leigh Anne BE Ashley, MJ TI Neurobehavioral Consequences of Combat-Related Blast Injury and Polytrauma SO TRAUMATIC BRAIN INJURY: REHABILITATION, TREATMENT, AND CASE MANAGEMENT, 3RD EDITION LA English DT Article; Book Chapter ID TRAUMATIC BRAIN-INJURY; OPERATION-IRAQI-FREEDOM; MENTAL-HEALTH PROBLEMS; POSTTRAUMATIC-STRESS-DISORDER; PEER SUPPORT PROGRAM; QUALITY-OF-LIFE; ENDURING FREEDOM; BREAST-CANCER; MILITARY PERSONNEL; COGNITIVE REHABILITATION C1 [Uomoto, Jay M.] Def Ctr Excellence Psychol Hlth & Traumat Brain I, Silver Spring, MD USA. [Williams, Rhonda M.] Univ Washington, Sch Med, Seattle, WA USA. [Williams, Rhonda M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Randa, Leigh Anne] Seattle Pacific Univ, Seattle, WA 98119 USA. RP Uomoto, JM (reprint author), Def Ctr Excellence Psychol Hlth & Traumat Brain I, Silver Spring, MD USA. NR 88 TC 0 Z9 0 U1 0 U2 0 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA BN 978-1-4398-4982-8; 978-1-4200-7194-8 PY 2010 BP 63 EP 95 DI 10.1201/9781439849828-c3 D2 10.1201/9781439849828 PG 33 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA BF7QW UT WOS:000384329900004 ER PT J AU Kirchhausen, T AF Kirchhausen, Tom TI Imaging endocytic clathrin structures in living cells (vol 19, pg 596, 2009) SO TRENDS IN CELL BIOLOGY LA English DT Correction C1 Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA. RP Kirchhausen, T (reprint author), Harvard Univ, Sch Med, Immune Dis Inst, W Alpert Bldg Room 128,200 Longwood Ave, Boston, MA 02115 USA. EM kirchhausen@crystal.harvard.edu NR 1 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0962-8924 J9 TRENDS CELL BIOL JI Trends Cell Biol. PD JAN PY 2010 VL 20 IS 1 BP 5 EP 5 DI 10.1016/j.tcb.2009.10.007 PG 1 WC Cell Biology SC Cell Biology GA 548AE UT WOS:000273930400003 ER PT J AU Yilmaz, U Ciol, MA Berger, RE Yang, CC AF Yilmaz, Ugur Ciol, Marcia A. Berger, Richard E. Yang, Claire C. TI Sensory Perception Thresholds in Men With Chronic Pelvic Pain Syndrome SO UROLOGY LA English DT Article ID CENTRAL SENSITIZATION; FIBROMYALGIA; NEUROPATHY; SYSTEM AB OBJECTIVES To compare sensory thresholds in different nerve-fiber types in men with chronic pelvic pain syndrome (CPPS) and healthy controls, using thermal sensory testing and measuring current perception thresholds (CPT). METHODS We enrolled 22 men with CPPS and 20 healthy control participants. We determined the thermal sensory perception thresholds of C and A delta nerve fibers on the perineum and left posterior thigh. To test CPT, we used sine wave electrical stimulation at 5, 250, and 2000 Hz, resulting in the selective depolarization of small unmyelinated C fibers, small myelinated A delta, and large myelinated A beta fibers, respectively. We bilaterally tested the hypothenar surface of the palms, medial parts of soles, midshaft of penis, and 1 site in the midperineum, for a total of 7 sites. RESULTS The mean age of men with CPPS was similar to that of controls [42.8 (standard deviation, 9.4) and 40.4 (standard deviation, 13.2) years, respectively, P = .548]. There was no significant difference between the 2 groups for thermal perception thresholds in both the perineum and left thigh (P >.05). There was also no difference between the 2 groups for CPT values of all 3 frequencies of stimuli in each area tested (P >.05 for all comparisons). CONCLUSIONS The absence of sensory threshold differences between men with CPPS and controls, with either thermal stimulation of C and A delta fiber afferents or electrical stimulation of C, A delta, and A beta fiber afferents, discounts the existence of a peripheral neuropathy as a cause for pain in men with CPPS. UROLOGY 75: 34-37, 2010. Published by Elsevier Inc. C1 [Yang, Claire C.] Univ Washington, Dept Urol, Seattle, WA 98195 USA. Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. VA Puget Sound Healthcare Syst, Seattle, WA USA. RP Yang, CC (reprint author), Univ Washington, Dept Urol, Box 356510, Seattle, WA 98195 USA. EM cyang@u.washington.edu FU Paul G. Allen Family Foundation FX Supported by the Paul G. Allen Family Foundation. NR 25 TC 6 Z9 7 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 J9 UROLOGY JI Urology PD JAN PY 2010 VL 75 IS 1 BP 34 EP 37 DI 10.1016/j.urology.2009.08.013 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA 553UV UT WOS:000274393200011 PM 19854487 ER PT J AU Paxton, SJ Franko, DL AF Paxton, Susan J. Franko, Debra L. BE Cucciare, MA Weingardt, KR TI Body image and eating disorders SO USING TECHNOLOGY TO SUPPORT EVIDENCE-BASED BEHAVIORAL HEALTH PRACTICES: A CLINICIANS GUIDE LA English DT Article; Book Chapter ID BULIMIA-NERVOSA; E-MAIL; ADOLESCENT GIRLS; ANOREXIA-NERVOSA; CONTROLLED-TRIAL; INTERVENTION; BINGE; PREVENTION; ONLINE; RISK C1 [Paxton, Susan J.] La Trobe Univ, Melbourne, Vic, Australia. [Franko, Debra L.] NE Univ, Boston, MA USA. [Franko, Debra L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Paxton, SJ (reprint author), La Trobe Univ, Melbourne, Vic, Australia. NR 60 TC 6 Z9 6 U1 0 U2 0 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-203-86753-2 PY 2010 BP 151 EP 168 PG 18 WC Psychology, Clinical; Computer Science, Interdisciplinary Applications; Psychiatry; Psychology SC Psychology; Computer Science; Psychiatry GA BUW80 UT WOS:000290534400009 ER PT J AU Mullins, CD Seal, B Seoane-Vazquez, E Sankaranarayanan, J Asche, CV Jayadevappa, R Lee, WC Romanus, DK Wang, JL Hay, JW Smeeding, J AF Mullins, C. Daniel Seal, Brian Seoane-Vazquez, Enrique Sankaranarayanan, Jayashri Asche, Carl V. Jayadevappa, Ravishankar Lee, Won Chan Romanus, Dorothy K. Wang, Junling Hay, Joel W. Smeeding, Jim TI Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report-Part IV SO VALUE IN HEALTH LA English DT Article DE cost study; drug cost; Medicaid; Medicare; pharmacoeconomic AB Objectives: Public programs finance a large share of the US pharmaceutical expenditures. To date, there are not guidelines for estimating the cost of drugs financed by US public programs. The objective of this study was to provide standards for estimating the cost of drugs financed by US public programs for utilization in pharmacoeconomic evaluations. Methods: This report was prepared by the ISPOR Task Force on Good Research Practices-Use of Drug Costs for Cost-Effectiveness Analysis Medicare, Medicaid, and other US Government Payers Subgroup. The Subgroup was convened to assess the methodological and practical issues confronted by researchers when estimating the cost of drugs financed by US public programs, and to propose standards for more transparent, accurate and consistent costing methods. Results: The Subgroup proposed these recommendations: 1) researchers must consider regulation requirements that affect the drug cost paid by public programs; 2) drug cost must represent the actual acquisition cost, incorporating any rebates or discounts; 3) transparency with respect to cost inputs must be ensured; 4) inclusion of the public program's perspective is recommended; 5) high cost drugs require special attention, particularly when drugs represent a significant proportion of health-care expenditures for a specific disease; and 6) because of variations across public programs, sensitivity analyses for actual acquisition cost, real-world adherence, and generics availability are warranted. Specific recommendations also were proposed for the Medicare and Medicaid programs. Conclusions: As pharmacoeconomic evaluations for coverage decisions made by US public programs grows, the need for precise and consistent estimation of drug costs is warranted. Application of the proposed recommendations will allow researchers to include accurate and unbiased cost estimates in pharmacoeconomic evaluations. C1 [Mullins, C. Daniel] Univ Maryland, Sch Pharm, PHSR Dept, Baltimore, MD 21201 USA. [Seal, Brian] Sanofi Aventis, Whitehouse Stn, NJ USA. [Seoane-Vazquez, Enrique] Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA. [Seoane-Vazquez, Enrique] Ohio State Univ, Coll Publ Hlth, Columbus, OH 43210 USA. [Sankaranarayanan, Jayashri] Univ Nebraska Med Ctr, Coll Pharm, Omaha, NE USA. [Asche, Carl V.] Univ Utah, Coll Pharm, Dept Pharmacotherapy, Salt Lake City, UT 84112 USA. [Jayadevappa, Ravishankar] Univ Penn, Philadelphia, PA 19104 USA. [Lee, Won Chan] IMS Consulting, Falls Church, VA USA. [Romanus, Dorothy K.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Wang, Junling] Univ Tennessee, Coll Pharm, Dept Pharmaceut Sci, Div Hlth Outcomes & Policy Res, Memphis, TN USA. [Wang, Junling] Univ Tennessee, Coll Pharm, Dept Clin Pharm, Div Hlth Outcomes & Policy Res, Memphis, TN USA. [Hay, Joel W.] Univ So Calif, Dept Clin Pharm Pharmaceut Econ & Policy, Los Angeles, CA USA. [Smeeding, Jim] JestaRx Grp, Dallas, TX USA. RP Mullins, CD (reprint author), Univ Maryland, Sch Pharm, PHSR Dept, 220 Arch St,12th Floor, Baltimore, MD 21201 USA. EM dmullins@rx.umaryland.edu NR 23 TC 7 Z9 7 U1 0 U2 5 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD JAN-FEB PY 2010 VL 13 IS 1 BP 18 EP 24 DI 10.1111/j.1524-4733.2009.00604.x PG 7 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 541PI UT WOS:000273429000006 PM 19807903 ER PT J AU Ge, PS Ng, G Ishaque, BM Gelabert, H de Virgilio, C AF Ge, Phillip S. Ng, Gladys Ishaque, Brandon M. Gelabert, Hugh de Virgilio, Christian TI Iatrogenic Pseudoaneurysm of the Superior Gluteal Artery Presenting as Pelvic Mass With Foot Drop and Sciatica: Case Report and Review of Literature SO VASCULAR AND ENDOVASCULAR SURGERY LA English DT Article DE pseudoaneurysm; gluteal artery; bone marrow biopsy; foot drop; sciatica; iatrogenic; gluteal pain; vascular surgery; coil embolization; aneurysm ID BONE-MARROW BIOPSY; COIL EMBOLIZATION; FALSE ANEURYSM; COMPLICATION; DIAGNOSIS; PAIN AB We report an unusual case of a pseudoaneurysm of the superior gluteal artery as a complication of bone marrow biopsy. A 51-year-old man presented with sciatic pain and foot drop after undergoing bone marrow biopsy and was initially diagnosed as having degenerative disc disease based on his past medical history. Pelvic magnetic resonance imaging (MRI) revealed a large heterogeneous mass suggestive of a neurogenic tumor, but pulsatile blood was instead encountered during computed tomography (CT)-guided needle biopsy. Subsequent workup established the diagnosis of a superior gluteal artery pseudoaneurysm, which was treated with coil embolization, followed by surgical evacuation of the hematoma, which relieved his sciatic pain. However, the patient continues to have a persistent foot drop. Gluteal artery pseudoaneurysms are exceedingly uncommon but should be considered in the workup of a patient with gluteal pain or sciatic nerve palsy following trauma or medical procedures in the gluteal region. C1 [Ge, Phillip S.; Ng, Gladys; Ishaque, Brandon M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Gelabert, Hugh; de Virgilio, Christian] W Los Angeles VA Med Ctr, Dept Surg, Los Angeles, CA USA. RP de Virgilio, C (reprint author), Harbor UCLA Med Ctr, Dept Surg, 1000 W Carson St, Torrance, CA 90309 USA. EM cdevirgilio@labiomed.org NR 21 TC 7 Z9 9 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1538-5744 J9 VASC ENDOVASC SURG JI Vasc. Endovasc. Surg. PD JAN PY 2010 VL 44 IS 1 BP 64 EP 68 DI 10.1177/1538574409351990 PG 5 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 546DY UT WOS:000273791100014 PM 19917559 ER PT J AU Taft, CT Schumm, J Orazem, RJ Meis, L Pinto, LA AF Taft, Casey T. Schumm, Jeremiah Orazem, Robert J. Meis, Laura Pinto, Lavinia A. TI Examining the Link Between Posttraumatic Stress Disorder Symptoms and Dating Aggression Perpetration SO VIOLENCE AND VICTIMS LA English DT Article DE PTSD; dating aggression; physical aggression; psychological aggression ID ALCOHOLISM-SCREENING-TEST; TRAIT ANGER; ARTICULATED THOUGHTS; PHYSICAL AGGRESSION; GENDER DIFFERENCES; MARITALLY VIOLENT; VIETNAM VETERANS; CONFLICT-TACTICS; COMBAT VETERANS; FIT INDEXES AB This study examined the role of posttraumatic stress disorder (PTSD) symptoms with respect to dating aggression perpetration among a sample of 199 undergraduates. Almost one-third of the overall sample reported physical dating aggression perpetration in the past year, and approximately 80% reported engaging in psychological dating aggression. Structural equation modeling (SEM) analyses indicated that the effects of trauma exposure on dating aggression were fully indirect via PTSD symptoms. PTSD symptoms were associated with psychological dating aggression in part through its association with anger, and alcohol problems were also directly related to this outcome. Results generalize findings from other populations suggesting the salience of trauma and PTSD symptoms in intimate relationship aggression and point to possible etiological pathways for these associations. C1 [Taft, Casey T.; Pinto, Lavinia A.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA. [Taft, Casey T.] Boston Univ, Sch Med, Boston, MA 02215 USA. [Schumm, Jeremiah] Cincinnati VA Med Ctr, Cincinnati, OH USA. [Orazem, Robert J.; Meis, Laura] Minneapolis VA Med Ctr, Minneapolis, MN USA. [Meis, Laura] Univ Minnesota, Minneapolis, MN 55455 USA. RP Taft, CT (reprint author), VA Boston Healthcare Syst 116B 4, Natl Ctr PTSD, 150 S Huntington Ave, Boston, MA 02130 USA. EM casey.taft@va.gov NR 58 TC 25 Z9 26 U1 3 U2 8 PU SPRINGER PUBLISHING CO PI NEW YORK PA 11 WEST 42ND STREET, NEW YORK, NY 10036 USA SN 0886-6708 J9 VIOLENCE VICTIMS JI Violence Vict. PY 2010 VL 25 IS 4 BP 456 EP 469 DI 10.1891/0886-6708.25.4.456 PG 14 WC Criminology & Penology SC Criminology & Penology GA 793KA UT WOS:000292819100003 PM 20712145 ER PT J AU Taft, C Schwartz, S Liebschutz, JM AF Taft, Casey Schwartz, Sonia Liebschutz, Jane M. TI Intimate Partner Aggression Perpetration in Primary Care Chronic Pain Patients SO VIOLENCE AND VICTIMS LA English DT Article DE chronic pain; aggression; primary health care; substance use; posttraumatic stress disorder ID INTERNATIONAL DIAGNOSTIC INTERVIEW; SF-12 HEALTH SURVEY; MARITAL INTERACTIONS; DOMESTIC VIOLENCE; SPOUSE RESPONSES; ANGER; RELIABILITY; BEHAVIORS; VALIDITY; ABUSE AB This study examined the prevalence and correlates of partner aggression perpetration in 597 primary care chronic pain patients. Approximately 30% of participants reported perpetrating low-level aggression, 12% reported injuring their partner, and 5% reported engaging in sexual coercion. Women reported more low-level aggression perpetration than men, and men reported more engagement in sexual coercion than women. Substance use disorders (SUD) were associated with all outcomes, and both aggression victimization and lifetime ratings of posttraumatic stress disorder (PTSD) were associated with low-level aggression and injuries. In multivariate analyses, gender, aggression victimization, PTSD, and SUD evidenced associations with one or more outcomes. Findings indicate a need for aggression screening in this population and highlight avenues for intervention. C1 [Taft, Casey] VA Boston Healthcare Syst, Boston, MA USA. [Schwartz, Sonia; Liebschutz, Jane M.] Boston Univ, Sch Med, Boston Med Ctr, Boston, MA 02215 USA. [Liebschutz, Jane M.] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA. RP Taft, C (reprint author), VA Boston Healthcare Syst 116B 4, 150 S Huntington Ave, Boston, MA 02130 USA. EM casey.taft@va.gov OI Liebschutz, Jane/0000-0003-3492-1521 FU NIAAA NIH HHS [K24 AA015674]; NIDA NIH HHS [K23 DA016665] NR 39 TC 3 Z9 3 U1 4 U2 5 PU SPRINGER PUBLISHING CO PI NEW YORK PA 11 WEST 42ND STREET, NEW YORK, NY 10036 USA SN 0886-6708 J9 VIOLENCE VICTIMS JI Violence Vict. PY 2010 VL 25 IS 5 BP 649 EP 661 DI 10.1891/0886-6708.25.5.649 PG 13 WC Criminology & Penology SC Criminology & Penology GA 793KE UT WOS:000292819500006 PM 21061870 ER PT B AU Fiorino, S Bihl, F Gramenzi, A Lorenzini, S Cursaro, C Loggi, E Fortini, C Bernardi, M Andreone, P AF Fiorino, Sirio Bihl, Florian Gramenzi, Annagiulia Lorenzini, Stefania Cursaro, Carmela Loggi, Elisabetta Fortini, Cinzia Bernardi, Mauro Andreone, Pietro BE Galos, EB TI VITAMIN E ACTIVITY IN IMMUNE RESPONSE: A POSSIBLE IMMUNOHENANCING ROLE IN CHRONIC VIRAL INFECTIONS SO VIRAL GENE EXPRESSION REGULATION SE Genetics-Research and Issues LA English DT Article; Book Chapter DE Vitamin E; immune response; interleukins; aging; viral infections ID REGULATORY T-CELLS; TOCOPHEROL TRANSFER PROTEIN; CHRONIC HEPATITIS-B; MAJOR HISTOCOMPATIBILITY COMPLEX; T-HELPER-1 CYTOKINE PRODUCTION; RANDOMIZED CONTROLLED-TRIAL; HUMAN PERIPHERAL-BLOOD; CONTROLLED PILOT TRIAL; ALL-CAUSE MORTALITY; HIGH-RISK PATIENTS AB In recent years, many roles of Vitamin E have been demonstrated and include not only antioxidant functions, but also cell signaling and immunemodulatory functions. In this paper the experimental and clinical evidence of vitamin E immunomodulatory properties as well as the vitamin E biological activities able to stimulate and enhance immune activities are briefly reviewed. Several lines of evidence suggest that vitamin E might be useful to improve immune unresponsiveness induced by several pathological conditions such as chronic viral infections and make its use in this setting promising. Further studies investigating the effects of Vitamin E on are of interest as they might help to identify its therapeutic utility in chronic infections. C1 [Andreone, Pietro] Univ Bologna, Policlin S Orsola Malpighi, Dipartimento Med Interna, I-40138 Bologna, Italy. [Bihl, Florian] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Partners AIDS Res Ctr, Boston, MA USA. RP Andreone, P (reprint author), Univ Bologna, Policlin S Orsola Malpighi, Dipartimento Med Interna, Via Massarenti 9, I-40138 Bologna, Italy. EM andreone@med.unibo.it NR 145 TC 0 Z9 0 U1 0 U2 1 PU NOVA SCIENCE PUBLISHERS, INC PI HAUPPAUGE PA 400 OSER AVE, STE 1600, HAUPPAUGE, NY 11788-3635 USA BN 978-1-60741-224-3 J9 GEN-RES ISSUES PY 2010 BP 143 EP 161 PG 19 WC Genetics & Heredity SC Genetics & Heredity GA BPD12 UT WOS:000278552100004 ER PT S AU Yee, J AF Yee, J. BE Lefere, P Gryspeerdt, S TI Patient Preparation for CT Colonography SO VIRTUAL COLONOSCOPY: A PRACTICAL GUIDE, SECOND EDITION SE Medical Radiology Diagnostic Imaging LA English DT Article; Book Chapter ID ORAL SODIUM-PHOSPHATE; CONTRAST BARIUM ENEMA; GLYCOL ELECTROLYTE LAVAGE; BOWEL CLEANSING METHODS; CARBON-DIOXIDE; COLONOSCOPY PREPARATION; COLONIC DISTENSION; RANDOMIZED TRIAL; ANTISPASMODIC DRUGS; INSUFFLATION AGENTS C1 Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Yee, J (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM Judy.Yee@med.va.gov NR 46 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0942-5373 BN 978-3-540-79879-8 J9 MED RADIOL DIAGN IMA PY 2010 BP 49 EP 59 DI 10.1007/978-3-540-79886-6_5 D2 10.1007/978-3-540-79886-6 PG 11 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA BMQ91 UT WOS:000273363400005 ER PT S AU Yoshida, H AF Yoshida, H. BE Lefere, P Gryspeerdt, S TI The Future: Computer-Aided Detection SO VIRTUAL COLONOSCOPY: A PRACTICAL GUIDE, SECOND EDITION SE Medical Radiology Diagnostic Imaging LA English DT Article; Book Chapter ID COLONOGRAPHY VIRTUAL COLONOSCOPY; CONTRAST BARIUM ENEMA; CT COLONOGRAPHY; TOMOGRAPHIC COLONOGRAPHY; COLONIC POLYPS; DIAGNOSIS SCHEME; COLORECTAL NEOPLASIA; VOLUMETRIC FEATURES; FALSE POSITIVES; DISPLAY MODES C1 [Yoshida, H.] Massachusetts Gen Hosp, Deapartment Radiol, Boston, MA 02114 USA. [Yoshida, H.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Yoshida, H.] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Yoshida, H (reprint author), Massachusetts Gen Hosp, Deapartment Radiol, 75 Blossom Court, Boston, MA 02114 USA. EM yoshida@uchicago.edu NR 79 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0942-5373 BN 978-3-540-79879-8 J9 MED RADIOL DIAGN IMA PY 2010 BP 175 EP 189 DI 10.1007/978-3-540-79886-6_14 D2 10.1007/978-3-540-79886-6 PG 15 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA BMQ91 UT WOS:000273363400014 ER PT S AU Dachman, AH Obara, PR Zalis, ME AF Dachman, Abraham H. Obara, Piotr R. Zalis, Michael E. BE Lefere, P Gryspeerdt, S TI Quality and Consistency in Reporting CT Colonography SO VIRTUAL COLONOSCOPY: A PRACTICAL GUIDE, SECOND EDITION SE Medical Radiology Diagnostic Imaging LA English DT Article; Book Chapter ID CONVENTIONAL COLONOSCOPY; COLORECTAL NEOPLASMS; OPTICAL COLONOSCOPY; ASYMPTOMATIC ADULTS; POLYP MEASUREMENT; LESIONS C1 [Dachman, Abraham H.; Obara, Piotr R.] Univ Chicago, Dept Radiol, Chicago, IL 60645 USA. [Zalis, Michael E.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Dachman, AH (reprint author), Univ Chicago, Dept Radiol, 5841 S Maryland Ave, Chicago, IL 60645 USA. EM ahdachma@uchicago.edu; mzalis@partners.org NR 15 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0942-5373 BN 978-3-540-79879-8 J9 MED RADIOL DIAGN IMA PY 2010 BP 191 EP 197 DI 10.1007/978-3-540-79886-6_15 D2 10.1007/978-3-540-79886-6 PG 7 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA BMQ91 UT WOS:000273363400015 ER PT J AU Mylonakis, E Riedmann, EM AF Mylonakis, Eleftherios Riedmann, Eva M. TI Virulence A new multi-disciplinary journal SO VIRULENCE LA English DT Editorial Material C1 [Mylonakis, Eleftherios] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Mylonakis, Eleftherios] Harvard Univ, Sch Med, Div Infect Dis, Boston, MA USA. [Riedmann, Eva M.] Landes Biosci, Austin, TX USA. RP Mylonakis, E (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM EMylonakis@partners.org NR 1 TC 0 Z9 0 U1 0 U2 1 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 2150-5594 J9 VIRULENCE JI Virulence PD JAN-FEB PY 2010 VL 1 IS 1 BP 1 EP 1 DI 10.4161/viru.1.1.9235 PG 1 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 788TQ UT WOS:000292467700001 ER PT J AU Means, TK AF Means, Terry K. TI Evolutionarily conserved recognition and innate immunity to fungal pathogens by the scavenger receptors SCARF1 and CD36 SO VIRULENCE LA English DT Article DE fungi; toll-like receptors; scavenger receptors; macrophages; Caenorhabditis elegans ID TOLL-LIKE RECEPTOR; CRYPTOCOCCUS-NEOFORMANS INFECTION; NOD-LIKE RECEPTORS; CANDIDA-ALBICANS; BETA-GLUCANS; HOST-DEFENSE; SREC-I; CAENORHABDITIS-ELEGANS; ENDOTHELIAL-CELLS; DENDRITIC CELLS AB Macrophages are important cells in the host resistance to fungal infections, and fungal recognition by macrophages triggers phagocytosis, intracellular killing, induction of inflammatory cytokines and chemokines, and initiation of the adaptive immune response. All of the receptors that mediate binding and engulfment of fungal pathogens and the signaling pathways triggered by fungal pathogens that regulate anti-fungal immunity are not fully understood. Using an RNAi screen we recently demonstrated that the C. elegans receptors CED-1 and C03F11.3, and their mammalian orthologues, the scavenger receptors SCARF1 and CD36 mediate host defense against the fungal pathogen, Cryptococcus neoformans. Finally, SCARF1 and CD36 function as co-receptors by binding and engulfing fungal pathogens to facilitate Toll-like receptor 2 signaling. Here we will summarize and expand upon our previous findings. C1 [Means, Terry K.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Charlestown, MA USA. [Means, Terry K.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Charlestown, MA USA. [Means, Terry K.] Harvard Univ, Sch Med, Charlestown, MA USA. [Means, Terry K.] Broad Inst MIT & Harvard, Cambridge, MA USA. RP Means, TK (reprint author), Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Charlestown, MA USA. EM tmeans@partners.org FU NIAID NIH HHS [R01 AI084884] NR 55 TC 7 Z9 10 U1 4 U2 13 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 2150-5594 J9 VIRULENCE JI Virulence PD JAN-FEB PY 2010 VL 1 IS 1 BP 37 EP 41 DI 10.4161/viru.1.1.10228 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 788TQ UT WOS:000292467700009 PM 21178411 ER PT B AU Demay, MB AF Demay, Marie B. BE Holick, MF TI Inherited Defects of Vitamin D Metabolism SO VITAMIN D: PHYSIOLOGY, MOLECULAR BIOLOGY, AND CLINICAL APPLICATIONS, SECOND EDITION SE Nutrition and Health Series LA English DT Article; Book Chapter DE Vitamin D resistance; rickets; vitamin D-resistant rickets; pseudovitamin D deficiency rickets; 25-hydroxyvitamin D; 1,25-dihydroxyvitamin D; 1-hydroxylase; vitamin D receptor ID D-DEPENDENT RICKETS; END-ORGAN RESISTANCE; D-RECEPTOR; HEREDITARY RESISTANCE; ALPHA-HYDROXYLASE; CALCIUM INFUSIONS; INBORN ERROR; D DEFICIENCY; 1,25-DIHYDROXYVITAMIN-D; ALOPECIA AB Inherited defects that interfere with vitamin D metabolism and action have contributed significantly to our understanding of the molecular and physiological actions of the vitamin D endocrine system. This chapter reviews the genetic syndromes that result from impaired hydroxylation of vitamin D. from impaired vitamin D receptor action, and the biological basis for the resultant phenotypes. C1 Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. RP Demay, MB (reprint author), Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. NR 40 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-60327-300-8 J9 NUTR HEALTH SER JI Nutr. Health Ser. PY 2010 BP 679 EP 689 DI 10.1007/978-1-60327-303-9_36 D2 10.1007/978-1-60327-303-9 PG 11 WC Nutrition & Dietetics SC Nutrition & Dietetics GA BOR11 UT WOS:000277365800036 ER PT B AU Bhan, I Tamez, H Thadhani, R AF Bhan, Ishir Tamez, Hector Thadhani, Ravi BE Holick, MF TI Role of Vitamin D and Vitamin D Analogs for Bone Health and Survival in Chronic Kidney Disease SO VITAMIN D: PHYSIOLOGY, MOLECULAR BIOLOGY, AND CLINICAL APPLICATIONS, SECOND EDITION SE Nutrition and Health Series LA English DT Article; Book Chapter DE Chronic kidney disease; vitamin D; 25-hydroxyvitamin D; kidney disease; 1,25-dihydroxyvitamin D; 1 alpha-hydroxylase; bone disease; osteomalacia; vitamin D deficiency; parathyroid hormone ID CHRONIC-RENAL-FAILURE; RENIN-ANGIOTENSIN SYSTEM; SECONDARY HYPERPARATHYROIDISM; HEMODIALYSIS-PATIENTS; 1,25-DIHYDROXYVITAMIN D-3; PARATHYROID-HORMONE; 25-HYDROXYVITAMIN D; CALCITRIOL THERAPY; CARDIAC MYOCYTES; ADYNAMIC BONE AB Chronic kidney disease (CKD) is accompanied by reduced conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D and is often also associated with a deficiency of 25-hydroxyvitamin D. These and other metabolic changes can lead to secondary hyperparathyroidism and a range of disorders of bone turnover, mineralization, and volume, the most prominent of which is osteitis fibrosa cystica. Attempts to prevent this disorder have led to widespread use of vitamin D receptor agonists, but may increase the risk of adynamic bone disease. Beyond its use in regulating bone metabolism, several studies suggest that vitamin D may influence survival in advanced CKD. Potential mechanisms for this effect are likely to influence cardiovascular disease, the leading cause of death in CKD. Alterations in left ventricular function and the renin angiotensin aldosterone axis appear to be modulated by vitamin D. We discuss these and other aspects of the role vitamin D may play in the CKD population as well as the current state of evidence supporting, therapeutic use. C1 [Bhan, Ishir; Tamez, Hector; Thadhani, Ravi] Massachusetts Gen Hosp, Renal Unit, Boston, MA 02114 USA. RP Bhan, I (reprint author), Massachusetts Gen Hosp, Renal Unit, Boston, MA 02114 USA. NR 64 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-60327-300-8 J9 NUTR HEALTH SER JI Nutr. Health Ser. PY 2010 BP 955 EP 965 DI 10.1007/978-1-60327-303-9_52 D2 10.1007/978-1-60327-303-9 PG 11 WC Nutrition & Dietetics SC Nutrition & Dietetics GA BOR11 UT WOS:000277365800052 ER PT B AU Camargo, CA Ginde, AA Mansbach, JM AF Camargo, Carlos A., Jr. Ginde, Adit A. Mansbach, Jonathan M. BE Holick, MF TI Vitamin D, Respiratory Infections, and Obstructive Airway Diseases SO VITAMIN D: PHYSIOLOGY, MOLECULAR BIOLOGY, AND CLINICAL APPLICATIONS, SECOND EDITION SE Nutrition and Health Series LA English DT Article; Book Chapter DE Respiratory infections; bronchiolitis; asthma; chronic obstructive pulmonary disease; obstructive airway disease; hCAP-18; interleukin-10; atopic dermatitis; anaphylaxis ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; REGULATORY T-CELLS; D-RECEPTOR GENE; BONE-MINERAL DENSITY; D DEFICIENCY; SYNCYTIAL VIRUS; 1,25-DIHYDROXYVITAMIN D-3; EMERGENCY-DEPARTMENT; D SUPPLEMENTATION AB Over the past decade, interest has grown in the effects of vitamin D on respiratory infections and obstructive airway diseases (OADs), such as asthma and chronic obstructive pulmonary disease (COPD). Studies suggest that low vitamin D levels increase the risk of acute respiratory infections, which may contribute to incident wheezing illness and cause asthma exacerbations. Although unproven, the increased risk of susceptible hosts to specific respiratory pathogens may contribute to some cases of incident asthma. Likewise, the effect of vitamin D on COPD, while intriguing, is largely unknown. Emerging evidence provides biological plausibility or some of these respiratory findings. For example, vitamin D-mediated innate immunity, particularly through enhanced expression of the human cathelicidin antimicrobial peptide, is important in host defenses against respiratory pathogens. Vitamin D also modulates regulatory I-cell function and interleukin-10 production, which may increase the therapeutic response to corticosteroids in corticosteroid-resistant asthma. Finally, low vitamin D levels may have a role in the pathogenesis of allergies, including anaphylaxis. Further studies, especially randomized controlled trials, are needed to better understand vitamin D's effects on respiratory infections and OADs. C1 [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA 02115 USA. [Ginde, Adit A.] Univ Colorado, Denver Sch Med, Dept Emergency Med, Aurora, CO USA. [Mansbach, Jonathan M.] Harvard Univ, Sch Med, Dept Med, Childrens Hosp Boston, Boston, MA USA. RP Camargo, CA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA 02115 USA. NR 139 TC 4 Z9 4 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-60327-300-8 J9 NUTR HEALTH SER JI Nutr. Health Ser. PY 2010 BP 997 EP 1021 DI 10.1007/978-1-60327-303-9_55 D2 10.1007/978-1-60327-303-9 PG 25 WC Nutrition & Dietetics SC Nutrition & Dietetics GA BOR11 UT WOS:000277365800055 ER PT B AU Bird, TD AF Bird, Thomas D. BE Speicher, MR Antonarakis, SE Motulsky, AG TI Genetic Factors in Alzheimer Disease and Dementia SO VOGEL AND MOTULSKY'S HUMAN GENETICS, FOURTH EDITION: PROBLEMS AND APPROACHES LA English DT Article; Book Chapter ID FRONTOTEMPORAL LOBAR DEGENERATION; APOLIPOPROTEIN-E GENOTYPE; PLACEBO-CONTROLLED TRIAL; AMYOTROPHIC-LATERAL-SCLEROSIS; BETA-PEPTIDE DEPOSITION; DOWN-SYNDROME; NEUROPATHOLOGIC CHANGES; COGNITIVE IMPAIRMENT; 1ST-DEGREE RELATIVES; PROSPECTIVE COHORT AB Alzheimer disease (AD) is a common and complex disorder affecting several million people world-wide. It is defined clinically as a progressive dementing illness associated with A beta-amyloid neuritic plaques and neurofibrillary tangles in the brain. From a genetic standpoint it is a heterogeneous disorder. Three separate genes (APP, PSEN1, PSEN2) each cause an autosomal dominant, highly penetrant, early-onset, familial form of the disease. The three proteins encoded by these genes all influence the production of the toxic A beta(1-42) form of amyloid. Commercial genetic testing is available for these rare forms of AD. However, mutations in these genes represent less than 2% of all cases of AD. The more common late-onset form of AD is thought to be polygenic and multi factorial. The epsilon 4 allele of apolipoprotein E (ApoE) is a known genetic risk factor for late-onset AD, lowering the average age of onset by unknown mechanisms. Numerous other candidate risk genes are being identified through genome wide association studies, but have been difficult to confirm. Other familial forms of dementia, such as frontotemporal dementia (FTD), prion-associated diseases, and CADASIL, may be caused by autosomal dominant mutations occurring in their respective genes (MAPT, GRN, PRNP, Notch-3). C1 Univ Washington, Geriatr Res Educ & Clin Ctr 182, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Bird, TD (reprint author), Univ Washington, Geriatr Res Educ & Clin Ctr 182, VA Puget Sound Hlth Care Syst, 1600 S Columbian Way, Seattle, WA 98108 USA. EM tomnroz@u.washington.edu NR 136 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-3-540-37653-8 PY 2010 BP 681 EP 697 DI 10.1007/978-3-540-37654-5_23.3 D2 10.1007/978-3-540-37654-5 PG 17 WC Genetics & Heredity SC Genetics & Heredity GA BNM20 UT WOS:000274935100028 ER PT S AU Peroni, M Stancanello, J Muacevic, A Riboldi, M Spadea, MF Sharp, GC Baroni, G AF Peroni, M. Stancanello, J. Muacevic, A. Riboldi, M. Spadea, M. F. Sharp, G. C. Baroni, G. BE Dossel, O Schlegel, WC TI Feasibility Study of B-Spline Deformable Registration between CT and MRI Atlas for Trigeminal Neuralgia Application to Radiosurgery SO WORLD CONGRESS ON MEDICAL PHYSICS AND BIOMEDICAL ENGINEERING, VOL 25, PT 4: IMAGE PROCESSING, BIOSIGNAL PROCESSING, MODELLING AND SIMULATION, BIOMECHANICS SE IFMBE Proceedings LA English DT Proceedings Paper CT 11th International Congress of the IUPESM/World Congress on Medical Physics and Biomedical Engineering CY SEP 07-12, 2009 CL Munich, GERMANY SP IUPESM, Int Org Med Phys (IOMP) DE Radiosurgery; Multi-modality deformable registration; Segmentation; Trigeminal Neuralgia AB The objective of this work is to extend a B-spline deformable registration method to the multi-modality problem of matching a T1 Magnetic Resonance (MR) atlas to a Computed Tomography (CT) scan for improving image guidance in radiosurgery treatments of trigeminal neuralgia (TN). Trigeminal Rhyzotomy has been used in an attempt to alleviate TN in patients in whom pharmaceutical treatment fails in pain control or induces unendurable side effects. We tested the developed algorithm on a two patients dataset, using a 3 Tesla MR scan as ground truth. The validation was conducted by means of visual inspection and computing the surface distance between the trigeminal nerve outlined both on the warped atlas and CT. Three raters contoured the region of interest on both scans, thus providing inter-rater accuracy evaluation. Good results in terms of qualitative trigeminal nerve overlap were supported by the median distance (below 1.3mm and 1.5mm for patient 1 and 2, respectively) and the consistency between the raters judgment. Though subject to inaccuracies mainly caused by manual contouring variations, suggest the proposed approach can be a valid alternative to 3Tesla MR scanning. C1 [Peroni, M.; Riboldi, M.; Spadea, M. F.; Baroni, G.] Politecn Milan, Dept Bioengn, Via Golgi 39, I-20133 Milan, Italy. [Stancanello, J.] Siemens AG, Res & Clin Collaborat, Erlangen, Germany. [Muacevic, A.] European Cyberknife Ctr, D-81377 Munich, Germany. [Spadea, M. F.] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, Catanzaro, Italy. [Sharp, G. C.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Sharp, G. C.] Harvard Med Sch, Radiat Oncol, Boston, MA USA. RP Peroni, M (reprint author), Politecn Milan, Dept Bioengn, Via Golgi 39, I-20133 Milan, Italy. EM marta.peroni@mail.polimi.it NR 8 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1680-0737 BN 978-3-642-03881-5 J9 IFMBE PROC PY 2010 VL 25 BP 1649 EP 1652 PN 4 PG 4 WC Engineering, Biomedical SC Engineering GA BZB27 UT WOS:000300975300437 ER PT J AU Eppsteiner, RW Shin, JJ Johnson, J van Dam, RM AF Eppsteiner, Robert W. Shin, Jennifer J. Johnson, Jonas van Dam, Rob M. TI Mechanical Compression Versus Subcutaneous Heparin Therapy in Postoperative and Posttrauma Patients: A Systematic Review and Meta-Analysis SO WORLD JOURNAL OF SURGERY LA English DT Review ID MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; TOTAL HIP-REPLACEMENT; INTERMITTENT PNEUMATIC COMPRESSION; GYNECOLOGIC ONCOLOGY SURGERY; RANDOMIZED CLINICAL-TRIAL; RISK TRAUMA PATIENTS; LOW-DOSE HEPARIN; VENOUS THROMBOSIS; FOOT-PUMP AB The risk of postoperative venous thromboembolic disease is as high as 30%, with an associated fatality risk of 1%. Therefore, prophylaxis is essential, but the optimal regimen remains controversial. This study was designed to systematically review and quantitatively summarize the impact of mechanical compression versus subcutaneous heparin on venous thromboembolic disease and posttreatment bleeding in postsurgical and posttrauma patients. Computerized searches of the MEDLINE and EMBASE databases through November 2008 were performed and supplemented with manual searches. We included studies that had: (1) a patient population undergoing surgery or admitted immediately posttrauma, (2) a randomized comparison of prophylaxis with mechanical compression versus subcutaneous heparin, (3) outcome measured in terms of deep vein thrombosis (DVT), pulmonary embolism (PE), or bleeding. Two reviewers independently extracted data from the original articles, which represented 16 studies, including a total of 3,887 subjects. Meta-analysis was performed using a random effects model. The pooled relative risk for mechanical compression compared with subcutaneous heparin was 1.07 (95% confidence interval [CI] 0.72, 1.61) for DVT and 1.03 (95% CI 0.48, 2.22) for PE. Mechanical compression was associated with a significantly reduced risk of postoperative bleeding compared with subcutaneous heparin (risk ratio 0.47; 95% CI 0.31, 0.70). Subgroup analyses by heparin type suggested that low molecular weight heparin may reduce risk of DVT compared with compression (relative risk 1.80; 95% CI 1.16, 2.79) but remains similarly associated with an increased risk of bleeding. These results suggest that the overall bleeding risk profile favors the use of compression over heparin, with the benefits in term of venous thromboembolic disease prophylaxis being similar between groups. Subgroup analyses suggest that low molecular weight heparin may have a differential effect; this observation should be further evaluated in future studies. C1 [Shin, Jennifer J.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02114 USA. [Eppsteiner, Robert W.] Univ Iowa, Dept Otolaryngol Head & Neck Surg, Iowa City, IA 52242 USA. [Johnson, Jonas] Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA 15213 USA. [van Dam, Rob M.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. RP Shin, JJ (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, 243 Charles St, Boston, MA 02114 USA. EM robert-eppsteiner@uiowa.edu; jennifer_shin@meei.harvard.edu RI van Dam, Rob/F-9674-2010; Shin, Jennifer/A-3169-2016 OI van Dam, Rob/0000-0002-7354-8734; NR 35 TC 22 Z9 25 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0364-2313 J9 WORLD J SURG JI World J.Surg. PD JAN PY 2010 VL 34 IS 1 BP 10 EP 19 DI 10.1007/s00268-009-0284-z PG 10 WC Surgery SC Surgery GA 534OJ UT WOS:000272906700003 PM 20020289 ER PT S AU Billings, LK Florez, JC AF Billings, Liana K. Florez, Jose C. BE Powers, AC Ahima, RS TI The genetics of type 2 diabetes: what have we learned from GWAS? SO YEAR IN DIABETES AND OBESITY SE Annals of the New York Academy of Sciences LA English DT Article; Book Chapter DE gnome-wide association studies; type 2 diabetes; genetics; single nucleotide polymorphisms ID GENOME-WIDE ASSOCIATION; FASTING PLASMA-GLUCOSE; ZINC TRANSPORTER ZNT8; C-REACTIVE PROTEIN; BETA-CELL FUNCTION; HOMEOSTASIS MODEL ASSESSMENT; LARGE-SCALE ASSOCIATION; INSULIN-SECRETION; COMMON VARIANTS; SUSCEPTIBILITY LOCI AB Type 2 diabetes mellitus has been at the forefront of human diseases and phenotypes studied by new genetic analyses. Thanks to genome-wide association studies, we have made substantial progress in elucidating the genetic basis of type 2 diabetes. This review summarizes the concept, history, and recent discoveries produced by genome-wide association studies for type 2 diabetes and glycemic traits, with a focus on the key notions we have gleaned from these efforts. Genome-wide association findings have illustrated novel pathways, pointed toward fundamental biology, confirmed prior epidemiological observations, drawn attention to the role of beta-cell dysfunction in type 2 diabetes, explained similar to 10% of disease heritability, tempered our expectations with regard to their use in clinical prediction, and provided possible targets for pharmacotherapy and pharmacogenetic clinical trials. We can apply these lessons to future investigation so as to improve our understanding of the genetic basis of type 2 diabetes. C1 [Billings, Liana K.; Florez, Jose C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Billings, Liana K.; Florez, Jose C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Billings, Liana K.; Florez, Jose C.] Massachusetts Gen Hosp, Dept Med, Diabet Res Ctr, Diabet Unit, Boston, MA 02114 USA. [Florez, Jose C.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA. RP Florez, JC (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, Simches Res Bldg,CPZN 5-250,185 Cambridge St, Boston, MA 02114 USA. EM joflorez@partners.org FU NIDDK NIH HHS [5 T32 DK007028-35, T32 DK007028] NR 114 TC 153 Z9 155 U1 8 U2 36 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA SN 0077-8923 BN 978-1-57331-756-6 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2010 VL 1212 BP 59 EP 77 DI 10.1111/j.1749-6632.2010.05838.x PG 19 WC Endocrinology & Metabolism; Multidisciplinary Sciences SC Endocrinology & Metabolism; Science & Technology - Other Topics GA BTO16 UT WOS:000287463600005 PM 21091714 ER PT S AU Sankaran, VG Lettre, G Orkin, SH Hirschhorn, JN AF Sankaran, Vijay G. Lettre, Guillaume Orkin, Stuart H. Hirschhorn, Joel N. BE Casanova, JL Abel, L Lyonnet, S TI Modifier genes in Mendelian disorders: the example of hemoglobin disorders SO YEAR IN HUMAN AND MEDICAL GENETICS: NEW TRENDS IN MENDELIAN GENETICS SE Annals of the New York Academy of Sciences LA English DT Article; Book Chapter DE sickle cell disease; beta-thalassemia; fetal hemoglobin; association studies ID SICKLE-CELL-DISEASE; GENOME-WIDE ASSOCIATION; QUANTITATIVE-TRAIT LOCUS; BETA-GLOBIN GENE; FETAL-HEMOGLOBIN; ALPHA-THALASSEMIA; RISK-FACTORS; ABNORMAL-HEMOGLOBINS; CHROMOSOME 6Q23; SUDAN SAVANNA AB The disorders of hemoglobin, including sickle cell disease (SCD) and beta-thalassemia, are the most common "Mendelian" genetic diseases in the world. Numerous studies have demonstrated the complexity in making genotype- phenotype correlations in both SCD and beta-thalassemia. Indeed, patients with exactly the same set of pathogenic globin mutations can have dramatically variable clinical courses. We discuss natural history studies that have attempted to delineate the factors responsible for the variability among the numerous clinical complications noted in these diseases. We then discuss, in depth, two well characterized ameliorating factors in the beta-hemoglobin disorders, concomitant alpha-thalassemia, and elevated levels of fetal hemoglobin (HbF). We use the study of HbF regulation to illustrate how important insights into the genetic modifiers in Mendelian diseases can be achieved through the study of such factors. We finally go on to discuss future avenues of research that may allow us to gain further insight into the poorly understood clinical heterogeneity of this fascinating set of common genetic diseases. C1 [Hirschhorn, Joel N.] Childrens Hosp, Div Genet, Boston, MA 02115 USA. [Hirschhorn, Joel N.] Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA. [Hirschhorn, Joel N.] Childrens Hosp, Program Genom, Boston, MA 02115 USA. [Hirschhorn, Joel N.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA. [Sankaran, Vijay G.; Orkin, Stuart H.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. [Sankaran, Vijay G.; Orkin, Stuart H.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Lettre, Guillaume] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada. [Lettre, Guillaume] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada. RP Hirschhorn, JN (reprint author), Childrens Hosp, Div Genet, 300 Longwood Ave, Boston, MA 02115 USA. EM stuart_orkin@dfci.harvard.edu; joelh@broadinstitute.org NR 78 TC 17 Z9 18 U1 1 U2 9 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA SN 0077-8923 BN 978-1-57331-789-4 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2010 VL 1214 BP 47 EP 56 DI 10.1111/j.1749-6632.2010.05821.x PG 10 WC Genetics & Heredity; Multidisciplinary Sciences SC Genetics & Heredity; Science & Technology - Other Topics GA BTH63 UT WOS:000286946700004 PM 21039591 ER PT S AU Kong, YCM Wei, WZ Tomer, Y AF Kong, Yi-chi M. Wei, Wei-Zen Tomer, Yaron BE Rose, NR TI Opportunistic autoimmune disorders From immunotherapy to immune dysregulation SO YEAR IN IMMUNOLOGY 2 SE Annals of the New York Academy of Sciences LA English DT Article; Book Chapter DE opportunistic autoimmunity; immunotherapeutic sequelae; immunotherapy; autoimmunity; immune dysregulation ID CHRONIC HEPATITIS-C; STEM-CELL TRANSPLANTATION; LYMPHOCYTE-ASSOCIATED ANTIGEN-4; REGULATORY T-CELLS; INTERFERON-ALPHA THERAPY; CHRONIC VIRAL-HEPATITIS; LEUKOCYTE-DERIVED INTERFERON; MULTIPLE-SCLEROSIS PATIENTS; LONG-TERM THERAPY; THYROID-DISEASE AB Rapid advances in our understanding of the immune network have led to treatment modalities for malignancies and autoimmune diseases based on modulation of the immune response. Yet therapeutic modulation has resulted in immune dysregulation and opportunistic autoimmune sequelae, despite prescreening efforts in clinical trials. This review focuses on recent clinical data on opportunistic autoimmune disorders arising from three immunotherapeutic modalities: (1) systemic immunomodulators, including interferon-alpha (also used to treat hepatitis C patients) and interferon-beta; (2) monoclonal antibodies to CTLA-4 and CD52, and (3) hematopoietic stem cell transplantation. Uncategorized predisposing factors in these patients include major histocompatibility complex and gender genetics, prevalence of different autoimmune diseases, prior chemotherapy, underlying disorder (e.g., hepatitis C), and preconditioning regimens as part of organ and stem cell transplants. Not unexpectedly, the prevalent autoimmune thyroid disease surfaced frequently. Our combination models to study the balance between thyroid autoimmunity and tumor immunity upon regulatory T-cell perturbation are briefly described. C1 [Kong, Yi-chi M.] Wayne State Univ, Sch Med, Dept Immunol & Microbiol, Detroit, MI 48201 USA. [Wei, Wei-Zen] Wayne State Univ, Sch Med, Karmanos Canc Inst, Detroit, MI 48201 USA. [Tomer, Yaron] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Tomer, Yaron] James J Peters VA Med Ctr, New York, NY USA. RP Kong, YCM (reprint author), Wayne State Univ, Sch Med, Dept Immunol & Microbiol, 540 E Canfield Ave, Detroit, MI 48201 USA. EM ykong@med.wayne.edu FU NCI NIH HHS [CA125680, P30 CA022453, R01 CA125680]; NIDDK NIH HHS [DK073681, DK45960, DK61659, R01 DK045960, R01 DK061659, R01 DK073681] NR 116 TC 16 Z9 16 U1 1 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA SN 0077-8923 BN 978-1-57331-779-5 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2010 VL 1183 BP 222 EP 236 PG 15 WC Immunology SC Immunology GA BNG71 UT WOS:000274519000015 PM 20146718 ER PT S AU Xu, C Zon, LI AF Xu, Cong Zon, Leonard I. BE Perry, SF Ekker, M Farrell, AP Brauner, CJ TI THE ZEBRAFISH AS A MODEL FOR HUMAN DISEASE SO ZEBRAFISH SE Fish Physiology LA English DT Article; Book Chapter ID AUTOSOMAL-DOMINANT HEMOCHROMATOSIS; REGULATED TRANSGENIC ZEBRAFISH; ACUTE LYMPHOBLASTIC-LEUKEMIA; GENOMIC INSTABILITY MUTANTS; INTEGRIN-LINKED KINASE; T-CELL LEUKEMIA; CANCER SUSCEPTIBILITY; POSITIONAL CLONING; QT SYNDROME; MUTATION C1 [Xu, Cong; Zon, Leonard I.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Dana Farber Canc Inst,Harvard Stem Cell Inst, Boston, MA 02115 USA. [Zon, Leonard I.] Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA. [Zon, Leonard I.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. RP Xu, C (reprint author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dana Farber Canc Inst,Harvard Stem Cell Inst, Boston, MA 02115 USA. NR 54 TC 4 Z9 4 U1 1 U2 2 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 1546-5098 BN 978-0-08-096137-8 J9 FISH PHYSIOL JI Fish Physiology PY 2010 VL 29 BP 345 EP 365 DI 10.1016/S1546-5098(10)02909-2 PG 21 WC Fisheries SC Fisheries GA BCS94 UT WOS:000311303000010 ER PT S AU Stewart, RA Lee, JS Lachnit, M Look, AT Kanki, JP Henion, PD AF Stewart, Rodney A. Lee, Jeong-Soo Lachnit, Martina Look, A. Thomas Kanki, John P. Henion, Paul D. BE Detrich, HW Westerfield, M Zon, LI TI Studying Peripheral Sympathetic Nervous System Development and Neuroblastoma in Zebrafish SO ZEBRAFISH: CELLULAR AND DEVELOPMENTAL BIOLOGY, PT A, THIRD EDITION SE Methods in Cell Biology LA English DT Review; Book Chapter ID DOPAMINE-BETA-HYDROXYLASE; NEURAL CREST CELLS; TRANSCRIPTION FACTOR HAND2; ZINC-FINGER NUCLEASES; HOMEOBOX GENE PHOX2B; TYROSINE-HYDROXYLASE; GROWTH-FACTOR; NORADRENERGIC DIFFERENTIATION; CHROMAFFIN CELLS; IN-VIVO AB The combined experimental attributes of the zebrafish model system, which accommodates cellular, molecular, and genetic approaches, make it particularly well-suited for determining the mechanisms underlying normal vertebrate development as well as disease states, such as cancer. In this chapter, we describe the advantages of the zebrafish system for identifying genes and their functions that participate in the regulation of the development of the peripheral sympathetic nervous system (PSNS). The zebrafish model is a powerful system for identifying new genes and pathways that regulate PSNS development, which can then be used to genetically dissect PSNS developmental processes, such as tissue size and cell numbers, which in the past haves proved difficult to study by mutational analysis in vivo. We provide a brief review of our current understanding of genetic pathways important in PSNS development, the rationale for developing a zebrafish model, and the current knowledge of zebrafish PSNS development. Finally, we postulate that knowledge of the genes responsible for normal PSNS development in the zebrafish will help in the identification of molecular pathways that are dysfunctional in neuroblastoma, a highly malignant cancer of the PSNS. C1 [Stewart, Rodney A.; Lachnit, Martina] Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA. [Lee, Jeong-Soo; Look, A. Thomas; Kanki, John P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Henion, Paul D.] Ohio State Univ, Ctr Mol Neurobiol, Columbus, OH 43210 USA. [Henion, Paul D.] Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA. RP Stewart, RA (reprint author), Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA. OI Stewart, Rodney/0000-0003-1220-1830 FU NCI NIH HHS [R01 CA104605]; NINDS NIH HHS [R00 NS058608] NR 145 TC 5 Z9 5 U1 0 U2 4 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-679X BN 978-0-12-384892-5 J9 METHOD CELL BIOL JI Methods Cell Biol. PY 2010 VL 100 BP 127 EP 152 DI 10.1016/B978-0-12-384892-5.00005-0 PG 26 WC Cell Biology SC Cell Biology GA BSR05 UT WOS:000285524800005 PM 21111216 ER PT S AU Drummond, IA Davidson, AJ AF Drummond, Iain A. Davidson, Alan J. BE Detrich, HW Westerfield, M Zon, LI TI Zebrafish Kidney Development SO ZEBRAFISH: CELLULAR AND DEVELOPMENTAL BIOLOGY, PT A, THIRD EDITION SE Methods in Cell Biology LA English DT Review; Book Chapter ID SLIT DIAPHRAGM; PODOCYTE DIFFERENTIATION; DEVELOPING PRONEPHROS; GENE-EXPRESSION; COTRANSPORTER; MUTATIONS; PATTERN; NEPHRIN; EMBRYO; MUTANT AB The zebrafish pronephric kidney provides a useful and relevant model of kidney development and function. It is composed of cell types common to all vertebrate kidneys and pronephric organogenesis is regulated by transcription factors that have highly conserved functions in mammalian kidney development. Pronephric nephrons are a good model of tubule segmentation and differentiation of epithelial cell types. The pronephric glomerulus provides a simple model to assay gene function in regulating cell structure and cell interactions that form the blood filtration apparatus. The relative simplicity of the pronephric kidney combined with the ease of genetic manipulation in zebrafish makes it well suited for mutation analysis and gene discovery, in vivo imaging, functional screens of candidate genes from other species, and cell isolation by FACS. In addition, the larval and adult zebrafish kidneys have emerged as systems to study kidney regeneration after injury. This chapter provides a review of pronephric structure and development as well as current methods to study the pronephros. C1 [Drummond, Iain A.] Harvard Univ, Sch Med, Dept Med, Charlestown, MA USA. [Drummond, Iain A.] Harvard Univ, Sch Med, Dept Genet, Charlestown, MA USA. [Drummond, Iain A.] Massachusetts Gen Hosp, Div Nephrol, Charlestown, MA USA. [Davidson, Alan J.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. RP Drummond, IA (reprint author), Harvard Univ, Sch Med, Dept Med, Charlestown, MA USA. FU NIDDK NIH HHS [DK071041, DK070263, DK077186, DK53093, R01 DK070263] NR 74 TC 37 Z9 37 U1 0 U2 9 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-679X BN 978-0-12-384892-5 J9 METHOD CELL BIOL JI Methods Cell Biol. PY 2010 VL 100 BP 233 EP 260 DI 10.1016/B978-0-12-384892-5.00009-8 PG 28 WC Cell Biology SC Cell Biology GA BSR05 UT WOS:000285524800009 PM 21111220 ER PT J AU Lorenz, F Richter, H Zygmanski, P AF Lorenz, Friedlieb Richter, Henning Zygmanski, Piotr TI Optimizing an analytical dose calculation algorithm for fast 2D calculations SO ZEITSCHRIFT FUR MEDIZINISCHE PHYSIK LA English DT Article DE Dose calculation; MLC transmission; independent verification ID RADIATION-THERAPY COMMITTEE; SPATIAL DEPENDENCE; MLC TRANSMISSION; RADIOTHERAPY; DELIVERY; IMRT AB Previously, an analytical dose calculation algorithm for MLC-based radiotherapy was developed and commissioned, which includes a detailed model of various MLC effects as a unique feature [1]. The algorithm was originally developed as an independent verification of the treatment planning system's dose calculation and it explicitly modeled spatial and depth dependent MLC effects such as interleaf transmission, the tongue-and-groove effect, rounded leaf ends, MLC scatter, beam hardening, and divergence of the beam, which in turn resulted in a gradual MLC transmission frill-off with increasing off-axis distance. Originally the algorithm was implemented in Mathematica (TM) (Wolfram). To speed up the calculation time and to be able to calculate high resolution 2D dose distributions within a reasonable time frame (<2 s) the algorithm needs to be optimized and to be embedded in a user friendly environment. To achieve this goal, the dose calculation model is implemented in VisualBasic 6.0, which decreases the calculation time moderately. More importantly, the numerical algorithm for dose calculation is changed at two levels: the dose contributions are split into their x- and y-contributions and the calculation is aperture- rather than as originally point-based. Implementing these three major changes, the calculation time is reduced considerably without loosing accuracy. The time for a typical IMRT field with about 2500 calculation points decreased from 2387 seconds to 0.624 seconds (a factor of about 3800). The mean agreement of the optimized and the not optimized calculation algorithm at the isocenter fir a fairly complex IMRT plan with 23 fields is better than 1% relative to the local dose at the measuring point. C1 [Lorenz, Friedlieb] Univ Heidelberg, Dept Radiat Oncol, Mannheim Med Ctr, D-68167 Mannheim, Germany. [Richter, Henning] Tech Univ Kaiserslautern, Kaiserslautern, Germany. [Zygmanski, Piotr] Harvard Univ, Sch Med, Dept Radiat Oncol, Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. RP Lorenz, F (reprint author), Univ Heidelberg, Dept Radiat Oncol, Mannheim Med Ctr, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany. EM Friedlieb.Lorenz@web.de NR 10 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER GMBH, URBAN & FISCHER VERLAG PI JENA PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY SN 0939-3889 J9 Z MED PHYS JI Z. Med. Phys. PY 2010 VL 20 IS 1 BP 61 EP 67 DI 10.1016/j.zemedi.2009.12.001 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 586SZ UT WOS:000276934800008 PM 20211425 ER EF